

INDIAN BAR ASSOCIATION

(THE ADVOCATES' ASSOCIATION OF INDIA)

Regional Office: Office No. 2 & 3, Kothari House, A. R. Allana Marg, Fort, Mumbai-23,

Maharashtra (India) Tel: +91-22-49717796, Website: [www.indianbarassociation.in](http://www.indianbarassociation.in)

Contact us: [dipaliojha@indianbarassociation.in](mailto:dipaliojha@indianbarassociation.in)

30th July, 2021

Case number before Hon'ble President of India :- PRSEC/E/2021/20508

Case number before Hon'ble Prime Minister of India:- PMOPG/E/2021/ 0458101

To,

1. Hon'ble Shri Ram Nath Kovind

President of India

Rashtrapati Bhavan,

New Delhi-110004.

2. Hon'ble Shri Narendra Modi

Prime Minister of India

7, Lok Kalyan Marg,

New Delhi 110 011

Sub:- Urgently considering the request of 'Indian Doctors for Truth' regarding stopping the universal vaccination drive against COVID-19.

Ref:- Letter submitted by 'Doctors for Truth' on July 21, 2021

1

Respected Sirs,

1. We are in receipt of the letter submitted on 21st July, 2021 by 'Doctors for Truth' to your good offices regarding their appeal to immediately stop the mass vaccination drive in India.

2. We at the Indian Bar Association request for an urgent consideration and appropriate action, as the issue is concerned with life and liberty of every citizen of India.

3. We earnestly request you to take an immediate action on the said letter.

Date: 30.07.2021

Place: Mumbai.

Sincerely

Adv. Dipali N. Ojha

Head - Legal Cell

Indian Bar Association

[www.indianbarassociation.in](http://www.indianbarassociation.in)

Annexure:

1. Letter authored by twenty 'Indian Doctors for Truth'.

2

To,

The Hon'ble Prime Minister of India,

New Delhi

Dear Sir,

Sub: Urgent need to stop the overzealous universal vaccination drive against Covid-19.

We, the undersigned Indian Doctors for Truth, want to bring to your notice certain scientific facts about immunity achieved by Indian population among adults and children, alike, in the light of the latest sero-survey done by AIIMS along with WHO, for immediate action.

Looking at the evidence, we urge you to immediately stop the drive for vaccination of the entire population and limit it to voluntary vaccination of only those above 60 years and/or people with severe degree of comorbidity.

The first principle of medicine is Do No Harm. This is often considered a main component of the Hippocratic Oath, which of course is recited at most medical school graduations. Well, sort of. An actual translation of what is written in the Oath would be more like: "I will follow that system of regimen which, according to my ability and judgment, I consider for the benefit of my patients, and abstain from whatever is deleterious and mischievous."

In our submission we want to point out that by ignoring the Medical Knowledge established for last 100 years, and biased by western data and practice, the vaccination drive started in

India is doing more harm than any good for the people of India.

We present before you the scientific facts about SARS COV2 related immunity and vaccination.

1.

There is enough and robust evidence available now that those who have recovered from Covid 19 develop robust and long-lasting immunity against SARS CoV2, even after mild or asymptomatic infections, and that chances of reinfection among these people, even from the emerging variants of the same virus, are extremely rare or non-existent. The WHO in its interim guidance released on July 2, 2021 has also recognised the fact of acquired immunity in all those who have had previous infection with SARS-CoV-2. [1-11]

2.

There is no evidence to show that those who have recovered from the infection will get any additional benefit from vaccination. There is an elegant study from the Cleveland Health System which has conclusively reported that those infected do not get reinfected, whether vaccinated or not. [12-15]

3.

The epidemiology of Covid 19 in India is very different from other countries of the world and even within India, there are differences between urban and rural communities and between socioeconomic strata. Therefore, we need to have our own policies regarding prevention of covid19 here, including the policy on vaccination. According to available reports, the percentage of population infected in the US, UK, and such other countries is at 123%.

In India, recent sero-surveys at Delhi and Mumbai have reported a positivity of 5070%,

indicating that a significant proportion of our people have already been infected, reaching the levels of herd immunity, and will not need the vaccine. <https://www.hindustantimes.com/india-news/kids-adults-have-similar-antibodies-serosurvey-101623953000262.html>

And many reports of India achieving herd immunity have already appeared. The mathematical models have explained how what percentage of population is required to be infected is also different for different population and with mixing rates fitted to social activity, the disease-induced herd immunity level can be ~43%. [19-22]

4. Case Fatality Rate is the rate that is usually reported by the government, that is the number of deaths per 100 confirmed cases as detected by antigen or rt-PCR test. But as

renowned Epidemiologist Dr John Ioannidis, whose paper (Attached along with) on WHO site ([https://www.who.int/bulletin/online\\_first/BLT.20.265892.pdf](https://www.who.int/bulletin/online_first/BLT.20.265892.pdf)) shows proper way of

counting death rate in diseases with CFR less than 5 is Infection Mortality Rate. That is from

serosurveys the actual prevalence of the infection in community is found and death rate

counted from that is Infection Fatality Rate. The IFR is less than 0.1% world over and is

shown to be so in India from various serosurveys done by ICMR.

5.

Covid19 is now proven to be asymptomatic or mild disease with infection fatality rate

of 0.001-0.01% or lower, and particularly in the population younger than 30 years, it is

mostly asymptomatic and harmless. [23-26] Therefore, considering the fact of high level of

infections in India, near herd immunity, and very low levels of Infection Fatality Rates,

vaccinating the entire population will not serve any purpose. Looking at the negligible risk to

the children from Covid-19, trial of the vaccines for them or even consideration approval is

highly unethical.

6.

A very important development that has taken place because of 4 latest studies that

proves that almost 99.9% population has the memory from previous corona infection and that

whether to the actual corona infection or to vaccine it is our same immune memory gets

activated and vaccines in fact are more harmful in an already immune population. Based on

that Doctors for Covid Ethics have written letter to tens of thousands of doctors in Europe.

“Four recent scientific discoveries are herewith brought to your urgent

attention. They alter the entire landscape of the COVID-19 pandemic, and they force us to reassess the merits of vaccination against SARS-CoV-2.

#### Summary

Rapid and efficient memory-type immune responses occur reliably in virtually all unvaccinated individuals who are exposed to SARS-CoV-2. The effectiveness of further

boosting the immune response through vaccination is therefore highly doubtful.

Vaccination

may instead aggravate disease through antibody-dependent enhancement (ADE).

<https://doctors4covidethics.org/letter-to-physicians-four-new-scientific-discovers-crucial-to-the-safety-and-efficacy-of-covid-19-vaccines/>

7.

In

the light of availability of many treatments now proving to be effective for SARSCoV-2

and the realization that the overuse of certain medical procedures and drugs if not

repeated many lives can be saved without any vaccines which are not as harmless as

portrayed.

8.

Government's own Operative Guidelines have mentioned that "Covid-19 vaccines have limited safety data". Later advisory by the government about clotting is also quite

revealing. Adverse effects of the vaccine are found world over. As per the EUDRA report

dated June 19, more than 1.3 million people in the Europe have had vaccine adverse effects

and 13,867 people have died because of the vaccine. Similarly, as per VAERS, 6985 deaths

have occurred in the US because of the vaccine and 4,41,931 incidents of vaccine adverse

effect have been reported along with 34,065 severe ailments because of the vaccine from 14

December, 2020 to 25 June, 2021. As per MHRA of England, there have been 9,49,000

adverse effects and more than 1300 deaths because of the vaccine. In such circumstances,

after vaccinating more than 24 million people, only 488 deaths and a little more than 26,000

adverse effects by AEFI in India is unimaginable. Only the first death because of vaccines is

confessed as per AEFI on 15 June, which is also far away from the truth. The prime reason

behind this is the inappropriate system of reporting vaccine adverse effects and vaccine

deaths in our country.

9.

As in most countries, in India also, the death rate from Corona has increased with

increase in vaccination drive as is shown by data (Data compiled by Rahul C. Mehta, link



below) and the recorded Corona deaths with Vaccine drive in many countries. And that is a matter of investigation. Experts have given various reasons, for vaccinated (Intravascular clotting and Antibody Enhancement) and even nonvaccinated people because of leaking vaccine. It can be purely because lockdown with its deleterious effect on all facets of our lives has increased vulnerability to all infections. Our regular rise of respiratory infections in the months following Holi has just exaggerated because of this lockdown effect. And rt-PCR can detect previous Coronavirus, flu virus and give positive and patient's symptoms can be because of any other disease even if rt-PCR is positive. So, more cases and more deaths are a matter of investigation after vaccination. But because of serosurveys futility of vaccine drive is well established. (Refer: <https://drive.google.com/file/d/1eQJF3KZuAGaPbrPGk0sUUfzbknhD6K9/view>)

10.

The number of deaths per thousand population has not increased in the year 2020 in most countries as much as it increased in last 10 years, when the populations were dealing with Corona virus on their own, death rate has not increased in 2020 it is only after the vaccine drive the deaths have increased. Even in India the death per thousand increased 0.5% in 2019 but 0.49% in 2020.

Considering all the above, we strongly urge the following:

1.

The overzealous universal vaccination against Covid-19 drive, with widespread incidences of coercion and vaccination being made mandatory for jobs, examination for students, must be stopped immediately.

2.

The people above the age of 60 and people with severe comorbidities may be offered vaccination on voluntary basis with full disclosure of warnings about side effects and lack of safety data as are mentioned in Government's operative Guidelines for Covid-19 vaccination and later declared for Intravascular clotting.

3.

In the light of the fact that majority children in our country are also post Covid and on an average 56% of them are having antibodies without ever getting serious disease, All Trials on children for Covid-19 vaccine should stop and in upcoming meetings no consideration is required to approve the vaccines for children who have finished the trial.

4. We also urge the government to institute detailed studies to analyse the observation

that there has been surge in cases and deaths due to covid in India since March-April 2021, coinciding with the roll out of the vaccination drive.

We are ready to come and meet you to have a full discussion on this at its earliest and as the

matter is urgent and of grave concern, we expect an urgent call from you.

Expecting a prompt action on this front from you,

Indian Doctors for Truth,

Dr. Maya Valecha, MD, DGO

Dr. Ajay Gupta, MS, ORTHO (AIIMS)

Dr. Deepika Naytial. DGO DNB

Dr. Archana Satyam, MBBS, Diploma in Emergency Medicine

Dr. Harpreet Singh Walia BDS

Dr. Piyush Kumar, MBBS, EMOC, Public Health

Dr. Nisheetha Dixit, MBBS

Dr. Juhi Mittal, MBBS

Dr. Shams Scheik, MB BS, MD ( Med), ABAARM ( USA), DOrtMed (Germany)

Dr. Megha Consul, MD, DNB Pediatrics

Dr. Praveen Saxena, Radiologist & Clinical metal toxicologist, MBBS, DMRD

Osmania

Dr.M.A.Khuddus, MD, DM, Ph.D. FNR (Glasgow), FCR (Edinburgh), Acute Medicine (Lond.), NHS (England), Senior Consultant Neurologist

Dr. Kuldeep Kumar, MS

Dr. Veena Raghav, MBBS

Dr. Vijay Raghav, MBBS

Dr. Gautam Das, MBBS

Dr. Priya mohod shirsat, MBBS

Dr. Rashmi R. Raut, MBBS, Fellowship in Family Medicine

Dr. Madhab Nayak, MBBS, MD Community Medicine

Swapnali Nikam, Nutritionist & Diabetes Educator

Enclosure: References and Evidence for the all Facts mentioned above.

I Natural Immunity vs Vaccine Induced Immunity:

Without any scientific data GoI has declared that Vaccine will benefit to even those who had

Corona Infection. Whereas naturally acquired immunity is robust and lasts is argued by many

individual Doctors in India and abroad and WHO has agreed to it now.

WHO in its 10th May, 2021 report concludes:

([https://drive.google.com/file/d/1Gm9NYmf1R3ZUXmSEijCYeQ6Defh5bqb\\_/view](https://drive.google.com/file/d/1Gm9NYmf1R3ZUXmSEijCYeQ6Defh5bqb_/view))

Conclusions

Current evidence points to most individuals developing strong protective immune responses

following natural infection with SARS-CoV-2. However, inaccurate

immunodiagnostic tests

may falsely indicate infected individuals as naïve to the virus (not previously infected) or

may falsely label non-infected people as positive for immune markers of recent infection.

To conclude, available tests and current knowledge do not tell us about the duration of

immunity and protection against reinfection, but recent evidence suggests that natural

infection may provide similar protection against symptomatic disease as vaccination, at least

for the available follow up period.<sup>33</sup> The emergence of variants of concern poses challenges and their potential to evade immunity elicited by either natural infection or by vaccination, needs to be closely monitored.

[https://www.medscape.com/viewarticle/951949?src=WNL\\_dne\\_210528\\_mscpedit&uac=391223BT&impID=3404007&faf=1](https://www.medscape.com/viewarticle/951949?src=WNL_dne_210528_mscpedit&uac=391223BT&impID=3404007&faf=1)

Months after recovery from mild COVID-19, when antibody levels in the blood have declined, immune cells in bone marrow remain ready to pump out new antibodies against the coronavirus, researchers reported in Nature.

<https://dailycaller.com/2021/05/25/marty-makary-cdc-natural-immunity/>

Makary, however, disputed claims that natural immunity is inferior to that acquired through vaccination, saying that both are “probably life-long” and that no boosters will be needed.

“There is more data on natural immunity than there is on vaccinated immunity, because

natural immunity has been around longer,” Makary claimed. “We are not seeing reinfections, and when they do happen, they’re rare. Their symptoms are mild or are asymptomatic”

[https://www.medscape.com/viewarticle/952033?src=WNL\\_dne\\_210528\\_mscpedit&uac=391223BT&impID=3404007&faf=1](https://www.medscape.com/viewarticle/952033?src=WNL_dne_210528_mscpedit&uac=391223BT&impID=3404007&faf=1)

“The papers are consistent with the growing body of literature that suggests that immunity elicited by infection and vaccination for SARS-CoV-2 appears to be long-lived,” Scott

Hensley, an immunologist at the University of Pennsylvania who wasn't involved with the research, told The New York Times.

<https://www.theblaze.com/news/johns-hopkins-professor-ignore-cdc-natural-immunity-works>

A professor at the renowned Johns Hopkins School of Medicine advised Americans recently to “ignore” guidance from the U.S. Centers for Disease Control and Prevention due to the

public health agency's puzzling refusal to recognize natural immunity from previous infection.

<https://theprint.in/opinion/majority-indians-have-natural-immunity-vaccinating-entire-population-can-cause-great-harm/582174/>

“The scientific evidence is overwhelming that natural immunity attained after recovery from

Covid infection is effective and long lasting. The immune system responds to infection by

various mechanisms, including the production of specific antibodies, T-cells, and B-cells to

protect nearly every recovered Covid patient from reinfection. After almost a year of

pandemic, globally, only 34 cases and two deaths have been definitively identified as

reinfections at the time of writing, out of the 90 million Covid cases and

likely hundreds of millions of infections worldwide.

Vaccines cause the immune system of those inoculated to mimic the immune response that

natural infection induces. While the immunity conferred by the Covid vaccines documented

in the clinical trials is excellent, it is not as effective as the immunity conferred by natural

infection. (Emphasis added)

Furthermore, those who have already developed immunity to Covid through natural infection

are extremely unlikely to develop additional immunity from vaccination. For instance, in the

Pfizer randomised trial, the vaccine was tested in previously infected patients to check for its

safety in that group. But those same patients were excluded from the analysis of efficacy,

presumably because the scientists understood that the vaccine would confer no additional

benefit to them.”

Sanjiv Agarwal is the founder of the Good Governance India Foundation, Mumbai.

Jay

Bhattacharya is Professor of Medicine at Stanford University.

<https://7news.com.au/lifestyle/health-wellbeing/study-suggests-some-people-may-have-protection-against-covid-due-to-their-immune-system-c-1215337>

A

large percentage of the population appears to have immune cells that are able to recognise

parts of the SARS-CoV-2 virus, and that may possibly be giving them a head start in fighting

off an infection.

In other words, some people may have some unknown degree of protection.

“What we found is that people that had never been exposed to SARS Cov2 ... about half of

the people had some T-cell reactivity,” co-author of the paper Alessandro Sette from the

Center for Infectious Disease and Vaccine Research at La Jolla Institute for Immunology,

told CNN.

It's T cells like those, which reacted to the SARS-CoV-2 virus, that Sette and his co-author

Shane Crotty discovered - quite by accident - in the blood of people collected several years

before this pandemic began.

They were running an experiment with COVID-19 convalescent blood.

Because they needed a “negative control” to compare against the convalescent blood, they

picked blood samples from healthy people collected in San Diego between 2015 and 2018.

‘People that have never seen this virus have some T-cell reactivity against the virus.’

“It is conceivable that if you have 10 people that have reactivity and 10 people that don't

have the pre-existing reactivity and you vaccinate them with a SARS CoV-2

vaccine, the ones that have the pre-existing immunity will respond faster or better to a vaccine,” said Sette.

“The beauty of that is that that is a relatively fast study with a smaller number (of people)...

“So, we have been suggesting to anybody that is running vaccine trials to also measure T-cell response.”

“The implications of having some pre-existing immunity suggests that maybe you need a

small proportion of the population to be impacted before the epidemic wave.

[https://m.dailyhunt.in/news/india/english/outlook-epaperoutlooke/vaccinating+those+who+have+recovered+from+covid19+is+a+wasteful+exercise+scientists-newsidn252717142?s=a&uu=0x830173843ae3c60d&ss=pd&fbclid=IwAR2kPbkIwfuNrZQR3lncn6](https://m.dailyhunt.in/news/india/english/outlook-epaperoutlooke/vaccinating+those+who+have+recovered+from+covid19+is+a+wasteful+exercise+scientists-newsidn252717142?s=a&uu=0x830173843ae3c60d&ss=pd&fbclid=IwAR2kPbkIwfuNrZQR3lncn6D0uLLK6_okYJl7BbxzTyUnJxTdgtzF0ZLifJc)

[D0uLLK6\\_okYJl7BbxzTyUnJxTdgtzF0ZLifJc](https://m.dailyhunt.in/news/india/english/outlook-epaperoutlooke/vaccinating+those+who+have+recovered+from+covid19+is+a+wasteful+exercise+scientists-newsidn252717142?s=a&uu=0x830173843ae3c60d&ss=pd&fbclid=IwAR2kPbkIwfuNrZQR3lncn6D0uLLK6_okYJl7BbxzTyUnJxTdgtzF0ZLifJc)

Meanwhile,

Dr Sanjay Rai, President, Indian Public Health Association (IPHA), says that current scientific studies on Covid-19 show that natural immunity lasts very long and so

Covid-recovered population should be excluded from the current vaccination drive.

'As India is very close to herd immunity, we should not waste taxpayers' money on

inoculating those people who have already recovered from Covid-19,' Dr Rai, who is also one

of the principal investigators of a vaccine clinical trial, said.

He seconds Dr Muliylil and says that scientific evidence states that the human body produces

long lasting antibodies against all such viruses which spread through respiration such as

smallpox, measles and influenza.

"There is no disease in which the antibodies developed through vaccines last longer than

natural antibodies," Dr Rai said.

<https://www.news-medical.net/news/20210426/Prior-SARS-CoV-2-infection-and-Pfizer-BioNTech-28099s-COVID-19-vaccine-provide-similar-immunity.aspx>

The

overall estimated efficacy of vaccination was 92.8% for documented infection, 94.2%

for hospitalization, 94.4% for severe illness and 93.7% for death.

Similarly, the overall estimated level of protection among individuals with prior SARS-CoV2

infection was 94.% for documented infection, 94.1% for hospitalization and 96.4% for

severe illness.

<https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1>

Vaccination was highly effective with overall estimated efficacy for documented infection of

92.8% (CI:[92.6, 93.0]); hospitalization 94.2% (CI:[93.6, 94.7]); severe illness 94.4%

(CI:[93.6, 95.0]); and death 93.7% (CI:[92.5, 94.7]).

Similarly, the overall estimated level of protection from prior SARS-CoV-2

infection for documented infection is 94.8% (CI:[94.4, 95.1]); hospitalization 94.1% (CI:[91.9, 95.7]); and severe illness 96.4% (CI:[92.5, 98.3]). Our results question the need to vaccinate previously-infected individuals. (Emphasis added) Similarly National Institute of Health of US also also in its Research Matters observes on 26th January, 2021.  
<https://www.nih.gov/news-events/nih-research-matters/lasting-immunity-found-after-recovery-covid-19>

- The immune systems of more than 95% of people who recovered from COVID-19 had durable memories of the virus up to eight months after infection. II & III Serosurveys in India showing large population has already Developed Immunity and Infection Fatality Rate very low: But in India right from the month of June it was known that sizable population of India already was exposed to Corona and in next few months India was heading towards Herd Immunity. As explained by renowned Epidemiologist Dr John Ionnidis whose article on WHO website shows the method of counting Infection Mortality Rate from serosurveys, these serosurveys also proved low IFR in India. Before showing the full sequence of antibody development in Indian population starting from the month of June, 2020, we want to point out how the latest sero-survey done by AIIMS along with WHO in the month of April-May, 2021 shows that majority of not only adults but even children are exposed to Coronavirus and have antibodies, and therefore they are immune and even herd immunity levels are achieved.  
<https://www.hindustantimes.com/india-news/kids-adults-have-similar-antibodies-serosurvey-101623953000262.html>

The seroprevalence, presence of virus-fighting antibodies against Sars-CoV-2, among children was 55.7% across five study sites, in comparison to 63.5% among adults -- the difference was judged to be statistically insignificant. "Wherever the prevalence of antibodies was high among the adults, it was high among the children, busting the myth that so far children have been less affected. The thing is, the binding of the virus to the human cell receptors is not very good in children and hence they mostly develop either asymptomatic or mildly symptomatic infection," said Dr Sanjay Rai, one of the authors of the study and the head of the department of community medicine at the AIIMS.

He added, "People have been saying that after the young, the third wave will impact children more. The fact is most of them have been already exposed to the infection along with their families. And, numerous studies have now shown that natural infection can provide better and longer protection against a second infection."(Emphasis added)

<https://science.thewire.in/.../icmr-seroprevalence.../>

So, by June 4th, they knew from the sero survey that there are already 64 lacs cases in India,

infection mortality rate very low 0.08%, less than seasonal flu.

Now instead of telling the nation the obvious that it is not a dangerous disease, what they say

is that they detected only 52592 cases and missed others.

Other people not tested had corona, recovered and had antibodies so what is the problem?

And once infected test can remain positive up to 2 months!

And as it later came out for whatever reason in this scientific study also some facts were

hidden which were showing even larger number of people were actually affected.

And so the

IFR was still lower.

<https://www.telegraphindia.com/india/how-covid-numbers-were-hushed-up/cid/1792482>

Independent health experts tracking India's response to the Covid-19 pandemic said the

directive to conceal high prevalence data in cities in early May might have been part of

efforts to portray the lockdown as a success.

"The abrupt nationwide lockdown with a four-hour notice had brought misery and tragedies

to many," said a senior physician at the All India Institute of Medical Sciences, New Delhi,

who requested anonymity. "The country's health research community has been used to

portray the lockdown as a success."

The professor added: "India was under complete lockdown during April and May – a paper

reporting 30 or 48 per cent prevalence rates in early May would have put a question mark on

the claims about a successful lockdown and containment."

High prevalence means low infection mortality rate so do they want to hide high prevalence

rate or low mortality rate?

Most surveys in India at various places showed increasing prevalence and reaching towards

Herd Immunity.

<https://indianexpress.com/article/cities/mumbai/two-private-labs-in-mumbai-find-antibodypositivity-rate-at-24-3-pc-6517163/>

This

is good news. This shows a large number of people who were exposed to coronavirus

had no symptoms and got immunity," said Dr Sujata Baveja, head of microbiology in Sion

hospital.

So in July, 2020,

Latest data also suggests Delhi is more exposed to coronavirus than Mumbai.

Combined data

of sero surveillance conducted by the National Centre for Disease Control (NCDC) and

samples tested by Thyrocare show a 25.10 per cent positivity rate. The NCDC did an IgG

antibody test on 21,387 people in 11 districts of Delhi and found around 5,022 positive (23.48

per cent). Private laboratory Thyrocare tested 3,956 people and found antibodies in 1,340

(33.8 per cent).

But those in slums like Dharavi had even 57% seroprevalence without any high mortality.

<https://www.livemint.com/news/india/mumbai-sero-prevalence-of-57-found-in-slums-and-16-in-residential-societies-11595952896909.html>

Mumbai:

Sero-prevalence of 57% found in slums and 16% in residential societies.

[https://mumbaiirror.indiatimes.com/coronavirus/news/mumbai-sero-survey-57-per-cent-respondents-in-slums-16-per-cent-in-residential-societies-exposed-to-coronavirus/articleshow/77227080.cms?utm\\_source=contentofinterest&utm\\_medium=text&utm\\_campaign=cppst](https://mumbaiirror.indiatimes.com/coronavirus/news/mumbai-sero-survey-57-per-cent-respondents-in-slums-16-per-cent-in-residential-societies-exposed-to-coronavirus/articleshow/77227080.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst)

Overall,

the sero-survey found that 40 per cent had the coronavirus infection.

<https://indianexpress.com/article/india/india-covid-19-august-sero-survey-6637821/>

ICMR did sero survey, the blood test, from 17th August to 22nd September to detect

antibodies, to know how many persons already had Corona.

And it was found that 6.6 % of the people above 10 years of age already had it, which means

7.48 crore people had it.

It takes 15 days to produce antibodies so these were the patients between 2nd August to 7th

September.

Number of deaths during those days was around 37000 total.

If we count only this much the death rate is 0.049 percent which is less than seasonal flu.

How is it a serious disease?

Doctors must know that within 2 months antibodies go down and as such because it was told

to the people to scare them, now even people know it.

When such a survey was done in in July end, more than 50% of the people had antibody in

slums. And in this survey which was extended upto 22nd September 15.6% of people in

slums had antibodies but because people had immunity not many new cases there.

[https://theprint.in/india/punes-first-sero-survey-shows-over-51-infected-by-covid-in-5-highincidence-areas/483945/?fbclid=IwAR0GMXTi8vH5j9vDv3p2smu6R\\_RiKXFgEUnr8kOhbfy8Oo7RD3pU5-zdVs](https://theprint.in/india/punes-first-sero-survey-shows-over-51-infected-by-covid-in-5-highincidence-areas/483945/?fbclid=IwAR0GMXTi8vH5j9vDv3p2smu6R_RiKXFgEUnr8kOhbfy8Oo7RD3pU5-zdVs)

The

study, conducted between 20 July and 5 August in five high-incidence administrative



wards of Pune, shows that an average of 51.5 per cent of the people had been infected by Covid-19. The incidence ranged from 36.1 per cent to 65.4 per cent in the selected areas.

On July 24,

<https://indianexpress.com/article/cities/ahmedabad/only-17-61-per-cent-has-antibodiesahmedabad-civic-body-sero-survey-6520952/>

This

means out of 5570000 population of Ahmadabad 980320 got infected and 99% of them had no symptoms even and got antibodies, that is some immunity which protected them and

did not get any symptoms.

1500 deaths from 980320 gives case fatality rate of 0.14 percent. 0.08% in Delhi, can call it

nearly same.

Head of microbiology dept Mumbai explains Mumbai like this. Dr Ioannidis of Stanford

university, one of the top ten most quoted Epidemiologist explains like this.

Why the media

not calling such scientists?

Let us understand, Corona is not a deadly virus.

City after city is giving same results!

<https://indianexpress.com/article/cities/mumbai/mumbai-75-test-positive-for-covid-19antibodies-sero-survey-finds-7072331/>

In

one of the highest sero-prevalence rates reported in the country, 605 of 806 patients who

underwent antibody testing at five slums in Cuffe Parade tested positive for coronavirus

antibodies.

Conducted between October 5 and 10 at five locations in the ward, the tests showed that 75%

of the population tested positive for Covid antibodies.

[https://indianexpress.com/article/india/first-signs-of-herd-immunity-in-small-populationgroups-in-pune7057931/?fbclid=IwAR2v4i\\_LFWx8LQcFwHmBDJl1Rwt62zyfMF4eHefATpPn8ZpSxwnxPbtVCE](https://indianexpress.com/article/india/first-signs-of-herd-immunity-in-small-populationgroups-in-pune7057931/?fbclid=IwAR2v4i_LFWx8LQcFwHmBDJl1Rwt62zyfMF4eHefATpPn8ZpSxwnxPbtVCE)

xPbtVCE

This

is the first study that followed up on an earlier sero-survey to detect the presence of

'neutralising' antibodies in infected persons. And though the researchers who carried out the

study are careful not to suggest that the city was approaching 'herd immunity', this is the first

documented case in the country where the infection rate in a population group had gone up so

high that the concept of herd immunity could already be playing out.

<https://indianexpress.com/article/cities/pune/almost-50-in-karnataka-were-infected-byaugust-sero-study-7049909/?fbclid=IwAR00PdgyOONg00X0sbEffqRok6G6xecF9I8JgHBd5IGlIbcKxzBdv1a-t8>

Almost

half of Karnataka's population was infected with Covid-19 by August. A seroprevalence study indicated that at least 44.1 per cent of the population in rural areas of

Karnataka and 53.8 per cent in urban areas were exposed to the coronavirus, and have therefore developed antibodies for the infection.

<https://fastkashmir.com/2020/11/first-ever-district-wise-sero-survey-of-sars-cov-2-in-kashmir-shows-overall-prevalence-of-38-8/>

Srinagar,

Nov 18: The first ever sero-prevalence study in Kashmir division for SARS COV-2 specific IgG antibodies conducted across all ten districts shows IgG antibodies among 38.8% sampled population.

In a population of 15 lacs, where newspapers were shouting hotspot!, Total deaths till 27th

September were 285 deaths.

Sero survey from 15th October, counting total deaths is to count on higher side, and still it

comes to 0.057%, less than seasonal flu! NO VACCINE NEEDED!

<https://theprint.in/health/india-is-missing-about-90-infections-for-every-covid-case-latestgovt-analysis-shows/567898/>

Latest analysis by DST panel, that predicted end of Covid pandemic in India in February

2021, finds that about 60 per cent Indians have been infected so far.

An analysis of India's Covid numbers till last month has thrown up these figures. It was

conducted by members of a panel formed by the Department of Science and Technology

(DST), the same committee that developed the India-specific supermodel that predicted that

the pandemic will taper off by February 2021 in India. An analysis in September had shown

that India had missed about 60-65 infections for every detected case.

"The India figure is about 90 infections missed for every case. If you compare that with

countries like Italy and the United Kingdom, it is about 10-15 missed infections for every

case. It is important to understand that these people were never tested because they never

exhibited any symptoms," he added.

January, 1, 2021

<https://www.india.com/news/india/india-moving-towards-herd-immunity-as-covid-19-cases-declining-no-need-to-panic-over-uk-strain-health-experts-4302153/>

New

Delhi: Health experts said on Thursday that India seems to be moving towards getting

herd immunity from COVID-19 as cases decline. Dr (Prof) Sanjay Rai, Professor of Community Medicine at AIIMS said there is no need to panic over the new coronavirus

strain detected in the UK as according to reports it is not as virulent. Also Read - In a First,

Signs of 'Herd Immunity' Witnessed in Small Population Groups in Pune: Report "Perhaps, we are moving towards herd immunity because in India the cases are coming

down. One of the classical examples is Dharavi slum of Maharashtra. As far as the number of

cases is concerned, it depends upon testing," he said

By January 27, 2021

<https://indianexpress.com/article/india/sero-survey-delhi-past-50-near-herd-immunity7161606/>

The

fifth round of serological surveillance conducted in Delhi has suggested that more than 50 per cent of those surveyed have developed antibodies against Covid, officials told The Indian Express.

This is the highest seroprevalence found during surveys conducted by the Delhi government

since the Covid outbreak and, according to experts, indicates that the city is moving closer to achieving herd immunity.

Then why vaccinate the whole population?

While it is true that people who do not show any antibody increase in current wave and never

tested positive can also have immunity against Covid-19 as

Is explained here:

<https://lockdownsceptics.org/what-sage-got-wrong/>

I say this because it's well understood that not every person, infected by a respiratory virus,

goes on to produce antibodies. And many people, having prior immunity, never get properly

infected anyway. We know that almost all those who became very unwell and were in

hospital did produce antibodies, sometimes such that this could be detected months later. But

those who had milder responses to the virus did not all produce antibodies.

(Emphasis added)

But India having impossibility of lockdown or isolation in strict sense because of our

objective conditions in slums and villages actually lesser number of percentage to get

infected is required to achieve Herd immunity is explained in this paper.

<https://science.sciencemag.org/content/369/6505/846.full>

“Using a model, we show that population heterogeneity can affect disease-induced immunity

considerably because the proportion of infected individuals in groups with the highest contact

rates is greater than that in groups with low contact rates. We estimate that if  $R_0 = 2.5$  in an

age-structured community with mixing rates fitted to social activity, then the disease-induced

herd immunity level can be ~43%, which is substantially less than the classical herd

immunity level of 60% obtained through homogeneous immunization of the population. Our

estimates should be interpreted as an illustration of how population heterogeneity affects herd

immunity rather than as an exact value or even a best estimate.”

IV The death rate per thousand in the year 2020 in India as well as around the World,

does not show excess deaths when compared to the data of last 10 years.

Below find the data:

<https://www.macrotrends.net/countries/IND/india/death-rate>

<https://knoema.com/atlas/United-States-of-America/Death-rate>

<https://knoema.com/atlas/United-Kingdom/Death-rate>

<https://www.macrotrends.net/countries/ESP/spain/death-rate>

<https://www.macrotrends.net/countries/ITA/italy/death-rate>

<https://www.macrotrends.net/countries/BRA/brazil/death-rate>

V That the increase in Corona deaths is a fact world over after Vaccination Drive.

<https://www.globalresearch.ca/terminate-emergency-use-authorization-eua-complete-phase-3-trials/5743896>

For

example, we are now being told that the sudden uptick in deaths in various parts the

country, are the sign of a "4th Wave". Naturally, these fatalities are being blamed on the

"variant" which is the current 'hobgoblin du jour.' What the media and the pundits fail to

mention is that the unexpected rise in cases and deaths is only taking place in areas that are

engaged in mass vaccination campaigns, a fact that can be easily extrapolated from the chart

below.

I don't know why this is happening, and I certainly don't think the drug companies have

laced their injections with Covid-19. But it certainly deserves to be investigated, don't you

think?

For India how the vaccine drive has affected Corona death rate and with vaccine shortage the

death rate is going down, but with vigorous drive from 21st June it is anybody's guess what

can happen when this is what is happening world over.

If Indian population is having the required immunity for the virus for which the

vaccines are made, and as studies are showing the immunity is long lasting. Then why

should the drive to vaccinate whole population with its potential serious side-effects

which Government itself has recently warned and lack of safety data is also accepted in

Government document along with the other warnings by experts, carried out? (Attached are GoI warnings and document)

Even after issuing such warnings about blood clotting side-effects, our medical authorities are

not doing such simple tests to establish or confirm such serious side-effects of these genebased

vaccines.

<https://dissident.one/2021/06/04/prof-bhakdi-levensbedreigend-letsel-verstoordeloesdrolling-bij-alle-gevaccineerden/>

During

his speech at the symposium, Prof. Bhakdi about a phone call from a medical colleague. He had examined the blood of all the people in his practice before and after the

mRNA vaccination: The blood clotting was activated ("turned on") in more than 30 percent of the vaccinates, or 20 of the 60. According to Bhakdi, the activation of blood clotting is basically a life-threatening injury. Or in other words. "The blood clots in the veins".

Vaccinations must be stopped: Potentially fatal side effect

Administering a substance that activates blood clotting in the body would be extremely

dangerous, according to Bhakdi, Report24 reports . The process must be stopped immediately, he said. Currently, a second specialist from Bavaria is said to have already

confirmed the results - confirming activation of blood clotting in 100% of all vaccinated

individuals. In total, the Bhakdi research group is conducting similar studies with 50 different

doctors in different countries. A precise study design was developed for this purpose. The

doctor's results are just being verified and will be published soon.

Antibody Dependent Enhancement As A Consequence To Vaccination:

In a letter to European Medicines Agency experts have highlighted this point again along

with many other untested side-effects.

<https://doctors4covidethics.medium.com/doctors-and-scientists-write-to-the-european-medicines-agency-warning-of-covid-19-vaccine-dangers-edfebb0419a7>

"1e. Furthermore, long term adverse effects, in particular the danger of immune dependant

enhancement of disease and adverse effects of subsequent vaccinations are impossible to

predict.

The European Medicines Agency, as the regulator re vaccines for almost 450 million people

across 27 European Union member states, must inform the public and the relevant authorities

of this profoundly important issue.

2. We believe that the number of deaths due to the gene-based vaccines to which you have

publicly admitted is but a small percentage of the actual number of deaths due to the genebased

vaccines."

Conclusion:

All the available literature points to the fact that on one hand as surveys have shown a

large proportion of population is already infected with Corona at one or the other time and

umpteen number of studies have shown that the immunity from natural infection is better and

long lasting. So vaccine is not required.

And on the other hand the vaccination drive has its own harmful effects which was warned by

experts and now proving right in studies and data of our country.

That our government was warned in the month of August, 2020 and again in, 2021 February

against following WHO advices blindly not only about vaccination but also

against

disproportionate measures taken by GoI.

[https://drive.google.com/file/d/1hghf8Bh3AIUi5HxrnPA8FZeQqo77e\\_xN/edit](https://drive.google.com/file/d/1hghf8Bh3AIUi5HxrnPA8FZeQqo77e_xN/edit)

<https://drive.google.com/file/d/1r1h4Hck08k6QWH2enq-3xgPQRGUWfq2r/view>

Also letters like this kept on warning about the course being taken by most governments

being not scientific.

<https://www.bmj.com/content/371/bmj.m4425/rr-31>

Many scientific facts are suppressed these days. Apart from one quoted below, facts about rtPCR

test, number of deaths, etc are enumerated in this letter to editor.

The third and possibly the most consequential suppression of science relates to the narrative

that people do not develop immunity following a Covid infection. We know that immunity to

SARS-CoV-1 is very durable, persisting for at least 12-17 years [8-10].

Immunologists know

that immunity to SARS-Cov-2 is no different. This is confirmed by many eminent scientists

including Beda M Stadler, the former Director of the Institute for Immunology at the

University of Bern and Professor Emeritus (Ivor Cummins, Ep91 Emeritus Professor of

Immunology

[https://www.livescience.com/new-coronavirus-compare-withflu.html?fbclid=IwAR1xrQir2CO2WKmFvrukXavODG2xJNvFuxOfXR8LnFA\\_1YMZH9F](https://www.livescience.com/new-coronavirus-compare-withflu.html?fbclid=IwAR1xrQir2CO2WKmFvrukXavODG2xJNvFuxOfXR8LnFA_1YMZH9F)

0VBMPDAC

“The

death rate from seasonal flu is typically around 0.1% in the U.S., according to news reports.”

Serological survey interpretation of in India shows case fatality rate for Corona 0.035, 0.08,

0.1 And 0.14%. How is it different?

And we don't carry out mass vaccination for seasonal Flu then why suddenly for Covid-19?

It is recommended that the vigorous drive to vaccinate the whole population must be stopped

immediately, in the light of already immunised population with antibodies because of

potential and already reported risks of vaccinating an already immune population.

Attachments:

1.

Video link showing death Rate increase with Vaccine drive in 89 countries.

[https://youtu.be/xSrc\\_s2Gqfw](https://youtu.be/xSrc_s2Gqfw)

2.

The site of statistical data from which the above mentioned video is made.

<https://covid19.healthdata.org/albania?view=cumulative-deaths&tab=trend>

References:

1.

2.

Zuo J, Dowell AC, Pearce H et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol 2021;22:620-626.

<https://doi.org/10.1038/s41590-021-00902-8>

Turner JS, Kim W, Kalaidina E et al. SARS-CoV-2 infection induces long-lived bone

marrow plasma cells in humans. *Nature* 2021.

<https://doi.org/10.1038/s41586-021-03647-4>

3.

Turner JS, O'Halloran JA, Kalaidina E et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. *Nature*. 2021.

<https://doi.org/10.1038/s41586021-03738-2>

4.

Radbruch

A, Chang H-D. A long-term perspective on immunity to COVID. *Nature*

June 14, 2021. doi: <https://doi.org/10.1038/d41586-021-01557-z>

5.

6.

7.

Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat Immunol*. 2020 Nov;21(11):1336-1345. doi: 10.1038/s41590-020-0782-6.

Dan JM, Mateus J, Kato Y et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection *Science* 05 Feb 2021;371(6529):eabf4063. DOI: 10.1126/science.abf4063

Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to

COVID-19. *Nat Rev Immunol* 2020;20:581-582.

<https://doi.org/10.1038/s41577-020-004364>

8.

Wang Z, Muecksch F, Schaefer-Babajew D et al. Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. *bioRxiv* 2021.05.07.443175

<https://doi.org/10.1101/2021.05.07.443175>

9.

Hall VJ, Foulkes S, Charlett A et al. SARS-CoV-2 infection rates of antibody-positive

compared with antibody-negative health-care workers in England: a large, multicentre,

prospective cohort study (SIREN). *Lancet*. APRIL 17, 2021;397(10283):1459-1469.

DOI:

[https://doi.org/10.1016/S0140-6736\(21\)00675-9](https://doi.org/10.1016/S0140-6736(21)00675-9)

10.

Krutikov M, Palmer T, Tut G et al. Incidence of SARS-CoV-2 infection according to

baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a

prospective cohort study. *Lancet Health Longevity*. JUNE 01, 2021;2(6):E362-E370.

DOI:

[https://doi.org/10.1016/S2666-7568\(21\)00093-3](https://doi.org/10.1016/S2666-7568(21)00093-3)

11. WHO. Technical considerations for implementing a risk-based approach to international travel in the context of COVID-19: Interim guidance; Annex to: Policy

considerations for implementing a risk-based approach to international travel in the context of

COVID-19. WHO. 2 July 2021. Available at

<https://apps.who.int/iris/rest/bitstreams/1353961/retrieve>

12.

Shrestha NK, Burke PC, Nowacki AS, Terpeluk P, Gordon SM. Necessity of COVID19 Vaccination in Previously Infected Individuals: A Retrospective Cohort Study. medRxiv

2021.06.01.21258176; doi: <https://doi.org/10.1101/2021.06.01.21258176>

13.

Goldberg Y, Mandel M, Woodbridge Y et al. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide

experience from Israel. medRxiv 2021.04.20.21255670; doi:

<https://doi.org/10.1101/2021.04.20.21255670>

14.

15.

PTI. Covid-Recovered Should Take Vaccine After 6 Months, Says Advisory: Report. May 13, 2021. NDTV. Available at

<https://www.ndtv.com/india-news/covid-19-vaccine-jabfor-covid-recovered-after-6-months-suggests-government-panel-report-2440894>

Hindustan

Times. Defer vaccination for 6 months after recovery from Covid-19, says govt panel. Available at

<https://www.hindustantimes.com/india-news/defer-vaccination-for6-months-after-recovery-from-covid-19-says-govt-panel-101620884434595.html>

16.

Raw RK, Kelly C, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection but not Long-COVID is associated with increased adverse events following BNT162b2/Pfizer

vaccination. medRxiv 2021.04.15.21252192;

<https://doi.org/10.1101/2021.04.15.21252192>

17.

18.

Krammer F, Srivastava K, Alshammary H et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *New England Journal of Medicine*. 2021;384(14):1372-1374. doi:10.1056/NEJMc2101667

Krammer F, Srivastava K, the PARIS team, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of

SARS-CoV-2 mRNA vaccine. medRxiv 2021.01.29.21250653; doi:

<https://doi.org/10.1101/2021.01.29.21250653>

19. Ranjan A, Singh PK, Pandey S, Singh CM, Ayub A. Socio-economic inequality in national incidence and mortality rates of COVID-19 in India: An Ecological Study. *Indian J*

*Community Health*. 2020 Dec. 31;32(4):665-76. Available from:

<https://www.iapsmupuk.org/journal/index.php/IJCH/article/view/1965>

20.

Stout RL, Rigatti SJ. Seroprevalence of SARS-CoV-2 Antibodies in the US Adult Asymptomatic Population as of September 30, 2020. *JAMA Netw Open*.

2021;4(3):e211552.

doi:10.1001/jamanetworkopen.2021.1552

21. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in

the US as of September 2020. *JAMA Intern Med*. 2021;181(4):450-460.

doi:10.1001/jamainternmed.2020.7976

22. BBC News. Covid-19 in the UK: How many coronavirus cases are there in my area?

Available at <https://www.bbc.com/news/uk-51768274>



23. Cai R, Novosad P, Tandel V, Asher S, Malani A. Representative Estimates of COVID-19 Infection Fatality Rates from Three Locations in India. medRxiv 2021.01.05.21249264; doi: <https://doi.org/10.1101/2021.01.05.21249264>
- 24.
- 25.
- O'Driscoll M, Ribeiro Dos Santos G, Wang L. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021;590:140-145. <https://doi.org/10.1038/s41586-020-2918-0>
- Levin AT, Hanage WP, Owusu-Boaitey N. et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol 2020;35:1123-1138. <https://doi.org/10.1007/s10654-02000698-1>
- 26.
- Ioannidis  
JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bulletin of the World Health Organization. Article ID: BLT.20.265892
27. ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021. Available at <https://www.health.gov.au/news/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021>
- 28.
- Mao F. Covid vaccine: Why are Australians cancelling AstraZeneca jabs? BBC News, Sydney. 22 June. Available at <https://www.bbc.com/news/world-australia-57549796>
- 29.
- adults. Available at <https://www.canada.ca/en/public-health/news/2021/03/use-ofastrazeneca-covid-19-vaccine.html>
- 30.
- NY Times. Italy halts the use of AstraZeneca's vaccine in those under 60, and other news from around the world. Available at <https://www.nytimes.com/2021/06/11/world/italyastrazeneca-covid-vaccine.html>
- 31.
- Reuters. Don't give Oxford/AstraZeneca vaccine to under-30s: U.K. London, April 07, 2021. Available at <https://www.thehindu.com/news/international/dont-giveoxfordastrazeneca-vaccine-to-under-30s-uk/article34266521.ece>
- Public Health Agency of Canada. Use of AstraZeneca COVID-19 vaccine in younger

# A “SHOT” HEARD AROUND THE WORLD



## INTRODUCTION

“A Shot Heard Around the World,” is a compilation of almost 500 references with citations predominately coming from original sources, scientific journals, medical journals, peer reviewed studies, lawsuit filings, original letters, and includes direct links to the CDC, FDA, clinical trials, and manufacturers’ own reports. In some categories, experts are warning there may be devastating problems with the mass inoculation policies. Because children are likely to be the next group authorized under the EUA, this stands as a warning to parents to be informed in your decision. It is extremely concerning for children to be next on the list in mass inoculation. For all medical decisions, informed consent is critical.

Let this compilation of hundreds of links, sources, and references, serve as a summary and launching pad for everyone’s own thorough investigation and research into the covid injections. Regardless, if someone has gotten one shot, two, or none, this information matters for all. In a time where information is being deleted, censored, banned, canceled, and withheld, many do not know where to find information to answer their questions. This summary is an essential resource. This can be shared with elected officials, school officials, employers, and others.

As an organization who watches over issues affecting children, we are greatly concerned.

The heart of this project is driven by the sole purpose to share important, even critical information with family, friends, and loved ones. Many of them do not know. The goal is to provide original source information from sources those searching, would see as credible and have a resource all in one place. The ultimate goal is not to tell any one person what to think, but instead allow them to think for themselves.

A “SHOT” heard around the world is symbolic for a historic global moment. A careful evaluation may give credence to the thousands of experts who have been censored, removed from online, targeted with removal of their licenses, as they lay it all on the line to get this information to the public. May we hear the “SHOT heard around the word” before our children are unnecessarily harmed.

**\*\*\*Medical disclaimer:** *This pdf, information, resource list, and website information was created for informational purposes only and has no ties to any drug company or physician. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. In addition, no one involved in this website has financial ties to any of the suggested therapies. We are merely advocates of informed consent, open dialogue on all sides of an issue, and fight medical censorship.\*\*\**





<b>LIPID MODEL RISKS</b>	<b>25</b>
<b>PEG ANAPHYLACTIC REACTIONS</b>	<b>25</b>
<b>ANTI-PEG ANTIBODIES</b>	<b>25</b>
<b>IMMUNE ESCAPE, VIRAL VARIANTS</b>	<b>26</b>
<b>VACCINE RESISTANT VIRUS</b>	<b>27</b>
<b>LOSS OF INNATE IMMUNE SYSTEM</b>	<b>28</b>
<b>WARNING FROM EXPERTS AROUND THE GLOBE</b>	<b>29</b>
<b>FULLY VACCINATED BREAK OUTS</b>	<b>32</b>
<b>PREVIOUS CRIMINAL HISTORY AND BEHAVIOR</b>	<b>33</b>
<b>40 BILLION IN PROFITS</b>	<b>35</b>
<b>NOTEWORTHY LEGAL CASES</b>	<b>36</b>
<b>REPORT SUBMITTED TO ISRAEL ATTORNEY GENERAL</b>	<b>37</b>
<b>IVERMECTIN TREATMENT TESTIMONIES GIVEN TO HOMELAND SECURITY</b>	<b>38</b>
<b>ADDENDUM 1: DANGER INGREDIENT SM-102, MODERNA PATENT, SPIKE PROTEIN INJURY, PRION'S DISEASES, AND DARPA (DEPARTMENT OF DEFENSE PROGRAM FOCUSED ON BIOTECH</b>	<b>40</b>
<b>CONCLUSION</b>	<b>51</b>
<b>ADDITIONAL RESOURCE LINKS</b>	<b>52</b>

## **OPERATING UNDER EMERGENCY USE AUTHORIZATION**

Currently, no covid shots are approved or licensed, including Moderna, Pfizer, Johnson and Johnson, AstraZeneca, and 70+ others. Current ones in use are under EUA: Emergency Use Authorization and have specific conditions to adhere to under EUA.

**Moderna:** On December 18, 2020, the Moderna biological product was issued (EUA) status by the FDA. This is the first product they have ever brought to market. (the FD&C Act or the Act) (21 U.S.C. 360bbb-3). <https://www.fda.gov/media/144636/download> Page 1 <https://www.modernatx.com/covid19vaccine-eua/recipients/>

**Pfizer:** On December 11, 2020, FDA issued an EUA for the unapproved **biological** product, Pfizer-BioNTech COVID-19 Vaccine, for active immunization against COVID-19 in individuals 16 years of age and older. (Pfizer fact sheet)  
<https://www.fda.gov/media/144412/download>  
<https://www.fda.gov/media/144413/download> Page 1  
<https://www.fda.gov/media/144413/download?fbclid=IwAR00a48tUcKooxjGKeTk7ySQjeryewJEZAVvBLv-3RYIlnTLQFY5WtQ>

**Johnson and Johnson:** Although J&J has never brought a vaccine to market before, on February 27, 2021, the FDA issued an Emergency Use Authorization for use of Johnson and Johnson single dose vaccine.  
<https://www.fda.gov/media/146303/download>  
<https://www.fda.gov/media/146304/download>  
<https://www.fda.gov/media/146305/download>

## **FULL LICENSURE EXPECTED IN 2022**

Currently, under EUA (Emergency Use Authorization), even if the FDA rushes approval the soonest the Moderna and Pfizer/BioNTech experimental vaccines could be considered by FDA for full licensure (in adults only) is when the trials are expected to conclude, on October 27, 2022 and January 31, 2023, respectively. Neither Pfizer/BioNTech nor Moderna have completely disclosed everything in their vaccines, nor is full disclosure required by the FDA. [22] See e.g., *Lorillard Tobacco Co. v. Reilly*, 533 U.S. 525, 570-71 (2001)

## **PREVIOUS APPROVAL PROBLEMS**

Previously from Moderna, "No mRNA drug has been approved in this new potential category of medicines, and **may never be approved** as a result of efforts by others or us. mRNA drug development has substantial clinical development and regulatory risks due to the **novel** and **unprecedented nature of this new category of medicines.**" <https://www.statnews.com/2017/01/10/moderna-trouble-mrna/>

“As a potential new category of medicines, no mRNA medicines have been approved to date by the FDA or other regulators. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of mRNA medicine, or other products that are perceived to be similar to mRNA medicines, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our large pipeline of development candidates and investigational medicines could result in a greater quantity of reportable adverse events...”

[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473\\_6](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473_6)

## **BIOLOGICS APPLICATION REQUIRED**

Currently, Pfizer, Moderna, J&J are under EUA. They are not FDA approved, nor licensed. J&J was just paused in the US due to serious blood clotting reactions, but then reinstated after short consideration. They are required to apply for a biologic application for full approval. **“Some of our investigational medicines are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that our investigational medicines will be reviewed within its Center for Biologics Evaluation and Research, or CBER.”**

<https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber>

<https://www.foxnews.com/health/pfizer-request-full-approval-coronavirus-vaccine-first-half-2021-fda>

[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473\\_6](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473_6)  
(Pg.26-27)

## **EUA ONSITE VISITS NOT REQUIRED, ONLY 2 MONTHS OF DATA REQUIRED**

FDA does NOT have to do an onsite visit to the vaccine manufacturing facility before approval of the EUA. Also, it states that only 4 months of EUA may be required before full approval is given. Before emergency approval, FDA required only two month's of safety data.

<https://www.foxnews.com/health/pfizer-request-full-approval-coronavirus-vaccine-first-half-2021-fda>

## **SAFETY DATA ANALYZED AFTER 100 MILLION DOSES- MAY NOT BE IN PLACE UNTIL AFTER LICENSURE**

Currently, a passive reporting system through the CDC called VAERS is in place to monitor adverse events. There are indications the system is overwhelmed with injury reports, backlogged, and not updated. It is not live, reporting and monitoring of adverse reactions. An active monitoring of adverse reactions/events will **NOT be in place until AFTER licensure of products, AFTER approval, and likely after 100 million+ people** have already received the doses. “In interviews, F.D.A. officials acknowledged that a promised monitoring system, known as BEST, is still in its developmental stages. They expect it to start analyzing vaccine safety data sometime *soon* — but likely not until *after* the Biden administration reaches its goal of vaccinating *100 million people*.”

In other words, there is NOT a system in place now to accurately capture the adverse reactions. 22 Side Effects listed in FDA documents. “Following authorization of the vaccine, use in large numbers of individuals may reveal additional, potentially less frequent and/or more serious adverse events not detected in the trial safety population”

[https://www.fda.gov/media/143557/download?fbclid=IwAR1UxM\\_ZwbMfzLFbFCMci\\_DbU0fq-fqy1LJIEwxHpGkLTqN8kz1AaGx-h08](https://www.fda.gov/media/143557/download?fbclid=IwAR1UxM_ZwbMfzLFbFCMci_DbU0fq-fqy1LJIEwxHpGkLTqN8kz1AaGx-h08) (p. 8, 9)

<https://www.openvaers.com/covid-data>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>

<https://www.nytimes.com/2021/02/12/health/covid-vaccine-how-safe.html>

## **INJURY STORIES HERE**

Evidence of Backlogging on reporting injuries to VAERS

US VAERS	5/21	262,521	(likely higher due to VAERS ID numbers skyrocketing)
UK Yellow Card	5/12	869,764	(suspected reactions)
Sweden	4/15	22,000	
Israel	3/21	See report	

\*Note most people, including health care practitioners do not know about VAERS in the US. See note on Harvard evaluation of VAERS passive reporting system.

<https://drive.google.com/file/d/1uS4krGJX-7sa8fuRIH7mhod-Xa5ZBsXU/view>

<http://covidvaccinevictims.com/>



<https://www.openvaers.com/covid-data>  
<https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>  
<https://raysahelian.com/covidvaccinesideeffects.html>

### **“EXPECTED HIGH VOLUME OF COVID-19 VACCINE ADVERSE DRUG REACTION”**

UK-The MHRA contracted out an (AI) software tool to process the “expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs).” 300,000 + Yellow Card Reported Injuries. (Pfizer, Moderna, AstraZeneca) **UK yellow cards reporting hundreds of thousand injuries below.**

<https://ted.europa.eu/udl?uri=TED:NOTICE:506291-2020:TEXT:EN:HTML&src=0>  
<https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>

### **EVIDENCE OF BACKLOGGING ON REPORTING INJURIES TO VAERS**

Previous capacity of VAERS reporting system handled a few reported deaths a week and a few thousand a month. Currently, VAERS ID (unique identification numbers) have skyrocketed from December to now. Possibility of Hundreds of Thousand Adverse reactions in the US. Indicating 200,000 more injuries. GDIIT posted positions to hire additional staff and professionals to report and code VAERS injury reporting. On March 8, CDC gave GD a budget supplement of \$16 million; GD is now hiring more “service representatives” to take reports and medical coders to review them... (Search job posting General Dynamics, which manages VAERS)

<https://twitter.com/alexberenson/status/1376280404513161227?s=21>

### **GOALS OF MANUFACTURERS TO GIVE THE MRNA VAX TO 6 MONTH OLD BABIES**

Beginning trials on 6month-12 year old’s now. <https://www.statnews.com/2021/03/25/pfizer-and-biotech-to-begin-testing-covid-19-vaccine-in-children/>

### **SEE REAL TIME, LIVE ADVERSE EVENTS HAPPENING HERE:**

(In the social media era, Put the link to injuries, real time, social media) **(100+ PAGES of live injury stories have been removed twice from internet access.)**

<http://covidvaccinevictims.com/>  
[https://drive.google.com/file/d/1YK0JR\\_lFy88Zu3rcC3L5NvL\\_Xr3ib6zY/view](https://drive.google.com/file/d/1YK0JR_lFy88Zu3rcC3L5NvL_Xr3ib6zY/view) (Removed from Online)  
<https://www.openvaers.com/covid-data>

### **UNDERREPORTING INJURIES**

VAERS Underreporting. Disputes 1 in a Million claims. Recent JAMA reports injuries 50-120 Times more than VAERS and CDC reporting; 2.47/per 10,000 anaphylaxis reaction. Long discussed, but ignored, we need to reform the reporting system as it may hinder identifying safety issues with the new vaccines.

Documented insufficient system post surveillance, 30+decades of underreporting issues (See Lazarus Harvard Report pg. 6), VAERS system inefficacies; public officials continue to promote the inaccurate statement that “injuries are rare.” Red flags are emerging even without a real time reporting system in place.

<https://jamanetwork.com/journals/jama/fullarticle/2777417>  
<https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf>  
<https://www.icandecide.org/wp-content/uploads/2020/12/Lazarus-report.pdf>

### **PHARMACO-VIGILANCE TRACKING SYSTEM**

Where is the data? The Department of Defense of the federal government has contracted with tech giants, Google and Oracle to track vaccinated persons. In the document entitled “From the Factory to the Frontlines,” the Department of Health and Human Services (HHS) and the Department of Defense (DOD) stated that, because Warp Speed vaccine candidates use new unlicensed technology, “The key objective... is to determine each vaccine’s performance in real-life scenarios, to study efficacy, and to discover any

infrequent and rare side effects not identified in clinical trials... Robust analytical tools will be used to leverage large amounts of data and the benefits of using such data across the value chain, including regulatory obligations." Where are the real-life studies and reporting? All we have seen is VAERS backlogged reporting system.

<https://www.thelastamericanvagabond.com/google-oracle-monitor-americans-who-get-warp-speeds-COVID-19-vaccine-for-two-years/>

## **INVESTIGATION OF ELDERLY DEATHS**

### **Blood clots aren't the only problem. Countries investigating elderly deaths after inoculation.**

Countries around the world and different states are investigating and pausing the administration of the COVID vaccine, particularly to the elderly. Quick snapshot-

Norway (investigating 33+ deaths in elderly after getting vaccine)

Germany (investigating deaths after the vaccine)

China (at one point completely paused the vaccine for elderly)

UK (for a while paused on second dose after so many anaphylactic reactions)

Israel (see data on injuries)

Australia (health minister considering pause)

CA (about a month ago said there is a "hot batch" and are pausing 330,000 vials)

[https://www.theepochtimes.com/deaths-of-elderly-who-recovered-from-covid-19-but-died-after-vaccine-raise-questions\\_3692259.html?utm\\_source=newsnoe&utm\\_medium=email&utm\\_campaign=breaking-2021-02-10-4](https://www.theepochtimes.com/deaths-of-elderly-who-recovered-from-covid-19-but-died-after-vaccine-raise-questions_3692259.html?utm_source=newsnoe&utm_medium=email&utm_campaign=breaking-2021-02-10-4)

## **PRESCREENING REQUIREMENT**

Patients should be screened prior to receipt of each vaccine dose, and those with a contraindication should not receive the shot. A [COVID-19 prevaccination questionnaire pdf icon](#)[6 pages] is available to assist with screening. CDC <https://www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-screening-form.pdf> <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html>

## **ALL VACCINES USED IN ISRAEL ARE FROM PFIZER: ISRAEL INJURY ANYALYSIS**

Dr Hervé Seligmann works at the Emerging Infectious and Tropical Diseases Research Unit, Faculty of Medicine, Aix-Marseille University, Marseille, France. He is of Israeli-Luxembourg nationality. He has a B. Sc. In Biology from the Hebrew University of Jerusalem and has written over 100 scientific publications. Dr. Hervé Seligmann and engineer Haim Yativ through their research and data analysis claim that Pfizer's experimental shot causes "mortality hundreds of times greater in young people compared to mortality from coronavirus without the vaccine, and dozens of times more in the elderly, when the documented mortality from coronavirus is in the vicinity of the vaccine dose, thus adding greater mortality from heart attack, stroke, etc."

"Our analyses indicate orders of **magnitude increases in deaths rates** during the 5-week long vaccination process, as compared to the unvaccinated and those after completing the vaccination process."

"The data in the table, rather than indicating the vaccine efficacy, indicate the vaccine's adverse effects," the authors conclude. There is a mismatch between the data published by the authorities and the reality on the ground. Compared to other years, mortality is 40 times higher." An independent legal body that calls itself the Civilian Probe (CP)\* published its finding regarding the catastrophic impact of the Pfizer vaccine on the nation.

<https://archive.ph/jiIVR>

<https://static1.squarespace.com/static/544680b5e4b0149c3cfddd3b/t/6059e7669fb7f95bb994f934/1616504728303/%D7%9E%D7%9B%D7%AA%D7%91+%D7%AA%D7%95%D7%A4%D7%A2%D7%95%D7%AA+%D7%94%D7%9C%D7%95%D7%95%D7%90%D7%99+%D7%A0%D7%95%D7%A1%D7%97+%D7%A1%D7%95%D7%A4%D7%99+%D7%9C%D7%94%D7%A4%D7%A6%D7%94+-+22-3-21.pdf>

## **ASTRAZENECA SAFETY SIGNALS IGNORED, NOT INCLUDED IN ADVERSE REACTION REPORTING**

The AstraZeneca brand primarily being used in Europe and other countries was put on HOLD by up to 24 countries. WHY? In spite of the PR team for the manufacturing company saying it was safe and effective, the results showed a different story. On March 16, 2021, Luxembourg, Estonia, Lithuania, were 3 more countries added to the halt list. Other countries include Sweden, Norway, Denmark, Finland, and France (who limit shots to 55 year old's and above.) Safety concerns over AstraZeneca creating blood clots notable in women 25 and under. The UK has not paused it but has stated if you have a headache continually for four days post vaccination, they tell you to go get help. AstraZeneca is going to Africa and 92 other third world countries by the end of 2021. Under the umbrella of COVA X, who partners with WHO, GAVI, at least 29 million doses are in Italy waiting for shipment. Despite safety warnings, the United States is gearing up to authorize EUA status for the US. Even though officials have begun calling out AstraZeneca's misleading effective rate because they are using OLD data.

## **LIABILITY REMOVED FROM COVID MANUFACTURERS**

The public has become increasingly aware that manufacturers of vaccines have not been liable for their products since 1986 and that our very own tax dollars pay for our own injuries. On February 4, 2020, according to the Centers for Disease Control (CDC) website, there were only 11 active CV cases , Yet the U.S. quietly pushed through Federal regulations giving coronavirus vaccine makers full immunity from liability. Although, these are new, investigational, and long-term consequences unknown, ALL manufacturers have indemnity. They are not liable for any harm, adverse reactions, death, etc. short-term or long-term. <https://www.cnn.com/2020/12/16/covid-vaccine-side-effects-compensation-lawsuit.html>

## **NO LIABILITY DUE TO THE PREP ACT**

The PREP Act allows covid vaccine manufacturers to create, develop, and market vaccines with zero liability. Manufacturers have been allowed to bypass animal studies and go directly to human trials [REDACTED] <https://www.phe.gov/Preparedness/legal/prepact/Pages/default.aspx>

## **EXPIRATION END OF 2024, BEYOND LIABILITY**

This was put into the Federal Register in March of 2020 and “does not expire till the end of 2024. The consequences surpass liability. It also means that anything that is developed over the next four years that has to do with a biological agent, such as a vaccine or drug or biotechnology, is protected from liability under the umbrella of COVID-19.”

[Federal Register :: Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19](#)

## **BEFORE LIABILITY REMOVED LOSSES FOR MANUFACTURES**

“We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.” “Risks related to the research, development, regulatory review, and approval of our existing and future pipeline.” “Preclinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to the clinic” “Clinical testing is expensive and complex and can take many years to complete, and its outcome is inherently uncertain.” pg. 24 (Moderna 2018 Report) [REDACTED]

[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473\\_6](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473_6)

[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473\\_6](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473_6)

### **COUNTERMEASURES INJURY COMPENSATION**

The Countermeasures Injury Compensation Program (CICP) is a federal program [taxpayer funded] that has been created to help pay for related costs of medical care and other specific expenses to compensate people injured after use of certain medical countermeasures. Medical countermeasures are specific vaccines, medications, devices, or other items used to prevent, diagnose, or treat the public during a public health emergency or a security threat.

<https://www.fda.gov/media/144434/download>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>:

### **ANIMAL STUDIES BYPASSED**

These inoculations bypassed animal studies. Previously, for decades, they were not able to pass the animal studies due to pathogenic priming, cytokine storms, enhanced antibody dependence, and the inability to survive (in one ferret study, all of the ferrets died in the challenge phase) after vaccination when exposed to the wild virus (because of an altered immune system response.) Ferrets pg 17-18. Note the challenge results in the previous animal trials, including accelerated autoimmune issues.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115540/> (ferrets)

[https://www.jstage.jst.go.jp/article/jvms/advpub/0/advpub\\_18-0702/\\_pdf](https://www.jstage.jst.go.jp/article/jvms/advpub/0/advpub_18-0702/_pdf)

<https://jvi.asm.org/content/jvi/87/12/6551.full.pdf>

<https://pubs.acs.org/doi/full/10.1021/acsinfecdis.6b00006>

<https://www.sciencedirect.com/science/article/pii/S1090023314001786>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115629/>

<https://jvi.asm.org/content/jvi/85/23/12201.full.pdf>

### **FAILURE IN PREVIOUS ANIMAL STUDIES**

Previously, coronavirus trials failed in animals. When animal trials were skipped in 1960, infants post vaccination got sicker when exposed to wild virus, including **80% of the vaccinated infants requiring hospitalization**. Review of previous trial outcomes. Caution due to disease enhancement, sicker, death, and lung diseases post vaccination in Ferrets, mice, civets, and other animals.

“the insufficient ability of our translational models to reduce risk or predict outcomes in humans, particularly given that each component of our investigational medicines and development candidates, may have a dependent or independent effect on safety, tolerability, and efficacy, which may, among other things, be species-dependent”

<https://www.nature.com/articles/s41579-020-00462-y#Sec11>

<https://www.frontiersin.org/articles/10.3389/fmicb.2018.02991/full>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC525089/>

<https://www.nature.com/news/2005/050110/full/050110-3.html#ref-CR1>

[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473\\_6](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473_6)

<https://www.pnas.org/content/102/3/797>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/>

<https://www.tandfonline.com/doi/full/10.1080/21645515.2016.1177688?scroll=top&needAccess=true&>

<https://science.sciencemag.org/content/303/5660/944>

<https://www.reuters.com/article/us-rsv-shot/research-shows-why-1960s-rsv-shot-sickened-children-idUSTRE4BM4SH20081223>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335060/>

<https://pubmed.ncbi.nlm.nih.gov/12810865/> (ADE mice)

<https://www.ncbi.nlm.nih.gov/pubmed/28817732> (White rabbits)

<https://pubmed.ncbi.nlm.nih.gov/19122397/> (feline)



<https://pubmed.ncbi.nlm.nih.gov/2154621/> (feline)  
<https://pubmed.ncbi.nlm.nih.gov/6754243/> (feline in Dengue)  
<https://pubmed.ncbi.nlm.nih.gov/17049691/> (hamsters)  
<https://www.ncbi.nlm.nih.gov/pubmed/21937658> (Mice, increase lung inflammation on challenge)  
<https://pubmed.ncbi.nlm.nih.gov/29029938/> (vaccine enhanced disease)

Kusters IC, Matthews J, Saluzzo JF. Manufacturing vaccines for an emerging viral infection – Specific issues associated with the development of a prototype SARS vaccine. In: Barrett ADT, Stanberry LR, editors. Vaccines for biodefense and emerging and neglected diseases. City: Elsevier; 2009. pp. 147–156



### **NO INDEPENDENTLY PUBLISHED ANIMAL STUDIES FROM MANUFACTURERS**

“Most other previous vaccines have performed and published results on animal studies prior to being giving to humans. This is critical because deadly effects are often not seen until this step. Vaccines that have been given to humans prior to animal trials have frequently resulted in deaths that caused the governments to yank the vaccines. Most scientists believe that human death is inevitable if there are no prior peer-reviewed animal studies. We learn about these studies only from the company itself.”

<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-preclinical-studies-mrna>

[https://assets.website-files.com/606d3a50c62e44338008303d/6076e4fd8bde421370729e47\\_Vaccine-PP.pdf](https://assets.website-files.com/606d3a50c62e44338008303d/6076e4fd8bde421370729e47_Vaccine-PP.pdf)  
(p.14)

### **PROBLEM WITH DENGUE VIRUS, EBOLA VIRUS, HIV, RSV, AND THE FAMILY OF CORONAVIRUSES**

Virus amplification or enhancement of virus infection is a common problem in the coronavirus family. In some viruses, if a person harbors a non-neutralizing antibody to the virus, a subsequent infection by the virus can cause that person to elicit a more severe reaction to the virus due to the presence of the non-neutralizing antibody. This is not true for all viruses, only particular ones. This is called Antibody Dependent Enhancement (ADE), and is a common problem with Dengue Virus, Ebola Virus, HIV, RSV, and the family of coronaviruses. The problem of ADE is a major reason why many previous vaccine trials for other coronaviruses failed. Major safety concerns were observed in animal models. If ADE occurs in an individual, their response to the virus can be worse than their response if they had never developed an antibody in the first place.

“This can cause a hyperinflammatory response, a cytokine storm, and a general dysregulation of the immune system that allows the virus to cause more damage to our lungs and other organs of our body. In addition, new cell types throughout our body are now susceptible to viral infection due to the additional viral entry pathway. There are many studies that demonstrate that ADE is a persistent problem with coronaviruses in general, and in particular, with SARS-related viruses.”

<https://pubmed.ncbi.nlm.nih.gov/24182427/>

Antibody-dependent enhancement of virus infection and disease. *Viral immunology*, 16(1), 69-86.

<https://www.liebertpub.com/doi/abs/10.1089/088282403763635465>

"Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications." Reviews in medical virology 13, no. 6 (2003): 387-398.

<https://onlinelibrary.wiley.com/doi/abs/10.1002/rmv.405>

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.

Biochemical and biophysical research communications 451, no. 2 (2014): 208-214.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092860/>

[https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=1075&context=vmpm\\_pubs](https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=1075&context=vmpm_pubs) (Ebola)

<https://pubmed.ncbi.nlm.nih.gov/27339099/> (zika)

<https://technology.inquirer.net/69907/pharma-firm-issues-caution-anti-dengue-vaccine-sanofi-dengvaxia-vaccine-health-dengue> (Pharma firm issues caution on use of anti-dengue)

<https://pubmed.ncbi.nlm.nih.gov/30410732/>

<https://www.rappler.com/nation/child-vaccination-rate-philippines-as-of-september-2018> (Dengue distrust in free vaccines post scare of Dengue outcome.)

<https://www.telegraph.co.uk/news/2018/02/05/philippines-immunisation-rates-plummet-amid-dengue-vaccination/> (Philippines)



### **ADE (ANTIBODY ENHANCEMENT) MORE SEVERE DISEASE**

ADE(Antibody enhancement is a very serious paradox. This could mean that people who are vaccinated might, paradoxically, suffer more severe disease when exposed to the wild virus than if they hadn't been vaccinated. Direct from manufactures. "risk of vaccine-enhanced disease over time, potentially associated with waning immunity, remains unknown and needs to be evaluated further." The accurate incidence of ADE may never be known, as many cases will likely just be falsely described as a "new strain," "new variant," or "more severe strain" and new outbreaks attributed to those not vaccinated.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311339/>

<https://academic.oup.com/cid/article-abstract/19/3/500/459343>

<https://academic.oup.com/cid/article-abstract/19/3/500/459343>

### **ENHANCED IMMUNE RESPONSE (PATHOGENIC PRIMING, ALSO CALLED CYTOKINE STORM)**

Outspoken vaccine advocate, Dr Peter Hotez previously warned of potentially fatal consequences from skipping animal studies. "If there is immune enhancement in animals, that's a show-stopper". During the past decade, previous Coronavirus vaccines DID NOT pass the animal trials. Prior to the Emergency Use Authorization, Moderna was unable to bring to market through clinical trials an approved CV vaccine, despite billions of dollars invested into it. The ferrets tested in previous coronavirus animal trials all DIED when placed in a "challenge" round where they were exposed to the wild virus, after being vaccinated. ADE is

unique because it is a delayed reaction. "It has mainly been observed with positive-strand RNA viruses." Initially everything seems fine with the person having a great immune response but then becomes deadly when the person is exposed to the virus in the wild. The paradox is the inoculation is what AMPLIFIES the infection, possibly within months or years. This is why it must be ruled out in animal trials. Unfortunately, ADE is well known to be a risk for coronavirus-mediated infections, as well as dengue.

<https://www.liebertpub.com/doi/abs/10.1089/088282403763635465>

<https://onlinelibrary.wiley.com/doi/abs/10.1002/rmv.405>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092860/>

<https://bmcproc.biomedcentral.com/track/pdf/10.1186/1753-6561-5-S1-P62?site=http://bmcproc.biomedcentral.com>

<https://europepmc.org/article/PMC/3837288>

<https://www.sciencedirect.com/science/article/pii/S1074761319303334>

<https://muse.jhu.edu/article/459161/pdf>

<https://jvi.asm.org/content/jvi/77/13/7539.full.pdf>

Takada, Ayato, Shinji Watanabe, Katsunori Okazaki, Hiroshi Kida, and Yoshihiro Kawaoka. "Infectivity-enhancing antibodies to Ebola virus glycoprotein." *Journal of virology* 75, no. 5 (2001): 2324-2330.

[https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=1075&context=vmpm\\_pubs](https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=1075&context=vmpm_pubs)

*Journal of General Virology* 97, no. 7 (2016): 1489-1499.

[https://www.microbiologyresearch.org/docserver/fulltext/jgv/97/7/1489\\_vir000468.pdf?expires=1591728632&id=id&accname=guest&checksum=5007EAF2D1FCFBE1C2DD06ED7D1C8FFE](https://www.microbiologyresearch.org/docserver/fulltext/jgv/97/7/1489_vir000468.pdf?expires=1591728632&id=id&accname=guest&checksum=5007EAF2D1FCFBE1C2DD06ED7D1C8FFE)

## **BLOOD CLOTS**

J & J was just paused in the US (4/13/2021), resumed (4/23/2021) for this very reason. The UK and 23+ other countries are seeing strong indicators of blood clotting (particularly in younger women). So much so, almost 24 countries at one point have paused the administration of the AstraZeneca vaccine. (while simultaneously still authorizing it to be sent to 3<sup>rd</sup> world countries!)

[https://www.researchgate.net/profile/Andreas\\_Hocke/publication/6259977\\_Extracellular\\_RNA\\_Mediates\\_Endothelial\\_Cell\\_Permeability\\_via\\_Vascular\\_Endothelial\\_Growth\\_Factor/links/00463523c326a4024e000000/Extracellular-RNA-Mediates-Endothelial-Cell-Permeability-via-Vascular-Endothelial-Growth-Factor.pdf](https://www.researchgate.net/profile/Andreas_Hocke/publication/6259977_Extracellular_RNA_Mediates_Endothelial_Cell_Permeability_via_Vascular_Endothelial_Growth_Factor/links/00463523c326a4024e000000/Extracellular-RNA-Mediates-Endothelial-Cell-Permeability-via-Vascular-Endothelial-Growth-Factor.pdf)

"Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation."

<https://www.pnas.org/content/pnas/104/15/6388.full.pdf>

## **HEART INFLAMMATION, HEADACHES, NEUROLOGICAL SYMPTOMS**

A recent leaked report from the Israeli Health Ministry is investigating cases of "Myocarditis", heart inflammation in predominately men following their second dose of the Pfizer shot. In addition, a recent peer-reviewed journal reported other side effects/symptoms after receiving the shot.

<https://pubmed.ncbi.nlm.nih.gov/33053430/>

<https://www.health.com/condition/infectious-diseases/coronavirus/pfizer-vaccine-heart-inflammation-myocarditis>

## **POSSIBLE INCREASE ON AUTOIMMUNE DISEASES & CONTAMINANTS IN VACCINES**

### **AUTOIMMUNITY LINK, CONTAMINANTS IN VACCINES**

Dr. Vanessa Schmidt-Kruger, a Cell Biologist with over 20 years' experience in molecular medicine working at the Max Delbrück Center for Molecular Medicine gave a report on contaminants in the vaccines (which is in the EMA's Open Assessment Report), problems in the dosage of clinical trials, risks of LPNS, and long-term consequences of autoimmune disease.



“The BioNTech vaccine that is currently already being used is not highly purified, it contains contaminants of certain components... And finally if we have time I would like to talk about the long-term consequences relating to immune disease, that is an aspect that has not yet been discussed in public at all.”

[http://enformtk.u-aizu.ac.jp/howard/gcep\\_dr\\_vanessa\\_schmidt\\_krueger/](http://enformtk.u-aizu.ac.jp/howard/gcep_dr_vanessa_schmidt_krueger/)  
<https://www.mdc-berlin.de/person/dr-vanessa-schmidt-kruger>

Potential Autoimmunity increase. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.”

Clin Immunol. 2021 Mar; 224: 108665. Published online 2021 Jan 8. doi: 10.1016/j.clim.2021.108665

PMCID: PMC7833091, PMID: 33429060

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833091/>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246018/>

### **TOXICITY OVERLOAD, INSTABILITY IN THE BODY**

Dr Suhab Siddiqi, Moderna’s Ex-Director of Chemistry, told CNN, “I would not let the [vaccine] be injected in my body. I would demand: Where is the toxicity data?” Potential toxicity is a problem.

BNT 162 B2 study had 78% CLASS 3 adverse events. It was an anti-cancer study that all studies were quoting as their "proof" that it was safe, despite that terrible result- of liver toxicity. The conclusion of the study was "generally safe," in spite of the study including terrible statistics as well as being a poorly powered study. In a cancer immunotherapy study, before covid, lots of toxicities are noted-especially when synthetic nucleosides are used. It’s particularly alarming that no blood is being drawn after a few months into the study. How will they detect immunological dyscrasias, or liver toxicity if no blood is drawn for abnormalities? They are testing antibody levels, but no longer a cbc, cmp or crp. after 60-80 days. This is likely a problem with a shot that already has precedence for liver toxicity.

### **HIV VECTOR INCREASE IN AIDS SUSCEPTIBILITY IN MEN**

Liability free manufacturers claim DNA of a viral vector vaccine is carried within a harmless adenovirus. Veteran researchers raise a warning flag that it may not be “harmless.” This is very concerning for men in particular. 4 Veteran Researchers are raising a warning flag about COVID vaccines containing the Ad5 vector carrier and the correlation leaving people more vulnerable to the AIDS virus. “Additional exploratory studies suggest that Ad5 immune complexes activate the dendritic cell–T cell axis, which might enhance HIV-1 replication in CD4 T cells. Additionally, Ad5-specific CD4 T cells could have an increased susceptibility to HIV infection.” These are important red flags and indicators to watch for.

**Lancet link:** [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32156-](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32156-5/fulltext?fbclid=IwAR3NknTJTMjgrLHqvK96hJqsi56nzH37QrzQusJddmeDGetiSFpE0ssiEU)

[5/fulltext?fbclid=IwAR3NknTJTMjgrLHqvK96hJqsi56nzH37QrzQusJddmeDGetiSFpE0ssiEU](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32156-5/fulltext?fbclid=IwAR3NknTJTMjgrLHqvK96hJqsi56nzH37QrzQusJddmeDGetiSFpE0ssiEU)

**Another summary:** <https://www.sciencemag.org/.../could-certain-covid-19...>

<https://www.cnn.com/2020/12/10/australia/australia-vaccine-hiv-intl-hnk/index.html>

### **SAFETY TESTING NOT PROPERLY DONE**

**After decades of failed animal trials, current trials have been conducted without an inert double-blind placebo-controlled environment, insufficient time to observe effects on the human subjects, numerous unknowns, no long-term studies, lead to serious safety concerns.**

### **SAFETY AND EFFECTIVENESS QUESTIONS AND CONCERNS**

“Vaccine safety requires proper animal trials and peer-reviewed data, neither of which has occurred during operation warp speed. This is especially concerning considering the fatal failure of prior coronavirus vaccine attempts such as SARS-CoV-1, the virus that is 78% identical to SARS-CoV-2 (COVID-19). Prior coronavirus (and other respiratory) vaccines have failed due to the scientific phenomena known as pathogenic priming that makes the vaccine recipient more likely to suffer a sudden fatal outcome due to massive cytokine



storm when exposed to the wild virus. In addition to pathogenic priming there are three other potential safety issues that are being minimized. While we are hopeful that the vaccine is both effective and safe, hope is not science. Because these experimental shots have not been tested in accordance with the usual standards, we have serious concerns about safety.” Moderna and J&J have never brought a vaccine to market before covid. <https://raypeatforum.com/community/threads/implications-for-possible-consequences-of-covid-19-vaccines.38726/>

### **NO SAFETY FOR CHILDREN UNDER 18 YEARS OLD, ELDERLY OVER 85, OR IMMUNOCOMPROMISED**

No data in clinical trials. **“There are currently insufficient data to make conclusions about the safety of the vaccine in subpopulations such as children less than 18 years of age” “subgroups not yet studied in the clinical trial such as pregnant, immunocompromised and very elderly (>85 years of age) persons. ”**

<https://www.fda.gov/media/144434/download>

[https://www.clinicaltrials.gov/ct2/show/study/NCT04665258:](https://www.clinicaltrials.gov/ct2/show/study/NCT04665258)

<https://www.fda.gov/media/144246/download>

<https://www.fda.gov/media/144413/download>

### **SHORT TERM SAFETY DATA WITHOUT A ROBUST MONITORING SYSTEM**

With only limited short term safety data and absolutely no long-term safety studies, the proper length of safety study has not been done to ensure that any of these injections do not cause cancer, seizures, pathogenic priming, heart disease, reverse transcription, immune escape, fertility issues, allergies, and autoimmune diseases, as observed in earlier coronavirus animal studies. Because animal studies were bypassed, millions of humans are now the primary test animal. With only a passive injury reporting system, using a completely new mRNA technology that has never been licensed for human use, since viruses mutate frequently, we have absolutely no long-term knowledge of what to expect from these new injections. Previously rushed Dengue imprudence is noteworthy.

<https://www.biologicalmedicineinstitute.com/post/covid-19-mrna-vaccines>

[https://www.sciencemag.org/news/2019/04/dengue-vaccine-fiasco-leads-criminal-charges-researcher- Philippines](https://www.sciencemag.org/news/2019/04/dengue-vaccine-fiasco-leads-criminal-charges-researcher-Philippines)

### **TWO MONTHS OF IMMUNITY FROM SHOT**

“We only have data to support 2 months.”

CDC notes that "observed outcome of vaccine efficacy at two months does not directly inform vaccine efficacy for any duration longer than two months." In other words, there is no way to know whether the vaccine is effective for any period longer than the time period it has been given to patients. CDC information on Pfizer vaccine: Fauci describes no long term immunity, does not prevent transmission, may lessen symptoms. From the clinical trials “As the interim and final analyses have a limited length of follow-up, it is not possible to assess sustained efficacy over a period longer than 2 months.”

<https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-19/05-COVID-Clark-508.pdf>

<https://www.dailymail.co.uk/news/article-8884031/Dr-Fauci-warns-early-COVID-19-vaccines-prevent-symptoms-not-block-infection.html>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>

<https://www.fda.gov/media/144246/download>

<https://www.fda.gov/media/144413/download>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>

### **UNKNOWN: MUTATIONS, CO-INFECTION, TRANSMISSION, LONG-TERM EFFECT, STOPPING DEATH**

### **UNKNOWN EFFECTIVENESS ON MUTATIONS OR CO-INFECTIONS**

This has not been studied. “Additional evaluations will be needed to assess the effect of the vaccine in preventing asymptomatic infection” **Future vaccine effectiveness if there are mutations/changes in the virus, and/or potential effects of co-infections?** “Continued evaluation of vaccine effectiveness following issuance of an EUA and/or licensure will be critical to address these uncertainties.”

<https://www.fda.gov/media/144434/download>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>:

<https://www.fda.gov/media/144246/download>

<https://www.fda.gov/media/144413/download>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>

### **EFFECT ON TRANSMISSION UNKNOWN**

See statements from Moderna and Pfizer’s own words. NIH..“the studies **aren’t** designed to assess transmission. They don’t ask that question and there’s really no information on this at this point in time.” “Data are limited to assess the effect of the vaccine against transmission of SARS-CoV-2 from individuals who are infected despite vaccination. ...data from clinical trials and from vaccine use post-authorization will be needed to assess the effect of the vaccine in preventing virus shedding and transmission, in particular in individuals with asymptomatic infection.”

<https://www.fda.gov/media/144434/download>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>:

<https://www.fda.gov/media/144246/download>

<https://www.fda.gov/media/144413/download>

<https://www.medscape.com/viewarticle/941388>

### **UNKNOWN EFFECTIVENESS AGAINST LONG-TERM EFFECTS OF COVID-19 DISEASE**

There are only 2 months of data. “COVID-19 disease may have long-term effects on certain organs, and at present it is not possible to assess whether the vaccine will have an impact on specific long-term sequelae of COVID-19 disease in individuals who are infected despite vaccination.”

<https://www.fda.gov/media/144434/download>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>:

<https://www.fda.gov/media/144246/download>

<https://www.fda.gov/media/144413/download>

### **UNKNOWN EFFECTIVENESS IN STOPPING DEATHS FROM COVID-19 DISEASE**

“A larger number of individuals at high risk of COVID-19 and higher attack rates would be needed to confirm efficacy of the vaccine against mortality.” “The protocol had prespecified stopping rules that included monitoring of severe COVID-19 cases, and these stopping criteria were not met.”

<https://www.fda.gov/media/144434/download>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>:

<https://www.fda.gov/media/144246/download>

<https://www.fda.gov/media/144413/download>

### **WARNING: RED FLAGS INNOCULATING PEOPLE WHO ALREADY HAD COVID**

#### **PREVIOUSLY HAVING COVID-CLINICAL TRIALS- NO DATA**

#### **Will the vaccine protect individuals previously infected with SARS-CoV-2? UNKNOWN**

“Regarding the benefit of the mRNA-1273 for individuals with prior infection with SARS-CoV2, participants with a known history of SARSCoV-2 infection **were excluded from the Phase 3 study**...Thus, the study was not designed to assess the benefit in individuals with prior SARS-CoV-2 infection.”

<https://www.fda.gov/media/144434/download>

<https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>

<https://www.fda.gov/media/144246/download>  
<https://www.fda.gov/media/144413/download>

### **WARNING: RED FLAGS INNOCULATING PEOPLE WHO ALREADY HAD COVID:**

The clinical studies *excluded* participants who were previously infected. Dr. Hooman Noorchasm in a letter to Dr. Whelan, FDA's Janet Woodcock warns that Pfizer and Moderna must consider the danger COVID vaccines pose to the recently convalescent or asymptomatic carriers of SARS-CoV-2 — especially the elderly, frail or anyone with significant cardiovascular risk factors. Inoculating patients with occult SARS-CoV-2 infections or lingering viral antigens, is a clear and present potential danger to the health of these patients. In the case of vaccines, previous infected persons with Covid may be more at higher risk for allergic reactions and other adverse events. "Recently, or asymptotically, infected persons are very highly likely to be at risk of an exacerbated and dangerous hyper-inflammatory immune response when indiscriminately vaccinated — several cases of this complication in the recently infected and vaccinated have emerged over the past few weeks across the nation, including the deaths."

<https://noorchasm.medium.com/>

<http://fullmeasure.news/news/cover-story/cdc-investigation>

<https://www.regulations.gov/document/FDA-2020-N-1898-0246>

<https://noorchasm.medium.com/uregnt-fda-communication-catastrophic-blood-clot-risk-absent-medical-necessity-of-covid-19-a6bb35b806df>

<https://noorchasm.medium.com/a-letter-of-urgent-warning-to-the-university-of-notre-dame-president-rev-831f29535973>

### **HEAVIER PERIODS IN WOMEN**

#### **HEAVIER PERIOD POST VAX- WARNING: UNKNOWN IMPACT ON REPRODUCTIVE SYSTEM**

25,000+ Women are now reporting to an Illinois research team, regarding abnormal changes and unusual occurrences in periods, menstruation, unregulated periods, bruising, bleeding, blood clots, 400% increase in miscarriages, etc. for both women receiving the shot and also reactions in women being in close proximity to recently inoculated persons. Possible speculation includes the protein spike is shedding from those who have received it and the implications on fertility and reproductive health are concerning, but unclear.

<https://www.dailymail.co.uk/femail/article-9446907/Some-women-report-heavier-painful-PERIODS-getting-COVID-19-vaccine.html>

[https://madison.com/news/state-and-regional/abnormal-periods-after-covid-19-vaccine-university-of-illinois-professor-researching-reports/article\\_2de33962-9f32-5814-b805-c953758b9d61.html](https://madison.com/news/state-and-regional/abnormal-periods-after-covid-19-vaccine-university-of-illinois-professor-researching-reports/article_2de33962-9f32-5814-b805-c953758b9d61.html)

<https://redcap.healthinstitute.illinois.edu/surveys/index.php?s=LL8TKKC8DP>

<https://twitter.com/KateClancy/status/1364671490772320259>

<https://montanadailygazette.com/2021/04/16/unvaccinated-women-report-miscarriages-after-interactions-with-vaccinated-people/>

### **ABNORMAL PHENOMENON ALARMING WOMEN**

#### **PHENOMENON OF BLEEDING AND CLOTTING**

Phenomenon happening. Thousands of reports are coming in. Uncertain outcomes. It's so new, there is no data in clinical trials, or peer reviewed literature to explain it. Except for SAE (Secondary Adverse Events) reports.

<https://envirowatchrangitikei.wordpress.com/2021/04/25/six-doctors-discuss-the-phenomenon-of-bleeding-and-clotting-in-women-who-have-received-the-cv-injection/>

## INVESTIGATION OF VACCINE (SAE) FROM SKIN OR INHALING BREATH

**Separate from the clinical trial participants, reports into investigations into (SAE) serious adverse events from exposure to a vaccinated person, are kept in a separate study.** “An occupational exposure occurs when a person receives unplanned direct contact with a vaccine test subject, which may or may not lead to the occurrence of an adverse event. These people may include health care providers, family members, and other people who are around the trial participant.”

“A female family member or healthcare provider reports that she is pregnant after having been exposed to the study intervention by inhalation or skin contact.”

“A male family member or healthcare provider who has been exposed to the study intervention by inhalation or skin contact then exposes his female partner prior to or around the time of conception.” (See 8.3.5.1, 8.3.5.3, p. 65-70)

[https://media.tghn.org/medialibrary/2020/11/C4591001\\_Clinical\\_Protocol\\_Nov2020\\_Pfizer\\_BioNTech.pdf](https://media.tghn.org/medialibrary/2020/11/C4591001_Clinical_Protocol_Nov2020_Pfizer_BioNTech.pdf)

## FERTILITY, BREAST FEEDING, PREGNANCY

UK states shot should not be used by pregnant, breast-feeding mother, or children.

**Fertility-** Unknown “Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3)” But alarmingly the guide has only one thing to say about the vaccine’s impact on fertility: they don’t know if it does or doesn’t. “It is unknown whether COVID-19 mRNA Vaccine BNT162b2 has an impact on fertility.”

**Pregnancy-** Unknown impact. “There is limited experience with use of the COVID-19 mRNA Vaccine BNT162b2 in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/fetal development, parturition or post-natal development (see section 5.3).

**Breast-feeding-** Unknown impact. “It is unknown whether the COVID-19 mRNA Vaccine BNT162b2 is excreted in human milk.” “There are currently insufficient data to make conclusions about the safety of the vaccine in subpopulations such as... pregnant and lactating individuals” (MODERNA/PFIZER)

**2 Months-** Avoid pregnancy at least 2 months after shot. Unknown impacts. This means that it could take a relatively long time before a noticeable number of cases of post vaccination infertility could be observed. “women of child-bearing potential” can take part only if they are not pregnant or breastfeeding and are using contraception, it could take “a relatively long time before a noticeable number of cases of post-vaccination infertility could be observed.”

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/973884/Temporary\\_Authorisation\\_HCP\\_Information\\_BNT162\\_8\\_0\\_UK.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/973884/Temporary_Authorisation_HCP_Information_BNT162_8_0_UK.pdf)

<http://virological.org/t/response-to-ncov2019-against-backdrop-of-endogenous-retroviruses/396>[https://2020news.de/wp-content/uploads/2020/12/Wodarg\\_Yeadon\\_EMA\\_Petition\\_Pfizer\\_Trial\\_FINAL\\_01DEC2020\\_EN\\_unsigned\\_with\\_Exhibits.pdf](https://2020news.de/wp-content/uploads/2020/12/Wodarg_Yeadon_EMA_Petition_Pfizer_Trial_FINAL_01DEC2020_EN_unsigned_with_Exhibits.pdf)

**Dr. Stephanie Seneff**, an expert in protein synthesis who is a Ph.D. senior research scientist at MIT. “The potential for blood clotting disorders and the potential for sterilization are only part of the story. There are other potential long-term effects of these vaccines as well, such as autoimmune disease and immune escape, whereby the vaccines administered to immune-compromised people accelerate the mutation rate of the virus so as to render both naturally acquired and vaccine-induced antibodies no longer effective.” “This massive clinical trial on the general population could have devastating and irreversible effects on a huge number of people.”



<https://www.jennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/>

## **CONCERNS REGARDING THE FORMATION OF THE PLACENTA**

Former Vice President of Pfizer's petition called for a halt to Phase 3 clinical trials of Pfizer's mRNA vaccine. Yeadon and Wodart warn that some of the vaccines may prevent the safe development of placentas in pregnant women, resulting in "vaccinated women essentially becoming infertile." In part due to the concern that if a woman's immune system starts reacting against syncytin-1, there is the possibility she could become infertile. Because the spike protein is derived from human endogenous retroviruses (HERV) and is responsible for the development of a placenta in mammals and humans. If the mRNA vaccine triggers your body to produce "antibodies against the SARS-CoV-2 spike protein, and spike proteins in turn contain syncytin-homologous proteins that are essential for various functions in your body, including the *formation of the placenta* in pregnant women." Previously infected covid-19 patients with the wild virus had placental problems. Dr. Jennifer Margulis describes concerns around spike proteins and the fertility issue as well.

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/973884/Temporary\\_Authorisation\\_HCP\\_Information\\_BNT162\\_8\\_0\\_UK.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/973884/Temporary_Authorisation_HCP_Information_BNT162_8_0_UK.pdf)

<http://virological.org/t/response-to-ncov2019-against-backdrop-of-endogenous-retroviruses/396>

[https://web.archive.org/web/20201209042033/https://2020news.de/wpcontent/uploads/2020/12/Wodarg\\_Yeadon\\_EMA\\_Petition\\_Pfizer\\_Trial\\_FINAL\\_01DEC2020\\_EN\\_unsigned\\_with\\_Exhibits.pdf](https://web.archive.org/web/20201209042033/https://2020news.de/wpcontent/uploads/2020/12/Wodarg_Yeadon_EMA_Petition_Pfizer_Trial_FINAL_01DEC2020_EN_unsigned_with_Exhibits.pdf)

<https://jamanetwork.com/journals/jama/fullarticle/2765616>

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30311-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30311-1/fulltext)

<https://www.jennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/>

XI. Several vaccine candidates are expected to induce the formation of humoral antibodies against spike proteins of SARS-CoV-2. Syncytin-1 (see Gallaher, B., "Response to nCoV2019 Against Backdrop of Endogenous Retroviruses" - <http://virological.org/t/response-to-ncov2019-against-backdrop-of-endogenous-retroviruses/396>), which is derived from human endogenous retroviruses (HERV) and is responsible for the development of a placenta in mammals and humans and is therefore an essential prerequisite for a successful pregnancy, is also found in homologous form in the spike proteins of SARS viruses. There is no indication whether antibodies against spike proteins of SARS viruses would also act like anti-Syncytin-1 antibodies. However, if this were to be the case this would then also prevent the formation of a placenta which would result in vaccinated women essentially becoming infertile. To my knowledge, Pfizer BioNTech has not yet released any samples of written materials provided to patients, so it is unclear what, if any, information regarding (potential) fertility-specific risks caused by antibodies is included.

According to section 10.4.2 of the Pfizer/BioNTech trial protocol, a woman of childbearing potential (WOCBP) is eligible to participate if she is not pregnant or breastfeeding, and is using an acceptable contraceptive method as described in the trial protocol during the intervention period (for a minimum of 28 days after the last dose of study intervention).

This means that it could take a relatively long time before a noticeable number of cases of post-vaccination infertility could be observed.

XII. It appears that Pfizer/BioNTech have not yet released any samples of written materials provided to patients, so it is unclear what, if any, instructions/information patients/subjects were given regarding ADE and PEG-related issues and (potential) fertility- or pregnancy-specific issues.

## **LOWER SPERM COUNT FOR MEN DURING CLINICAL TRIALS:**

Has not yet been studied but there are strong enough concerns that studies are being proposed. Sperm counts are lowered post vaccination. <https://www.clinicaltrials.gov/ct2/show/study/NCT04665258>

## **PFIZER CLINICAL TRIAL- DEFECTIVE DESIGN CLAIM**

## **PFIZER APPROVAL BASED ON DEFICIENT, UNRELIABLE CLINICAL TRIAL DATA, DEFECTIVELY DESIGNED**

Stating in a joint petition, accusations were made that the current study designs for the Phase II/III trials of BNT162b (“the Pfizer/BioNTech trial”) are inadequate to accurately assess efficacy, the designs of the clinical trials were faulty, flawed, and that the vaccines were NOT properly tested. Trials and widespread use of the product were based on misleading evidence, and therefore should not be recommended for widespread use. “Vaccine candidates were not designed to stop transmission of the virus, the public will suffer irreparable harm, the cases and non-cases were not accurate in the trial (using the faulty PCR test rather than a Sanger test and cross examining).” Dr. Yeadon claims the design trial and results are inaccurate and not appropriately designed to reduce transmission and reduction of COVID disease and deaths. “First, none of the leading vaccine candidate trials is designed to test if the vaccine can reduce severe COVID-19 symptoms, defined as: hospital admissions, ICU or death. And, second, the trials are not designed to test if the vaccine can interrupt transmission.”

“Design flaws include PCR tests that are identical to or modeled after what is sometimes called the “Drosten-Test” this can lead to false-positive results in trials designed such that PCR results are the primary evidence of infection.” The complaint asserts that without the assuring proper safety trials of the vaccines now, the people will not have the opportunity to object to receiving the vaccine based on deficient clinical trials later.  
[https://2020news.de/wp-content/uploads/2020/12/Wodarg\\_Yeadon\\_EMA\\_Petition\\_Pfizer\\_Trial\\_FINAL\\_01DEC2020\\_EN\\_unsigned\\_with\\_Exhibits.pdf](https://2020news.de/wp-content/uploads/2020/12/Wodarg_Yeadon_EMA_Petition_Pfizer_Trial_FINAL_01DEC2020_EN_unsigned_with_Exhibits.pdf)

## **ONE SYMPTOM AND PCR DESIGN FLAW IN CASE DEFINITION IN CLINICAL TRIALS**

"Evaluable cases consisted of a positive virological test [PCR test] plus at least one COVID-19 symptom... Fever • New or increased cough • New or increased shortness of breath • Chills • New or increased muscle pain • New loss of taste or smell • Sore throat • Diarrhea • Fatigue • Headache • Nasal congestion or runny nose • Nausea." “External peer review of the RTPCR test to detect SARS-CoV-2 reveals 10 major scientific flaws at the molecular and methodological level: consequences for false positive results.”

<https://www.fda.gov/media/144246/download>

<https://www.fda.gov/media/144413/download>

## **NO DATA IN CLINICAL TRIALS**

Clinical trials were done on the “healthiest” subjects. There is no data to suggest safety or efficacy regarding: auto-immune conditions, cancer patients, immunocompromised individuals, 3 doses, repeated annual doses, safety in children under 18 or persons older than 55, pregnant or lactating mothers, fertility, transmission of covid, duration of protection or immunity from covid, mortality prevention from covid, long-term health impacts, interaction of different brands, interaction between other traditional vaccines, variants, and more.

<https://www.fda.gov/media/144245/download> (Pfizer pg 46-48)

<https://www.fda.gov/media/144434/download> (Moderna pg 46-48)

## **95% EFFICACY REPORTS IN CLINICAL TRIALS QUESTIONED**

BMJ Questions 95% efficacy reports when reviewing the clinical trials. “3410 total cases of suspected, but unconfirmed covid-19 in the overall study population, 1594 occurred in the vaccine group vs. 1816 in the placebo group.” If these were accounted for, EUA qualifications would not have been met, causing the clinical trials to fall below 50% efficacy.

<https://www.fda.gov/media/144245/download#page=42> (pg 42 FDA report)

[https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/?utm\\_source=feedburner&utm\\_medium=feed&utm\\_campaign=Feed%3A+bmj%2Fblogs+%28Latest+BMJ+blogs%29&g=w\\_bmj-com](https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bmj%2Fblogs+%28Latest+BMJ+blogs%29&g=w_bmj-com)

### **PFIZER FORMER VICE PRESIDENT YEADON PETITION REQUEST**

His request was to pause all trials until vaccine efficacy is determined in the Phase 3 or 2/3 trials. One of the biggest reasons they cited was based upon the deaths of the ferrets in the prior SARS vaccine trials. They requested to confirm infection status with Sanger sequencing, given the high cycle thresholds of the PCR test used in some trials. If verified by Sanger sequencing, rather than PCR, that would confirm that the tested samples in fact contain a unique SARS-CoV-2 genomic RNA. This would remain consistent with the FDA requirements for a confirmed diagnosis of human papillomavirus (HPV) using PCR, the sequencing electropherogram must show a minimum of 100 contiguous bases matching the reference sequence with an Expected Value.

[https://web.archive.org/web/20201209042033/https://2020news.de/wp-content/uploads/2020/12/Wodarg\\_Yeadon\\_EMA\\_Petition\\_Pfizer\\_Trial\\_FINAL\\_01DEC2020\\_EN\\_unsigned\\_with\\_Exhibits.pdf](https://web.archive.org/web/20201209042033/https://2020news.de/wp-content/uploads/2020/12/Wodarg_Yeadon_EMA_Petition_Pfizer_Trial_FINAL_01DEC2020_EN_unsigned_with_Exhibits.pdf)

<https://www.bmj.com/content/bmj/371/bmj.m4037.full.pdf>

### **GENEVA ETHICISTS SOUND THE ALARM ABOUT THE MRNA**

For decades Geneva ethicists were concerned. It's actually more accurate to describe the new injections as gene therapy rather than a vaccine. Traditional vaccines stimulate the immune system through an antigen and adjuvant. Moderna plugs a small piece of coronavirus genetic code into human cells, attempting to "reprogram" the cells in the body. Previous to now, it has been called off by Ethicists. It was previously referred to as "germ line gene editing."

### **CONSIDERED GENE THERAPY FROM MODERNA & FDA**

"Currently, mRNA is considered a gene therapy product by the FDA. Unlike certain gene therapies that irreversibly alter cell DNA and could act as a source of side effects, mRNA-based medicines are designed to not irreversibly change cell DNA; however, side effects observed in gene therapy could negatively impact the perception of mRNA medicines despite the differences in mechanism. In addition, because no product in which mRNA is the primary active ingredient has been approved, the regulatory pathway for approval is uncertain. The number and design of the clinical and preclinical studies required for the approval of these types of medicines have not been established, may be different from those required for gene therapy products or may require safety testing like gene therapy products. Moreover, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one pharmaceutical product to the next and may be difficult to predict.

[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473\\_6](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473_6)

### **GENETICALLY ENGINEERED RNA OR DNA, SEQUENCING IDENTIFIED**

The new mRNA products through Pfizer, J&J, and Moderna are viral vector vaccines. Viral Vector use 50 billion adenovirus particles virus that have been **genetically engineered** to generate an artificial immune response. RNA and DNA vaccines use genetically engineered RNA or DNA to generate a protein that itself prompts an artificial immune response. It is unknown if the spike protein can be turned off. See the sequence discovered by Stanford University Scientists using left overs in shot vials.

Figure 2: Spike-encoding contig assembled from Moderna mRNA-1273 vaccine.



<https://www.the-scientist.com/news-opinion/scientists-reverse-engineer-mrna-sequence-of-moderna-vaccine-68640>

<https://github.com/NAalytics/Assemblies-of-putative-SARS-CoV2-spike-encoding-mRNA-sequences-for-vaccines-BNT-162b2-and-mRNA-1273/blob/main/Assemblies%20of%20putative%20SARS-CoV2-spike-encoding%20mRNA%20sequences%20for%20vaccines%20BNT-162b2%20and%20mRNA-1273.docx.pdf>

<https://berthub.eu/articles/posts/reverseengineering-source-code-of-the-biontech-pfizer-vaccine/>

### **GENETICALLY ENGINEERED AND INTRODUCE FOREIGN DNA AND RNA INTO CELLS OF THE BODY:**

Introducing a non-human substances and foreign synthetic material (mRNA vaccines) have created instability in the body and ineffective delivery in the past. **Synthetic mRNA leads to instability in the body, possible toxicity.** In studies of mRNA vaccines it is described along with a comparison to DNA vaccines, **the greater inherent inflammatory nature of the mRNA vaccines is discussed for both its potential immunological utility for vaccines and for the potential toxicity.**

ProTherImmune, 3656 Happy Valley Road, Lafayette, CA 94549, USA

Vaccines 2019, 7(2), 37; <https://doi.org/10.3390/vaccines7020037>

[https://www.mdpi.com/journal/vaccines/special\\_issues/advances\\_DNA\\_vaccines](https://www.mdpi.com/journal/vaccines/special_issues/advances_DNA_vaccines)

### **A NEW FIELD CALLED EPITRANSCRIPTOMICS AND POSSIBLE ROLE IN CANCER**

Epigenetic gene regulation is studied by examining dynamic modifications of DNA and proteins—so-called **epigenetic modifications**. The modifications can turn genes on or off without changing the underlying genetic code. Over the last five years, there has been an enormous increase in the amount of research into RNA modifications—a field called epitranscriptomics. ("Deciphering the epitranscriptome in cancer." Trends in cancer 4, no. 3 (2018): 207-221. "Epitranscriptomic signatures in lncRNAs and their possible roles in cancer." Genes 10, no. 1 (2019): 52.)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997933/>

<https://genomebiology.biomedcentral.com/articles/10.1186/s13059-017-1336-6?optIn=true>

### **POSSIBLE REVERSE TRANSCRIPTION PROBLEMS, RNA AND DNA- COMMON IN HIV**

SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. Detection of reverse transcriptase activity in human cells. Here are samples of three nonmalignant and seven leukemic human cells that were examined for DNA polymerase activity that could be identified as RNA tumor virus reverse transcriptase. This is common in HIV retroviruses.

<https://doi.org/10.1101/2020.12.12.422516>

<https://www.ncbi.nlm.nih.gov/books/NBK19424/>

<https://pubmed.ncbi.nlm.nih.gov/87260/>

[https://www.jbc.org/article/S0021-9258\(20\)78303-1/fulltext](https://www.jbc.org/article/S0021-9258(20)78303-1/fulltext)



## **GENE THERAPY RISKS WITH ALTERING CELL DNA IRREVERSIBLY**

Directly from the Moderna 2018 report. “In the EU, mRNA has been characterized as a Gene Therapy Medicinal Product... a clinical hold on gene therapy products across the field due to risks associated with altering cell DNA irreversibly may apply to our mRNA investigational medicines irrespective of the mechanistic differences between gene therapies and mRNA. Adverse events reported with respect to gene therapies or genome editing therapies could adversely impact one or more of our programs. Although our mRNA development candidates and investigational medicines *are designed* not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapies products caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our mRNA investigational therapies, and as a result may delay one or more of our trials or impose additional testing for long-term side effects.

**Pg.26-27**

[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473\\_6](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473_6)

1. Anti-PEG Antibodies

## **LIPID MODEL**

### **LIPID CARRYING VECTOR**

The lipid carrier (vector) is problematic= aids in vulnerability

The spike in protein interaction with PEG in the body. Causing allergic reactions. (Anaphylactic)

Immunologist Says the foreign, synthetic mRNA, creates significant instability in the body: (see sources in anti-PEG section.)

“Gene therapies and mRNA based medicines may activate one or more immune responses against any and all components of the drug product (e.g., the mRNA or the delivery vehicle, such as a lipid nanoparticle) (LNP) as well as against the encoded protein, giving rise to potential immune reaction related adverse events.

Eliciting an immune response against the encoded protein may impede our ability to achieve a pharmacologic effect upon repeat administration or a side-effect.” Page 22

[https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473\\_6](https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm#toc577473_6)

### **LIPID MODEL PREVIOUSLY PROBLEMATIC**

Lipid nano particles can cross the blood brain barrier. It was never proved safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project. Covid 19 clinical trials for both Pfizer and Moderna show increased reactions, with repeated injections, increased inflammation due to Lipid Nano Particle model.

<https://www.statnews.com/2017/01/10/moderna-trouble-mrna/>

[https://pubmed.ncbi.nlm.nih.gov/29886842/#:%7E:text=Background%3A%20Brain%20is%20a%20delicate,Blood%20Brain%20Barrier%20\(BBB\).&text=Nevertheless%2C%20lipid%20nanoparticles%20are%20taken,because%20of%20their%20lipophilic%20nature.](https://pubmed.ncbi.nlm.nih.gov/29886842/#:%7E:text=Background%3A%20Brain%20is%20a%20delicate,Blood%20Brain%20Barrier%20(BBB).&text=Nevertheless%2C%20lipid%20nanoparticles%20are%20taken,because%20of%20their%20lipophilic%20nature.)

<https://pubmed.ncbi.nlm.nih.gov/30370619/>

### **LNP CROSSING BLOOD BRAIN BARRIER**

**Impact on CNS, Brain, and entering cells, watch for danger signals**

<https://pubmed.ncbi.nlm.nih.gov/30370619/>

[https://pubmed.ncbi.nlm.nih.gov/29886842/#:%7E:text=Background%3A%20Brain%20is%20a%20delicate,Blood%20Brain%20Barrier%20\(BBB\).&text=Nevertheless%2C%20lipid%20nanoparticles%20are%20taken,because%20of%20their%20lipophilic%20nature.](https://pubmed.ncbi.nlm.nih.gov/29886842/#:%7E:text=Background%3A%20Brain%20is%20a%20delicate,Blood%20Brain%20Barrier%20(BBB).&text=Nevertheless%2C%20lipid%20nanoparticles%20are%20taken,because%20of%20their%20lipophilic%20nature.)

<https://pubmed.ncbi.nlm.nih.gov/18313785/>

<https://pubmed.ncbi.nlm.nih.gov/32116044/>

## **LIPID MODEL RISKS, mRNA TECHNOLOGY NEVER APPROVED, SAFETY ISSUES**

Previous attempts at mRNA technology from Moderna resulted in troubling effects on the liver in animal studies. Just a few years ago, Moderna could not demonstrate that its technology can safely treat a disease. In their corporate prospectus<sup>9</sup> released in 2018 at the time of their stock market launch, Moderna acknowledged that their LNPs carried risks. "No mRNA drug has been approved in this new potential category of medicines, and may never be approved as a result of efforts by others or us. mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines." Before COVID, the company was teetering on bankruptcy with \$1.5 billion debt.

"Gene therapies and mRNA based medicines may activate one or more immune responses against any and all components of the drug product (e.g., the mRNA or the delivery vehicle, such as a lipid nanoparticle (LNP)) as well as against the encoded protein, giving rise to potential immune reaction related adverse events.

<https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm>

<https://www.statnews.com/2017/01/10/moderna-trouble-mrna/>

[https://pubmed.ncbi.nlm.nih.gov/29886842/#:%7E:text=Background%3A%20Brain%20is%20a%20delicate,Blood%20Brain%20Barrier%20\(BBB\),&text=Nevertheless%2C%20lipid%20nanoparticles%20are%20taken,because%20of%20their%20lipophilic%20nature.](https://pubmed.ncbi.nlm.nih.gov/29886842/#:%7E:text=Background%3A%20Brain%20is%20a%20delicate,Blood%20Brain%20Barrier%20(BBB),&text=Nevertheless%2C%20lipid%20nanoparticles%20are%20taken,because%20of%20their%20lipophilic%20nature.)

<https://pubmed.ncbi.nlm.nih.gov/30370619/>

## **PEG ANAPHYLACTIC REACTIONS**

### **PEG PROTEINS ARE A PROBLEM, SERIOUS ANAPHYLACTIC REACTIONS FOR SOME**

CDC, Pfizer, UK knew allergic reactions were coming. It is important to note that individuals with a "history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s)" were **excluded** from Pfizer's clinical trials. [Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults. Exclusion Criteria.](#)

['Very inconsistent': 2 allergic reactions in the UK to COVID-19 vaccine puzzle researchers, USA Today Dec. 9, 2020.](#)

[https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F%2F%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F%2F%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html)

<https://healthimpactnews.com/wp-content/uploads/sites/2/2020/12/CDC-05-covid-clark.pdf>

<https://www.fda.gov/media/144413/download>

[https://jamanetwork.com/journals/jama/fullarticle/2777417?guestAccessKey=e4d454f9-7f06-42b5-81e1-0ea01d143ed3&utm\\_source=silverchair&utm\\_medium=email&utm\\_campaign=article\\_alert-jama&utm\\_content=olf&utm\\_term=030821](https://jamanetwork.com/journals/jama/fullarticle/2777417?guestAccessKey=e4d454f9-7f06-42b5-81e1-0ea01d143ed3&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=030821)

### **ANTI-PEG ANTIBODIES (Allergic Reactions)**

These mRNA vaccines are coated with PEGylated lipid nanoparticles (polyethylene glycol). Unfortunately, PEGylated lipid nanoparticles (which have been used for years in several drugs) have been shown to imbalance certain immune responses and can induce allergies and even autoimmune diseases. A majority of the population unknowingly have anti-PEG antibodies.

"While we have continued to optimize our LNPs, there can be **no assurance that our LNPs will not have undesired effects**. Our LNPs could contribute, in whole or in part, to one or more of the following: immune reactions, infusion reactions, complement reactions, opsonation reactions, antibody reactions including IgA, IgM, IgE or IgG or some combination thereof, or reactions to the PEG from some lipids or PEG otherwise associated with the LNP."

PEG antibodies may also reduce vaccine effectiveness. Pfizer/BioNTech is also inserting an ingredient derived from a marine invertebrate, mNeonGreen, into its vaccine. The ingredient has bioluminescent qualities, making it attractive for medical imaging purposes, but it is unclear why an injected vaccine would need to have that quality. mNeonGreen has unknown antigenicity.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515207/>

<https://www.randfonline.com/doi/pdf/10.1517/17425247.2012.720969>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747248/>

[https://www.jacionline.org/article/S0091-6749\(15\)01667-X/fulltext](https://www.jacionline.org/article/S0091-6749(15)01667-X/fulltext)

<https://www.karger.com/Article/Abstract/233512>

<https://www.sciencedirect.com/science/article/abs/pii/S0168365907002428>

<https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm>

[https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fanaphylaxis-management.html)

[anaphylaxis.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fanaphylaxis-management.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fanaphylaxis-management.html)

## **IMMUNE ESCAPE, VIRAL VARIANTS**

### **VACCINE INTERFERENCE CATASTROPHIC**

While a virus is transmitting through the population, vaccination interference may cause catastrophic problems. “As mass vaccination campaigns have started in the vulnerable population, not only vaccinated subjects but also not yet vaccinated younger age groups will become a breeding ground for new infectious variants. There can be no doubt that continued mass vaccination campaigns will enable new, more infectious viral variants to become increasingly dominant and ultimately result in a dramatic incline in new cases despite enhanced vaccine coverage rates. There can be no doubt either that this situation will soon lead to complete resistance of circulating variants to the current vaccines.”

**(33 Studies/Links: Peer Reviewed, Resources, Science Journals supporting immune escapes, NK cells, Innate Immune System, Vaccine Induced Immune Escape, Reduced Protection from Stronger Variants)** [https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_1ca60c7d40d141b89dbf26c7afb9f50b.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_1ca60c7d40d141b89dbf26c7afb9f50b.pdf)

### **NATURAL AND VACCINE-INDUCED IMMUNE ESCAPE**

Due to the intervention of mass inoculation, Immune pressure (immune escape), redirects the virus into the asymptomatic population, creating worse viral variants, and altering natural immunity. Interventions of vaccines create “Immune pressure” which causes virus adaptation, with new worse viral variants. Immune escape. Without vaccination interventions, the virus does not have this immune escape. Before vaccine intervention, the natural immune system was equipped to limit variants. Mass inoculation of vulnerable groups does not abrupt viral transmission chains but increasingly redirects transmission events to asymptomatic carriers. Evident in the form of having transformed “a quite harmless virus into an uncontrollable monster.”

<https://www.biorxiv.org/content/10.1101/2020.12.28.424451v1>

<https://science.sciencemag.org/content/371/6527/329>

<https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002198>

doi: [https://doi.org/10.1016/S2468-2667\(21\)00036-0](https://doi.org/10.1016/S2468-2667(21)00036-0)

doi: [https://doi.org/10.1016/S0140-6736\(21\)00183-5](https://doi.org/10.1016/S0140-6736(21)00183-5)

<https://immunology.sciencemag.org/content/6/57/eabg6461>

doi: [https://doi.org/10.1016/S0140-6736\(21\)00468-2](https://doi.org/10.1016/S0140-6736(21)00468-2)

<https://www.sciencedirect.com/science/article/pii/S0092867421003676?via%3Dihub>

<https://www.the-scientist.com/news-opinion/will-delaying-vaccine-doses-cause-a-coronavirus-escape-mutant--68424>

[https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(21\)00036-0/fulltext](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00036-0/fulltext)

<https://science.sciencemag.org/content/371/6527/329>  
<https://vancouver.sun.com/news/covid-19-cases-of-vaccine-resistant-variant-more-than-doubles-in-b-c>  
<https://www.tagesspiegel.de/wissen/die-angst-vor-der-supermutante-was-wenn-kein-impfstoff-mehr-wirkt/27048992.html>  
<https://www.nature.com/articles/s41591-021-01318-5>

### **VIRAL VARIANTS SIGNS OF IMMUNE ESCAPE, POTENTIAL FOR REINFECTION**

The multiple emerging, “much more infectious” viral variants, are already examples of “immune escape” from our ‘innate immunity’, and were most-likely created by the government interventions. Variants emerging in conjunction with mass inoculation.

- Ongoing mass vaccination deployments are “highly-likely to further enhance ‘adaptive’ immune escape as none of the current vaccines will prevent replication/transmission of viral variants”
- As such, “The more we use these vaccines for immunizing people in the midst of a pandemic, the more infectious the virus will become”.
- “With increasing infectiousness comes an increased likelihood of viral resistance to the vaccines”.
- “One shouldn’t use a prophylactic vaccine in populations exposed to high infectious pressure (which is now certainly the case as multiple highly infectious variants are currently circulating”).
- To “fully escape”, the highly mutable virus, “only needs to add another few mutations in its receptor-binding domain”.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641391/>

doi : <https://doi.org/10.1099/jgv.0.001439>

<https://science.sciencemag.org/content/371/6527/329>

(Brazil) <https://www.bmj.com/content/373/bmj.n879>

(Indian) <https://www.thehindu.com/sci-tech/science/what-is-driving-the-second-wave-in-india/article34232390.ece>

(Turkey) <https://www.aninews.in/news/world/middle-east/turkeys-daily-covid-19-cases-hit-a-new-record20210402074805>

### **MORE DANGEROUS STRAINS POST VACCINATION**

In 2001, research with poultry viruses led to the conclusion that low-efficacy vaccines could even promote the development of more dangerous virus strains. *Deutsche Welle*, January 26,

2021, <https://www.dw.com/en/coronavirus-the-dangers-of-weak-vaccines/a-56339759>

<https://www.biorxiv.org/content/10.1101/2021.01.18.427166v2.full.pdf>

### **VARIANTS MORE LETHAL AND MORE INFECTIOUS**

- "Covid-19 cases have soared throughout Brazil in the past month and have been attributed to the spread of P.1, which is estimated to be 1.4-2.2 times more transmissible than previous variants. Growing evidence shows that young people are not only more likely to get infected with P.1 but also to die from it, some experts have warned. (...) Yet the increase is higher in regions where P.1 is more prevalent, suggesting that it is not only more transmissible but also more lethal. (...) P.1 appears to be more lethal among young men and women than the original strain." *British Medical Journal*, April 1,

2021, <https://www.bmj.com/content/373/bmj.n879> Unresolved Questions

<https://www.geertvandenbossche.org/unresolvedquestions>

### **VACCINE RESISTANT VIRUS**

#### **MASS INNOCULATION CREATES VACCINE RESISTANT VIRUS**

Vaccinologist Geert Vanden Bossche calls for a halt to the mass vaccination program. He has written urgent letters to the WHO and others across the world. Geert Vanden Bossche, PhD, DVM, is a vaccine research expert. He has a long list of companies and organizations he’s worked with on vaccine discovery and preclinical research, including GSK, Novartis, Solvay Biologicals, and Bill & Melinda Gates Foundation. Dr



Vanden Bossche also coordinated the Ebola vaccine program at GAVI (Global Alliance for Vaccines and Immunization). He is board-certified in Virology and Microbiology, the author of over 30 publications, and inventor of a patent application for universal vaccines.

“It is, indeed, my interpretation of the science that ongoing mass vaccination campaigns will only drive the emergence of additional, more infectious variants as a result from selective immune escape and ultimately lead to full ant-vaccine resistance.” In the middle of a pandemic alters the natural immune system AND makes the virus mutate and eventually become vaccine resistant, more serious for children, and alters the body’s ability to respond. The problem centers in interfering with the natural immune system’s NK Cells ability to respond to other strains. He wrote his letter to the WHO about immune escape and enhancing the virus to dangerous levels. Based upon the findings of Professor Bieniasz’s team and those made by several other scientists, it can no longer be denied that selective immune pressure and will, therefore, selectively drive emergence of viral variants.

[https://37b32f5a-6ed9-4d6d-b3e1-](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_9fe5cca1171c48b29c6a3c5af4840c90.pdf)

[5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_9fe5cca1171c48b29c6a3c5af4840c90.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_9fe5cca1171c48b29c6a3c5af4840c90.pdf)

<https://www.pnas.org/content/102/3/797>

**(Gert Slide Show Presentation Ohio)** [https://37b32f5a-6ed9-4d6d-b3e1-](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_1ca60c7d40d141b89dbf26c7afb9f50b.pdf)

[5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_1ca60c7d40d141b89dbf26c7afb9f50b.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_1ca60c7d40d141b89dbf26c7afb9f50b.pdf)

**(Gert response to criticism and questions)** [https://37b32f5a-6ed9-4d6d-b3e1-](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_46f8422498b94078987c32f36bc82ba2.pdf)

[5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_46f8422498b94078987c32f36bc82ba2.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_46f8422498b94078987c32f36bc82ba2.pdf)

**(Gert 11 page Summary)** [https://37b32f5a-6ed9-4d6d-b3e1-](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_d4ac099217c547ba8213783697ad85c5.pdf)

[5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_d4ac099217c547ba8213783697ad85c5.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_d4ac099217c547ba8213783697ad85c5.pdf)

**(Gert Interview and Videos)** <https://www.geertvandenbossche.org/>

## **LOSS OF INNATE IMMUNE SYSTEM**

### **LOSS OF NATURAL ‘INNATE’ IMMUNITY’ POSSIBLE CONSEQUENCE**

Experts are “beyond worried”, that the humankind may severely damage it’s own, natural immune system because of the mass deployment of vaccination programs at this critical juncture. Our ‘innate’ immunity would be lost (a rich, variant-nonspecific, form of natural immunity).

It would also mean that vaccine-induced protection would be lost.

<https://dryburgh.com/byram-bridle-coronavirus-vaccine-concerns/>

<https://dryburgh.com/wp-content/uploads/2021/02/Bryram-Bridle-PlanB-2021-Slides.pdf>

**(Gert Slide Show Presentation Ohio)** [https://37b32f5a-6ed9-4d6d-b3e1-](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_1ca60c7d40d141b89dbf26c7afb9f50b.pdf)

[5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_1ca60c7d40d141b89dbf26c7afb9f50b.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_1ca60c7d40d141b89dbf26c7afb9f50b.pdf)

**(Gert response to criticism and questions)** [https://37b32f5a-6ed9-4d6d-b3e1-](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_46f8422498b94078987c32f36bc82ba2.pdf)

[5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_46f8422498b94078987c32f36bc82ba2.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_46f8422498b94078987c32f36bc82ba2.pdf)

**(Gert 11 page Summary)** [https://37b32f5a-6ed9-4d6d-b3e1-](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_d4ac099217c547ba8213783697ad85c5.pdf)

[5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_d4ac099217c547ba8213783697ad85c5.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_d4ac099217c547ba8213783697ad85c5.pdf)

**(Gert Interview and Videos)** <https://www.geertvandenbossche.org/>

**(Gert letter to the who)** [https://37b32f5a-6ed9-4d6d-b3e1-](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_266039aeb27a4465988c37adec9cd1dc.pdf)

[5ec648ad9ed9.filesusr.com/ugd/28d8fe\\_266039aeb27a4465988c37adec9cd1dc.pdf](https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_266039aeb27a4465988c37adec9cd1dc.pdf)

[https://youtu.be/1\\_ksalhIi5c](https://youtu.be/1_ksalhIi5c)

<https://www.washingtonexaminer.com/news/study-covid-variant-pfizer-vaccinated-unvaccinated>

<https://science.sciencemag.org/content/early/2021/03/24/science.abg9175>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291398/>

<https://www.medrxiv.org/content/10.1101/2020.12.18.20248447v1>

<https://www.nature.com/articles/s41392-021-00525-3>

### **DISRUPTING NK CELLS ABILITY TO ATTACK CONSTANT MUTATING VIRUS:**

Intervention with a mass inoculation program, WHILE the virus is circulating has potentially dangerous problems. TK cells and NK cells are our bodies natural protectors. With the possibility of NK cells to acquire immunological memory. The wild virus is constantly mutating. Our body is designed for a general immune response to wild infection, where you will make antibodies that are not totally specific but can protect against a wider range of changes that occur in nature. They are capable of recognizing and attacking a broad and diversified spectrum of pathogenic agents, including mutations. If this natural innate immune system is disrupted or programmed through slight alterations, it no longer may be able to recognize and attack variants or mutated strains. The shot may program your body to create specific antibodies, but may not hit the mutated strains, leaving you to think you are protected but you may not be. (mRNA programs the body for only focused set, while the virus continues to mutate, and the body is now at a disadvantage.)

<https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002198>

### **WARNING FROM EXPERTS AROUND THE GLOBE**

#### **ADDITIONAL EXPERT VOICE CONCERN OF IMMUNE ESCAPE, VACCINE RESISTANT VARIANTS, INNATE IMMUNE SYSTEM, RETROVIRUSES, VACCINE INDUCED MORE INFECTIOUS VARIANTS, IMMUNE ESCAPE-REDUCED VACCINE EFFECTIVENESS, AND LACK OF PROTECTION**

**Paul Bienasz** "Rolling out a partially effective vaccine regime in the peak of a highly prevalent viral epidemic is just not a great idea if one of your goals is to avoid vaccine resistance (...) There's a chance, (...) that people waiting for their second dose may have a sub-optimal level of immunity that places selective pressure on the virus. If someone were to become infected during the interval between jabs, that pressure could allow for the emergence of a mutant version of SARS-CoV-2 able to shake off a person's immune response — a so-called escape variant. Any such variant that also proved capable of causing severe disease could potentially spark a whole new, devastating wave of infections and deaths." PhD, Howard Hughes Medical Institute/Rockefeller University, New York, February 10, 2021.

**Viola Priesemann** (PhD, Max Planck Institut, Göttingen) According to Viola Priesemann, (PhD, Max Planck Institut, Göttingen) new Coronavirus variants capable of escaping vaccine-induced immune protection could develop. Such immune escape variants can particularly develop in places where many people are vaccinated on a background of a high incidence rate. In a worst case scenario, this would require to restart vaccinations from scratch. - March 25, 2021 - RND /ARD.

**Theo Dingermann** "Mutants also occur in the absence of selection pressure. However, selection pressure substantially increases if the reservoir for the virus is drying up. In this regard, Mr. Vanden Bossche is absolutely right." PhD, Goethe Universität Frankfurt, March, 2021 .

**Byran Bridle** "Although Geert gets there by a slightly different route, we both end up at the same conclusion: that current design of the vaccines and the way they are being rolled out creates risk of the emergence of immunoevasive variants. (...) I can guarantee that he knows what he is talking about." - (PhD, Ontario Veterinary College, University of Guelph, Canada) March 19, 2021. Career vaccine developer, Viral Immunologist.

<https://dryburgh.com/byram-bridle-coronavirus-vaccine-concerns/>

<https://dryburgh.com/wp-content/uploads/2021/02/Bryram-Bridle-PlanB-2021-Slides.pdf>

**Andrew Read** "But new findings from the British government's "New and Emerging Virus Threats Advisory Group" suggest that the variant first discovered in the UK might not just be up to 70 percent more contagious, but perhaps deadlier as well. There's not enough data to prove this yet, though. (...) When weak

vaccines are used, however, or the second dose is delayed for too long, the vaccine has the exact opposite of the desired effect. In 2001, his research with poultry viruses led him to the conclusion that low-efficacy vaccines could even promote the development of more dangerous virus strains. -Pennsylvania State University virologist, *Deutsche Welle*, January 26, 2021,

<https://www.dw.com/en/coronavirus-the-dangers-of-weak-vaccines/a-56339759>

**Björn Meyer** "We can't really put a number on it," a virologist at the Pasteur Institute in Paris, referring to the risk of delayed dosing leading to the evolution of an escape variant. Every time the virus replicates there is a chance that it could mutate into a more transmissible or more deadly form. In a single individual, the odds of this happening are vanishingly small but the picture changes somewhat when you consider that tens of millions of people are currently waiting for their second dose." *The Scientist*, Feb. 4, 2021, <https://www.the-scientist.com/news-opinion/will-delaying-vaccine-doses-cause-a-coronavirus-escape-mutant--68424>  
<https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002198>  
<https://immunology.sciencemag.org/content/6/57/eabg6461>  
<https://www.thehindu.com/sci-tech/science/what-is-driving-the-second-wave-in-india/article34232390.ece>  
<https://www.aninews.in/news/world/middle-east/turkeys-daily-covid-19-cases-hit-a-new-record20210402074805>

**Laetitia Atlani-Duault, Bruno Lina, Franck Chauvin, Jean-François Delfraissy, Denis Malvy,**

"If substantial immune evasion occurs, current vaccines are likely to still offer some benefit to individuals. At the population level, however, they could induce viral selection and escape. (...) This virological game changer has numerous consequences, not only for vaccines and treatment, but also for prevention and control strategies. The fervently awaited end of this global health crisis might be continually postponed, as new variants emerge and immune evasion reduces vaccination effectiveness in the short and medium term. (...) We scientists working against COVID-19 must have the courage to address those in power, who bear ultimate responsibility for the policies chosen and their consequences. If this responsibility is shirked or delayed, the inevitable day of reckoning might be terrible."

-Members of the French COVID-19 Scientific Council, in *The Lancet*, Feb. 18, 2021,

[https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(21\)00036-0/fulltext](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00036-0/fulltext)

**Salim S Abdool Karim** "Immune-escape variants have raised concerns about the effectiveness of vaccines as the world scales up SARS-CoV-2 immunization. (...) New variants, especially 501Y.V2 (B.1.351), which escape natural-induced and vaccine-induced immunity, have created uncertainty on whether the vaccines are effective in preventing both mild and severe COVID-19." *The Lancet, Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection*, March 22,

2021, [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00468-](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00468-2/fulltext?fbclid=IwAR1K_tzlvBP4_yJ95jnpsj0yBxqjClZrcEQDemR5xMA64HopMZMmSV1JkKw)

[2/fulltext?fbclid=IwAR1K\\_tzlvBP4\\_yJ95jnpsj0yBxqjClZrcEQDemR5xMA64HopMZMmSV1JkKw](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00468-2/fulltext?fbclid=IwAR1K_tzlvBP4_yJ95jnpsj0yBxqjClZrcEQDemR5xMA64HopMZMmSV1JkKw)

**Kai Kupferschmidt** "But now, they're also focusing on a potential new threat: variants that could do an end run around the human immune response. Such "immune escapes" could mean more people who have had COVID-19 remain susceptible to reinfection. ... - *Science*, Jan. 22, 2021,

<https://science.sciencemag.org/content/371/6527/329>

"The P1 variant is especially concerning because it contains a mutation that makes it both highly contagious and more resistant to the antibodies produced from vaccines and previous coronavirus infections. It has the potential to infect people who have been vaccinated and even reinfect people who have had COVID-19. (...) It is concerning because this is a variant that we've seen be very destructive in Brazil and there is concern about the effectiveness of vaccines." - *The Vancouver Sun, 'Cases of vaccine-resistant variant more than doubles in B.C.'* - March 28, 2021, <https://vancouver.sun.com/news/covid-19-cases-of-vaccine-resistant-variant-more-than-doubles-in-b-c>

**Dr. Stephanie Seneff**, an expert in protein synthesis who is a Ph.D. senior research scientist at MIT. “The potential for blood clotting disorders and the potential for sterilization are only part of the story. There are other potential long-term effects of these vaccines as well, such as autoimmune disease and immune escape, whereby the vaccines administered to immune-compromised people accelerate the mutation rate of the virus so as to render both naturally acquired and vaccine-induced antibodies no longer effective.” “This massive clinical trial on the general population could have devastating and irreversible effects on a huge number of people.”  
<https://www.jennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/>

**Chancellery Chief Helge Braun** “Will a third pandemic wave enhance circulation of viral mutants? This is what Chancellery Minister, Helga Braun (CDU), has been warning against. If infectivity rates show a steep rise despite ongoing vaccination campaigns, there will be an increased risk that a new virus mutant resists the vaccine, as Braun told “Bild am Sonntag”. In case of a such mutation, we would be standing here empty-handed,” *Der Tagesspiegel*, March 29, 2021, <https://www.tagesspiegel.de/wissen/die-angst-vor-der-supermutante-was-wenn-kein-impfstoff-mehr-wirkt/27048992.html>

**Delphine Planas, Timothee Bruel, Oliver Schwartz**, “Thus, faster-spreading SARS-CoV-2 variants acquired a partial resistance to neutralizing antibodies generated by natural infection or vaccination, which was most frequently detected in individuals with low antibody levels. Our results indicate that SARS-CoV-2 variants may increase the risk of infection in immunized individuals” - “In conclusion, our results demonstrate that suboptimal or declining antibody responses are associated with a loss of cross-reactivity against novel emerging viral strains.” *Nature Medicine*, March 26, 2021, <https://www.nature.com/articles/s41591-021-01318-5>

“These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines” - March 1, 2021, <https://www.biorxiv.org/content/10.1101/2021.01.18.427166v2.full.pdf>

**Dr. Sucharit Bhakdi**, World-renown, award winning researcher, German-Thai-American microbiologist, former head of the Institute of Medical Microbiology and Hygiene in Germany. A professor of virology and microbiology for 30 years in Germany. Dr. Sucharit Bhakdi warns, “...that the COVID “vaccines” are set to cause a global catastrophe and a decimation of the human population. He explains that the PCR test has been abused to produce fear in a way that is unscientific. He explains what the mRNA vaccines are going to do to the human body in terms and using analogies that anyone can understand. He expects massive deadly clotting as well as immune system responses that will destroy the human body.  
<https://healthimpactnews.com/2021/german-microbiologist-they-are-killing-people-with-these-covid-vaccines-to-reduce-the-worlds-population/?fbclid=IwAR1SdA7nay-51zSodkaSLXooKaynZCZ1TizEBJjFrYlz1H81XJJaXzKod0>  
<https://rumble.com/vfx0h3-german-microbiologist-they-are-killing-people-with-covid-vaccines-to-reduce.html>

**Dr. Carrie Madej, Dr. Lee Merritt & Dr. Christiane Northrup** “Unique phenomena happening around those who recently had the shot and those who have not. Thousands of stories coming in. Uncertainty about what is happening, but this the beginning of a round table discussions below. Discussion includes blood clotting in women. Christiane Northrup is an expert gynecologist who has written numerous books, 3 New York Best Sellers, Oprah Show, 8 Public TV specials, Readers Digest most trusted Doctors, and decades of expertise in reproductive health.  
<https://rumble.com/vfyvsn-critically-thinking-with-dr.-t-and-dr.-p-episode-44.html>  
<https://mamm.org/could-their-shot-be-harming-you/?fbclid=IwAR14kQB40WfIQw4GS-4b9CKy7pUzMuR-tXEXxGGavm9WBj-fdYyPwvXTRc>



**Dr. Lawrence Palevsky** a renowned board certified pediatrician, published author, and sought-after lecture. Hundreds of thousands of women are experiencing abnormalities. Warning that something is not right. Top and Bottom video. (Youtube videos are being removed, people are taking to rumble, bitchute, etc.)

<http://www.truthunmasked.org/p/stay-away.html?fbclid=IwAR3kWEMEv6s7muV9oMArGKRKUq4y4lITNnNzdqdgE5UxykqEIXEeqjDI.5Q&m=1>

<https://www.bitchute.com/video/iN8JWKJfyP4e/>

**Judy Mikovitz** A 20 year veteran of the National Cancer Institute. On July 22, 2009, a special meeting was held with twenty-four leading scientists at the National Institutes of Health to discuss early findings that a newly discovered retrovirus was linked to chronic fatigue syndrome (CFS), prostate cancer, lymphoma, and eventually neurodevelopmental disorders in children. In recent interviews, she has been outspoken surrounding warnings that the CV shot will negatively impact millions. Most of her interviews are censored and removed. Here are few. Pastor Rob McCoy hosted Dr. Mikovitz for a Q&A at his church in California.

<https://rumble.com/vbsu1p-dr.-judy-mikovitz-and-rob-mccoy-deleted-by-youtube.html>

<https://rumble.com/vcri2t-dr.-judy-mikovits-and-robert-f.-kennedy-jr.-q-a-godspeak-calvary-chapel.html>

<https://drcharlieward.com/dr-judy-mikovits/> (April 15)

<https://www.bitchute.com/video/RaLH5EWHhMUh/?fbclid=IwAR2ZUDVLKy56nTQ5tLK9oHi6LebDgiZQS7sf9aURALDdxdTr7WwN3H9rb4>

<https://z3news.com/w/dr-judy-mikovits-50-million-people-die-america-vaccine/>

### **19 DOCTORS AROUND THE WORLD WARNING**

<https://rumble.com/vescil-world-doctors-warn-do-not-take-mrna-shot.html>

<https://principia-scientific.com/professor-dolores-cahill-people-will-start-dying-after-covid-vaccine/> Cahill

<https://z3news.com/w/dr-judy-mikovits-50-million-people-die-america-vaccine/>

### **FULLY VACCINATED BREAK OUTS: WA, HI, SC, LONG ISLAND, MI, TX, MN, KY**

More examples of consequences from mass inoculation. Media calls it break through cases or blames those who have NOT gotten the shot. Governments are preparing for additional lock downs. Instead, a careful evaluation may give more credibility to the numerous experts warning of ADE, immune escape, ineffective protection from the shot, short immune protection beyond 2 months was never achieved in clinical trials, red flags inoculation previously infected with covid, including asymptomatic carriers, allergic reactions to PEG, instability in the body, toxicity, new unforeseen results from a new, investigational product, stronger variants consequentially from mass inoculation, enhanced disease as seen in failed animal trials, faulty designed clinical trials based on ineffective case definition, trials deficient in safety and efficacy, transmission not stopped after inoculation, no long term studies, no data on mass population responses to the shots, no data on mutations, no data on co-infections, no data on immunocompromised taking shot, unknown reactions to mNeonGreen, ignoring warnings of pathogenic priming, ignoring the censorship of: (scientists, doctors, researchers, virologists, whistleblowers, across the globe), and game changing altering of our innate immune systems.

(5800) [https://www.pbs.org/newshour/health/the-shock-and-reality-of-catching-covid-after-being-vaccinated?utm\\_source=facebook&utm\\_medium=news\\_tab&utm\\_content=algorithm](https://www.pbs.org/newshour/health/the-shock-and-reality-of-catching-covid-after-being-vaccinated?utm_source=facebook&utm_medium=news_tab&utm_content=algorithm)

<https://www.kiro7.com/news/local/doh-vaccine-breakthrough-cases-confirmed-washington/UXIAR3OU4JB63GQQRHTSK45QAA/>

<https://www.foxnews.com/health/ny-woman-contracts-coronavirus-month-after-covid-19-vaccination-report-says>

[https://www.theepochtimes.com/over-100-fully-vaccinated-people-in-washington-state-test-positive-for-covid-19\\_3757218.html](https://www.theepochtimes.com/over-100-fully-vaccinated-people-in-washington-state-test-positive-for-covid-19_3757218.html)

<https://pix11.com/news/coronavirus/faces-of-the-pandemic/long-island-woman-tests-positive-for-covid-after-2-vaccine-shots/>

[https://www.deadlinedetroit.com/articles/27635/updated\\_vaccinated\\_oakland\\_county\\_woman\\_gets\\_covid\\_michigan\\_identifies\\_145\\_others](https://www.deadlinedetroit.com/articles/27635/updated_vaccinated_oakland_county_woman_gets_covid_michigan_identifies_145_others)

<https://www.doh.wa.gov/Newsroom/Articles/ID/2720/Cases-of-COVID-19-vaccine-breakthrough-confirmed-in-Washington-state>  
<https://www.wistv.com/2021/03/29/hospitals-see-rare-covid-cases-fully-vaccinated-patients/>  
<https://www.newschannel6now.com/2021/03/30/seven-covid-vaccine-breakthrough-cases-active-wichita-county/>  
<https://www.startribune.com/minnesota-reports-89-covid-19-cases-in-vaccinated-individuals/600038033/>  
<https://www.lifesitenews.com/news/several-nuns-die-after-taking-first-shot-of-covid-vaccine>

## **RESURGENCE IN HOSPITALIZATIONS AND DEATHS DOMINATED BY 2 DOSES**

In this study found on the website of the British government, entitled "SPI-M-O: Summary of further modelling of easing restrictions - Roadmap Step 2" dated March 31, 2021, states that: "The resurgence in both hospitalizations and deaths is dominated by those that have received two doses of the vaccine, comprising around 60% and 70% of the wave respectively. This can be attributed to the high levels of uptake in the most at-risk age groups, such that immunization failures account for more serious illness than unvaccinated individuals." (in paragraphs 55 and 56)

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/97590/9/S1182\\_SPI-M-O\\_Summary\\_of\\_modelling\\_of\\_easing\\_roadmap\\_step\\_2\\_restrictions.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/97590/9/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf)

[https://blog.fdik.org/2021-04/S1182\\_SPI-M-](https://blog.fdik.org/2021-04/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf)

[O\\_Summary\\_of\\_modelling\\_of\\_easing\\_roadmap\\_step\\_2\\_restrictions.pdf](https://blog.fdik.org/2021-04/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf)

## **PREVIOUS CRIMINAL HISTORY AND BEHAVIOR**

### **PFIZER, J&J, AND ASTRAZENECA PREVIOUS CRIMINAL HISTORY**

Tens of billion in damages from other drugs such as Bextra, Celebrex, Thalidomide, and Opioids. Commonality in suits: ***bringing products to market even though they knew injuries and deaths would result.*** Pfizer, Johnson and Johnson, and AstraZeneca are considered serial felons. J&J lost major suits 1995-2019. Also convicted of fraud, knowingly bringing harmful products to market, destroying documents, federal charges, billions in settlements, testing new drugs on children without parental consent, bribery settlements, improper payments, deliberately misleading about hazards and harm, fatalities unwarned, knowing dangerous side effects of (VIOXX, Bextra, Celebrex), product safety issues, environmental issues, dumping toxic waste products, chemicals released, violations of international law, human rights violations for testing on children without parental consent, labor issues with employees, worker safety problems, endless violations and lawsuits.

<https://www.mp-22.com/vax>

<https://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations>

<https://www.sec.gov/news/press-release/2012-2012-152htm>

<https://www.washingtonpost.com/wp-dyn/content/article/2007/07/02/AR2007070201255.html>

<https://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing>

<https://www.reuters.com/article/us-astrazeneca-texas-lawsuits-idUSKBN1KT0Q9>

### **PFIZER PREVIOUS CRIMINAL HISTORY**

**Pfizer** has the distinction of the biggest criminal payout in history. Fraud, knowingly bringing harmful products to market, federal charges, billions in settlements, testing new drugs on children without parental consent, bribery settlements, improper payments, deliberately misleading about hazards and harm, fatalities unwarned, knowing dangerous side effects of (same as VIOXX, Bextra, Celebrex), product safety issues, environmental issues, dumping toxic waste products, chemicals released, violations of international law, human rights violations for testing on children without parental consent, labor issues with employees, worker safety problems, endless violations and lawsuits. In the category of vaccine manufacturing, they have ZERO

liability. They are demanding that countries where they don't have liability protection to put up collateral, such as embassies, military bases, and bank reserves to cover vaccine-injury lawsuits.

<https://www.mp-22.com/vax>

<https://www.wionews.com/world/how-pfizer-tried-to-bully-argentina-and-brazil-in-exchange-for-vaccines-366037>

<https://www.sec.gov/news/press-release/2012-2012-152htm>

<https://www.washingtonpost.com/wp-dyn/content/article/2007/07/02/AR2007070201255.html>

### **J&J RITTLED WITH FRAUD, FALSE CLAIMS, HIDING PRODUCTS DEFECTS**

Johnson and Johnson have never brought a vaccine to market before covid. Pfizer, Johnson and Johnson, and AstraZeneca are considered serial felons. J&J lost major suits 1995-2019. Johnson and Johnson does have a track record with previous products including: False claims, destroying documents, bribery, fraud, hiding defects from public, billions in settlements, prison, purposefully misleading products, misbranding, carcinogenic ingredients (baby powder knowingly containing asbestos), 45 states filed civil suits, illegal heart drug, 2.2 Billion more penalties (DOJ), no warning about internal bleeding, 25,000 plaintiffs, 14,000 lawsuits about talcum cancer risk, opioid crises come from same manufacturers, the company had to partner with Merck (who is no less trustworthy) to manufacture its COVID vaccine to meet demand.

<https://fcpublog.com/2020/07/27/johnson-johnson-discloses-new-fcpa-investigation/>

<https://www.justice.gov/criminal-fraud/foreign-corrupt-practices-act>

<https://www.reuters.com/article/us-brazil-corruption-healthcare-exclusiv-idUSKCN1SN0ZZ>

<https://www.sec.gov/news/press/2011/2011-87.htm>

<https://www.nytimes.com/2013/11/20/business/johnson-johnson-to-offer-2-5-billion-hip-device-settlement.html>

<https://www.washingtonpost.com/wp-dyn/content/article/2010/05/27/AR2010052705484.html>

<https://abcnews.go.com/Health/PainManagement/fda-official-testify-agency-knew-johnson-johnson-recall/story?id=11765649>

<https://www.nytimes.com/1995/04/11/business/ortho-fined-7.5-million-in-retin-a-case.html>

<https://www.ftc.gov/news-events/press-releases/1996/01/ftc-gives-final-approval-consent-agreement-johnson-johnson>

### **J&J CORRUPTION, FALSE LABEL CLAIMS, ILLEGAL SALES, TOXIC INGREDIENTS**

The extensive track record continues. Corruption, bribery, false label claims, toxic ingredients for children, and endless settlements. There is a difference between this list of products and manufacturing the CV shot. There will be no settlements, lawsuits, or criminal proceedings. If there is foul play with yet another product in mass production to the entire population, they have full indemnity and all liability has been removed.

<https://www.nytimes.com/2001/04/18/business/johnson-johnson-settles-lawsuits-over-contact-lenses.html>

<https://www.justice.gov/opa/pr/two-johnson-johnson-subsidiaries-pay-over-81-million-resolve-allegations-label-promotion>

<https://www.cbsnews.com/news/jj-settles-criminal-case-alleging-ceo-reviewed-illegal-heart-drug-sales-plan/>

<https://www.forbes.com/sites/amywestervelt/2011/11/01/as-report-reveals-toxic-ingredients-in-baby-shampoo-johnson-johnson-goes-public-with-plans-to-clean-up-products/?sh=a9b9ba94b5ad>

<https://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations>

<https://childrenshealthdefense.org/defender/russel-brand-opiod-crisis-pandemic/>

<https://www.nytimes.com/2019/11/15/health/opioids-oklahoma-johnson-fine.html>

### **J&J BRIBERY, CORRUPT PRACTICES GLOBALLY**

“Brazil’s Public Prosecution Service started an investigation into J&J’s antitrust activities under the Foreign Corrupt Practices Act (FCPA) for “possible improper payments in its medical device industry. The company had to pay out a [\\$70 million penalty](#) for buying off officials in Greece, Poland and Romania. In 2010, an executive for J&J’s subsidiary DePuy was sentenced to a year in prison for corrupt payments to physicians within the Greek national healthcare system.”

<https://www.sec.gov/news/press/2011/2011-87.htm>

### **J&J FAILED QUALITY CONTROL AND HEALTH CITATIONS**

Fifteen million doses of Johnson & Johnson (J&J's) vaccine [failed quality control](#) after workers at a Baltimore manufacturing plant negligently combined ingredients from [AstraZeneca](#) and J&J's COVID vaccine. Plant has a series of health citations already. <https://www.chicagotribune.com/coronavirus/vaccine/ct-aud-nw-johnson-and-johnson-coronavirus-vaccine-20210401-btekuav34vfjtlbo4iuugjroy4-story.html>  
<https://www.nytimes.com/2021/03/31/world/johnson-and-johnson-vaccine-mixup.html>  
<https://www.emergentbiosolutions.com/>

### **ASTRAZENECA SUSPENSION**

<https://www.cnbc.com/2021/03/31/germany-suspends-use-of-astrazenecas-covid-shot-for-the-under-60s.html>  
<https://www.businessinsider.com/astrazeneca-covid-vaccine-countries-suspend-denmark-thailand-batch-blood-clots-2021-3?op=1>  
[https://www.rki.de/EN/Content/infections/Vaccination/Vaccination\\_node.html](https://www.rki.de/EN/Content/infections/Vaccination/Vaccination_node.html)  
[https://gth-online.org/wp-content/uploads/2021/03/GTH\\_Stellungnahme\\_AstraZeneca\\_3\\_19032021-3.pdf](https://gth-online.org/wp-content/uploads/2021/03/GTH_Stellungnahme_AstraZeneca_3_19032021-3.pdf)  
<https://apnews.com/article/germany-cities-suspend-astrazeneca-vaccine-under-60-c6da4f4ed846ebbbe24505bfbf9bfce>  
<https://thehighwire.com/videos/astrazeneca-vaccine-falls-from-grace/>

### **NIH (NIAID IS PART OF) CLAIMS JOINT OWNERSHIP OF MODERNA'S VACCINE**

Contracts reflect jointly owned-Contract between NIH and Moderna. NIH Director statement, NIH has particular stake in IP behind Moderna's Coronavirus vaccine.  
<https://www.axios.com/moderna-nih-coronavirus-vaccine-ownership-agreements-22051c42-2dee-4b19-938d-099afd71f6a0.html>  
<https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html#document/p105/a568569> (Contract)  
<https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html>(NIH)  
<https://www.economicclub.org/events/dr-francis-collins-chris-nassetta-and-mary-brady>  
<https://www.nature.com/articles/nbt.2785>  
[https://childrenshealthdefense.org/defender/truth-rfk-jr-naomi-wolf-constitutional-rights/?utm\\_source=salsa&eType=EmailBlastContent&eId=26b5c090-223d-4d5d-9526-e0f692535e8c](https://childrenshealthdefense.org/defender/truth-rfk-jr-naomi-wolf-constitutional-rights/?utm_source=salsa&eType=EmailBlastContent&eId=26b5c090-223d-4d5d-9526-e0f692535e8c)  
(Patents and Fauci)

### **40 BILLION IN PROFITS**

#### **\$40 BILLION PROFITS AND PROFIT MARGINS:**

4000% Increase in profits for Moderna, who previously couldn't get funds for CV vaccines. \$18.4 billion in revenue this year. Overall, the liability free manufacturers are expecting a \$41 Billion dollar business profits this year alone. mRNA vaccines are faster and cheaper to produce than traditional vaccines and for vaccine manufacturers, more cost-effectiveness translates to greater profits. Bernstein market analyst Ronny Gal also predicts COVID-19 vaccine sales will reach \$40 billion this year.  
<https://www.fool.com/investing/2020/12/10/how-much-money-will-moderna-make-from-its-covid-vaccine/>  
<https://investorplace.com/2021/03/covid-19-vaccine-orders-are-piling-up-mrna-stock-has-room-to-grow/>  
<https://www.theguardian.com/business/2021/feb/25/moderna-forecasts-18bn-in-sales-of-covid-vaccine-this-year>

### **BILLIONS IN CONTRACTS AND MARKETING DOLLARS**



### **BILLIONS IN SIGNED CONTRACTS AND MARKETING CAMPAIGN TO THE PUBLIC:**

Governments across the world are locked into contractual deals to push the acceptance, marketing, and distribution of these new vaccines. **\$4 Billion Marketing Dollars, Marketing analysis on how to persuade people to take the vaccine.** U.S. government's [\\$1 billion deal](#) with J&J to buy 100 million doses of its experimental vaccine.

<https://www.hhs.gov/sites/default/files/strategy-for-distributing-COVID-19-vaccine.pdf>

<https://www.theguardian.com/business/2021/feb/25/moderna-forecasts-18bn-in-sales-of-covid-vaccine-this-year>

<https://www.bloomberg.com/news/articles/2020-03-30/j-j-surges-after-1-billion-vaccine-deal-with-u-s-government>

### **IF TREATMENTS BELOW EXIST, VACCINE MANUFACTURES AND BILLION DOLLAR CONTRACTS ARE NOT NEEDED**

[https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-epar-product-information_en.pdf)

<https://budesonideworks.com/validation-2/>

<https://covid19criticalcare.com/wp-content/uploads/2020/12/One-Page-Summary-of-the-Clinical-Trials-Evidence-for-Ivermectin-in-COVID-19.pdf>

<https://c19early.com>

[https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(21\)00160-0/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00160-0/fulltext)

### **BRAZIL AND ARGENTINA EMBASSIES, MILITARY BASES, BANK RESERVES**

#### **BRAZIL AND ARGENTINA EMBASSIES, MILITARY BASES, BANK RESERVES**

Argentina and Brazil both rejected Pfizer contracts because of demands from Pfizer:

**Pfizer demands from Argentina:** compensations from the government from any future lawsuits, the government should buy an international insurance for any future lawsuits, sovereign assets as collateral (bank reserves, military bases, embassy buildings).

**Pfizer demands from Brazil:** the government should create a "guarantee fund" and deposit money in a foreign bank account, waiving sovereignty of abroad assets, Brazilian laws should not be applied to Pfizer, exempt Pfizer from all civil liability

<https://www.wionews.com/world/how-pfizer-tried-to-bully-argentina-and-brazil-in-exchange-for-vaccines-366037>

<https://greatgameindia.com/pfizer-demanding-military-bases-vaccines/>

#### **FINANCIAL DISCLOSURE FORM FOR COVID INJECTIONS**

<https://pandemic.solari.com/family-financial-disclosure-form-for-covid-19-injections/>

### **NOTEWORTHY LEGAL CASES**

#### **REINER IN GERMANY WON 4/22/2021 A FAVORABLE RULING**

Reiner in Germany filed a case for "crimes against humanity," cases in Norway, Israel, against the WHO, and won a favorable ruling for one of them from the German court this week.

<https://m.youtube.com/watch?v=7RG3k76zTRM>

<https://www.israelnationalnews.com/News/News.aspx/297626>

<https://www.covidtruths.co.uk/2021/03/dr-reiner-fuellmich-pcr-lawsuit-update-march-2021/>

<https://goldenageofgaia.com/2021/03/30/government-of-norway-indicted-for-crimes-against-humanity/>

#### **ROCCO GALATI IN CANADA CONSTITUTIONAL LAWYER LITIGATE AGAINST CA**

<https://www.youtube.com/watch?v=OotKzj7yU9o>

[https://www.youtube.com/channel/UCU\\_5kkoB3taGIDfwbyWh1Aw/videos](https://www.youtube.com/channel/UCU_5kkoB3taGIDfwbyWh1Aw/videos)

### **ISRAEL NUREMBERG CASE FILED**

Unvaccinated threatened to be expelled, Threatening to deny unemployment benefits, Unvaccinated law proposed to prevent unvaccinated to enter work place, Preventing entry into schools, theatres, entertainment, and other receipt of services and goods. Applying social pressure, economic pressure, aggression from insurance, health authorities. Financial benefit cards and incentives promoting vaccination. Separating unvaccinated from society through green card system and passport. Heavily redacted contract agreement between Israel and Pfizer. The contract between Israel government and Pfizer is required Israel to transfer all the personal and medical records of citizens to Pfizer, without consent of the people. Israeli's were told and marketed that the vaccine was fully approved rather than EUA status. No voluntary participation or informed consent given. Nuremberg case is brought because the force upon the people is also without the ability to opt out or refuse. Including false advertisement about FDA approval.

<https://www.archyde.com/international-criminal-court-accepts-israeli-governments-nuremberg-code-violation-complaint/>

### **ISRAEL INFORMATION RELENTLESSLY BEING SUPRESSED**

#### **REPORT SUBMITTED TO ISRAEL ATTORNEY GENERAL AND THE HEALTH MINISTER**

In Israel yesterday, an independent legal body that calls itself the Civilian Probe (CP)\* published its finding regarding the catastrophic impact of the Pfizer vaccine on the nation. “Every world citizen who is concerned about the future of humanity should be alarmed by the CP’s findings and particularly by the **desperate and relentless attempts to suppress free academic, scientific and ethical discussion** about Covid, the so-called ‘vaccines’ or anything else.” The CP study also presents alarming medical findings regarding the **scale of lethal side effects and possible attempt to mislead not just Israelis but also the entire world.**

<http://www.nakim.org/israel-forums/viewtopic.php?t=270812>

<https://www.francesoir.fr/videos-debriefings/vaccination-en-israel-des-chiffres-de-mortalite-qui-interpellent-video>

<https://archive.ph/o/jiIVR/https://www.israelnationalnews.com/News/News.aspx/297051>

### **ISRAEL PROMISED SAFETY MONITORING SYSTEM NOT IN PLACE**

“Monitoring systems that enable the detection of side effects are a basic and critical condition for granting permission for mass use of any new medicine, certainly when a mass operation of treatment that is defined as experimental is given to millions, and especially when this treatment is given to an entire country...”

“In the absence of a transparent monitoring system that reports on side effects, not only have the Israeli government and the Ministry of Health failed citizens by **providing them with misleading information**, the Israeli government have failed both Pfizer and the rest of the world awaiting the results of the (so called) **‘real world experiment’** (that is taking place in Israel).”

“On the one hand, the state did **not inform the citizens that Pfizer’s vaccine is in experimental stages** that have not yet been completed, and that at this stage they are actually taking part in the experiment. On the other hand, the state did **not maintain transparent and open control and monitoring systems for the public**. As a result, there is a serious concern that this critical and negligent omission stems from: (a) the fear that such disclosure could interfere with the fulfilment of the objectives that may be implied by the Israel-Pfizer agreement or (b) the fear of diminishing demand for the exceptional number of vaccines that were purchased by Israel in advance, and / or (c) the fear of revealing unflattering results of the ‘experiment’ being carried out in Israel.”

<http://www.nakim.org/israel-forums/viewtopic.php?t=270812>

<https://www.francesoir.fr/videos-debriefings/vaccination-en-israel-des-chiffres-de-mortalite-qui-interpellent-video>

<https://archive.ph/o/jiIVR/https://www.israelnationalnews.com/News/News.aspx/297051>

### **INTERNATIONAL COURT TAKES ON ISRAEL NUREMBERG VIOLATION CASE**

The CP argues that “in order to generate demand (amongst the people) for the vaccine, the government and the Ministry of Health have **launched an unprecedented aggressive campaign, aiming to make Israelis rush to ‘get vaccinated.’** During that campaign, all the basic rules of medical caution and ethics were disregarded, and with them also key guidelines formed after WWII regarding participation in medical trials (the Nuremberg Code). Instead of transparent and clear explanations, the public was **misled by repeated official statements** that the (Pfizer vaccine) has been ‘approved by the FDA’ after passing ‘rigorous tests.’”

“the Pfizer-Israel agreement is suffocated with redacted segments, consequently, it is not possible to analyze it legally and/or fully grasp Its implications as far as public health is concerned... **This concealment casts a heavy shadow over anyone who took part in the (Israeli/Pfizer) negotiations...**”

<https://www.archyde.com/international-criminal-court-accepts-israeli-governments-nuremberg-code-violation-complaint/>

## **IVERMECTIN TREATMENT TESTIMONIES GIVEN TO HOMELAND SECURITY**

Ivermectin, miracle drug for COVID. Dr. Pierre Kory, president of the FLCCC Alliance testifies before Senate Committee on Homeland Security and Governmental Affairs looking into early outpatient COVID-19 treatment. FLCCC discovered ivermectin has a potent real-world properties in mild, moderate, and severe disease states. Database below of all IVERMECTIN COVID-19 studies. (89 studies, 48 peer-reviewed, 52 with treatment and control groups.)

<https://www.c-span.org/video/?c4929855/user-clip-dr-pierre-kory-president-flccc-alliance-testifies-senate-committee-homeland-security>

<https://c19ivermectin.com> (Database of Ivermectin studies including 48 peer reviewed.)

<https://covid19criticalcare.com/ivermectin-in-covid-19/>

<https://covid19criticalcare.com/wp-content/uploads/2020/12/One-Page-Summary-of-the-Clinical-Trials-Evidence-for-Ivermectin-in-COVID-19.pdf>

<https://osf.io/wx3zn/>

## **HDROX**

Database of all HCQ Covid-19 studies. 285 studies, 213 peer-reviewed, 236 comparing to control groups.

<https://c19hcq.com>

<https://pubmed.ncbi.nlm.nih.gov/33430933/>

<https://pubmed.ncbi.nlm.nih.gov/32616063/>

<https://budesonideworks.com/validation-2/>

## **VITAMIN D, QUERCITIN, SURAMIN**

74 Studies on Vitamin D. Database of all vitamin D Covid-19 studies. Analyzing outcomes and effect.

<https://c19vitamind.com>

<https://odysee.com/@SaveMedia:5/capitol-clarity-ryan-cole-on-covid-19-vitamin-d-vaccine-concerns:2>

<https://pubmed.ncbi.nlm.nih.gov/33278625/>

## **BUDESONIDE CASE STUDY AND MEDICAL JOURNALS**

The **most recent study by Oxford University** (randomized control trial) showed a 90% reduction in hospitalization for people with COVID. Below are links to a peer-reviewed studies, articles in medical journals, or news articles regarding the **efficacy of budesonide**. Medical Journals Articles and Studies in Additional Resource Section Addendum.

<https://www.medrxiv.org/content/10.1101/2021.02.04.21251134v1>

<https://www.ox.ac.uk/news/2021-02-09-common-asthma-treatment-reduces-need-hospitalisation-covid-19-patients-study>

<https://budesonideworks.com>

[https://covidsilverbullet.com/wp-content/uploads/2020/07/Bartlett\\_COVID\\_Case\\_Study.pdf](https://covidsilverbullet.com/wp-content/uploads/2020/07/Bartlett_COVID_Case_Study.pdf)  
<http://stateofthenation.co/?p=19630>

*Common asthma treatment reduces need for hospitalisation [by 90%] in COVID-19 patients, study suggests (University of Oxford)*

*Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection – ScienceDirect (from the American Journal of Medicine)*

### **HOME-BASED TREATMENT RESOURCES**

From the association of American Physicians and Surgeons, a group representing over 500,000 medical professionals across the United States.

<https://aapsonline.org>

### **Additional topics covered below in Addendum 1**

Including ingredient sm-102, Moderna Patent, Spike protein injuries, Prion's Disease and Covid Vaccine, and DARPA (A program operating under the DOD specializing in BioTech.)



**ADDENDUM 1**  
**ADDITIONAL SIGNIFICANT RESOURCES**

**Table of Contents**

10 BILLION IN ADDITIONAL MARKETING CAMPAIGNS .....	41
DANGER INGREDIENT SM-102 "THIS PRODUCT IS NOT FOR HUMAN OR VETERINARY USE." .....	41
MODERNA PATENT 16 CITATIONS OF GENE THERAPY, GENE TRANSFER, GENE THERAPEUTIC, GENE EDITING, GENE LINING REFERENCES.....	41
GENETICALLY ENGINEERED DNA VACCINES AND TUMORS .....	42
DOCTORS CENSORED FOR INTRODUCING EARLY PREVENTION TREATMENTS.....	42
MOST COMPREHENSIVE LIST OF VAX SIDE EFFECTS DR. RAY SAHELIAN, M.D. ....	43
INJURY RELATED TO SPIKE PROTEIN .....	44
INJURY RELATED TO ANTI-S-ANTIBODY AND ILLNESS DUE TO IMMUNE SYSTEM SUPPRESSION .....	44
PRION DISEASE AND COVID VACCINE .....	45
17 YEARS OF IMMUNITY FROM PREVIOUS COVID INFECTION .....	45
COVID SURVISORS IMMUNITY COULD LAST FOR YEARS.....	46
WOMEN'S PERIOD STORIES, PERIOD DISRUPTION, AND RESEARCH.....	46
POSSIBLE 3RD WAVE DOMINATED IN THE UK BY 60% VACCINATED IN HOSPITAL .....	46
NEW STANDFORD STUDY, INFLATED DISEASE SEVERITY IN CHILDREN.....	47
FORMER HHS ADVISOR WARNS VAX WILL HARM CHILDREN .....	47
MAMMOGRAM RESULTS SIDE EFFECT .....	47
75% OF VAERS INJURY REPORTS IN APRIL IS ABNORMALLY ONLY J&J REPORTS .....	48
LINK FOR INJURY STORIES.....	48
ESTIMATED CLINICAL TRIALS STUDY COMPLETION DATE.....	48
DARPA FUNDED MODERNA .....	48
DARPA+MODERNA+PROFUSA+GOOGLE+NIH+CEPHEID .....	49
DARPA (DIGET) .....	49
DARPA HYDROGEL.....	49
Copyright and intellectual property of Protection of the Educational Rights of Kids .....	40
www.perk-group.com	

## **10 BILLION IN ADDITIONAL MARKETING CAMPAIGNS**

Biden approved nearly \$10,000,000,000.00 for marketing campaigns, anticipating an oversupply. The U.S. government funded vaccine research to the tune of more than \$9 billion, spent \$22 billion to support vaccine distribution, shelled out another \$10 billion to expand access and currently announced \$3 billion to spend on an ad campaign to combat vaccine hesitancy.

<https://www.nytimes.com/2021/04/01/us/politics/coronavirus-vaccine-hesitancy.html>

<https://www.nytimes.com/2021/04/01/us/politics/coronavirus-vaccine-hesitancy.html>

<https://www.aanp.org/news-feed/nurse-practitioners-mobilize-to-increase-vaccinations-across-minority-communities-and-combat-vaccine-hesitancy>

## **DANGER INGREDIENT SM-102 "THIS PRODUCT IS NOT FOR HUMAN OR VETERINARY USE."**

Connecticut Department of Public Health recently released Moderna Ingredient (sm-102). SM-102 is an ingredient in Moderna's lipid nanoparticle mixture. The SM-102 product likely comes from Cayman Chemical, as their page lists it being used in lipid nanoparticle preparation and cites a publication by Moderna-affiliated authors. It's 10% SM-102 (ionizable lipid) and 90% chloroform (solvent). The Safety Data Sheet (SDS) for their product states it is an extremely toxic and hazardous substance, suspected of causing cancer, developmental toxicity, suspected of damaging fertility or the unborn child, damage to the central nervous system, the kidneys, the liver and the respiratory system through prolonged or repeated exposure. The company states: "This product is not for human or veterinary use."

<http://www.abovetopsecret.com/forum/thread1286756/pg1>

<https://fags.in.gov/hc/en-us/articles/360054156652-What-are-the-ingredients-in-the-Moderna-COVID-19-Vaccine->

<https://www.fda.gov/media/144637/download> (See 13. Pg. 20 DESCRIPTION of the FDA vaccine sheet)

<https://www.caymanchem.com/product/33474/sm-102>

<https://www.caymanchem.com/msdss/33474m.pdf> (pg. 1, 2, 10)

## **MODERNA PATENT 16 CITATIONS OF GENE THERAPY, GENE TRANSFER, GENE THERAPEUTIC, GENE EDITING, GENE LINING REFERENCES**

16 Citations and references in Moderna's official patent referencing mRNA therapy medicine as gene therapy, gene transfer, gene therapeutics, gene delivery, mRNA encoding humans.

<https://www.modernatx.com/sites/default/files/US10702600.pdf>

Page 5-6

- Kuhn , A.N. , et al . , mRNA as a versatile tool for exogenous protein expression . Current **Gene Therapy** . Oct. 2012 ; 12 ( 5 ) : 347-361 .
- Lorenzi , J.C. , et al . , Intranasal vaccination with messenger RNA as a **new approach in gene therapy** : Use against tuberculosis . BMC Biotechnol . Oct. 2010 ; 10 ( 77 ) : 1-11 .
- Rabinovich , P.M. , et al . , Synthetic messenger RNA as a tool for **gene therapy** . Hum . Gene Ther . Oct. 2006 ; 17 : 1027-1035 .
- Schott , J.W. , et al . , Viral and non - viral approaches for transient delivery of mRNA and proteins . Current **Gene Ther** . 2011 ; 11 ( 5 ) : 382-398 .

- Segura , J. , et al . , Monitoring **gene therapy** by external imaging of mRNA : Pilot study on murine erythropoietin . Ther Drug Monit . Oct. 2007 ; 29 ( 5 ) : 612-8 .
- Smits , E. , et al . , RNA - based **gene transfer** for adult stem cells and T cells . Leukemia . 2004 ; 18 : 1898-1902 .
- Strong , V.T. et al . , Incorporation of beta - globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression . Gene Ther . Jun . 1997 ; 4 ( 6 ) : 624-7 .
- Tavernier , G. , et al . , mRNA as **gene therapeutic** : How to control protein expression . J. of Controlled Release . Mar. 2011 ; 150 ( 3 ) : 238-247 .
- Wang et al . , Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer **gene therapy** . Mol Ther . Feb. 2013 ; 21 ( 2 ) : 358-67 . doi : 10.1038 / mt.2012.250 . Epub Dec. 11 , 2012 .
- Yamamoto et al . , Current prospects for mRNA **gene delivery** , European Journal of Pharmaceutics and Biopharmaceutics 71 ( 2009 ) 484-489 .
- Sahin et al . , mRNA - based therapeutics developing **a new class of drugs** . Nat Rev Drug Discov . Oct. 2014 ; 13 ( 10 ) : 759-80 . doi : 10.1038 / nrd4278 . Epub Sep. 19 , 2014 .
- Hecker , J.G. et al . , Non - Viral DNA and mRNA **Gene Delivery** to the CNS Pre - Operatively for Neuroprotection and Following Neurotrauma . Molecular Therapy . 2004 ; 9 , S258 - S258 .
- Hoerr , I. et al . , Stabilized Messenger RNA ( RNActive™ ) as a Tool for Innovative **Gene Delivery** . Tissue Engineering . Apr. 2007 ; 13 ( 4 ) : 865-925 . Hoerr ,
- More than a messenger : A new class of drugs - mRNA - based **therapeutics . Genetic Engineering & Biotechnology** News . Jun . 18 , 2013 . <http://www.genengnews.com/gen-articles/more-than-a-messenger-a-new-class-of-drugs-mrna-based-therapeutics/4916/> [ last accessed Mar. 25 , 2016 ] .
- Kisich et al . , Antimycobacterial agent based on **mRNA encoding human** beta - defensin 2 enables primary macrophages to restrict growth of Mycobacterium tuberculosis . Infect Immun . Apr. 2001 ; 69 ( 4 ) : 2692-9 .

## **GENETICALLY ENGINEERED DNA VACCINES AND TUMORS**

Deoxyribonucleic acid (DNA) vaccination is one technique used to stimulate humoral and cellular immune responds to foreign antigens, such as hMPV antigens and/or PIV antigens and/or RSV antigens. The direct injection of genetically engineered DNA (e.g. naked plasmid DNA) into a living host results in a small number of its cells directly producing an antigen, resulting in a protective immunological response, including the possibility of insertional mutagenesis, which could lead to the activation of oncogenes or the **inhibition of tumor suppressor genes.**

<https://www.modernatx.com/sites/default/files/US10702600.pdf> (Modern patent Pg. 31)

## **DOCTORS CENSORED FOR INTRODUCING EARLY PREVENTION TREATMENTS**

One of America's most-published physicians, **Peter McCullough**, MD, has been repeatedly censored. Peter A. McCullough, M.D., M.P.H., Vice Chief of Internal Medicine, Baylor University Medical Center. Doctors discuss suppression of treatment. Countless Doctors have stated their successful treatments have been suppressed. Including renowned Dr. **His Testimony to US Senate Committee Hearing:**



Video on November 19<sup>th</sup>, 2020 – **Early Outpatient Treatment: An Essential Part of a COVID-19 Solution.** Dr. McCullough and other witnesses give testimony at a US Senate Committee Hearing <https://www.hsgac.senate.gov/hearings/early-outpatient-treatment-an-essential-part-of-a-covid-19-solution>

**Video on His Treatment Publication:** October 11, 2020, see video of Dr. McCullough providing a critical update: **Ambulatory Treatment of COVID-19.** (Association of American Physicians and Surgeons) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410805/>  
[http://pb-site.com/1/bB-QG0ZVx/r1\\_kx\\_WuV8jN](http://pb-site.com/1/bB-QG0ZVx/r1_kx_WuV8jN)

### **UNPRECEDENTED PULL OF PEER REVIEWED MANUSCRIPT**

This was the second time this happened. The prior issue of IVERMECTIN manuscript was pulled at the last minute in February. Unprecedented in medicine, interference and suppression of completed and successfully acceptance of peer-review work. It was then picked up by the American Journal of Therapeutics, 3 rounds peer-review and was published on 4/29. See the full resignation LETTER and unprecedented interference below. Dr. Marik is one of eleven doctors with the Frontline Covid-19 Critical Care Alliance, and the second most published critical care doctor in the world. Dr. Pierre Kory, “I was trying to be fair and generous before now. This is clear censorship. There is no other possible rational explanation. It’s indefensible in science to reject a peer-reviewed accepted publication. It went through three rounds of peer review by experts in the field. It’s well-defensed. Our conclusions in that paper match exactly the conclusions of the international effort which is the British IVM Recommendation Development Guideline Committee meeting which is experts, researchers, clinicians from all over the world. Those conclusions are the same. Yet this journal did not want to publish our paper and they removed it. It is unconscionable.”

<https://www.hartgroup.org/.../05/ResignationsFrontiers.pdf>  
<https://tinyurl.com/y6yuytp7>

### **MOST COMPREHENSIVE LIST OF VAX SIDE EFFECTS DR. RAY SAHELIAN, M.D.**

After reviewing thousands of VAERS reports, Dr. Sahelian describes side effect details more thoroughly than most. His description and summary of the spike protein covid shot is also enlightening and informative. Giving readers the most comprehensive informed consent on risks and adverse reactions.

<https://raysahelian.com/covidvaccinesideeffects.html>  
<https://raysahelian.com/index.html>

## **CHILDREN EUA APPROVAL OF COVID SHOT WITH NO SAFETY DATA ON CO-ADMINISTRATION OF OTHER VACCINES**

On May 12, 2021, the ACIP committee approved the EUA authorization of the Pfizer shot for 12-15 year old's. They also are allowing CO-ADMINISTRATION with other shots on the same day. There aren't any studies or data on the interaction of a new mRNA shot with the existing other shots.

[https://www.bmj.com/content/373/bmj.n1244/rr-1?fbclid=IwAR1thWVZTPnHp\\_TYU9TMmCqd6K9Qah8Wtn5gnhOoriNI-H986M5oNPRWTEI](https://www.bmj.com/content/373/bmj.n1244/rr-1?fbclid=IwAR1thWVZTPnHp_TYU9TMmCqd6K9Qah8Wtn5gnhOoriNI-H986M5oNPRWTEI)  
<https://www.hhs.gov/live/live-1/index.html#13231>

## **INJURY RELATED TO SPIKE PROTEIN**

Spike protein - immobilize M2 macrophages;, cardiac damage, ACE2 Receptors, spike proteins bind tightly to ACE2, multi-organ system failure, pulmonary artery hypertension, spike proteins attach to sperm and eggs, (Syncytin - "Quite simply, syncytin is critical and without it, human life could never form."), spike proteins: loss of BBB integrity, Amyotrophic Lateral Sclerosis (ALS), prion disease, damage to FUS gene and TDP-43 protein: The RNA sequence in the vaccine [3] contains sequences believed to induce TDP-43 and FUS to aggregate in their prion based conformation leading to the development of common neurodegenerative diseases, 5 Types frontotemporal lobe degeneration, FUS gene and cancer, adenoviruses and cancer, 20 mechanisms of injury (MOI). Compiled by Dr. Sherri Tenpenny. [www.DrTenpenny.com](http://www.DrTenpenny.com)  
<https://insight.jci.org/articles/view/123158> (cardiac damage)  
<https://www.salk.edu/news-release/the-novel-coronavirus-spike-protein-plays-additional-keyrole-> (in illness)  
<https://pubmed.ncbi.nlm.nih.gov/15141377/> (ACE2 Receptors)  
<https://www.preprints.org/manuscript/202003.0422/v1> (Spike Proteins bind tightly to ACE2)  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533045/> (Multiorgan system failure)  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827936/> (pulmonary artery hypertension)  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941816> (spike proteins: attach to sperm and eggs)  
<http://isciencemag.co.uk/features/the-syncytin-gene-viruses-responsible-for-human-life/> Syncytin- "without it, human life could never form."  
<https://www.sciencedirect.com/science/article/pii/S096999612030406X?via%3Dihub> (loss BBB integrity)  
<https://carterheavyindustries.files.wordpress.com/2021/02/covid19-rna-based-vaccines-and-therisk-> (ALS)  
<https://www.hopkinsmedicine.org/health/conditions-and-diseases/prion-diseases> (prion disease)  
<https://principia-scientific.com/covid-19-rna-based-vaccines-and-the-risk-of-priondisease/> neurodegenerativ  
<https://pubmed.ncbi.nlm.nih.gov/23041957/> (frontotemporal lobe degeneration)  
<https://medlineplus.gov/genetics/gene/fus/#conditions> (FUS gene and cancer)  
<https://www.ncbi.nlm.nih.gov/books/NBK8503/> (adenoviruses and cancer)

## **INJURY RELATED TO ANTI-S-ANTIBODY AND ILLNESS DUE TO IMMUNE SYSTEM SUPPRESSION**

Already cited are acute reactions (anaphylaxis, cardiac arrest) and illness or damage caused by spike proteins. Cited below is injury caused by anti-S-antibody and illness/damage to immune system (macrophage damage, ADE, original antigenic sin, etc)

<https://insight.jci.org/articles/view/123158> (anti-S-antibody damage, lung damage)  
<https://www.frontiersin.org/articles/10.3389/fimmu.2020.617089/full#f1> (28 of 55 tissue types react- antibody)  
<https://www.frontiersin.org/articles/10.3389/fimmu.2020.01120/full> (original antigenic sin)  
<https://peerj.com/articles/10112/> (flu shots and COVID deaths)  
<https://jamanetwork.com/journals/jama/article-abstract/2777390> (severe and prolonged illness)  
<https://www.frontiersin.org/articles/10.3389/fimmu.2020.01120/full>  
<https://www.sbi-online.org/Portals/0/Position%20Statements/2021/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf> (Swollen lymph node)  
<https://jamanetwork.com/journals/jama/article-abstract/2777390> (mutant strains)



<https://www.sciencedirect.com/science/article/abs/pii/S1286457920300344?via%3Dihub> (ADE on re-exposure)  
<https://www.fda.gov/media/146219/download> (Injected of transgenes and DNA can lead to anti-DNA antibodies. Foreign DNA can integrate into human DNA. JJ Shot pg 12 – Transgene.  
<https://www.i-sis.org.uk/transgenicLinesUnstable2.php> (Instability of transgene lines)  
[https://www.academia.edu/23304303/Medical\\_conditions\\_associated\\_with\\_a\\_positive\\_anti\\_double\\_stranded\\_deoxyribonucleic\\_acid\\_\(dsDNA\\_Antibodies\\_associated\\_with\\_long\\_list\\_of\\_illnesses\)](https://www.academia.edu/23304303/Medical_conditions_associated_with_a_positive_anti_double_stranded_deoxyribonucleic_acid_(dsDNA_Antibodies_associated_with_long_list_of_illnesses))  
<https://covid19-sciencetable.ca/sciencebrief/vaccine-induced-prothrombotic-immunothrombocytopenia-vipit-following-astrazeneca-covid-19-vaccination/> (deadly blood clots)  
(MOI) Compiled by Dr. Sherri Tenpenny. [www.DrTenpenny.com](http://www.DrTenpenny.com)

## **ACUTE REACTIONS**

MOI #1 anaphylaxis/PEG:

<https://www.sciencedirect.com/science/article/pii/S2451945619300352>

## **PRION DISEASE AND COVID VACCINE**

**"Covid-19 RNA Based Vaccines and the Risk of Prion Diseases,"** just published in MICROBIOLOGY AND INFECTIONS DISEASES, **addresses one of the many potential, unintended, adverse health effects of the experimental mRNA Covid-19 vaccines presently being deployed worldwide, namely, their possible induction of prion diseases, a category of highly fatal brain disorders.** The concluding paragraph in the 3-page journal article: "Many have raised the warning that the current epidemic of COVID-19 is actually the result of a bioweapons attack released in part by individuals in the United States government [10,11]. Such a theory is not far fetched given that the 2001 anthrax attack in the US originated at Fort Detrick, a US army bioweapon facility. Because the FBI's anthrax investigation was closed against the advice of the lead FBI agent in the case, there are likely conspirators still working in the US government. In such a scenario the primary focus of stopping a bioweapons attack must be to apprehend the conspirators or the attacks will never cease. Approving a vaccine, utilizing novel RNA technology without extensive testing is extremely dangerous. The vaccine could be a bioweapon and even more dangerous than the original infection."

<https://scivisionpub.com/pdfs/covid19-rna-based-vaccines-and-the-risk-of-prion-disease-1503.pdf>

<https://www.greenmedinfo.com/blog/study-finds-plausible-link-between-deadly-prion-brain-diseases-experimental-mrna-3>

## **17 YEARS OF IMMUNITY FROM PREVIOUS COVID INFECTION**

Robust immune response from T-Cells with protective cross over immunity, protection, and qualities protective of other COVID viruses and infections. Memory T-cells persist with cross over protection for years. Studies include convalescent SARS-CoV-2 patients and found they had also produced similar T-cells. While SARS-CoV-2 is a new virus and distinct from SARS-CoV-1, there is strong reason to believe that T-Cell memory produced by the body to protect from future relapses of this virus would not be weaker or more short-lived than T-cell memory from SARS-1.

<https://www.nature.com/articles/s41586-020-2550-z>

<https://immunology.sciencemag.org/content/2/14/eaan5393>

<https://www.nature.com/articles/nri820>

<https://linkinghub.elsevier.com/retrieve/pii/S1074761313000526>

<https://linkinghub.elsevier.com/retrieve/pii/0140673693930637>

<https://www.frontiersin.org/articles/10.3389/fimmu.2018.02225/full>

[https://www.cell.com/cell-reports/fulltext/S2211-1247\(20\)30515-](https://www.cell.com/cell-reports/fulltext/S2211-1247(20)30515-5?returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124720305155%3Fshowall%3Dtrue)

[5?returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124720305155%3Fshowall%3Dtrue](https://www.cell.com/cell-reports/fulltext/S2211-1247(20)30515-5?returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124720305155%3Fshowall%3Dtrue)

<https://rupress.org/jem/article/201/5/675/40209/Heterologous-T-cell-immunity-in-severe-hepatitis-C>

<https://www.sciencedirect.com/science/article/pii/S0264410X16002589?via%3Dihub>

[https://www.cell.com/cell-host-microbe/fulltext/S1931-3128\(20\)30072-X?\\_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS193131282030072X%3Fshowall%3Dtrue](https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(20)30072-X?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS193131282030072X%3Fshowall%3Dtrue)  
[https://www.cell.com/immunity/fulltext/S1074-7613\(20\)30181-3?\\_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761320301813%3Fshowall%3Dtrue](https://www.cell.com/immunity/fulltext/S1074-7613(20)30181-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761320301813%3Fshowall%3Dtrue)

### **COVID SURVISORS IMMUNITY COULD LAST FOR YEARS**

The human immune system is more than just antibodies. T-cells, NK cells, antibodies, and more are critical to a healthy immune system. Previous Sars Covid infections have the potential of 17 years of immunity.

<https://www.technologyreview.com/2021/01/06/1015822/covid-19-immunity-likely-lasts-for-years/?fbclid=IwAR1CcU339aQL8kxwtQY3WL5kSjB72ZPtYejH6JbZcs3I0Sve7CyLn3A2x-8>  
[https://www.cell.com/cell/fulltext/S0092-8674\(20\)30610-3](https://www.cell.com/cell/fulltext/S0092-8674(20)30610-3)  
<https://www.lji.org/news-events/news/post/exposure-to-common-cold-coronaviruses-can-teach-the-immune-system-to-recognize-sars-cov-2/>  
<https://science.sciencemag.org/content/371/6529/eabf4063>  
<https://www.psychologytoday.com/us/blog/live-better-longer/202104/are-we-immune-covid-19-if-weve-been-exposed>  
<https://www.nature.com/articles/s41577-020-00436-4>

### **QUESTIONS SURROUNDING SPIKE PROTEIN SHEDDING**

Can people shed the spike that the vaccine is asking their cells to make?

<https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075>

### **WOMEN'S PERIOD STORIES, PERIOD DISRUPTION, AND RESEARCH**

Concerning stories coming from women.

[https://www.risemamarise.com/cycles?fbclid=IwAR0l6utHbFeW\\_LD9PZFh6qqKucHHIHRQmgj3QOLuNdkjmQReCcur1\\_4TLA](https://www.risemamarise.com/cycles?fbclid=IwAR0l6utHbFeW_LD9PZFh6qqKucHHIHRQmgj3QOLuNdkjmQReCcur1_4TLA)  
<https://www.risemamarise.com/cycles>  
<https://mycyclestory.com/>

### **POSSIBLE 3RD WAVE DOMINATED IN THE UK BY 60% VACCINATED IN HOSPITAL**

According to a UK government study on the government website, entitled "SPI-M-O: Summary of further modelling of easing restrictions - Roadmap Step 2" dated March 31, 2021, states that:

"The resurgence in both hospitalizations and deaths is dominated by those that have received two doses of the vaccine, comprising around 60% and 70% of the wave respectively. This can be attributed to the high levels of uptake in the most at-risk age groups, such that immunization failures account for more serious illness than unvaccinated individuals. This is discussed further in paragraphs 55 and 56." The study states that people with already two doses of vaccination now make up the rise in Corona deaths and hospitalizations. They account for about two-thirds of all cases. Link of the study & back up link below.

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/975909/S1182\\_SPI-M-O\\_Summary\\_of\\_modelling\\_of\\_easing\\_roadmap\\_step\\_2\\_restrictions.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/975909/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf)  
[https://blog.fdik.org/2021-04/S1182\\_SPI-M-O\\_Summary\\_of\\_modelling\\_of\\_easing\\_roadmap\\_step\\_2\\_restrictions.pdf](https://blog.fdik.org/2021-04/S1182_SPI-M-O_Summary_of_modelling_of_easing_roadmap_step_2_restrictions.pdf) (page 10)

### **COVID VACCINE CONSENT FORM**

"I understand that these may not be all the side effects of the COVID-19 vaccine as the vaccine is still being studied in clinical trials. I also understand that it is not possible to predict all possible side effects or complications which could be associated with the vaccine. I understand that the long-term

**side effects or complications of this vaccine are not known at this time.”**

<https://principia-scientific.com/have-you-actually-read-a-covid19-vaccine-consent-form-yet/?fbclid=IwAR3lgpK152gzwIX9-IgeLYFlyQShPTagTL2a9q96OFDBerrA-nGfreL-128>

### **NEW STANFORD STUDY, INFLATED DISEASE SEVERITY IN CHILDREN**

Dr. Schroeder and his team suggested that pediatric hospitalization rates are used as a marker of coronavirus disease 2019 (COVID-19) disease severity in children but may be inflated by the detection of mild or asymptomatic infection via universal screening.

<https://hosppeds.aappublications.org/content/hosppeds/early/2021/05/21/hped.2021-006001.full.pdf>

### **FORMER HHS ADVISOR WARNS VAX WILL HARM CHILDREN**

Former HHS COVID advisor, Dr. Paul Alexander warns against children getting the COVID19 vaccine. Fox news is one of the few stations willing to carry this warning. “Kids have a 1 in 50,000 chance of dying if they are covid infected. It’s a very, very small risk. Again the issue is why would they be placing parents in this position to vaccinate these children with such low risk. When this is an experimental vaccine. It’s highly untested as to safety and they will not have the requisite time duration and sample size to get the power to detect any meaningful differences. So, I think they are absolutely wrong...The risk to children is so small. There is no reason too put our children in harms way at this point. Not with these untested vaccines and with a sample size of 3000...There is no way they can derive meaningful results and safety data for parents. This is reckless.”

“Exposing children to an untested Emergency Use medication implies that there is a dire risk to the children without it. There are no data to support such a potential risk.” “The key for parents to understand is this, these will NOT provide you the type of safety data to give you the level of confidence to put these vaccines in your children’s arms. Because we are talking about, children have 70-80 years more life to live. There could be devastated by these vaccines if something goes wrong. And again the issue is the liability waiver.”

<https://www.aier.org/article/why-we-must-not-be-forced-into-vaccinating-our-children-from-covid-beware/>  
<https://video.foxnews.com/v/6252603254001>

<https://www.lifesitenews.com/news/its-reckless-to-vaccinate-children-for-covid-19-former-hhs-coronavirus-advisor>

### **TESTIMONY FROM DOCTOR SCIENTIST CALLS FOR A HALT**

A sobering testimony to the CDC from a research scientist who saw ovarian destruction in novel contraceptive tests earlier. Menses disruptions, blood clotting, sperm issues, immunosuppressive issues, fertility issues, now, highlighted. She calls for a halt.

<https://www.jennifermargulis.net/halt-covid-vaccine-research-scientist-urges-cdc/>

### **VACCINE CHECKERS GOING DOOR TO DOOR IN CALIFORNIA**

Thousands hired to go door to door.

<https://californiaglobe.com/section-2/gov-newsom-sending-vax-checkers-door-to-door/>

[https://www.msn.com/en-us/news/us/knock-knock-have-you-had-your-vaccine-yet-california-sends-out-thousands-to-check/ar-BB1gUqD0?fbclid=IwAR3aG3vgKnW-Ympm4AlzR04WI2UAN\\_UWvq3nxQs7wz54kIMhNtrpdGtRIi0](https://www.msn.com/en-us/news/us/knock-knock-have-you-had-your-vaccine-yet-california-sends-out-thousands-to-check/ar-BB1gUqD0?fbclid=IwAR3aG3vgKnW-Ympm4AlzR04WI2UAN_UWvq3nxQs7wz54kIMhNtrpdGtRIi0)

### **MAMMOGRAM RESULTS SIDE EFFECT**

As women get their yearly mammograms, doctors have noticed something impacting results: the presence of swollen lymph nodes, a common side effect of the COVID-19 vaccine.

<https://www.thv11.com/article/news/health/covid-vaccine-side-effect-imammogram-results/91-1ab98fb0-eda0-4bc3-9aef-100c26a93667>



## **75% OF VAERS INJURY REPORTS IN APRIL IS ABNORMALLY ONLY J&J REPORTS**

Reporter Berenson shows evidence today that HHS is rushing to add J&J adverse event reports to VAERS while slow walking reports for Pfizer & Moderna. But the harms from Pfizer & Moderna are greater than from the J&J product. “So you've gotta ask WHY? Is this a story of financial conflicts of interest (shared patents with NIH for the mRNA products). Or something else? Why kill the adenovirus vector products and protect the mRNA product line when the mRNA safety profile is actually worse?”

<https://twitter.com/AlexBerenson/status/1392499188794003460>

## **PRO VACCINE PEDIATRICIAN DOCTOR TESTIFIED BEFORE TEXAS SENATE TO PROTECT CHILDREN FROM THIS SHOT**

In public testimony, Pediatrician Dr. Angelina Farella said, “Never in history before have we given medications that were not FDA approved to people who were not initially studied in the trial. There were no trial patients under the age 18. There were no trial patients previously had covid. . . I have given tens of thousands of vaccines in my office. At the recent ACIP meeting, one of the things that is extremely troubling, and it’s on their ACIP guidelines for the Pfizer vaccine in particular, is that recommendations about safety and efficacy and adverse events will come out AFTER authorization.”

“We are currently allowing children to get this vaccine, and they were never studied in the clinical trial. On top of that. . . they are extrapolating the data from adults down to children and adolescents. . . Children are not little adults. This is unacceptable. Children have a 99.997% survivability.”

<https://youtu.be/mIPb0AtEvAE>

## **THE CONTROL GROUP NO LONGER EXISTS**

If the unblinding and the offer to placebo recipients to get vaccinated in a randomized placebo-controlled trial (RCT) began within weeks of EUA, then we had an RCT for only the duration of time till EUA (2-3 months). After that, the trial can no longer be deemed a randomized placebo-controlled trial, as the control group, which is needed to know the baseline rates of COVID and adverse events against which to compare the rates in the vaccinated group, no longer exists. They might as well terminate the trials altogether right after EUA instead of continuing with this false and pretending they are doing science.

Peter Doshi's article in the BMJ: <https://www.bmj.com/content/373/bmj.n1244/rr-1>

## **LINK FOR INJURY STORIES**

<http://covidvaccinevictims.com/>

## **ESTIMATED CLINICAL TRIALS STUDY COMPLETION DATE**

**April 6, 2023**

<https://clinicaltrials.gov/ct2/show/NCT04368728>

## **DARPA FUNDED MODERNA**

Moderna, The first company in the United States to enter clinical trials with a vaccine for the virus was funded by DARPA. Additionally, the second company, working was also funded by DARPA as well. Receiving over \$1.5 Billion dollars this year. Without disclosing DARPA and government invested funds. The Defense Advanced Research Projects Agency (DARPA) is a research and development agency of the United States Department of Defense responsible for the development of emerging technologies for use by the military. The DARPA SIGMA+ program is developing networked sensors to detect a variety of chemical, biological, and explosive threats. Key to this undertaking are technologies centered on DNA and RNA— including some developed under DARPA’s, ADEPT program. Using these tools, through a biological version

of **reverse engineering, manufacture genetic constructs** that, when delivered, can instruct an individual's body to produce similar protective antibodies.

<https://www.statnews.com/pharmalot/2020/08/28/moderna-covid19-vaccine-coronavirus-patents-darpa/>

<https://www.darpa.mil/work-with-us/covid-19>

<https://www.darpa.mil/news-events/2017-02-06a>

<https://www.darpa.mil/program/autonomous-diagnostics-to-enable-prevention-and-therapeutics>

### **DARPA+MODERNA+PROFUSA+GOOGLE+NIH+CEPHEID**

DARPA funds Moderna (after years of DARPA initiatives and focused RNA and DNA vaccines technologies. DARPA funds Profusa which created a wearable injected biosensor, which syncs up to a smart phone app. Google backs Profusa, while Google also is intimately involved in surveillance programs, censorship, and contact tracing initiatives. Profusa is also partnered and funded by the NIH and DARPA. DARPA's years-old goal of creating a national, web-based database of preemptive diagnoses is noticed in the current "push" for a national contact tracing system, vaccine passports, and health pass systems based on citizens' private health data and vaccine status. The additional overlap runs deep as the co-founder of Profusa is also a co-founder in Cepheid the diagnostic company of a rapid coronavirus test, who won FDA approval.

<https://www.theguardian.com/science/2017/dec/04/us-military-agency-invests-100m-in-genetic-extinction-technologies>

<https://profusa.com/our-team/>

<https://www.theverge.com/platform/amp/interface/2020/4/14/21219289/apple-google-contact-tracing-app-android-ios-pros-cons-quarantine-testing>

<https://profusa.com/partners-investors/>

<https://techstartups.com/2020/03/21/fda-approves-rapid-coronavirus-test-results-45-minutes-test-conducted-california-based-diagnostic-testing-company-cepheid/>

### **DARPA (DIGET)**

DARPA began the Detect It with Gene Editing Technologies (DIGET) and the Epigenetic Characterization and Observation (ECHO) programs focused on rapid discovery, validation, and manufacture of diagnostics detecting any threat, anytime, anywhere. DARPA provided near-real-time diagnostic results during a 2 month study... The team is now focusing on expanding the cohort and tracking long-term host response. DARPA Gel or hydrogel is part of the vaccines.

<https://www.darpa.mil/work-with-us/covid-19>

### **DARPA MICROCHIP SENSOR**

Sensor under the skin.

<https://www.dailymail.co.uk/news/article-9460389/Pentagon-scientists-invent-microchip-senses-COVID-19-body-symptoms.html>

### **DARPA HYDROGEL**

DARPA's ongoing web series highlighting the agency's active programs focused on the diagnosis, detection, treatment, prevention and manufacture of *medical countermeasures*. Over the years, DARPA-funded projects have created the building blocks of GPS, the first computer mouse, protocols that underpin the modern Internet. The agency pioneered stealth technology that made American fighter jets all but invisible to enemy radar. It advanced a bevy of new weaponry, including drones. As DARPA shifted to biotechnology, including funding Profusa's creation of a wearable sensor, it's not so far-fetched that DARPA hydrogel contains nanoparticles and nanotechnology.

<https://www.darpa.mil/work-with-us/covid-19>

<https://www.darpa.mil/>

[https://www.washingtonpost.com/national-security/how-a-secretive-pentagon-agency-seeded-the-ground-for-a-rapid-coronavirus-cure/2020/07/30/ad1853c4-c778-11ea-a9d3-74640f25b953\\_story.html](https://www.washingtonpost.com/national-security/how-a-secretive-pentagon-agency-seeded-the-ground-for-a-rapid-coronavirus-cure/2020/07/30/ad1853c4-c778-11ea-a9d3-74640f25b953_story.html)

### CATEGORIES COVERED

\$10 Billion in Marketing	Sm-102
Moderna Patent 16 Gene Therapy Citations	Tumors
Early Treatment Suppression	Most Cited Doctor Censored
Peer-Reviewed Journal Problems	Most Comprehensive List of Vaccine Side Effects
No Safety Data on Co-Administration on Children	Spike Protein (MOI)- 20 Mechanisms of Injury
Prion Disease	17 Years of Immunity, Covid Survivors
DARPA Funded Moderna	Disrupted Menstruation Cycles
Projection of 3 <sup>rd</sup> Wave in the UK	Informed Consent Form
Stanford Study- Inflated Hospital Numbers in Children	HHS Advisor Warning About Children
Doctor Warns to Halt Everything	Door to Door Vaccine Checkers
Mammogram Disruption	Abnormal J&J Reporting
The Control Group No Longer Exists	

**\*\*\*Medical disclaimer:** *This pdf, information, resource list, and website information was created for informational purposes only and has no ties to any drug company or physician. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. In addition, no one involved in this website has financial ties to any of the suggested therapies. We are merely advocates of informed consent, open dialogue on all sides of an issue, and fight medical censorship.\*\*\**

# CONCLUSION

From the beginning, professionals have raised concerns and warnings of ADE, immune escape, ineffective protection from the shot, short immune protection beyond 2 months was never shown in clinical trials, red flags concerning inoculating previously infected with covid, including asymptomatic carriers, allergic reactions to PEG, and instability in the body, toxicity. Many voiced problems about new unforeseen results from a new, investigational product, never before approved, including problems with stronger variants consequentially from mass inoculation. Others alerted of a failed injury surveillance system and enhanced disease as seen in failed animal trials.

Whistleblowers claimed faulty designed clinical trials were based on ineffective case definition with trials deficient in safety and efficacy. Still yet, clinical trials did not prove transmission would be stopped after inoculation. There are no long-term studies, no long-term data on mass population responses to the shots, no data on effectiveness on mutations, no data on co-infections, no data on immunocompromised taking the shot. Prevalent with numerous unknown reactions including to mNeonGreen. What happens if there continues to be an ignoring of warnings signs of pathogenic priming? The unexplained phenomenon is shaking women across the world to the core. A minimum of thousands of women are reporting having reproductive health issues including abnormal bleeding, bruising, clotting reactions, including women who were not injected with the new shot, but are simply around recently inoculated persons. If we ignore the censorship of: (scientists, doctors, researchers, virologists, whistleblowers, across the globe), and game changing altering of our innate immune systems, what happens to our children, this generation, and humanity?

Previously convicted criminals leading the charge in manufacturing, brand new medicine that itself had been plagued with ethical concerns and high risks. Those convicted with fraud, bribery, corruption, false labeling, defective products, toxic products, knowingly letting them stay in public circulation with consumers, NOW, have no liability or way to be held accountable if past behavior patterns transfer into these golden “liability free” products.

This list predominately comes from the original sources, credible scientific journals, peer reviewed studies, to allow people access to original source information. Information has been withheld from traditional searches or labeled with blanket misinformation stamps. Leaving truth seekers unsure what is true and reliable. Those warning from around the world are being canceled, attacked, dismissed, and their information is being deleted.

A “SHOT” heard around the world is symbolic for a historic global moment. A careful evaluation may give credence to the thousands of experts who have been censored, removed from online, targeted with removal of their licenses, as they lay it all on the line to get this information to the public. May we hear the “SHOT heard around the word” before our children are unnecessarily harmed.

*\*\*\*Medical disclaimer: This pdf, information, and website information was created for informational purposes only and has no ties to any drug company or physician. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. In addition, no one involved in this website has financial ties to any of the suggested therapies. We are merely advocates of informed consent, trying to save lives, and fight medical censorship.\*\*\**

## **ADDITIONAL RESOURCE LINKS**

### **MORE RESOURCES IN JOURNALS ABOUT PREVIOUS ADE IN CV FAMILY OF VIRUSES:**

<https://pubmed.ncbi.nlm.nih.gov/32428113/>  
<https://pubmed.ncbi.nlm.nih.gov/32229574/>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165470/>  
<https://pubmed.ncbi.nlm.nih.gov/32092539/>  
<https://pubmed.ncbi.nlm.nih.gov/12725690/>  
<https://pubmed.ncbi.nlm.nih.gov/29740424/>  
<https://pubmed.ncbi.nlm.nih.gov/21200427/>  
<https://pubmed.ncbi.nlm.nih.gov/21401915/>  
<https://pubmed.ncbi.nlm.nih.gov/30796434/>  
<https://pubmed.ncbi.nlm.nih.gov/24182427/>  
<https://www.ncbi.nlm.nih.gov/pubmed/28360135>  
<https://pubmed.ncbi.nlm.nih.gov/12810865/> (ADE mice)  
<https://www.ncbi.nlm.nih.gov/pubmed/28817732> (White rabbits)  
<https://pubmed.ncbi.nlm.nih.gov/19122397/> (feline)  
<https://pubmed.ncbi.nlm.nih.gov/2154621/> (feline)  
<https://pubmed.ncbi.nlm.nih.gov/6754243/> (feline in Dengue)  
<https://pubmed.ncbi.nlm.nih.gov/17049691/> (hamsters)  
<https://www.ncbi.nlm.nih.gov/pubmed/21937658> (Mice, increase lung inflammation on challenge)  
<https://pubmed.ncbi.nlm.nih.gov/29029938/> (vaccine enhanced disease)  
<https://www.nature.com/articles/d41586-020-00751-9> (don't rush CV vaccine without guarantees)  
<https://pubmed.ncbi.nlm.nih.gov/32179860/>  
<https://pubmed.ncbi.nlm.nih.gov/32317716/> (danger antibody response in rushed CV-shots)  
[https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=1075&context=vmpm\\_pubs](https://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=1075&context=vmpm_pubs) (Ebola)  
<https://pubmed.ncbi.nlm.nih.gov/27339099/> (zika)  
<https://technology.inquirer.net/69907/pharma-firm-issues-caution-anti-dengue-vaccine-sanofi-dengvaxia-vaccine-health-dengue> (Pharma firm issues caution on use of anti-dengue)  
<https://pubmed.ncbi.nlm.nih.gov/30410732/>  
<https://www.rappler.com/nation/child-vaccination-rate-philippines-as-of-september-2018> (Dengue distrust in free vaccines post scare of Dengue outcome.)  
<https://www.telegraph.co.uk/news/2018/02/05/philippines-immunisation-rates-plummet-amid-dengue-vaccination/> (Philippines)

### **BUDESONIDE MEDICAL JOURNAL ARTICLES AND STUDIES**

*Common asthma treatment reduces need for hospitalisation [by 90%] in COVID-19 patients, study suggests (University of Oxford)*  
*Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection – ScienceDirect (from the American Journal of Medicine)*  
*Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) (Reviews in Cardiovascular Medicine)*  
*Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective (from European Respiratory Journal)*  
*Inhaled corticosteroids in virus pandemics: a treatment for COVID-19? (From The Lancet)*  
*SARS-CoV-2 and The Case for Empirical Treatment (The Global Journal of Science Frontier Research – Volume 20, Issue 4)*  
*Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection (US National Library of Medicine National Institutes of Health)*  
*Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients (US National Library of Medicine National Institutes of Health)*

*Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/ acute respiratory distress syndrome (US National Library of Medicine National Institutes of Health)*

#### **IVERMECTIN ADDITIONAL LINKS**

<https://pubmed.ncbi.nlm.nih.gov/32251768/>  
<https://pubmed.ncbi.nlm.nih.gov/33234158/>  
<https://pubmed.ncbi.nlm.nih.gov/33115543/>  
<https://pubmed.ncbi.nlm.nih.gov/32513289/>  
<https://pubmed.ncbi.nlm.nih.gov/33038449/>  
<https://pubmed.ncbi.nlm.nih.gov/33341233/>  
<https://pubmed.ncbi.nlm.nih.gov/33397429/>  
<https://pubmed.ncbi.nlm.nih.gov/33430924/>  
<https://pubmed.ncbi.nlm.nih.gov/33662102/>  
<https://pubmed.ncbi.nlm.nih.gov/32493494/>  
<https://pubmed.ncbi.nlm.nih.gov/33407777/>

#### **VITAMIN D ADDITIONAL SOURCES**

<https://pubmed.ncbi.nlm.nih.gov/32252338/>  
<https://pubmed.ncbi.nlm.nih.gov/32755992/>  
<https://pubmed.ncbi.nlm.nih.gov/32474141/>  
<https://pubmed.ncbi.nlm.nih.gov/32946517/>  
<https://pubmed.ncbi.nlm.nih.gov/32784601/>  
<https://pubmed.ncbi.nlm.nih.gov/32605780/>  
<https://budesonideworks.com/validation-2/>

#### **JOHN HOPKINS SECOND DOSE WORSE SIDE EFFECTS**

<https://www.jhsph.edu/covid-19/articles/side-effects-and-covid-19-vaccines-what-to-expect.html>  
<https://pubmed.ncbi.nlm.nih.gov/30370619/>

#### **PFIZER, ASTRAZENECA, MODERNA HEALTH CARE INFORMATION UK**

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/967860/Temporary\\_Authorisation\\_Patient\\_Information\\_BNT162\\_7\\_0\\_UK\\_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/967860/Temporary_Authorisation_Patient_Information_BNT162_7_0_UK_.pdf)  
[https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/01/Information\\_for\\_UK\\_recipients\\_COVID-19\\_Vaccine\\_AstraZeneca.pdf](https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/01/Information_for_UK_recipients_COVID-19_Vaccine_AstraZeneca.pdf)  
[https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-product-information_en.pdf)  
[https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-epar-product-information_en.pdf)

#### **DATA ON DEATHS AND RECLASSIFICATIONS**

<https://drive.google.com/file/d/1-Xgb7aKGd5K-hOCjL4pY440R-DeWISDF/view>

#### **RE-EXPOSURE TO S PROTEIN IN SUBJECTS PREVIOUSLY PRIMED BY NATURAL INFECTION ELICITS CROSS-VARIANT NEUTRALIZING ANTIBODIES**

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (*Science*)

#### **INFLUENZA PANDEMIC 1918: AUTOPSY SAMPLES INDICATE NO NEW VARIANTS OCCURRED**

[1918 Influenza Pandemic Caused by Highly Conserved Viruses with Two Receptor-Binding Variants](#)  
[1918 Influenza: the Mother of All Pandemics](#)



### **ABORTED FETAL CELL LINES USED IN TESTING AND VACCINE**

<https://soundchoice.org/vaccines/covid-19-vaccine-chart/>

<https://cogforlife.org/wp-content/uploads/CovidCompareMoralImmoral.pdf>

### **ADDITIONAL REFERENCES ON IMMUNE ESCAPE, NK CELLS, INATE IMMUNITY, VARIANTS, CURRENT CDC RATES, AND MORE**

#### **NATURAL ANTIBODIES (B-1A CELLS, SIGM, NATURAL ABS & INNATE IMMUNITY TO COV AND COVID-19)**

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202830/>

doi: [https://doi.org/10.1016/S2352-4642\(20\)30135-8](https://doi.org/10.1016/S2352-4642(20)30135-8)

<https://www.frontiersin.org/articles/10.3389/fimmu.2020.02139/full>

<https://www.nature.com/articles/s41385-020-00359-2>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526850/>

<https://www.frontiersin.org/articles/10.3389/fimmu.2020.595535/full>

[https://journals.lww.com/shockjournal/fulltext/2020/11000/therapeutic\\_potential\\_of\\_b\\_1a\\_cells\\_in\\_covid\\_19.2.aspx](https://journals.lww.com/shockjournal/fulltext/2020/11000/therapeutic_potential_of_b_1a_cells_in_covid_19.2.aspx)

<https://www.frontiersin.org/articles/10.3389/fphar.2020.01309/full>

<https://pubmed.ncbi.nlm.nih.gov/23692567/>

<https://pubmed.ncbi.nlm.nih.gov/20948548/>

<https://www.sciencedirect.com/science/article/pii/S1939455120303793>

<https://www.frontiersin.org/articles/10.3389/fimmu.2019.00483/full>

#### **ROLE OF NATURAL ABS AND NK CELLS IN ASYMPTOMATIC CARRIERS**

- Substantial transmission by asymptotically infected subjects ; protection of asymptomatic carriers not due to Abs

<https://www.medrxiv.org/content/10.1101/2020.12.18.20248447v1>

<https://pubmed.ncbi.nlm.nih.gov/33391280/>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608887/>

<https://www.nature.com/articles/s41392-021-00525-3>

#### **NATURAL ABS FACILITATE MHC CLASS I-RESTRICTED ANTIGEN PRESENTATION**

Conserved, CoV-associated cell surface-expressed MHC cl. I peptides

<https://www.nature.com/articles/nm933>

<https://pubmed.ncbi.nlm.nih.gov/19439480/>

#### **CDC SURVIVAL RATES FOR COVID**

The CDC has quietly revised its infection fatality rates estimates on 03/19/2021:

New estimates for survival rates by age: 0-17 99.998% 18-49 99.95% 50-64 99.4% 65+ 91%

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html>

#### **ABS MAY BIND TO SARS-COV-2 WITHOUT NEUTRALIZING THE VIRUS/ PREVENTING INFECTION**

<https://www.pennmedicine.org/news/news-releases/2021/february/antibodies-to-common-cold-coronaviruses-do-not-protect-against-sars-cov2>

#### **MECHANISM OF VIRAL SHEDDING**

[https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247\(20\)30172-5/fulltext](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30172-5/fulltext)

#### **FDA MANDATED ADVERSE EVENTS REPORTING IN QUESTION**

<https://www.fda.gov/media/144413/download>

<https://vaers.hhs.gov/reportevent.html>

<https://www.fda.gov/media/78526/download>  
<https://journals.sagepub.com/doi/10.1177/0960327112440111>  
<https://www.congress.gov/106/crpt/hrpt977/CRPT-106hrpt977.pdf>  
<https://digital.ahrq.gov/ahrq-funded-projects/electronic-support-public-health-vaccine-adverse-event-reporting-system>  
<https://pubmed.ncbi.nlm.nih.gov/31580725/>  
<https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html>  
<https://jamanetwork.com/journals/jama/fullarticle/2772137>

### **MORE J&J CRIMINAL RECORD**

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/020272s056,020588s044,021346s033,021444s031bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s031bl.pdf)  
<https://www.theguardian.com/business/2019/oct/09/johnson-johnson-risperdal-female-breast-tissue-boys>  
<https://www.nytimes.com/2019/03/25/health/xarelto-blood-thinner-lawsuit-settlement.html>  
<https://www.nytimes.com/2018/12/14/business/baby-powder-asbestos-johnson-johnson.html>  
<https://www.cNBC.com/2019/07/19/judge-denies-jjs-request-to-transfer-talc-lawsuits-to-federal-court.html>

### **JOHNSON & JOHNSON INFO:**

[Polysorbate 80](#), an ingredient in J&J's vaccine, is a [suspected](#) underlying cause of [anaphylactic](#) COVID vaccine [adverse reactions](#). [Studies show](#) that polysorbate 80 disrupts the normally protective blood-brain barrier. J&J 1 Billion contract with US government, promise of 100 Million doses. Is this why it has resumed?

<https://snacksafely.com/2021/03/johnson-johnson-covid-19-vaccine-list-of-ingredients/>  
<https://www.bloomberg.com/news/articles/2020-03-30/j-j-surges-after-1-billion-vaccine-deal-with-u-s-government>

### **SWITZERLAND REJECTS ASTRAZENECA, CANADA SUSPENDS EXPERIMENTAL COVID BIOLOGIC, INDIA REJECTS PFIZER**

<https://www.express.co.uk/news/politics/1392962/eu-vaccine-latest-astrazeneca-switzerland-ban-oxford-vaccine-uk-latest>  
<https://www.cbc.ca/news/politics/astrazeneca-under-55-1.5968128>  
<https://theprint.in/health/why-indias-expert-panel-rejected-emergency-use-nod-for-pfizer-vaccine/599529/>

### **50 TOPICS COVERED BELOW WITH RESOURCE LINKS**

1. Operating under Emergency Use Authorization
2. Biologics Application
3. Full Licensure
4. Previous Approval Problems
5. Capturing Adverse Reactions AFTER Licensure
6. Injuries, Injury Backlog, Underreporting
7. Liability Removed
8. PREP Act
9. Animal Studies Bypassed
10. Failure in Previous Animal Studies
11. ADE (antibody enhancement, cytokine storm, pathogenic priming)
12. Blood Clots
13. Increase in Autoimmune issues
14. Increase in Liver Toxicity Problems
15. HIV Vector Increase in Aids Susceptibility in Men
16. Safety and Effectiveness Questions and Problems
17. Safety Not Properly Done
18. Short-term Safety Data Without Robust Monitoring System

19. 2 Month Immunity
20. Unknowns (Mutations, Co-Infection, Transmission, Long-term Effect, Stopping Death)
21. Safety Data on Children under 16, elderly 85+, Immunocompromised
22. Red Flags in People Previously Infected with Covid
23. Heavier Periods in Women (25,000 reports)
24. Abnormal Phenomenon Alarming Women
25. Fertility, Breast Feeding, Pregnancy
26. Concerns Around Formation of Placenta
27. Lower Sperm Count
28. Pfizer Clinical Trial-Defective Design Claim
29. No Data
30. Gene Therapy
31. Genetically Engineered RNA, DNA Sequence
32. Epitranscriptomics
33. Reverse Transcription Concerns (mRNA and DNA)
34. Gene Therapy Risks
35. Lipid Carrying Vector
36. Lipid Model Previously Problematic
37. PEG Anaphylactic Reactions
38. Anti-PEG Antibodies
39. Immune Escape, Viral Variants
40. Vaccine Resistant Virus
41. Loss of Innate Immune System
42. Warning from Experts Around the Globe
43. Fully Vaccinated Outbreaks
44. Profits and Profit Margins
45. Billions in Marketing and Contracts
46. Brazil, Argentina, Switzerland, California, India, Israel
47. Closer Look at Israel
48. Note Worthy Lawsuits
49. Previous Track Record and Criminal Behavior
50. Successes with Ivermectin and More (Direct Links to hundreds of clinical trials & peer reviewed)
51. Additional References

## **COVID patient with sepsis makes 'remarkable' recovery following megadose of vitamin C**

By national medical reporter [Sophie Scott](#) and the specialist reporting team's [Lucy Kent](#) and [Loretta Florance](#)

Posted Thu 3 Dec 2020 at 5:01am, updated Thu 3 Dec 2020 at 12:05pm



Researchers Dr Yugeesh Lankadeva and Professor Clive May reversed sepsis in animals with a megadose of vitamin C. *(ABC News: Loretta Florance)*

A young Australian man who was critically ill with COVID-19 and suffering early stages of sepsis made a remarkable recovery after being given massive doses of vitamin C, according to his doctors.

Professor Rinaldo Bellomo, director of Intensive Care at Melbourne's Austin Health, said the 40-year-old's health had started to deteriorate significantly from COVID-19, with the man losing kidney function, and his blood pressure plummeting.

### **Key points:**

- Sepsis is a common cause of death for people gravely ill with COVID-19

Sepsis — a life-threatening condition which occurs when the body damages its own organs while responding to an infection — was starting to take hold of his body and time was running out.

"We were dealing with somebody who was very unwell. We felt we were in a very difficult situation, and the patient's life was under serious threat," he said.

Professor Bellomo knew researchers at the Florey Institute had some promising experimental findings using megadose vitamin C to treat sepsis.

- Researchers at the Florey Institute used megadoses of vitamin C to treat sepsis in animals
- Doctors at Austin Hospital tried the technique on a critically ill patient, who then made a "remarkable" recovery

[Read our full coverage of the coronavirus pandemic](#)

With the family's consent, doctors gave the patient the same treatment the Florey researchers had trialled in animals.



Professor Rinaldo Bellomo hoped the researchers' promising laboratory results would translate into a good outcome for his patient. *(ABC News: Loretta Florance)*

The man was given an initial dose of 30 grams of sodium ascorbate (vitamin C) over 30 minutes, then a maintenance dose of 30 grams over six and a half hours.

"This is the equivalent of 5,000 oranges pumping through his veins," Professor Bellomo said.

An over-the-counter vitamin C supplement is 500mg, meaning this megadose was 60 times the normal dosage, and had to be administered under hospital conditions.

Sepsis is a life-threatening condition that occurs when the body's response to an infection damages its own organs and tissues.

Organs start to fail and the patient goes into septic shock.

It's the most common cause of death in intensive care units, and a common cause of death for people gravely ill with COVID-19.

Often patients [need to have limbs amputated to survive](#).

Professor Bellomo said after the patient had the megadose of vitamin C, the changes were "remarkable".

"In a short period of time, we saw improved regulation of blood pressure, arterial blood oxygen levels and kidney function," he said.

His temperature also improved.

"The patient was able to be taken off machine ventilation 12 days after starting sodium ascorbate treatment and discharged from hospital without any complications 22 days later," he said.

### **'This can't be true'**

The Florey Institute's Professor Clive May had collaborated with Professor Bellomo for many years, keeping him up to date with the promising results they were seeing in the lab with the sepsis treatment.

"He didn't believe us. He said 'this can't be true'," Professor May said.

Colleague Dr Yugeesh Lankadeva sent the intensive care doctor videos of what was happening in the lab.



**"Professor Bellomo literally rocked up at the laboratory door the next day ... because he was just like, 'I need to see this for my own eyes'," he said.**

**"When he came and when they saw it, they were all very amazed at how quickly the disease just reversed by doing this treatment."**



Researchers Dr Yugeesh Lankadeva and Professor Clive May had been trialling the treatment on animals. *(Supplied: The Florey Institute of Neuroscience and Mental Health)*

**Professor May has been studying sepsis for almost two decades.**

**His research, which has just been published in the journal Critical Care Medicine, showed giving megadose vitamin C to animals with sepsis could reverse the effects of the disease.**

**"I have never seen any treatment before this being able to do that," he said.**

**"Giving this dose of vitamin C is just totally revolutionary. The response was quite remarkable."**

He said the function of the animal's heart, kidneys, liver, lungs and brain began to significantly improve just three hours after getting the megadose of the vitamin.

"If the treatment works as well in patients as it does in our animal studies, I think it's going to totally revolutionise the treatment of septic patients in intensive care units all over the world," Professor May said.



Dr Yugeesh Lankadeva, Professor Rinaldo Bellomo and Professor Clive May (left to right) were thrilled when the treatment was successful. (Supplied: The Florey Institute of Neuroscience and Mental Health)

But he stressed people with COVID-19 or any other illness should not try the same treatment at home.

"We don't want people going out and buying ten bottles of Vitamin C and think it's going to solve their problems — that would just make them feel very sick."

### **Experts urge caution**

While the result seems promising for the seriously ill Melbourne patient, and the animal studies, experts said previous studies using large doses of vitamin C to treat sepsis have been mixed.

Professor Simon Finfer, from the George Institute for Global Health, has been researching sepsis for more than 25 years.

**"We have seen so many treatments that seem to work in animal models and case reports but haven't proven effective in big studies," he said.**

**"The pharmaceutical industry has spent \$10 billion trying to find a magic bullet for sepsis."**



The researchers use Sodium Ascorbate Solution vitamin C, which does not have the same acidity as regular vitamin C. (ABC News: Loretta Florance)

[Read our full coverage of the coronavirus pandemic](#)

---

But also he said it was important to keep an open mind.

"If something is proving useful, we need to conduct trials to determine if there is a benefit or not."

A 2020 review of scientific evidence published in the Journal of the American Medical Association found high dose vitamin C given on its own or with steroids did not provide "significant survival benefit" for patients with sepsis or septic shock.

The review found giving high dose Vitamin C "just in case" or "as a measure of last resort" could have negative consequences such as delaying proven therapies, such as prompt use of antibiotics.

### **New trial could bring answers**

Professor Bellomo said many of the previous trials used a lower dose of vitamin C than the researchers did in both the animal study and the Austin did in the COVID-19 patient.

The amount of vitamin C given in this trial was 50 times greater than any other tried before for sepsis.

Doctors at Melbourne's Austin Health have now begun a randomised controlled trial, giving some patients with septic shock a megadose of vitamin C and some a placebo.

Blood samples will be collected to gauge the patients' immune response.



Researchers Dr Yugeesh Lankadeva and Professor Clive May's lab results were showing great promise. *(Supplied: The Florey Institute of Neuroscience and Mental Health)*

Researcher Dr Yugeesh Lankadeva said the trial **would help** establish the "optimal dose and treatment" that could be used by intensive care doctors in treating sepsis as a "potential life-saving option for patients with multi-organ failure".

As for the Melbourne man who was able to walk out of hospital after the experimental treatment, his doctor Professor Bellomo said it's an incentive to keep trialling this approach.

"We were encouraged, of course," he said.

"This has provided us with further ammunition to investigate this intervention, to understand what the mechanisms might be and the extent of the achievement that might come from it."

While Australia is doing well keeping COVID-19 under control, he said doctors from around the world have already been in touch to find out more about the megadose treatment.

[Ask us your coronavirus questions](#)





The Fauci/COVID-19 Dossier

This document is prepared for humanity by Dr. David E. Martin.

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

1

The Fauci/COVID-19 Dossier

This document is prepared for humanity by Dr. David E. Martin.

This work was supported, in part, by a fund-raising effort in which approximately 330 persons contributed funds in support

of the New Earth technology team and Urban Global Health Alliance. It is released under a Creative Commons license CCBY-NC-SA.

Any derivative use of this dossier must be made public for the benefit of others. All documents, references and

disclosures contained herein are subject to an AS-IS representation. The author does not bear responsibility for errors in

the public record or references therein. Throughout this document, uses of terms commonly accepted in medical and

scientific literature do not imply acceptance or rejection of the dogma that they represent.

Background:

Over the past two decades, my company – M·CAM – has been monitoring possible violations of the 1925 Protocol for

the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare

(the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of

Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In our 2003-2004 Global Technology

Assessment: Vector Weaponization M·CAM highlighted China's growing involvement in Polymerase Chain Reaction

(PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a

weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not

limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC),

the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC),

Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, many other

research institutions, and their commercial affiliations.

The National Institute of Health's grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at

Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci's NIAID by at least 2003) began the work on

synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic

enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21,

2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.<sup>1</sup> In one

of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full

length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on

a composite of DNA segments.

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.”<sup>2</sup>

On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans.

1 U.S. Provisional Application No. 60/206,537, filed May 21, 2000

2 <https://www.pnas.org/content/100/22/12995>

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

2

Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries. In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United States could be conducted without permission or infringement. We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock

Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.

These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October

2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be

completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario

emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi

and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.

This dossier is by no means exhaustive. It is, however, indicative the numerous criminal violations that may be

associated with the COVID-19 terrorism. All source materials are referenced herein. An additional detailed breakdown

of all the of individuals, research institutions, foundations, funding sources, and commercial enterprises can be accessed upon request.

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

3

Contents

35 U.S.C. § 101

.....  
.....  
..... 5

18 U.S.C. §2339 C et seq. – Funding and Conspiring to Commit Acts of Terror ..... 7

18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens ..... 10

18 U.S.C. § 1001 – Lying to Congress

.....  
..... 12

15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity

.....  
..... 16

15 U.S.C. §8 – Market Manipulation and Allocation

.....  
..... 20

15 U.S.C. § 19 – Interlocking Directorates

.....  
..... 21

35 U.S.C. §200 - 206 – Disclosure of Government Interest

.....  
..... 23

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial

.....

..... 25  
The Commercial Actors

.....  
..... 27

Fauci/COVID-19 Dossier  
CC-BY-NC-SA Dr. David E. Martin  
4

35 U.S.C. § 101

From Justice Clarence Thomas' opinion for the majority  
Section 101 of the Patent Act provides: "Whoever invents or discovers any new and useful ... composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title." 35 U.S.C. § 101.

We have "long held that this provision contains an important implicit exception[:] Laws of nature, natural phenomena, and abstract ideas are not patentable." Mayo, 566 U.S., at \_\_\_, 132 S.Ct., at 1293 (internal quotation marks and brackets omitted). Rather, "they are the basic tools of scientific and technological work" that lie beyond the domain of patent protection. Id., at \_\_\_, 132 S.Ct., at 1293. As the Court has explained, without this exception, there would be considerable danger that the grant of patents would "tie up" the use of such tools and thereby "inhibit future innovation premised upon them." Id., at \_\_\_, 132 S.Ct., at 1301. This would be at odds with the very point of patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and "manifestations... of nature [are] free to all men and reserved exclusively to none").<sup>3</sup>

In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had "long held" that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, "A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV."<sup>4</sup> No "causal" data was provided for this statement.

When they filed their patent application on April 25, 2003 their first claim (and the only one that survived to ultimate issuance over the objection of the patent examiner in 2006 and 2007) was the genome for SARS CoV.

While this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC insist on its granting over non-final and final rejections, but they also continued to pay maintenance fees on the patent after the 2013 Supreme Court decision confirmed that it was illegal.

In addition, the CDC patented the detection of SARS CoV using a number of methods including reverse transcription polymerase chain reaction (RT-PCR). With this patent, they precluded anyone outside of their licensed or conspiring interest from legally engaging in independent verification of their claim that

they had isolated a virus, that it was a causative agent for SARS, or that any therapy could be effective against the reported pathogen.

It is important to note that the CDC's patent applications were also rejected in non-final and final rejections for ineligibility under 35 U.S.C. § 102 for being publicly disclosed prior to their own filing. In the first non-final rejection, the USPTO stated that the CDC's genome was published in four Genbank accession entries on April 14, 18, and 21, 2003 with identity ranging from 96.8% to 99.9% identical sequences.<sup>5</sup> Dr. Fauci knew, and failed to disclose evidence that the CDC patent was illegal, based on work he had funded in the years leading up to the SARS outbreak.

After seeking an illegal patent, petitioning to override the decision of an examiner to reject it, and ultimately prevailing with the patent's grant, the CDC lied to the public by stating they were controlling the patent so that it would be "publicly available".<sup>6</sup> Tragically, this public statement is falsified by the simple fact that their own publication in *3 Association for Molecular Pathology v. Myriad Genetics, Inc.*, 569 U.S. 576 (2013)

<sup>4</sup> U.S. Patent 7,220,852

<sup>5</sup> USPTO Non-Final Rejection File #10822904, September 7, 2006, page 4.

<sup>6</sup> <https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0>

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

5

Genbank had, in fact, made it public domain and thereby unpatentable. This fact, confirmed by patent examiners, was overridden by CDC in a paid solicitation to override the law.

While not covered under 35 U.S.C. §101, Dr. Fauci's abuse of the patent law is detailed below. Of note, however, is his willful and deceptive use of the term "vaccine" in patents and public pronouncements to pervert the meaning of the term for the manipulation of the public.

In the 1905 *Jacobson v. Mass* case, the court was clear that a PUBLIC BENEFIT was required for a vaccine to be

mandated. Neither Pfizer nor Moderna have proved a disruption of transmission. In *Jacobson v. Massachusetts*, 197 U.S.

11 (1905), the court held that the context for their opinion rested on the following principle:

"This court has more than once recognized it as a fundamental principle that 'persons and property are subjected to all kinds of restraints and burdens in order to secure the general comfort, health, and prosperity of the state...'"

The Moderna and Pfizer "alleged vaccine" trials have explicitly acknowledged that their gene therapy technology has no impact on viral infection or transmission whatsoever and merely conveys to the recipient the capacity to produce an S1

spike protein endogenously by the introduction of a synthetic mRNA sequence. Therefore, the basis for the

Massachusetts statute and the Supreme Court's determination is moot in this case.

Further, the USPTO, in its REJECTION of Anthony Fauci's HIV vaccine made the

following statement supporting their rejection of his bogus "invention" Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin

6

18 U.S.C. §2339 C et seq. – Funding and Conspiring to Commit Acts of Terror Indirectly, unlawfully and willfully provides or collects funds with the intention that such funds be used, or with the knowledge that such funds are to be used, in full or in part, in order to carry out–

(A) an act which constitutes an offense within the scope of a treaty specified in subsection (e)(7), as

implemented by the United States, or

(B) any other act intended to cause death or serious bodily injury to a civilian, or to any other person not

taking an active part in the hostilities in a situation of armed conflict, when the purpose of such act, by its

nature or context, is to intimidate a population, or to compel a government or an international

organization to do or to abstain from doing any act...

By no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the association of SARS with bioterror

potential. Leveraging the fear of the anthrax bioterrorism of 2001, he publicly celebrated the economic boon that

domestic terror had directed towards his budget. He specifically stated that NIAID was actively funding research on a

“SARS Chip” DNA microarray to rapidly detect SARS (something that was not made available during the current

“pandemic”) and two candidate vaccines focused on the SARS CoV spike protein.<sup>7</sup>

Led by three Chinese researchers

under his employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least one DNA vaccine in animal

trials by 2004.<sup>8</sup> This team, part of the Vaccine Research Center at NIAID, was primarily focused on HIV vaccine

development but was tasked to identify SARS vaccine candidates as well. Working in collaboration with Sanofi, Scripps

Institute, Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as a primary intervention for

several designated “infectious diseases” precluded proven therapies from being applied to the sick and dying.<sup>9</sup>

The CDC and NIAID led by Anthony Fauci entered into trade among States (including, but not limited to working with

EcoHealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy

of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights. This

research was known to involve surface proteins in coronavirus that had the capacity to directly infect human respiratory

systems. In flagrant violation of the NIH moratorium on gain of function research, NIAID and Ralph Baric persisted in

working with chimeric coronavirus components specifically to amplify the pathogenicity of the biologic material.

By October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein was described in NIAID’s funded work



in China. This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained high risk for severe human response.<sup>10</sup>

By March 2015, both the virulence of the S1 spike protein and the ACE II receptor was known to present a considerable risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not sufficiently concerned about coronavirus to adequately fund their desired research.<sup>11</sup>

Dr. Peter Daszak of EcoHealth Alliance offered the following assessment:

7 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/>

8 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/>

9 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/>

10 Ge, XY., Li, JL., Yang, XL. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535-538 (2013).

11 Forum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: [https://www.ncbi.nlm.nih.gov/books/NBK349040/Fauci/COVID-19 Dossier](https://www.ncbi.nlm.nih.gov/books/NBK349040/Fauci/COVID-19%20Dossier)

CC-BY-NC-SA Dr. David E. Martin

7

“Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process, Daszak stated.”<sup>12</sup>

Economics will follow the hype.

The CDC and NIAID entered into trade among States (including, but not limited to working with University of North

Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of

Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National

Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place during

a time when the work being performed was prohibited by the United States National Institutes of Health.

The public was clearly advised of the dangers being presented by NIAID-funded research by 2015 and 2016 when the

Wuhan Institute of Virology material was being manipulated at UNC in Ralph Baric's lab.

"The only impact of this work is the creation, in a lab, of a new, non-natural risk," agrees Richard Ebright, a molecular biologist and biodefence expert at Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are long-standing critics of gain-of-function research.

In their paper, the study authors also concede that funders may think twice about allowing such experiments in the future. "Scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky to pursue," they write, adding that discussion is needed as to "whether these types of chimeric virus studies warrant further investigation versus the inherent risks involved".

But Baric and others say the research did have benefits. The study findings "move this virus from a candidate emerging pathogen to a clear and present danger", says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the EcoHealth Alliance, an international network of scientists, headquartered in New York City, that samples viruses from animals and people in emerging-diseases hotspots across the globe.

Studies testing hybrid viruses in human cell culture and animal models are limited in what they can say about the threat posed by a wild virus, Daszak agrees. But he argues that they can help indicate which pathogens should be prioritized for further research attention."<sup>13</sup>

Knowing that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID, and their funded laboratories and commercial partners) had patents on each proposed element of medical counter measures and their funding, Dr. Fauci, Dr. Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to commit acts of terror on the global population – including the citizens of the United States – when, in September 2019, they published the following mandate:

"Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate nonpharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any

<sup>12</sup> Ibid.

<sup>13</sup>

<https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787>

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

8

new pathogen for public health purposes along with the means to share limited medical countermeasures across countries.

Progress indicator(s) by September 2020

- Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.
  - Donors, countries and multilateral institutions develop a multi-year plan and approach for strengthening R&D research capacity, in advance of and during an epidemic.
  - WHO, the United Nations Children’s Fund, the International Federation of Red Cross and Red Crescent Societies, academic and other partners identify strategies for increasing capacity and integration of social science approaches and researchers across the entire preparedness/response continuum.”<sup>14</sup>
- As if to confirm the utility of the September 2019 demand for “financing and development of” vaccine and the fortuitous SARS CoV-2 alleged outbreak in December of 2019, Dr. Fauci began gloating that his fortunes for additional funding were likely changing for the better. In a February 2020 interview in STAT, he was quoted as follows:

““The emergence of the new virus is going to change that figure, likely considerably, Fauci said. “I don’t know how much it’s going to be. But I think it’s going to generate more sustained interest in coronaviruses because it’s very clear that coronaviruses can do really interesting things.””<sup>15</sup>

<sup>14</sup> [https://apps.who.int/gpmb/assets/annual\\_report/GPMB\\_annualreport\\_2019.pdf](https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf) (page 8)

<sup>15</sup>

<https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/>

CC-BY-NC-SA Dr. David E. Martin  
Fauci/COVID-19 Dossier

9

18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens

Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded the definition of terrorism to cover "domestic," as opposed to international, terrorism. A person engages in domestic terrorism if they do an act "dangerous to human life" that is a violation of the criminal laws of a state or the United States, if the act appears to be intended to: (i) intimidate or coerce a civilian population; (ii) influence the policy of a government by intimidation or coercion;

Dr. Anthony Fauci has intimidated and coerced a civilian population and sought to influence the policy of a government by intimidation and coercion.

With no corroboration, Dr. Anthony Fauci promoted<sup>16</sup> Professor Neil Ferguson’s computer simulation derived claims that,

“The world is facing the most serious public health crisis in generations. Here we provide concrete estimates of the scale of the threat countries now face.

“We use the latest estimates of severity to show that policy strategies which

aim to mitigate the epidemic might halve deaths and reduce peak healthcare demand by two-thirds, but that this will not be enough to prevent health systems being overwhelmed. More intensive, and socially disruptive interventions will therefore be required to suppress transmission to low levels. It is likely such measures – most notably, large scale social distancing – will need to be in place for many months, perhaps until a vaccine becomes available.”<sup>17</sup> Reporting to the President that as many as 2.2 million deaths may result from a pathogen that had not yet been isolated and could not be measured with any accuracy, Dr. Fauci intimidated and coerced the population and the government into reckless, untested, and harmful acts creating irreparable harm to lives and livelihoods.<sup>18</sup> Neither the Imperial College nor the “independent” Institute for Health Metrics and Evaluation (principally funded by the Bill and Melinda Gates Foundation)<sup>19</sup> had any evidence of success in estimating previous burdens from coronavirus but, without consultation or peer-review, Dr. Fauci adopted their terrifying estimates as the basis for interventions that are explicitly against medical advice.

☒ The imposition of social distancing was based on computer simulation and environmental models with NO disease transmission evidence whatsoever.

☒ The imposition of face mask wearing was directly against controlled clinical trial evidence and against the written policy in the Journal of the American Medical Association. “Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”<sup>20</sup>

☒ In both the Imperial College and the IHME simulations, quarantines were modeled for the sick, not the healthy.

<sup>16</sup> <https://www.cato.org/blog/did-mitigation-save-two-million-lives>

<sup>17</sup>

<https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/>

<sup>18</sup>

<https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline>

<sup>19</sup>

<https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement>

<sup>20</sup>

[https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJUdKG\\_21N4oL5zAfcIQfWCyHasetJmo](https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJUdKG_21N4oL5zAfcIQfWCyHasetJmo)

<sup>10</sup>

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

Insisting on vaccines while blockading the emergency use of proven pharmaceutical interventions may have contributed to the death of many patients and otherwise healthy individuals.<sup>21</sup>

Using the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively

suppressed proven medical countermeasures used by, and validated in scientific proceedings, that offered alternatives to the products funded by his conspiring entities for which he had provided direct funding and for whom he would receive tangible and intangible benefit.

21

<https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/Fauci/COVID-19-Dossier>

CC-BY-NC-SA Dr. David E. Martin

11

18 U.S.C. § 1001 - Lying to Congress

(a) Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully—

(1) falsifies, conceals, or covers up by any trick, scheme, or device a material fact;

(2) makes any materially false, fictitious, or fraudulent statement or representation; or

(3) makes or uses any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry;

shall be fined under this title, imprisoned not more than 5 years or, if the offense involves international or domestic terrorism (as defined in section 2331), imprisoned not more than 8 years, or both. If the matter relates to an offense under chapter 109A, 109B, 110, or 117, or section 1591, then the term of imprisonment imposed under this section shall be not more than 8 years.

On October 22, 2020, the United States Government Accountability Office (GAO) published a report entitled:

BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property.

In this document, the authors reported that the National Institutes of Health (NIH) received, “up to \$2 billion in royalties from its contributions to 34 drugs sold from 1991-2019.”<sup>22</sup>

A casual review of the NIH Office of Technology Transfer report of active licenses<sup>23</sup> appears to conflict with the GAO

report on several important facts. Conspicuously absent from the GAO report are over 30 patents associated with active

compounds generating billions of dollars in revenue. Why would it be that the GAO and the NIH couldn't agree on

something as simple as drugs generating income for NIH?

Since the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally funded research has been an

economic bonanza for U.S. universities, federal agencies, and their selected patronage. For the first decade following

Bayh Dole, NIH funding doubled from \$3.4 billion to \$7.1 billion. A decade later, it doubled again to \$15.6 billion. In the

wake of September 2001, the National Institute for Allergy and Infectious Diseases (NIAID) saw its direct budget increase

over 300% without accounting for DARPA funds of as much as \$1.7 billion annually from 2005 forward. In 2020, NIH's

budget was over \$41 billion.

What has become of the \$763 billion of taxpayer funds allocated to making America healthier since inventors have been commercially incentivized? Who has been enriched?

The answer, regrettably, is that no accountability exists to answer these questions.

The NIH is the named owner of at least 138 patents since 1980.

The United States Department of Health and Human Services is the named owner of at least 2,600 patents.

NIAID grants or collaboration have resulted in 2,655 patents and patent applications of which only 95 include an

assignment to the Department of Health and Human Services as an owner. Most of these patents are assigned to

universities thereby making the ultimate commercial beneficiaries entirely opaque. One of the largest holders is SIGA

Technologies (NASDAQ: SIGA) who, while publicly reporting close affiliation with NIAID, is not referenced in the NIH GAO

report. SIGA's CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing its vaccine program for HIV, SARS, Ebola,

West Nile Virus, and Influenza before exiting to commercial ventures. While their technology is clearly derived from

NIAID science, the company reports revenue from NIAID but no royalty or commercial payments to NIH or any of its

programs.

22 <https://www.gao.gov/products/GAO-21-52>

23 [https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics-Fauci/COVID-19 Dossier](https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics-Fauci/COVID-19-Dossier)

CC-BY-NC-SA Dr. David E. Martin

12

NIAID's Director, Dr. Anthony Fauci is listed as an inventor on 8 granted U.S. patents. None of them are reported in

NIAID, NIH, or GAO reports of active licensing despite the fact that Dr. Fauci reportedly was compelled to get paid for his

interleukin-2 "invention" – payments he reportedly donated to an unnamed charity.<sup>24</sup>

Of the 21 patents listed in the U.S. Food and Drug Administration's (FDA) Orange book itemized in the GAO report, none

of Dr. Anthony Fauci's patents are listed. Furthermore, none of the NIAID patents are listed despite clear evidence that

Gilead Sciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) have generated over \$2 billion annually

from sales that were the direct result of NIAID funded science. Missing from the GAO report are 2 patents for Velclade<sup>®</sup>

which has been generating sales in excess of \$2.18 billion annually for several years. None of the patents for Yescarta<sup>®</sup>

are listed in the GAO report. None of the Lumoxiti<sup>®</sup> patents are listed in the GAO report. None of the Kepivance<sup>®</sup>

patents are listed in the GAO report. In violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in the

GAO report fail to disclose government interest despite being the direct result of NIH funding.

Dr. Anthony Fauci's Own Patent Track Record:

US Patent 6,190,656 and 6,548,055 Immunologic enhancement with intermittent interleukin-2 therapy



A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an antiretroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient. This application is a continuation of U.S. patent application Ser. No. 08/487,075, filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S. patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S. Pat. No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May 26, 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of which are incorporated herein by reference.

Filed May 19, 1993

Issued a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998 and April 12, 1999. Reduced and modified claims granted May 8, 2000.

This family of patents was the basis of Fauci's lie to the British Medical Journal in which he falsely stated:

"Dr Anthony Fauci told the BMJ that as a government employee he was required by law to put his name on the patent for the development of interleukin 2 and was also required by law to receive part of the payment the government received for use of the patent. He said that he felt it was inappropriate (sic) to receive payment and donated the entire amount to charity."<sup>25</sup>

He was not "required by law" to commit fraud on the patent office and then get paid for it!

<sup>24</sup> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/>

<sup>25</sup> Ibid.

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

13

US Patent 6,911,527 HIV related peptides

This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.

Filed May 6, 1999

Rejected as unpatentable January 22, 2003. Issued with a final rejection on July 15, 2004 after submitting reconsideration requests. Modified and restricted claims allowed September 29, 2004.

US Patent 7,368,114 Fusion protein including of CD4

Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody and a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.

Filed October 24, 2002

Rejected as unpatentable August 18, 2006. Paid appeal to overturn examiner's findings February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants further narrowed the construction of what was clearly not a patent and the USPTO granted less than half the claims that had been sought in the original filing.

US Patent 9,896,509, 9,193,790 and 9,441,041 Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin

Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or .beta.7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

Rejected May 22, 2017 as Double Patenting. In their response, the applicants acknowledge the illegal act and seek only those components of their application that extend beyond the life of the issued patents. On October 11, 2017, the limited claims were issued.

A sample of the convoluted flow of funds that evades public disclosure.

U.S. Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby, British Columbia. In their patent, they disclose that their research was supported by a grant from the National Institute of Allergy and Infectious Disease (Grant HHSN26620060012C). Ironically, this \$23 million grant was awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.26

26

<https://www.technologynetworks.com/genomics/news/alnylam-awarded-23-million-us-government-contract-to-develop-rnai-therapeutics186097>  
Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

14

In 2012, Alnylam agreed to pay Tekmira \$65 million to settle legal disputes including a \$1 billion damages claim for “relentless and egregious” misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest priority of November 10, 2008, there is no public record stating Tekmira as the beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle technology developed from this grant is the technology now used in the Moderna COVID-19 intervention. In their 10-Q filing, Alnylam reports to have a license to technology from Arbutus – formerly Tekmira – which has accused Acuitas of misappropriating trade secrets and licensing them to Moderna and Pfizer’s collaboration with BioNTech.

Additional references can be found at:

<https://www.ott.nih.gov/nih-and-its-role-technology-transfer>

[https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2017/206288Orig1s000TALtr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2017/206288Orig1s000TALtr.pdf)

<https://www.gao.gov/assets/720/710287.pdf>

<https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22>

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

15

### 15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity

Every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding \$100,000,000 if a corporation, or, if any other person, \$1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.

The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.<sup>27</sup> In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full

length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.”<sup>28</sup>

On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans.

Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries. In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.

27 U.S. Provisional Application No. 60/206,537, filed May 21, 2000

28 <https://www.pnas.org/content/100/22/12995>

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

16

1986-1990 NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant

Coronavirus” Filed 2002 and issued 2007

<https://patents.google.com/patent/US7279327B2/ru>

The paper first published from the NIAID grant is

<https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf>

1990

Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000

which was abandoned April 2010 making it public domain.

1990s Work focused on CoV association with cardiomyopathy (see above)

Early reference to the “emergence” of CoV as a respiratory pathogen in

[https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0\\_91.pdf](https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf)

2000

2001

2002

2003

Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant

CoV

National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus

Infectious cDNA Construct.” 4/1/2001-3/31/005 \$1.0 million total costs/yr. RS

Baric, PI

Asia CoV SARS outbreak

April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA

sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S.

Department of Health and Human Services the ability to control the commercial exploitation of SARS

coronavirus.

Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges

Scientific Advisory Board (served through 2010).

April 28, 2003 Sequoia Pharmaceuticals \$953K for pathogen response and patent US7,151,163

<https://www.sbir.gov/node/305319>

July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued

on November 17, 2009. <https://patents.google.com/patent/US7618802B2>

Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS

CoV. This research is supported by several NIH grants including National Institutes of Health Grants

A128785, A148436, and A1053822.

2004

January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases:

antimicrobials, therapeutics and immune modulators.

<https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706>

At this conference, the term “The New Normal” was introduced by Merck  
FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and  
Infectious Diseases.

SARS Reverse Genetics. AI059136-01. \$1.7 million total costs, RS Baric, PI. 10%  
effort. 4/1/04- 3/31/09.

The project develops a SARS-CoV full length infectious cDNA, the development of  
SARS-CoV replicon

particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice,  
producing a pathogenic

mouse model for SARS-CoV infection.

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

17

National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling  
the SARS Coronavirus

Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. \$2.1 million  
November 22, 2004 University of Hong Kong patents SARS associated spike protein

on CoV and

pursues patent US 7,491,489

2005

DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological  
Warfare Enabling

Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited  
Speaker

Review timeline from [https://www.youtube.com/watch?v=r0\\_EeYB0i0U](https://www.youtube.com/watch?v=r0_EeYB0i0U) and

<https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf>

2008

2009

2010

Biodefense Grant U54 AI057157 commences with \$10,189,682 to UNC Chapel Hill

[https://taggs.hhs.gov/Detail/AwardDetail?arg\\_awardNum=U54AI057157&arg\\_ProgOfficeCode=104](https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104)

Biodefense Grant U54 AI057157 continues with \$5,448,656 to UNC Chapel Hill  
(non-competitive grant

from NIAID)

Biodefense Grant U54 AI057157 continues with \$8,747,142 to UNC Chapel Hill

(non-competitive grant

from NIAID)

Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391  
issued patents.

August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164  
which attracted the

investment of (and “inventorship” for) venture capitalists at Flagship Ventures.  
This patent grew out of

the work of Dr. Jason P. Schrum of Harvard Medical School supported by National  
Science Foundation

Grant #0434507. While the application claims priority to August 2010, the  
application didn't get

finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final  
rejection on this

original patent rejecting all claims.

[https://www.nsf.gov/awardsearch/showAward?AWD\\_ID=0434507](https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507) with reference to the  
grant funding



in

[https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak\\_pdfs/Schrum\\_et\\_al\\_JACS\\_2009.pdf](https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf)

2011

Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology.

Biodefense Grant U54 AI057157 continues with \$7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID)

2012

MERS isolated in Egypt

Biodefense Grant U54 AI057157 continues with \$7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID)

2013

2014

Biodefense Grant U54 AI057157 continues with \$7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID)

April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

18

2015

Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella.

<https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html>

2016

NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1

“Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology.

<https://patents.google.com/patent/WO2018081318A1/en> Lead Inventor Barney Scott Graham was well

known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS

CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in

Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director

of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”)

<https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html>

In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the

Chinese government filed in Australia in 2013

<https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN>.

2017

2018

2019

August – Sanofi buys Protein Science Corp with considerable SARS patent holdings

June – Sanofi buys Ablynx with considerable SARS patent holdings

March,

<https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-affordable-molecular-diagnostics/>

funded by Open Philanthropy – the same organization that would be

the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in

October 2019.

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

19

15 U.S.C. §8 – Market Manipulation and Allocation

Every combination, conspiracy, trust, agreement, or contract is declared to be contrary to public policy, illegal, and

void when the same is made by or between two or more persons or corporations, either of whom, as agent or

principal, is engaged in importing any article from any foreign country into the United States, and when such

combination, conspiracy, trust, agreement, or contract is intended to operate in restraint of lawful trade, or free

competition in lawful trade or commerce, or to increase the market price in any part of the United States of any

article or articles imported or intended to be imported into the United States, or of any manufacture into which such

imported article enters or is intended to enter. Every person who shall be engaged in the importation of goods or any

commodity from any foreign country in violation of this section, or who shall combine or conspire with another to

violate the same, is guilty of a misdemeanor, and on conviction thereof in any court of the

United States such person shall be fined in a sum not less than \$100 and not exceeding \$5,000, and shall be further

punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve

months.

Around March 12, 2020, in an effort to enrich their own economic interests by way of securing additional funding from

both Federal and Foundation actors, the CDC and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by

capricious symptom presentation alone. Forcing the public to rely on The COVID Tracking Project – funded by the

Bloomberg, Zuckerberg and Gates Foundation and presented by a media outlet (The Atlantic) – not a public health

agency – Dr. Fauci used fraudulent testing technology (RT-PCR) to conflate

“COVID cases” with positive PCR tests in the living while insisting that COVID deaths be counted by symptoms alone. This perpetuated a market demand for his desired vaccine agenda which was recited by him and his conspiring parties around the world until the present. Not surprisingly, this was necessitated by the apparent fall in cases that constituted Dr. Fauci’s and others’ criteria for depriving citizens of their 1st Amendment rights.

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

20

#### 15 U.S.C. § 19 – Interlocking Directorates

(1) No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are–

(A) engaged in whole or in part in commerce; and

(B) by virtue of their business and location of operation, competitors, so that the elimination of competition

by agreement between them would constitute a violation of any of the antitrust laws; if each of the

corporations has capital, surplus, and undivided profits aggregating more than \$10,000,000 as adjusted

pursuant to paragraph (5) of this subsection.

Dr. Fauci is on the Leadership Council of the Bill and Melinda Gates Global Vaccine Action Plan

Dr. Fauci while controlling the economic dispensation of Federal research funding, Dr. Fauci has been, and continues to

be, on the World Health Organization’s Global Preparedness Monitoring Board. He is joined on this board by the

conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias and the State Council of China’s Dr. George

F. Gao of the Chinese CDC. This GPMB stipulated that all member states must take part in a global simulation of the

release of a respiratory pathogen.

Dr. Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4 facility and sits on the International

Committee on Taxonomy of Virus Coronaviridae Working Group tasked to confirm the presence of absence of the

pathogen for which he is directly compensated.

As referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous undisclosed commercial

relationships exist between funded researchers, their funding agencies, and commercial interests in which disclosed and

undisclosed commercial terms exist. A complete list of all potential implicated parties is listed in the section below

entitled “The Commercial Actors”.

It appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on

genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci

(hereinafter “NIAID” and “Dr Fauci”, respectively) entered into trade among States (including, but not limited to working

with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese

Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights.

It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter "NIAID") entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on generic material was illegal, the CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of novel coronavirus material with specific virulence properties prior to, during, and following the determination made by the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity and safety standards.

In this inquiry, it is presumed that the CDC and its associates were: a) fully aware of the work being performed using their patented technology; b) entered into explicit or implicit agreements including licensing, or other consideration; and, c) willfully engaged one or more foreign interests to carry forward the exploitation of their proprietary technology

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

21

when the U.S. Supreme Court confirmed that such patents were illegal and when the National Institutes of Health issued a moratorium on such research.

Reportedly, in January 2018, the U.S. Embassy in China sent investigators to Wuhan Institute of Virology and found that,

"During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory." The

Washington Post reported that this information was contained in a cable dated 19 January 2018. Over a year later, in

June 2019, the CDC conducted an inspection of Fort Detrick's U.S. Army Medical Research Institute of Infectious Diseases

(hereinafter "USAMRIID") and ordered it closed after alleging that their inspection found biosafety hazards. A report in

the journal Nature in 2003 (423(6936): 103) reported cooperation between CDC and USAMRIID on coronavirus research

followed by considerable subsequent collaboration. The CDC, for what appear to be the same type of concern identified

in Wuhan, elected to continue work with the Chinese government while closing the

U.S. Army facility.

The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC's Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a "novel coronavirus"; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests for a "novel" pathogen when their own subsequent record on development and deployment of tests has been shown to be without reliability  
Fauci/COVID-19 Dossier  
CC-BY-NC-SA Dr. David E. Martin  
22

35 U.S.C. §200 - 206 - Disclosure of Government Interest

35 U.S.C. §202 (c)(6)

An obligation on the part of the contractor, in the event a United States patent application is filed by or on its behalf or by any assignee of the contractor, to include within the specification of such application and any patent issuing thereon, a statement specifying that the invention was made with Government support and that the Government has certain rights in the invention.

Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of 1998. They are summarized below.

file

issue

priority

total

1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020											
0	0	0	0	10	10	12	12	0	0	29	29	0	0	0	0	120	338	290	328	297	256	188	198	207	244	371	407	466	451	416	326	199	9
63	135	179	224	275	334	391	61																										

0

0

0

0

10

10

12

12

0

0

29

29

0

0

0

0

120 338 290 328 297 256 188 198 207 244 371 407 466 451 416 326 199 9

63 135 179 224 275 334 391 61

1

8

38 129 506 487 408 335 370 279 256 303 279 322 330 348 342 208 95

0

0

file

314 431 420 504 513 449 578 231 issue

25

38 129 627 888 833 842 891 810 778 892 547 574 1015 1186 1228 1163 1024 800 777

240 total

priority

total

5111

5111

5111

15333

On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and Trademark Office rejected

Moderna's efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally

owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the

core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.

mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna

thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus' prior company

Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.

M-CAM and Knowledge Ecology International have independently confirmed that Moderna has violated U.S. law in

failing to disclose the U.S. government's funding interest in their patents and patent applications. While this negligence

impacts all of Moderna's over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 ('600)

which is the patent relating to, "a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a

betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle." The specific claims

addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS CoV-2

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

23

outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (New

England Journal of Medicine) but the government funds were not acknowledged in the patent.

In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to

Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant

was W911NF-13-1-0417. The company used that technology to develop its COVID-19 vaccine, currently undergoing



Phase I clinical trials in conjunction with NIH.<sup>29</sup>

Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information

regarding intellectual property infringement issues as part of their contract.

Under FAR §27.201-1(c) and (d), the

Government both requires a notice of infringement or potential infringement as well as retention of economic liability

for patent infringements. Specifically, in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its

officers, agents, and employees against liability, including costs for infringement of any United States Patent...”. In

addition to the patents cited by the USPTO in their examination of ‘600, M-CAM has identified fourteen other issued

patents preceding the ‘600 patent which were used by patent examiners to limit patents arising from the same funded

research including patents sought by CureVac.

In short, while Moderna enjoys hundreds of millions of dollars of funding allegiance and advocacy from Anthony Fauci

and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S.

Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed

infringement risks potentially contributing to the very infringement for which they are indemnified.

<sup>29</sup> <https://crsreports.congress.gov/product/pdf/IN/IN11446>

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

24

<sup>21</sup> C.F.R. § 50.24 et seq., Illegal Clinical Trial

It is unlawful to conduct medical research (even in the case of emergency) without a series of steps taken to:

a. Establish the research with a duly authorized and independent institutional review board;

b. Secure informed consent of all participants including a statement of risks and benefits; and,

c. Engage in consultation with the community in which the study is to be conducted.

Dr. Anthony Fauci has forced upon the healthy population of the United States an unlawful clinical trial in which the U.S.

Department of Health and Human Services are extrapolating epidemiologic data. No informed consent has been sought

or secured for any of the “medical countermeasures” forced upon the population and no independent review board – as

defined by the statute – has been empaneled.

Through April 2020, the official recommendation by the Journal of the American Medical Association was

unambiguous.

“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection

because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people

from becoming ill.”<sup>30</sup>

Part of that lack of evidence in fact showed that cloth facemasks actually increased influenza-linked illness.<sup>31</sup>

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that face masks limit the spread of SARS CoV-2. To date, not a single study has confirmed that a mask prevented the transmission of, or the infection by SARS CoV-2.

All parties mandating the use of facemasks are not only willfully ignoring established science but are engaging in what amounts to a whole population clinical trial. This conclusion is reached by the fact that facemask use and COVID-19 incidence are being reported in scientific opinion pieces promoted by the United States Centers for Disease Control and Prevention and others.<sup>32</sup>

Social distancing of up to 6 feet has been promoted as a means of preventing person-to-person transmission of influenza-like viruses. While one study hypothesized that infection could happen in a 6 foot range, the study explicitly states that person-to-person transfer was not tested and viability of the virus at 6 feet was not even a subject of the investigation.<sup>33</sup> That did not stop the misrepresentation of the study to be used as the basis for an unverified medical counter measure of social distancing. To date, no study has established the efficacy of social distancing to modify the transmission of SARS CoV-2. Public health officials have referenced:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43>

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.

<sup>30</sup> <https://jamanetwork.com/journals/jama/fullarticle/2762694>

<sup>31</sup> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/>

<sup>32</sup>

<https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html>

<sup>33</sup> Werner E. Bischoff, Katrina Swett, Iris Leng, Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient Care, The Journal of Infectious Diseases, Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, <https://doi.org/10.1093/infdis/jis773>

CC-BY-NC-SA Dr. David E. Martin

Fauci/COVID-19 Dossier

25

It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, wellcontrolled human clinical studies, substantiating that the claims are true at the time they are made. As a result, every party promoting the use of face masks is violating the FTC Act. All of these laws have been broken. All relevant authorities in the United States must cease and desist the use of face

masks until the matters above are rectified.

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

26

#### The Commercial Actors

SARS coronavirus is a new topic for many individuals. Since 1999, the ability to manipulate and exploit coronavirus for a variety of purposes has attracted the attention of individuals, institutions and commercial organizations in public, private, and not-for-profit sectors. The following is the list of over 5,100 patents and patent applications filed for the express purpose of controlling some aspect of the SARS coronavirus.

#### PATENT Title

US9995706 Amperometric gas sensor

US9995705 Amperometric gas sensor

US9994558 Multicyclic compounds and methods of using same

US9994550

US9993543

Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

Immunogenic compositions comprising silicified virus and methods of use

US9982257 Chiral control

US9982241 Recombinant HCMV and RHCMV vectors and uses thereof

US9982025 Monomeric griffithsin tandemers

US9981036

Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same

US9975885 Broad-spectrum non-covalent coronavirus protease inhibitors

US9974850 Immunogenic compositions and uses thereof

US9974848 Tetanus toxoid and CCL3 improve DC vaccines

US9974845 Combination of vaccination and inhibition of the PD-1 pathway

US9970061 Bioagent detection oligonucleotides

#### Owner

Steris Corporation

Steris Corporation

Karyopharm Therapeutics Inc.

3-V Biosciences, Inc.

Portland State University

WAVE LIFE SCIENCES LTD.

Oregon Health & Science University

The United States of America, as represented by the Secretary, Department of Health and Human Services

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

PURDUE RESEARCH FOUNDATION

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Duke University

CureVac AG

IBIS BIOSCIENCES, INC.

US9969793 Compositions and methods for the treatment of immunodeficiency ADMA  
Biologics, Inc.

US9963718

US9963611

LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virusproducing

cells for the therapy of tumors  
Composition for use in decreasing the transmission of human  
pathogens  
US9963427 Dithiol mucolytic agents  
US9962439 Injectable vaccine composition  
US9957302 Treating cancer with viral nucleic acid  
US9957300  
US9957238  
Virus-like particles, methods of preparation, and immunogenic  
compositions  
Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel  
blocking compounds  
US9951317 Highly efficient influenza matrix (M1) proteins  
VIRATHERAPEUTICS GMBH  
Innonix Technologies, Incorporated  
PARION SCIENCES, INC.  
NITTO DENKO CORPORATION  
Mayo Foundation for Medical Education and Research  
Emory University  
Parion Sciences, Inc.  
NOVAVAX, INC.  
Prio  
ri  
ty  
25Jun12  
25Jun12  
20Sep13  
7Jan14  
31Jan13  
13Jul-12  
14May10  
5Jun13  
12Dec11  
28Apr16  
25Mar15  
14Nov13  
22Feb13  
27Dec11  
28Oct14  
8Oct08  
29May09  
23Aug13  
30Oct13  
20Feb07  
17May02  
13Dec13  
11Jul-03  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
File  
d  
Dat  
e  
30Sep

-14  
30Sep  
-14  
19Sep  
-14  
7Jan  
-15  
31Jan  
-14  
12Jul13  
10Oct  
-15  
5Jun  
-14  
26Feb  
-16  
28Apr  
-17  
25Mar  
-16  
14Nov  
-14  
21Feb  
-14  
27Dec  
-12  
13Nov  
-17  
7Apr  
-17  
21May  
-10  
11Mar  
-16  
20Oct  
-14  
6Jul15  
4May  
-15  
1Mar  
-17  
6Oct  
-16  
27  
Issu  
e  
Dat  
e  
12Jun18  
12Jun18  
12Jun18  
12Jun18  
12Jun18  
29May

-18

29May

-18

29May

-18

29May

-18

22May

-18

22May

-18

22May

-18

22May

-18

15May

-18

15May

-18

8May

-18

8May

-18

8May

-18

8May

-18

1May

-18

1May

-18

1May

-18

24Apr18

27US9951124

Antibody producing non-human mammals

US9951122 Antibodies against influenza virus and methods of use thereof

US9950062 Compounds and compositions as TLR activity modulators

US9945856

US9945780

US9944928

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics

Use of a fluorescent material to detect failure or deteriorated performance of a fluorometer

Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions

US9944695 Antibody producing non-human mammals

US9944686 Treatment of tumors with recombinant interferon alpha

US9944649 Compounds and compositions as toll-like receptor 7 agonists

US9943614

US9938300

US9938275

Cationic steroid antimicrobial diagnostic, detection, screening and



imaging methods

Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors  
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

MERUS N.V.

BURNHAM INSTITUTE FOR MEDICAL RESEARCH

GLAXOSMITHKLINE BIOLOGICALS SA

AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.

GEN-PROBE INCORPORATED

York Yuan Yuan Zhu

Merus N.V.

SUPERLAB FAR EAST LIMITED

Novartis Ag

BRIGHAM YOUNG UNIVERSITY

Forma Therapeutics, Inc.

3M Innovative Properties Company

US9938258 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof  
Karyopharm Therapeutics Inc.

US9932351 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors

US9932323

US9931316

US9926340

Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones

Antiviral activity from medicinal mushrooms and their active constituents

NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants

US9925215

Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for prophylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative

Forma Therapeutics, Inc.

Rutgers, The State University of New Jersey

Not Available

Biolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH

Jun08

6Dec07

2Sep09

18Aug03

14Jun12

23Jul-07

27Jun08

28Feb01

1May14

17Jun08

5Feb15

18Jun04

29Nov12  
5Feb15  
11Sep12  
31Mar15  
8Apr15  
25Jan  
-13  
12Aug  
-13  
1Sep  
-10  
13Aug  
-14  
7Jun  
-13  
2Jul15  
30Apr  
-14  
5Sep  
-13  
29Apr  
-15  
16Jun  
-09  
4Feb  
-16  
23Jan  
-17  
27Nov  
-13  
4Feb  
-16  
13Jan  
-17  
14Sep  
-15  
1Apr  
-16  
24Apr18  
24Apr18  
24Apr18  
17Apr18  
17Apr18  
17Apr18  
17Apr18  
17Apr18  
17Apr18  
17Apr18  
17Apr18  
10Apr18  
10Apr18  
10Apr18  
3Apr18  
3Apr18  
3Apr18

27Mar

-18

UNIWERSYTET

JAGIELLONSKI

29Jul-14

25Oct

-17

27Mar

-18

21US9920314

Compositions for and methods of identifying antigens

US9920128 Synthetic antiserum for rapid-turnaround therapies

US9919034

US9915613

Methods of treating and prophylactically protecting mammalian

patients infected by viruses classified in Baltimore group V

Systems and methods for distinguishing optical signals of different

modulation frequencies in an optical signal detector

US9914976 Methods and compositions for prostate cancer metastasis

US9913801

US9909176

Treatment of evolving bacterial resistance diseases including

Klebsiella pneumoniae with liposomally formulated glutathione

Efficient deep sequencing and rapid genomic speciation of RNA

viruses (vRNAseq)

US9908946 Generation of binding molecules

US9908675 Powdered pouch and method of making same

Fauci/COVID-19 Dossier

President and Fellows of Harvard College

The Johns Hopkins University

TAMIR BIOTECHNOLOGY, INC.

GEN-PROBE INCORPORATED

FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY

(FA

YOUR ENERGY SYSTEMS, LLC

The Johns Hopkins University

Merus N.V.

MONOSOL, LLC

CC-BY-NC-SA Dr. David E. Martin

Feb06

28Jan15

28Mar14

24Feb11

25Mar11

15Feb13

8Sep14

26Sep11

16Apr12

6May

-15

20Jan

-16

10Jun

-15

21Mar

-14

27May

-16

15Mar

-13

1Sep

-15

16Sep

-15

19Jul16

28

20Mar

-18

20Mar

-18

20Mar

-18

13Mar

-18

13Mar

-18

13Mar

-18

6Mar

-18

6Mar

-18

6Mar

-18

4US9907796

Methods of treating tumoral diseases, or bacterial or viral infections  
INHIBIKASE THERAPEUTICS, INC.

US9895692 Sample-to-answer microfluidic cartridge

US9895411 Analogs of C5a and methods of using same

US9895341 Inflammation and immunity treatments

US9894888 Transgenic immunodeficient mouse expressing human SIRP-alpha

US9890419 Nanoreporters and methods of manufacturing and use thereof

US9890408 Multiple displacement amplification

US9890362 Compositions, methods and uses for inducing viral growth

US9890361

Methods for increasing the infectivity of viruses utilizing alkynemodified  
fatty acids

US9890206 H1N1 flu virus neutralizing antibodies

US9890169 Triazolinone compounds as HNE inhibitors

US9890124 Benzazepine sulfonamide compounds

US9889194 Immunogenic composition for MERS coronavirus infection

US9885092 Materials and methods for detection of HPV nucleic acids

US9885082 Embodiments of a probe and method for targeting nucleic acids

US9885037 Chiral control

US9884895 Methods and compositions for chimeric coronavirus spike proteins

US9884876

Anti-viral compounds, pharmaceutical compositions, and methods of  
use thereof

US9884129 Release of agents from cells  
US9884032  
Esters of short chains fatty acids for use in the treatment of  
immunogenic disorders  
US9884026 Modular particles for immunotherapy  
US9880151  
Method of determining, identifying or isolating cell-penetrating  
peptides  
US9879026 Substituted spirocycles  
US9879003 Host targeted inhibitors of dengue virus and other viruses  
US9878988  
Dendrimer like amino amides possessing sodium channel blocker  
activity for the treatment of dry eye and other mucosal diseases  
US9873678 Chemical compounds  
US9873674 C-Rel inhibitors and uses thereof  
US9872900 Nucleic acid vaccines  
US9872898  
US9872895  
Compositions and methods for treating and preventing porcine  
reproductive and respiratory syndrome  
TLR5 ligands, therapeutic methods, and compositions related  
thereto  
Fauci/COVID-19 Dossier  
Micronics, Inc.  
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA  
Ocean Spray Cranberries, Inc.  
INSTITUT PASTEUR  
NanoString Technologies, Inc.  
IBIS BIOSCIENCES, INC.  
Takeda Vaccines, Inc.  
LIFE TECHNOLOGIES CORPORATION  
Medigen Biotechnology Corporation  
CHIESI FARMACEUTICI S.P.A.  
Hoffmann-La Roche Inc.  
New York Blood Center, Inc.  
QIAGEN GAITHERSBURG INC.  
University of Idaho  
WAVE LIFE SCIENCES LTD.  
The University of North Carolina at Chapel Hill  
Kineta, Inc.  
The Brigham and Women's Hospital, Inc.  
PROPONENT BIOTECH GMBH  
YALE UNIVERSITY  
Phylogica Limited  
Boehringer Ingelheim International GmbH  
Dana-Farber Cancer Institute, Inc.  
PARION SCIENCES, INC.  
AstraZeneca AB  
CORNELL UNIVERSITY  
ModernaTX, Inc.  
Ohio State Innovation Foundation  
Emory University  
CC-BY-NC-SA Dr. David E. Martin  
Oct12

29Jan10  
29Jun10  
1Apr11  
26Mar12  
23Dec05  
15Oct09  
5Dec08  
26Jan12  
20Aug15  
14Dec15  
15Dec15  
1Mar13  
24Feb11  
19Jul-11  
13Jul-12  
20Mar14  
9May14  
15Oct09  
30Oct12  
1Nov13  
23May11  
12Sep14  
11Apr12  
29May12  
18Mar14  
21Sep12  
23Apr14  
24Apr12  
24Sep10  
15Sep  
-16  
5Aug  
-15  
29Jun  
-11  
30Mar  
-12  
26Mar  
-13  
20May  
-16  
15Oct  
-10  
19Sep  
-14  
25Jan  
-13  
20Aug  
-15  
12Dec  
-16  
14Jun  
-17  
28Feb

-14  
23Feb  
-12  
19Jul12  
12Jul13  
20Mar  
-15  
8May  
-15  
5Jan  
-15  
3Mar  
-16  
31Oct  
-14  
23May  
-12  
29Nov  
-16  
15Mar  
-13  
5Jan  
-16  
17Mar  
-15  
19Sep  
-13  
5Apr  
-16  
30Oct  
-16  
20Sep  
-11  
29  
6Mar  
-18  
20Feb  
-18  
20Feb  
-18  
20Feb  
-18  
20Feb  
-18  
13Feb  
-18  
13Feb  
-18  
13Feb  
-18  
13Feb  
-18  
13Feb  
-18



13Feb  
-18  
13Feb  
-18  
13Feb  
-18  
6Feb  
-18  
6Feb  
-18  
6Feb  
-18  
6Feb  
-18  
6Feb  
-18  
6Feb  
-18  
6Feb  
-18  
6Feb  
-18  
30Jan18  
30Jan18  
30Jan18  
30Jan18  
23Jan18  
23Jan18  
23Jan18  
23Jan18  
23Jan18  
23Jan18  
US9868952  
Compositions and methods for "resistance-proof" SiRNA  
therapeutics for influenza  
US9868740 Pyrimidinone compounds which are HNE inhibitors  
US9868736 Deubiquitinase inhibitors and methods for use of the same  
US9867882 Carbohydrate conjugates as delivery agents for oligonucleotides  
US9867877 Methods for preparing squalene  
US9862706 Compounds  
US9861614 Nuclear transport modulators and uses thereof  
US9856254 Alkoxy substituted imidazoquinolines  
US9856241  
Substituted benzofuranyl and benzoxazolyl compounds and uses  
thereof  
US9856228 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors  
US9856224 Stable sodium channel blockers  
US9855287 Anti-viral azide containing compounds  
US9855284 Pharmaceutical compositions and methods  
US9849143 Broad spectrum antiviral and methods of use  
US9845342  
Fusion proteins, recombinant bacteria, and methods for using  
recombinant bacteria  
US9840731 Preservation of biological materials in non-aqueous fluid media  
US9840719

US9840491

US9839687

Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues

Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule

US9834812 Probe kit for detecting a single strand target nucleotide sequence  
Sirnaomics, Inc.

8-Jul12

12CHIESI

FARMACEUTICI S.p.A.

THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Alnylam Pharmaceuticals, Inc.

NOVARTIS AG

CHIESI FARMACEUTICI S.p.A.

Karyopharm Therapeutics Inc.

3M Innovative Properties Company

Karyopharm Therapeutics Inc.

PROZYMEX A/S

PARION SCIENCES, INC.

LIFE TECHNOLOGIES CORPORATION

Pop Test Oncology LLC

The Burlington HC Research Group, Inc.

Spogen Biotech Inc.

Gentegra, LLC

The Children's Hospital of Philadelphia

FORMA Therapeutics, Inc.

SUZHOU M-CONJ BIOTECH CO., LTD.

Fondazione Istituto Italiano Di Tecnologia

US9834791 CRISPR-related methods and compositions with governing gRNAs Editas  
Medicine, Inc.

US9834757

US9834595

Hand, foot, and mouth vaccines and methods of manufacture and use thereof

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

US9833504 Virus-like particles and process for preparing same

US9833492 Combinations of a caspase inhibitor and an antiviral agent

US9832998 Antiviral compositions

US9828382 Pyrimidinone compounds as human neutrophil elastase inhibitors

US9828379

Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

US9828370 Compositions and methods for inhibiting kinases

US9828346 N-myristoyl transferase inhibitors

Fauci/COVID-19 Dossier

Takeda Vaccines, Inc.

Ablynx N.V.

Folia Biotech Inc.

Centre National de la Recherche Scientifique

Long Island University  
Chiesi Farmaceutici S.p.A.  
ABIDE THERAPEUTICS, INC.  
INHIBIKASE THERAPEUTICS, INC.  
University of Dundee  
CC-BY-NC-SA Dr. David E. Martin

Jun14  
10Oct13  
4Dec07  
12May10  
31May16  
9May12  
30Oct03  
3-Jul13  
9Sep13  
30Jun14  
28Jul-10  
3Aug15  
17Apr06  
17Sep14  
14Mar13  
22Jul-13  
5Feb15  
15Jul-15  
27Dec12  
7Nov13  
7Nov14  
5Jun08  
13May11  
2Nov07  
30May07  
18Dec12  
3-Jul13  
23Apr15  
2Sep08  
Jul13  
12Jun  
-14  
10Oct  
-14  
25Aug  
-15  
22Nov  
-16  
26May  
-17  
23Jun  
-15  
13Jun  
-16  
3Jul14  
8Sep  
-14  
30Jan



12Dec  
-17  
12Dec  
-17  
12Dec  
-17  
12Dec  
-17  
5Dec  
-17  
5Dec  
-17  
5Dec  
-17  
5Dec  
-17  
5Dec  
-17  
5Dec  
-17  
5Dec  
-17  
28Nov  
-17  
28Nov  
-17  
28Nov  
-17  
28Nov  
-17  
716  
US9828342  
US9827190  
US9822339  
Isatin derivatives, pharmaceutical compositions thereof, and  
methods of use thereof  
24CITY  
OF HOPE  
Intradermal delivery of immunological compositions comprising tolllike  
receptor 7 agonists  
Means and methods for influencing the stability of antibody  
producing cells  
US9822173 Heterodimeric immunoglobulins  
US9822165  
US9822155  
Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41  
membrane proximal external region  
Method of preventively treating a subject at the risk of developing  
infections of a respiratory virus  
US9822127 GAK modulators as antivirals  
US9822065 Benzazepine dicarboxamide compounds  
US9821052 Reverse genetics systems  
US9821051 Reducing hospitalization in elderly influenza vaccine recipients  
US9816078

Compositions for increasing polypeptide stability and activity, and related methods  
GLAXOSMITHKLINE BIOLOGICALS SA  
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT  
VAN AMSTERDAM  
AMGEN INC.  
DANA-FARBER CANCER INSTITUTE, INC.  
Xiangxue Group (Hong Kong) Company Limited  
The Board of Trustees of the Leland Stanford Junior University  
Hoffmann-La Roche Inc.  
Seqirus UK Limited  
Seqirus UK Limited  
SOLIS BIODYNE OÃæ  
US9815886 Compositions and methods for the treatment of immunodeficiency ADMA BIOLOGICS, INC.  
US9815805  
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2carboxamides as dipeptidyl peptidase 1 inhibitors  
US9814777 Targeting lipids  
US9810683  
Use of live cell inteferometry with reflective floor of observation chamber to determine changes in mass of mammalian cells  
US9809845 Methods and reagents for amplifying nucleic acids  
US9809796 Animal protein-free media for cultivation of cells  
US9809632 Universal protein tag for double stranded nucleic acid delivery  
US9809591 Heterocyclic modulators of lipid synthesis  
US9808490 Induced hepatocytes and uses thereof  
US9803236  
Microarray-based assay integrated with particles for analyzing molecular interactions  
ASTRAZENECA AB  
Arbutus Biopharma Corporation  
The Regents of the University of California  
The United States of America, as represented by the Secretary, Department of Health and Human Services  
Baxalta GmbH  
University of Washington Through its Center for Commercialization  
3-V Biosciences, Inc.  
ACCELERATED BIOSCIENCES CORP.  
CapitalBio Corporation  
US9803197 Particle-nucleic acid conjugates and therapeutic uses related thereto Emory University  
US9802937 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors  
US9802919 Compounds  
US9801948 Antimicrobial compositions and methods of use thereof  
US9801947 Methods and compositions for enhancing immune response  
US9801935 Soluble needle arrays for delivery of influenza vaccines  
US9801897 Delivery of RNA to trigger multiple immune pathways  
US9797000  
Non-target amplification method for detection of RNA splice-forms in a sample  
US9796979 Oligonucleotide modulators of the toll-like receptor pathway

Fauci/COVID-19 Dossier  
ORIGENIS GMBH  
CHIESI FARMACEUTICI S.p.A.  
Yale University  
3M INNOVATIVE PROPERTIES COMPANY  
SEQIRUS UK LIMITED  
GLAXOSMITHKLINE BIOLOGICALS SA  
QIAGEN GAITHERSBURG INC.  
Quark Pharmaceuticals Inc.  
CC-BY-NC-SA Dr. David E. Martin  
Feb12  
1Feb13  
9Dec05  
21Nov12  
18Jun09  
9May13  
23Jul-14  
6Mar15  
31Jul-09  
28Oct10  
19Nov09  
28Oct14  
24Jan14  
4Dec07  
6May09  
6Aug12  
29Oct04  
23Oct13  
8Mar11  
26Nov14  
6Aug10  
25Jun12  
21Apr11  
31May16  
21Sep11  
10Apr03  
20Aug10  
6-Jul10  
1May09  
3Mar11  
25Feb  
-13  
30Jan  
-14  
26Aug  
-15  
21Nov  
-13  
18Jun  
-10  
23Aug  
-16  
23Jul15  
14Feb



-17  
30Jul10  
21Oct  
-11  
11Mar  
-16  
8Jan  
-15  
8Nov  
-16  
22Oct  
-13  
25Nov  
-13  
6Aug  
-12  
18May  
-17  
22Oct  
-14  
5Oct  
-15  
25Nov  
-15  
6Aug  
-10  
27Feb  
-13  
23Apr  
-12  
26May  
-17  
21Sep  
-12  
6Oct  
-14  
11Oct  
-16  
6Jul11  
30Apr  
-10  
28Jul16  
31  
28Nov  
-17  
28Nov  
-17  
21Nov  
-17  
21Nov  
-17  
21Nov  
-17  
21Nov

-17

21Nov

-17

21Nov

-17

21Nov

-17

21Nov

-17

14Nov

-17

14Nov

-17

14Nov

-17

14Nov

-17

7Nov

-17

7Nov

-17

7Nov

-17

7Nov

-17

7Nov

-17

7Nov

-17

31Oct17

31Oct17

31Oct17

31Oct17

31Oct17

31Oct17

31Oct17

31Oct17

24Oct17

24Oct17

20US9796735

Boron-containing small molecules

US9795669

US9795668

US9795666

Lipidated immune response modifier compound compositions,  
formulations, and methods

Delivery of self-replicating RNA using biodegradable polymer  
particles

High-yield transgenic mammalian expression system for generating  
virus-like particles

US9791437 Multianalyte assay

US9789180

D-amino acid derivative-modified peptidoglycan and methods of use  
thereof

US9786050 Stain-free histopathology by chemical imaging  
US9783595 Neutralizing GP41 antibodies and their use  
US9782470 Method of obtaining thermostable dried vaccine formulations  
US9782434  
Methods of treating or preventing inflammation and hypersensitivity  
with oxidative reductive potential water solution  
US9770504 Generating peptoid vaccines  
US9770463 Delivery of RNA to different cell types  
US9765395  
System and method for DNA sequencing and blood chemistry  
analysis  
US9765133 Antibody producing non-human mammals  
US9765071 Substituted imidazo ring systems and methods  
US9764027 Outer membrane vesicles  
US9759723 B-cell antigen presenting cell assay  
US9758840 Parasite detection via endosymbiont detection  
US9758820 Organism identification panel  
US9758775 TAL effector-mediated DNA modification  
US9758568 Oligopeptide-free cell culture media  
US9758553  
Yeast strain for the production of proteins with terminal alpha-1,3linked  
galactose  
Anacor Pharmaceuticals, Inc.  
3M INNOVATIVE PROPERTIES COMPANY  
GlaxoSmithKline Biologicals S.A.  
Academia Sinica  
Nexus Dx, Inc.  
The Regents of the University of California  
The Board of Trustees of the University of Illinois  
The United States of America, as represented by the  
Secretary, Department of Health and Human Services  
Merck Sharp & Dohme Corp.  
Sonoma Pharmaceuticals, Inc.  
The Board of Regents of the University of Texas System  
GLAXOSMITHKLINE BIOLOGICALS SA  
Nanomedical Diagnostics, Inc.  
Merus N.V.  
3M INNOVATIVE PROPERTIES COMPANY  
GLAXOSMITHKLINE BIOLOGICALS SA  
University of Pittsburgh of the Commonwealth System of  
Higher Education  
IBIS BIOSCIENCES, INC.  
BioFire Diagnostics, LLC  
Iowa State University Research Foundation, Inc.  
Baxalta GmbH  
MERCK SHARP & DOHME CORP.  
US9757478 Mutant protease biosensors with enhanced detection characteristics  
Promega Corporation  
US9757470 Peptides for assisting delivery across the blood brain barrier  
US9757446 Influenza virus vectors and uses therefor  
US9757407  
Treatment of viral infections by modulation of host cell metabolic  
pathways  
US9751945 Sortase-modified VHH domains and uses thereof

US9750798

Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses

US9750797 Sustained release vaccine composition

US9750690

Circulation of components during microfluidization and/or homogenization of emulsions

Fauci/COVID-19 Dossier

Children's Medical Center Corporation

FLUGEN, INC.

The Trustees of Princeton University

Whitehead Institute for Biomedical Research

STICHTING WAGENINGEN RESEARCH

VIRBAC CORPORATION

NOVARTIS AG

Jun07

17Aug10

6-Jul10

5Sep06

30Apr07

30Nov12

15Mar13

7Nov11

16Oct13

20Jan06

3May13

6-Jul10

28Apr14

27Jun08

25Nov03

18Sep12

8Apr10

14Mar10

2Apr07

10Dec09

4Jan06

30May08

11May10

22May06

17Mar14

1Jun07

13Apr12

21May13

16Jun04

3Dec09

CC-BY-NC-SA

Dr. David E. Martin

7Nov

-14

15Dec

-15

23Nov

-15

11Feb

-15  
15Jun  
-15  
31Mar  
-16  
14Mar  
-14  
2Aug  
-16  
13Oct  
-14  
7Jul15  
2May  
-14  
7Jun  
-11  
10Apr  
-15  
29Apr  
-14  
14Mar  
-16  
18Sep  
-13  
21Mar  
-16  
11Mar  
-11  
1Apr  
-08  
14Apr  
-14  
16Nov  
-15  
2Jul14  
7Jan  
-16  
30Apr  
-14  
13Mar  
-15  
21Dec  
-15  
15Apr  
-13  
21May  
-14  
16Jun  
-05  
5Sep  
-14  
32  
24Oct17  
24Oct17

24Oct17  
24Oct17  
17Oct17  
17Oct17  
10Oct17  
10Oct17  
10Oct17  
10Oct17

26Sep  
-17

26Sep  
-17

19Sep  
-17

19Sep  
-17

19Sep  
-17

19Sep  
-17

12Sep  
-17

12Sep  
-17

12Sep  
-17

12Sep  
-17

12Sep  
-17

12Sep  
-17

12Sep  
-17

12Sep  
-17

12Sep  
-17

12Sep  
-17

5Sep  
-17

5Sep  
-17

5Sep  
-17

5Sep  
-17

US9746985

System and method for detecting, collecting, analyzing, and  
communicating event-related information

25Georgetown

University

US9746459 Antigen presenting cell assay

US9745306

2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl)quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors

US9744231

US9744229

Quality control methods for oil-in-water emulsions containing squalene

Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same

US9744183 Nucleic acid prodrugs and methods of use thereof

US9738894 Short interfering RNA (siRNA) analogues

US9738624 Nuclear transport modulators and uses thereof

US9737618

Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses therefor

US9737593 Carbon nanotube compositions and methods of use thereof

US9730997 Alphavirus vectors for respiratory pathogen vaccines

US9730912 Pharmaceutical compounds

US9727810 Spatially addressable molecular barcoding

US9726607 Systems and methods for detecting multiple optical signals

US9725770

Methods and compositions for identification of source of microbial contamination in a sample

US9725487 Compositions and methods for measles virus inhibition

US9719106

Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof

US9719083 Bioagent detection methods

US9718774 Indole carboxamide derivatives as P2X7 receptor antagonist

US9717755 Method of treating inflammation

US9717749 Production of stable non-polyadenylated RNAs

US9717732 Drug combination

US9714411 Animal protein-free media for cultivation of cells

University of Pittsburgh of the Commonwealth System of Higher Education

Respivert Limited

Feb08

8Apr10

15Mar13

8NOVARTIS

AG

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

WAVE LIFE SCIENCES LTD.

Roche Innovation Center Copenhagen A/S

Karyopharm Therapeutics Inc.

The Trustees of the University of Pennsylvania

Yale University

Novartis Vaccines and Diagnostics, Inc.

ASTEX THERAPEUTICS LIMITED

Cellular Research, Inc.

GEN-PROBE INCORPORATED

The Regents of the University of California  
Autoimmune Technologies, LLC  
The Trustees of the University of Pennsylvania  
IBIS BIOSCIENCES, INC.  
IDORSIA PHARMACEUTICALS LTD  
Cytosorbents Corporation  
Massachusetts Institute of Technology  
VERONA PHARMA PLC  
Baxalta GmbH  
US9714283 Compositions and methods for the treatment of immunodeficiency ADMA  
BIOLOGICS, INC.  
US9714226 Hydrazone containing nuclear transport modulators and uses thereof  
Karyopharm Therapeutics Inc.  
US9713641 Anti-TIGIT antigen-binding proteins and methods of use thereof  
US9713606  
Methods for treating pulmonary emphysema using substituted  
2Aza-bicyclo[2.2.1]heptane-3-carboxylic  
acid (benzyl-cyano-methyl)amides  
inhibitors of cathepsin C  
US9708375 Inhibitory polypeptides specific to WNT inhibitors  
US9707278  
Methods of modulating immune responses by modifying Akt3  
bioactivity  
Fauci/COVID-19 Dossier  
Potenza Therapeutics, Inc.  
Nov06  
4Apr08  
6-Jul09  
21Mar03  
21Jun13  
30Sep03  
19Mar08  
21May04  
12Oct06  
27Feb15  
10Mar05  
6Mar12  
4Nov03  
29Apr13  
8Mar09  
12Dec12  
1Apr10  
16Oct12  
15Mar13  
29Oct04  
28Oct14  
29Jul-11  
13Feb17  
14Boehringer  
Ingelheim International GmbH  
Mar13  
15Amgen  
Inc.  
Augusta University Research Institute, Inc.



CC-BY-NC-SA Dr. David E. Martin

Mar13

17Apr14

20Apr

-11

11Oct

-13

14Mar

-14

27Aug

-13

28Apr

-14

6Jul10

28Mar

-16

20Jun

-14

20Jul15

15Mar

-13

20Aug

-14

12Oct

-07

26Feb

-16

3Mar

-14

6Mar

-13

13May

-15

29Apr

-14

8Mar

-10

11Dec

-13

1Apr

-11

16Oct

-13

17Mar

-14

30Nov

-15

2Jul15

13Nov

-15

13Feb

-17

1Dec

-15

14Mar  
-14  
17Apr  
-15  
33  
29Aug  
-17  
29Aug  
-17  
29Aug  
-17  
29Aug  
-17  
29Aug  
-17  
29Aug  
-17  
22Aug  
-17  
22Aug  
-17  
22Aug  
-17  
22Aug  
-17  
15Aug  
-17  
15Aug  
-17  
8Aug  
-17  
8Aug  
-17  
8Aug  
-17  
8Aug  
-17  
1Aug  
-17  
1Aug  
-17  
1Aug  
-17  
1Aug  
-17  
1Aug  
-17  
1Aug  
-17  
25Jul17  
25Jul17  
25Jul17  
25Jul17  
25Jul17

18Jul17

18Jul17

US9701736

Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection

20New

York Blood Center, Inc.

US9701638 Therapeutic hydroxyquinolones

US9700616

Arranging interaction and back pressure chambers for microfluidization

US9700614 Intranasal vaccination dosage regimen

US9700558

Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist

US9696247 Sample fixation and stabilisation

US9695445

Method for production of reprogrammed cell using chromosomally unintegrated virus vector

US9695135 Therapeutic catechols

US9695134

US9689018

US9688982

3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide compounds

Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses

Methods and compositions for the treatment of cancer or other diseases

US9687536 Methods and compositions for intranasal delivery

US9683256 Biological specimen collection and transport system

US9683017 Inhibitory peptides of viral infection

US9682133 Disrupted adenovirus-based vaccine against drugs of abuse

US9677089

US9676867

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody

US9676857 Soluble engineered monomeric Fc

US9676727 Myxovirus therapeutics, compounds, and uses related thereto

US9675550

Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

US9670507 Directed evolution and in vivo panning of virus vectors

US9670166

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

US9669092 Antagonism of the VIP signaling pathway

US9669089

Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

US9669088 Vaccination with multiple clades of H5 influenza A virus

US9661856 Synergy of plant antimicrobials with silver  
US9657278 Methods to produce bunyavirus replicon particles  
US9657076  
GM-CSF and IL-4 conjugates, compositions, and methods related thereto  
US9657048 Enantiomers of the 1 $\alpha$ ,6 $\alpha$ -isomer of neplanocin A  
Rutgers, The State University of New Jersey  
NOVARTIS AG  
Eurocine Vaccines AB  
VERONA PHARMA PLC  
RNASSIST LTD.  
ID Pharma Co., Ltd.  
Rutgers, The State University of New Jersey  
Parion Sciences, Inc.  
Diagnostic Hybrids, Inc.  
CITY OF HOPE  
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.  
Longhorn Vaccines and Diagnostics, LLC  
UNIVERSITY TENNESSEE RESEARCH FOUNDATION  
CORNELL UNIVERSITY  
The Trustees of the University of Pennsylvania  
Dana-Farber Cancer Institute Inc.  
The United States of America, as represented by the Secretary, Department of Health and Human Services  
Children's Healthcare of Atlanta, Inc.  
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
The University of North Carolina at Chapel Hill  
Boehringer Ingelheim International GmbH  
Emory University  
Oct10  
9Nov12  
3Dec09  
17Dec12  
15Mar13  
1Mar13  
16Jul-08  
12May14  
17Dec12  
24Apr98  
26Jan07  
15Apr10  
10ct07  
17Jul-14  
17Mar10  
17Dec01  
2Dec05  
16Mar12  
24Oct11  
26Jul-10  
30Apr08  
6Feb13  
2Feb11  
15CureVac  
AG

Feb12  
26Seqirus  
UK Limited  
The Arizona Board of Regents on Behalf of The University  
of Arizona  
Stichting Dienst Landbouwkundig Onderzoek  
Children's Healthcare of Atlanta, Inc.  
Auburn University  
Nov07  
24Aug12  
20Sep10  
23Oct12  
4Aug14  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
9Oct  
-14  
8Nov  
-13  
22Mar  
-16  
17Dec  
-13  
17Mar  
-14  
28Feb  
-14  
29Jul15  
11May  
-15  
8Jan  
-15  
4Aug  
-14  
11Oct  
-13  
15Apr  
-11  
15Dec  
-15  
16Jul15  
17Mar  
-11  
30Mar  
-16  
8May  
-13  
14Mar  
-13  
7Jul16  
25Jan  
-13  
28Jun

-16  
5Aug  
-16  
31Jan  
-12  
15Feb  
-13  
25Nov  
-08  
26Aug  
-13  
10Jul15  
23Oct  
-13  
4Aug  
-15  
34  
11Jul17  
11Jul17  
11Jul17  
11Jul17  
11Jul17  
4Jul17  
4Jul17  
4Jul17  
4Jul17  
27Jun17  
27Jun17  
27Jun17  
20Jun17  
20Jun17  
20Jun17  
13Jun17  
13Jun17  
13Jun17  
13Jun17  
13Jun17  
6Jun17  
6Jun17  
6Jun17  
6Jun17  
6Jun17  
30May  
-17  
23May  
-17  
23May  
-17  
23May  
-17

US9657015

US9655896

Substituted bicyclic dihydropyrimidinones and their use as inhibitors  
of neutrophil elastase activity

Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity  
US9655845 Oil-in-water emulsions that contain nucleic acids  
US9655367 Disinfecting composition and wipes with reduced contact time  
US9651543 Malaria antigen screening method  
US9650685 Selective detection of human rhinovirus  
US9650649  
LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virusproducing cells for the therapy of tumors  
US9649324 Use of tylvalosin as antiviral agent  
US9649309  
Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity  
US9644180 Synthetic membrane-receiver complexes  
US9642876  
US9642873  
US9637524  
Method of preventing or treating sinusitis with oxidative reductive potential water solution  
Combinations of TGF $\beta$ 2 and COX-2 inhibitors and methods for their therapeutic application  
Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector  
US9637491 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors  
US9636410 Cationic oil-in-water emulsions  
US9636397 Adjuvant compositions and related methods  
US9636370 AAV vectors targeted to oligodendrocytes  
US9629907  
Compositions for and methods of inducing mucosal immune responses  
US9624173 Heterocyclic modulators of lipid synthesis  
US9623040  
Immunomodulation by controlling expression levels of microRNAs in dendritic cells  
US9618508 Flow cytometry analysis of materials adsorbed to metal salts  
US9618476 System and method for electronic biological sample analysis  
US9618429 Polymer stabilization of chromogen solutions  
US9611481  
US9611474  
Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof  
Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof  
US9605276 Replication defective adenovirus vector in vaccination  
US9603864 Substituted nucleosides, nucleotides and analogs thereof  
US9603850 MerTK-specific pyrazolopyrimidine compounds  
US9599606 ADP-ribose detection reagents  
US9598459 Pharmaceutical compositions and methods  
Fauci/COVID-19 Dossier  
Boehringer Ingelheim International GmbH  
31Jul-14  
27PARION  
SCIENCES, INC.

GlaxoSmithKline Biologicals, S.A.  
LONZA, INC.  
The United States of America as Represented by the  
Secretary of the Navy  
The United States of America, as represented by the  
Secretary, Department of Health and Human Services  
VIRATHERAPEUTICS GMBH  
CAMBRIDGE UNIVERSITY TECHNICAL SERVICES  
The University of North Carolina at Chapel Hill  
RUBIUS THERAPEUTICS, INC.  
SONOMA PHARMACEUTICALS, INC.  
Sirnaomics, Inc.  
The Regents of the University of California  
ORIGENIS GMBH  
GLAXOSMITHKLINE BIOLOGICALS SA  
Vaxliant, LLC  
The University of North Carolina at Chapel Hill  
The Trustees of the University of Pennsylvania  
3-V Biosciences, Inc.  
The Board of Trustees of the Leland Stanford Junior  
University  
GlaxoSmithKline Biologicals SA  
NANOMEDICAL DIAGNOSTICS, INC.  
Ventana Medical Systems, Inc.  
UNIVERSITE DE MONTPELLIER  
QUARK PHARMACEUTICALS, INC.  
Etubics Corporation  
Alios BioPharma, Inc.  
The University of North Carolina at Chapel Hill  
The Board of Regents of the University of Texas System  
Pop Test Oncology LLC  
CC-BY-NC-SA Dr. David E. Martin  
Jun11  
6-Jul11  
6Nov13  
31Aug05  
5Dec08  
8Oct08  
13Jul-06  
11Apr14  
18Nov13  
30Dec03  
4May10  
27Feb09  
19Oct12  
6-Jul11  
24Mar15  
28Sep12  
19Nov04  
8Mar11  
14Jul-14  
14Dec10  
28Apr14  
23Jan12



24Sep09  
12Sep12  
24Aug12  
24Jun14  
11Apr14  
10Jun14  
3Aug15  
27Jul15  
12Jan  
-15  
6Jul12  
4Nov  
-14  
19Apr  
-13  
15Dec  
-14  
8Oct  
-09  
8Jun  
-15  
3Apr  
-15  
12Jun  
-15  
27Oct  
-15  
4May  
-11  
5Nov  
-14  
18Oct  
-13  
6Jul12  
24Mar  
-16  
27Sep  
-13  
28Oct  
-11  
19Mar  
-15  
10Jul15  
14Dec  
-11  
28Apr  
-14  
18Jan  
-13  
23Sep  
-10  
12Sep  
-13  
15Mar

-13  
22Jun  
-15  
3Apr  
-15  
9Jun  
-15  
28Jul16  
35  
May  
-17  
23May  
-17  
23May  
-17  
23May  
-17  
16May  
-17  
16May  
-17  
16May  
-17  
16May  
-17  
16May  
-17  
9May  
-17  
9May  
-17  
9May  
-17  
2May  
-17  
2May  
-17  
2May  
-17  
2May  
-17  
2May  
-17  
25Apr17  
18Apr17  
18Apr17  
11Apr17  
11Apr17  
11Apr17  
4Apr17  
4Apr17  
28Mar  
-17  
28Mar

-17

28Mar

-17

21Mar

-17

21Mar

-17

23

6US9597333

Benzazepine dicarboxamide compounds

US9593334

Use of the chromosome 19 microRNA cluster (C19MC) for treating viral disease and promoting autophagy

Hoffmann-La Roche Inc.

University of Pittsburgh of the Commonwealth System of Higher Education

US9593331 Double-stranded nucleic acid molecule for gene expression control

Osaka City University

US9593084

US9592284

US9592277

Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity

Immunization regimen with E4-deleted adenovirus prime and E1deleted adenovirus boost

Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases

US9588069 Methods for performing thermal melt analysis

US9587250

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

US9586998 Methods of propagating monkey adenoviral vectors

US9586911

Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

US9586910

3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide

US9585968

US9585953

Hydrazino

1H-imidazoquinolin-4-amines and conjugates made therefrom

Immunogenic compositions in particulate form and methods for producing the same

US9585874 Nuclear transport modulators and uses thereof

US9585849 Broad spectrum antiviral and methods of use

US9580474 Polyionic papilloma virus-like particle (VLP) vaccines

US9580468

Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells

Parion Sciences, Inc.

The Trustees of the University of Pennsylvania

Avirid, Inc.  
GEN-PROBE INCORPORATED  
Trustees of the University of Pennsylvania  
GenVec, Inc.  
Parion Sciences, Inc.  
Mar15  
7Mar12  
2Nov11  
17Dec12  
28Apr04  
14Apr04  
31Jul-12  
17Dec01  
9Nov09  
13Dec13  
27Parion  
Sciences, Inc.  
Jun11  
33M  
Innovative Properties Company  
MUCOSIS B.V.  
Karyopharm Therapeutics Inc.  
The Burlington HC Research Group, Inc.  
THE JOHNS HOPKINS UNIVERSITY  
CENTRE DE INVESTIGACION BIOMEDICA EN RED  
BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER  
BBN)  
US9580429 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy  
AstraZeneca AB  
US9574189 Enzymatic encoding methods for efficient synthesis of large libraries  
Nuevolution A/S  
US9574181 Influenza virus reassortment method  
US9573955 Compounds  
US9573938  
Therapeutic hydroxypyridinones, hydroxypyrimidinones and  
hydroxypyridazinones  
US9572899 Compositions for enhancing transport of molecules into cells  
US9572864 Compositions and uses of lectins  
US9572823 Boron-containing small molecules  
US9567336 Conjugated TLR7 and/or TLR8 and TLR2 agonists  
US9566326 Adjuvanted influenza vaccines for pediatric use  
US9566291 Nutritional composition comprising indigestible oligosaccharides  
US9566290 Boron-containing small molecules  
Fauci/COVID-19 Dossier  
Seqirus UK Limited  
Chiese Farmaceutici S.p.A.  
Rutgers, The State University of New Jersey  
AVI BIOPHARMA, INC.  
Emory University  
Anacor Pharmaceuticals, Inc.  
INVIVOGEN  
Seqirus UK Limited  
N.V. Nutricia  
Anacor Pharmaceuticals, Inc.

CC-BY-NC-SA Dr. David E. Martin

Jun11

22Mar11

9May12

17Apr06

8Sep10

13Jan11

6Dec04

1Dec05

21May10

16Dec13

11Sep12

29Apr03

12Feb10

16Feb05

19Nov12

22Feb08

24Aug04

16Feb05

28Sep

-16

6Mar

-13

1Nov

-12

13Dec

-13

27Apr

-05

14Apr

-05

31Jul13

16Jan

-15

4Aug

-15

19Dec

-14

18Dec

-13

14Aug

-15

22Mar

-12

6Jan

-16

17Apr

-07

8Sep

-11

13Jan

-12

15Sep

-14



-17

28Feb

-17

28Feb

-17

21Feb

-17

21Feb

-17

21Feb

-17

21Feb

-17

21Feb

-17

21Feb

-17

21Feb

-17

14Feb

-17

14Feb

-17

14Feb

-17

14Feb

-17

16US9566289

Boron-containing small molecules

US9565857 Antimicrobial solutions

US9562110 Bispecific antibody

US9561263 Treatment of inflammatory illnesses with ACE2

US9556237 Antiviral rift valley fever virus peptides and methods of use

US9556229 Modification of peptides using a bis(thioether)arylbridge approach

US9556184 Phosphoinositide 3-kinase inhibitors

US9556117 Indole carboxamide derivatives as P2X7 receptor antagonists

US9555031

US9555030

US9550773

Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity

Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity

Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

US9550757 Nuclear transport modulators and uses thereof

US9549949 Antiviral agent

US9549938 Boron-containing small molecules

US9546371

Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions

Anacor Pharmaceuticals, Inc.

Board of Regents, The University of Texas System

Wuhan YZY Biopharma Co., Ltd.  
Apeiron Biologics AG  
The United States of America, as represented by the  
Secretary of the Army, on behalf of the U.S. Army Medical  
Research Institute of Infectious Diseases  
The Regents of the University of California  
Respivert, Ltd.

ACTELION PHARMACEUTICALS LTD.  
The University of North Carolina at Chapel Hill  
The University of North Carolina at Chapel Hill  
3M Innovative Properties Company  
Karyopharm Therapeutics Inc.  
NBC MESHTEC, INC.  
Anacor Pharmaceuticals, Inc.

Feb05

10Sep10

21Nov12

18Dec07

6Dec12

18May12

15Mar13

18Dec12

11Apr14

11Apr14

18Jun04

5Mar10

3Sep08

16Feb05

18CENTRE

NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Mar08

13US9546184

Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines 3M INNOVATIVE  
PROPERTIES COMPANY

US9546150

Substituted quinazolin-4-ones for inhibiting ubiquitin specific  
protease 7

US9545440 Methods for preparing squalene

US9540373 Substituted spirocycles

US9539321 HMGB1-derived peptides enhance immune response to antigens

US9539217 Nanoparticle compositions

US9533978

US9533037

US9529974

Pyrimidine derivatives and their use in the treatment of cancer and  
further diseases

Methods for designing and preparing vaccines comprising directed  
sequence polymer compositions via the directed expansion of  
epitopes

System and method for detecting, collecting, analyzing, and  
communicating event-related information

US9527903 Engineered antibody constant domain molecules

US9526803 Diagnostic chewing gum for pathogens

US9526700 Composition for inactivating an enveloped virus



US9522962

US9522894

Peptides, conjugates and method for increasing immunogenicity of a vaccine

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2carboxamides as dipeptidyl peptidase 1 inhibitors

Fauci/COVID-19 Dossier

HYBRIGENICS SA

NOVARTIS AG

Boehringer Ingelheim International GmbH

The Regents of the University of California

Allertein Therapeutics, LLC

Sumitomo Dainippon Pharma Co., Ltd

Declion Holdings LLC

Georgetown University

The United States of America, as represent by the Secretary, Department of Health and Human Services

Julius-Maximilians-Universitaet Wuerzburg

VIROBLOCK SA

Academisch Ziekenhuis Leiden h.o.d.n. LUMC

AstraZeneca AB

CC-BY-NC-SA Dr. David E. Martin

Aug08

2Sep11

12May10

12Sep14

27Jul-10

3Apr13

21May09

16Oct07

25Feb08

31Jan08

8Mar12

19May06

15Mar10

24Jan14

17Feb

-16

9Sep

-11

21Nov

-12

18Dec

-08

4Jun

-15

17May

-13

4Dec

-15

17Dec

-13

3Apr

-15

3Apr  
-15  
13Apr  
-15  
28Jun  
-13  
31Aug  
-09  
11Mar  
-16  
18Mar  
-09  
8Jun  
-15  
29Aug  
-12  
23Oct  
-15  
10Sep  
-15  
9Mar  
-15  
3Apr  
-14  
26Aug  
-14  
16Oct  
-08  
27Jul11  
10Oct  
-13  
8Mar  
-13  
17Nov  
-14  
15Mar  
-11  
21Jan  
-15  
37  
14Feb  
-17  
14Feb  
-17  
7Feb  
-17  
7Feb  
-17  
31Jan17  
31Jan17  
31Jan17  
31Jan17  
31Jan17

24Jan17  
24Jan17  
24Jan17  
24Jan17  
17Jan17  
17Jan17  
17Jan17  
17Jan17  
10Jan17  
10Jan17  
10Jan17  
3Jan17  
3Jan17  
27Dec  
-16  
27Dec  
-16  
27Dec  
-16  
27Dec  
-16  
20Dec  
-16  
20Dec  
-16

US9522171

EV576 for use in the treatment of viral infections of the respiratory tract

US9518093 Topical formulation of arginine-rich cyclic antimicrobial peptides

US9518083 Gadd45beta targeting agents

US9517263 Benzonaphthyridine-containing vaccines

US9517205 Soluble needle arrays for delivery of influenza vaccines

US9512471 Methods and kits for detecting human papillomavirus

8Volution

Immuno Pharmaceuticals SA

NOVABIOTICS LIMITED

Imperial Innovations Limited

GlaxoSmithKline Biologicals SA

Seqirus UK Limited

DIACARTA Inc

US9512443 Recombinant expression of multiprotein complexes using polygenes ETH ZURICH

US9512181

Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor

US9511070 Heterocyclyl carboxamides for treating viral diseases

US9506063

SiRNA compositions and methods for treatment of HPV and other infections

US9504747 Lipids and lipid compositions for the delivery of active agents

US9504673

Agent for the prophylaxis and treatment of highly pathogenic infectious diseases

US9504255 Physical antimicrobial method

US9499799  
Cells and methodology to generate non-segmented negative-strand RNA viruses  
US9499535 Kinase inhibitors  
US9499489 Myxovirus therapeutics, compounds, and uses related thereto  
US9498548  
US9498544  
Method of using oxidative reductive potential water solution in dental applications  
Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents  
US9498527 Vaccine composition  
US9494571 Methods of testing for intracellular pathogens  
US9493788  
US9493572  
US9493518  
Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor  
GITR antibodies and methods of inducing or enhancing an immune response  
Compositions and methods for treating clostridium difficile associated diseases  
US9492528 Influenza virus-like particles (VLPS) comprising hemagglutinin  
US9492413  
US9489495  
Use of salt of an acetylsalicylic acid for the treatment of viral infections  
System and method for detecting, collecting, analyzing, and communicating event-related information  
US9487838 Oligonucleotide probe for the detection of adenovirus  
US9487837  
Exosome-mediated diagnosis of hepatitis virus infections and diseases  
US9487778 Oligonucleotide modulators of the toll-like receptor pathway  
Tetragenetics, Inc.  
NovaDrug, LLC  
Sirnaomics, Inc.  
Novartis AG  
LTD â€œValenta-Intellektâ€  
NMS TECHNOLOGIES CO., LTD.  
Centre National De La Recherche Scientifique  
ORIGENIS GMBH  
Children's Healthcare of Atlanta, Inc.  
Oculus Innovative Sciences, Inc.  
Tissue Regeneration Therapeutics Inc.  
NITTO DENKO CORPORATION  
Novartis AG  
The Trustees of the University of Pennsylvania  
GITR, Inc.  
National Health Research Institutes  
MEDICAGO INC.  
Ventaleon GMBH  
GEORGETOWN UNIVERSITY  
QIAGEN HAMBURG GMBH

MOREHOUSE SCHOOL OF MEDICINE  
QUARK PHARMACEUTICALS, INC.  
US9487749 Use of methylsulfonylmethane (MSM) to modulate microbial activity  
Biogenic Innovations, LLC

Jan10

24Feb06

22Oct09

10Jun09

20Aug10

30Jun10

8Nov05

27May11

31Aug12

29Jul-10

8Mar13

21May09

1Aug12

22Dec06

21Apr11

24Oct11

2May05

21Apr08

4Apr12

8Mar10

17Dec01

25Mar05

14Mar13

13Jul-07

14Jan08

25Feb08

28Dec10

6Oct08

3Mar11

30Oct09

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

2Jan

-15

9Nov

-15

10Feb

-15

10Jun

-10

19Aug

-11

30Jun

-10

6Nov

-06

29May

-12

30Aug

-13  
29Jan  
-13  
7Mar  
-14  
10May  
-10  
16Jul13  
15Oct  
-13  
23Apr  
-12  
24Oct  
-12  
2May  
-06  
13Mar  
-15  
3Apr  
-13  
7Mar  
-11  
16Jan  
-15  
23Mar  
-15  
13Mar  
-14  
2Jul09  
14Jan  
-09  
28Aug  
-08  
28Dec  
-10  
21Jan  
-14  
1Mar  
-12  
12Aug  
-14  
38  
20Dec  
-16  
13Dec  
-16  
13Dec  
-16  
13Dec  
-16  
13Dec  
-16  
6Dec  
-16

6Dec

-16

6Dec

-16

6Dec

-16

29Nov

-16

29Nov

-16

29Nov

-16

29Nov

-16

22Nov

-16

22Nov

-16

22Nov

-16

22Nov

-16

22Nov

-16

22Nov

-16

15Nov

-16

15Nov

-16

15Nov

-16

15Nov

-16

15Nov

-16

15Nov

-16

8Nov

-16

8Nov

-16

8Nov

-16

8Nov

-16

8Nov

-16

9US9487528

Compounds

US9486479

US9481912

Antimicrobial solutions containing dichloride monoxide and methods of making and using the same

Compositions and methods for detecting and identifying nucleic acid sequences in biological samples  
US9481724 hDC-sign binding peptides  
US9481630  
Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same  
US9476090 Signal propagation biomolecules, devices and methods  
US9476032 Attenuated viruses useful for vaccines  
US9475872  
Nucleic acid molecules encoding monoclonal antibodies specific for IL17F  
US9475862 Neutralizing GP41 antibodies and their use  
Chiesi Farmaceutici S.p.A.  
Oculus Innovative Sciences, Inc.  
Longhorn Vaccines and Diagnostics, LLC  
Sloan-Kettering Institute for Cancer Research  
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY  
STC.UNM  
The Research Foundation for The State University of New York  
ImmunoQure AG  
The United States of America, as represented by the Secretary, Department of Health and Human Services  
US9475832 Phosphonates with reduced toxicity for treatment of viral infections  
The Regents of the University of California  
US9475804  
US9475779  
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom  
Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity  
US9475775 Benzazepine dicarboxamide compounds  
US9474844  
US9474759  
Methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto  
Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses  
US9469876 Circulating biomarkers for metastatic prostate cancer  
US9464276 Highly efficient influenza matrix (M1) proteins  
US9464123  
US9463240  
US9459247  
Peptides having activity of inhibiting infections of respiratory viruses and use of the same  
Arranging interaction and back pressure chambers for microfluidization  
Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometry  
US9459233 Amperometric gas sensor  
US9458492 Methods and cells for identifying RIG-I pathway regulators



US9458470

Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin

US9458184 Compositions of TLR7 and/or TLR8 agonists conjugated to lipids

US9458113

US9457074

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

US9453043 Nucleic acid chemical modifications

US9452973 Modulators of the relaxin receptor 1

US9452210

Influenza virus-like particles (VLPs) comprising hemagglutinin produced within a plant

Fauci/COVID-19 Dossier

3M Innovative Properties Company

Boehringer Ingelheim International GmbH

Hoffmann-La Roche Inc.

Hemalux LLC

Kansas State University Research Foundation

Caris Life Sciences Switzerland Holdings GmbH

Novavax, Inc.

XIANGXUE GROUP (HONG KONG) COMPANY LIMITED

NOVARTIS AG

Academia Sinica

Steris Corporation

Kineta, Inc.

MEDICAGO INC.

INVIVOGEN

Boehringer Ingelheim International GmbH

Ohio State Innovation Foundation

ALNYLAM PHARMACEUTICALS, INC.

THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES

MEDICAGO INC.

CC-BY-NC-SA Dr. David E. Martin

Jun14

13Mar07

12Sep06

19Dec11

19Oct11

21May13

30Mar07

28Dec11

7Nov11

14Apr10

3Jun11

31Jul-14

6Mar15

22Oct14

27Sep11

6Apr10

11Jul-03

9May13  
3Dec09  
29Mar10  
25Jun12  
25Feb11  
21Jan08  
15Jun12  
31Jul-14  
24Apr12  
2Mar09  
4May12  
13Jul-07  
5Jun  
-15  
21Jul14  
8Oct  
-13  
10Dec  
-12  
28Sep  
-12  
21May  
-14  
31Mar  
-08  
2Jan  
-13  
7Nov  
-12  
29Sep  
-14  
1Jun  
-12  
27Jul15  
4Mar  
-16  
29Dec  
-15  
27Sep  
-12  
6Apr  
-11  
23Feb  
-15  
21Feb  
-14  
11Jul14  
29Mar  
-11  
26Feb  
-13  
23Feb  
-12  
23Jan

-13  
15Mar  
-13  
27Jul15  
23Feb  
-15  
22Jan  
-15  
15Mar  
-13  
4Jan  
-13  
39  
8Nov  
-16  
8Nov  
-16  
1Nov  
-16  
1Nov  
-16  
1Nov  
-16  
25Oct16  
25Oct16  
25Oct16  
25Oct16  
25Oct16  
25Oct16  
25Oct16  
25Oct16  
25Oct16  
25Oct16  
25Oct16  
18Oct16  
11Oct16  
11Oct16  
11Oct16  
4Oct16  
4Oct16  
4Oct16  
4Oct16  
4Oct16  
4Oct16  
4Oct16  
27Sep  
-16  
27Sep  
-16  
27Sep  
-16  
US9447462  
**Methods** for concurrent identification and quantification of an  
unknown bioagent  
18IBIS

BIOSCIENCES, INC.

US9447132 Highly active nucleoside derivative for the treatment of HCV

US9447097 4-amino-imidazoquinoline compounds

US9446062 Methods of treating ischemia-reperfusion injury with siRNAs

US9442107

Antibody-nanoparticle conjugates and methods for making and using such conjugates

US9441247 TC-83-derived alphavirus vectors, particles and methods

US9440960 Substituted oxetanes and their use as inhibitors of cathepsin C

US9440930

Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

US9435795 Enhanced deposition of chromogens utilizing pyrimidine analogs

US9435000 Primate T-lymphotropic viruses

US9434997

US9434769

US9433672

Methods, compounds and systems for detecting a microorganism in a sample

Peptide compositions and methods for inhibiting herpesvirus infection

Compositions and methods for activating innate and allergic immunity

US9430610 Re-sequencing pathogen microarray

US9428739 Norovirus and Sapovirus antigens

US9428574

Polypeptides and uses thereof for treatment of autoimmune disorders and infection

US9428571 Antibodies and processes for preparing the same

US9428490 Nuclear transport modulators and uses thereof

US9428439 Hydrobenzamide derivatives as inhibitors of Hsp90

US9426989 Organic peroxide compounds for microorganism inactivation

US9422367 Antigenic GM-CSF peptides and antibodies to GM-CSF

US9421254

Immunostimulatory combinations of TLR ligands and methods of use

Achillion Pharmaceuticals, Inc.

Hoffmann-La Roche Inc.

Quark Pharmaceuticals, Inc.

Ventana Medical Systems, Inc.

ALPHAVAX, INC.

Boehringer Ingelheim International GmbH

Boehringer Ingelheim International GmbH

Ventana Medical Systems, Inc.

Johns Hopkins University

Lawrence Livermore National Security, LLC

The Administrators of the Tulane Educational Fund

ID Biomedical Corporation of Quebec

The United States of America, as represented by the Secretary of the Navy

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

COMPUGEN LTD.

TAIGA BIOTECHNOLOGIES, INC.

Karyopharm Therapeutics Inc.

ASTEX THERAPEUTICS LTD.  
NOVARTIS AG  
Morphotek, Inc.  
The United States of America, as represented by the  
Secretary, Department of Health and Human Services  
US9416416 Biological specimen collection/transport compositions and methods  
Longhorn Vaccines and Diagnostics, LLC  
US9416409  
US9416396  
Capture primers and capture sequence linked solid supports for  
molecular diagnostic tests  
Covalently linked thermostable kinase for decontamination process  
validation  
US9415392 Slip chip device and methods  
US9415087 Compositions and methods for treating coronavirus infection  
US9415033  
US9409987  
Esters of short chains fatty acids for use in the treatment of  
immunogenic disorders  
Polypeptides and polynucleotides, and uses thereof for treatment of  
immune related disorders and cancer  
US9409917 Heterocyclic amide derivatives as P2X7 receptor antagonists  
IBIS BIOSCIENCES, INC.  
The Secretary of State for Health  
The University of Chicago  
Ludwig-Maximilians-Universitaet Muenchen  
PROPONENT BIOTECH GMBH  
COMPUGEN LTD  
ACTELION PHARMACEUTICALS LTD.  
Feb04  
12Apr13  
22Apr14  
25Oct06  
27Apr10  
18May04  
1Aug14  
31Jul-14  
30Dec10  
21Feb05  
24Aug07  
30Oct09  
26Apr12  
2-Jul04  
24Mar01  
30Jun11  
16May08  
29Jul-11  
12Oct06  
6May10  
7Feb06  
24Sep07  
10Oct07  
31Jul-09  
20Feb08

24Mar09  
11Mar14  
30Oct12  
15Apr11  
20Jan12  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
27Jan  
-14  
14Apr  
-14  
7Apr  
-16  
8Jan  
-15  
21Apr  
-15  
6Jul15  
31Jul15  
27Jul15  
6Oct  
-14  
20Sep  
-13  
21Aug  
-08  
9Jul14  
28Apr  
-14  
10Apr  
-08  
27Nov  
-12  
1Jul12  
18Mar  
-15  
26Jul12  
7Jan  
-14  
6May  
-11  
26Nov  
-13  
24Sep  
-08  
16Dec  
-11  
30Jul10  
18Feb  
-09  
23Mar  
-10  
8May

-15  
30Oct  
-13  
16Apr  
-12  
18Jan  
-13  
40  
20Sep  
-16  
20Sep  
-16  
20Sep  
-16  
20Sep  
-16  
13Sep  
-16  
13Sep  
-16  
13Sep  
-16  
13Sep  
-16  
6Sep  
-16  
6Sep  
-16  
6Sep  
-16  
6Sep  
-16  
6Sep  
-16  
30Aug  
-16  
30Aug  
-16  
30Aug  
-16  
30Aug  
-16  
30Aug  
-16  
30Aug  
-16  
23Aug  
-16  
23Aug  
-16  
16Aug  
-16

16Aug

-16

16Aug

-16

16Aug

-16

16Aug

-16

16Aug

-16

9Aug

-16

9Aug

-16

15US9409870

Compounds

US9408908 Combination adjuvant formulation

US9408907

Homogenous suspension of immunopotentiating compounds and uses thereof

US9404160 Methods for the detection of microorganisms

US9403868 Crystalline tripeptide epoxy ketone protease inhibitors

US9402921 Directed evolution and in vitro panning of virus vectors

US9402878 Depsipeptide and uses thereof

US9402812 Methods for the preparation of liposomes

US9394092 Powdered pouch and method of making same

US9393564 Bioagent detection systems, devices, and methods

US9393295 Nanoparticles for use in pharmaceutical compositions

US9393215 Nanoparticles for use in immunogenic compositions

US9388429

US9388234

Method for propagating adenoviral vectors encoding inhibitory gene products

Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds

US9388198 Heterocyclic amide derivatives as P2X7 receptor antagonists

US9388197 Heterocyclic amide derivatives as P2X7 receptor antagonists

US9387242

Chimeric viruses presenting non-native surface proteins and uses thereof

US9382590 Methods and compositions for prostate cancer metastasis

US9382545

US9382288

CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action

US9381244 VISTA modulators for diagnosis and treatment of cancer

US9381239

VLPS derived from cells that do not express a viral matrix or core protein

US9381226 Methods and compositions related to inhibition of viral entry

US9381220 Sceletium extract and uses thereof

US9380785 Antiviral resin member



US9376486

Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof

US9376398 Carboxylic acid compounds

US9375465

US9372156

Conjugates of GM-CSF and IL-7, compositions and methods related thereto

System for processing contents of a receptacle to detect an optical signal emitted by the contents

US9371563 Nanoreporters and methods of manufacturing and use thereof

CHIESI FARMACEUTICI S.p.A.

Not Available

GlaxoSmithKline Biologicals SA

Becton, Dickinson and Company

Onyx Therapeutics, Inc.

The University of North Carolina at Chapel Hill

NovoBiotic Pharmaceuticals, LLC

Indu Javeri

MONOSOL, LLC

IBIS BIOSCIENCES, INC.

Novartis AG

Novartis AG

GenVec, Inc.

Not Available

ACTELION PHARMACEUTICALS LTD.

ACTELION PHARMACEUTICALS LTD.

Icahn School of Medicine at Mount Sinai

FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY

(FAMU)

COLEY PHARMACEUTICAL GMBH

Justus-Liebig-Universitat Giessen

KING'S COLLEGE LONDON

Novavax, Inc.

UNIVERSITY OF UTAH RESEARCH FOUNDATION

H. L. Hall & Sons Limited

NBC MESHTEC, INC.

DSO National Laboratories

Astrazeneca Aktiebolag

Children's Healthcare of Atlanta, Inc.

GEN-PROBE INCORPORATED

NanoString Technologies, Inc.

Dec14

16Oct08

15Dec09

22Dec09

20Mar09

30Apr08

3Dec12

23Sep09

16Apr12

30Mar09

28Apr08

2Dec05

10Nov05  
6Jun03  
21Jan14  
22Jan13  
2Dec05  
25Mar11  
27Sep06  
6Oct10  
7Sep12  
25May07  
8Feb07  
20Mar09  
6-Jul11  
14Dec10  
18May12  
14Nov11  
10Mar05  
23Dec05  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
27Nov  
-15  
15Feb  
-13  
15Dec  
-10  
21Dec  
-10  
5Mar  
-15  
22Oct  
-14  
1Jul15  
23Sep  
-10  
14Mar  
-13  
30Mar  
-10  
28Apr  
-09  
1Dec  
-06  
28May  
-14  
19Jun  
-13  
21Jan  
-14  
21Jan  
-14  
1Dec  
-06

20May  
-15  
4Oct  
-13  
6Oct  
-11  
9Sep  
-13  
14Apr  
-14  
8Feb  
-08  
15Jul14  
6Jul12  
14Dec  
-11  
17May  
-13  
13Nov  
-12  
22Feb  
-11  
11Mar  
-13  
41  
9Aug  
-16  
9Aug  
-16  
9Aug  
-16  
2Aug  
-16  
2Aug  
-16  
2Aug  
-16  
2Aug  
-16  
19Jul16  
19Jul16  
19Jul16  
19Jul16  
12Jul16  
12Jul16  
12Jul16  
12Jul16  
12Jul16  
5Jul16  
5Jul16  
5Jul16  
5Jul16

5Jul16

5Jul16

5Jul16

5Jul16

28Jun16

28Jun16

28Jun16

21Jun16

21Jun16

4US9370582

Carbohydrate conjugates as delivery agents for oligonucleotides

US9370581 Carbohydrate conjugates as delivery agents for oligonucleotides

US9370570 Polychlorinated biphenyls and squalene-containing adjuvants

US9370531

Method of providing patient specific immune response in amyloidoses and protein aggregation disorders

US9365577 Pyrimidinone compounds as human neutrophil elastase inhibitors

US9365567 Alkoxy substituted imidazoquinolines

US9365523 Imidazolyl amide compounds and uses related thereto

US9365506 Compounds and compositions as TLR2 agonists

US9364511 Antiviral preparations obtained from a natural cinnamon extract

US9359360 TLR agonists

US9358280

Decreasing potential iatrogenic risks associated with influenza vaccines

US9353133 Boron-containing small molecules

US9352048 Carbohydrate conjugates as delivery agents for oligonucleotides

US9347055

Method and kit for preparation of sample for use in nucleic acid amplification

US9346866 Inhibition of tace activity with cyclic peptides

US9346794

Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity

US9346769 Tetrazolones as inhibitors of fatty acid synthase

US9346753 Dithiol mucolytic agents

US9345760

US9340507

IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the same

Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity

ALNYLAM PHARMACEUTICALS, INC.

ALNYLAM PHARMACEUTICALS, INC.

Novartis AG

New York University

Chiesi Farmaceutici S.p.A.

3M Innovative Properties Company

Children's Healthcare of Atlanta, Inc.

NOVARTIS AG

RAMOT AT TEL-AVIV UNIVERSITY LTD.

The Regents of The University of California

Novartis AG

Anacor Pharmaceuticals, Inc.

ALNYLAM PHARMACEUTICALS, INC.  
EIKEN KAGAKU KABUSHIKI KAISHA  
The Regents of the University of California  
Boehringer Ingelheim International GmbH  
Infinity Pharmaceuticals, Inc.  
PARION SCIENCES, INC.  
Advanced Bionutrition Corporation  
Boehringer Ingelheim International GmbH  
US9339561 Mutant protease biosensors with enhanced detection characteristics  
PROMEGA CORPORATION  
US9339525 Inhibition of biofilm organisms  
US9334268 4-amino-imidazoquinoline compounds  
US9328110 Substituted imidazo ring systems and methods  
US9328093  
Selective inhibitors of ubiquitin specific protease 7, the  
pharmaceutical compositions thereof and their therapeutic  
applications  
US9326972  
Use of phenylmethimazoles, methimazole derivatives, and  
tautomeric cyclic thiones for the treatment of  
autoimmune/inflammatory diseases associated with toll-like  
receptor overexpression  
US9322827 B-cell antigen presenting cell assay  
US9321999  
US9321847  
Compositions for increasing polypeptide stability and activity, and  
related methods  
Activatable toxin complexes comprising a cleavable inhibitory  
peptide  
Fauci/COVID-19 Dossier  
Novabiotics Limited  
HOFFMAN-LA ROCHE INC.  
3M INNOVATIVE PROPERTIES COMPANY  
HYBRIGENICS SA  
Dec07  
4Dec07  
28Dec07  
31Aug07  
18Dec12  
30Oct03  
31Mar11  
23Mar10  
24Dec03  
22Aug05  
9Sep04  
16Feb05  
4Dec07  
5Nov07  
2Jun11  
23Aug12  
5May10  
23Aug13  
9Sep11  
23Aug12

11May10  
31Mar09  
22Apr14  
25Nov03  
15Jan10  
16Ohio  
University  
Mar04  
University  
of Pittsburgh - Of the Commonwealth System of  
Higher Education  
SOLIS BIODYNE OÃæ  
RAMOT at Tel Aviv University Ltd.  
CC-BY-NC-SA Dr. David E. Martin  
8Apr10  
19Nov09  
20Sep10  
11Jul14  
11Jul14  
10Dec  
-13  
1Sep  
-08  
17Dec  
-13  
30Sep  
-14  
28Mar  
-12  
9Jul14  
22Jun  
-06  
20Nov  
-12  
11Jan  
-13  
7Mar  
-14  
22Jul14  
5Nov  
-08  
19Sep  
-14  
29Dec  
-15  
23Aug  
-13  
13Aug  
-14  
7Sep  
-12  
2Sep  
-15  
5May

3May  
-16  
10May  
-16  
17May  
-16  
17May  
-16  
17May  
-16  
24May  
-16  
24May  
-16  
24May  
-16  
24May  
-16  
24May  
-16  
24May  
-16  
31May  
-16  
31May  
7Jun16  
7Jun16  
14Jun16  
14Jun16  
14Jun16  
14Jun16  
14Jun16  
21Jun16  
21Jun16  
21Jun16  
21Jun16  
21Jun16  
42  
-11  
22Aug  
-10  
19Nov  
-11  
8Apr  
-12  
9Feb  
-14  
17Sep  
-14  
11Mar  
-15  
22Apr  
-10  
31Mar  
-14

-16  
3May  
-16  
3May  
-16  
26Apr16  
26Apr16  
26Apr16  
1US9321831  
RSV-specific binding molecules and means for producing them  
US9320784  
Peptides shared among lethal cancers and therapeutic compositions  
comprising said peptides  
US9320748 Immunologically useful arginine salts  
US9315530 Adsorption of immunopotentiators to insoluble metal salts  
US9310375  
Luminophore-labeled molecules coupled with particles for  
microarray-based assays  
US9310088  
Device and method for reducing spread of microorganisms and  
airborne health hazardous matter and/or for protection from  
microorganisms and airborne health hazardous matter  
US9309325 Antibodies and methods of use thereof  
US9303068  
D-amino acid derivative-modified peptidoglycan and methods of use  
thereof  
US9303000 Olefin containing nuclear transport modulators and uses thereof  
US9297010 Short interfering RNA (siRNA) analogues  
US9295732 Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists  
US9295708 Modified release formulations for oprozomib  
US9295646 Cationic oil-in-water emulsions  
US9291628 Direct clone analysis and selection technology  
US9291597 Detecting targets using mass tags and mass spectrometry  
MedImmune Limited  
Not Available  
Novartis AG  
Novartis AG  
CapitalBio Corporation  
Jun07  
7Aug09  
7Mar12  
1Sep10  
27Oct10  
Technical  
University of Denmark  
17Jul-09  
7The  
Regents of the University of California  
The Regents of the University of California  
KARYOPHARM THERAPEUTICS INC.  
Roche Innovation Center Copenhagen A/S  
INVIVOGEN  
Onyx Therapeutics, Inc.  
Novartis AG



Dublin City University  
VENTANA MEDICAL SYSTEMS, INC.  
US9290794 Mutant protease biosensors with enhanced detection characteristics  
PROMEGA CORPORATION  
US9290786 Monoclonal antibody production by EBV transformation of B cells  
US9290760 Modified iRNA agents  
US9290745 Luciferase biosensor  
US9290545 Compositions and methods for the treatment of viral infections  
US9290459  
US9290457  
Substituted bicyclic dihydropyrimidinones and their use as inhibitors  
of neutrophil elastase activity  
Substituted dihydropyrimidinones and their use as inhibitors of  
neutrophil elastase activity  
US9289487 II-key/antigenic epitope hybrid peptide vaccines  
US9284560  
US9278128  
Application of highly conserved domain sequences from viral  
genome as template to design therapeutic siRNAs  
Vaccines and immunotherapeutics comprising IL-15 receptor alpha  
and/or nucleic acid molecules encoding the same, and methods for  
using the same  
US9278126 Influenza vaccines with reduced amounts of squalene  
US9272024  
US9271494  
Compositions, comprising improved IL-12 genetic constructs and  
vaccines, immunotherapeutics and methods of using the same  
Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid  
antimicrobial compositions  
US9266844 Suppression of SARS replication by SARS helicase inhibitors  
Fauci/COVID-19 Dossier  
Institute for Research in Biomedicine  
ALNYLAM PHARMACEUTICALS, INC.  
PROMEGA CORPORATION  
Dana-Farber Cancer Institute, Inc.  
Boehringer Ingelheim International GmbH  
Boehringer Ingelheim International GmbH  
Antigen Express, Inc.  
Biocross Institute of Molecular Medicine (Nantong) Co., Ltd.  
The Trustees of the University of Pennsylvania  
Seqirus UK Limited  
The Trustees of the University of Pennsylvania  
Ecolab USA, Inc.  
The Curators of the University of Missouri  
CC-BY-NC-SA Dr. David E. Martin  
May09  
30Nov12  
17Jan11  
21Mar03  
22Feb13  
24Oct12  
6-Jul10  
13Jul-10  
2-Jul10

11May10  
26Feb03  
15Sep10  
10Oct03  
23Jan08  
6Feb13  
31Jul-14  
14Sep99  
19Sep11  
14Sep09  
10Feb09  
12Dec11  
30Aug07  
15Jun12  
13Sep  
-13  
19Jul12  
7Mar  
-13  
1Sep  
-11  
27Oct  
-10  
14Jul10  
4May  
-10  
27Nov  
-13  
16Jan  
-12  
11Feb  
-14  
22Feb  
-13  
24Oct  
-13  
18Sep  
-11  
13Jul11  
1Jul11  
12Nov  
-12  
25Apr  
-13  
14Sep  
-11  
14Feb  
-14  
23Jul10  
9Nov  
-15  
27Jul15  
11Jan  
-05



8Mar

-16

1Mar

-16

1Mar

-16

23Feb

-16

9US9266843

Nuclear transport modulators and uses thereof

US9265876

US9260398

Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto

Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases

US9255144 Anti-IL-18 antibodies and their uses

US9255140

US9254315

Adjuvancy and immune potentiating properties of natural products of *Onchocerca volvulus*

Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds

US9254265 Small liposomes for delivery of immunogen encoding RNA

US9249427 Recombinant HCMV and RHCMV vectors and uses thereof

US9249195 Reovirus vaccines and methods of use therefor

Karyopharm Therapeutics Inc.

Hemalux Technologies LLC

PARION SCIENCES, INC.

MedImmune Limited

NEW YORK BLOOD CENTER, INC.

Not Available

NOVARTIS AG

Oregon Health & Science University

Vanderbilt University

US9248201 Mutant protease biosensors with enhanced detection characteristics

PROMEGA CORPORATION

US9248178

US9242980

US9238809

Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens

Lipidated immune response modifier compound compositions, formulations, and methods

Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange material

US9234175 Creating bioengineered lymph nodes

US9233148

Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza

US9227977 Phosphoinositide 3-kinase inhibitors

US9222075 Animal protein-free media for cultivation of cells

US9221832 Heterocyclic amide derivatives as P2X7 receptor antagonists

US9221807

US9220768

US9217745

Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity

Decreasing potential iatrogenic risks associated with influenza vaccines

Arrayed detector system for measurement of influenza immune response

US9217157 Recombinant influenza viruses and uses thereof

US9216192 Toll-like receptor agonist formulations and their use

US9213027

US9212399

Lipoparticles comprising proteins, methods of making, and using the same

Biological specimen collection and transport system and method of use

US9212205 Nucleic acid binding compounds and methods of use

US9206396 Methods and devices for quantitative viral assays

Not Available

3M Innovative Properties Company

QIAGEN GAITHERSBURG, INC.

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Not Available

Respivert Ltd.

Baxalta GmbH

ACTELION PHARMACEUTICALS LTD.

Boehringer Ingelheim International GmbH

Novartis AG

University of Rochester

Icahn School of Medicine at Mount Sinai

VentiRx Pharmaceuticals, Inc.

Integral Molecular, Inc.

Longhorn Vaccines and Diagnostics, LLC

University of Rochester

Wisconsin Alumni Research Foundation

US9206158 Hydrazide containing nuclear transport modulators and uses thereof

Karyopharm Therapeutics Inc.

US9200329 Rapid epidemiologic typing of bacteria

BioFire Diagnostics, LLC

May12

22Oct14

29May12

20Dec10

15Jun04

28Apr04

31Aug10

14May10

7Apr10

11May10

8Jun09

17Aug10

24Sep09

17Nov09

9Jan09

15Mar13  
29Oct04  
22Jul-11  
21Feb14  
9Sep04  
2May08  
27Jul-09  
1Aug08  
30Jul-03  
10ct07  
26Jul-07  
16Nov05  
29Jul-11  
19May08  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
9May  
-13  
22Oct  
-14  
9Dec  
-14  
20Dec  
-11  
23Mar  
-09  
3Feb  
-10  
31Aug  
-11  
14Nov  
-12  
4Apr  
-11  
5May  
-14  
8Jun  
-10  
16Aug  
-11  
5Aug  
-10  
16Nov  
-10  
16Oct  
-09  
14Mar  
-14  
2May  
-14  
20Jul12  
12Feb  
-15

14Oct  
-11  
11Jul13  
27Jul10  
16Jul12  
1Nov  
-13  
7Jan  
-14  
28Jul08  
16Nov  
-06  
10Jun  
-15  
18May  
-09  
44  
23Feb  
-16  
23Feb  
-16  
16Feb  
-16  
9Feb  
-16  
9Feb  
-16  
9Feb  
-16  
9Feb  
-16  
2Feb  
-16  
2Feb  
-16  
2Feb  
-16  
26Jan16  
19Jan16  
12Jan16  
12Jan16  
5Jan16  
29Dec  
-15  
29Dec  
-15  
29Dec  
-15  
29Dec  
-15  
22Dec  
-15

22Dec  
-15

22Dec  
-15

15Dec  
-15

15Dec  
-15

15Dec  
-15

8Dec  
-15

8Dec  
-15

1Dec  
-15

US9200287

US9200280

US9200279

Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity

18AduTide

Pharmaceuticals GmbH

Methods and compositions for the treatment of cancer or other diseases

Methods and compositions for the treatment of cancer or other diseases

US9200074 Antibodies to IL-1 R1 and methods of making them

US9199981 Compounds and compositions as C-kit kinase inhibitors

US9199897 Methods for preparing squalene

US9198927

US9193780

US9192661

Targeting opposite strand replication intermediates of singlestranded viruses by RNAI

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Delivery of self-replicating RNA using biodegradable polymer particles

CITY OF HOPE

CITY OF HOPE

MEDIMMUNE LIMITED

NOVARTIS AG

NOVARTIS AG

ALNYLAM PHARMACEUTICALS, INC.

Ablynx N.V.

Novartis AG

US9187748 Compositions and methods for silencing ebola virus gene expression Not Available

US9187426 Organic compounds

US9186419 Directed evolution and in vitro panning of virus vectors

US9186399

Immune stimulatory oligonucleotide analogs containing modified



sugar moieties  
Novartis AG  
The University of North Carolina at Chapel Hill  
AdiutTide Pharmaceuticals GmbH  
US9181303 Treatment of bacterial infections with cyclic antimicrobial peptides  
NovaBiotics Limited  
US9181290  
Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-Dglucopyranose  
US9175047  
Peptidomimetic macrocycles  
US9174925  
Phorbol type diterpene compound, pharmaceutical composition for  
treatment or prevention of viral infectious diseases including same  
US9169318 Neutralizing molecules to viral antigens  
US9168318  
US9168299  
US9168269  
Oxidative reductive potential water solution and methods of using  
the same  
Methods for treating juvenile arthritis with ant-bile salt-stimulated  
lipase (BSSL) antibodies  
Inhibitors of long and very long chain fatty acid metabolism as  
broad spectrum anti-virals  
US9163222 Mutations in OAS1 genes  
US9163065 Depsipeptide and uses thereof  
US9161976 Immunotherapy comprising TLR9 ligand and CD40 ligand  
US9156811 N-myristoyl transferase inhibitors  
US9155309 Virus inactivating sheet  
US9149473  
US9149445  
Targeted whole genome amplification method for identification of  
pathogens  
Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and  
associated enzymes for treatment of viral infections  
US9145588 Generation of binding molecules  
CHANG GUNG UNIVERSITY  
Aileron Therapeutics, Inc.  
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND  
BIOTECHNOLOGY  
Sea Lane Biotechnologies, Inc.  
Oculus Innovative Sciences, Inc.  
LIPUM AB  
THE TRUSTEES OF PRINCETON UNIVERSITY  
Kineta Two, LLC  
NovoBiotic Pharmaceuticals, LLC  
Trustees of Dartmouth College  
Univeristy of Dundee  
NBC MESHTEC, INC.  
IBIS BIOSCIENCES, INC.  
THE TRUSTEES OF PRINCETON UNIVERSITY  
MERUS BIOPHARMACEUTICALS B.V.  
May07  
26Jan07  
26Jan07

7Nov08  
1Sep11  
12May10  
24Sep04  
5Jun08  
6-Jul10  
20Jul-09  
27Jun08  
30Apr08  
9Oct07  
22Dec05  
17Jun11  
14Jan09  
26Oct11  
28Mar08  
30Dec03  
8Apr09  
18Feb10  
4May05  
3Dec12  
30Dec02  
2Sep08  
20Oct09  
14Sep06  
27Jul-09  
26Sep11  
15May  
-08  
9Jun  
-14  
14Jan  
-14  
16Apr  
-14  
27Aug  
-12  
12May  
-11  
1Mar  
-10  
5Jun  
-09  
7Jun  
-11  
28Mar  
-14  
25Jun  
-09  
17Jan  
-14  
29Sep  
-08  
20Jun  
-14

19Sep  
-11  
14Jan  
-10  
28Sep  
-12  
18Jul11  
11Aug  
-04  
30Oct  
-13  
18Feb  
-11  
14Nov  
-12  
3Dec  
-13  
22Oct  
-12  
29Aug  
-09  
4Oct  
-10  
14Sep  
-07  
27Jul10  
26Sep  
-12  
1Dec  
-15  
1Dec  
-15  
1Dec  
-15  
1Dec  
-15  
1Dec  
-15  
1Dec  
-15  
24Nov  
-15  
24Nov  
-15  
17Nov  
-15  
17Nov  
-15  
17Nov  
-15  
17Nov  
-15

10Nov  
-15

10Nov  
-15

3Nov  
-15

3Nov  
-15

27Oct15

27Oct15

27Oct15

27Oct15

20Oct15

20Oct15

20Oct15

13Oct15

13Oct15

6Oct15

6Oct15

29Sep

-15

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

45

1US9145585

Method for using permuted nucleic acid probes

US9145410 Pyrazolopyridines and analogs thereof

US9144575 Anti-viral azide containing compounds

US9139833 Modified small interfering RNA molecules and methods of use

US9139647 Diagnosis and treatment of cancer using anti-TM4SF20 antibody

US9139620 Feline morbillivirus and uses thereof

US9138472 CD40L vaccines, compositions, and methods related thereto

US9134247

Method and apparatus for two-step surface-enhanced raman spectroscopy

US9133248 Methods of propagating monkey adenoviral vectors

US9132423 Sample-to-answer microfluidic cartridge

US9132175 Bacillus based delivery system and methods of use

US9128101 Biomarkers for theranostics

US9127256

US9127251

US9127028

US9125952

US9115093

Method for production of reprogrammed cell using chromosomally unintegrated virus vector

Means and methods for influencing the stability of antibody producing cells

Substrates for chromogenic detection and methods of use in detection assays and kits

Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes

Substituted bicyclic dihydropyrimidinones and their use as inhibitors

of neutrophil elastase activity

US9115065

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses

US9109199 Methods to produce bunyavirus replicon particles

US9107970 Method and a filter for capturing airborne agents

US9107958

Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom

Ventana Medical Systems, Inc.

3M Innovative Properties Company

LIFE TECHNOLOGIES CORPORATION

Arrowhead Research Corporation

FORERUNNER PHARMA RESEARCH CO., LTD.

THE GOVERNMENT OF THE HONG KONG SPECIAL

ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA

EMORY UNIVERSITY

REAL-TIME ANALYZERS, INC.

GenVec, Inc.

Micronics, Inc.

The Curators of the University of Missouri

Caris Life Sciences Switzerland Holdings GmbH

DNAVEC CORPORATION

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Ventana Medical Systems, Inc.

Industry Academic Cooperation Foundation, Hallym University

Boehringer Ingelheim International GmbH

Sep06

30Oct03

28Jul-10

26Jul-02

25Dec08

20Jan12

28Sep10

16Dec11

9Nov09

29Jan10

18Apr11

1Mar10

16Jul-08

9Dec05

16Aug10

17Jul-09

4Mar13

6Kineta,  
Inc.

Dec04

20STICHTING

DIENST LANDBOUWKUNDIG ONDERZOEK

Not Available

3M Innovative Properties Company  
US9107906 Compositions and methods for the treatment of immunodeficiency ADMA  
BIOLOGICS, INC.  
US9107904 Immunostimulatory compositions and methods of use thereof  
US9102938 2' and 5' modified monomers and oligonucleotides  
US9102911 High density self-contained biological analysis  
US9102741 GAS57 mutant antigens and GAS57 antibodies  
Massachusetts Institute of Technology  
ALNYLAM PHARMACEUTICALS, INC.  
BioFire Diagnostics, LLC  
Novartis AG  
US9102740 Cna-B domain antigens in vaccines against gram positive bacteria  
NOVARTIS AG  
US9102633  
US9102624  
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel  
blocking compounds  
Substituted 4-pyridones and their use as inhibitors of neutrophil  
elastase activity  
Parion Sciences, Inc.  
Boehringer Ingelheim International GmbH  
Sep10  
15Jul-08  
3Jun11  
28Oct14  
5Apr12  
31Mar11  
15May09  
12Sep07  
12Jan09  
13Dec13  
23Aug12  
5Aug  
-14  
26Jan  
-12  
28Jul11  
12Mar  
-13  
25Dec  
-09  
22Jan  
-13  
28Sep  
-11  
16Dec  
-11  
9Nov  
-10  
28Jan  
-11  
18Apr  
-11  
1Mar

-11  
16Jul09  
8Dec  
-06  
12Aug  
-11  
13Aug  
-14  
20Feb  
-14  
26Feb  
-13  
20Sep  
-11  
13Jul09  
1Jun  
-12  
8Jan  
-15  
15Mar  
-13  
31Mar  
-11  
28Jan  
-13  
13Oct  
-14  
7Jun  
-13  
13Dec  
-13  
20Aug  
-13  
29Sep  
-15  
29Sep  
-15  
29Sep  
-15  
22Sep  
-15  
22Sep  
-15  
22Sep  
-15  
22Sep  
-15  
15Sep  
-15  
15Sep  
-15  
15Sep  
-15  
15Sep

-15

8Sep

-15

8Sep

-15

8Sep

-15

8Sep

-15

8Sep

-15

25Aug

-15

25Aug

-15

18Aug

-15

18Aug

-15

18Aug

-15

18Aug

-15

18Aug

-15

18Aug

-15

11Aug

-15

11Aug

-15

11Aug

-15

11Aug

-15

11Aug

-15

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

46

14US9101597

Immunoprotective primary mesenchymal stem cells and methods Autoimmune Technologies, LLC

US9101582

Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen

US9096585 Antiviral compounds and uses thereof

US9096543 Nuclear transport modulators and uses thereof

US9090897 Production of IFN-lambda by conventional dendritic cells

US9085641 Peptides regulating the surface expression of the T cell receptor

US9084808 Modified small interfering RNA molecules and methods of use

US9084758

Antiviral compositions comprising ethanol extract of Tetracera



scandens and use thereof

The United States of America as represented by the  
Secretary of the Department of Health and Human  
Services, Centers for Disease Control and Prevention  
Icahn School of Medicine at Mount Sinai  
Karyopharm Therapeutics Inc.

Bavarian Nordic A/S

Max-Delbruck-Centrum Fur Molekulare Medizin

Arrowhead Research Corporation

The Catholic University of Korea Industry-Academic

Cooperation Foundation

US9080209 Non-mass determined base compositions for nucleic acid detection IBIS  
BIOSCIENCES, INC.

US9080204

Compositions and methods for rapid, real-time detection of  
influenza a virus (H1N1) Swine 2009

US9079965 Bispecific antibody

US9079943 TC-83-derived alphavirus vectors, particles and methods

Longhorn Vaccines and Diagnostics, LLC

Wuhan YZY Biopharma Co., LTD.

ALPHAVAX, INC.

US9079865 Hydrazide containing nuclear transport modulators and uses thereof  
Karyopharm Therapeutics Inc.

US9078885 Respiratory disease treatment

US9078868

US9073869

US9072738

US9072726

Therapeutic agent for accelerating recovery of animal under medical  
treatment

Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic  
acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C

Chemically and metabolically stable dipeptide possessing potent  
sodium channel blocker activity

Methods of treating or preventing inflammation and hypersensitivity  
with oxidative reductive potential water solution

US9072702 Reverse genetics using non-endogenous pol I promoters

US9067873

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical  
compositions thereof, and methods for treating hemorrhagic fever  
viruses, including infections associated with arenaviruses

US9066964 Use of tylvalosin as antiviral agent

US9063150

Method for detection of antigen-specific antibodies in biological  
samples

US9061001 Combination adjuvant formulation

US9056900 Compositions and methods for coronavirus inhibition

US9056898 Attenuated RNA virus and applications thereof

US9056071 Compounds and methods for preventing or treating a viral infection

US9051619 Methods and compositions for prostate cancer metastasis

US9051564 Compositions for and methods of identifying antigens

US9051353 Crystalline tripeptide epoxy ketone protease inhibitors

Fauci/COVID-19 Dossier

Pulmagen Therapeutics (Inflammation) Limited

DAIICHI SANKYO COMPANY, LIMITED  
Boehringer Ingelheim International GmbH  
PARION SCIENCES, INC.  
Oculus Innovative Sciences, Inc.  
Novartis AG  
Mar13  
31Jul-08  
28May10  
9May12  
18Dec09  
23Jun06  
10ct04  
24Jul-12  
6Aug09  
12Sep06  
21Nov12  
18May04  
29Jul-11  
7Aug08  
15Jan10  
14Mar13  
27Jun11  
20Jan06  
21May09  
6Kineta  
Four, LLC  
Dec04  
Cambridge  
University Technical Services  
The United States of America as represented by the  
Secretary of the Department of Health and Human  
Services, Centers for Disease Control Prevention  
Dalhousie University  
Autoimmune Technologies, LLC.  
Washington University  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  
(C.N.R.S.)  
FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY  
(FAMU)  
President and Fellows of Harvard College  
Onyx Therapeutics, Inc.  
CC-BY-NC-SA Dr. David E. Martin  
13Jul-06  
2Sep08  
16Oct08  
4Nov03  
20Sep07  
2Nov07  
25Mar11  
21Feb06  
20Mar09  
14Mar  
-13  
27Mar

-13  
31May  
-11  
9May  
-13  
17Dec  
-10  
23Jun  
-07  
9May  
-14  
25Aug  
-14  
6Aug  
-10  
30Dec  
-11  
13Mar  
-14  
28Mar  
-14  
29Jul12  
7Apr  
-14  
14Jan  
-11  
11Sep  
-14  
27Jun  
-12  
21Dec  
-09  
21May  
-10  
19Dec  
-13  
13Jul07  
25Aug  
-09  
15Oct  
-09  
8Aug  
-13  
22Sep  
-08  
19Jun  
-13  
23Mar  
-12  
21Feb  
-07  
24Sep  
-13  
47

11Aug  
-15

11Aug  
-15

4Aug  
-15

4Aug  
-15

28Jul15

21Jul15

21Jul15

21Jul15

14Jul15

14Jul15

14Jul15

14Jul15

14Jul15

14Jul15

14Jul15

7Jul15

7Jul15

7Jul15

7Jul15

30Jun15

30Jun15

23Jun15

23Jun15

16Jun15

16Jun15

16Jun15

9Jun15

9Jun15

9Jun15

7US9050376

Conjugates of synthetic TLR agonists and uses therefor

US9046523 Rapid bioluminescence detection system

US9045855 Anti-viral member

US9045727

Virus-like particles, methods of preparation, and immunogenic compositions

US9045472 Imidazoquinoline compounds

US9045470 Compounds and compositions as TLR activity modulators

US9044420

US9040310

US9034646

US9034313

US9029413

US9029382

Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses

Antibody-nanoparticle conjugates and methods for making and using such conjugates

Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof

Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same  
Treatment of viral infections by modulation of host cell metabolic pathways  
3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide compounds  
US9029315 Soluble PD-1 variants, fusion constructs, and uses thereof  
US9028841  
Synergistic bacterial compositions and methods of production and use thereof  
US9028837 Methods and compositions for poxvirus A35R protein  
US9028823  
Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies  
US9024001 Alphavirus replicon packaging constructs  
US9023855 Compounds  
US9023839 Compounds and compositions as c-kit kinase inhibitors  
US9017699  
Adjuvancy and immune potentiating properties of natural products of *Onchocerca volvulus*  
US9017696 Adenovirus vectors  
US9012622  
US9011767  
US9006264  
US9006194  
Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer  
Transportable vacuum assisted decontamination unit and decontamination process  
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines  
Compositions and methods for diminishing viral infection and inflammation associated with viral infection  
US9005974 Means and methods for influencing the stability of cells  
US9005665  
US9005599  
Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome  
Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents  
The Regents of the University of California  
THE SECRETARY OF STATE FOR HEALTH  
NBC Meshtec, Inc.  
EMORY UNIVERSITY  
ASTRAZENECA AB  
IRM LLC  
IMMUNE DESIGN CORP.  
Ventana Medical Systems, Inc.  
ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.  
Inovio Pharmaceuticals, Inc.  
The Trustees of Princeton University  
Parion Sciences, Inc.  
The University of Hong Kong  
Seres Health, Inc.

East Carolina University  
GITR, Inc.  
Novartis Vaccines and Diagnostics, Inc.  
Chiesi Farmaceutici S.p.A.  
IRM LLC  
New York Blood Center, Inc.  
Isis Innovation Limited  
Not Available  
STERIS Inc.  
3M Innovative Properties Company  
Drexel University  
Academisch Medisch Centrum Bij de Universiteit van  
Amsterdam  
Ohio State Innovation Foundation  
Tissue Regeneration Therapeutics Inc.  
US8999996 Hydrazide containing nuclear transport modulators and uses thereof  
Karyopharm Therapeutics Inc.  
Feb07  
7Jan09  
26Dec08  
17May02  
16Dec10  
2Sep09  
8Apr11  
27Apr10  
25May10  
8Feb10  
1Jun07  
17Dec12  
11Nov10  
23Nov12  
7Jun12  
25Mar05  
25May04  
14Sep11  
1Sep11  
15Jun04  
10Apr07  
31Dec08  
1Apr13  
18Jun04  
19Dec08  
9Dec05  
24Apr12  
21Apr08  
29Jul-11  
19Jun  
-14  
2Aug  
-13  
28Dec  
-09  
4Apr  
-06

16Dec

-11

1Sep

-10

6Apr

-12

27Apr

-11

26Nov

-12

8Feb

-11

3Apr

-12

13Dec

-13

11Nov

-11

20Mar

-14

20Dec

-12

1Mar

-13

20May

-05

11Feb

-14

22Apr

-14

18Feb

-10

10Apr

-08

31Dec

-09

31Mar

-14

9Sep

-13

17Dec

-09

9Dec

-05

24Apr

-13

20Apr

-09

19Mar

-14

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

48

9Jun15  
2Jun15  
2Jun15  
2Jun15  
2Jun15  
2Jun15  
2Jun15  
26May  
-15  
19May  
-15  
19May  
-15  
12May  
-15  
12May  
-15  
12May  
-15  
12May  
-15  
12May  
-15  
12May  
-15  
5May  
-15  
5May  
-15  
5May  
-15  
28Apr15  
28Apr15  
21Apr15  
21Apr15  
14Apr15  
14Apr15  
14Apr15  
14Apr15  
14Apr15  
7Apr15

US8999975

Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C

US8999678 Method of increasing the function of an AAV vector

US8999349 HMGB1-derived peptides enhance immune response to antigens

US8999316 Antiviral compounds

US8993717 Gadd45beta targeting agents

US8993581 Methods for treating viral disorders

US8993295

Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting

US8992939 Highly efficient influenza matrix (M1) proteins

US8987249



Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid  
(benzylcyano-methyl)-amides  
inhibitors of Cathepsin C  
US8987191 Bioactive peptides and methods of using same  
US8986933 Selective detection of human rhinovirus  
US8986926  
Compositions comprising oriented, immobilized macromolecules and  
methods for their preparation  
US8986702 Antibodies and processes for preparing the same  
US8980898  
Dendrimer like amino amides possessing sodium channel blocker  
activity for the treatment of dry eye and other mucosal diseases  
US8980338 Sceletium extract and uses thereof  
US8980281  
High-yield transgenic mammalian expression system for generating  
virus-like particles  
US8975389 Nucleic acid chemical modifications  
US8969362 9-substituted 8-oxoadenine compound  
US8969350  
US8962580  
US8962332  
US8962330  
Pharmaceutical product comprising a p38 kinase inhibitor and a  
second active ingredient  
Chemical modifications of monomers and oligonucleotides with  
cycloaddition  
Adeno-associated virus (AAV) serotype 8 sequences, vectors  
containing same, and uses therefor  
Adeno-associated virus (AAV) serotype 8 sequences, vectors  
containing same, and uses therefor  
US8961983 Mucosal vaccine using cationic nanogel  
US8961477 Delivery of immune response modifier compounds  
US8956863 Agents from cells  
US8956616  
Constructs binding to phosphatidylserine and their use in disease  
treatment  
US8951768 Mutations in OAS1 genes  
US8951528 Immune response modifier conjugates  
US8945943  
Personal glucose meters for detection and quantification of a broad  
range of analytes  
US8945904 Influenza virus reassortment  
Fauci/COVID-19 Dossier  
19Boehringer  
Ingelheim International GmbH  
The Trustees of the University of Pennsylvania  
The Regents of the University of California  
Long Island University  
Imperial Innovations Limited  
Trustees of Boston University  
The General Hospital Corporation  
Novavax, Inc.  
Boehringer Ingelheim International GmbH  
Compugen Ltd.

The United States of America as represented by the  
Secretary of the Department of Health and Human  
Services, Centers for Disease Control  
NanoString Technologies, Inc.  
Taiga Biotechnologies, Inc.  
Parion Sciences, Inc.  
H.L. Hall & Sons Limited  
Academia Sinica  
Alnylam Pharmaceuticals, Inc.  
AstraZeneca Aktiebolag  
Astrazeneca AB  
Alnylam Pharmaceuticals, Inc.  
The Trustees of the University of Pennsylvania  
The Trustees of the University of Pennsylvania  
National University Corporation Tokyo Medical and Dental  
University  
3M Innovative Properties Company  
The Brigham and Women's Hospital, Inc.  
Board of Regents, The University of Texas System  
Kineta Two, LLC  
3M Innovative Properties Company  
The Board of Trustees of the University of Illinois  
Novartis AG  
CC-BY-NC-SA Dr. David E. Martin  
Sep11  
7Apr05  
27Jul-10  
30May07  
22Oct09  
24Sep09  
20Jul-06  
11Jul-03  
14Mar13  
12Jul-07  
5Dec08  
23Dec05  
16May08  
29May12  
20Mar09  
5Sep06  
2Mar09  
26Mar04  
18Dec08  
23Sep08  
17Dec01  
17Dec01  
31Oct08  
25Aug03  
15Oct09  
24Jan05  
4May05  
22Feb06  
26May10  
21May10

14Sep  
-12  
7Apr  
-06  
27Jul11  
30May  
-08  
22Oct  
-10  
11Jun  
-13  
20Jul07  
24Oct  
-11  
12Mar  
-14  
21Jun  
-13  
5Dec  
-08  
22Dec  
-06  
18May  
-09  
29May  
-13  
16Mar  
-10  
12Feb  
-10  
2Mar  
-10  
21Oct  
-13  
17Dec  
-09  
23Sep  
-09  
13Sep  
-13  
31Oct  
-07  
5Sep  
-14  
25Aug  
-04  
15Oct  
-10  
24Jan  
-06  
11Jul11  
21Feb  
-07  
26May

-11  
20May  
-11  
49  
7Apr15  
7Apr15  
7Apr15  
7Apr15  
31Mar  
-15  
31Mar  
-15  
31Mar  
-15  
31Mar  
-15  
24Mar  
-15  
24Mar  
-15  
24Mar  
-15  
24Mar  
-15  
24Mar  
-15  
17Mar  
-15  
17Mar  
-15  
17Mar  
-15  
10Mar  
-15  
3Mar  
-15  
3Mar  
-15  
24Feb  
-15  
24Feb  
-15  
24Feb  
-15  
24Feb  
-15  
24Feb  
-15  
17Feb  
-15  
17Feb  
-15  
10Feb  
-15

10Feb

-15

3Feb

-15

3Feb

-15

US8945610

Condensation products based on bicyclic or polycyclic aromatics or heteroaromatics

US8940864 Stabilized therapeutic small helical antiviral peptides

US8940501 Methods for ligation and uses thereof

US8937154 Stabilized therapeutic small helical antiviral peptides

14BASF

SE

New York Blood Center, Inc.

Whitehead Institute for Biomedical Research

New York Blood Center, Inc.

US8933210 Label-free functional nucleic acid sensors for detecting target agents

The Board of Trustees of the University of Illinois

US8933019 Antiviral cell-penetrating peptides

US8916552 Pharmaceutical combinations

US8916340

US8906872

US8906863

Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assay

Antisense antiviral compound and method for treating ssRNA viral infection

Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

New York Blood Center, Inc.

Astex Therapeutics Limited

The John Hopkins University

Sarepta Therapeutics, Inc.

The Regents of the University of California

US8906862 Multiple antigen delivery system using hepatitis E virus-like particle

National Institute of Infectious Disease

US8901071 Compounds and their use

US8900585

Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection

US8895629 Circulation of components during homogenization of emulsions

US8895577 Compounds and compositions as TLR activity modulators

US8895570 Purine derivatives

US8895534 Boron containing small molecules

US8895295 High density self-contained biological analysis

US8889708

US8889692

Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C

Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses

US8889656 Boron-containing small molecules

US8889398 Composition for inactivating an enveloped virus

US8889181  
US8889118  
Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes  
Anticancer agent containing dendritic cell having RNA virus transferred thereinto  
US8889117 Modular nanoparticles for adaptable vaccines  
US8884020 Indole compounds  
US8883790 Pharmaceutical combinations  
US8883500  
Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy  
US8883481 Reverse genetics methods for virus rescue  
US8883477 Oligoadenylate synthetase (OAS)  
Novabiotics Limited  
New York Blood Center, Inc.  
Novartis AG  
Not Available  
AstraZeneca AB  
Anacor Pharmaceuticals, Inc.  
Biofire Diagnostics, LLC  
Boehringer Ingelheim International GmbH  
AstraZeneca AB  
Anacor Pharmaceuticals, Inc.  
Viroblock SA  
Industry Academic Cooperation Foundation, Hallym University  
DNA VEC Research Inc.  
Yale University  
Ironwood Pharmaceuticals, Inc.  
Astex Therapeutics Limited  
Northeastern University  
Novartis AG  
Kineta Two, LLC  
Nov07  
5Oct06  
30Jan09  
5Oct06  
6Oct10  
6May08  
12Oct06  
6Jan06  
16Sep04  
27Feb09  
27Feb09  
31Mar10  
20Oct10  
3Dec09  
3Mar08  
17Dec10  
20Jun07  
15Nov06  
14Mar13  
27Jun07

16Feb05  
19May06  
17Jul-09  
24Jun04  
15Feb07  
7Aug06  
12Oct06  
5Dec08  
20Oct09  
23Nov05  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
11Nov  
-08  
20Oct  
-07  
1Feb  
-10  
2Feb  
-12  
6Oct  
-11  
31Oct  
-12  
12Oct  
-07  
8Jan  
-07  
22Dec  
-11  
1Sep  
-11  
29Aug  
-11  
30Mar  
-11  
20Oct  
-11  
3Dec  
-10  
22Apr  
-13  
14Dec  
-11  
30Jul10  
14Nov  
-07  
12Mar  
-14  
14Sep  
-12  
30Apr  
-13





18Nov  
-14

18Nov  
-14

18Nov  
-14

18Nov  
-14

18Nov  
-14

11Nov  
-14

11Nov  
-14

11Nov  
-14

11Nov  
-14

11Nov  
-14

US8882484

US8881040

US8877775

US8877187

Methods and compositions for production of recombinant protein in  
HBX-expressing mammalian cells

System and method for detecting, collecting, analyzing, and  
communicating event-related information

Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid  
(benzylcyano-methyl)-amides

inhibitors of cathepsin C

Therapeutic antibodies for treatment and prophylaxis of  
transmittable viral diseases

US8877060 Methods for removing pathogens from a platelet preparation

US8871816 Methods for producing vaccine adjuvants

US8871790 Heterocyclic modulators of lipid synthesis

US8871783

Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyanomethyl)-amides  
inhibitors of cathepsin C

US8871782 Alkoxy substituted imidazoquinolines

US8871503 Construct

US8871487 Compositions, methods and uses for inducing viral growth

US8871442 Enhanced deposition of chromogens

US8865865

N-terminally modified tetrapeptide derivatives having a C-terminal  
arginine mimetic

US8865166 Antibodies to IL-17A and uses thereof

28Bayer

HealthCare LLC

Georgetown University

Boehringer Ingelheim International GmbH

Avianax, LLC

Biovec Transfusion, LLC

Novartis AG

3-V Biosciences, Inc.  
Boehringer Ingelheim International GmbH  
3M Innovative Properties Company  
Isis Innovation Limited  
Takeda Vaccines, Inc.  
Ventana Medical Systems, Inc.  
Philipps-Universität Marburg  
MedImmune Limited  
US8859568 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy  
Astrazeneca AB  
US8859251 Oligoadenylate synthetase (OAS)  
US8858958 Adjuvant comprising aluminum, oligonucleotide and polycation  
US8858957 GAS57 mutant antigens and GAS57 antibodies  
US8854617 Compounds and markers for surface-enhanced Raman scattering  
US8853382 Expression of antibody or a fragment thereof in lactobacillus  
US8846710 Method of preferentially inducing the biosynthesis of interferon  
US8846697 Purine analogs  
Kineta Two, LLC  
Novartis AG  
Novartis AG  
Julius-Maximilians-Universität Würzburg  
Hera Pharmaceuticals, Inc.  
3M Innovative Properties Company  
The Regents of the University of California  
US8846643 Phosphonates with reduced toxicity for treatment of viral infections  
The Regents of the University of California  
US8846051  
Modulation of replicative fitness by deoptimization of synonymous  
codons  
The United States of America as represented by the  
Secretary of the Department of Health and Human  
Services, Centers for Disease Control and Prevention  
US8841100 Use of methylsulfonylmethane (MSM) to modulate microbial activity  
Biogenic Innovations, LLC  
US8840899 Use of mTOR inhibitors to enhance T cell immune responses  
US8840890  
US8840873  
US8840774  
US8835107  
Rapid expression cloning of human monoclonal antibodies from  
memory B cells  
Method of treating second and third degree burns using oxidative  
reductive potential water solution  
Electrochemistry and electrogenerated chemiluminescence with a  
single faradaic electrode  
Coronavirus, nucleic acid, protein, and methods for the generation  
of vaccine, medicaments and diagnostics  
Fauci/COVID-19 Dossier  
Emory University  
University of Maryland, Baltimore  
Oculus Innovative Sciences, Inc.  
Board of Regents of the University of Texas System  
Amsterdam Institute of Viral Genomics B.V.  
May08

28Aug08  
14Mar13  
25Jul-05  
23Nov10  
3Dec09  
8Mar11  
14Mar13  
30Oct03  
28Mar06  
5Dec08  
30Dec10  
29Oct08  
23Jun06  
6Dec04  
23Nov05  
27Aug09  
12Sep07  
24Sep07  
5Aug10  
23Feb05  
31May06  
14Apr10  
8Oct04  
30Oct09  
5Aug08  
12Nov08  
23Mar05  
3Jun05  
18Aug03  
CC-BY-NC-SA  
Dr. David E. Martin  
27May  
-09  
2Dec  
-09  
12Mar  
-14  
23Nov  
-10  
31Oct  
-11  
3Dec  
-10  
8Mar  
-12  
12Mar  
-14  
10Oct  
-04  
28Mar  
-07  
4Dec  
-09  
28Dec

-11  
29Oct  
-09  
22Jun  
-07  
3Nov  
-10  
1Jul13  
27Aug  
-10  
14Mar  
-13  
24Sep  
-08  
4Aug  
-11  
22Feb  
-06  
23Apr  
-07  
11Oct  
-12  
7Oct  
-05  
16Feb  
-11  
5Aug  
-09  
12Nov  
-09  
23Mar  
-06  
28Oct  
-13  
26Jul10  
51  
11Nov  
-14  
4Nov  
-14  
4Nov  
-14  
4Nov  
-14  
4Nov  
-14  
28Oct14  
28Oct14  
28Oct14  
28Oct14  
28Oct14  
28Oct14  
28Oct14  
28Oct14  
210ct14

21Oct14  
14Oct14  
14Oct14  
14Oct14  
14Oct14  
7Oct14  
7Oct14  
30Sep  
-14  
30Sep  
-14  
30Sep  
-14  
30Sep  
-14  
23Sep  
-14  
23Sep  
-14  
23Sep  
-14  
23Sep  
-14  
23Sep  
-14  
16Sep  
-14

US8834445

US8828962

Methods of treating or preventing peritonitis with oxidative reductive potential water solution

200culus

Innovative Sciences, Inc.

SiRNA compositions and methods for potently inhibiting viral infection

US8828956 Carbohydrate conjugates as delivery agents for oligonucleotides

US8828940

US8828929

US8828673

Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands

Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof

Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses

US8828659 Method for producing nucleic acid probes

US8828407 Chimaeric protein

US8828406 Influenza viruses and uses thereof

US8822512 Crystalline tripeptide epoxy ketone protease inhibitors

US8822409

Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith

US8821897 Viral adjuvants

US8816089

US8816053

Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity

Methods for treating viral infection using IL-28 and IL-29 cysteine mutants

US8815837 Respiratory disease treatment

Xiangxue Group (Hong Kong) Company Limited

Alnylam Pharmaceuticals, Inc.

Compugen Ltd.

Japan as Represented by Director-General of National

Institute of Infectious Diseases

Diagnostic Hybrids Inc

Ventana Medical Systems, Inc.

The Pirbright Institute

Icahn School of Medicine at Mount Sinai

Onyx Therapeutics, Inc.

Phylogica Limited

The University of North Carolina at Chapel Hill

Masatoshi Hagiwara

ZymoGenetics, Inc.

Pulmagen Therapeutics (Inflammation) Limited

US8815831 Treatment of Acinetobacter with alginate oligomers and antibiotics

Algipharma AS

US8815611 Surface for label independent detection and method thereof

US8815249 Ii-key/antigenic epitope hybrid peptide vaccines

US8815244 Method for production of antibody using ostrich

US8809377 Deubiquitinase inhibitors and methods for use of the same

US8808703

Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc

US8808686 Adjuvant-sparing multi-dose influenza vaccination regimen

US8802853 Arylalkenyl and arylalkynyl substituted imidazoquinolines

US8802647

US8802106

US8796423

Materials and methods for prevention and treatment of RNA viral diseases

Peptide compositions and methods for inhibiting herpesvirus infection

Anti-TSG101 antibodies and their uses for treatment of viral infections

US8790655 Conjugates of synthetic TLR agonists and uses therefor

US8785408

Compositions and methods for reducing or protecting against delayed graft function (DGF)

US8785375 Cyclic antimicrobial peptides for treating bacterial infections

Corning Incorporated

Antigen Express, Inc.

Japan Science and Technology Agency

The Regents of the University of Michigan

Not Available

Novartis AG  
3M Innovative Properties Company  
University of South Florida  
The Administrators of the Tulane Educational Fund  
Eli Lilly and Company  
The Regents of The University of California  
Quark Pharmaceuticals, Inc.  
Novabiotics Ltd.

Jan06  
11Dec08  
4Dec07  
18Sep06  
28Nov08  
24Apr98  
1Sep06  
7-Jul09  
30Jul-09  
20Mar09  
20Jun07  
9-Jul04  
26Dec03  
2Apr04  
7Aug08  
3Jun09  
10Apr08  
4Sep99  
29Aug05  
24Sep10  
23Mar10  
15Jun06  
29Dec03  
30Apr02  
30Oct09  
15Nov06  
7Feb07  
27Jun07  
22Dec05

Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
30Mar  
-12  
12Dec  
-11  
4Dec  
-12  
14Dec  
-10  
27Nov  
-09  
1Mar  
-12  
11Mar  
-13

5Jul10  
29Jul10  
20Sep  
-11  
20Jun  
-08  
24Nov  
-10  
19Nov  
-12  
7Sep  
-12  
29Jun  
-12  
3Jun  
-10  
3Apr  
-09  
26Jul10  
16Aug  
-11  
23Sep  
-11  
23Mar  
-11  
19Sep  
-11  
17Dec  
-04  
17Sep  
-12  
29Oct  
-10  
18Apr  
-08  
8Jan  
-13  
26Jun  
-08  
22Aug  
-12  
52  
16Sep  
-14  
9Sep  
-14  
9Sep  
-14  
9Sep  
-14  
9Sep  
-14  
9Sep  
-14



9Sep

-14

9Sep

-14

9Sep

-14

2Sep

-14

2Sep

-14

2Sep

-14

26Aug

-14

26Aug

-14

26Aug

-14

26Aug

-14

26Aug

-14

26Aug

-14

26Aug

-14

19Aug

-14

19Aug

-14

19Aug

-14

12Aug

-14

12Aug

-14

12Aug

-14

5Aug

-14

29Jul14

22Jul14

22Jul14

US8784900

Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same

US8779132 Pharmaceutical compounds

US8778963

Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

US8778846 Composition, device and associated method

US8778845 Composition, device and associated method

US8778358

Immunogenic compositions for gram positive bacteria such as

Streptococcus agalactiae  
US8778275 Methods for producing vaccine adjuvants  
US8772471 Targeted delivery of siRNA  
US8765939  
Pyrimidine derivatives having immune modulating properties that  
act via TLR7 for the treatment of viral or allergic diseases and  
cancers  
US8765704 Modified small interfering RNA molecules and methods of use  
US8765643 Composition, device and associated method  
US8765146 Adenoviral vector-based malaria vaccines  
US8765138 Antiviral and antibacterial activity from medicinal mushrooms  
US8765133 Method of producing anti-CD166 antibody in ostrich  
US8759307  
Oligonucleotide compound and method for treating nidovirus  
infections  
US8758763 Archaeal polar lipid aggregates for administration to animals  
US8758680 Method and device for cleaning air  
US8754071 Compounds and compositions as c-kit kinase inhibitors  
US8754015  
Modified phage for displaying post-translationally modified proteins  
and uses thereof  
US8748567 Method for delivery across the blood brain barrier  
US8748464  
US8748405  
Use of SIRT1 activators or inhibitors to modulate an immune  
response  
Methods and compositions for the treatment of cancer or other  
diseases  
US8748156 Animal protein-free media for cultivation of cells  
US8741813 Composition, device and associated method  
US8741653 Single recombination system and methods of use  
US8741604 Nucleic acid molecule encoding a specific IL-1R1 antibody  
US8741564  
Quantitative nuclease protection assay (QNPA) and sequencing  
(QNPS) improvements  
US8741311 Methods and compositions for immunization against virus  
130culus  
Innovative Sciences, Inc.  
Astex Therapeutics Limited  
3M Innovative Properties Company  
General Electric Company  
General Electric Company  
Novartis Vaccines and Diagnostics, Inc.  
Novartis AG  
Immune Disease Institute  
AstraZeneca AB  
Novartis AG  
General Electric Company  
GenVec, Inc.  
Not Available  
Japan Science and Technology Agency  
Sarepta Therapeutics, Inc.  
National Research Council of Canada  
Not Available

Not Available  
University of Rochester  
Children's Medical Center Corporation  
The J. David Gladstone Institutes  
City of Hope  
Baxter Healthcare SA  
General Electric Company  
Emergent Product Development GmbH  
Medimmune Limited  
HTG Molecular Diagnostics, Inc.  
Academia Sinica  
US8735567 Multi-targeted RNAi therapeutics for scarless wound healing of skin  
Not Available  
US8735559 Mutant protease biosensors with enhanced detection characteristics  
Promega Corporation  
Fauci/COVID-19 Dossier  
CC-BY-NC-SA Dr. David E. Martin  
Mar07  
12Oct06  
25Nov03  
4Dec06  
15Dec05  
29Jul-04  
3Dec09  
26Jan07  
22Nov07  
28Feb08  
4Dec06  
31Aug05  
6Jan04  
29Aug05  
24Dec03  
15Dec06  
29Sep10  
1Sep11  
21Nov06  
22May06  
7Feb08  
26Jan07  
29Oct04  
15Dec05  
22Dec08  
7Nov08  
4May11  
27Mar09  
6Nov07  
11May10  
13Mar  
-08  
12Oct  
-07  
24Nov  
-04  
1Mar

-07  
1Mar  
-07  
18Oct  
-10  
3Dec  
-10  
25Jan  
-08  
16Aug  
-12  
14Dec  
-11  
1Mar  
-07  
31Aug  
-06  
24Sep  
-08  
16Aug  
-11  
25Apr  
-08  
23Jan  
-13  
27Sep  
-11  
19Sep  
-13  
20Nov  
-07  
22May  
-07  
16Jul10  
9Sep  
-11  
16Apr  
-13  
28Feb  
-07  
16Dec  
-09  
14Sep  
-12  
26Apr  
-12  
26Mar  
-10  
6Nov  
-08  
11May  
-11  
53  
22Jul14

15Jul14  
15Jul14  
15Jul14  
15Jul14  
15Jul14  
15Jul14  
8Jul14  
1Jul14  
1Jul14  
1Jul14  
1Jul14  
1Jul14  
1Jul14  
24Jun14  
24Jun14  
24Jun14  
17Jun14  
17Jun14  
10Jun14  
10Jun14  
10Jun14  
10Jun14  
3Jun14  
3Jun14  
3Jun14  
3Jun14  
3Jun14  
27May  
-14  
27May  
-14

30US8735421

Imidazoquinolinyl sulfonamides

US8735410 Quinazoline derivatives as tyrosine kinase inhibitors

US8735348 Casein derived peptides and uses thereof

US8734823

Device including altered microorganisms, and methods and systems of use

US8728793 Amphipathic alpha-helical peptide compositions as antiviral agents

US8722917 Boron-containing small molecules

US8722741

US8722725

US8718948

Biphenyloxyacetic acid derivatives for the treatment of respiratory disease

Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof

Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector

3M Innovative Properties Company

AstraZeneca AB

Peptera Ltd.

The Invention Science Fund I, LLC

The Board of Trustees of the Leland Stanford Junior

University  
Anacor Pharmaceuticals, Inc.  
AstraZeneca AB  
Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical  
Factory  
Gen-Probe Incorporated  
US8716464 Compositions and methods for silencing Ebola virus gene expression Not  
Available  
US8716461 Human parvovirus  
US8710224 Heterocyclic compounds as CCR2B antagonists  
US8709730  
US8709496  
US8709447  
Methods of preventing and treating viral infections by inhibiting the  
deISGylation activity of OTU domain-containing viral proteins  
Use of deuterium oxide for the treatment of virus-based diseases of  
the respiratory tract  
Compositions and methods for activating innate and allergic  
immunity  
US8709441 TC-83-derived alphavirus vectors, particles and methods  
US8704169 Direct impact ionization (DII) mass spectrometry  
US8703748  
US8703467  
US8702958  
US8697873  
Cleaning composition for treating tissue for transplantation derived  
from human/animal  
Inactivation of a pathogen in a sample by a treatment with formalin  
and UV light  
Electrochemistry and electrogenerated chemiluminescence with a  
single faradaic electrode  
Amide substituted imidazopyridines, imidazoquinolines, and  
imidazonaphthyridines  
US8697853 TAL effector-mediated DNA modification  
US8697659 Analogues of glycolipids useful as immunoadjuvants  
US8697140 Virucidal disinfectant  
US8697088  
US8697087  
VLPs derived from cells that do not express a viral matrix or core  
protein  
Influenza vaccines including combinations of particulate adjuvants  
and immunopotentiators  
US8691837 Substituted imidazo ring systems and methods  
US8691826 Compounds  
Blood Systems, Inc.  
AstraZeneca AB  
Icahn School of Medicine at Mount Sinai  
D2 Bioscience Group Ltd.  
ID Biomedical Corporation of Quebec  
Alphavax, Inc.  
The United States of America, as represented by the  
Secretary, Department of Health and Human Services  
CG BIO Co., Ltd.  
Baxter Healthcare SA

Board of Regents of the University of Texas System  
3M Innovative Properties Company  
Iowa State University Research Foundation, Inc.

Luigi Panza

B. Braun Medical AG

Novavax, Inc.

Novartis AG

3M Innovative Properties Company

Chiesi Farmaceutici S.p.A.

US8691781 Compositions for treating respiratory viral infections and their use  
Sirnaomics, Inc.

Dec03

26Feb05

1Mar00

14Dec05

19Jul-07

16Feb05

24Aug04

23Mar07

24Feb11

20Jul-09

24May04

24Dec04

5Apr07

6Jan10

22Oct03

18May04

11Oct11

11Feb09

27May04

3Jun05

24Mar04

10Dec09

12Oct07

28Jan05

25May07

4Nov05

25Nov03

14Sep11

5Nov04

23Dec

-04

24Feb

-06

5Sep

-12

28May

-10

14Jul08

23Jan

-12

6Dec

-11

21Mar

-08  
24Feb  
-12  
20Jul10  
24May  
-05  
13Sep  
-13  
7Apr  
-08  
23May  
-12  
26Apr  
-12  
6Jul10  
11Oct  
-11  
10Feb  
-10  
26May  
-05  
31May  
-12  
24Mar  
-05  
10Jan  
-13  
10Oct  
-08  
28May  
-09  
27May  
-08  
6Nov  
-06  
24Nov  
-04  
13Sep  
-12  
4Nov  
-05  
27May  
-14  
27May  
-14  
27May  
-14  
27May  
-14  
20May  
-14  
13May  
-14  
13May



-14

13May

-14

6May

-14

6May

-14

6May

-14

29Apr14

29Apr14

29Apr14

29Apr14

29Apr14

22Apr14

22Apr14

22Apr14

22Apr14

15Apr14

15Apr14

15Apr14

15Apr14

15Apr14

15Apr14

8Apr14

8Apr14

8Apr14

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

54

27US8691777

Combination therapy

US8686152

US8682619

4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)

Device including altered microorganisms, and methods and systems of use

US8679839 Cell line from rousettus as host cell for pathogen amplification

US8678184 Methods for producing vaccine adjuvants

Emory University

Janssen Pharmaceutica NV

The Invention Science Fund I, LLC

Probiogen AG

Novartis AG

US8678002 Devices and methods for decreasing human pathogen transmission

Filligent Limited

US8673983 Melanins synthesized chemically or via enzyme catalysis

US8673932 Oxime substituted imidazo-containing compounds

US8673907

Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino-2butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4ylpropyl)

amino] methyl }phenyl) acetate and their use in therapy  
US8673904 Epoxide inhibitors of cysteine proteases  
US8673558 Luciferase biosensor  
US8673331  
Composition with sterilizing activity against bacteria, fungus and  
viruses, application thereof and method for preparation thereof  
US8669263 Use of TAM receptor inhibitors as antimicrobials  
US8669262  
3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6pentahydroxyhexyl)amino)ethox  
y)phenyl)butyl)carbamimidoyl)pyra  
zine-2-carboxamide  
US8669240  
Biological  
specimen collection and transport system and method of  
use  
US8664274  
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical  
compositions thereof, and methods for treating hemorrhagic fever  
viruses, including infections associated with arena viruses  
US8664218 Pharmaceutical compounds  
US8664188  
siRNA compositions and methods for potently inhibiting viral  
infection  
US8663922 Systems and methods for detecting multiple optical signals  
US8658767 Lipidated polyepitope vaccines  
US8658697  
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical  
compositions thereof, and methods for treating hemorrhagic fever  
viruses, including infections associated with arenaviruses  
US8658666 Substituted imidazoquinolines and imidazonaphthyridines  
US8658178 Carbon nanotube compositions and methods of use thereof  
US8653252 Short interfering RNA (siRNA) analogues  
US8653084 Hydrobenzamide derivatives as inhibitors of Hsp90  
US8653034  
US8652836  
Compositions and methods comprising phosphatidylethanolaminebinding  
peptide derivatives  
Defective ribosomal products in blebs (DRibbles) and methods of  
use to stimulate an immune response  
Fauci/COVID-19 Dossier  
Loyola University Chicago  
3M Innovative Properties Company  
Jan11  
10Mar10  
14Dec05  
4Mar08  
3Dec09  
26Jun07  
21Dec07  
12Aug03  
17AstraZeneca  
AB  
The Board of Trustees of the Leland Stanford Junior  
University

Promega Corporation  
GP&E  
Salk Institute for Biological Studies  
Dec07  
13Jun06  
10Oct03  
18Nov11  
9Nov07  
27Parion  
Sciences, Inc.  
Jun11  
1Longhorn  
Vaccines & Diagnostics, LLC  
Oct07  
6Siga  
Technologies, Inc.  
Dec04  
11Astex  
Therapeutics Ltd.  
Xiangxue Group (Hong Kong) Company Limited  
Gen-Probe Incorporated  
National Health Research Institutes  
Apr08  
11Dec08  
10Mar05  
15Nov10  
6Siga  
Technologies, Inc.  
Dec04  
113M  
Innovative Properties Company  
Yale University  
Santaris Pharma A/S  
Astex Therapeutics Ltd.  
Board of Regents, The University of Texas System  
Providence Health System  
Feb05  
19Mar08  
21Mar03  
12Oct06  
15Jul-02  
29Jul-05  
25Jan  
-12  
9Mar  
-11  
28May  
-10  
4Mar  
-09  
3Dec  
-10  
25Jun  
-08

22Dec  
-08  
12Aug  
-04  
16Dec  
-08  
13Jun  
-07  
24Apr  
-12  
18Nov  
-11  
8Mar  
-13  
26Jun  
-12  
19Mar  
-13  
6Jul11  
30Jan  
-13  
11Dec  
-09  
1Jun  
-10  
15Nov  
-11  
26Oct  
-10  
10Feb  
-06  
19Mar  
-09  
22Mar  
-04  
12Oct  
-07  
8May  
-08  
27Jul06  
CC-BY-NC-SA  
Dr. David E. Martin  
55  
8Apr14  
1Apr14  
25Mar  
-14  
25Mar  
-14  
25Mar  
-14  
25Mar  
-14  
18Mar

-14  
18Mar  
-14  
18Mar  
-14  
18Mar  
-14  
18Mar  
-14  
11Mar  
-14  
11Mar  
-14  
11Mar  
-14  
4Mar  
-14  
4Mar  
-14  
4Mar  
-14  
4Mar  
-14  
25Feb  
-14  
25Feb  
-14  
25Feb  
-14  
25Feb  
-14  
18Feb  
-14  
18Feb  
-14  
18Feb  
-14  
18Feb  
-14

US8652782

Compositions and methods for detecting, identifying and  
quantitating mycobacterial-specific nucleic acids

12Longhorn

Vaccines & Diagnostics, LLC

US8652533 Durable biocides and disinfectants

US8648076 Cysteine protease inhibitors and their therapeutic applications

US8647676 Antimicrobial composition from copepods

US8642596

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical  
compositions thereof, and methods for treating hemorrhagic fever  
viruses, including infections associated with arena viruses

US8642260 Single quantum-dot based aptameric nanosensors

US8633322 Alkynyl derivatives useful as DPP-1 inhibitors  
US8633308  
Compounds for preventing or treating viral infections and methods  
of use thereof  
US8632764 Directed evolution and in vivo panning of virus vectors  
US8629283  
Compounds that modulate negative-sense, single-stranded RNA  
virus replication and uses thereof  
US8629271 Compounds  
Mitsui Norin Co., Ltd.  
Hybrigenics SA  
Nofima Ingrediens  
Sep06  
7-Jul04  
5Aug05  
28Oct08  
6Siga  
Technologies, Inc.  
Dec04  
21The  
Research Foundation of the City University of New York  
Janssen Pharmaceutica NV  
The Governors of The University of Alberta  
University of North Carolina at Chapel Hill  
Icahn School of Medicine at Mount Sinai  
AstraZeneca AB  
US8629098 Compositions and methods for adoptive and active immunotherapy Yale  
University  
US8628786 Polychlorinated biphenyls and squalene-containing adjuvants  
US8624011  
Vaccines and immunotherapeutics comprising IL-15 receptor alpha  
and/or nucleic acid molecules encoding the same, and methods for  
using the same  
US8623419 Technology for preparation of macromolecular microspheres  
Novartis AG  
The Trustees of the University of Pennsylvania  
Ansun Biopharma, Inc.  
US8623382 Immunogenic compositions for inducing an immune response to HIV Wyeth  
LLC  
US8623364 Antigenic GM-CSF peptides and antibodies to GM-CSF  
US8617838 Fluorescent proteins and related methods and compounds  
US8615368 Method for determining the amount of an analyte in a sample  
US8609370  
US8609101  
Highly active glycoproteins-process conditions and an efficient  
method for their production  
Granulocyte-macrophage colony-stimulating factor (GM-CSF)  
neutralizing antibodies  
US8604215 Crystalline tripeptide epoxy ketone protease inhibitors  
US8603469  
Methods of treating cancer with human monoclonal antibodies  
against interleukin 8  
US8599383 Optical cytometry  
US8598192 Hydroxylamine substituted imidazoquinolines

US8598134  
RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof  
US8598116 Treatment of influenza virus infection  
US8598106  
US8597650  
Anti-microbial composition exhibiting residual anti-microbial properties on a surface  
Methods for treating rheumatoid arthritis with anti-bile saltstimulated lipase (BSSL) antibodies  
Fauci/COVID-19 Dossier  
Morphotek, Inc.  
University of Massachusetts  
Gen-Probe Incorporated  
Glycotope GmbH  
Theraclone Sciences, Inc.  
Onyx Therapeutics, Inc.  
Genmab A/S  
The Regents of the University of California  
3M Innovative Properties Company  
South Alabama Medical Science Foundation  
Educational Fund and Autoimmune Technologies, LLC  
Byotrol PLC  
HERNELL OLLE  
CC-BY-NC-SA Dr. David E. Martin  
Oct08  
29Oct09  
28Feb07  
30Apr08  
6Mar08  
6Feb08  
15Jan08  
28Dec07  
14Sep09  
24Jan06  
17Jun04  
8Feb06  
20Sep04  
10Mar05  
13Feb04  
23Apr09  
20Mar09  
16Dec02  
6May09  
14Nov03  
22Oct04  
4Nov03  
17Sep07  
8Apr09  
26Apr  
-11  
5Jul05  
26Jul06  
28Oct

-09  
6Dec  
-05  
21Oct  
-09  
28Oct  
-10  
27Feb  
-08  
29Apr  
-09  
6Mar  
-09  
2Apr  
-12  
14Jan  
-09  
2Dec  
-11  
14Sep  
-10  
4Nov  
-11  
18Jan  
-11  
24Oct  
-12  
20Sep  
-05  
10Mar  
-06  
14Feb  
-05  
23Apr  
-10  
22Mar  
-10  
27Dec  
-11  
6May  
-09  
12Nov  
-04  
23Jul10  
29May  
-12  
5Jul11  
6Apr  
-10  
56  
18Feb  
-14  
18Feb  
-14



11Feb  
-14

11Feb  
-14

4Feb  
-14

4Feb  
-14

21Jan14

21Jan14

21Jan14

14Jan14

14Jan14

14Jan14

14Jan14

7Jan14

7Jan14

7Jan14

7Jan14

31Dec

-13

24Dec

-13

17Dec

-13

17Dec

-13

10Dec

-13

10Dec

-13

3Dec

-13

3Dec

-13

3Dec

-13

3Dec

-13

3Dec

-13

3Dec

-13

US8592567

Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the same

US8592391 Method for therapeutic, clinical and veterinary use poly-ICLC

US8586770 Unsaturated steroid compounds

US8586364

Cells and methodology to generate non-segmented negative-strand RNA viruses

US8586363 TAL effector-mediated DNA modification

US8581584 Membrane proteins, mechanisms of action and uses thereof

US8580927 Engineered antibody constant domain molecules

US8580268

CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

US8569283 Compounds and compositions as c-Kit kinase inhibitors

US8562996 RSV-specific binding molecules and means for producing them

US8562943

US8560339

US8557767

Quality control methods for oil-in-water emulsions containing squalene

System and method to predict the global spread of infectious agents via commercial air travel

Synthetic apolipoprotein E mimicking polypeptides and methods of use

US8557248 Methods and compositions for treating malaria

US8552051 Use of pharmaceutical compositions containing mesembrenone

US8552032 Bicyclic derivatives useful as inhibitors of DPP-1

US8551968 Methods for generation of antibodies

US8551756 Avian influenza chimeric VLPS

US8551750

US8551749

Device including bone cage and method for treatment of disease in a subject

Device including bone cage and method for treatment of disease in a subject

13The

Trustees of the University of Pennsylvania

SALAZAR ANDRES

Harbor Therapeutics, Inc.

Institut Pasteur

Iowa State University Research Foundation, Inc.

Florida State University Research Foundation

The United States of America, as represented by the Secretary, Department of Health and Human Services

Coley Pharmaceutical GmbH

LIU XIAODONG

MedImmune Limited

Novartis AG

Kamran Khan

UAB Research Foundation

Cyvax, Inc.

H. L. Hall & Sons Limited

Janssen Pharmaceutica NV

National Jewish Health

Novavax, Inc.

The Invention Science Fund I, LLC

The Invention Science Fund I, LLC

US8551738 Systems and methods for rapid identification of nucleic acid variants

Ibis Biosciences, Inc.

US8551469

Treatment of tumors and viral diseases with recombinant interferon alpha

US8546432 Tetrazolones as inhibitors of fatty acid synthase

US8546383 Chiral fused [1,2]imidazo[4,5-c] ring compounds

US8546082 Methods for identification of sepsis-causing bacteria  
US8541568  
US8541457  
US8541438  
Compositions and methods using siRNA molecules for treatment of gliomas  
Aminothiazole derivatives as human stearyl-CoA desaturase inhibitors  
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines  
US8541221 Primate T-lymphotropic viruses  
US8541003  
Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using  
Fauci/COVID-19 Dossier  
Superlab Far East Limited  
Infinity Pharmaceuticals, Inc.  
3M Innovative Properties Company  
Ibis Biosciences, Inc.  
BIGNER DARELL D  
Xenon Pharmaceuticals Inc.  
3M Innovative Properties Company  
Johns Hopkins University  
Protein Sciences Corporation  
CC-BY-NC-SA Dr. David E. Martin  
Jan06  
1-Jul03  
29Sep04  
22Dec06  
10Dec09  
26May10  
31Jan08  
27Sep06  
1Sep11  
1Jun07  
8Nov06  
2Apr07  
28Aug07  
9Aug10  
20Mar09  
18Dec09  
13Mar07  
11Jul-03  
23Apr09  
23Apr09  
21Jul-05  
28Feb01  
5May10  
30Dec04  
11Sep03  
24May08  
3Jun05  
18Jun04

21Feb05  
20Jun03  
3May  
-12  
17Oct  
-08  
18Feb  
-11  
21Dec  
-07  
10Dec  
-10  
26May  
-11  
30Jan  
-09  
27Sep  
-07  
29Aug  
-12  
30May  
-08  
6Nov  
-07  
2Apr  
-08  
27Aug  
-08  
9Aug  
-11  
16Mar  
-10  
16Dec  
-10  
13Mar  
-08  
19Jan  
-10  
28Jul09  
23Apr  
-09  
11Nov  
-09  
6Oct  
-08  
5May  
-11  
25May  
-12  
25May  
-07  
26May  
-09  
5Jun

-06

21Dec

-10

1Jul10

21Jun

-04

57

26Nov

-13

26Nov

-13

19Nov

-13

19Nov

-13

19Nov

-13

12Nov

-13

12Nov

-13

12Nov

-13

29Oct13

22Oct13

22Oct13

15Oct13

15Oct13

15Oct13

8Oct13

8Oct13

8Oct13

8Oct13

8Oct13

8Oct13

8Oct13

8Oct13

8Oct13

10Oct13

10Oct13

10Oct13

24Sep

-13

24Sep

-13

24Sep

-13

24Sep

-13

24Sep

-13

US8529968

US8524715

US8524488

Decontaminating composition having simultaneously bactericidal,

fungicidal and virocidal properties, methods for obtaining and using said composition  
Phenoxyacetic acid derivatives useful for treating respiratory diseases  
Methods and devices for determining a cell characteristic, and applications employing the same  
29Hightech  
Bio-Activities Holding GmbH  
Astrazeneca AB  
The Regents of the University of California  
US8524241 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A  
The General Hospital Corporation  
US8519106 Monoclonal human tumor-specific antibody  
US8507545 Cytotoxic T cell activator comprising EP4 agonist  
US8507544 Bi-aryl amide compounds as CRTh2 receptor modulators  
US8507455 Folate conjugates  
University of Zurich  
National University Corporation, Hamamatsu University  
School of Medicine  
Astrazeneca AB  
Alnylam Pharmaceuticals, Inc.  
US8506968 SARS vaccine compositions and methods of making and using them Eli Lilly and Company  
US8506966 Adjuvanted influenza vaccines for pediatric use  
US8501746 Organic compounds  
US8501699 Bicyclic nucleosides and nucleotides as therapeutic agents  
US8501461 System for performing multi-formatted assays  
US8497405 Process for dispersing vaporous hydrogen peroxide  
US8497112 Method for producing viral vaccines  
US8494781  
Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds  
US8492329 Bioactive peptides and methods of using same  
US8486959 Dibenzo[f,h]isoquinoline derivatives  
US8486678 Pharmaceutical compositions for the treatment of virus infection  
US8486619  
Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses  
US8486420 Live virus vaccines  
US8481547  
US8481270  
Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1  
Method for chromogenic detection of two or more target molecules in a single sample  
US8481255 Scytovirin domain 1 related polypeptides  
US8476292  
Amide and carbamate derivatives of  
N-{2-[4-amino-2(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1dimethylethyl}methanesulfonamide and methods  
US8476288 Salts 756  
US8476265 Compounds-801

US8470771

US8470769

Method and medicament for inhibiting the infection of influenza virus

Method of treatment of bacterial infection by administration of polylysine  
Fauci/COVID-19

Dossier

Novartis AG

Novartis AG

Biota Scientific Management Pty Ltd

Gen-Probe Incorporated

STERIS Inc.

Baxter Healthcare SA

BOGOCH ELENORE S

Compugen Ltd.

National Health Research Institutes

Kineta Two, LLC

University of Rochester

Children's Hospital, Inc.

Janssen Pharmaceutica NV

Ventana Medical Systems, Inc.

The United States of America, as represented by the  
Secretary, Department of Health and Human Services

3M Innovative Properties Company

Mar04

23Nov04

10Sep02

20Jul-07

13Mar07

8May07

5-Jul07

4Dec07

29Jun00

22Feb08

5Jun06

3-Jul08

10Mar05

6Mar07

28Aug07

6Jun03

12Jul-07

14Jan10

23Nov05

2May08

15Feb05

18Dec09

22Aug08

25May05

9Sep05

21AstraZeneca

AB

AstraZeneca AB

Institute of Microbiology, Chinese Academy of Sciences

Novabiotics, Ltd.

CC-BY-NC-SA Dr. David E. Martin  
May09  
30Jul-10  
14Nov07  
18Aug04  
29Mar  
-05  
22Nov  
-05  
9Mar  
-05  
18Jul08  
13Mar  
-08  
7May  
-08  
3Jul08  
4Dec  
-08  
28Dec  
-09  
20Feb  
-09  
4Jun  
-07  
7Sep  
-12  
3Dec  
-09  
28Feb  
-13  
28Aug  
-08  
10Dec  
-10  
11Jul08  
14Jan  
-11  
1Feb  
-12  
1May  
-09  
15Feb  
-06  
16Dec  
-10  
21Aug  
-09  
30Sep  
-11  
8Sep  
-06  
20May  
-10



14Sep

-12

18Dec

-07

30Nov

-11

58

10Sep

-13

3Sep

-13

3Sep

-13

3Sep

-13

27Aug

-13

13Aug

-13

13Aug

-13

13Aug

-13

13Aug

-13

13Aug

-13

6Aug

-13

6Aug

-13

6Aug

-13

30Jul13

30Jul13

23Jul13

23Jul13

16Jul13

16Jul13

16Jul13

16Jul13

9Jul13

9Jul13

9Jul13

2Jul13

2Jul13

2Jul13

25Jun13

25Jun13

10US8470346

Anti-viral pharmaceutical compositions

US8470335

US8466284

Recombinant SARS-CoV nsp12 and the use of thereof and the

method for producing it  
Some 2-pyrazinone derivatives and their use as inhibitors of  
neutrophile elastase  
US8466167 Compounds and compositions as TLR activity modulators  
US8466124  
RNA sequence motifs in the context of defined internucleotide  
linkages inducing specific immune modulatory profiles  
Mast Therapeutics, Inc.  
Industry-Academic Cooperation Foundation, Yonsei  
University Kookmin University Industry Academy  
Cooperation Foundation  
Astra Zeneca AB  
IRM LLC  
Coley Pharmaceutical GmbH  
US8465751 Cna $\epsilon$ B domain antigens in vaccines against gram positive bacteria  
Novartis AG  
US8461125 Compositions and methods to treat asthma  
US8460914  
Decreasing potential iatrogenic risks associated with vaccines and  
vaccine antigens  
US8460605 Decontaminant dispenser suitable for use as a projectile  
US8455483 Compounds $\epsilon$ 801  
US8450471 TAL effector-mediated DNA modification  
US8450467 Carbohydrate conjugates as delivery agents for oligonucleotides  
US8450350 Triazoles as inhibitors of fatty acid synthase  
US8450284  
Coiled-coil lipopeptide helical bundles and synthetic virus-like  
particles  
US8450055 Malaria antigen screening method  
US8445650  
US8445447  
US8444961  
Mutant botulinum neurotoxin serotype A polypeptide and uses  
thereof  
B7-DC variants immunogenic compositions and methods of use  
thereof  
RNA virus infection inhibitor, method for inhibition of infection by  
RNA virus, RNA virus infection-inhibiting product, and use as RNA  
virus infection inhibitor  
US8440704 Quercetin-containing compositions  
US8440649 Phenanthroindolizidine analogues  
US8440642 Boron-containing small molecules  
US8440432 Tal effector-mediated DNA modification  
US8440431 TAL effector-mediated DNA modification  
US8440408 Animal protein-free media for cultivation of cells  
US8436178 Imidazoquinolines with immuno-modulating properties  
US8436024 2-pyridone compounds  
US8431160  
US8431134  
Microparticles containing biodegradable polymer and cationic  
polysaccharide for use in immunogenic compositions  
Use of a pneumococcal P4 peptide for enhancing  
opsonophagocytosis in response to a pathogen  
US8426565 Dendritic cell marker and uses thereof

US8420798 Method for producing nucleic acid probes  
Fauci/COVID-19 Dossier  
The Children's Hospital of Philadelphia  
Novartis AG  
STERIS Inc.  
AstraZeneca AB  
Iowa State University Research Foundation, Inc.  
Alnylam Pharmaceuticals, Inc.  
Infinity Pharmaceuticals, Inc.  
Universitaet Zuerich  
The United States of America as Represented by the  
Secretary of the Navy  
Thomas Jefferson University  
The Johns Hopkins University  
Sekisui Chemical Co., Ltd.  
Quercegen Pharmaceuticals LLC  
National Health Research Institutes  
Anacor Pharmaceuticals, Inc.  
Iowa State University Research Foundation, Inc.  
Iowa State University Research Foundation, Inc.  
Baxter Healthcare S.A.  
AstraZeneca AB  
Astrazeneca AB  
Novartis AG  
The United States of America as represented by the  
Secretary of the Department of Health and Human  
Services, Centers for Disease Control and Prevention  
Walter and Eliza Hall Institute of Medical Research  
Ventana Medical Systems, Inc.  
CC-BY-NC-SA Dr. David E. Martin  
Dec03  
13Jun08  
6Nov07  
3Mar08  
13Aug07  
12Jan09  
14Feb08  
9Sep04  
6Mar07  
31Jul-09  
10Dec09  
4Dec07  
5May10  
9Dec06  
31Aug05  
25Sep07  
13Jul-07  
16Jun09  
17Jul-06  
24Feb09  
16Feb05  
10Dec09  
10Dec09  
29Oct04

8May07  
20Oct09  
24Feb06  
31Jul-08  
30Aug07  
1Sep06  
19May  
-11  
13Jun  
-08  
5Nov  
-08  
27Feb  
-09  
12Jun  
-12  
12Jan  
-10  
13Aug  
-10  
10Jan  
-13  
20Feb  
-08  
30Jul10  
22Mar  
-12  
14Dec  
-11  
5May  
-11  
6Dec  
-07  
25Aug  
-06  
25Sep  
-08  
7Mar  
-12  
16Jun  
-10  
16Dec  
-09  
11Feb  
-10  
1Sep  
-11  
22Mar  
-12  
22Mar  
-12  
10Dec  
-10  
6May

-08  
10ct  
-10  
24Feb  
-07  
31Jul09  
29Aug  
-08  
31Aug  
-07  
59  
25Jun13  
25Jun13  
18Jun13  
18Jun13  
18Jun13  
18Jun13  
11Jun13  
11Jun13  
11Jun13  
4Jun13  
28May  
-13  
28May  
-13  
28May  
-13  
28May  
-13  
28May  
-13  
21May  
-13  
21May  
-13  
21May  
-13  
14May  
-13  
14May  
-13  
14May  
-13  
14May  
-13  
14May  
-13  
14May  
-13  
14May  
-13  
7May  
-13  
7May  
-13  
30Apr13

30Apr13

23Apr13

16Apr13

27US8420784

Interleukin 10 receptor, (IL-10R) antibodies

US8420096

Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling

Kyowa Hakko Kirin Co., Ltd.

Vanderbilt University

US8420094 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A

The General Hospital Corporation

US8415394

Biphenyloxyacetic acid derivatives for the treatment of respiratory disease

US8415361 Use of TAM receptor inhibitors as antimicrobials

US8415330

Biological specimen collection and transport system and method of use

US8415309 Bicyclic nucleosides and nucleotides as therapeutic agents

US8415118 Porcine DC-SIGN, ICAM-3 and LSEctin and uses thereof

US8415102

Methods and computer systems for identifying target-specific sequences for use in nanoreporters

US8410149

Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses

US8410114

2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

US8409589 Mutant forms of streptolysin O

US8399651 Nucleic acids encoding GAS57 mutant antigens

US8398992 Methods and compositions for polytopic vaccination

US8394986 Phenoxiacetic acid derivatives

US8394945 Compositions for use in identification of bacteria

US8394386

Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations

Astrazeneca AB

The Salk Institute for Biological Studies

Longhorn Vaccines & Diagnostics, LLC

Biota Scientific Management Pty Ltd

Virginia Tech Intellectual Properties, Inc.

NanoString Technologies, Inc.

May08

4Mar04

20Jul-07

6Oct05

9Nov07

10Oct07

1-Jul09

29Oct07

10Apr07

6Siga  
Technologies Inc.  
Dec04  
8AstraZeneca  
AB  
Novartis AG  
Novartis AG  
Polytopos LLC  
AstraZeneca AB  
Ibis Biosciences, Inc.  
The Trustees of the University of Pennsylvania  
US7829712 Pyridazine derivatives for inhibiting human stearyl-CoA-desaturase  
Xenon Pharmaceuticals Inc.  
US7829707 Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy  
AstraZeneca AB  
US7829302 Method for detecting the specificity of activated lymphocyte  
US7820210  
Methods and apparatus to prevent, treat, and cure the symptoms of  
nausea caused by chemotherapy treatments of human cancers  
US7812135 GITR-binding antibodies  
US7803918  
US7803796  
US7803765  
Coronavirus, nucleic acid, protein, and methods for the generation  
of vaccine, medicaments and diagnostics  
Homopiperazine compounds that inhibit ribosomal frameshifting by  
binding to RNA pseudoknot structure of SARS coronavirus  
Methods of constructing biodiverse gene fragment libraries and  
biological modulators isolated therefrom  
US7799800 Lipid-modified immune response modifiers  
US7794998 Primate T-lymphotropic viruses  
HU JUN  
Inhalation, Inc.  
TOLERRX, Inc.  
Amsterdam Institute of Viral Genomics B.V.  
Sungkyunkwan University Foundation For Corporate  
Collaboration  
Phylogica Limited  
3M Innovative Properties Company  
Johns Hopkins University  
US7794659 Signal measuring system having a movable signal measuring device  
Gen-Probe Incorporated  
US7790878  
RNAi modulation of RSV, PIV and other respiratory viruses and uses  
thereof  
Fauci/COVID-19 Dossier  
Alnylam Pharmaceuticals, Inc.  
CC-BY-NC-SA Dr. David E. Martin  
May06  
21Dec07  
12Sep07  
29Apr05  
21Aug03  
11Sep03

28Apr04  
20Sep04  
6Dec04  
8Dec03  
3Apr00  
25Mar05  
18Aug03  
22Dec06  
20Feb04  
30Oct03  
21Feb05  
10Mar05  
22Oct04  
27May  
-09  
4Mar  
-05  
18Jul08  
21Dec  
-11  
7Nov  
-08  
10oct  
-12  
11Jan  
-12  
29Oct  
-08  
10Apr  
-08  
28Oct  
-10  
6Jan  
-12  
14Sep  
-11  
10Sep  
-12  
22Dec  
-11  
26Jul11  
7Mar  
-07  
27Apr  
-05  
20Sep  
-05  
5Dec  
-05  
7Dec  
-04  
18Mar  
-08  
27Mar



-06  
18Aug  
-04  
20Dec  
-07  
20Feb  
-04  
12Aug  
-04  
24Feb  
-07  
10Mar  
-06  
25Jun  
-09  
60  
16Apr13  
16Apr13  
16Apr13  
9Apr13  
9Apr13  
9Apr13  
9Apr13  
9Apr13  
9Apr13  
2Apr13  
2Apr13  
2Apr13  
19Mar  
-13  
19Mar  
-13  
12Mar  
-13  
12Mar  
-13  
12Mar  
-13  
9Nov  
-10  
9Nov  
-10  
9Nov  
-10  
26Oct10  
12Oct10  
28Sep  
-10  
28Sep  
-10  
28Sep  
-10  
21Sep  
-10

14Sep  
-10  
14Sep  
-10  
7Sep  
-10  
US7790449  
US7790159  
US7786290  
US7785775  
Adeno-associated virus (AAV) serotype 8 sequences, vectors  
containing the same, and uses therefor  
17The  
Trustees of the University of Pennsylvania  
Methods, combinations and kits for treating viral infections using  
immunoconjugates and antibodies to aminophospholipids  
Double-stranded ribonucleic acid with increased effectiveness in an  
organism  
Human virus causing severe acute respiratory syndrome (SARS)  
and uses thereof  
US7785612 Polyamino acid for use as adjuvant  
US7781226 Particle on membrane assay system  
US7781203  
Supports for assaying analytes and methods of making and using  
thereof  
US7777036 Heterocyclic derivatives and their use as therapeutic agents  
US7777022  
Bioinformatically detectable group of novel regulatory viral and viral  
associated oligonucleotides and uses thereof  
US7776521 Coronavirus isolated from humans  
US7767817  
US7767677  
Water soluble boronic acid fluorescent reporter compounds and  
methods of use thereof  
Heterocyclic derivatives and their use as stearyl-CoA desaturase  
inhibitors  
US7767658 Vaccine composition  
US7767657 Boron-containing small molecules  
US7767210 RNA virus vaccines and methods  
US7763618 Pyridyl derivatives and their use as therapeutic agents  
US7758868  
Modified polymerases and attenuated viruses and methods of use  
thereof  
US7754711 Pyridazine derivatives and their use as therapeutic agents  
US7750123 Antibodies against SARS-CoV and methods of use thereof  
US7749445 Method and apparatus for analyzing bioprocess fluids  
US7745486 Quercetin-containing compositions  
US7745442 Methods of reducing risk of infection from pathogens  
US7745147 Methods and uses of antibodies in the purification of interferon  
US7745119 System for detecting polynucleotides  
US7745118 Comparative genomic resequencing  
US7741450 Antibodies to GM-CSF  
US7741360 Bi-aryl or aryl-heteroaryl substituted indoles  
US7740858 SARS-CoV-specific B-cell epitope and applications thereof

US7737135

Biphenyloxyacetic acid derivatives for the treatment of respiratory disease

US7736850 Strain of SARS-associated coronavirus and applications thereof

Board of Regents, The University of Texas System

Alnylam Pharmaceuticals, Inc.

Versitech Limited

Masanori Baba

The Board of Regents of the University of Texas System

Corning Incorporated

Xenon Pharmaceuticals Inc.

Rosetta Genomics, Ltd.

The United States of America as represented by the

Secretary of the Department of Health and Human

Services, Centers for Disease Control and Prevention

FANG HAO

Xenon Pharmaceuticals Inc.

Aventis Pasteur SA

Anacor Pharmaceuticals, Inc.

The Board of Regents of the University of Oklahoma

Xenon Pharmaceuticals Inc.

The Penn State Research Foundation

Xenon Pharmaceuticals Inc.

Dana Farber Cancer Institute, Inc.

BioScale, Inc.

Quercegen Pharma LLC

Parion Sciences, Inc.

ViraNative AB

Investigen, Inc.

Roche Nimblegen, Inc.

Morphotek Inc.

AstraZeneca AB

National Taiwan University

AstraZeneca AB

Centre National de la Recherche Scientifique

Dec01

15Jul-02

13Jun03

24Mar03

20Apr05

27Feb04

29Dec05

20Sep04

26Nov02

25Apr03

5Sep03

20Sep04

17Nov03

16Feb05

14Dec05

29Jul-03

22Dec06

30Jul-03

25Nov03

2May05  
17Jul-06  
20Aug03  
12Feb05  
20May03  
8Apr04  
8Feb06  
26May06  
21Sep04  
24Aug04  
2Dec03  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
6Sep  
-07  
15Aug  
-03  
14Jun  
-04  
8Jun  
-07  
19Apr  
-06  
22Dec  
-04  
7Jun  
-06  
20Sep  
-05  
26May  
-04  
14May  
-07  
7Sep  
-04  
20Sep  
-05  
9Jan  
-08  
16Aug  
-06  
14Dec  
-06  
29Jul04  
24Dec  
-07  
9Feb  
-05  
24Nov  
-04  
19Dec  
-06  
16Jul07

18Aug  
-04  
13Feb  
-06  
21Nov  
-05  
8Apr  
-05  
8Feb  
-07  
25May  
-07  
21Sep  
-04  
22Aug  
-05  
2Dec  
-04  
61  
7Sep  
-10  
7Sep  
-10  
31Aug  
-10  
31Aug  
-10  
31Aug  
-10  
24Aug  
-10  
24Aug  
-10  
17Aug  
-10  
17Aug  
-10  
17Aug  
-10  
3Aug  
-10  
3Aug  
-10  
3Aug  
-10  
3Aug  
-10  
3Aug  
-10  
27Jul10  
20Jul10  
13Jul10  
6Jul10  
6Jul10

29Jun10  
29Jun10  
29Jun10  
29Jun10  
29Jun10  
22Jun10  
22Jun10  
22Jun10  
15Jun10  
15Jun10

23US7732177

Oligoadenylate Synthetase (OAS)

US7731978 Mutant forms of streptolysin O

US7728110 Antibodies to SARS coronavirus

US7725565

System and method for detecting, collecting, analyzing, and communicating event related information

US7723570 Edible vaccines expressed in soybeans

US7723041

US7722886

US7714109

US7713515

US7709521

Assay for SARS coronavirus by amplification and detection of the replicase sequence

Compositions and methods for treatment of severe acute respiratory syndrome (SARS)

Combinations and kits for cancer treatment using selected antibodies to aminophospholipids

Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis

Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases

US7709511 Benzothiazolone derivatives

US7709188 Multi-allelic detection of SARS-associated coronavirus

US7700782 Compounds 569

US7700728

Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors

US7700727 Compositions and kits for detecting pathogen infection

US7700273

US7700120

Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor

Adjuvancy and immune potentiating properties of natural products of *Onchocerca volvulus*

US7696406 Expression of a recombinant transgene

US7696330 Binding molecules against SARS-coronavirus and uses thereof

US7691877 Pharmaceuticals

US7691646

Hazardous substance removing method, hazardous substance

removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof

Illumigen Biosciences, Inc.  
Novartis AG  
Amgen, Inc.  
Georgetown University  
SoyMeds, Inc.  
Becton, Dickinson and Company  
Wyeth  
Board of Regents, The University of Texas System  
R.E.D. Laboratories N.V.  
AstraZeneca AB  
AstraZeneca AB  
Birch Biomedical Research LLC  
AstraZeneca AB  
Schering Corporation  
Biokit, S.A.  
The United States of America as represented by the  
Department of Health and Human Services  
New York Blood Center  
Board of Trustees Operating Michigan State University  
CruceCell Holland B.V.  
Pfizer Inc.  
Nov05  
21Dec07  
19May06  
25Feb08  
12Oct04  
12Sep03  
20May04  
15Jul-02  
27May03  
18Aug03  
9Aug05  
22Aug03  
19Dec07  
24Mar05  
23Dec03  
9Apr04  
15Jun04  
3-Jul03  
22Jul-03  
17Feb06  
28Daikin  
Industries, Ltd.  
Mar03  
2US7691599  
Mammalian genes involved in viral infection and tumor suppression Zirus, Inc.  
US7691390 Viral protein  
US7687535 Substituted 3-sulfur indoles  
US7687475 RNA interference in respiratory epithelial cells  
US7682688  
Microporous materials, methods, and articles for localizing and  
quantifying analytes  
US7678774 Treating severe acute respiratory syndrome  
US7678386

US7674795

Liposomes coated with selected antibodies that bind to  
aminophospholipids

Fluorene derivatives, composition containing said derivatives and  
the use thereof

Fauci/COVID-19 Dossier

CHANG MING-FU

AstraZeneca AB

University of Iowa Research Foundation

University of Utah Research Foundation

Hemispherx Biopharma

Board of Regents the University of Texas

Aventis Pharma SA

CC-BY-NC-SA Dr. David E. Martin

May02

2Mar04

27May03

9-Jul04

26Nov02

16May03

15Jul-02

19May05

17Nov

-06

19Dec

-08

21May

-07

19Nov

-08

12Oct

-05

3Feb

-09

20May

-04

15Aug

-03

26May

-04

16Aug

-04

3Aug

-06

13Aug

-04

19Dec

-07

24Mar

-06

27Apr

-05

11Apr

-05



15Jun  
-05  
2Jul04  
20Jan  
-06  
16Feb  
-07  
21Nov  
-08  
2May  
-03  
19Sep  
-07  
25May  
-04  
16Oct  
-07  
20Nov  
-03  
26Jan  
-07  
15Aug  
-03  
14Nov  
-07  
62  
8Jun10  
8Jun10  
11Jun10  
25May  
-10  
25May  
-10  
25May  
-10  
25May  
-10  
11May  
-10  
11May  
-10  
4May  
-10  
4May  
-10  
4May  
-10  
20Apr10  
20Apr10  
20Apr10  
20Apr10  
13Apr10  
13Apr10

6Apr10

6Apr10

6Apr10

6Apr10

30Mar

-10

30Mar

-10

23Mar

-10

16Mar

-10

16Mar

-10

9Mar

-10

US7670807

RNA-dependent DNA polymerase from *Geobacillus stearothermophilus*

10East

Tennessee State Univ. Research Foundation

US7670565 Building decontamination with vaporous hydrogen peroxide

US7666996 Casein derived peptides and uses thereof

US7666592

US7662860

Methods for concurrent identification and quantification of an unknown bioagent

3D-structure model of SARS coronavirus 3CL protease and antiSARS drugs

US7648997 Hydroxylamine substituted imidazoquinolines

US7648844

Method and apparatus for detection of analyte using an acoustic device

US7645881 Methods for treating hepatitis C

US7642350 Purine derivatives

US7636637 Variable length probe selection

US7635557 Enzymatic diagnostic test for SARS and other viral diseases

US7635485 Method of accelerated vaccination against Ebola viruses

US7632638

US7629443

Methods and apparatus for detecting viruses using an acoustic device

Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus

US7629385 Sphingolipid-derived pharmaceutical compositions

US7629137

US7629114

US7625563

Methods and apparatus for detecting bacteria using an acoustic device

Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer

Cancer treatment methods using selected immunoconjugates for

binding to aminophospholipids  
US7625492 Charge-based water filtration systems  
US7625428 Bioagent air filtration systems  
US7623997  
Computer-implemented biological sequence identifier system and method  
US7622559 Human monoclonal antibodies against interleukin 8 (IL-8)  
US7622125 Polycistronic HIV vector constructs  
US7622118  
Cancer treatment methods using selected antibodies to aminophospholipids  
US7622112 Anti-SARS monoclonal antibodies  
US7619067 Evolved interferon-alpha polypeptides  
US7618802  
US7618788  
Compositions of coronaviruses with a recombination-resistant genome  
Proteome epitope tags and methods of use thereof in protein modification analysis  
US7618635 Super-antigen fusion proteins and the use thereof  
US7615381  
Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device  
Fauci/COVID-19 Dossier  
Steris Inc  
Peptera Pharmaceuticals Ltd  
Ibis Biosciences, Inc.  
Shanghai Institute of Materia Medica, Chinese Academy of Sciences  
Coley Pharmaceutical Group, Inc.  
BioScale, Inc.  
PTC Therapeutics, Inc.  
Pfizer Limited  
Roche NimbleGen, Inc.  
MND Diagnostic Ltd.  
The United States of America as represented by the Department of Health and Human Services  
BioScale, Inc.  
New York Blood Center, Inc.  
Jado Technologies GmbH  
BioScale, Inc.  
World Sense Technology Limited  
Board of Regents, The University of Texas System  
The University of Wyoming Research Corporation  
The University of Wyoming Research Corporation  
The United States of America as represented by the Secretary of the Navy  
Genmab A/S  
Novartis Vaccines and Diagnostics, Inc.  
Board of Regents, The University of Texas System  
Not Available  
Maxygen, Inc.  
The University of North Carolina at Chapel Hill  
Millipore Corporation

Healthbanks Biotech Co., Ltd.  
BioScale, Inc.  
CC-BY-NC-SA Dr. David E. Martin

Mar04

31Jan03

1Mar00

18Feb04

4Jun03

12Aug03

2May05

22Jul-04

4May05

18Jun04

23Jun03

1Aug03

2May05

2Jun04

29Jun04

2May05

26Aug03

15Jul-02

28Jan03

28Jan03

2-Jul04

16Dec02

5May04

15Jul-02

5Dec03

18May05

21Jul-03

10May02

21Jul-04

2May05

10Mar

-04

3Mar

-08

1Mar

-04

17Feb

-05

2Dec

-05

12Aug

-04

2May

-06

14Jul05

3May

-06

20Jun

-05

23Jun

-04

17Jan  
-06  
2May  
-06  
8Feb  
-06  
29Jun  
-05  
2May  
-06  
20Aug  
-04  
15Aug  
-03  
28Jan  
-04  
28Jan  
-04  
6Jun  
-06  
27Jun  
-07  
5May  
-05  
15Aug  
-03  
6Dec  
-04  
17May  
-06  
19Jan  
-06  
5Feb  
-04  
19Jul05  
2May  
-06  
63  
2Mar  
-10  
2Mar  
-10  
23Feb  
-10  
23Feb  
-10  
16Feb  
-10  
19Jan10  
19Jan10  
12Jan10  
5Jan10  
22Dec  
-09

22Dec  
-09  
22Dec  
-09  
15Dec  
-09  
8Dec  
-09  
8Dec  
-09  
8Dec  
-09  
8Dec  
-09  
1Dec  
-09  
1Dec  
-09  
1Dec  
-09  
24Nov  
-09  
24Nov  
-09  
24Nov  
-09  
24Nov  
-09  
24Nov  
-09  
17Nov  
-09  
17Nov  
-09  
17Nov  
-09  
17Nov  
-09  
10Nov  
-09

US7615223 Selected immunoconjugates for binding to aminophospholipids

US7611908

US7611704

Method and apparatus for therapeutic drug monitoring using an acoustic device

Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids

US7605161 Pyridyl derivatives and their use as therapeutic agents

US7605135 Baicalin as a treatment for SARS infection

US7604960 Transient protein expression methods

US7604801 Methods for detecting parvovirus infections

US7598382 Aryl substituted imidazoquinolines

US7598094

Methods and apparatus for detecting cardiac injury markers using

an acoustic device

US7598072 Assay to detect viral uncoating  
Board of Regents, The University of Texas System  
15Jul-02  
2BioScale,  
Inc.

Board of Regents, The University of Texas System  
Xenon Pharmaceuticals Inc.  
The University of Hong Kong  
Crucell Holland B.V.  
The Research Foundation of State University of New York  
Coley Pharmaceutical Group, Inc.  
BioScale, Inc.

Wisconsin Alumni Research Foundation  
US7597936 Method of producing a pigmented composite microporous material  
University of Utah Research Foundation

US7595381 Method for detecting SARS coronavirus

US7595163 Method for detecting SARS coronavirus

US7592343

US7592322

Pyridazine-piperazine compounds and their use as stearyl-CoA  
desaturase inhibitors

RNAi modulation of RSV, PIV and other respiratory viruses and uses  
thereof

US7592008 Membrane scaffold proteins

US7589092 Prodrugs of heteroaryl compounds

US7585647 Nucleic acid encoding recombinant interferon

US7582740 Methods and kits for detecting SARS-associated coronavirus

US7582621 Boron-containing small molecules

US7579396 Polymer composite

US7579359 1-alkoxy 1H-imidazo ring systems and methods

US7572621

US7572448

Detection, characterization and treatment of viral infection and  
methods thereof

Combined cancer treatment methods using selected antibodies to  
aminophospholipids

Eiken Kagaku Kabushiki Kaisha

Eiken Kagaku Kabushiki Kaisha

Xenon Pharmaceuticals Inc.

Alnylam Pharmaceuticals, Inc.

The Board of Trustees of the University of Illinois, a body  
corporate and politic of the State of Illinois

Koronis Pharmaceuticals, Incorporated

WEI GUANGWEN

The Trustees of Columbia University In the City of New  
York

Anacor Pharmaceuticals, Inc.

Eastman Kodak Company

3M Innovative Properties Company

Canadian Blood Services

Board of Regents, The University of Texas System

US7572442 Selected antibody compositions for binding to aminophospholipids Board  
of Regents, The University of Texas System

US7569536

Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity

US7569384 Albumin fusion proteins

US7550140 Antibody to the human OX40 receptor

US7547698

US7547516

Bicyclic heterocyclic derivatives and their use as inhibitors of stearyl-coadesaturase (SCD)

Method for reducing the presence of amplification inhibitors in a reaction receptacle

Fauci/COVID-19 Dossier

Masatoshi Hagiwara

Human Genome Sciences, Inc.

Crucell Holland B.V.

Xenon Pharmaceuticals Inc.

Gen-Probe Incorporated

CC-BY-NC-SA Dr. David E. Martin

May05

15Jul-02

30Jul-03

10Nov03

15Apr99

5May03

20Dec02

2May05

9Dec03

26Nov02

27Jun03

27Jun03

20Sep04

22Oct04

20Nov00

20Jun03

28Aug03

17Apr03

16Feb05

31Jan07

2Sep04

9Apr03

15Jul-02

15Jul-02

26Dec03

9Feb04

13Jun02

20Sep04

10Mar05

Aug

-03

2May

-06

15Aug

-03



29Jul04  
8Nov  
-04  
1Jun  
-07  
16Oct  
-08  
13Jan  
-06  
2May  
-06  
8Dec  
-04  
26May  
-04  
10Jun  
-08  
10Jun  
-08  
20Sep  
-05  
14Jun  
-05  
11Jan  
-05  
27Dec  
-06  
26Aug  
-04  
23Jan  
-04  
16Feb  
-06  
31Jan  
-07  
1Sep  
-05  
11Oct  
-05  
15Aug  
-03  
15Jul03  
24Dec  
-04  
8Aug  
-06  
13Jun  
-03  
20Sep  
-05  
10Mar  
-06  
64  
Nov

-09  
3Nov  
-09  
3Nov  
-09  
20Oct09  
20Oct09  
20Oct09  
20Oct09  
6Oct09  
6Oct09  
6Oct09  
6Oct09  
29Sep  
-09  
29Sep  
-09  
22Sep  
-09  
22Sep  
-09  
22Sep  
-09  
15Sep  
-09  
8Sep  
-09  
1Sep  
-09  
1Sep  
-09  
25Aug  
-09  
25Aug  
-09  
11Aug  
-09  
11Aug  
-09  
11Aug  
-09  
4Aug  
-09  
4Aug  
-09  
23Jun09  
16Jun09  
16Jun09  
1510

US7547512

High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)

24The

University of Hong Kong

US7544697 Pyrazolopyridines and analogs thereof  
US7541436 Interferon-alpha polypeptides and conjugates  
US7541163 Interferon-alpha polypeptides and conjugates  
US7531630 Interferon-alpha polypeptides and conjugates  
US7531324 Interferon-alpha polypeptides and conjugates  
US7521424 Albumin fusion proteins  
US7521185  
Assay for SARS coronavirus by amplification and detection of the replicase sequence  
US7514436 Pyridazine derivatives and their use as therapeutic agents  
US7511124  
Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents  
US7504384 Use of lipid conjugates in the treatment of infection  
US7504382  
US7504205  
Protease inhibitors for coronaviruses and SARS-CoV and the use thereof  
Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMPdependent kinase and a target for SARS therapy  
US7504097 Interferon-alpha polypeptides and conjugates  
Coley Pharmaceutical Group, Inc.  
Maxygen, Inc.  
Maxygen, Inc.  
Maxygen, Inc.  
Maxygen, Inc.  
Human Genome Sciences, Inc.  
Becton, Dickinson and Company  
Xenon Pharmaceuticals Inc.  
Board of Regents, The University of Texas System  
Yissum Research Development Company of the Hebrew University of Jerusalem  
Cytovia, Inc.  
The Burnham Institute  
Maxygen, Inc.  
US7498409 Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists  
Schering Corporation  
US7498152 Interferon-alpha polypeptides and conjugates  
US7495011 Anti-coronavirus drug  
US7491793 Influenza virus inhibiting peptides  
US7491706  
US7491508  
US7491489  
Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof  
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses  
Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof  
US7491397 Receptor binding polypeptides  
US7488801 Interferon-alpha polypeptides and conjugates  
US7488589 Interferon-alpha polypeptides and conjugates  
US7488473 Interferon-alpha polypeptides and conjugates

US7485432 Selective modulation of TLR-mediated biological activity  
US7482334 Therapeutic treatment methods  
US7482149  
US7479484  
US7470666  
Inhibition of SARS coronavirus infection with clinically approved  
antiviral drugs  
Peptides and peptidomimetics having immune-modulating, antiinflammatory,  
and anti-viral activity  
Use of Ulinastatin and its pharmaceutical composition for treating  
severe acute respiratory syndrome  
Fauci/COVID-19 Dossier  
Maxygen, Inc.  
aRigen Pharmaceuticals, Inc.  
The Administrators of the Tulane Educational Fund  
Changchun Huapu Biotechnology Co., Ltd.  
The Trustees of the University of Pennsylvania  
The University of Hong Kong  
National Health Research Institutes  
Maxygen, Inc.  
Maxygen, Inc.  
Maxygen, Inc.  
3M Innovative Properties Company  
Hollis-Eden Pharmaceuticals, Inc.  
Genome Institute of Singapore  
Takeda Pharmaceutical Company Limited  
Guangdong Techpool Biochem. Pharma. Co., Ltd.  
CC-BY-NC-SA Dr. David E. Martin  
Mar03  
30Oct03  
19May04  
19May04  
19May04  
19May04  
22Jan03  
12Sep03  
30Jul-03  
15Jul-02  
10Jan00  
6May03  
17May04  
18Nov02  
24Mar05  
18Nov02  
15Jul-03  
4Nov03  
25Jul-03  
20Jun03  
22Nov04  
9Jan04  
18Nov02  
18Nov02  
18Nov02  
27Feb03

28Aug02  
9Jun03  
25Jun03  
26May03  
24Mar  
-04  
1Apr  
-05  
4May  
-07  
14Aug  
-07  
13Sep  
-06  
13Sep  
-06  
7Jul05  
13Sep  
-04  
29Jul04  
15Aug  
-03  
8Sep  
-05  
6May  
-04  
17May  
-05  
30Oct  
-06  
23Mar  
-06  
30Oct  
-06  
14Jul04  
3Nov  
-04  
26Jul04  
15Jun  
-04  
28Oct  
-05  
10Jan  
-05  
30Oct  
-06  
30Oct  
-06  
30Oct  
-06  
27Feb  
-04  
12Feb  
-07

9Jun  
-04  
25Jun  
-04  
25May  
-04  
65  
16Jun09  
9Jun09  
2Jun09  
2Jun09  
12May  
-09  
12May  
-09  
21Apr09  
21Apr09  
7Apr09  
31Mar  
-09  
17Mar  
-09  
17Mar  
-09  
17Mar  
-09  
17Mar  
-09  
3Mar  
-09  
3Mar  
-09  
24Feb  
-09  
17Feb  
-09  
17Feb  
-09  
17Feb  
-09  
17Feb  
-09  
17Feb  
-09  
10Feb  
-09  
10Feb  
-09  
10Feb  
-09  
3Feb  
-09  
27Jan09  
27Jan09

20Jan09

30Dec

-08

US7470548

Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof

US7468418 Compositions for enhancing transport of molecules into cells

US7465836

US7462615

US7460960

Hydrolytically-resistant boron-containing therapeutics and methods of use

Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications

Proteome epitope tags and methods of use thereof in protein modification analysis

US7456180 Piperazine derivatives and their use as therapeutic agents

US7455833

Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids

US7452542 Live attenuated coronavirus vaccines

US7445889 Methods for detecting parvovirus infections

US7442761 Replikin peptides and uses thereof

US7442508 Methods for detection and production of influenza viruses

US7439349

Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof

US7439052 Method of making modified immunodeficiency virus particles

US7435588

US7435538

Systems for detection and production of respiratory, herpes and enteric viruses

High throughput screening method of drug for physiologically active protein

US7432045 Method of inhibiting influenza infection with antiviral peptides

US7429656

US7427479

US7424370

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference

Methods and kits for identifying target nucleotides in mixed populations

Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential

US7407663 Modified immunodeficiency virus particles

US7407662

Modified viral particles with immunogenic properties and reduced lipid content

US7405207

Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof

US7405046 Compositions and methods for treatment of rhinovirus  
US7399588 Method for detecting SARS coronavirus  
US7396914 SARS nucleic acids, proteins, antibodies, and uses thereof  
US7393856 Anti-viral uses of borinic acid complexes  
US7393638 Assay system and methods for detecting SARS-CV  
US7387271 Immunostimulatory combinations  
28Daikin  
Industries, Ltd.  
Mar03  
29AVI  
BioPharma., Inc.  
Anacor Pharmaceuticals, Inc.  
Hybrigenics SA  
Epitome Biosystems, Inc.  
Xenon Pharmaceuticals Inc.  
Board of Regents, The University of Texas System  
Vanderbilt University  
The Research Foundation of State University of New York  
BOGOCH ELENORE S  
Diagnostic Hybrids, Inc.  
Not Available  
Lipid Sciences  
Diagnostic Hybrids, Inc.  
CellFree Sciences Co., Ltd.  
Wisconsin Alumni Research Foundation  
The University of Hong Kong  
Applera Corporation  
Council of Scientific and Industrial Research  
Lipid Sciences, Inc.  
Lipid Sciences, Inc.  
Apr03  
16Jun03  
8Dec05  
10May02  
30Jul-03  
15Jul-02  
21May04  
5May03  
6Jun03  
24Apr98  
3-Jul02  
29Jun00  
20Sep05  
8Sep03  
1Dec03  
19May03  
30Apr04  
20Jul-04  
29Jun00  
29Jun00  
17Epigenesis  
Pharmaceuticals, Inc.  
Jun02  
6The



Quigley Corporation  
Eiken Kagaku Kabushiki Kaisha  
University of Massachusetts  
Anacor Pharmaceuticals, Inc.  
AsiaGEN Corporation  
3M Innovative Properties Company  
Aug01  
27Jun03  
4Aug03  
14Jun04  
1-Jul03  
30Dec02  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
26Mar  
-04  
29Apr  
-04  
15Jun  
-04  
8Dec  
-05  
13Nov  
-03  
29Jul04  
15Aug  
-03  
23May  
-05  
5May  
-04  
4Jun  
-04  
28Apr  
-06  
1Jul03  
10Apr  
-06  
28Apr  
-06  
8Sep  
-04  
1Dec  
-04  
14Jun  
-06  
29Apr  
-05  
7Feb  
-05  
20Jun  
-03  
21Jun

-04  
17Jun  
-03  
27Oct  
-06  
15Jun  
-04  
4Aug  
-04  
14Jun  
-05  
1Jul03  
30Dec  
-03  
66  
30Dec  
-08  
23Dec  
-08  
16Dec  
-08  
9Dec  
-08  
2Dec  
-08  
25Nov  
-08  
25Nov  
-08  
18Nov  
-08  
4Nov  
-08  
28Oct08  
28Oct08  
21Oct08  
21Oct08  
14Oct08  
14Oct08  
7Oct08  
30Sep  
-08  
23Sep  
-08  
9Sep  
-08  
5Aug  
-08  
5Aug  
-08  
29Jul08  
29Jul08  
15Jul08  
8Jul08

1Jul08

1Jul08

17Jun08

US7384909

US7378386

US7375210

US7375202

US7375180

US7374883

Anti-viral treatment methods using phosphatidylethanolaminebinding peptides linked to anti-viral agents

Anti-viral treatment methods using phosphatidylethanolaminebinding peptide derivatives

PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARSCoronavirus using the same

Human virus causing severe acute respiratory syndrome (SARS) and uses thereof

Methods and compositions related to IRM compounds and Toll-like receptor 8

Method and kit for the detection of a novel coronavirus associated with the severe acute respiratory syndrome (SARS)

US7371850 Method and composition for reducing expression of ROCK-II

US7371837 Human virus causing respiratory tract infection and uses thereof

US7371525

US7361747

Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS)

Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus

US7361304 Building decontamination with vaporous hydrogen peroxide

US7358068 Antiviral oligonucleotides

US7354908

Materials and methods for prevention and treatment of RNA viral diseases

US7354551 Room decontamination with hydrogen peroxide vapor

US7344740

Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers

US7344720 Vaccine composition

US7339051

Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)

US7335658 Pyridazine derivatives and their use as therapeutic agents

US7332475 Preventive or therapeutic composition for viral infectious disease

US7332294 CXCL10-based diagnosis and treatment of respiratory illnesses

US7320857

Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof

US7318918 Interferon-alpha polypeptides and conjugates

US7314613 Interferon-alpha polypeptides and conjugates

US7312036

Compositions for use in identification of viral hemorrhagic fever viruses

US7297786 RNA interference in respiratory epithelial cells  
US7291498  
Methods of generating chimeric adenoviruses and uses for such  
chimeric adenoviruses  
US7282568 Human monoclonal antibodies against interleukin 8 (IL-8)  
US7282199  
US7267942  
Adeno-associated virus (AAV) serotype 8 sequences, vectors  
containing same, and uses therefor  
Diagnostic assay for the human virus causing severe acute  
respiratory syndrome (SARS)  
Fauci/COVID-19 Dossier  
Board of Regents, The University of Texas System  
15Jul-02  
Board  
of Regents, The University of Texas System  
Samsung Electronics Co., Ltd.  
The University of Hong Kong  
3M Innovative Properties Company  
QIAGEN Diagnostics GmbH  
Myriad Genetics, Inc.  
The University of Hong Kong  
The Chinese University of Hong Kong  
The University of Hong Kong  
Steris Inc.  
Replicor, Inc.  
University of South Florida  
Steris Inc  
Inhalation, Inc.  
Sanofi Pasteur SA  
Isis Pharmaceuticals, Inc.  
Xenon Pharmaceuticals Inc.  
Kyowa Hakko Kogyo Co., Ltd.  
University Health Network  
Chinese National Human Genome Center at Shanghai  
Maxygen, Inc.  
Maxygen, Inc.  
ISIS Pharmaceuticals, Inc.  
University of Iowa Research Foundation  
The Trustees of the University of Pennsylvania  
Genmab A/S  
The Trustees of the University of Pennsylvania  
The University of Hong Kong  
CC-BY-NC-SA Dr. David E. Martin  
15Jul-02  
12Dec03  
24Mar03  
13Feb03  
30Apr03  
20Aug03  
21Jul-04  
29Jul-03  
22May03  
31Jan03

13Sep02  
30Apr02  
8-Jul04  
3Apr00  
17Nov03  
28Apr03  
30Jul-03  
22Jul-03  
17Aug04  
9-Jul04  
19May04  
18Nov02  
22Mar04  
9-Jul04  
20Jun03  
16Dec02  
17Dec01  
24Mar03  
Aug  
-03  
15Aug  
-03  
24Nov  
-04  
24Mar  
-04  
12Feb  
-04  
30Apr  
-04  
20Aug  
-04  
16May  
-05  
28Jul04  
24May  
-04  
29Jan  
-04  
12Sep  
-03  
30Apr  
-03  
8Jul04  
27Nov  
-04  
15Nov  
-04  
26Apr  
-04  
29Jul04  
22Jul04  
17Aug  
-04

9Jul04  
18May  
-05  
19May  
-04  
21Mar  
-05  
11Jul05  
20Jun  
-03  
16Dec  
-03  
25Apr  
-03  
24Mar  
-04  
67  
Jun08  
27May  
-08  
20May  
-08  
20May  
-08  
20May  
-08  
20May  
-08  
13May  
-08  
13May  
-08  
13May  
-08  
22Apr08  
22Apr08  
15Apr08  
8Apr08  
8Apr08  
18Mar  
-08  
18Mar  
-08  
4Mar  
-08  
26Feb  
-08  
19Feb  
-08  
19Feb  
-08  
22Jan08  
15Jan08  
1Jan08

25Dec

-07

20Nov

-07

6Nov

-07

16Oct07

16Oct07

11Sep

-07

1510

US7261867

Production of silver sulfate grains using organo-sulfate or organosulfonate additives

US7247303 Selected antibody CDRs for binding to aminophospholipids

US7244732 Prodrugs of heteroaryl compounds

US7223787

Prenylation inhibitors reduce host cell permissiveness to viral replication

US7220852 Coronavirus isolated from humans

US7183300

US7166435

Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof

Compositions and methods for reducing the transmissivity of illnesses

US7163947 1-Amino 1H-imidazoquinolines

US7151163

Antiviral agents for the treatment, control and prevention of infections by coronaviruses

US7151091 Compositions and methods for preventing infection

US7148248

US7129223

US7129042

Method of treating or inhibiting the development of brain inflammation and sepsis

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference

Compositions and methods for detecting severe acute respiratory syndrome coronavirus

US7115563 Composition and its therapeutic use

US7091214 Aryl substituted Imidazoquinolines

US7048953

Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)

US7023593 Apparatus for forming nano-grating device

US6946291 Mixed cell diagnostic systems

US20200176

079

US20200173

925

US20200172

883

US20200172

879

US20200172

600

US20200172

513

US20200172

480

US20200171

085

US20200171

060

US20200166

505

US20200165

632

METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME  
DETERMINATION OF DISEASE STATES

MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY  
DETECTION METHOD, AND MICROSCOPIC BODY DETECTION  
DEVICE

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND  
ACTIVITY, AND RELATED METHODS

DHFR TUNABLE PROTEIN REGULATION

7Eastman

Kodak Company

Board of Regents, The University of Texas System

Koronis Pharmaceuticals, Incorporated

Board of Regents, The University of Texas System

The United States of America as represented by the

Secretary of the Department of Health and Human

Services, Centers for Disease Control and Prevention

AGARWAL ATUL

The Quigley Corporation

3M Innovative Properties Company

Sequoia Pharmaceuticals, Inc.

La Jolla Biosciences LLC

NOZAKI MASAKO

The University of HongKong

Diagnostic Hybrids, Inc.

Insignion Holding Limited

3M Innovative Properties Co.

Inhalation, Inc.

Industrial Technology Research Institute

Diagnostic Hybrids, Inc.

Not Available

JAPAN SCIENCE AND TECHNOLOGY AGENCY

Not Available

Not Available

RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME GLAXOSMITHKLINE

BIOLOGICALS, SA

DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc.

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC

AGENTS



Method of Treating Respiratory Tract Infection  
FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST  
FILOVIRUSES AND FLAVIVIRUSES  
METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC  
ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING  
NEODYMIUM MAGNETS  
ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR  
rAAV VECTOR PRODUCTION  
Fauci/COVID-19 Dossier  
HANGZHOU DAC BIOTECH CO., LTD.  
Not Available  
Not Available  
The U.S.A., as represented by the Secretary, Department  
of Health and Human Services  
Spark Therapeutics, Inc.  
CC-BY-NC-SA Dr. David E. Martin  
Apr06  
15Jul-02  
20Jun03  
21Oct03  
25Apr03  
11Nov04  
6Aug01  
7Mar03  
28Apr03  
20Sep02  
29Nov02  
19May03  
3Nov03  
29May02  
20Dec02  
3Apr00  
28Nov03  
24Apr98  
19Jul-17  
29Mar17  
19Nov09  
3Mar17  
15Jul-09  
12Jun16  
12Jul-12  
19May17  
31Jul-17  
1Sep15  
7Jun17  
7Apr  
-06  
15Aug  
-03  
31Mar  
-04  
21Oct  
-03  
12Apr

-04  
10Nov  
-05  
14Dec  
-04  
3Sep  
-04  
28Apr  
-04  
22Sep  
-03  
26Nov  
-03  
19May  
-04  
3Nov  
-03  
29May  
-03  
18Dec  
-03  
2May  
-03  
17Mar  
-04  
30Mar  
-04  
18Jul18  
28Mar  
-18  
13Sep  
-19  
2Sep  
-19  
16Aug  
-17  
5Feb  
-20  
5Feb  
-20  
18May  
-18  
26Jan  
-18  
30Jan  
-20  
6Jun  
-18  
68  
28Aug  
-07  
24Jul07  
17Jul07  
29May

-07  
22May  
-07  
27Feb  
-07  
23Jan07  
16Jan07  
19Dec  
-06  
19Dec  
-06  
12Dec  
-06  
31Oct06  
31Oct06  
30Oct06  
15Aug  
-06  
23May  
-06  
4Apr06  
20Sep  
-05  
4Jun20  
4Jun20  
4Jun20  
4Jun20  
4Jun20  
4Jun20  
4Jun20  
4Jun20  
4Jun20  
4Jun20  
28May  
-20  
28May  
-20  
US20200165  
630  
US20200165  
613  
US20200165  
594  
US20200165  
585  
US20200165  
357  
US20200164  
334  
US20200164  
067  
US20200164  
058  
US20200164  
020

US20200163  
878  
US20200157  
600  
US20200157  
222  
US20200157  
221  
US20200155  
704  
US20200155  
699  
US20200155  
667  
US20200155  
664  
US20200155  
662  
US20200155  
660  
US20200155  
646  
US20200149  
062  
US20200149  
048  
US20200148  
749  
US20200147  
203  
US20200147  
193  
US20200147  
171  
US20200140  
547  
US20200140  
493  
US20200140  
398

29COMPOSITIONS

FOR THE TREATMENT OF DISEASE

VIRUS LIKE PARTICLE

CRISPR SYSTEM BASED ANTIVIRAL THERAPY

NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS

CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF  
USE THEREOF

MICROSPOTTING DEVICE

Methods and Compositions for Inhibiting Akt3

TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE

EAST RESPIRATORY SYNDROME-CORONAVIRUS

PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION

LIPID NANOPARTICLE MRNA VACCINES

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME

AMPLIFICATION

ANTI-PD-L1 ANTIBODIES AND USES THEREOF

ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS

CONTAINING SAME, AND USES THEREFOR

MODIFIED VIRUS-LIKE PARTICLES OF CMV

VACCINE COMPOSITIONS

Not Available

The University of Leeds

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Not Available

Not Available

Not Available

Not Available

King Abdulaziz University

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE Not Available

COMBINATION IMMUNOTHERAPIES COMPRISING IL-15

SUPERAGONISTS

COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER

NANOPARTICLE DELIVERY

EV576 For Use in the Treatment of Viral Infections of the

Respiratory Tract

ENGINEERED TSC2

Transbiotic Regulation of Bacterial Gene Expression

ANTIBODIES AND PROCESSES FOR PREPARING THE SAME

VACCINATION OF IMMUNOCOMPROMISED SUBJECTS

COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND

IMMUNOTHERAPY INVOLVING HER ANTIGENS

COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR

MODULATING AN IMMUNE RESPONSE AGAINST CANCERS,

INFECTIONS DISEASES AND DISORDERS

MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE

IMMUNE TOLERANCE

Engineering Virus-like Nanocarriers for Biomolecule Delivery

HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS

Fauci/COVID-19 Dossier

Not Available

Not Available

Volution Immuno Pharmaceuticals SA

Not Available

Not Available

Not Available

Not Available

Not Available

Apr16

1Jun17

7-Jul17  
27Jul-17  
2Dec05  
18Apr12  
15Jan16  
27Nov18  
12Apr17  
26Oct16  
19Nov18  
29Mar18  
30Jun16  
30Sep03  
22Oct14  
27Jul-17  
10Feb09  
26May17  
23Sep15  
8Jan10  
14Jul-17  
22May17  
16May08  
26Sep14  
2Jun17  
18Not  
Available  
Not Available  
Not Available  
AZIENDA OSPEDALIERA UNIVERSITARIA SENESE  
CC-BY-NC-SA Dr. David E. Martin  
Sep18  
26May17  
26Oct18  
13Feb15  
28Apr  
-17  
31May  
-18  
6Jul18  
27Jul18  
21Oct  
-19  
11Oct  
-19  
5Feb  
-20  
27Nov  
-18  
12Apr  
-17  
26Oct  
-17  
19Nov  
-18  
29Mar



-20  
21May  
-20  
21May  
-20  
21May  
-20  
21May  
-20  
21May  
-20  
21May  
-20  
21May  
-20  
21May  
-20  
21May  
-20  
21May  
-20  
14May  
-20  
14May  
-20  
14May  
-20  
14May  
-20  
14May  
-20  
14May  
-20  
14May  
-20  
7May  
-20  
7May  
-20  
7May  
-20  
US20200138  
937  
US20200138  
936  
US20200138  
818  
US20200138  
780  
US20200131  
518  
US20200129  
487  
US20200127  
954  
US20200124



599

US20200123

233

US20200123

205

US20200123

203

US20200115

448

US20200115

434

US20200113

996

US20200113

967

US20200113

831

US20200113

830

US20200109

403

US20200108

136

US20200102

558

US20200102

550

US20200102

544

US20200102

362

US20200102

292

US20200101

158

US20200101

153

US20200101

142

2Genetically

Attenuated Nucleic Acid Vaccine

Phenotypically Wild-Type and Genetically Attenuated Viruses

METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS

USING LAPATINIB

METHODS FOR TREATING PULMONARY EMPHYSEMA USING

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC

ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF

CATHEPSIN C

CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES

PRODUCED IN CELL CULTURE

CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND

RNA TARGETING METHODS AND COMPOSITIONS

ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE

DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF

DETECTION SIGNAL

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE  
PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME  
FOR THE TREATMENT OF VIRAL DISEASES

Inhibition Of TCR Signaling With Peptide Variants

COMPOSITIONS COMPRISING CURONS AND USES THEREOF

CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND

CHIMERIC STIMULATING RECEPTORS AND USES THEREOF

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES  
THEREOF

CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS

ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES

PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS

LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA  
MOLECULES

PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING  
RNA

IN VIVO DELIVERY OF OLIGONUCLEOTIDES

Not Available

Not Available

Not Available

Jun17

2Jun17

7Nov18

14Not

Available

Mar13

14Not

Available

TAIHO PHARMACEUTICAL CO., LTD.

Salk Institute for Biological Studies

CELLEMEDY CO., LTD

Mar17

30Jun17

22Aug17

13Apr17

5Ablynx

N.V.

Jun08

22Not

Available

FLAGSHIP PIONEERING INNOVATIONS V, INC.

Not Available

Not Available

Not Available

Not Available

GLAXOSMITHKLINE BIOLOGICALS SA

GLAXOSMITHKLINE BIOLOGICALS S.A.

Not Available

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available

TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID  
DELIVERY

TAL EFFECTOR-MEDIATED DNA MODIFICATION

POXVIRUS-PLASMIDIUM RECOMBINANTS, COMPOSITIONS

CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND  
METHODS OF MAKING AND USING THE SAME  
TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN  
COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY  
SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS  
AND USES THEREOF  
ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE  
THEREOF

Not Available

Not Available

Oct18

13Jun17

26Apr17

23Oct15

23Jun17

26May17

6-Jul11

31Aug11

12Dec11

6Apr07

3Apr17

10Dec09

30Not

Available

Dec13

6Not

Available

Not Available

Not Available

MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN Not Available

PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY

Not Available

Apr17

3-Jul13

10Oct15

6Apr17

12Jun17

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

1Jun

-18

1Jun

-18

6Nov

-19

19Dec

-19

14Mar

-18

29Jun

-18

31Dec

-18

13Apr  
-18  
1Aug  
-19  
18Dec  
-19  
13Jun  
-18  
22Oct  
-19  
29Oct  
-19  
21Jun  
-18  
26May  
-17  
16Dec  
-19  
16Dec  
-19  
18Dec  
-19  
22Nov  
-19  
30ct  
-19  
28Aug  
-19  
11Sep  
-19  
5Apr  
-18  
10Jul19  
22Oct  
-19  
6Apr  
-18  
12Jun  
-18  
70  
7May  
-20  
7May  
-20  
7May  
-20  
7May  
-20  
30Apr20  
30Apr20  
23Apr20  
23Apr20  
23Apr20

23Apr20  
16Apr20  
16Apr20  
16Apr20  
16Apr20  
16Apr20  
16Apr20  
9Apr20  
9Apr20  
2Apr20  
2Apr20  
2Apr20  
2Apr20  
2Apr20  
2Apr20  
2Apr20  
2Apr20  
US20200101  
119  
US20200101  
087  
US20200100  
480  
US20200095  
324  
US20200093  
919  
US20200093  
909  
US20200093  
855  
US20200093  
841  
US20200087  
655  
US20200087  
646  
US20200087  
630  
US20200087  
359  
US20200087  
313  
US20200087  
298  
US20200087  
280  
US20200086  
324  
US20200085  
984  
US20200085  
947  
US20200085

943

US20200085

872

US20200085

852

US20200085

756

US20200080

141

US20200080

111

US20200079

820

US20200079

781

US20200078

335

US20200072

836

US20200071

723

27METHODS

OF TREATMENT OF INFECTIONS USING BACTERIA

PHARMACEUTICAL COMPOSITIONS AND METHODS

TRAIT SELECTION IN AVIANS

ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE

THEREOF

MODIFIED PEDV SPIKE PROTEIN

PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND

TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO

ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC

OXIDE

Broad Spectrum Antiviral and Methods of Use

PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM

OXIDES

OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION

CASSETTES AND THEIR USE

INFLUENZA VIRUS AND TYPE 1 DIABETES

GRIFFITHSIN MUTANTS

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted

Benzamide Groups

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC

PROTEASE 7 INHIBITORS

DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION

APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING

AND/OR KILLING A VIRUS

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Istituto Zooprofilattico Sperimentale delle Venezie

The United States of America, as represented by the

Secretary, Department of Health and Human Services

Not Available

Not Available

Not Available

Not Available

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF

NEW YORK

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available

PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC

CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR

PEPTIDE ANTIGEN

CureVac AG

IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS Not Available

EPIDERMAL MRNA VACCINE

NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE

THEREOF

METHODS AND COMPOSITIONS FOR ENRICHMENT OF

AMPLIFICATION PRODUCTS

Methods for Autocatalytic Genome Editing and Neutralizing

Autocatalytic Genome Editing and Compositions Thereof

DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A

CELL BINDING MOLECULE

Substituted 2,4 diamino-quinoline as new medicament for fibrosis,

autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related

diseases

COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS

MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES

(MENSA) AND USES THEREOF

RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL

Fauci/COVID-19 Dossier

Not Available

Not Available

Not Available

Not Available

Hangzhou DAC Biotech Co., Ltd.

Not Available

Not Available

Not Available

Not Available

CC-BY-NC-SA Dr. David E. Martin

Sep18

3Aug15

31May17

30Mar17

20Sep18

19Apr17

11Sep17

17Apr06

14Jul-15

31May17  
10Oct12  
10Feb15  
29Jul-11  
1Mar17  
5Feb15  
30Jun16  
7Mar11  
7Sep12  
31Jan12  
19Apr17  
5Aug15  
14Sep18  
11Dec13  
18Sep15  
20Apr16  
5Sep18  
1May17  
5May14  
30Aug18  
26Sep  
-19  
21Nov  
-19  
31May  
-18  
30Mar  
-18  
18Sep  
-19  
19Apr  
-18  
3Jun  
-19  
30Apr  
-19  
22Nov  
-19  
31May  
-18  
25Jul19  
27Nov  
-19  
25Apr  
-19  
27Feb  
-18  
25Nov  
-19  
27Dec  
-18  
25Nov  
-19  
14May





19Mar  
-20  
19Mar  
-20  
19Mar  
-20  
19Mar  
-20  
19Mar  
-20  
12Mar  
-20  
12Mar  
-20  
12Mar  
-20  
12Mar  
-20  
12Mar  
-20  
5Mar  
-20  
5Mar  
-20  
US20200071  
421  
US20200069  
814  
US20200062  
764  
US20200061  
187  
US20200061  
185  
US20200060  
981  
US20200056  
221  
US20200056  
159  
US20200055  
927  
US20200055  
926  
US20200054  
731  
US20200054  
660  
US20200054  
259  
US20200048  
722  
US20200048  
649

US20200048

636

US20200046

865

US20200046

826

US20200046

692

US20200040

408

US20200040

042

20BISPECIFIC

ANTIBODY

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE  
ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING  
AND USING SAME

METHODS FOR PREPARING SQUALENE

PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE

CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS  
CAPACITY OF LIVE VIRUSES

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING  
ADSORPTION MEDIA

NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND  
USES THEREFOR

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA  
AND VIRAL INFECTION

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA  
AND VIRAL INFECTION

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE  
THEREOF

DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY  
HIGH DENSITY ANALOG MULTIPLEXING

METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION  
AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN  
NUCLEIC ACIDS

VIRUS-LIKE PARTICLES AND USES THEREOF

Not Available

Hangzhou DAC Biotech Co., Ltd.

Not Available

Not Available

The Scripps Research Institute

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

St. Jude Children's Research Hospital

EnLiSense, LLC

Not Available

Not Available

IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA GLAXOSMITHKLINE BIOLOGICALS  
SA

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION

METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS

SPECIFIC AKT3 INHIBITOR AND USES THEREOF

HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION

CHIMERIC MOLECULES AND USES THEREOF

US20200038

871

DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS

US20200038

373

US20200033

343

US20200032

255

US20200031

871

US20200031

819

US20200030

441

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES

NOVEL DEPSIPEPTIDES AND USES THEREOF

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

Lipidated Immune Response Modifier Compound Compositions, Formulations, and Methods

Fauci/COVID-19 Dossier

Not Available

Academia Sinica

Not Available

Not Available

Not Available

Nov13

6Apr17

17Nov16

12May10

25Oct16

9Dec16

8Nov13

28Feb17

8Sep16

8Sep16

7Jan14

9Dec16

17Aug18

8May15  
13Mar17  
6-Jul10  
29Dec17  
27Mar09  
15Jan16  
8Feb16  
30Mar17  
29Not  
Available  
Mar17  
9Not  
Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
May12  
6Oct08  
26Jan07  
4Apr17  
23Apr15  
17Aug10  
CC-BY-NC-SA  
Dr. David E. Martin  
8Apr  
-19  
6Apr  
-17  
17Nov  
-17  
4Nov  
-19  
25Oct  
-17  
11Dec  
-17  
25Oct  
-19  
27Feb  
-18  
25Oct  
-19  
25Oct  
-19  
15Jul19  
7Dec  
-17  
16Aug  
-19  
24Aug  
-19  
13Mar



-20  
13Feb  
-20  
13Feb  
-20  
13Feb  
-20  
13Feb  
-20  
6Feb  
-20  
6Feb  
-20  
6Feb  
-20  
6Feb  
-20  
30Jan20  
30Jan20  
30Jan20  
30Jan20  
30Jan20  
US20200030  
432  
US20200030  
422  
US20200024  
616  
US20200024  
310  
US20200020  
420  
US20200017  
926  
US20200017  
832  
US20200017  
588  
US20200017  
554  
US20200017  
514  
US20200017  
455  
US20200016  
589  
US20200016  
286  
US20200016  
280  
US20200016  
161

US20200010  
883  
US20200010  
519  
US20200009  
244  
US20200002  
674  
US20200000  
931  
US20190391  
150  
US20190390  
249  
US20190390  
229  
US20190390  
179  
US20190390  
176  
US20190389  
816  
US20190388  
473  
US20190382  
799  
17ZOO NOTIC  
DISEASE RNA VACCINES  
COMBINATION OF VACCINATION AND OX40 AGONISTS  
NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH  
ENHANCED HUMAN PANCREATIC TROPISM  
NOVEL DEPSIPEPTIDE AND USES THEREOF  
Method for Establishing Machine Learning Model for Predicting  
Toxicity of siRNA to Certain Type of Cells and Application Thereof  
CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN  
MICROBIOME AND COMPONENTS THEREOF  
COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC  
CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES  
THEREOF  
MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM  
SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIXHELIX  
BUNDLE PROTEINS  
ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS  
INFECTION  
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4OXAZEPANE-2-CARBOXAMIDES  
AS DIPEPTIDYL PEPTIDASE 1  
INHIBITORS  
LOADING VIALS  
Production of Immune-Response-Stimulating Aerosols By NonThermal  
Plasma Treatment Of Airborne Pathogens  
Compositions For Enhancing Transport Of Molecules Into Cells  
METHODS FOR TREATING VIRAL DISORDERS  
METHODS AND COMPOSITIONS FOR ENRICHMENT OF  
AMPLIFICATION PRODUCTS



NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY  
HOMOLOGY-DIRECTED TRANSGENE INTEGRATION  
NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL  
COMPONENTS

ModernaTX, Inc.

CureVac AG

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

TRUSTEES OF BOSTON UNIVERSITY

Not Available

Not Available

Not Available

ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE Not Available

SYNTHETIC NANOPARTICLES FOR DELIVERY OF

IMMUNOMODULATORY COMPOUNDS

COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES

Not Available

Not Available

BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM Longhorn Vaccines and  
Diagnostics, LLC

GENE EDITING REAGENTS WITH REDUCED TOXICITY

SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH

ENHANCED HUMAN SKELETAL MUSCLE TROPISM

ANTIVIRAL COMPOUNDS AND METHODS

METHODS AND COMPOSITIONS FOR IMMUNOMODULATION

VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS

Not Available

Not Available

Not Available

Biotron Limited

Not Available

Not Available

Mar17

9Sep16

30Mar18

3Dec12

8Dec16

7Nov13

5Apr17

14Oct16

23Mar17

12Jul-18

24Jan14

10Nov11  
13Jul-18  
29Apr03  
24Sep09  
9Oct15  
10Mar17  
13Jun18  
18Nov13  
15Jul-16  
1May15  
10Oct07  
21Apr16  
12Apr16  
2Dec15  
26Jun03  
1Apr14  
27Oct16  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
16Mar  
-18  
15Apr  
-19  
29Mar  
-19  
1Aug  
-19  
7Dec  
-17  
28Aug  
-19  
5Apr  
-18  
16Oct  
-17  
22Mar  
-18  
12Jul18  
19Mar  
-19  
24Sep  
-19  
12Jul19  
9Apr  
-19  
22Jul19  
7Jun  
-19  
9Mar  
-18  
13Jun  
-19  
16Sep



-19

US20190382

433

US20190381

180

US20190381

162

US20190381

155

US20190380

995

US20190380

891

US20190376

151

US20190376

034

US20190375

801

US20190374

650

US20190374

610

US20190374

576

US20190370

834

US20190367

553

US20190367

525

US20190367

453

US20190365

925

US20190365

756

US20190359

990

US20190359

635

US20190359

629

US20190358

335

US20190358

312

GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF

FOR USE IN THERAPY

HYBRID CARRIERS FOR NUCLEIC ACID CARGO

PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF  
MAKING

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1  
PATHWAY

PREVENTION AND TREATMENT OF VIRAL INFECTIONS  
MOBILE CLINICS  
MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS  
AND USE THEREOF FOR DETECTING NUCLEIC ACIDS  
PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES  
THEREOF  
HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR  
TREATMENT OF INFECTIOUS DISEASE  
COMPOSITIONS AND METHODS FOR DELIVERY OF  
POLYMER/BIOMACROMOLECULE CONJUGATES  
MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF  
FIBROSIS  
VIRAL METHODS OF T CELL THERAPY  
SYSTEM FOR DETERMINING PUBLIC SENTIMENT TOWARDS  
PATHOGENS  
COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE  
RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1  
PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC  
PROTEASE 7 INHIBITORS  
CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC  
AGENTS  
AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM  
PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS  
4THE  
UNIVERSITY OF NOTTINGHAM  
Not Available  
Not Available  
CureVac AG  
Not Available  
Baylor College of Medicine  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
HANGZHOU DAC BIOTECH CO., LTD.  
Not Available  
Not Available  
VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF Not Available  
ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND  
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7  
INHIBITORS  
THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7  
INHIBITORS  
STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER  
CONJUGATES  
Not Available  
Not Available  
Not Available  
ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USE Not Available

US20190358

304

ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)  
OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS  
ATTENUATES PULMONARY HYPERTENSION, CARDIAC  
DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND  
EXPERIMENTALLY INDUCED OCULAR DISORDERS

US20190358

170

US20190352

639

US20190352

615

Lipids and Lipid Compositions for the Delivery of Active Agents  
GENOME EDITING REAGENTS AND THEIR USE  
METHOD FOR PURIFYING VIRUS

Apr14

9Jun16

28Mar16

22Feb13

2Jun16

12Nov14

4Apr12

18Nov13

9Sep16

22Feb17

20Dec16

27Oct16

1Jun18

27Oct17

30Dec14

12Jul-12

21Nov14

4Jun18

25Jan17

5Feb15

5Feb15

12Jan17

19Dec17

18Not

Available

Oct13

19Not

Available

Not Available

Not Available

Dec13

10Feb17

22Dec16

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

25Jul19

9Jun

-17  
27Mar  
-17  
29Aug  
-19  
3Jul19  
28Aug  
-19  
8Feb  
-19  
23Aug  
-19  
8Sep  
-17  
21Feb  
-18  
20Dec  
-17  
19Apr  
-19  
1Jun  
-18  
26Apr  
-19  
19Jul19  
13Aug  
-19  
13Jun  
-19  
3Jun  
-19  
25Jan  
-18  
18Jul19  
18Jul19  
12Jan  
-18  
19Dec  
-18  
29May  
-19  
12Aug  
-19  
12Feb  
-18  
21Dec  
-17  
74  
19Dec  
-19  
19Dec  
-19  
19Dec  
-19

19Dec  
-19  
19Dec  
-19  
19Dec  
-19  
12Dec  
-19  
12Dec  
-19  
12Dec  
-19  
12Dec  
-19  
12Dec  
-19  
12Dec  
-19  
5Dec  
-19  
5Dec  
-19  
5Dec  
-19  
5Dec  
-19  
5Dec  
-19  
5Dec  
-19  
28Nov  
-19  
28Nov  
-19  
28Nov  
-19  
28Nov  
-19  
28Nov  
-19  
28Nov  
-19  
28Nov  
-19  
21Nov  
-19  
21Nov  
-19  
US20190352  
608  
US20190352  
357  
US20190346  
443



US20190345  
504  
US20190345  
503  
US20190345  
481  
US20190345  
221  
US20190345  
166  
US20190343  
862  
US20190337  
990  
US20190336  
969  
US20190336  
611  
US20190336  
608  
US20190336  
597  
US20190336  
456  
US20190330  
618  
US20190330  
572  
US20190330  
245  
US20190330  
187  
US20190330  
164  
US20190330  
149  
US20190328  
869  
US20190328  
865  
US20190328  
804  
US20190323  
068  
US20190322  
989  
US20190322  
725  
US20190321  
481  
US20190321  
403

CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING  
LYMPHOCYTE SELECTION

16Not

Available

HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT  
PROTEIN-PROTEIN INTERACTIONS

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS  
INFECTIONS AND DISEASES

ARTIFICIAL NUCLEIC ACID MOLECULES

CIRCULAR RNAs AND THEIR USE IN IMMUNOMODULATION

PURIFICATION OF NUCLEIC ACIDS USING METAL-TITANIUM  
OXIDES

BROAD SPECTRUM VACCINE, PREPARING METHOD AND  
APPLICATION THEREOF

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7  
AGONISTS

DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS

POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC  
PROTEINS AND THEIR USE IN GENE THERAPY

PARALLELIZED SAMPLE HANDLING

HYBRID CARRIERS FOR NUCLEIC ACID CARGO

CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY

METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE  
RESPONSES

USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL  
INFECTIONS

ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF  
LARGE LIBRARIES

Colorado State University Research Foundation

Not Available

CureVac AG

Not Available

Not Available

Tianjin Dongya Biological Technology Co., Ltd.

Not Available

GLAXOSMITHKLINE BIOLOGICALS, SA

Not Available

Not Available

CureVac AG

CureVac AG

Not Available

ABIOGEN PHARMA S.P.A.

Not Available

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available

Boron-Containing Small Molecules

Chemical Compounds

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND  
USES THEREOF

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC  
AGENTS

IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR

COMBINATION THERAPY

IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS  
INFECTION

AAV Vectors Targeted to Oligodendrocytes

PCR Ready Compositions and Methods for Screening Biological

Samples

PRODUCTION OF VIRUSES IN CELL CULTURE  
COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY  
CONSTRUCTS AND USES THEREOF  
IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING  
THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS  
ENGINEERED B CELLS AND RELATED COMPOSITIONS AND  
METHODS

Anacor Pharmaceuticals, Inc.

Not Available

Not Available

HANGZHOU DAC BIOTECH CO., LTD.

Transgene SA

Not Available

Not Available

Longhorn Vaccines and Diagnostics, LLC

Not Available

Not Available

NantBio, Inc.

Juno Therapeutics, Inc.

Sep13

7Nov14

6Oct08

30Dec14

20Jun16

14Jul-15

9May18

1May14

6-Jul10

13Feb15

19Apr13

9Jun16

9Jun16

8Jan13

15Jul-16

1Dec05

8Sep16

16Feb05

18Mar14

29Jul-11

12Jul-12

10Oct16

28Jul-14

28Sep12

12Sep06

24Nov15

13May14

11Nov16

2Dec16

30Jan

-19

7Aug

-19

28Jun

-19  
26Jul19  
15Jun  
-17  
5Jul19  
9May  
-18  
24Jul19  
16Jul19  
5Jun  
-19  
27Mar  
-19  
9Jun  
-17  
9Jun  
-17  
17May  
-19  
13Jul17  
22Jan  
-19  
21Jun  
-19  
12Jul19  
10May  
-19  
28Nov  
-18  
9May  
-19  
10Oct  
-17  
17Nov  
-17  
15Jul19  
28Jun  
-19  
25Jan  
-19  
2Jul19  
9Nov  
-17  
30Nov  
-17  
21Nov  
-19  
21Nov  
-19  
14Nov  
-19  
14Nov  
-19  
14Nov

-19  
14Nov  
-19  
14Nov  
-19  
14Nov  
-19  
14Nov  
-19  
7Nov  
-19  
7Nov  
-19  
7Nov  
-19  
7Nov  
-19  
7Nov  
-19  
7Nov  
-19  
31Oct19  
31Oct19  
31Oct19  
31Oct19  
31Oct19  
31Oct19  
31Oct19  
31Oct19  
31Oct19  
31Oct19  
31Oct19  
24Oct19  
24Oct19  
24Oct19  
24Oct19  
24Oct19  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
75  
US20190316  
109  
US20190316  
091  
US20190316  
090  
US20190316  
089  
US20190315  
840  
US20190315  
807  
US20190314  
496  
US20190314

483  
US20190314  
482  
US20190314  
480  
US20190314  
471  
US20190314  
455  
US20190314  
372  
US20190310  
168  
US20190309  
357  
US20190309  
262  
US20190309  
261  
US20190309  
048  
US20190309  
039  
US20190308  
980  
US20190308  
969  
US20190308  
943  
US20190307  
878  
US20190307  
722  
US20190298  
824  
US20190298  
752  
US20190298  
750  
US20190293  
656  
US20190292  
580

COMPOSITION COMPRISING A GENE VECTOR THAT SELECTIVELY  
DEPLETES P16 POSITIVE SENESCENT CELLS  
ERYTHROID CELLS COMPRISING ARGINASE  
ERYTHROID CELLS COMPRISING ARGININE DEIMINASE  
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES  
ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING  
VARIANT FC REGIONS, AND METHODS OF USE  
VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR  
INDUCING THE EXPRESSION OF ANTIBODIES  
POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN  
IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT

Vaccines Including Antigen From Four Strains of Influenza Virus  
VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE  
STRANDED RNA VIRUSES  
IMMUNOGENIC COMPOSITIONS AND USES THEREOF  
MOLECULAR VACCINES FOR INFECTIOUS DISEASE  
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE  
AND INFECTIOUS DISEASES  
PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS  
AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND  
DEVICES FOR MONITORING AIRBORNE AGENTS  
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS  
ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE  
ERYTHROID CELLS COMPRISING LYSINE OXIDASE  
Optimized Human Clotting Factor VIII Gene Expression Cassettes  
and Their Use  
CRYPTIC POLYPEPTIDES AND USES THEREOF  
PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS  
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS  
3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)  
PYRAZINE-2- CARBOXAMIDE COMPOUNDS  
IMMUNE COMPLEX  
ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS  
LINKED TO CORONAVIRUSES  
ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND  
METHODS OF USE THEREOF  
METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE  
(ADPR)  
Nucleotide and Nucleoside Therapeutic Compositions and Uses  
Related Thereto  
NON-RADIOACTIVE CYTOTOXICITY ASSAYS  
DNA LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR  
BIOCHEMICAL SENSING  
17Not  
Available  
Not Available  
RUBIUS THERAPEUTICS, INC.  
Not Available  
Not Available  
Not Available  
CureVac AG  
Not Available  
Medigen, Inc.  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
MASSACHUSETTS INSTITUTE OF TECHNOLOGY  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available

Not Available  
Parion Sciences, Inc.  
The Rockefeller University  
Not Available  
THE UNITED STATES OF AMERICA, as represented by the  
Secretary, Department of Health and Human Serv  
Invirsa, Inc.  
Not Available  
Not Available  
Rutgers, The State University of New Jersey  
Apr12  
18Nov13  
18Nov13  
18Nov13  
16Sep16  
27Jul-16  
1Apr14  
6Dec06  
28Nov16  
25Mar15  
20Oct08  
3Aug17  
5Dec16  
22Jul-14  
9Dec16  
18Nov13  
18Nov13  
6Feb15  
29Jan15  
30Dec14  
11Nov16  
17Dec12  
20Mar15  
21Oct16  
4May16  
27Mar18  
11Sep13  
19Sep16  
23Mar18  
Fauci/COVID-19  
Dossier  
10Jun  
-19  
30May  
-19  
30May  
-19  
10May  
-19  
10Jun  
-19  
26Jul17  
18Jun  
-19



30Nov  
-18

21Nov  
-17

23Apr  
-19

27Jun  
-19

7Jun  
-19

25Mar  
-19

4Mar  
-19

25Feb  
-19

4Jun  
-19

4Jun  
-19

20May  
-19

22Apr  
-19

24Jun  
-19

13Nov  
-17

13Mar  
-19

10May  
-19

20Oct  
-17

4May  
-17

26Mar  
-19

21Nov  
-18

19Sep  
-17

22Mar  
-19

CC-BY-NC-SA

Dr. David E. Martin

76

17Oct19

17Oct19

17Oct19

17Oct19

17Oct19

17Oct19

17Oct19

17Oct19  
17Oct19  
17Oct19  
17Oct19  
17Oct19  
17Oct19  
10Oct19  
10Oct19  
10Oct19  
10Oct19  
10Oct19  
10Oct19  
10Oct19  
10Oct19  
10Oct19  
10Oct19  
10Oct19  
30Oct19  
30Oct19  
30Oct19  
26Sep  
-19  
26Sep  
-19  
    US20190292  
563  
US20190292  
561  
US20190292  
236  
US20190292  
216  
US20190292  
178  
US20190290  
674  
US20190285  
632  
US20190284  
575  
US20190284  
531  
US20190284  
230  
US20190282  
694  
US20190282  
608  
US20190276  
523  
US20190275  
519  
US20190275  
101

US20190269  
694  
US20190269  
672  
US20190264  
267  
US20190264  
177  
US20190263  
934  
US20190262  
448  
US20190262  
371  
US20190256  
585  
US20190256  
579  
US20190255  
085  
US20190254  
968  
US20190250  
153  
US20190248  
883  
US20190248  
866  
ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,  
VECTORS CONTAINING SAME, AND USES THEREFOR  
17The  
Trustees of the University of Pennsylvania  
SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENOASSOCIATED  
VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION  
CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE  
MODULATION OF IFI16 AND STING ACTIVITY  
Cyclic Di-Nucleotide Induction of Type I Interferon  
HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER  
VIRUSES  
Dec01  
1SPARK  
THERAPEUTICS, INC.  
Dec15  
9Not  
Available  
Not Available  
Dana-Farber Cancer Institute, Inc.  
Composition for Promoting Production of Immunostimulatory Factor Kyoto  
University  
METABALOMICS AND VIRAL DIAGNOSTICS SUITE  
Excision Biotherapeutics, Inc.  
REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS Not Available  
DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL  
COSTIMULATION AND USES THEREOF

ASSEMBLED GLYCOPROTEINS

IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS

Method Of Treating Inflammation

Not Available

Not Available

AUTOIMMUNE TECHNOLOGIES, LLC

Not Available

COMPOSITION AND METHODS OF TREATING B CELL DISORDERS Not Available

SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS Not Available

STRUCTURE OF GII.4 NOROVIRUS PROTEASE - DESIGN OF BROADSPECTRUM

PROTEASE INHIBITORS

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

Specific Akt3 Inhibitor and Uses Thereof

PHASING

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

FC VARIANTS WITH ENHANCED BINDING TO FCRN AND

PROLONGED HALF-LIFE

Cationic Oil-In-Water Emulsions

METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL

INFECTIONS

ANTIBODY SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE

DERIVED FROM VIMENTIN OR A FRAGMENT BINDING TO THE

PEPTIDE

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS

IMMUNOGENS, ANTIBODIES, AND THEIR USE

METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE

VIRUS INFECTIONS

OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS

MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING

SAME

Not Available

Not Available

Not Available

Wave Life Sciences Ltd.

Not Available

Not Available

GLAXOSMITHKLINE BIOLOGICALS, SA

Not Available

Not Available

The U.S.A., as represented by the Secretary, Department of Health and Human Services

Not Available

GLAXOSMITHKLINE BIOLOGICALS S.A.

Board of Regents, The University of Texas System

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available

POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF

AUTOIMMUNE DISORDERS AND INFECTION

Fauci/COVID-19 Dossier

Not Available

CC-BY-NC-SA Dr. David E. Martin

Aug16

3May13

11Apr12

2Aug16  
24May16  
21May09  
15May15  
29Sep16  
14Mar13  
1Apr10  
2Sep16  
8Nov16  
5Oct16  
8Mar11  
15Jan16  
25Jul-16  
18Nov13  
26Jan18  
18Sep11  
20Oct16  
10Jun15  
24Feb15  
16Sep15  
6-Jul11  
20Oct16  
16Dec02  
30Jun11  
8Apr  
-19  
1Dec  
-16  
9Aug  
-17  
19Feb  
-19  
26Jan  
-18  
31Jul17  
24May  
-17  
30Jan  
-19  
24May  
-19  
22Sep  
-17  
30May  
-19  
29May  
-19  
5Sep  
-17  
8Nov  
-17  
5Oct  
-17  
11Oct

-18  
20May  
-19  
24Jul17  
10May  
-19  
25Jan  
-19  
7Mar  
-19  
20Oct  
-17  
10Jun  
-16  
3May  
-19  
1Feb  
-19  
2May  
-19  
19Oct  
-17  
20Feb  
-19  
30Apr  
-18  
77  
26Sep  
-19  
26Sep  
-19  
26Sep  
-19  
26Sep  
-19  
26Sep  
-19  
26Sep  
-19  
19Sep  
-19  
19Sep  
-19  
19Sep  
-19  
19Sep  
-19  
19Sep  
-19  
12Sep  
-19  
12Sep

-19  
12Sep  
-19  
5Sep  
-19  
5Sep  
-19  
29Aug  
-19  
29Aug  
-19  
29Aug  
-19  
29Aug  
-19  
29Aug  
-19  
22Aug  
-19  
22Aug  
-19  
22Aug  
-19  
22Aug  
-19  
15Aug  
-19  
15Aug  
-19  
15Aug  
-19  
US20190248  
865  
US20190247  
529  
US20190247  
489  
US20190247  
485  
US20190247  
440  
US20190247  
367  
US20190241  
646  
US20190241  
618  
US20190240  
317  
US20190233  
447  
US20190232  
282  
US20190231

004

US20190225

986

US20190225

971

US20190224

339

US20190223

445

US20190220

524

US20190219

563

US20190218

574

US20190218

277

US20190218

207

US20190216

951

US20190216

917

US20190216

915

US20190216

841

US20190211

361

US20190211

355

US20190211

024

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF

METHOD AND SYSTEM FOR DECONTAMINATING SMALL ENCLOSURES

ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING

Dimethyl Fumarate and Vaccination Regimens

METHODS AND COMPOSITIONS FOR IMMUNOMODULATION

TREATMENT OF INFECTIOUS DISEASES

ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION

INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS

HPIV3 RNA VACCINES

PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED HAPTENS

METHODS AND COMPOSITIONS FOR DETECTING ANALYTES

MASK

GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING

LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA

VIRUS SPIKE PROTEIN

METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA



MOLECULE  
COMPOSITIONS FOR THE TREATMENT OF DISEASE  
ANTIMICROBIAL GEOPOLYMER COMPOSITIONS  
DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN  
KNOWLEDGE GRAPHS  
Assay for Detecting TH1 and TH2 Cell Populations  
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR  
ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING  
VARIANT FC REGIONS, AND METHODS OF USE  
3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide  
Derivatives and Their Use as PAK or NAMPT Modulators  
METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED  
PROTEINS  
HMPV RNA VACCINES  
TRANSGENIC VERO-CD4/CCR5 CELL LINE  
Regimens and Compositions for AAV-Mediated Passive  
Immunization of Airborne Pathogens  
COMPOSITIONS COMPRISING CURONS AND USES THEREOF  
DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING  
AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND  
USES THERE OF  
SMALL MOLECULES HAVING ANTIVIRAL PROPERTIES  
23Not  
Available  
Not Available  
Not Available  
Biogen MA Inc.  
Not Available  
CHILDREN'S MEDICAL CENTER CORPORATION  
Not Available  
Not Available  
ModernaTX, Inc.  
Not Available  
Not Available  
NBC MESHTEC INC.  
Oct15  
29Dec17  
20Oct11  
14Mar14  
1Apr14  
26Jan15  
15Mar17  
30Sep09  
22Oct15  
28Aug15  
23Sep16  
17Oct16  
28Not  
Available  
Oct05  
10Not  
Available  
Not Available  
Not Available

Not Available  
Not Available  
The Trustees of the University of Pennsylvania  
Not Available  
Not Available  
CureVac AG  
ModernaTX, Inc.  
Not Available  
Not Available  
Not Available  
Not Available  
General Research Laboratory  
Aug15  
29Apr16  
14Jul-16  
16Jan18  
16May14  
20Oct07  
16Sep16  
17Aug15  
21Aug13  
22Oct15  
20Oct15  
20Apr11  
13Jun17  
5Jan15  
19Aug16  
21Oct  
-16  
23Apr  
-19  
16Nov  
-18  
23Apr  
-19  
12Apr  
-19  
23Apr  
-19  
15Apr  
-19  
22Oct  
-18  
28Mar  
-19  
25Feb  
-19  
20Sep  
-17  
13Oct  
-17  
30Nov  
-18  
4Aug

-16  
28Apr  
-17  
13Jul17  
29Mar  
-18  
17Dec  
-18  
28Mar  
-19  
15Sep  
-17  
17Aug  
-16  
1Apr  
-19  
28Mar  
-19  
15Feb  
-19  
20Mar  
-19  
27Mar  
-19  
4Jan  
-16  
19Aug  
-17  
15Aug  
-19  
15Aug  
-19  
15Aug  
-19  
15Aug  
-19  
15Aug  
-19  
15Aug  
-19  
8Aug  
-19  
8Aug  
-19  
8Aug  
-19  
1Aug  
-19  
1Aug  
-19  
1Aug  
-19  
25Jul19  
25Jul19

25Jul19  
25Jul19  
18Jul19  
18Jul19  
18Jul19  
18Jul19  
18Jul19  
18Jul19  
18Jul19  
18Jul19  
18Jul19  
11Jul19  
11Jul19  
11Jul19  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
78  
    US20190209  
678  
US20190209  
604  
US20190207  
890  
US20190204  
330  
US20190203  
268  
US20190203  
186  
US20190203  
170  
US20190202  
929  
US20190202  
868  
US20190202  
854  
US20190201  
565  
US20190201  
564  
US20190201  
552  
US20190201  
433  
US20190201  
352  
US20190201  
337  
US20190194  
728  
US20190194  
717

US20190194  
628  
US20190194  
322  
US20190194  
299  
US20190194  
226  
US20190194  
150  
US20190192  
691  
US20190192  
581  
US20190187  
151  
US20190187  
130  
US20190185  
922  
MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS  
WITH ENHANCED STABILITY  
2Not  
Available  
OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD.  
RNA TARGETING METHODS AND COMPOSITIONS  
APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION  
IN IHC AND ISH ASSAYS  
LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) BASED  
ASSAY FOR DETECTING MICROBES  
PRODUCTION OF VIRUSES IN AVIAN EGGS  
Avian Cells for Improved Virus Production  
COMPOSITIONS AND METHODS FOR IDENTIFICATION,  
ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING  
USP10 BIOMARKERS AND MODULATORS  
CORONAVIRUS PROTEINS AND ANTIGENS  
ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A  
DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC  
CAVITATION  
DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC  
CAVITATION  
Aptamer Compositions and Methods of Use Thereof  
2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR  
RNA VIRUS TREATMENT  
DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER  
NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY  
HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE  
ADJUVANTS  
Salk Institute for Biological Studies  
Not Available  
Not Available  
Not Available  
Not Available  
Dec14

3Jun16  
22Aug17  
28Jun16  
2Jan18  
24Nov15  
5Jun13  
20Not  
Available  
Sep16  
7Phibro  
Animal Health Corporation  
Not Available  
Not Available  
Not Available  
Not Available  
Atea Pharmaceuticals, Inc.  
Not Available  
Not Available  
Systemic inflammatory and pathogen biomarkers and uses therefor Not Available  
METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISM JAPAN SCIENCE AND  
TECHNOLOGY AGENCY  
METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION  
IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE  
CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY  
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS  
NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF  
FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED  
WITH GUANIDINO GROUPS  
COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION  
REGULATED BIO-CIRCUIT SYSTEMS  
Methods of Populating a Gastrointestinal Tract  
ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING  
STABLE ISOTOPE STANDARDS  
COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTIDYE  
QUINONE METHIDE AND TYRAMIDE CONJUGATES  
LUMINO-PHORE-LABELED MOLECULES COUPLED WITH PARTICLES  
FOR MICROARRAY-BASED ASSAYS  
Takeda Pharmaceutical Company Limited  
BIO-TECHNE CORPORATION  
Not Available  
Not Available  
Arrakis Therapeutics, Inc.  
Not Available  
Not Available  
UVic Industry Partnerships Inc.  
Not Available  
CapitalBio Corporation  
Feb14  
4Aug14  
29Dec17  
29Dec17  
28Dec17  
7Sep16  
30Jan15

3Dec09  
24Aug16  
5Sep16  
1Sep16  
3Aug16  
25Apr14  
26Aug16  
1-Jul16  
11Apr16  
4Feb13  
6Jun16  
28Jun16  
5Dec13  
12Mar  
-19  
2Jun  
-17  
31Dec  
-18  
19Dec  
-18  
31Dec  
-18  
25Jan  
-19  
21Dec  
-18  
20Sep  
-17  
15Mar  
-19  
8Mar  
-19  
11Sep  
-18  
29Dec  
-17  
28Dec  
-18  
5Mar  
-19  
12Mar  
-19  
3Jan  
-19  
24Aug  
-17  
4Sep  
-17  
1Sep  
-17  
3Aug  
-17  
19Nov

-18  
1Aug  
-17  
30Jun  
-17  
11Apr  
-17  
1Aug  
-18  
7Apr  
-17  
19Dec  
-18  
20Nov  
-18  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
79  
11Jul19  
11Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
4Jul19  
27Jun19  
27Jun19  
27Jun19  
27Jun19  
27Jun19  
27Jun19  
27Jun19  
27Jun19  
27Jun19  
27Jun19  
20Jun19  
20Jun19  
20Jun19  
US20190185  
832  
US20190184  
067  
US20190184  
018  
US20190183



968  
US20190183  
918  
US20190177  
739  
US20190175  
716  
US20190175  
528  
US20190169  
677  
US20190169  
639  
US20190169  
595  
US20190167  
787  
US20190167  
786  
US20190167  
636  
US20190166  
866  
US20190160  
129  
US20190160  
063  
US20190154  
687  
US20190154  
550  
US20190153  
471  
US20190153  
086  
US20190151  
844  
US20190151  
474  
US20190144  
930  
US20190144  
929  
US20190144  
827  
US20190144  
556  
US20190144  
484

DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING  
CAS9 NUCLEASE AND USES THEREOF  
MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND  
APPLICATIONS  
CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR

OLIGONUCLEOTIDES

METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS  
SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES  
RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)  
PRODUCED IN TRANSGENIC PLANTS

Adenoviral Vector

INHIBITION OF BIOFILM ORGANISMS

PORTABLE MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR THE DETECTION OF TARGET VIRUSES

CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAs

RNA TARGETING METHODS AND COMPOSITIONS

Methods and Compositions for Inhibiting Akt3

EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX FROM A CRUSTACEAN CATCH

Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

DETECTION DEVICE AND DETECTION METHOD

BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE  
COMPOSITIONS FOR THE TREATMENT OF DISEASE

Heterodimeric Immunoglobulins

DEVICES AND METHODS FOR THE DETECTION OF MOLECULES USING A FLOW CELL

RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS, APTAMERS AND SMALL MOLECULES

ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES

ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE

THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

3Not

Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Click Diagnostics, Inc.

EDITAS MEDICINE, INC.

Salk Institute for Biological Studies

Not Available

Not Available

Jun16  
1Nov15  
4Dec07  
13Jan11  
12Jun13  
21Jan08  
23Jun16  
31Mar09  
9Nov17  
7Nov13  
22Aug17  
15Jan16  
4Nov05  
14Not  
Available  
Mar13  
4Not  
Available  
Not Available  
Not Available  
Kabushiki Kaisha Toshiba  
Not Available  
Not Available  
Not Available  
Click Diagnostics, Inc.  
Kyoto University  
Not Available  
Not Available  
RUBIUS THERAPEUTICS, INC.  
Not Available  
Not Available  
Dec17  
10Oct15  
31Dec15  
17Nov17  
6Apr16  
29Apr16  
21Nov12  
29Jun16  
8Sep14  
6Dec13  
15Mar17  
18Nov13  
13May16  
28Apr16  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
2Jun  
-17  
28Feb  
-19  
20Nov  
-18

27Feb  
-19  
29Oct  
-18  
13Dec  
-18  
23Jun  
-17  
13Feb  
-19  
9Nov  
-18  
24Jan  
-19  
25Jan  
-19  
6Feb  
-19  
9Jul18  
8Feb  
-19  
30Nov  
-18  
1Feb  
-19  
30Dec  
-16  
7Mar  
-18  
6Apr  
-17  
28Apr  
-17  
5Feb  
-19  
21Dec  
-18  
8Sep  
-15  
9Jan  
-19  
15Mar  
-18  
19Nov  
-18  
12May  
-17  
28Apr  
-17  
80  
20Jun19  
20Jun19  
20Jun19  
20Jun19

20Jun19  
13Jun19  
13Jun19  
13Jun19  
6Jun19  
6Jun19  
6Jun19  
6Jun19  
6Jun19  
6Jun19  
30May  
-19  
30May  
-19  
23May  
-19  
23May  
-19  
23May  
-19  
23May  
-19  
23May  
-19  
23May  
-19  
16May  
-19  
16May  
-19  
16May  
-19  
16May  
-19  
16May  
-19  
US20190142  
929  
US20190142  
927  
US20190136  
226  
US20190136  
215  
US20190135  
875  
US20190135  
873  
US20190135  
788  
US20190134  
214  
US20190134

193

US20190134

186

US20190134

062

US20190128

893

US20190128

810

US20190127

441

US20190127

405

US20190127

401

US20190127

400

US20190127

399

US20190125

858

US20190125

806

US20190125

724

US20190119

744

US20190119

743

US20190119

701

US20190119

266

US20190119

220

US20190117

793

US20190117

702

US20190112

596

US20190112

394

INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED  
STRAINS

LOW-ADDITIVE INFLUENZA VACCINES

DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION

10Not

Available

Not Available

Not Available

Replication Conditional Virus that Specifically Kills Senescent Cells Not  
Available

TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS

COMPOSITIONS AND METHODS FOR TREATING DISEASES BY  
INHIBITING EXOSOME RELEASE

Not Available

Not Available

DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc.  
GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and  
Uses Thereof

USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND  
TAM ACTIVATORS AS IMMUNOSUPPRESSORS

INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION  
ADJUVANT

PHARMACEUTICAL COMPOSITIONS AND METHODS  
QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION  
SYSTEM FOR MEASURING OPTICAL SIGNAL DETECTOR  
PERFORMANCE

Not Available

SALK INSTITUTE FOR BIOLOGICAL STUDIES

Not Available

Not Available

Not Available

Not Available

METHODS AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITY University of Vermont  
and State Agricultural College

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION  
CHARGED LINKERS AND THEIR USES FOR CONJUGATION  
CHARGED LINKERS AND THEIR USES FOR CONJUGATION  
CHARGED LINKERS AND THEIR USES FOR CONJUGATION

COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE  
ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY

Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral  
Member, and Method for Producing Antimicrobial and Antiviral Agent

PREVENTION AND TREATMENT OF VIRAL INFECTIONS

CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID  
SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE  
VARIANTS

METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND  
COMPOSITIONS THEREOF

COMPOSITIONS AND METHODS FOR INHIBITING KINASES  
CARBOXYLIC ACID COMPOUNDS

MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES

USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS  
TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES,  
KITS AND ASSAYS

USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR  
PROTEIN LIGATION

Fauci/COVID-19 Dossier

Not Available

HANGZHOU DAC BIOTECH CO., LTD.

HANGZHOU DAC BIOTECH CO., LTD.

HANGZHOU DAC BIOTECH CO., LTD.

Not Available

Murata Manufacturing Co., Ltd.

Not Available

Not Available  
Not Available  
Not Available  
Not Available  
Sumitomo Dainippon Pharma Co., Ltd.  
Not Available  
Indiana University Research and Technology Corporation  
Not Available  
Whitehead Institute for Biomedical Research  
CC-BY-NC-SA Dr. David E. Martin  
Feb09  
27Jun07  
11May16  
17Apr12  
18May16  
19Dec16  
12Jun16  
6May16  
9Nov07  
4Nov05  
3Aug15  
24Feb14  
31Dec15  
13Apr16  
24Feb14  
12Aug16  
12Aug16  
12Aug16  
18Apr16  
13Jun16  
2Jun16  
31Jul-09  
15Aug16  
8Sep17  
23Apr15  
18May12  
15Feb07  
6May14  
4Apr12  
28Jun11  
15Oct  
-18  
26Jun  
-18  
9Nov  
-18  
6Jul18  
17May  
-17  
19Dec  
-18  
7Dec  
-18  
4May



-17  
9Aug  
-18  
10Jul18  
8Jan  
-19  
7Nov  
-18  
13Dec  
-18  
13Apr  
-17  
7Nov  
-18  
20Dec  
-18  
20Dec  
-18  
20Dec  
-18  
18Apr  
-17  
13Dec  
-18  
27Nov  
-18  
5Nov  
-18  
26Oct  
-18  
7Sep  
-18  
24Oct  
-18  
23Oct  
-18  
10Oct  
-18  
31Oct  
-18  
12Apr  
-18  
24Sep  
-18  
81  
16May  
-19  
16May  
-19  
9May  
-19  
9May  
-19  
9May

-19  
9May  
-19  
9May  
-19  
9May  
-19  
9May  
-19  
9May  
-19  
9May  
-19  
2May  
-19  
2May  
-19  
2May  
-19  
2May  
-19  
2May  
-19  
2May  
-19  
2May  
-19  
2May  
-19  
25Apr19  
25Apr19  
25Apr19  
25Apr19  
25Apr19  
25Apr19  
25Apr19  
18Apr19  
18Apr19  
US20190111  
141  
US20190105  
653  
US20190105  
381  
US20190105  
334  
US20190100  
586  
US20190099  
493

US20190099  
479  
US20190094  
224  
US20190091  
329  
US20190091  
221  
US20190085  
057  
US20190085  
024  
US20190085  
013  
US20190084  
943  
US20190083  
602  
US20190083  
592  
US20190083  
569  
US20190083  
525  
US20190083  
520  
US20190083  
408  
US20190083  
397  
US20190078  
060  
US20190078  
051  
US20190077  
847  
US20190077  
764  
US20190077  
763  
US20190076  
520  
US20190076  
468  
6A

PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE  
PORTABLE PATHOGEN ANALYSIS SYSTEM FOR DETECTING  
WATERBORNE PATHOGENS  
METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC  
DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING  
CANCER

Anti-Viral Azide Containing Compounds

Humanized Anti-Claudin-1 Antibodies and Uses Thereof  
Targeting Lipids

Ewha University - Industry Collaboration Foundation

Not Available

Not Available

Not Available

Chu Strasbourg, Les Hôpitaux Universitaires de  
Strasbourg

Arbutus Biopharma Corporation

RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF Not Available

METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL

RECEPTOR AFFINITY AND SEQUENCE

CATIONIC OIL-IN-WATER EMULSIONS

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY INDUCED  
CONDITIONS

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA  
AND VIRAL INFECTION

Alpha-Ketoamide Inhibitors Of Cysteine Proteases

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND

USES RELATED THERETO

CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL  
SODIUM CHANNEL BLOCKING ACTIVITY

METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS

IMMUNOSTIMULATORY COMBINATIONS

MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF  
VIRAL INFECTIONS

COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR

AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS

N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related  
Thereto

CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES  
THEREOF

OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACID

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH  
INFLUENZA VACCINES

Animal Protein-Free Media for Cultivation of Cells

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE

PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME  
FOR THE TREATMENT OF VIRAL DISEASES

BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY  
AMIDE FUNCTION

BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY  
AMIDE FUNCTION

VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND  
COMPOSITIONS AND METHODS OF USING

ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC  
OXIDE

Not Available

GLAXOSMITHKLINE BIOLOGICALS, SA

TRUSTEES OF BOSTON UNIVERSITY

Not Available

Not Available

Not Available

Parion Sciences, Inc.

Not Available

Not Available

Not Available  
Not Available  
Not Available  
Not Available  
NOVARTIS AG  
Novartis AG  
Baxalta GmbH  
Apr16  
5Oct17  
16Mar16  
28Jul-10  
22Mar16  
4Dec07  
14May10  
11Apr16  
6-Jul11  
11Mar10  
8Sep16  
15Sep17  
7Mar16  
17Dec12  
22Dec15  
30Dec02  
11Jun15  
11Jul-17  
10Mar16  
2Dec11  
23Dec15  
9Sep04  
29Oct04  
5Ablynx  
N.V.  
Jun08  
23Hoffmann-La  
Roche Inc.  
Hoffmann-La Roche Inc.  
Not Available  
Not Available  
May16  
23May16  
4Apr08  
11Sep17  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
6Apr  
-17  
5Oct  
-18  
16Mar  
-16  
3Dec  
-18  
21Mar

-17  
10Oct  
-17  
27Apr  
-18  
6Apr  
-17  
6Dec  
-18  
23Apr  
-18  
15Nov  
-18  
17Sep  
-18  
7Mar  
-17  
23Aug  
-18  
22Dec  
-16  
22Oct  
-18  
24Jul18  
10Jul18  
10Mar  
-17  
4Dec  
-18  
21Dec  
-16  
8Nov  
-18  
29Oct  
-18  
17Oct  
-17  
13Nov  
-18  
13Nov  
-18  
11Sep  
-18  
11Sep  
-17  
82  
18Apr19  
11Apr19  
11Apr19  
11Apr19  
4Apr19  
4Apr19  
4Apr19  
28Mar

-19  
28Mar  
-19  
28Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
21Mar  
-19  
14Mar  
-19  
14Mar  
-19  
14Mar  
-19  
14Mar  
-19  
14Mar  
-19  
14Mar  
-19  
14Mar  
-19  
14Mar  
-19  
14Mar  
-19  
US20190071  
423  
US20190071  
422  
US20190071  
421  
US20190071  
420  
US20190071  
419  
US20190071  
418  
US20190062

785

US20190062

724

US20190062

713

US20190062

408

US20190062

380

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS

MULTIVALENT VACCINES FOR RABIES VIRUS AND  
CORONAVIRUSES

RNA TARGETING METHODS AND COMPOSITIONS

HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS

CONSERVED HEMAGGLUTININ EPI TOPE, ANTIBODIES TO THE  
EPI TOPE, AND METHODS OF USE

FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE,  
NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND  
USE THEREOF

US20190062

326

US20190062

323

US20190060

435

US20190060

364

US20190060

363

US20190060

262

US20190060

239

US20190056

122

US20190055

256

US20190055

241

US20190055

234

US20190054

188



US20190054

127

US20190054

122

US20190049

378

US20190048

344

US20190048

082

2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE  
DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS,  
FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS

PI-Kinase Inhibitors with Anti-Infective Activity

PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR  
INDUCING AN IMMUNE RESPONSE

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF  
THERAPY

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF  
THERAPY

ENHANCED EXPRESSION OF RNA VECTORS

Technology for the Preparation of Microparticles

Clean Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and  
Methods of Use Thereof

ANTI-VIRAL DRUG

GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS  
CONTAINING SAME, AND USES THEREFOR

ANTIVIRAL AGENT AND ANTIVIRAL FOOD

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF  
THERAPY

CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC  
ACID AMPLIFICATION ASSAYS

CHEMICAL MODIFICATIONS OF MONOMERS AND

OLIGONUCLEOTIDES WITH CYCLOADDITION

PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC  
POLYPEPTIDES

Fauci/COVID-19 Dossier

5Not

Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Salk Institute for Biological Studies

Not Available

Not Available

Not Available

Feb15

5Feb15

5Feb15

5Feb15  
5Feb15  
5Feb15  
4Apr16  
22Aug17  
11Jul-03  
25Aug08  
7Sep12  
10BAYER  
PHARMA AKTIENGESELLSCHAFT  
Dec15  
26Not  
Available  
The United States of America, as represented by the  
Secretary, Dept of Health and Human Service  
Not Available  
Not Available  
UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH  
Not Available  
Synexis LLC  
DORING INTERNATIONAL GMBH  
Not Available  
Not Available  
Not Available  
EDUCATIONAL CORPORATION MUKOGAWA GAKUIN  
Not Available  
Not Available  
Not Available  
Not Available  
CC-BY-NC-SA Dr. David E. Martin  
Feb16  
27Feb16  
31Jul-15  
31Jul-15  
25Mar13  
24Jul-07  
20Apr15  
24Feb16  
31Aug15  
23Apr15  
30Sep03  
4Mar16  
31Jul-15  
10Mar05  
23Sep08  
30Jun16  
2Nov  
-18  
2Nov  
-18  
2Nov  
-18  
2Nov  
-18

2Nov  
-18  
2Nov  
-18  
31Mar  
-17  
27Mar  
-18  
22Mar  
-18  
20Jun  
-18  
28Aug  
-18  
7Dec  
-16  
24Feb  
-17  
27Feb  
-17  
6Nov  
-18  
6Nov  
-18  
5Sep  
-18  
17Oct  
-18  
20Apr  
-16  
24Feb  
-17  
22Oct  
-18  
24Oct  
-18  
20Oct  
-18  
22Nov  
-16  
5Nov  
-18  
21Jun  
-18  
16Aug  
-18  
25Oct  
-18  
83  
7Mar  
-19  
7Mar  
-19  
7Mar

-19  
7Mar  
-19  
7Mar  
-19  
7Mar  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
28Feb  
-19  
21Feb  
-19  
21Feb  
-19  
21Feb  
-19  
21Feb  
-19  
21Feb  
-19  
21Feb  
-19  
21Feb  
-19  
21Feb  
-19  
14Feb  
-19  
14Feb  
-19  
14Feb  
-19  
US20190048  
049  
US20190048

026  
US20190046  
690  
US20190046  
654  
US20190046  
635  
US20190040  
451  
US20190040  
378  
US20190040  
370  
US20190040  
105  
US20190038  
742  
US20190032  
077  
US20190032  
041  
US20190031  
740  
US20190031  
679  
US20190031  
605  
US20190030  
187  
US20190030  
094  
US20190025  
292  
US20190024  
096  
US20190023  
799  
US20190023  
779  
US20190023  
769  
US20190022  
249  
US20190022  
216  
US20190022  
214  
US20190022  
213  
US20190022  
116  
US20190017  
112  
US20190017

068

10CARGOMERS

Boron-Containing

Small Molecules

MATERIALS WITH IMPROVED PROPERTIES

CERENIS THERAPEUTICS HOLDING SA

Anacor Pharmaceuticals, Inc.

Not Available

ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF Not Available

COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND

VACCINE PHARMACEUTICAL COMPOSITION

FULLY INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC

NUCLEIC ACID SEQUENCES

NOVEL NUCLEIC ACID MOLECULES

TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR

DELIVERY OF CRISPR/CAS9

Method for Preventing and Treating Hyperpermeability

MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND

METHODS FOR USING THE SAME

ARTIFICIAL NUCLEIC ACID MOLECULES

NITTO DENKO CORPORATION

Not Available

Not Available

Not Available

Not Available

Longeveron LLC

CureVac AG

COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS Not Available

COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY

CONSTRUCTS AND USES THEREOF

NOVEL MONOTHIOL MUCOLYTIC AGENTS

TETRAHYDRONAPHTHALENE DERIVATIVE

siRNA/Nanoparticle Formulations for Treatment of Middle-East

Respiratory Syndrome Coronaviral Infection

BACTERIAL STRAIN AS AGENTS FOR PREVENTING AND/OR

TREATING RESPIRATORY DISORDERS

ANTIGEN PRESENTING CELL ASSAY

Not Available

Not Available

ONO PHARMACEUTICAL CO., LTD.

Sirnaomics, Inc.

Not Available

University of Pittsburgh - Of the Commonwealth System of

Higher Education

PROCESS FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELL Not Available

GITR Antibodies And Methods Of Inducing Or Enhancing An Immune

Response

METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH

DESIRED SPECIFICITY

COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN

INFECTION

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS

CONTAINING SAME, AND USES THEREFOR

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES

THEREOF

Attenuated Infectious Bronchitis Virus

MERS-CoV Vaccine

N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related

Thereo

METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE

PROTECTION

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,

VECTORS CONTAINING SAME, AND USES THEREFOR

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

HTG Molecular Diagnostics, Inc.

Not Available

Aug17

16Feb05

1Nov15

9Aug17

2Feb16

8Jan16

4-Jul17

23Nov15

5Mar09

4Feb16

30Dec13

21Feb06

13May14

30Jan15

29Jan16

8Sep15

27Jan16

8Apr10

7Aug15

25Mar05

28Dec11

29Oct12

30Sep03

23Oct15

27Jan16

29Nov13

26Dec14

11Feb16

17Dec01

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

10Aug

-18

18Oct

-18  
2Nov  
-16  
9Aug  
-18  
1Feb  
-17  
9Jan  
-17  
3Jul18  
3Aug  
-18  
19Oct  
-18  
2Feb  
-17  
9Jul18  
12Feb  
-18  
15Oct  
-18  
5Sep  
-18  
27Jan  
-17  
7Sep  
-16  
27Jan  
-17  
25Sep  
-18  
7Aug  
-15  
28Jun  
-18  
5Oct  
-18  
21Sep  
-18  
20Oct  
-18  
4Sep  
-18  
26Jan  
-17  
29Jun  
-18  
16Dec  
-15  
10Feb  
-17  
26Sep  
-18  
84



14Feb  
-19  
14Feb  
-19  
14Feb  
-19  
14Feb  
-19  
14Feb  
-19  
7Feb  
-19  
7Feb  
-19  
7Feb  
-19  
7Feb  
-19  
7Feb  
-19  
31Jan19  
31Jan19  
31Jan19  
31Jan19  
31Jan19  
31Jan19  
31Jan19  
24Jan19  
24Jan19  
24Jan19  
24Jan19  
24Jan19  
24Jan19  
24Jan19  
24Jan19  
24Jan19  
24Jan19  
17Jan19  
17Jan19  
US20190017  
000  
US20190016  
785  
US20190016  
772  
US20190016  
710  
US20190016  
690  
US20190015  
527  
US20190015  
522  
US20190015

501  
US20190015  
432  
US20190010  
469  
US20190010  
240  
US20190010  
132  
US20190008  
954  
US20190008  
948  
US20190008  
833  
US20190004  
061  
US20190002  
477  
US20190002  
448  
US20190002  
393  
US20190001  
010  
US20190000  
959  
US20190000  
745  
US20180372  
747  
US20180372  
733  
US20180371  
536  
US20180371  
461  
US20180371  
410  
US20180369  
386  
US20180369  
364

8CLEANING

COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available

ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS

AND USES THEREOF

GM-CSF and IL-4 Conjugates, Compositions, and Methods Related

Thereeto

MULTICYCLIC COMPOUNDS AND USES THEREOF

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS

CONTAINING SAME, AND USES THEREFOR

IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE

THEREOF

NUCLEIC ACID VACCINES

Lipid Disulfide Prodrugs and Uses Related Thereto

ATTENUATED VIRUSES USEFUL FOR VACCINES

COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF  
SUPERFAMILY LIGAND

ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL  
SODIUM CHANNEL BLOCKING COMPOUNDS

NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES  
FOR IMMUNOSTIMULATION

NUCLEIC ACID VACCINES

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

DETECTING TARGETS USING MASS TAGS AND MASS  
SPECTROMETRY

ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND  
METHODS OF USE THEREOF

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS  
AND USES THEREOF

Lipids and Lipid Compositions for the Delivery of Active Agents

ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND  
METHODS THEREOF

NUCLEIC ACID VACCINES

POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS  
OF USE THEREOF

METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE  
TUMOR TISSUE

ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR  
MAKING AND USING SUCH CONJUGATES

METHODS FOR RNA QUANTIFICATION

APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES,  
SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS  
VIRUSES AND TREATING PRRS VIRUS INFECTION

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

ModernaTX, Inc.

Not Available

Not Available

Not Available

Parion Sciences, Inc.

CureVac AG

ModernaTX, Inc.

Not Available

Not Available

Kineta, Inc.

Not Available

Not Available

Not Available

ModernaTX, Inc.

eXion labs Inc.

Not Available

Not Available  
Not Available

Sep16

7Oct15

23Oct12

31Dec15

31Dec15

30Sep03

5Apr12

23Apr14

13Jul-17

30Mar07

15Mar13

13Dec13

31Jan12

23Apr14

9May12

2-Jul10

9May14

31Dec15

5Sep14

8Dec14

23Apr14

28Jul-16

22Nov15

27Apr10

1Jun15

10Not

Available

Dec15

4MEANS

AND METHODS FOR INFLUENCING THE STABILITY OF CELLS Not Available

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE

AGENTS

RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE

IMMUNODEFICIENCY VIRUS GAG PROTEIN

Fauci/COVID-19 Dossier

Not Available

Not Available

CC-BY-NC-SA Dr. David E. Martin

Dec09

8Mar13

2-Jul15

19Sep

-18

7Oct

-16

20ct

-18

29Dec

-16

30Dec

-16

25Jul18

19Jul18  
27Sep  
-18  
13Jul18  
16Jul18  
2Aug  
-18  
4Apr  
-18  
11Jun  
-18  
16Jul18  
17Jul18  
4Aug  
-18  
31Jan  
-18  
29Dec  
-16  
19Sep  
-18  
13Jul18  
27Jul18  
4Sep  
-18  
21May  
-18  
21Jun  
-18  
26May  
-16  
1Dec  
-16  
28Aug  
-18  
29Aug  
-18  
1Jul16  
85  
17Jan19  
17Jan19  
17Jan19  
17Jan19  
17Jan19  
17Jan19  
17Jan19  
17Jan19  
17Jan19  
10Jan19  
10Jan19  
10Jan19  
10Jan19  
10Jan19  
10Jan19

3Jan19  
3Jan19  
3Jan19  
3Jan19  
3Jan19  
3Jan19  
3Jan19  
27Dec  
-18  
27Dec  
-18  
27Dec  
-18  
27Dec  
-18  
27Dec  
-18  
27Dec  
-18  
27Dec  
-18  
US20180368  
417  
US20180365  
375  
US20180363  
027  
US20180362  
625  
US20180360  
877  
US20180360  
736  
US20180355  
017  
US20180353  
594  
US20180346  
574  
US20180346  
573  
US20180346  
522  
US20180346  
516  
US20180346  
485  
US20180346  
480  
US20180344  
877  
US20180344  
832  
US20180344

751

US20180340

219

US20180340

218

US20180340

215

US20180340

154

US20180340

153

US20180339

991

US20180339

988

US20180339

014

US20180334

480

US20180333

485

US20180327

800

23ANTIMICROBIAL

COMPOSITIONS AND METHODS

METHODS AND SYSTEMS FOR MULTIPLE TAXONOMIC

CLASSIFICATION

STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF  
RIBONUCLEIC ACID

REGULATION OF CYTOKINE PRODUCTION

METHODS FOR EXPANDING A POPULATION OF ALVEOLAR

MACROPHAGES IN A LONG TERM CULTURE

FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE  
PARTICLES

COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES

Not Available

Not Available

Not Available

Not Available

Not Available

Intelgenx Corp.

Not Available

METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available

ANTI-PD-L1 ANTIBODIES AND USES THEREOF

ANTI-PD-L1 ANTIBODIES AND USES THEREOF

HUMAN RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS,  
NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM,  
AND METHODS OF USING THE SAME

PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS

ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND  
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7  
INHIBITORS

THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7

INHIBITORS

RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN  
EXPRESSION IN LIVER AND USE THEREOF  
METHODS AND COMPOSITIONS FOR COMBINATION  
IMMUNOTHERAPY  
Broad Spectrum Antiviral and Methods of Use  
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS  
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS  
SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET  
SEQUENCE  
PRODUCTION OF VIRUSES IN AVIAN EGGS  
PRODUCTION OF VIRUSES IN CELL CULTURE  
PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS  
PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC  
PROTEASE 7 INHIBITORS  
PEPTIDOMIMETIC MACROCYCLES  
CORONAVIRUSES EPITOPE-BASED VACCINES  
Compositions, Comprising Improved Il-12 Genetic Constructs And  
Vaccines, Immunotherapeutics And Methods Of Using The Same  
MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION  
OF B CELLS  
Fauci/COVID-19 Dossier  
Not Available  
Not Available  
Sep14  
24Apr15  
6Oct06  
4Dec15  
8Dec15  
2Dec13  
7Jun17  
26Jul-13  
13Jun16  
13Jun16  
10Not  
Available  
Apr12  
27Not  
Available  
Not Available  
Not Available  
Children's Healthcare of Atlanta, Inc.  
Not Available  
Not Available  
MASSACHUSETTS INSTITUTE OF TECHNOLOGY  
MASSACHUSETTS INSTITUTE OF TECHNOLOGY  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
RAMOT AT TEL-AVIV UNIVERSITY LTD.  
Not Available



Not Available

Nov15

5Feb15

5Feb15

16Apr15

20Apr15

17Apr06

9Dec16

9Dec16

28Aug15

24Nov15

24Nov15

30Dec14

30Dec14

14Jan09

17Sep15

12Dec11

26Feb03

CC-BY-NC-SA

Dr. David E. Martin

19Jun

-18

4Oct

-17

15May

-18

2Dec

-16

8Dec

-16

23Aug

-18

6Jun

-18

21Aug

-18

9Aug

-18

9Aug

-18

6Aug

-18

28Nov

-16

27Feb

-18

1Mar

-18

8Aug

-18

20Apr

-16

26Dec

-17



-18  
6Dec  
-18  
29Nov  
-18  
29Nov  
-18  
29Nov  
-18  
29Nov  
-18  
29Nov  
-18  
29Nov  
-18  
29Nov  
-18  
22Nov  
-18  
22Nov  
-18  
15Nov  
-18  
US20180327  
738  
US20180327  
697  
US20180327  
484  
US20180326  
070  
US20180326  
051  
US20180326  
045  
US20180326  
044  
US20180326  
039  
US20180325  
076  
US20180321  
242  
US20180319  
811  
US20180319  
779  
US20180318  
447  
US20180318  
366  
US20180318

350

US20180312

575

US20180312

545

US20180312

544

US20180311

338

US20180311

273

US20180305

773

US20180305

760

US20180305

451

US20180305

412

US20180305

357

US20180305

356

US20180303

874

US20180303

768

US20180303

090

20STABILIZED

REAGENTS FOR GENOME MODIFICATION

Not Available

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available

RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM

CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND

COMPOSITIONS, FORMULATIONS, AND METHODS

COMBINATION PIV3/HMPV RNA VACCINES

NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES,

THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL

APPLICATIONS

VACCINE COMPOSITIONS

ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL

POLYMERIC BINDING SYSTEM

VIRAL BIOMARKERS AND USES THEREFOR

DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION

AND THEIR USE FOR TREATING VIRAL INFECTIONS

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS

AND USES THEREOF

COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR

EFFICIENCY

METHOD OF TREATMENT USING ONCOLYTIC VIRUSES

Immune Cells with DNMT3A Gene Modifications and Methods  
Related Thereto

ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE  
THEREOF

OPTIMIZED NUCLEIC ACID MOLECULES

RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3  
(B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3 F PROTEIN AND  
USES THEREOF

MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME  
Method of Treating Inflammation

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA  
DETECTION

Pathogen biomarkers and uses therefor

HIDE1 COMPOSITIONS AND METHODS

COMPOSITIONS AND METHODS FOR TREATING DISEASES BY  
INHIBITING EXOSOME RELEASE

IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHDOS

NOVEL KINASE INHIBITORS

Not Available

Not Available

Not Available

ModernaTX, Inc.

Not Available

Not Available

OXISCIENCE, LLC

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

The United States of America, as represented by the  
Secretary, Dept. of Health and Human Services

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Compositions and Methods for the Prevention of Microbial Infections Not  
Available

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER  
NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY  
TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL  
BENEFIT

Fauci/COVID-19 Dossier

Not Available

Not Available

CC-BY-NC-SA Dr. David E. Martin

Nov15

8Sep16  
1Jun07  
4Dec07  
17Aug10  
22Oct15  
13Oct15  
16Sep15  
28Aug14  
6Nov15  
30Oct15  
3-Jul13  
3Dec15  
15Jun15  
4Nov15  
6Dec07  
9Nov15  
20Jan15  
11Jan16  
1Apr10  
12Apr17  
30Sep15  
13Jul-15  
19Dec16  
22Dec06  
19Oct12  
10Nov11  
30Jan15  
30Oct15  
18Nov  
-16  
12Jun  
-18  
23Jul18  
20Nov  
-17  
24Jul18  
20Jul18  
13Oct  
-16  
16Sep  
-16  
24Jul18  
4Nov  
-16  
28Oct  
-16  
4Dec  
-17  
30Nov  
-16  
15Jun  
-16  
4Nov  
-16

20Mar  
-18  
9Nov  
-16  
20Jan  
-16  
11Jul18  
26Jun  
-18  
12Apr  
-18  
30Sep  
-16  
13Jul16  
9Jul18  
25Jun  
-18  
18May  
-18  
30Nov  
-17  
2Jul18  
17Oct  
-16  
87  
15Nov  
-18  
15Nov  
-18  
15Nov  
-18  
15Nov  
-18  
15Nov  
-18  
15Nov  
-18  
15Nov  
-18  
15Nov  
-18  
15Nov  
-18  
8Nov  
-18  
8Nov  
-18  
8Nov  
-18  
8Nov  
-18  
8Nov  
-18  
8Nov

-18  
1Nov  
-18  
1Nov  
-18  
1Nov  
-18  
1Nov  
-18  
1Nov  
-18  
250ct18  
250ct18  
250ct18  
250ct18  
250ct18  
250ct18  
250ct18  
250ct18  
250ct18  
US20180267  
031  
US20180265  
847  
US20180265  
822  
US20180265  
574  
US20180265  
507  
US20180264  
098  
US20180258  
162  
US20180258  
160  
US20180258  
159  
US20180258  
151  
US20180251  
737  
US20180251  
540  
US20180251  
436  
US20180250  
602  
US20180250  
381  
US20180245  
056  
US20180245  
053



US20180244

759

US20180244

756

US20180244

669

US20180244

660

US20180243

347

US20180237

835

US20180237

788

US20180237

786

US20180237

502

US20180237

435

US20180236

058

US20180236

054

METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS

The U.S.A., as represented by the Secretary, Department of Health and Human Services

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOF

Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection

HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES

MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS

Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections

Optimized Crosslinkers for Trapping a Target on a Substrate

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY

RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF

COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH

Not Available

Not Available

Not Available

Dana-Farber Cancer Institute, Inc.

The Government of the USA as represented by the Secretary of the Dept. of Health and Human Service

Not Available

Not Available

Not Available

Not Available

Not Available

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available  
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4OXAZEPANE-2-CARBOXAMIDES  
AS DIPEPTIDYL PEPTIDASE 1

INHIBITORS

PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR  
STIMULATION OF THE INNATE IMMUNE RESPONSE

Not Available

Not Available

SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available  
COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND  
ACTIVITY, AND RELATED METHODS

VIRAL VACCINES AND METHODS OF FORMING THE SAME  
NOVEL METHODS OF GENERATING ANTIBODIES

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS  
IMMUNOGENS, ANTIBODIES, AND THEIR USE

IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED  
GUANIDINE GROUPS

CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE  
INHIBITORS

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE  
THEREOF

METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS  
IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION  
ARTIFICIAL NUCLEIC ACID MOLECULES

PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES,  
ANTIBODIES, AND ANTIBODY COCKTAILS

GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS  
REVERSE GENETICS SYSTEMS

Tetanus Toxoid and CCL3 Improve DC Vaccines

Not Available

Not Available

Rutgers, The State University of New Jersey  
The United States of America, as Represented by the  
Secretary, Dept. of Health and Human Services

Not Available

Not Available

Not Available

American International Biotechnology, LLC  
The Regents of the University of California

CUREVAC AG

Integrated BioTherapeutics, Inc.

Not Available

Not Available

Duke University

1Sep15

18Nov13

8Sep16

15Mar17

11Apr12

8Oct04

2Jan15  
13Nov15  
28Oct14  
28Feb01  
5Dec08  
16Dec02  
24Jan14  
11Feb14  
20Aug10  
19Nov09  
27Feb17  
19Aug15  
24Feb15  
31Aug15  
17Aug15  
25Aug15  
31Jul-15  
8Aug15  
28Aug15  
11Mar15  
31Aug15  
31Jul-09  
14Nov13  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
8Aug  
-16  
29Mar  
-18  
21May  
-18  
15Mar  
-17  
26Jan  
-18  
31May  
-18  
22May  
-18  
11May  
-18  
14May  
-18  
2Mar  
-18  
28Dec  
-17  
30Apr  
-18  
19Sep  
-17  
1May  
-18

12Oct  
-17  
9Oct  
-17  
27Feb  
-18  
18Aug  
-16  
24Feb  
-16  
26Aug  
-16  
17Aug  
-16  
22Aug  
-16  
29Jul16  
5Aug  
-16  
22Aug  
-16  
11Mar  
-16  
26Aug  
-16  
16Oct  
-17  
19Apr  
-18  
88  
20Sep  
-18  
20Sep  
-18  
20Sep  
-18  
20Sep  
-18  
20Sep  
-18  
20Sep  
-18  
13Sep  
-18  
13Sep  
-18  
13Sep  
-18  
13Sep  
-18  
6Sep  
-18  
6Sep  
-18

6Sep  
-18  
6Sep  
-18  
6Sep  
-18  
30Aug  
-18  
30Aug  
-18  
30Aug  
-18  
30Aug  
-18  
30Aug  
-18  
30Aug  
-18  
23Aug  
-18  
23Aug  
-18  
23Aug  
-18  
23Aug  
-18  
23Aug  
-18  
23Aug  
-18  
23Aug  
-18  
US20180235  
948  
US20180230  
521  
US20180230  
447  
US20180228  
695  
US20180223  
290  
US20180222  
906  
US20180221  
464  
US20180216  
164  
US20180216  
067  
US20180215  
831

US20180215  
801  
US20180215  
794  
US20180214  
430  
US20180209  
960  
US20180208  
897  
US20180208  
659  
US20180208  
653  
US20180207  
258  
US20180207  
145  
US20180201  
998  
US20180201  
907  
US20180201  
687  
US20180200  
365  
US20180200  
364  
US20180200  
224  
US20180200  
196  
US20180196  
061  
US20180195  
048

(S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE  
FOR THE  
TREATMENT OF CANCER  
BIOAGENT DETECTION OLIGONUCLEOTIDES  
ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN  
CONVERTING ENZYME 2 (ACE2)  
DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF  
ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN  
AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTS  
METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING  
INHIBITORY GENE PRODUCTS  
SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND  
IMIDAZONAPHTHYRIDINES  
IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS,  
AND METHODS OF GENERATING IMMUNE RESPONSES  
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS  
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

18Not  
Available  
Aug15  
27Not  
Available  
Northwestern University  
Dec11  
24Jan17  
11Not  
Available  
Aug15  
10GenVec,  
Inc.  
3M Innovative Properties Company  
Not Available  
Not Available  
Not Available  
Antibody Derivatives with Conditionally Enabled Effector Function Not Available  
CRYPTIC POLYPEPTIDES AND USES THEREOF  
TREATING CANCER WITH VIRAL NUCLEIC ACID  
Selective Inhibitors Of i-NOS For Use Against Viral Infection  
Method of Determining, Identifying or Isolating Cell-Penetrating  
Peptides  
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES  
ANTI-PD-L1 ANTIBODIES AND USES THEREOF  
METHODS FOR ENHANCING AN IMMUNE RESPONSE  
ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE  
PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR  
TREATING INFECTIOUS DISEASES  
COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC  
DEAFNESS GENE MUTATION  
METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES  
ANTIBODIES HAVING SPECIFICITY TO MYOSIN 18A AND USES  
THEREOF  
Methods and Compositions for Inhibiting Akt3  
LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND  
COMPOSITIONS, FORMULATIONS, AND METHODS  
Antiviral Activity from Medicinal Mushrooms and Their Active  
Constituents  
Modular Particulars for Immunotherapy  
INFLUENZA POTENCY ASSAYS  
METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION  
Not Available  
Mayo Foundation for Medical Education and Research  
UCL Business PLC  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
GlaxoSmithKline Intellectual Property (No. 2) Limited  
CapitalBio Corporation  
Not Available  
Not Available

Not Available  
3M Innovative Properties Company  
Not Available  
Not Available  
Not Available  
Takeda Vaccines, Inc.  
Nov05  
18Jun04  
3Aug15  
15Nov06  
18Nov13  
27Jul-15  
29Jan15  
20Feb07  
17Jul-15  
23May11  
18Nov13  
13Jun16  
20Jan17  
22Feb08  
12May14  
14Jul-15  
26Jan12  
7-Jul15  
17Jan17  
17Aug10  
31Mar15  
1Nov13  
7-Jul15  
13Feb15  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
18Aug  
-16  
13Apr  
-18  
24Jan  
-18  
11Aug  
-16  
7Sep  
-17  
9Apr  
-18  
3Aug  
-16  
19Mar  
-18  
29Mar  
-18  
27Jul16  
29Jan  
-16



27Mar  
-18  
15Jul16  
11Dec  
-17  
19Mar  
-18  
13Jun  
-17  
19Jan  
-18  
5Mar  
-18  
19Mar  
-18  
14Jul15  
13Mar  
-18  
7Jul16  
20Feb  
-18  
27Nov  
-17  
12Mar  
-18  
3Jan  
-18  
7Jul16  
12Feb  
-16  
89  
23Aug  
-18  
16Aug  
-18  
16Aug  
-18  
16Aug  
-18  
9Aug  
-18  
9Aug  
-18  
9Aug  
-18  
2Aug  
-18  
2Aug  
-18  
2Aug  
-18  
2Aug  
-18  
2Aug

-18  
2Aug  
-18  
26Jul18  
26Jul18  
26Jul18  
26Jul18  
26Jul18  
26Jul18  
19Jul18  
19Jul18  
19Jul18  
19Jul18  
19Jul18  
19Jul18  
19Jul18  
12Jul18  
12Jul18  
US20180194  
850  
US20180194  
829  
US20180194  
735  
US20180193  
477  
US20180187  
213  
US20180187  
211  
US20180187  
165  
US20180187  
154  
US20180187  
153  
US20180187  
131  
US20180186  
897  
US20180186  
821  
US20180186  
802  
US20180186  
792  
US20180186  
534  
US20180185  
469  
US20180185  
392  
US20180185  
345

US20180180

544

US20180179

300

US20180179

274

US20180177

863

US20180177

862

US20180177

860

US20180163

182

US20180162

838

US20180162

835

US20180161

425

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR  
SUPERFAMILY ANTIBODIES

15Not

Available

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR  
TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER  
Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines

Not Available

Hoffmann La-Roche Inc.

DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS Not Available

Variant AAV and Compositions, Methods and Uses for Gene Transfer  
to Cells, Organs and Tissues

METHODS AND COMPOSITIONS FOR COMBINATION

IMMUNOTHERAPY

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF  
MANUFACTURE AND USE THEREOF

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME  
AND USE THEREOF

The Children's Hospital of Philadelphia

Not Available

Takeda Vaccines, Inc.

Not Available

Not Available

COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX

ENERGIES ALTERNATIVES

NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA Not Available

PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN

EMBEDDED TISSUE USING CAGED HAPTENS

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7

AGONISTS

HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL

SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE

THEREFROM

Powdered Pouch And Method Of Making Same  
COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING  
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME

Pharmaceutical Compositions and Methods  
METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS  
INDUCED CONDITIONS

USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR  
DETERIORATED PERFORMANCE OF A FLUOROMETER  
GENERATION OF BINDING MOLECULES

PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES  
THEREOF

METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES  
ANTIGENICALLY MATCHED INFLUENZA VACCINES

VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA  
EXTRACT, AND PREPARATION METHOD THEREFOR  
PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC  
ACID-CONTAINING COMPOSITIONS

Chemical Compounds

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS

NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY  
PRODUCTION IN IMMUNIZATION

Not Available

Not Available

3M Innovative Properties Company

MONOSOL, LLC

Not Available

Not Available

Not Available

Not Available

Merus N.V.

Not Available

Not Available

Not Available

Not Available

Human Services

Not Available

Not Available

Not Available

May15

15Apr11

17Sep15

15Jul-15

22Jul-13

9Jan15

7Nov14

18Nov13

18Nov13

16Jun15

26Jun15

28Aug15

1May14

3Jun11

16Apr12  
24Apr12  
3Aug15  
19Jun15  
14Jun12  
26Sep11  
26Jun15  
23Sep15  
26Jun15  
11Jun15  
10Jun15  
18Mar14  
5Feb15  
10Dec14  
13May  
-16  
13Nov  
-17  
8Mar  
-18  
15Jul16  
6Dec  
-17  
7Jan  
-16  
27Oct  
-17  
20Feb  
-18  
20Feb  
-18  
15Jun  
-16  
24Jun  
-16  
28Feb  
-18  
27Feb  
-18  
26Feb  
-18  
29Dec  
-17  
14Dec  
-17  
29Nov  
-17  
17Jun  
-16  
22Feb  
-18  
22Nov  
-17  
24Jun

-16  
31Oct  
-17  
24Jun  
-16  
7Jun  
-16  
10Jun  
-16  
13Dec  
-17  
11Dec  
-17  
10Dec  
-15  
12Jul18  
12Jul18  
12Jul18  
12Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
5Jul18  
28Jun18  
28Jun18  
28Jun18  
28Jun18  
28Jun18  
28Jun18  
28Jun18  
14Jun18  
14Jun18  
14Jun18  
14Jun18  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
90  
US20180161  
422  
US20180161  
279  
US20180160  
662  
US20180149

659  
US20180148  
727  
US20180142  
239  
US20180142  
198  
US20180142  
006  
US20180142  
005  
US20180142  
004  
US20180142  
003  
US20180142  
002  
US20180140  
659  
US20180140  
625  
US20180140  
580  
US20180135  
099  
US20180135  
012  
US20180134  
783  
US20180134  
770  
US20180133  
246  
US20180127  
836  
US20180127  
783  
US20180127  
384  
US20180125  
965  
US20180125  
952  
US20180125  
883  
US20180112  
270  
US20180111  
991

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEMLOOP  
AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL  
FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC  
ANTIGEN  
GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR

OPROZOMIB AND PROCESS TO MAKE THEREOF

15CureVac

AG

Feb12

14Not

Available

Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha Institut Pasteur

DIAGNOSIS AND TREATMENT OF MERS-RELATED RENAL DISEASE Not Available

ARTIFICIAL NUCLEIC ACID MOLECULES

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

OR OTHER DISEASES

DELIVERY OF BIOMOLECULES TO IMMUNE CELLS

ANTIBODY PRODUCING NON-HUMAN ANIMALS

ANTIBODY PRODUCING NON-HUMAN ANIMALS

ANTIBODY PRODUCING NON-HUMAN ANIMALS

ANTIBODY PRODUCING NON-HUMAN ANIMALS

ANTIBODY PRODUCING NON-HUMAN ANIMALS

ANALOGS OF C5a AND METHODS OF USING SAME

PRODUCTION OF STABLE NON-POLYADENYLATED RNAs

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF

BRAIN INFLAMMATION AND SEPSIS

NANOREPORTERS AND METHODS OF MANUFACTURING AND USE

THEREOF

MEMBRANE-RECEIVER COMPLEX THERAPEUTICS

Not Available

Not Available

Not Available

Merus N.V.

Merus N.V.

Merus N.V.

Merus N.V.

Merus N.V.

Not Available

Massachusetts Institute of Technology

Not Available

Not Available

Not Available

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available

ANTIBODY PRODUCING NON-HUMAN ANIMALS

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY

DISEASES

IMPROVED COMPOSITIONS AND METHODS FOR DETECTION OF

VIRUSES

CRISPR-RELATED METHODS AND COMPOSITIONS WITH

GOVERNING gRNAs

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND

USES THEREOF

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF

MANUFACTURE AND USE THEREOF

PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT

LEAST ONE mRNA CONSTRUCT

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY

DISEASES

C-CBL MUTATIONS AND USES THEREOF



MODULATORS OF ACTIVIN AND METHODS FOR MODULATING  
IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS

Merus N.V.

Not Available

Not Available

EDITAS MEDICINE, INC.

Not Available

Takeda Vaccines, Inc.

Not Available

Not Available

Not Available

Not Available

Dec16

26Mar12

4Jun15

30Dec14

26Jan07

31Oct14

27Jun08

27Jun08

27Jun08

27Jun08

27Jun08

29Jun10

16Oct12

29Nov02

23Dec05

13May15

16Dec02

27Jun08

7Mar12

7May15

7Nov13

29Jul-11

7Nov14

15May15

7Mar12

4Jun10

2Dec14

8Feb

-18

13Dec

-17

25Jan

-18

3Jun

-16

29Dec

-15

14Jun

-17

30Oct

-15

12Jan

24May  
-18  
24May  
-18  
24May  
-18  
24May  
-18  
31May  
-18  
31May  
14Jun18  
14Jun18  
14Jun18  
-17  
2Jun  
-16  
22Mar  
-17  
20Sep  
-16  
13May  
-15  
6Nov  
-17  
21Jun  
-17  
29Nov  
-16  
6May  
-17  
1Nov  
-18  
12Jan  
-16  
26Apr  
-16  
13May  
-18  
2Jan  
-17  
23Oct  
31Jul17  
-18  
12Jan  
-18  
5Jan  
-18  
9Jan  
-18  
11Jan  
-18  
12Jan  
-18

-18  
24May  
-18  
24May  
-18  
24May  
-18  
24May  
-18  
24May  
-18  
24May  
-18  
17May  
-18  
17May  
-18  
17May  
-18  
17May  
-18  
17May  
-18  
17May  
-18  
10May  
-18  
10May  
-18  
10May  
-18  
10May  
-18  
10May  
-18  
10May  
-18  
10May  
-18  
26Apr18  
26Apr18  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
91  
US20180111  
907  
US20180110  
845  
US20180105  
815  
US20180105  
596  
US20180105  
514  
US20180104  
241  
US20180100

181

US20180099

999

US20180098

972

US20180092

932

US20180087

049

US20180086

818

US20180085

457

US20180085

432

US20180085

388

US20180079

746

US20180078

625

US20180078

532

US20180078

507

US20180073

073

US20180072

813

US20180072

796

US20180072

752

US20180071

219

US20180067

299

US20180066

228

US20180066

216

US20180065

981

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL  
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER  
MUCOSAL DISEASES

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN  
AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS

Bivalent siRNA Chimeras and Methods of Use Thereof

ANTI-TYRO3 ANTIBODIES AND USES THEREOF

HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS

CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE

POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY

METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS

FOR USE IN PRACTICING THE SAME  
FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR  
USING RECOMBINANT BACTERIA  
TREATMENT OF INFECTIOUS DISEASES  
Anti-Viral Azide Containing Compounds  
MAXIMIZING DNA YIELD OF BLOOD SPECIMENS COLLECTED IN  
RAPID CLOT TUBES  
COMPOSITIONS AND METHODS FOR THE TREATMENT OF  
IMMUNODEFICIENCY  
ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES  
THEREOF  
STING (Stimulator of Interferon Genes), A Regulator of Innate  
Immune Responses  
DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS  
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS  
COMPOSITIONS AND METHODS FOR DELIVERY OF  
BIOMACROMOLECULE AGENTS  
IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB  
BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN  
ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES  
THEREOF  
METHODS AND COMPOSITIONS FOR LABELING TARGETS AND  
HAPLOTYPE PHASING  
CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF  
USE THEREOF  
MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA  
AND VIRAL INFECTION  
COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL  
COMPOSITION THEREOF, ITS PREPARATION AND USE  
Technology for Preparation of Macromolecular Microspheres  
ENDOSCOPIC APPARATUS FOR THERMAL DISTRIBUTION  
MONITORING  
Detection of T Cell Exhaustion or Lack of T Cell Costimulation and  
Uses Thereof  
29Not  
Available  
May12  
31Not  
Available  
Not Available  
Not Available  
Not Available  
PARION SCIENCES, INC.  
Not Available  
Not Available  
CHILDREN'S MEDICAL CENTER CORPORATION  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
GLAXOSMITHKLINE BIOLOGICALS, SA  
Not Available  
Not Available

AMGEN INC.

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

ELECTRONICS AND TELECOMMUNICATIONS RESEARCH

INSTITUTE

Not Available

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available

HETEROCYCLYMETHYL-THIENOURACILE AS ANTAGONISTS OF THE

ADENOSINE-A2B-RECEPTOR

Fauci/COVID-19 Dossier

Not Available

CC-BY-NC-SA Dr. David E. Martin

Aug07

18Oct16

17Apr15

7Apr16

27Jun11

17Apr15

17Sep14

26Jan15

28Jul-10

27Sep16

28Oct14

23Oct15

4Aug08

6-Jul10

19Mar15

25Mar15

21Sep16

16Sep16

18Mar15

2Dec05

8Sep16

30Mar15

24Jan06

7Sep16

15May15

8Sep16

26Mar15

20Dec

-17

18Dec

-17

6Oct

-17

15Apr

-16

3Jan

-18

15Dec

-17  
15Apr  
-16  
14Dec  
-17  
26Jan  
-16  
7Dec  
-17  
7Sep  
-17  
13Nov  
-17  
1Dec  
-17  
15Sep  
-17  
5Oct  
-17  
15Mar  
-16  
25Mar  
-16  
18Sep  
-17  
15Sep  
-17  
16Mar  
-16  
9May  
-17  
17Nov  
-17  
2Feb  
-16  
25Sep  
-17  
31May  
-17  
15Nov  
-17  
6Sep  
-17  
21Mar  
-16  
92  
26Apr18  
26Apr18  
19Apr18  
19Apr18  
19Apr18  
19Apr18  
12Apr18  
12Apr18

12Apr18

5Apr18

29Mar

-18

29Mar

-18

29Mar

-18

29Mar

-18

29Mar

-18

22Mar

-18

22Mar

-18

22Mar

-18

22Mar

-18

15Mar

-18

15Mar

-18

15Mar

-18

15Mar

-18

15Mar

-18

8Mar

-18

8Mar

-18

8Mar

-18

8Mar

-18

US20180064

790

Composition for Treatment or Prevention of Infectious Inflammatory Diseases, or Composition for Immune Enhancement, Comprising Tryptophanyl-tRNA Synthetase as an Active Ingredient

26Not

Available

Feb15

25Aug

-17

8Mar

-18

US20180064

752

ANIONICALLY

MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF



ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS  
MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF  
INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN  
METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND  
INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND  
PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY  
MODIFIED POLYALLYLAMINE DERIVATIVE

Not Available

29Jul-14

25Oct

-17

Mar

-18

8US20180058

988

US20180057

871

US20180057

841

US20180057

817

US20180057

594

US20180057

509

US20180057

488

US20180055

925

US20180055

769

US20180051

267

US20180051

266

US20180050

059

US20180044

687

US20180044

328

US20180043

007

US20180037

952

US20180037

942

US20180037

871

US20180037

636

US20180037

634

US20180037

617

US20180036

398

1SAMPLE

FIXATION AND STABILISATION

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE

VARIANTS

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR

Particle-Nucleic Acid Conjugates and Therapeutic Uses Related  
Thereeto

PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC  
POLYPEPTIDES

ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND  
THIAZOLONAPHTHYRIDINES

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS

CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION

AND/OR HOMOGENIZATION OF EMULSIONS

TAL EFFECTOR-MEDIATED DNA MODIFICATION

TAL EFFECTOR-MEDIATED DNA MODIFICATION

DELIVERY OF RNA TO DIFFERENT CELL TYPES

ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN  
EXPRESSION

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I  
INHIBITORS

INFLUENZA VIRUS VECTORS AND USES THEREFOR

SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD

CHEMISTRY ANALYSIS

ENZYME-INDEPENDENT MOLECULAR INDEXING

CANCER INITIATING CELL AND USE THEREOF

STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF  
USE

ENGINEERED POLYPEPTIDES AND USES THEREOF

METHODS AND COMPOSITIONS FOR TREATING AND/OR

PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH

ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF  
PROTEINS

FLAVIVIRUS REPLICONS

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

The United States of America, as represented by the  
Secretary, Department of Health and Human Serv

Not Available

Not Available

Not Available

GLAXOSMITHKLINE BIOLOGICALS, SA

Not Available

Prozymex A/S

Not Available

Nanomedical Diagnostics, Inc.  
Not Available  
Not Available  
DANA-FARBER CANCER INSTITUTE, INC.  
Not Available  
Mar13  
15Aug16  
7Apr05  
25Jun12  
30Jun16  
9Feb05  
23Apr15  
3Mar15  
3Dec09  
10Dec09  
10Dec09  
6-Jul10  
12Dec14  
5Mar15  
17Mar14  
28Apr14  
3Aug16  
8Aug16  
18Jun09  
2Aug16  
22Institute  
of Biophysics, Chinese Academy of Sciences  
Aug14  
27Not  
Available  
Feb15  
14Aug  
-17  
1Nov  
-17  
27Oct  
-17  
9Oct  
-17  
29Sep  
-17  
2Nov  
-17  
7Nov  
-17  
7Aug  
-15  
26Jun  
-17  
5Oct  
-17  
21Aug  
-17  
30Aug

-17  
11Dec  
-15  
4Mar  
-16  
21Aug  
-17  
21Aug  
-17  
1Aug  
-17  
8Aug  
-16  
21Sep  
-17  
2Aug  
-17  
21Aug  
-15  
25Feb  
-16  
1Mar  
-18  
1Mar  
-18  
1Mar  
-18  
1Mar  
-18  
1Mar  
-18  
1Mar  
-18  
1Mar  
-18  
1Mar  
-18  
22Feb  
-18  
22Feb  
-18  
22Feb  
-18  
15Feb  
-18  
15Feb  
-18  
15Feb  
-18  
8Feb  
-18  
8Feb

-18  
8Feb  
-18  
8Feb  
-18  
8Feb  
-18  
8Feb  
-18  
8Feb  
-18  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
93  
US20180036  
237  
US20180031  
555  
US20180030  
429  
US20180030  
411  
US20180028  
677  
US20180028  
626  
US20180028  
562  
US20180028  
449  
US20180028  
431  
US20180023  
048  
US20180022  
781  
US20180021  
448  
US20180016  
307  
US20180016  
285  
US20180016  
243  
US20180015  
174  
US20180015  
052  
US20180010  
167  
US20180010  
125  
US20180009

787

US20180008

689

US20180002

743

US20180002

406

US20180000

929

US20180000

926

US20180000

868

US20180000

724

US20170369

843

US20170369

470

23OIL/SURFACTANT

MIXTURES FOR SELF-EMULSIFICATION

METHOD FOR SELECTING A SINGLE CELL EXPRESSING A

HETEROGENEOUS COMBINATION OF ANTIBODIES

Polypeptide Assemblies and Methods for the Production Thereof

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

Peptides for Assisting Delivery Across the Blood Brain Barrier

IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION

THERAPY

METHODS OF TREATING OR PREVENTING INFLAMMATION AND

HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL

WATER SOLUTION

Technology for the Preparation of Microparticles

POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS

OF USE THEREOF

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC

PROTEINS AND THEIR USE IN GENE THERAPY

Conjugates of Cell Binding Molecules with Cytotoxic Agents

GRIFFITHSIN MUTANTS

Boron-Containing Small Molecules

HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS

SYNTHETIC NANOPARTICLES FOR DELIVERY OF

IMMUNOMODULATORY COMPOUNDS

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER

NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY

ORGANISM IDENTIFICATION PANEL

DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4

AND METHODS OF USE THEREOF

NOVEL COMPOUNDS

RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL

ROBUSTNESS AND SEQUENCE SPACE

FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE

DETECTION OF TARGET RNA SEQUENCES

NEUTRALIZING GP41 ANTIBODIES AND THEIR USE

D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND  
METHODS OF USE THEREOF  
METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C  
VIRUS

Induced Hepatocytes and Uses Thereof

METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL  
AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

Cyclic Compounds and Uses Thereof

Fauci/COVID-19 Dossier

GLAXOSMITHKLINE BIOLOGICALS, SA

Merus N.V.

Not Available

Not Available

Children's Medical Center Corporation

Transgene SA

SONOMA PHARMACEUTICALS, INC.

Not Available

eXion labs Inc.

Not Available

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  
(CNRS)

Hangzhou DAC Biotech Co., Ltd.

The United States of America, as represented by the  
Secretary, Department of Health and Human Serv

Not Available

Not Available

Not Available

Not Available

Not Available

Quark Pharmaceuticals Inc.

CHIESI FARMACEUTICI S.P.A.

Not Available

Not Available

The United States of America, as represented by the  
Secretary, Department of Health and Human

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

CC-BY-NC-SA Dr. David E. Martin

Feb15

27Jun08

27Feb15

18Nov13

22May06

13Feb15

20Jan06

24Jul-07

28Jul-16

29Oct04

13Feb15

12Jul-12  
10Feb15  
20Jun07  
13Feb15  
15Jul-16  
30Jan15  
2Apr07  
12Sep12  
31May16  
28Jan15  
18Jun16  
7Nov11  
30Nov12  
15Jan15  
26Nov14  
26Jul-10  
18Nov13  
16Dec14  
23Feb  
-16  
18Jul17  
29Feb  
-16  
13Oct  
-17  
30Jun  
-17  
12Feb  
-16  
10Oct  
-17  
27Jun  
-17  
27Jul17  
22Sep  
-17  
12Feb  
-16  
16Apr  
-14  
10Feb  
-16  
28Sep  
-17  
12Feb  
-16  
14Jul17  
28Jan  
-16  
26Jul17  
15Feb  
-17  
22Sep  
-17



28Jan  
-16  
16Jun  
-17  
85ep  
-17  
14Sep  
-17  
15Jan  
-16  
15Sep  
-17  
10May  
-17  
29Mar  
-17  
16Dec  
-15  
94  
8Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
1Feb  
-18  
8Feb  
-18  
1Feb  
-18  
94  
8Feb  
-18  
1Feb  
-17  
15Sep  
-16  
15Jan  
-17  
14Sep  
-17  
85ep  
-17  
16Jun  
-16  
28Jan

4Jan18  
28Dec  
-17  
28Dec  
-17  
US20170368  
203  
US20170368  
201  
US20170368  
167  
US20170362  
300  
US20170362  
297  
US20170362  
187  
US20170362  
170  
US20170360  
962  
US20170360  
960  
US20170360  
908  
US20170360  
881  
US20170360  
875  
US20170358  
082  
US20170354  
727  
US20170348  
433  
US20170348  
402  
US20170348  
369  
US20170342  
442  
US20170342  
405  
US20170342  
056  
US20170340  
735  
US20170340  
725  
US20170340  
721  
US20170340  
611  
US20170337

459

US20170336

412

US20170336

411

US20170335

408

29Compositions

For Enhancing Transport Of Molecules Into Cells

SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT  
LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE  
SYSTEM

COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL  
DISORDERS

OLIGOPEPTIDE-FREE CELL CULTURE MEDIA

Not Available

The Children's Hospital of Philadelphia

Not Available

Not Available

CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF Not Available

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)

PYRAZINE-2- CARBOXAMIDE COMPOUNDS

HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS

RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES

AAV Vectors Targeted to the Central Nervous System

VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED

IMMUNITY CONTAINING BISPHOSPHONATES

PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF

Parion Sciences, Inc.

Not Available

Not Available

Not Available

NITTO DENKO CORPORATION

Not Available

METHODS FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONS MIDDLE TENNESSEE STATE  
UNIVERSITY

STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING

MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF  
SYNONYMOUS CODONS

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS

RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES

SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR

PROTEIN TO CELLS

Plant Extract and Its Therapeutic Use

RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA

MOLECULES

MOLECULAR INDEXING OF INTERNAL SEQUENCES

NOVEL COMPOUNDS

Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof

COMBINATION PIV3/HMPV RNA VACCINES

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE

RESPONSES

NOVEL COMPOUNDS

SPATIALLY ADDRESSABLE MOLECULAR BARCODING  
Multiplex Immuno Screening Assay  
B-CELL ANTIGEN PRESENTING CELL ASSAY  
Methods and Systems of Multi-Assay Processing and Analysis  
Not Available  
Not Available  
The Board of Trustees of the Leland Stanford Junior  
University  
Not Available  
Not Available  
GLAXOSMITHKLINE BIOLOGICALS, SA  
Not Available  
CHIESI FARMACEUTICI S.P.A.  
Not Available  
ModernaTX, Inc.  
Not Available  
CHIESI FARMACEUTICI S.P.A.  
Not Available  
Institut Pasteur  
The University of Pittsburgh - Of the Commonwealth  
System of Higher Education  
Not Available  
Apr03  
15Mar13  
21Aug12  
4Jan06  
19Dec14  
17Dec12  
3Aug07  
16Feb16  
21Nov14  
3Sep14  
17Jun16  
22Dec14  
15Mar13  
8Oct04  
16Feb16  
30Jul-14  
16May08  
11Oct11  
31May16  
31May16  
10Oct15  
22Oct15  
3Sep14  
31May16  
27Feb15  
4May12  
8Apr10  
15Mar16  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
10Jan

-17  
8Sep  
-17  
6Jun  
-16  
7Aug  
-17  
21Dec  
-15  
29Jun  
-17  
29Jun  
-17  
18Aug  
-17  
20Nov  
-15  
2Sep  
-15  
16Jun  
-17  
22Dec  
-15  
2Aug  
-17  
23Aug  
-17  
16Feb  
-17  
30Jul15  
18Jul17  
15Aug  
-17  
16May  
-17  
26May  
-17  
19Jun  
-17  
11Aug  
-17  
3Sep  
-15  
26May  
-17  
2Aug  
-17  
19Jul17  
9Aug  
-17  
15Mar  
-17  
95  
28Dec

-17  
28Dec  
-17  
28Dec  
-17  
21Dec  
-17  
21Dec  
-17  
21Dec  
-17  
21Dec  
-17  
21Dec  
-17  
21Dec  
-17  
21Dec  
-17  
21Dec  
-17  
21Dec  
-17  
21Dec  
-17  
14Dec  
-17  
14Dec  
-17  
7Dec  
-17  
7Dec  
-17  
7Dec  
-17  
30Nov  
-17  
30Nov  
-17  
30Nov  
-17  
30Nov  
-17  
30Nov  
-17  
30Nov  
-17  
30Nov  
-17  
23Nov  
-17  
23Nov  
-17  
23Nov  
-17  
23Nov

-17

US20170335

374

US20170334

984

US20170334

973

US20170334

941

METHODS AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE  
OF MICROBIAL CONTAMINATION IN A SAMPLE

6Not

Available

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available

NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS

MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE

GLYCOPROTEINS

2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE  
FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER

Not Available

Not Available

Mar12

16Dec02

28Oct14

31Oct14

US20170334

919

2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1HPYRAZOLO[3,4-D]PYRIMIDIN-1  
-YL)METHYL)-3-(2-(TRIFLUORO-MET

HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR  
USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS

6Jul17

26Apr

-16

27Oct

-15

30Oct

-15

23Nov

-17

23Nov

-17

23Nov

-17

23Nov

-17

15RESPIVERT  
LTD.

Mar13

27Jul17

23Nov

-17

US20170334

864

US20170333  
586  
US20170333  
553  
US20170333  
494  
US20170333  
457  
US20170333  
267  
US20170328  
819  
US20170327  
543  
US20170327  
472  
US20170327  
439  
US20170326  
256  
US20170326  
123  
US20170322  
682  
US20170322  
201  
US20170321  
192  
US20170319  
712  
US20170319  
673  
US20170319  
551  
US20170313  
765  
US20170313  
685  
US20170312  
371  
3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE  
27Parion  
Sciences, Inc.  
Jun11  
ADDITIVE  
COMPOSITIONS FOR PIGMENTED DISINFECTION AND  
METHODS THEREOF  
LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND  
COMPOSITIONS, FORMULATIONS, AND METHODS  
PROBIOTIC THERAPEUTIC APPLICATIONS  
Anti-Viral Azide Containing Compounds  
MOBILE CLINICS



SAMPLE FIXATION AND STABILISATION  
POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES  
CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL  
SODIUM CHANNEL BLOCKING ACTIVITY  
DIHYDRONAPHTHALENE DERIVATIVE  
RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN  
EXPRESSION IN LIVER AND USE THEREOF  
Throat solution for treatment of cold, flu and sore throat  
SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,  
AND COMMUNICATING EVENT-RELATED INFORMATION  
ANTIGEN PRESENTING CELL ASSAY  
Recombinant RNA Viruses and Uses Thereof  
METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE  
RESPONSE  
TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS  
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF  
DIRECT EXPRESSION OF ANTIBODIES  
BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE  
INHIBITORS  
MODIFIED VIRUS-LIKE PARTICLES OF CMV  
Fauci/COVID-19 Dossier  
8Not  
Available  
Not Available  
Not Available  
Not Available  
Not Available  
Baylor College of Medicine  
Not Available  
Not Available  
Parion Sciences, Inc.  
ONO PHARMACEUTICAL CO., LTD.  
Children's Healthcare of Atlanta, Inc.  
Not Available  
Georgetown University  
University of Pittsburgh - Of the Commonwealth System of  
Higher Education  
Icahn School of Medicine at Mount Sinai  
3M INNOVATIVE PROPERTIES COMPANY  
Not Available  
Not Available  
Not Available  
Purdue Research Foundation  
SAIBA GMBH  
Dec14  
21May13  
10Nov14  
28Jul-10  
12Nov14  
1Mar13  
8Sep10  
17Dec12  
3Dec14  
16Apr15  
12May16

25Feb08  
8Apr10  
6Jun10  
10Apr03  
13Nov14  
9May12  
29Oct14  
28Apr16  
22Oct14  
CC-BY-NC-SA  
Dr. David E. Martin  
1Mar  
-17  
23May  
-15  
1Aug  
-17  
9Nov  
-15  
8Aug  
-17  
11Nov  
-15  
30May  
-17  
31Jan  
-17  
7Mar  
-17  
3Dec  
-14  
15Apr  
-16  
12May  
-16  
27Jul17  
20Jul17  
6Apr  
-17  
27Jul17  
12Nov  
-15  
24Jan  
-17  
28Oct  
-15  
28Apr  
-17  
20Oct  
-15  
96  
23Nov  
-17  
23Nov

-17  
23Nov  
-17  
23Nov  
-17  
23Nov  
-17  
23Nov  
-17  
16Nov  
-17  
16Nov  
-17  
16Nov  
-17  
16Nov  
-17  
16Nov  
-17  
16Nov  
-17  
9Nov  
-17  
9Nov  
-17  
9Nov  
-17  
9Nov  
-17  
9Nov  
-17  
9Nov  
-17  
9Nov  
-17  
2Nov  
-17  
2Nov  
-17  
2Nov  
-17  
US20170312  
357  
US20170308  
679  
US20170307  
562  
US20170306  
354  
US20170306  
293  
US20170306  
001  
US20170305  
868  
US20170304

829  
US20170304  
466  
US20170304  
459  
US20170304  
429  
US20170304  
420  
US20170304  
354  
US20170299  
591  
US20170298  
100  
US20170296  
663  
US20170296  
574  
US20170292  
132  
US20170290  
909  
US20170281  
966  
US20170281  
759  
US20170275  
621  
US20170275  
592  
US20170275  
323  
US20170275  
253  
US20170275  
243  
US20170274  
064  
US20170274  
024

2MANUFACTURE

OF SURFACTANT-CONTAINING COMPOSITIONS  
BIOSECURITY SCREENING SYSTEM AND METHOD  
CHEMICALLY DIFFERENTIATED SENSOR ARRAY  
ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,  
VECTORS CONTAINING SAME, AND USES THEREFOR  
MEANS AND METHODS FOR INFLUENCING THE STABILITY OF  
ANTIBODY PRODUCING CELLS  
CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL  
ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS  
MULTIPLE INFLUENZA A H5N1 CLADES  
ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL  
SODIUM CHANNEL BLOCKING COMPOUNDS

PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION  
MODULE  
AAV-Based Gene Therapy  
METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF  
CONJUGATED OLIGONUCLEOTIDE  
VACCINATION OF IMMUNOCOMPROMISED SUBJECTS  
POLYMER ADJUVANT  
TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE  
NANOFIBERS  
EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS  
INFECTIONS AND DISEASES  
ANTI-VIRAL PEPTIDES  
Conjugates of Cell Binding Molecules with Cytotoxic Agents  
Method of Treating Inflammation  
TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION  
CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF  
METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION  
WITH RECOMBINANT MVA ENCODING FLAGELLIN  
Device to Kill Micro-Organisms Inside the Respiratory Tract  
BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL  
COMPOSITION FOR HUMORAL IMMUNITY  
CHIRAL CONTROL  
CULTURE MEDIUM  
GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF  
FOR USE IN THERAPY  
BENZAZEPINE SULFONAMIDE COMPOUNDS  
Lipids and Lipid Compositions for the Delivery of Active Agents  
MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES  
AAV Vectors Targeted to Oligodendrocytes  
Not Available  
Not Available  
Nanomedical Diagnostics, Inc.  
Not Available  
Not Available  
Dec14  
16Oct14  
28Apr14  
17Dec01  
9Dec05  
27NATIONAL  
UNIVERSITY OF SINGAPORE  
Mar14  
13Parion  
Sciences, Inc.  
Click Diagnostics, Inc.  
Not Available  
Not Available  
Not Available  
Oxford University Innovation Limited  
Marine Polymer Technologies, Inc.  
Not Available  
Not Available  
Hangzhou DAC Biotech Co., Ltd.  
Not Available

Not Available  
Bavarian Nordic A/S  
Not Available  
NITTO DENKO CORPORATION  
Not Available  
Koninklijke Nederlandse Akademie Van Wetenschappen  
THE UNIVERSITY OF NOTTINGHAM  
Hoffmann-La Roche Inc.  
Novartis AG  
Not Available  
Not Available  
Dec13  
22Apr16  
6Oct14  
10Oct14  
26Sep14  
10Oct14  
15Apr11  
6Oct08  
10Oct14  
16Apr14  
1Apr10  
29Apr13  
26Sep14  
1Apr16  
3Sep14  
13Jul-12  
27Nov14  
4Apr14  
18Dec14  
5Sep14  
5Sep14  
28Sep12  
2Dec  
-15  
12Oct  
-15  
8May  
-17  
1May  
-17  
2Jun  
-17  
27Mar  
-15  
1Mar  
-17  
21Apr  
-17  
6Oct  
-15  
7Oct  
-15  
25Sep

-15  
9Oct  
-15  
13Mar  
-17  
13Dec  
-16  
30Sep  
-15  
16Apr  
-14  
28Jun  
-17  
20Jun  
-17  
25Sep  
-15  
28Mar  
-17  
2Sep  
-15  
17Mar  
-17  
27Nov  
-15  
7Apr  
-15  
14Jun  
-17  
4Sep  
-15  
4Sep  
-15  
17Apr  
-17  
2Nov  
-17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
26Oct17  
19Oct17  
19Oct17  
19Oct17  
19Oct17  
12Oct17

12Oct17  
5Oct17  
5Oct17  
28Sep  
-17  
28Sep  
-17  
28Sep  
-17  
28Sep  
-17  
28Sep  
-17  
28Sep  
-17  
28Sep  
-17  
28Sep  
-17  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
97  
US20170267  
969  
US20170267  
722  
US20170267  
649  
US20170266  
272  
US20170266  
190  
US20170266  
160  
US20170261  
431  
US20170260  
223  
US20170260  
147  
US20170259  
976  
US20170258  
904  
US20170258  
893  
US20170253  
861  
US20170252  
430  
US20170252  
417  
US20170247  
688  
US20170247



453

US20170247

423

US20170246

347

US20170241

998

US20170240

639

US20170239

397

US20170239

364

US20170239

349

US20170239

291

US20170234

781

US20170226

593

US20170226

511

US20170226

232

29Animal

Protein-Free Media for Cultivation of Cells

INHIBITORY PEPTIDES OF VIRAL INFECTION

STABLE SODIUM CHANNEL BLOCKERS

TRANSGENIC VERO-CD4/CCR5 CELL LINE

DRUG COMBINATION

METHODS FOR TREATING PULMONARY EMPHYSEMA USING  
SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC  
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF  
CATHEPSIN C

CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC  
ACID AMPLIFICATION ASSAYS

ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A  
ANTIVIRAL COMPOUNDS AND METHODS

DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME

Antagonism of the VIP Signaling Pathway

MERS-CoV Vaccine

HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS

POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN  
IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT

PROTEIN-CHAPERONED T-CELL VACCINES

ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF  
LARGE LIBRARIES

SOLUBLE ENGINEERED MONOMERIC FC

STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES  
TO TREAT INFECTION

MATERIALS WITH IMPROVED PROPERTIES

METHOD FOR THE IMMOBILIZATION OF BIOMOLECULES

Baxalta GmbH

Not Available  
PARION SCIENCES, INC.  
Not Available  
Not Available  
Oct04  
17Jul-14  
30Jun14  
20Oct15  
15Mar13  
14Not  
Available  
Mar13  
10Not  
Available  
Not Available  
Biotron Limited  
MONOSOL, LLC  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
NUEVOLUTION A/S  
The United States of America, as represented by the  
Secretary, Department of Health and Human Serv  
Not Available  
Not Available  
Not Available  
ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY Not Available  
MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND  
APPLICATIONS  
METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL  
ENTRY  
COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL  
DISORDERS  
METHOD OF PREVENTING OR TREATING SINUSITIS WITH  
OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION  
MEMBRANE-ASSISTED PURIFICATION  
HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID  
IDENTIFICATION  
APTAMERS FOR BINDING FLAVIVIRUS PROTEINS  
MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND  
APPLICATIONS  
Not Available  
Not Available  
Not Available  
SONOMA PHARMACEUTICALS, INC.  
Accelerate Diagnostics, Inc.  
Not Available  
National University of Singapore  
Not Available  
Mar05  
4Aug14  
26Jun03

30Oct14  
2Feb11  
29Nov13  
11Jul-03  
1Apr14  
7Mar16  
1Dec05  
16Mar12  
29Feb16  
1Nov15  
22Feb16  
22Feb16  
1Nov15  
28Mar11  
20Feb15  
30Dec03  
7Mar11  
8Feb16  
13Nov13  
1Nov15  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
18May  
-17  
25May  
-17  
30Jan  
-17  
6Apr  
-17  
5Jun  
-17  
6Jun  
-17  
19May  
-17  
17May  
-17  
23May  
-17  
20ct  
-15  
22May  
-17  
26Nov  
-14  
6Oct  
-16  
1Apr  
-15  
7Mar  
-17  
12Dec



7Sep  
-17  
7Sep  
-17  
31Aug  
-17  
31Aug  
-17  
31Aug  
-17  
31Aug  
-17  
24Aug  
-17  
24Aug  
-17  
24Aug  
-17  
24Aug  
-17  
24Aug  
-17  
24Aug  
-17  
24Aug  
-17  
17Aug  
-17  
10Aug  
-17  
10Aug  
-17  
10Aug  
-17  
US20170226  
222  
US20170226  
173  
US20170224  
813  
US20170224  
812  
US20170224  
616  
US20170219  
560  
US20170216  
431  
US20170216  
430  
US20170216  
429  
US20170216  
427  
US20170216  
348

20BISPECIFIC  
ANTIBODY  
GM-CSF and IL-4 Conjugates, Compositions, and Methods Related  
Thereeto  
VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING  
APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION  
OF CTL  
LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND  
VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE  
THROMBOSIS TREATMENT DRUG  
OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS  
MALARIA ANTIGEN SCREENING METHOD  
VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL  
ADMINISTRATION  
IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING  
NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL  
COMPOSITION  
COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL  
IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION  
Coronavirus  
METAL NANOCCLUSERS AND USES THEREOF  
Not Available  
Not Available  
NITTO DENKO CORPORATION  
Nov13  
23Oct12  
4Aug14  
4NITTO  
DENKO CORPORATION  
Aug14  
GLAXOSMITHKLINE  
BIOLOGICALS SA  
United States of America as Represented by the Secretary  
of the Navy  
NITTO DENKO CORPORATION  
NITTO DENKO CORPORATION  
6-Jul11  
31Aug05  
20Oct14  
4Aug14  
4NITTO  
DENKO CORPORATION  
Not Available  
Not Available  
Aug14  
23Jul-14  
7Aug14  
18Jan  
-17  
19Apr  
-17  
4Aug  
-15  
4Aug

-15  
24Apr

-17  
10Apr

-17  
10Oct

-15  
4Aug

-15  
4Aug

-15  
23Jul15

7Aug

-15  
10Aug

-17  
10Aug

-17  
10Aug

-17  
10Aug

-17  
10Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

-17  
3Aug

US20170216

347

ANIONICALLY

MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF  
ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS  
MEDICINE, PARTICULARLY FOR PROPHYLAXIS AND TREATMENT OF  
INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN  
METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND  
INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND  
PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY  
MODIFIED POLYALLYLAMINE DERIVATIVE

UNIWERSYTET JAGIELLONSKI

29Jul-14

29Jul15

Aug

-17

3US20170212

116

US20170212  
019  
US20170211  
096  
US20170211  
069  
US20170211  
058  
US20170209  
844  
US20170209  
595  
US20170209  
590  
US20170209  
570  
US20170209  
376  
US20170205  
399  
BIOSENSORS  
FOR THE DETECTION OF INFECTION AND  
ASSOCIATED MALADIES  
31ULISSE  
BIOMED SRL  
POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS  
LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating VirusProducing  
Cells for the Therapy of Tumors  
USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR  
TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY  
METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF  
POOLED SAMPLES  
MICROSPOTTING DEVICE  
DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELLBINDING  
MOLECULE  
METHODS AND REAGENTS FOR EFFICIENT AND TARGETED  
DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS  
Carbon Nanotube Compositions and Methods of Use Thereof  
COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL  
NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND  
TREATMENT OF VIRAL DISEASES  
POLYMERS AND CONJUGATES COMPRISING THE SAME  
Fauci/COVID-19 Dossier  
Not Available  
Not Available  
University of Pittsburgh - Of the Commonwealth System of  
Higher Education  
Not Available  
Not Available  
Suzhou M-Conj Biotech Co., Ltd.  
Not Available  
Not Available  
Jan14  
23Jan12



29Jun11  
7Mar12  
6Aug14  
18Apr12  
15Jul-15  
13Jan11  
19Mar08  
14Not  
Available  
Apr04  
2Not  
Available  
CC-BY-NC-SA Dr. David E. Martin  
Oct14  
26Jan  
-15  
10Apr  
-17  
7Apr  
-17  
27Jan  
-17  
5Aug  
-15  
5Jan  
-17  
5Apr  
-17  
10Jan  
-17  
17Mar  
-17  
10Mar  
-17  
31Mar  
-17  
99  
27Jul17  
27Jul17  
27Jul17  
27Jul17  
27Jul17  
27Jul17  
27Jul17  
27Jul17  
27Jul17  
27Jul17  
20Jul17  
US20170204  
143  
US20170204  
083  
US20170202  
975

US20170202  
960  
US20170202  
959  
US20170202  
956  
US20170202  
955  
US20170202  
949  
US20170202  
829  
US20170196  
979  
US20170196  
954  
US20170191  
933  
US20170191  
079  
US20170190  
770  
US20170189  
521  
US20170175  
140  
US20170173  
585  
US20170173  
176  
US20170173  
168  
US20170173  
164  
US20170168  
052  
US20170168  
044  
US20170166  
574  
US20170165  
366  
US20170165  
359  
US20170165  
341  
US20170165  
230  
US20170160  
218

Constrained proteins and uses therefor

Not Available

THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES  
AND HYDROXYPYRIDAZINONES

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELLBINDING MOLECULE

CATIONIC OIL-IN-WATER EMULSIONS

ADJUVANT COMPOSITIONS AND RELATED METHODS

Methods and Compositions for Inhibiting Akt3

Adjuvanted Influenza Vaccines for Pediatric Use

DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND

METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE

Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS

PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR

Systems and Methods for Analyzing a Sample and for Monitoring the Performance of an Optical Signal Detector

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Suzhou M-Conj Biotech Co., Ltd.

GLAXOSMITHKLINE BIOLOGICALS, SA

Not Available

Not Available

Not Available

Providence Health & Services - Oregon

Not Available

Novartis AG

Not Available

Not Available

Not Available

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) CORMORANT PHARMACEUTICALS AB

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND

COMPOSITIONS, FORMULATIONS, AND METHODS

METHODS FOR USING A 5'-EXONUCLEASE TO INCREASE

HOMOLOGOUS RECOMBINATION IN EUKARYOTIC CELLS

POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR DISEASE DETECTION

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE

HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES

QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE MEASURING

NOVEL COMPOUNDS

Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof

IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND METHODS OF USE

3M Innovative Properties Company

Not Available

Not Available

SUZHOU M-CONJ BIOTECH CO., LTD.  
SUZHOU M-CONJ BIOTECH CO., LTD.

Not Available

Not Available

XIAMEN UNIVERSITY

CHIESI FARMACEUTICI S.P.A.

Not Available

Not Available

REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION Not Available

USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE

PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY

APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT

ANALYSES AND AMPLIFICATIONS

Not Available

Not Available

21Jul-14

11Sep12

15Jul-15

6-Jul11

24Mar15

15Jan16

22Feb08

29Jul-05

15Jan16

8Mar13

15Jul-14

31Dec15

7Apr05

16Dec02

17Aug10

16Dec15

11Jul-14

15Jul-15

15Jul-15

3Jun11

6Oct08

9Jun14

14Dec15

10Oct15

11Aug10

24Aug12

9Apr14

31Jul-12

21Jul15

13Jan

-17

5Apr

-17

23Mar

-17

23Mar

-17

17Jan

-17



6Jul17  
6Jul17  
6Jul17  
22Jun17  
22Jun17  
22Jun17  
22Jun17  
22Jun17  
15Jun17  
15Jun17  
15Jun17  
15Jun17  
15Jun17  
15Jun17  
15Jun17  
8Jun17  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
100  
  US20170159  
027  
US20170159  
026  
US20170158  
752  
US20170157  
262  
US20170157  
151  
US20170152  
274  
US20170152  
271  
US20170151  
346  
US20170151  
291  
US20170145  
394  
US20170144  
984  
US20170143  
845  
US20170143  
820  
US20170143  
758  
US20170143  
749  
US20170137  
527  
US20170137  
430

US20170136  
118  
US20170136  
043  
US20170131  
271  
US20170130  
200  
US20170129  
947  
US20170129  
891  
US20170128  
465  
US20170122  
853  
US20170121  
372  
US20170119  
872  
US20170119  
871  
US20170119  
820  
ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS  
CONTAINING SAME, AND USES THEREFOR  
Novel Recombinant Adeno-Associated Virus Capsids with Enhanced  
Human Skeletal Muscle Tropism  
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS  
NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF  
CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC  
AGENTS  
Broad Spectrum Antiviral and Methods of Use  
CHARGED LINKERS AND THEIR USES FOR CONJUGATION  
GAK MODULATORS AS ANTIVIRALS  
DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELLBINDING  
MOLECULE  
SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF  
PRODUCTION AND USE THEREOF  
TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR  
DELIVERY OF CRISPR/CAS9  
MODULATORS OF THE RELAXIN RECEPTOR 1  
ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC  
CONJUGATION OF A CELL-BINDING MOLECULE  
IMMUNOGENIC COMBINATIONS  
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY  
DISEASES  
SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS  
THEREOF  
GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING  
AN IMMUNE RESPONSE  
Nuclear Transport Modulators And Uses Thereof  
NEUTRALIZING MOLECULES TO VIRAL ANTIGENS  
THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE

COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY  
ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR  
MAKING AND USING SUCH CONJUGATES  
INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF  
THERAPY

REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND  
LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE  
SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND  
IMIDAZONAPHTHYRIDINES

Pharmaceutical Compositions and Methods

PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN  
VIVO

NOVEL DEPSIPEPTIDE AND USES THEREOF

30Not

Available

Not Available

Not Available

Not Available

Not Available

Not Available

Hangzhou DAC Biotech Co., Ltd.  
Katholieke Universiteit Leuven

SUZHOU M-CONJ BIOTECH CO., LTD.

Not Available

Not Available

Not Available

SUZHOU M-CONJ BIOTECH CO., LTD

GLAXOSMITHKLINE SA

Advanced Inhalation Therapies (AIT) Ltd.

Not Available

Not Available

Not Available

Not Available

The University of North Carolina at Chapel Hill

Not Available

Not Available

Kolltan Pharmaceuticals, Inc.

Not Available

Not Available

THE UNITED STATES OF AMERICA, AS REPRESENTED BY

THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN

SERV

Not Available

SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available

LOW-ADDITIVE INFLUENZA VACCINES

MODIFIED CELLS AND METHODS OF THERAPY

Fauci/COVID-19 Dossier

Not Available

Not Available

CC-BY-NC-SA Dr. David E. Martin

Sep03

2Dec15

25Apr14

12Jul-12

17Apr06



28Feb14  
23Jul-14  
15Jul-15  
25Nov13  
23Nov15  
4May12  
15Jul-15  
13Jun14  
11Sep13  
24Jun14  
25Mar05  
29Jul-11  
28Mar08  
11Apr14  
27Apr10  
31Jul-15  
25Jul-12  
18Jun04  
3Aug15  
8Aug14  
3Dec12  
20Aug10  
27Jun07  
31Jul-15  
15Feb  
-17  
2Dec  
-16  
27Apr  
-15  
12Jul12  
16Feb  
-17  
28Feb  
-14  
23Jul15  
13Feb  
-17  
25Nov  
-14  
22Nov  
-16  
25Aug  
-16  
3Feb  
-17  
12Jun  
-15  
4Jan  
-17  
2Feb  
-17  
7Nov  
-16

22Jul16  
8Jun  
-16  
30Jan  
-17  
12Sep  
-16  
29Jul16  
20Sep  
-16  
23Jan  
-17  
6Dec  
-16  
7Aug  
-15  
15Jun  
-16  
11Oct  
-16  
24Jun  
-16  
29Jul16  
8Jun17  
8Jun17  
8Jun17  
8Jun17  
8Jun17  
1Jun17  
1Jun17  
1Jun17  
1Jun17  
25May  
-17  
25May  
-17  
25May  
-17  
25May  
-17  
25May  
-17  
25May  
-17  
25May  
-17  
18May  
-17  
18May  
-17  
18May  
-17  
18May  
-17  
11May  
-17

11May  
-17  
11May  
-17  
11May  
-17  
11May  
-17  
4May  
-17  
4May  
-17  
4May  
-17  
4May  
-17  
4May  
-17  
101  
US20170119  
786  
US20170119  
734  
US20170118  
995  
US20170114  
053  
US20170112  
929  
US20170107  
254  
US20170107  
195  
US20170106  
077  
US20170101  
459  
US20170101  
413  
US20170100  
474  
US20170100  
385  
US20170096  
646  
US20170096  
455  
US20170096  
441  
US20170096  
417  
US20170095  
818  
US20170095

521

US20170089

911

US20170088

858

US20170088

848

US20170088

559

US20170086

463

US20170082

608

US20170082

607

US20170081

655

US20170081

393

US20170081

392

8HETEROCYCLIC

MODULATORS OF LIPID SYNTHESIS

TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE

MINERAL FUNCTIONAL WATER, METHOD FOR PRODUCING THE

SAME, AND METHOD FOR CONTROLLING UNICELLULAR

ORGANISMS AND/OR VIRUSES

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

Not Available

Not Available

Mar11

5May10

17Riken

Techno System Co., Ltd.

The United States of America, as represented by the

Secretary, Department of Health and Human Serv

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available

Modified Antimicrobial Peptides

Chemical Compounds

INFLUENZA VIRUS VECTORS AND USES THEREFOR

CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY

COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING

PEPTIDES

NOVEL COMPOUNDS

Not Available

AstraZeneca AB

Not Available

Not Available

CHIESI FARMACEUTICI S.p.A.

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available

PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR

TREATING INFECTIOUS DISEASES

Modified Adenovirus Hexon Protein and Uses Thereof

METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS

SPIKE PROTEINS

PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF  
VIRAL INFECTIONS

Multicyclic Compounds And Methods Of Using Same  
INTEGRATED MICROFLUIDIC DEVICE FOR TARGET AMPLIFICATION  
AND MICROARRAY DETECTION

Novel Polygonum Cuspidatum Extracts and Their Use as  
Photodynamic Inactivating Agents

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,  
VECTORS CONTAINING SAME, AND USES THEREFOR

Recombinant Influenza Virus-Like Particles (VLPs) Produced in  
Transgenic Plants Expressing Hemagglutinin

ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND  
THIAZOLONAPHTHYRIDINES

ANTIVIRAL AGENT

Assay for Detecting TH1 and TH2 Cell Populations

MALARIA ANTIGEN SCREENING METHOD

PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM  
OXIDES

ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES

COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY  
CONSTRUCTS AND USES THEREOF

GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2)  
LIMITED

Not Available

The University of North Carolina at Chapel Hill

Not Available

Karyopharm Therapeutics Inc.

CapitalBio Corporation

Not Available

Not Available

Not Available

Medicago Inc.

Not Available

Not Available

Not Available

Not Available

Not Available

The U.S.A., as represented by the Secretary, Department  
of Health and Human Services

Not Available

Sep14

12Jun14

7Sep12

2Apr14

18Mar14

17Mar14

6Jun14

12Jun14

6Apr07

12May14

28Apr06

20Mar14

14Apr10  
20Sep13  
31Mar14  
10Oct15  
24Feb14  
17Dec01  
21Jan08  
9Feb05  
3Sep08  
16May14  
31Aug05  
14Jul-15  
31Jan08  
13May14  
11Nov  
-16  
22Apr  
-16  
6Dec  
-16  
12Jun  
-15  
6Jun  
-16  
2Apr  
-15  
17Mar  
-15  
13Mar  
-15  
5Jun  
-15  
12Jun  
-14  
22Jul16  
8May  
-15  
20Dec  
-16  
20Mar  
-15  
9Sep  
-16  
19Sep  
-14  
31Mar  
-15  
30Sep  
-16  
24Aug  
-16  
20Oct  
-16  
2Sep

-16  
12Dec  
-16  
12Dec  
-16  
15May  
-15  
19Apr  
-13  
13Jul16  
2Dec  
-16  
13May  
-15  
4May  
-17  
4May  
-17  
4May  
-17  
27Apr17  
27Apr17  
20Apr17  
20Apr17  
20Apr17  
13Apr17  
13Apr17  
13Apr17  
13Apr17  
6Apr17  
6Apr17  
6Apr17  
6Apr17  
6Apr17  
6Apr17  
30Mar  
-17  
30Mar  
-17  
30Mar  
-17  
30Mar  
-17  
30Mar  
-17  
23Mar  
-17  
23Mar  
-17  
23Mar  
-17  
23Mar  
-17  
23Mar

-17

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

102

US20170080

084

US20170080

079

US20170080

078

US20170079

920

US20170079

916

US20170079

253

US20170073

738

US20170073

730

US20170073

727

US20170073

390

US20170073

352

US20170072

053

US20170071

980

US20170071

964

US20170071

867

US20170067

030

US20170067

021

US20170066

788

US20170066

787

US20170066

731

US20170065

706

US20170065

693

US20170065

677

US20170065

636

US20170058



430

US20170058

365

US20170057

978

US20170057

968

US20170057

938

17OIL/SURFACTANT

MIXTURES FOR SELF-EMULSIFICATION

METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING

PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME

Technology for the Preparation of Microparticles

COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER

NANOPARTICLE DELIVERY

TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY

COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND

APPLICATIONS

Compositions and Methods for Detecting and Quantifying Nucleic

Acid Sequences in Blood Samples

METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATION

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING

ADSORPTION MEDIA

Method for Identifying and Validating Dominant T Helper Cell

Epitopes Using an HLA-DM-Assisted Class II Binding Assay

NOVEL SUBSTITUTED SPIROCYCLES

METHODS FOR PREPARING SQUALENE

METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER

SOLUTION IN DENTAL APPLICATIONS

METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE

VIRUS INFECTIONS

NOVEL NANOPARTICLE COMPOSITIONS

ATTENUATED VIRUSES USEFUL FOR VACCINES

MODIFIED CELLS AND METHODS OF THERAPY

BORON-CONTAINING SMALL MOLECULES

BORON-CONTAINING SMALL MOLECULES

SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS

METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS

VECTOR FOR USE WITH MULTIPLE VACCINATIONS

Sequential administration of a replication defective adenovirus

vector in vaccination protocols

EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE

RESPIRATORY TRACT

MODIFIED CELLS AND METHODS OF THERAPY

BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONS

Not Available

Not Available

Not Available

Not Available

Not Available

INSTITUT PASTEUR

Longhorn Vaccines and Diagnostics, LLC

Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
OCULUS INNOVATIVE SCIENCES, INC.  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Volution Immuno Pharmaceuticals SA  
Not Available  
Not Available  
SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS Not Available  
ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND  
METHODS OF USE THEREOF  
COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7  
AGONISTS  
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4OXAZEPANE-2-CARBOXAMIDES  
AS DIPEPTIDYL PEPTIDASE 1  
INHIBITORS  
Fauci/COVID-19 Dossier  
Kineta, Inc.  
NOVARTIS AG  
Not Available  
CC-BY-NC-SA Dr. David E. Martin  
Mar14  
23Sep15  
24Apr12  
24Jul-07  
23Sep15  
30Jul-03  
10Oct07  
11Sep15  
8Nov13  
6Jan06  
12Sep14  
12May10  
2May05  
16Sep15  
3Apr13  
30Mar07  
31Jul-15  
16Feb05  
16Feb05  
7Mar14  
2-Jul07  
2-Jul07  
8Jan10

31Jul-15  
18Feb14  
1Sep15  
9May14  
1May14  
24Jan14  
17Mar  
-15  
23Sep  
-16  
30Oct  
-16  
5Dec  
-16  
23Sep  
-16  
17Jul12  
25Nov  
-16  
8Sep  
-16  
2Nov  
-16  
5Dec  
-14  
29Nov  
-16  
22Nov  
-16  
22Nov  
-16  
16Sep  
-16  
28Nov  
-16  
7Sep  
-16  
2Sep  
-16  
18Nov  
-16  
18Nov  
-16  
5Mar  
-15  
14Sep  
-16  
14Sep  
-16  
22Jul16  
29Aug  
-16  
18Feb  
-15



-17  
9Mar  
-17  
2Mar  
-17  
2Mar  
-17  
2Mar  
-17  
2Mar  
-17  
2Mar  
-17  
US20170052  
190  
US20170051  
053  
US20170051  
046  
US20170051  
022  
US20170051  
007  
US20170049  
813  
US20170044  
603  
US20170044  
595  
US20170044  
237  
US20170044  
168  
US20170042  
994  
US20170042  
898  
US20170039  
316  
US20170039  
314  
US20170038  
085  
US20170037  
457  
US20170037  
379  
US20170037  
376  
US20170037  
090  
US20170037  
045  
US20170035

878

US20170035

845

US20170029

877

US20170029

847

US20170029

489

US20170028

082

US20170028

054

US20170027

975

Covalently Linked Thermostable Kinase for Decontamination Process Validation

METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY

H1N1 FLU VIRUS NEUTRALIZING ANTIBODIES

ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY

PHARMACEUTICAL COMPOSITIONS AND METHODS

ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE

AND METHODS OF MAKING AND USING THE SAME

CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID

SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS

PCR Ready Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences

ANTIBODIES AND PROCESSES FOR PREPARING THE SAME

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7

AGONISTS

COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE

ANTIGEN TO DENDRITIC CELLS

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY INDUCED CONDITIONS

Compositions, processes and algorithms for microbial detection

BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE

BINDING

AIR CURTAIN DEVICE

NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING

MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAME

CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS

AND USES THEREOF

METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL,

COMPOSITION USED IN METHOD, AND USES THEREOF

RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING

POLYGENES

HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL

SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE

THEREFROM

Multi-Functional Mucosal Vaccine Platform

Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression

POLYTAG PROBES

ARTIFICIAL NUCLEIC ACID MOLECULES  
HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE  
VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF  
ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS  
CONTAINING SAME, AND USES THEREFOR  
VACCINE COMPOSITION

Methods of Treating Coronavirus Infection

20Not

Available

Not Available

MEDIGEN BIOTECHNOLOGY CORPORATION

Not Available

Not Available

OCULUS INNOVATIVE SCIENCES, INC.

Not Available

Longhorn Vaccines and Diagnostics, LLC

Not Available

NOVARTIS AG

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

HEMAQUEST PHARMACEUTICALS, INC.

Not Available

IOGENETICS, LLC

Not Available

Not Available

Icahn School of Medicine at Mount Sinai

GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH,

CHINESE ACADEMY OF SCIENCES

Not Available

3M Innovative Properties Company

Not Available

Not Available

Not Available

CureVac AG

Not Available

Feb08

28Dec11

20Aug15

30Apr14

3Aug15

13Mar07

31Jul-09

24Aug07

16May08

1May14

22Jul-11

11Mar10

12Nov03

23Mar10

7Aug15

5Feb14

2Dec05

15Nov13

8Nov05

3Jun11

11Feb14  
7Aug15  
26Feb10  
30Dec13  
14Dec10  
30Not  
Available  
NITTO DENKO CORPORATION  
United States Government as represented by the  
Secretary, Department of Health and Human Services  
Sep03  
4Apr12  
7Apr14  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
8Jul16  
7Sep  
-16  
20Aug  
-15  
30Apr  
-15  
28Jul16  
8Nov  
-16  
15Aug  
-16  
26Oct  
-16  
23Aug  
-16  
29Apr  
-15  
29Jul16  
27Oct  
-16  
25Oct  
-04  
13Sep  
-12  
19Nov  
-15  
29Jan  
-15  
3Mar  
-16  
12Nov  
-14  
26Oct  
-16  
24Oct  
-16  
11Feb





9Feb  
-17  
9Feb  
-17  
9Feb  
-17  
2Feb  
-17  
2Feb  
-17  
2Feb  
-17  
2Feb  
-17  
2Feb  
-17  
2Feb  
-17  
US20170027  
944  
US20170022  
577  
US20170022  
242  
US20170021  
013  
US20170020  
926  
US20170016  
048  
US20170015  
716  
US20170014  
496  
US20170014  
423  
US20170011  
131  
US20170010  
264  
US20170009  
237  
US20170007  
577  
US20170002  
042  
US20170000  
878  
US20170000  
873  
US20160376  
596  
US20160376  
321

US20160375  
137  
US20160375  
132  
US20160369  
268  
US20160368  
956  
US20160368  
904  
US20160367  
587  
US20160367  
188  
US20160363  
557  
US20160362  
730  
US20160362  
454  
US20160361  
382  
24METHODS  
FOR TREATING VIRAL DISORDERS  
METHODS OF TESTING FOR INTRACELLULAR PATHOGENS  
NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS  
D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND  
METHODS OF USE THEREOF  
METHODS AND COMPOSITIONS FOR IMMUNOMODULATION  
COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF  
NUCLEIC ACIDS  
STABILIZED ANTI-MICROBIAL PEPTIDES  
COMBINATION OF VACCINATION AND OX40 AGONISTS  
Benzazepine Dicarboxamide Compounds  
SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,  
AND COMMUNICATING EVENT RELATED INFORMATION  
EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS  
INFECTIONS AND DISEASES  
Short Interfering RNA (siRNA) Analogues  
METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF  
BRAIN INFLAMMATION AND SEPSIS  
PEPTIDOMIMETIC MACROCYCLES  
CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES  
THEREFOR  
Dimethyl Fumarate and Vaccination Regimens  
COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED  
IMMUNE RESPONSE USING POXVIRUS VECTORS  
A NOVEL SARS IMMUNOGENIC COMPOSITION  
TARGETING LIPIDS  
HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING  
COMPOUNDS AND USES THEREOF  
TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES  
AND METHODS OF SYNTHESIS AND USE  
METHOD OF PREVENTIVELY TREATING A SUBJECT AT THE RISK OF

DEVELOPING INFECTIONS OF A RESPIRATORY VIRUS  
SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS  
AND USES THEREOF

Systemic In Vivo Delivery of Oligonucleotides  
ORAL SENSOR ALERTING AND COMMUNICATION SYSTEM AND  
DEVELOPERS' TOOL KIT  
AMPEROMETRIC GAS SENSOR

Not Available

Novartis AG

KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D

Not Available

Not Available

Not Available

Not Available

Not Available

Hoffmann-La Roche Inc.

Georgetown University

Not Available

Not Available

Not Available

Not Available

Not Available

Not Available

Bavarian Nordic A/S

BAYLOR COLLEGE OF MEDICINE

Tekmira Pharmaceuticals Corporation

Not Available

The Board of Regents of the University of Texas System

Not Available

Not Available

OncoImmulin, Inc.

Not Available

Not Available

PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS Not Available

Identification and Attenuation of the Immunosuppressive Domains  
in Fusion Proteins of Enveloped RNA Viruses

MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF  
VIRAL INFECTIONS

Not Available

Not Available

Sep09

8Mar10

17Apr14

30Nov12

1Apr14

18May15

2-Jul15

12Mar14

6Mar15

25Feb08

6Oct08

21Mar03

29Nov02

1-Jul15

23Jun10  
14Mar14  
28Nov13  
26Nov13  
4Dec07  
15Dec09  
1-Jul13  
9May13  
3-Jul13  
12Jun13  
17Jun15  
25Jun12  
26Feb14  
7Oct11  
11Jun15  
Fauci/COVID-19  
Dossier  
18Feb  
-15  
23Sep  
-16  
17Apr  
-15  
31Mar  
-16  
13Mar  
-15  
17May  
-16  
1Jul16  
12Mar  
-14  
28Sep  
-16  
23Sep  
-16  
20Sep  
-16  
28Mar  
-16  
19Sep  
-16  
1Jul16  
9Aug  
-16  
13Mar  
-15  
25Nov  
-14  
21Nov  
-14  
22Oct  
-13  
5Jul16

25Jun  
-14  
23Aug  
-16  
3Jul14  
12Jun  
-14  
10Sep  
-15  
25Aug  
-16  
26Aug  
-16  
10Jun  
-16  
13Jun  
-16  
CC-BY-NC-SA  
Dr. David E. Martin  
105  
2Feb  
-17  
26Jan17  
26Jan17  
26Jan17  
26Jan17  
19Jan17  
19Jan17  
19Jan17  
19Jan17  
12Jan17  
12Jan17  
12Jan17  
12Jan17  
5Jan17  
5Jan17  
5Jan17  
29Dec  
-16  
29Dec  
-16  
29Dec  
-16  
29Dec  
-16  
22Dec  
-16  
22Dec  
-16  
22Dec  
-16  
22Dec  
-16  
22Dec

-16  
15Dec  
-16  
15Dec  
-16  
15Dec  
-16  
15Dec  
-16  
US20160361  
259  
US20160354  
451  
US20160354  
428  
US20160354  
347  
US20160348  
153  
US20160348  
132  
US20160348  
115  
US20160348  
110  
US20160347  
816  
US20160347  
814  
US20160347  
784  
US20160346  
309  
US20160340  
713  
US20160340  
319  
US20160339  
097  
US20160338  
998  
US20160333  
356  
US20160333  
089  
US20160333  
076  
US20160331  
828

23Methods

for the Preparation of Liposomes

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN  
AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS

METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL

ENTRY

Nuclear Transport Modulators and Uses Thereof  
EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES  
FROM PATHOGENS

Not Available

Not Available

Not Available

Not Available

THE UNITED STATES OF AMERICA, as represented by the  
Secretary, Department of Health and Human Serv  
TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available  
CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with  
Enhanced Immunostimulatory Activity

NUCLEIC ACID CHEMICAL MODIFICATIONS

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR  
TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER

VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR  
TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE  
RELATED DISEASES

Not Available

Not Available

Not Available

Sep09

31Aug07

8Feb07

9May12

29May15

18May04

27Sep06

2Mar09

15Apr11

11Not

Available

NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF Not Available  
TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL  
METABOLIC PATHWAYS

STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF  
RIBONUCLEIC ACID

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE  
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

CORONAVIRUS PROTEINS AND ANTIGENS

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND  
COMBINATIONS THEREOF

OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR  
PATHWAY

Antigenic GM-CSF Peptides and Antibodies to GM-CSF

NEUTRALIZING GP41 ANTIBODIES AND THEIR USE

NUCLEIC ACID VACCINES

US20160331

816

ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)  
OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS  
ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION  
AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY



INDUCED OCULAR DISORDERS

US20160331

758

US20160327

506

US20160327

484

US20160326

598

US20160326

325

Not Available

Not Available

Not Available

MJ Biologics, Inc.

3-V Biosciences, Inc.

Not Available

Not Available

The United States of America, as represented by the

Secretary, Department of Health and Human Serv

Moderna Therapeutics, Inc.

Sep13

6-Jul09

1Jun07

6Oct06

6Feb13

7Feb14

20Dec13

3Mar11

8Feb06

7Nov11

23Apr14

18Not

Available

Oct13

1TOLL-LIKE

RECEPTOR AGONIST FORMULATIONS AND THEIR USE Not Available

CAPACITIVE LIQUID CRYSTAL BIOSENSORS

A METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF

A PLANT OR YEAST HYDROLYSATE AND ITS USE

METHODS AND COMPOSITIONS FOR PROSTATE CANCER

METASTASIS

POWDERED POUCH AND METHOD OF MAKING SAME

Not Available

Not Available

Not Available

Not Available

Aug08

6May15

30Dec13

25Mar11

16Apr12

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

2Aug

-16

9Jun

-16

2Jun

-16

6Jan

-16

31May

-16

11Aug

-16

26May

-16

11Aug

-16

29Feb

-16

10Mar

-16

27May

-16

21Dec

-15

20May

-16

5Aug

-16

4Aug

-16

19Dec

-14

28Jul16

18Jul16

2Aug

-16

5Apr

-16

18Apr

-16

21Dec

-15

5May

-16

18Dec

-14

27May

-16

19Jul16

15Dec

-16

8Dec

-16

8Dec  
-16  
8Dec  
-16  
1Dec  
-16  
1Dec  
-16  
1Dec  
-16  
1Dec  
-16  
1Dec  
-16  
1Dec  
-16  
1Dec  
-16  
1Dec  
-16  
24Nov  
-16  
24Nov  
-16  
24Nov  
-16  
24Nov  
-16  
17Nov  
-16  
17Nov  
-16  
17Nov  
-16  
17Nov  
-16  
17Nov  
-16  
17Nov  
-16  
17Nov  
-16  
17Nov  
-16  
10Nov  
-16  
10Nov  
-16  
10Nov  
-16  
10Nov  
-16  
106  
US20160326  
233  
US20160326  
141  
US20160325

283  
US20160324  
834  
US20160320  
390  
US20160318  
985  
US20160318  
861  
US20160317  
647  
US20160317  
637  
US20160317  
496  
US20160317  
458  
US20160312  
276  
US20160311  
886  
US20160311  
835  
US20160311  
816  
US20160311  
759  
US20160310  
511  
US20160305  
936  
US20160304  
954  
US20160304  
942  
US20160304  
904  
US20160304  
883  
US20160304  
882  
US20160304  
586  
US20160304  
579  
US20160304  
472  
US20160303  
194  
US20160303  
052  
US20160299  
141  
US20160298

179

NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST  
HEPATITIS B VIRUS SURFACE ANTIGEN

16Not

Available

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE  
AGAINST CANCER AND VIRAL INFECTIONS

BIOAGENT DETECTION SYSTEMS, DEVICES, AND METHODS

Use of mTOR Inhibitors to Enhance T Cell Immune Responses

COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES

Chimeric Virus-Like Particles Incorporating Fusion GPI Anchored  
GM-CSF and IL-4 Conjugates

NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS

NUCLEIC ACID VACCINES

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE  
THEREOF

METHODS OF TREATING CANCER AND OTHER DISORDERS

Lipids and Lipid Compositions for the Delivery of Active Agents

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME

AMPLIFICATION

Constructs Binding to Phosphatidylserine and Their Use in Disease  
Treatment and Imaging

NOVEL ANTIBIOTICS

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

Lipids and Lipid Compositions for the Delivery of Active Agents

Myxovirus Therapeutics, Compounds, and Uses Related Thereto

DIRECT CLONE ANALYSIS AND SELECTION TECHNOLOGY

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE

VARIANTS

Enhanced Methods of Ribonucleic Acid Hybridization

Directed Evolution and In Vivo Panning of Virus Vectors

ARTIFICIAL NUCLEIC ACID MOLECULES

METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING

INHIBITORY GENE PRODUCTS

PROCESS FOR PREPARING INFLUENZA VACCINES

POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF

AUTOIMMUNE DISORDERS AND INFECTION

Hydrazide Containing Nuclear Transport Modulators and Uses  
Thereof

Compositions And Method For Treatment Of Inflammatory Bowel  
Disease

MODULAR PARTICLES FOR IMMUNOTHERAPY

NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN

DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS

LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES

FOR MICROARRAY-BASED ASSAYS

Fauci/COVID-19 Dossier

Not Available

Not Available

Not Available

Not Available

Not Available

PARION SCIENCES, INC.

Moderna Therapeutics, Inc.

Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
CureVac AG  
GenVec, Inc.  
Crucell Holland B.V.  
Not Available  
Not Available  
Not Available  
Not Available  
Biolog Life Science Institute Forschungslabor und  
Biochemica-Vertrieb GmbH  
CapitalBio Corporation  
CC-BY-NC-SA Dr. David E. Martin  
Jan14  
7Jan14  
30Mar09  
5Aug08  
1May15  
29Apr15  
30Apr15  
23Apr14  
7Jan14  
12Nov10  
19Dec13  
23Apr15  
24Jan05  
26May11  
23Apr15  
19Dec13  
24Oct11  
13Jul-10  
11Dec13  
6Dec13  
30Apr08  
30Dec13  
10Nov05  
5Dec13  
30Jun11  
29Jul-11  
2Jun11  
1Nov13  
8Apr15  
5Dec13

15Jan  
-15  
7Jan  
-15  
18Jul16  
16May  
-16  
1May  
-15  
29Apr  
-16  
2May  
-16  
1Apr  
-16  
7Jan  
-15  
27Jun  
-16  
17Dec  
-14  
21Apr  
-16  
12Jul16  
30Nov  
-15  
22Apr  
-16  
17Dec  
-14  
7Jul16  
18Feb  
-16  
11Dec  
-14  
5Dec  
-14  
28Jun  
-16  
28Jun  
-16  
27Jun  
-16  
4Dec  
-14  
29Feb  
-16  
13Nov  
-15  
21Apr  
-16  
31Oct  
-14  
1Apr

-16  
2Dec  
-14  
107  
10Nov  
-16  
10Nov  
-16  
10Nov  
-16  
10Nov  
-16  
3Nov  
-16  
3Nov  
-16  
3Nov  
-16  
3Nov  
-16  
3Nov  
-16  
3Nov  
-16  
3Nov  
-16  
3Nov  
-16  
27Oct16  
27Oct16  
27Oct16  
27Oct16  
27Oct16  
27Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
20Oct16  
13Oct16  
13Oct16  
US20160296  
617  
US20160296  
616  
US20160295  
844  
US20160292  
393  
US20160289



740  
US20160289  
191  
US20160288  
121  
US20160287  
697  
US20160287  
622  
US20160281  
109  
US20160280  
707  
US20160279  
237  
US20160279  
193  
US20160279  
165  
US20160279  
163  
US20160278  
349  
US20160272  
707  
US20160271  
241  
US20160271  
240  
US20160271  
137  
US20160267  
244  
US20160265  
025  
US20160264  
971  
US20160264  
962  
US20160263  
156  
US20160258  
949  
US20160257  
932  
US20160257  
653  
1Immunogenic

Composition for MERS Coronavirus Infection  
IMMUNOGENIC COMPOSITIONS AND USES THEREOF  
GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF  
USE THEREOF  
SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND  
PROVIDING RESULTS THEREOF

Not Available  
Not Available  
Not Available  
Not Available  
METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING Not Available  
ORGANIC COMPOUNDS  
Slip Chip Device and Methods  
INJECTABLE VACCINE COMPOSITION  
COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL  
DISORDERS AND MODULATING PROTEIN-RNA INTERACTION  
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING  
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA  
VIRUS SPIKE PROTEIN  
ALKOXY SUBSTITUTED IMIDAZOQUINOLINES  
ADJUVANT COMPOSITIONS AND RELATED METHODS  
IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY  
PULSE INHALATION OF NITRIC OXIDE FOR TREATING  
RESPIRATORY DISEASES  
Method of Treating Inflammation  
Immunocompromised Ungulates  
VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF  
CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES  
BUNYAVIRUSES WITH SEGMENTED GLYCOPROTEIN PRECURSOR  
GENES AND METHODS FOR GENERATING THESE VIRUSES  
Tetanus Toxoid and CCL3 Improve DC Vaccines  
INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID  
METABOLISM AS BROAD SPECTRUM ANTI-VIRALS  
METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN  
COUNTS  
NANOREPORTERS AND METHODS OF MANUFACTURING AND USE  
THEREOF  
COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS  
GENE EXPRESSION  
TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES,  
KITS AND ASSAYS  
RED BLOOD CELL MEMBRANE-DERIVED MICROPARTICLES AND  
THEIR USE FOR THE TREATMENT OF LUNG DISEASE  
CHIPS, DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX  
PNEUMOCOCCUS SEROLOGY  
GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS  
COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER  
POLYPEPTIDE  
Benzazepine Dicarboxamide Compounds  
Fauci/COVID-19 Dossier  
NOVARTIS AG  
Not Available  
NITTO DENKO CORPORATION  
Massachusetts Institute of Technology  
Mar13  
25Mar15  
13Apr15  
24Oct13  
30Mar15  
27Jun08

24Mar09  
30Oct13  
18Nov13  
28Not  
Available  
Oct05  
3Not  
Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Oct03  
24Mar15  
6Nov13  
24Mar15  
1Apr10  
27Oct08  
11Sep13  
21Stichting  
Dienst Landbouwkundig Onderzoek  
Duke University  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
University of Pittsburgh - Of the Commonwealth System of  
Higher Education  
Not Available  
Not Available  
Hoffmann-La Roche Inc.  
CC-BY-NC-SA Dr. David E. Martin  
May13  
14Nov13  
18Feb10  
8Aug08  
23Dec05  
20Jul-09  
4Apr12  
7Nov13  
9Oct13  
18Nov13  
6Mar15  
28Feb  
-14  
25Mar  
-16  
12Apr  
-16  
13Apr  
-16

29Mar  
-16  
9Oct  
-15  
25May  
-16  
20Oct  
-14  
7Nov  
-14  
10Jun  
-16  
13Jun  
-16  
24Mar  
-16  
6Nov  
-14  
24Mar  
-16  
3Jun  
-16  
23Mar  
-15  
11Sep  
-14  
21May  
-14  
14Nov  
-15  
27Oct  
-15  
19May  
-16  
20May  
-16  
9Oct  
-15  
28Jul15  
6Nov  
-14  
9Oct  
-14  
17May  
-16  
4Mar  
-16  
108  
13Oct16  
13Oct16  
13Oct16  
6Oct16  
6Oct16  
6Oct16

6Oct16  
6Oct16  
6Oct16  
29Sep  
-16  
29Sep  
-16  
29Sep  
-16  
29Sep  
-16  
29Sep  
-16  
29Sep  
-16  
29Sep  
-16  
22Sep  
-16  
22Sep  
-16  
22Sep  
-16  
22Sep  
-16  
15Sep  
-16  
15Sep  
-16  
15Sep  
-16  
15Sep  
-16  
15Sep  
-16  
8Sep  
-16  
8Sep  
-16  
8Sep  
-16  
US20160256  
870  
US20160256  
541  
US20160253  
584  
US20160251  
637  
US20160251  
631  
US20160251  
399  
US20160251

362  
US20160251  
319  
US20160250  
326  
US20160250  
278  
US20160250  
168  
US20160238  
601  
US20160238  
600  
US20160237  
455  
US20160237  
123  
US20160237  
082  
US20160235  
840  
US20160235  
837  
US20160235  
835  
US20160235  
675  
US20160230  
190  
US20160229  
904  
US20160229  
872  
US20160229  
864  
US20160229  
833  
US20160228  
540  
US20160228  
533  
US20160228  
532  
US20160228  
463

24Slip

Chip Device and Methods

Cationic Oil-In-Water Emulsions

SPATIALLY ADDRESSABLE MOLECULAR BARCODING

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND  
ACTIVITY, AND RELATED METHODS

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH  
INFLUENZA VACCINES

PEPTIDOMIMETIC MACROCYCLES

NOVEL COMPOUNDS

CARBOXYLIC ACID COMPOUNDS

Conjugates of GM-CSF and IL-7, and Compositions Thereof

PEPTIDOMIMETIC MACROCYCLES

ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE  
TREATMENT OF IMMUNOGENIC DISORDERS

METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS  
AND THERAPEUTICS

METHOD FOR SELECTING A SINGLE CELL EXPRESSING A  
HETEROGENEOUS COMBINATION OF ANTIBODIES

CRISPR-RELATED METHODS AND COMPOSITIONS

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL  
INFECTIONS

DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE  
SAME

Compositions, Comprising Improved Il-12 Genetic Constructs And  
Vaccines, Immunotherapeutics And Methods Of Using The Same

THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE  
EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)

INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE

Technology for the Preparation of Microparticles

Lentiviral Vectors Having a Mutated Integrase Protein and uses  
Thereof

Optimized Human Clotting Factor VIII Gene Expression Cassettes  
and Their Use

ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND  
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7  
INHIBITORS

THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7  
INHIBITORS

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS

NASAL MUCOSAL VACCINE COMPOSITION

Use of EGFR Pathway Inhibitors to Increase Immune Responses to  
Antigens

METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE  
FORMULATIONS

BORON-CONTAINING SMALL MOLECULES

Fauci/COVID-19 Dossier

Not Available

Not Available

Not Available

Not Available

Novartis AG

Not Available

CHIESI FARMACEUTICI S.P.A.

Astrazeneca Aktiebolag

Not Available

Not Available

Not Available

Not Available

Merus B.V.

Editas Medicine, Inc.

Not Available

Not Available  
Not Available  
Mar09  
6-Jul10  
27Feb15  
19Nov09  
9Sep04  
14Jan09  
18Dec12  
18May12  
14Nov11  
14Jan09  
30Oct12  
14Oct13  
30May03  
27Sep13  
23Jan08  
10Oct13  
12Dec11  
16Not  
Available  
Seqirus UK Limited  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
NITTO DENKO CORPORATION  
Emory University  
Merck Sharp & Dohme Corp.  
Not Available  
CC-BY-NC-SA Dr. David E. Martin  
Oct13  
10Feb09  
24Jul-07  
17Sep13  
6Feb15  
5Feb15  
5Feb15  
5Feb15  
30Oct13  
23Sep13  
16Oct13  
16Feb05  
25May  
-16  
11Mar  
-16  
26Feb  
-16  
11Mar  
-16  
9May



-16  
7Apr  
-16  
10May  
-16  
11May  
-16  
18May  
-16  
7Apr  
-16  
3Mar  
-16  
14Oct  
-14  
27Apr  
-16  
26Sep  
-14  
4May  
-16  
10Oct  
-14  
26Feb  
-16  
16Oct  
-14  
27Jan  
-16  
24Mar  
-16  
17Sep  
-14  
5Feb  
-16  
4Feb  
-16  
4Feb  
-16  
4Feb  
-16  
20ct  
-14  
23Sep  
-14  
13Oct  
-14  
20Apr  
-16  
8Sep  
-16  
8Sep  
-16  
1Sep



US20160222  
414  
US20160222  
072  
US20160222  
023  
US20160222  
010  
US20160221  
994  
US20160220  
664  
US20160220  
595  
CONSTRUCTS AND METHODS FOR DELIVERING MOLECULES VIA  
VIRAL VECTORS WITH BLUNTED INNATE IMMUNE RESPONSES  
Universal Protein Tag for Double Stranded Nucleic Acid Delivery  
NOVEL MONOTHIOL MUCOLYTIC AGENTS  
4-AMINO-IMIDAZOQUINOLINE COMPOUNDS  
14Not  
Available  
Not Available  
PARION SCIENCES, INC.  
Hoffmann-La Roche Inc.  
Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Not Available  
ANTIGEN AND METHOD FOR PRODUCTION THEREOF  
NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND  
USES RELATED THERETO  
US20160220  
536  
USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND  
TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF  
AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLLLIKE  
RECEPTOR OVEREXPRESSION  
US20160215  
282  
US20160215  
262  
US20160213  
776  
US20160213  
773  
US20160213  
761  
US20160213  
647  
US20160213  
610  
US20160207  
980  
US20160207  
949  
US20160207  
900

US20160206

729

US20160206

719

US20160206

638

US20160206

575

US20160202

258

US20160201

110

US20160201

088

US20160199

486

US20160199

449

SYNTHETIC ANTISERUM FOR RAPID-TURNAROUND THERAPIES

CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING

LYMPHOCYTE SELECTION

ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL

SALTS

MUCOSAL VACCINE COMPOSITION

CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE

THEREOF

Not Available

Not Available

Mar13

23Oct13

30Jan15

22Apr14

29Nov12

13Sep13

11Sep13

16Not

Available

Mar04

28Not

Available

Not Available

GlaxoSmithKline Biologicals SA

NITTO DENKO CORPORATION

Not Available

COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION Not Available

MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB

FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE,

CONSISTENT, AND REPRODUCIBLE GLYCOFORM PROFILES

NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL

BINDING MOLECULE

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I

INHIBITORS

IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME

CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1  
PATHWAY

BORON-CONTAINING SMALL MOLECULES

Inhibition of Biofilm Organisms

B-CELL ANTIGEN PRESENTING CELL ASSAY

DIAGNOSIS AND TREATMENT OF INCIPIENT DIABETES

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,

VECTORS CONTAINING SAME, AND USES THEREFOR

ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR  
MICROFLUIDIZATION

METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF  
VIRUSES IN A HOST ANIMAL USING ALPHA INTERFERON

Not Available

AMGEN INC.

Hangzhou DAC Biotech Co., Ltd

PROZYMEX A/S

Not Available

CureVac AG

Not Available

NOVABIOTICS LIMITED

University of Pittsburgh - Of the Commonwealth System of  
Higher Education

Not Available

Not Available

Not Available

Hemispherx Biopharma, Inc.

Jan15

16Sep13

1Sep10

30Oct13

19Mar08

28Jan15

24Oct12

5Sep13

2Sep13

9Sep13

19Sep13

22Feb13

16Feb05

31Mar09

8Apr10

9Jan15

17Dec01

3Dec09

21Aug13

15Apr

-16

22Oct

-14

29Jan

-16

7Apr

-16

27Nov

-13  
12Sep  
-14  
10Sep  
-14  
19Feb  
-16  
20Jan  
-16  
16Sep  
-14  
7Apr  
-16  
20Oct  
-14  
5Apr  
-16  
27Jan  
-16  
28Jan  
-16  
5Sep  
-14  
2Sep  
-13  
8Sep  
-14  
19Sep  
-14  
5Apr  
-16  
5Apr  
-16  
28Mar  
-16  
21Mar  
-16  
17Nov  
-15  
30Mar  
-16  
22Mar  
-16  
21Aug  
-14  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
110  
4Aug  
-16  
4Aug  
-16  
4Aug

-16  
4Aug  
-16  
4Aug  
-16  
4Aug  
-16  
4Aug  
-16  
28Jul16  
28Jul16  
28Jul16  
28Jul16  
28Jul16  
28Jul16  
28Jul16  
21Jul16  
21Jul16  
21Jul16  
21Jul16  
21Jul16  
21Jul16  
21Jul16  
14Jul16  
14Jul16  
14Jul16  
14Jul16  
US20160199  
416  
US20160199  
407  
US20160194  
387  
US20160194  
322  
US20160194  
278  
US20160193  
603  
US20160193  
327  
US20160193  
321  
US20160193  
315  
US20160192  
658  
US20160185  
786  
US20160185  
785

US20160184  
424  
US20160184  
334  
US20160177  
337  
US20160177  
336  
US20160175  
433  
US20160175  
394  
US20160175  
387  
US20160174  
631  
US20160168  
203  
US20160168  
101  
US20160166  
710  
US20160166  
676  
US20160160  
258  
US20160160  
178  
US20160159  
927  
US20160158  
341  
26Induced  
Hepatocytes and Uses Thereof  
HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION  
Methods Of Treating Inflammation Associated Airway Diseases And  
Viral Infections  
SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS  
DITHIOL MUCOLYTIC AGENTS  
SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE  
MUCOSAL VACCINE COMPOSITION  
MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS  
PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC  
COMPOSITIONS COMPRISING SAID PEPTIDES  
HYDROGEN-CONTAINING ANTIMICROBIAL AGENT  
PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITINSPECIFIC  
PROTEASE 7 INHIBITORS  
PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC  
PROTEASE 7 INHIBITORS  
INTRANASAL VACCINATION DOSAGE REGIMEN  
BORON-CONTAINING SMALL MOLECULES  
METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING  
CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR  
Expression Tools for Multiprotein Applications



LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND  
COMPOSITIONS, FORMULATIONS, AND METHODS  
Compositions and Uses of Lectins  
Use of Immune Suppressive Domains as Medicaments  
PROTECTIVE MASKS WITH COATING COMPRISING DIFFERENT  
ELECTROSPUN FIBERS INTERWEAVED WITH EACH OTHER,  
FORMULATIONS FORMING THE SAME, AND METHOD OF  
PRODUCING THEREOF  
Cyclic Antimicrobial Peptides  
NOVEL COMPOUNDS  
METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED  
PROTEINS  
Use of Immune Suppressive Peptides as Adjuvants  
MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION  
OF B CELLS  
IMMUNOTHERAPY USING STEM CELLS  
IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (VR)  
AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND  
ANTAGONISTS  
PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS  
Fauci/COVID-19 Dossier  
Not Available  
THE UNIVERSITY OF IOWA RESEARCH FOUNDATION  
Not Available  
Not Available  
PARION SCIENCES, INC.  
Not Available  
NITTO DENKO CORPORATION  
Novartis AG  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Emory University  
Not Available  
Nov14  
25Jan08  
2Jan15  
25Nov03  
23Aug13  
29Jan10  
30Oct13  
11Sep06  
7Aug09  
13Aug13  
30Dec14  
30Dec14  
17Dec12  
16Feb05

16Jul-08  
9Mar04  
17Aug10  
12Feb10  
10Apr13  
23Not  
Available  
Dec14  
24NOVABIOTICS  
LIMITED  
CHIESI FARMACEUTICI S.p.A.  
CureVac AG  
Not Available  
Not Available  
Not Available  
Not Available  
Novartis AG  
CC-BY-NC-SA Dr. David E. Martin  
Feb06  
15Dec14  
21Aug13  
10Apr13  
26Feb03  
9Dec14  
5Dec14  
18Mar08  
25Nov  
-15  
17Dec  
-15  
31Dec  
-15  
14Mar  
-16  
11Mar  
-16  
5Aug  
-15  
20ct  
-14  
5Nov  
-15  
17Mar  
-16  
5Aug  
-14  
29Dec  
-15  
29Dec  
-15  
17Dec  
-13  
11Mar  
-16

8Mar  
-16  
11Dec  
-15  
15Dec  
-15  
11Dec  
-15  
10Apr  
-14  
10Dec  
-15  
9Nov  
-15  
27Nov  
-15  
19Feb  
-16  
10Apr  
-14  
8Feb  
-16  
2Dec  
-15  
7Dec  
-15  
7Dec  
-15  
14Jul16  
14Jul16  
7Jul16  
7Jul16  
7Jul16  
7Jul16  
7Jul16  
7Jul16  
7Jul16  
7Jul16  
30Jun16  
30Jun16  
30Jun16  
30Jun16  
23Jun16  
23Jun16  
23Jun16  
23Jun16  
23Jun16  
23Jun16  
16Jun16  
16Jun16  
16Jun16  
16Jun16  
9Jun16  
9Jun16

9Jun16  
9Jun16  
111  
US20160158  
340  
US20160158  
339  
US20160158  
308  
US20160158  
294  
US20160158  
154  
US20160153  
034  
US20160152  
693  
US20160152  
676  
US20160152  
667  
US20160152  
596  
US20160151  
399  
US20160146  
806  
US20160146  
786  
US20160145  
246  
US20160144  
061  
US20160139  
143  
US20160137  
702  
US20160137  
649  
US20160135  
453  
US20160130  
367  
US20160130  
345  
US20160130  
265  
US20160129  
110  
US20160129  
104  
US20160129  
095  
US20160128

937

US20160122

412

INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX  
PROTEINS

27Not

Available

METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available

TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE

DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE

Methods of Populating a Gastrointestinal Tract

PROTEIN VESICLES AND METHODS OF MAKING AND USING

THEREOF

Rapid Epidemiologic Typing of Bacteria

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE

PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME

FOR THE TREATMENT OF VIRAL DISEASES

HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT

PROTEIN-PROTEIN INTERACTIONS

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL

INFECTIONS

Nuclear Transport Modulators and Uses Thereof

BORON-CONTAINING SMALL MOLECULES

RECEPTORS FOR B7-H4

Method of monitoring cellular trafficking of peptides

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

Compositions and Imaging Methods Comprising Detectably Labeled

Phosphatidylethanolamine-Binding Peptides

DETECTING TARGETS USING MASS TAGS AND MASS

SPECTROMETRY

GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES

PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL

USES THEREOF

SHELF STABLE, REDUCED CORROSION, READY TO USE

PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS

GENERATION OF BINDING MOLECULES

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1

PATHWAY

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF

NEUTROPHIL ELASTASE ACTIVITY

IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND

METHODS

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF

MANUFACTURE AND USE THEREOF

Immunostimulatory Combinations

CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION

AND/OR HOMOGENIZATION OF EMULSIONS

COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF

SUPERFAMILY LIGAND

CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Not Available

Not Available

Not Available

Jan06  
26Jul-13  
12Nov13  
4Feb13  
5Dec14  
19May08  
5Ablynx  
N.V.  
Jun08  
7COLORADO  
STATE UNIVERSITY RESEARCH FOUNDATION  
Not Available  
Karyopharm Therapeutics Inc.  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Merus B.V.  
Not Available  
Not Available  
AUTOIMMUNE TECHNOLOGIES, LLC  
Not Available  
Not Available  
Novartis AG  
Not Available  
Nov14  
23Jan08  
21Jun13  
16Feb05  
17May13  
26Jun13  
9May12  
15Jul-02  
2-Jul10  
12Sep07  
3-Jul13  
30Aug07  
26Sep11  
22Feb13  
23Aug12  
14Mar13  
7Nov14  
30Dec02  
3Dec09  
15Mar13  
4Dec  
-15  
24Jul14  
14Aug

-14  
4Feb  
-14  
7Dec  
-15  
11Nov  
-15  
29Oct  
-15  
9Nov  
-15  
9Feb  
-16  
20Jun  
-14  
17Feb  
-16  
19May  
-14  
26Jun  
-14  
23Jun  
-15  
4Feb  
-16  
28Dec  
-15  
7Aug  
-15  
1Jul14  
20Jan  
-16  
16Sep  
-15  
21Feb  
-14  
29Dec  
-15  
17Jul15  
6Nov  
-15  
10Sep  
-15  
5Sep  
-14  
16Mar  
-14  
9Jun16  
9Jun16  
9Jun16  
9Jun16  
2Jun16  
2Jun16

2Jun16  
2Jun16  
2Jun16  
2Jun16  
26May  
-16  
26May  
-16  
26May  
-16  
26May  
-16  
19May  
-16  
19May  
-16  
19May  
-16  
19May  
-16  
12May  
-16  
12May  
-16  
12May  
-16  
12May  
-16  
12May  
-16  
12May  
-16  
12May  
-16  
12May  
-16  
5May  
-16  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
112  
US20160122  
397  
US20160122  
312  
US20160122  
306  
US20160116  
462  
US20160115  
522  
US20160115  
221  
US20160114  
322



US20160114  
037  
US20160114  
027  
US20160114  
022  
US20160113  
929  
US20160113  
920  
US20160113  
881  
US20160113  
870  
US20160108  
463  
US20160108  
461  
US20160108  
359  
US20160108  
097  
US20160108  
096  
US20160108  
063  
US20160106  
842  
US20160102  
295  
US20160102  
091  
US20160101  
145  
US20160096  
899  
US20160096  
895  
US20160095  
936  
US20160090  
589

REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT  
OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY  
AND LETHALITY IN INFLUENZA

ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND  
METHODS OF USE THEREOF

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL  
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER  
MUCOSAL DISEASES

ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR  
MAKING AND USING SUCH CONJUGATES

MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION  
CHARACTERISTICS

COMPOSITIONS AND METHODS FOR THE TREATMENT OF  
IMMUNODEFICIENCY

PARALLELIZED SAMPLE HANDLING

COMPOSITIONS AND METHODS FOR THE TREATMENT OF  
IMMUNODEFICIENCY

23Not

Available

Apr09

Not

Available

16Jul-13

29PARION

SCIENCES, INC.

May12

27Not

Available

Not Available

Not Available

Not Available

Not Available

RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF Not Available

THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR

FILOVIRUSES INCLUDING EBOLAVIRUS AND MARBURG VIRUS

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLYINDUCED

CONDITIONS

COMPOSITIONS AND METHODS FOR INHIBITING BACTERIAL AND

VIRAL PATHOGENS

NOVEL NANOPARTICLE COMPOSITIONS

CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION

AND/OR HOMOGENIZATION OF EMULSIONS

Biological Specimen Collection and Transport System

TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR

IDENTIFICATION OF PATHOGENS

AVIAN CELLS FOR IMPROVED VIRUS PRODUCTION

MONOMERIC GRIFFITHSIN TANDEMERS

FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR

USING RECOMBINANT BACTERIA

BORON-CONTAINING SMALL MOLECULES

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE

AGENTS

MODIFIED ADENOVIRUS HEXON PROTEIN AND USES THEREOF

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

Not Available

Not Available

Not Available

Not Available

Novartis AG

Longhorn Vaccines and Diagnostics, LLC

Not Available

Not Available

The United States of America, as represented by the

Secretary, Department of Health and Human Serv

Not Available

Not Available

Not Available  
Not Available  
3-V BIOSCIENCES, INC.  
PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF Not Available  
METHODS FOR TREATING JUVENILE ARTHRITIS WITH ANTI-BILE  
SALT-STIMULATED LIPASE (BSSL) ANTIBODIES  
BINDING MEMBERS-513  
IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE  
THEREOF  
Not Available  
Not Available  
Not Available  
COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS Not Available  
Apr10  
11May10  
28Oct14  
19Apr13  
28Oct14  
14May10  
11Oct14  
11Mar10  
24Oct14  
3Apr13  
3Dec09  
10Oct07  
14Sep06  
5Jun13  
5Jun13  
17Sep14  
16Feb05  
8Mar13  
28Apr06  
8Mar11  
24Sep14  
8Apr09  
7Nov08  
5Apr12  
21Feb06  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
2Dec  
-15  
16Jul14  
5Jan  
-16  
21Apr  
-15  
7Jan  
-16  
2Jul15  
18Apr  
-14  
8Jan

-15  
10ct  
-15  
100ct  
-15  
2Jun  
-15  
230ct  
-15  
3Apr  
-14  
5Sep  
-14  
15Dec  
-15  
50ct  
-15  
3Jun  
-14  
5Jun  
-14  
17Sep  
-15  
21Dec  
-15  
6Mar  
-14  
22May  
-15  
50ct  
-15  
24Sep  
-15  
28Sep  
-15  
230ct  
-15  
2Jul15  
6May  
-15  
113  
5May  
-16  
5May  
-16  
5May  
-16  
28Apr16  
28Apr16  
28Apr16  
28Apr16  
28Apr16  
28Apr16  
28Apr16

28Apr16  
28Apr16  
28Apr16  
28Apr16  
21Apr16  
21Apr16  
21Apr16  
21Apr16  
21Apr16  
21Apr16  
21Apr16  
14Apr16  
14Apr16  
14Apr16  
7Apr16  
7Apr16  
7Apr16  
31Mar  
-16  
US20160090  
389  
US20160084  
835  
US20160083  
748  
US20160083  
689  
US20160082  
074  
US20160081  
982  
US20160081  
346  
US20160077  
094  
US20160076  
094  
US20160076  
053  
US20160075  
704  
US20160074  
507  
US20160074  
506  
US20160074  
481  
US20160068  
843  
US20160068  
587  
US20160068  
573  
US20160067

333

US20160060

598

US20160060

231

US20160060

230

US20160060

224

US20160058

814

US20160058

012

US20160058

008

US20160054

312

US20160053

308

US20160053

222

15Phosphoinositide

3-Kinase Inhibitors

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING  
ADSORPTION MEDIA

TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION  
CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF  
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS  
COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS  
INFECTION

METHODS FOR TREATING PULMONARY EMPHYSEMA USING  
SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC  
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF  
CATHEPSIN C

ANTIMICROBIAL COMPOSITIONS AND METHODS

Media Elaborated with Newly Synthesized Antibodies (MENSA) and  
Uses Thereof

Efficient Deep Sequencing and Rapid Genomic Speciation of RNA  
Viruses (vRNAseq)

Respivert Ltd.

EXTHERA MEDICAL CORPORATION

Not Available

Not Available

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Mar13

8Nov13

29Apr13

29Oct04

11Mar14

14Not

Available

Mar13

23Not

Available

Not Available  
Not Available  
REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION Not Available  
NOVEL SUBSTITUTED SPIROCYCLES  
METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC  
DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING  
IMMUNE RESPONSE  
DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE  
POLYMER PARTICLES  
Clottable Concentrate Of Platelet Growth Factors And Preparation  
Method Thereof  
Compositions and Methods for "Resistance-Proof" SiRNA  
Therapeutics for Influenza  
OLIGOPEPTIDE-FREE CELL CULTURE MEDIA  
PEPTIDOMIMETIC MACROCYCLES  
GENERATING PEPTOID VACCINES  
MEANS AND METHODS FOR INFLUENCING THE STABILITY OF  
ANTIBODY PRODUCING CELLS  
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE  
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY  
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE  
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY  
N-MYRISTOYL TRANSFERASE INHIBITORS  
PLANT EXTRACTS AND RELATED COMPOSITIONS, METHODS AND  
SYSTEMS  
WEAR RESISTANT ANTIMICROBIAL COMPOSITIONS AND METHODS  
OF USE  
ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL  
POLYMERIC BINDING SYSTEM  
CHEMICALLY DIFFERENTIATED SENSOR ARRAY  
PROBE KIT FOR DETECTING A SINGLE STRAND TARGET  
NUCLEOTIDE SEQUENCE  
BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE  
Not Available  
Not Available  
Not Available  
Zheng Yang Biomedical Technology Co., LTD.  
Sirnaomics, Inc.  
Not Available  
Not Available  
The Board of Regents of the University of Texas System  
Not Available  
Not Available  
Sep14  
5May14  
8Sep14  
24Aug12  
12Sep14  
16Sep14  
6-Jul10  
7Jan08  
8-Jul12  
3Jan07  
14Jan09

3May13  
9Dec05  
6Feb13  
6Not  
Available  
UNIVERSITY OF DUNDEE  
Not Available  
Not Available  
Not Available  
Nanomedical Diagnostics, Inc.  
Fondzione Istituto Italiano Di Tecnolgia  
Not Available  
Feb13  
2Sep08  
26Aug14  
14Dec10  
28Aug14  
28Apr14  
27Dec12  
18Apr11  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
4Dec  
-15  
16Oct  
-15  
29Apr  
-14  
30Nov  
-15  
8May  
-15  
1Dec  
-15  
22Sep  
-15  
5May  
-15  
1Sep  
-15  
15Mar  
-13  
10Sep  
-15  
16Sep  
-15  
23Nov  
-15  
30Nov  
-15  
7Jul13  
16Nov  
-15





-16  
10Mar  
-16  
10Mar  
-16  
10Mar  
-16  
3Mar  
-16  
3Mar  
-16  
3Mar  
-16  
3Mar  
-16  
3Mar  
-16  
3Mar  
-16  
3Mar  
-16  
25Feb  
-16  
25Feb  
-16  
25Feb  
-16  
US20160052  
959  
US20160051  
691  
US20160051  
670  
US20160051  
669  
US20160046  
705  
US20160046  
687  
US20160045  
547  
US20160041  
168  
US20160040  
161  
US20160039  
867  
US20160039  
860

RADIOLABELED CATIONIC STEROID ANTIMICROBIALS AND  
DIAGNOSTIC METHODS  
22BRIGHAM  
YOUNG UNIVERSITY  
CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR

OLIGONUCLEOTIDES

METHODS FOR PREPARING SQUALENE

COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING  
TREGS

HETERODIMERIC IMMUNOGLOBULINS

GM-CSF AND IL-4 CONJUGATES, COMPOSITIONS, AND METHODS  
RELATED THERETO

METHOD OF PREVENTING OR TREATING SINUSITIS WITH  
OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION

ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA  
IMMUNE RESPONSE

In Vivo Delivery of Oligonucleotides

SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS

ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A

US20160039

826

2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1HPYRAZOLO[3,4-D]PYRIMIDIN-1  
-YL)METHYL)-3-(2(TRIFLUOROMETHYL)BENZYL)

QUINAZOLIN-4(3H)-ONE

DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE

INHIBITORS

US20160039

812

US20160032

319

US20160031

861

US20160031

831

US20160031

830

US20160031

829

US20160031

825

US20160030

443

US20160025

675

US20160025

603

US20160024

525

US20160024

158

US20160022

801

US20160016

999

US20160016

986

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE  
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

VECTORS COMPRISING STUFFER/FILLER POLYNUCLEOTIDE

SEQUENCES AND METHODS OF USE  
SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF  
CATHEPSIN C  
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE  
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY  
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE  
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY  
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE  
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY  
SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS  
INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY  
METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T  
CELL FUNCTION  
METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS  
AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND  
DEVICES FOR MONITORING AIRBORNE AGENTS  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
OCULUS INNOVATIVE SCIENCES, INC.  
Not Available  
OncoImmunin Inc.  
Complix NV  
Not Available  
Aug14  
4Dec07  
12May10  
21Aug14  
21Nov12  
23Oct12  
30Dec03  
2May08  
12Dec11  
8Dec08  
4Aug14  
15Not  
Available  
Mar13  
19Aug  
-15  
25Aug  
-15  
23Oct  
-15  
21Aug  
-15  
21Nov  
-13  
23Oct  
-13  
27Oct  
-15

23Oct  
-15

12Dec  
-12

21Aug  
-15

4Aug  
-15

14Mar  
-14

25Feb  
-16

25Feb  
-16

25Feb  
-16

25Feb  
-16

18Feb  
-16

18Feb  
-16

18Feb  
-16

11Feb  
-16

11Feb  
-16

11Feb  
-16

11Feb  
-16

11Feb  
-16

Not

Available

31Jul-14

15THE

CHILDREN'S HOSPITAL OF PHILADELPHIA

Not Available

Not Available

Mar13

1Aug14

31Jul-14

Not

Available

31Jul-14

Not

Available

Not Available

Not Available

Nanomedical Diagnostics, Inc.

Not Available

REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS NOVARTIS AG

Inhibitory Polypeptides Specific to WNT Inhibitors  
RODENT HEPADNAVIRUS CORES WITH REDUCED CARRIERSPECIFIC  
ANTIGENICITY

INHIBITORY PEPTIDES OF VIRAL INFECTION

STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT

Fauci/COVID-19 Dossier

Not Available

Not Available

Not Available

Not Available

CC-BY-NC-SA Dr. David E. Martin

31Jul-14

31Jul-14

14Mar13

28Apr14

22Jul-14

21May09

15Mar13

15Mar13

17Jul-14

21Jul-14

27Jul15

14Mar

-14

31Jul15

27Jul15

27Jul15

27Jul15

27Jul15

14Mar

-14

10Oct

-15

21Jul15

7May

-15

14Mar

-14

14Mar

-14

16Jul15

21Jul15

11Feb

-16

4Feb

-16

4Feb

-16

4Feb

-16

4Feb

-16

4Feb

-16

4Feb  
-16

4Feb  
-16

28Jan16

28Jan16

28Jan16

28Jan16

28Jan16

21Jan16

21Jan16

115

US20160016

916

US20160015

826

US20160015

803

US20160011

183

US20160008

809

US20160008

461

US20160008

451

US20160008

397

US20160008

363

US20160003

747

US20160002

608

US20160000

905

US20160000

790

US20160000

754

US20150377

887

US20150376

621

Exo Olefin-Containing Nuclear Transport Modulators and Uses  
Thereof

15Not

Available

Constructs Binding to Phosphatidylserine and Their Use in Disease  
Treatment and Imaging

IMMUNOSTIMULATORY COMBINATIONS AND USE THEREOF

MULTIANALYTE ASSAY

METHODS AND COMPOSITIONS FOR PAPER-BASED AND HYBRID

MICROFLUIDIC DEVICES INTEGRATED WITH NUCLEIC ACID

AMPLIFICATION FOR DISEASE DIAGNOSIS

METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE  
RESPONSES

NANOPARTICLE-BASED COMPOSITIONS

IMMUNOMODULATION BY CONTROLLING EXPRESSION LEVELS OF  
MICRORNAS IN DENDRITIC CELLS

DRUG COMBINATION

Apparatus for two-step surface-enhanced raman spectroscopy

METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES

Nanoparticle Delivery of TLR Agonists and Antigens

DRUG COMBINATION

Antiviral Activity from Medicinal Mushrooms and their Active  
Constituents

IN SITU AFFINITY MATURATION OF ANTIBODIES

MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS  
OF USE

US20150376

584

METHODS OF TREATING VIRAL INFECTIONS, PARTICULARLY  
RABIES, MERS-COV, INFLUENZA, EBOLA, CHIKUNGUNYA,  
VENEZUELAN EQUINE ENCEPHALITUS, CANINE PARVOVIRUS,  
ADENOVIRUS, RESPIRATORY SYNCYTIAL VIRUS, RHINOVIRUS, AND  
POXVIRUS IN MAMMALIAN PATIENTS

US20150376

145

US20150376

131

US20150374

723

US20150374

626

US20150369

806

US20150368

661

US20150368

294

US20150366

888

US20150366

796

STABLE SODIUM CHANNEL BLOCKERS

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF  
NEUTROPHIL ELASTASE ACTIVITY

Anti-Viral Azide Containing Compounds

TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES  
INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY  
FORMULATED GLUTATHIONE

DETECTION OF VIRAL DISEASES USING A BIOCHIP THAT  
CONTAINS GOLD NANOPARTICLES

METHODS FOR PRODUCING ANTIBODIES

GADD45BETA TARGETING AGENTS

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS  
THEREOF



INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS  
COMPRISING TOLL-LIKE RECEPTOR AGONISTS

Not Available

Not Available

Not Available

Mar13

24Jan05

18Jul-14

30Apr07

University

of Texas at El Paso

10Jul-14

8Not

Available

Not Available

Not Available

VERONA PHARMA PLC

REAL-TIME ANALYZERS, INC

Not Available

Not Available

VERONA PHARMA PLC

Not Available

Not Available

ARROWHEAD RESEARCH CORPORATION

Jan13

14Mar13

14Jul-14

15Mar13

16Dec11

20Sep10

25Feb13

15Mar13

6Jan04

27Feb13

28Feb08

28TAMIR

BIOTECHNOLOGY, INC.

Mar14

30PARION

SCIENCES, INC.

Not Available

Not Available

Jun14

23Aug12

28Jul-10

15YOUR

ENERGY SYSTEMS, LLC

Feb13

19Not

Available

Not Available

Not Available

Not Available

Not Available

Jun14  
11Feb13  
22Oct09  
24Jun14  
1Feb13  
14Mar  
-14  
2Feb  
-15  
17Jul15  
15Jun  
-15  
10Jul15  
2Aug  
-14  
14Mar  
-14  
10Jul15  
17Mar  
-14  
11Sep  
-15  
10Jul15  
24Feb  
-14  
17Mar  
-14  
14Sep  
-15  
27Feb  
-14  
14May  
-15  
10Jun  
-15  
30Jun  
-15  
2Sep  
-15  
20Aug  
-15  
15Mar  
-13  
17Jun  
-15  
11Feb  
-14  
10Feb  
-15  
22Jun  
-15  
30Jan  
-14  
21Jan16

21Jan16  
21Jan16  
14Jan16  
14Jan16  
14Jan16  
14Jan16  
14Jan16  
14Jan16  
7Jan16  
7Jan16  
7Jan16  
7Jan16  
7Jan16  
31Dec  
-15  
31Dec  
-15  
31Dec  
-15  
31Dec  
-15  
31Dec  
-15  
31Dec  
-15  
31Dec  
-15  
31Dec  
-15  
24Dec  
-15  
24Dec  
-15  
24Dec  
-15  
24Dec  
-15  
24Dec  
-15  
24Dec  
-15  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
116  
US20150361  
432  
US20150361  
097  
US20150361  
096  
US20150359  
871  
US20150359  
746  
US20150355  
172  
US20150353

905

US20150353

596

US20150353

561

US20150352

218

US20150344

425

US20150343

028

US20150337

369

US20150337

334

US20150337

015

US20150335

733

US20150335

728

US20150335

657

US20150329

866

US20150329

834

US20150328

282

US20150322

491

US20150322

155

US20150322

137

US20150322

022

US20150322

008

US20150320

842

US20150320

801

US20150315

612

MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS  
OF USE

HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR  
ANTAGONISTS

HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR  
ANTAGONISTS

IMMUNOGENIC COMPOSITIONS COMPRISING SILICIFIED VIRUS  
AND METHODS OF USE

Technology for the Preparation of Microparticles

ADP-RIBOSE DETECTION REAGENTS

Not Available

26Jul-02

22Not

Available

Not Available

PORTLAND STATE UNIVERSITY

Not Available

The Board of Regents of the University of Texas System

CAS9-NUCLEIC ACID COMPLEXES AND USES RELATED THERETO Not Available

17-Substituted Steroid Compounds

NOVEL COMPOUNDS

HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES

MADE THEREFROM

INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR

ANTAGONISTS

METHODS OF MODULATING IMMUNE RESPONSES BY MODIFYING

AKT3 BIOACTIVITY

SINGLE CELL ANALYSIS OF T CELLS USING HIGH-THROUGHPUT

MULTIPLEX AMPLIFICATION AND DEEP SEQUENCING

METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING

CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR

ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF

USE

Immunogenic Composition and Methods of Using the Compositions

for Inducing Humoral and Cellular Immune Responses

METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST

VIRUS

Methods for Modulating Sirtuin Enzymes

NOVEL siRNAs AND METHODS OF USE THEREOF

METHODS OF PROPAGATING MONKEY ADENOVIRAL VECTORS

METHODS FOR TREATING VIRAL DISORDERS

High density self-contained biological analysis

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC

CONJUGATION OF A CELL-BINDING MOLECULE

HUMAN ANTIBODY SPECIFIC TO HUMAN METAPNEUMOVIRUS, OR

ANTIGEN-BINDING FRAGMENT THEREOF

THERAPEUTIC CATECHOLS

INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR

ANTAGONIST

A COMPOSITION FOR PREVENTING OR TREATING AN RNA VIRAL

INFECTION COMPRISING SAMHD1 OR A NUCLEIC ACID MOLECULE

ENCODING THE SAMHD1

USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS

CONTAINING SAME, AND USES THEREFOR

Fauci/COVID-19 Dossier

Not Available

CHIESI FARMACEUTICI S.P.A.

3M INNOVATIVE PROPERTIES COMPANY

ACTELION PHARMACEUTICALS LTD

Not Available

Not Available

Not Available

The United States of America, as represented by the  
Secretary of the Army, on behalf of the United

Not Available

Academia Sinica

Not Available

Not Available

GenVec, Inc.

Not Available

Not Available

Robert Yongxin Zhao

Not Available

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

ACTELION PHARMACEUTICALS LTD

SNU R&DB FOUNDATION

Not Available

Not Available

Jan13

22Jan13

31Jan13

24Jul-07

10Jun14

16Jan13

28Aug02

9Jun14

3Jun11

18Dec12

17Apr14

7May14

16Jul-08

6Dec12

8Apr11

27Mar09

5May14

25Oct06

9Nov09

24Sep09

15Nov06

15Jul-15

28Jan13

12May14

12Dec12

7Jan13

6May14

30Sep03

CC-BY-NC-SA

Dr. David E. Martin

Aug

-15

21Jan

-14

21Jan

-14

31Jan

-14

17Jun  
-15  
9Jun  
-15  
15Jan  
-14  
24Aug  
-15  
5Jun  
-15  
14Aug  
-15  
17Dec  
-13  
17Apr  
-15  
30Apr  
-15  
29Jul15  
4Jun  
-15  
27Apr  
-15  
18Feb  
-14  
4May  
-15  
8Jan  
-15  
4Aug  
-15  
5Aug  
-15  
16Jul15  
15Jul15  
28Jan  
-14  
11May  
-15  
11Dec  
-13  
7Jan  
-13  
6May  
-15  
20Jul15  
17Dec  
-15  
17Dec  
-15  
17Dec  
-15  
17Dec  
-15

17Dec  
-15  
10Dec  
-15  
10Dec  
-15  
10Dec  
-15  
10Dec  
-15  
10Dec  
-15  
3Dec  
-15  
3Dec  
-15  
26Nov  
-15  
26Nov  
-15  
26Nov  
-15  
26Nov  
-15  
26Nov  
-15  
26Nov  
-15  
19Nov  
-15  
19Nov  
-15  
19Nov  
-15  
12Nov  
-15  
12Nov  
-15  
12Nov  
-15  
12Nov  
-15  
12Nov  
-15  
12Nov  
-15  
12Nov  
-15  
5Nov  
-15  
117  
6  
US20150315  
574



US20150314  
017  
US20150313  
960  
US20150313  
929  
US20150313  
909  
US20150309  
018  
US20150307  
936  
US20150307  
935  
US20150307  
849  
US20150307  
572  
US20150307  
530  
US20150306  
213  
US20150306  
212  
US20150306  
205  
US20150306  
137  
US20150301  
055  
US20150299  
728  
US20150299  
707  
US20150299  
667  
US20150299  
271  
US20150299  
194  
US20150299  
142  
US20150297  
700  
US20150297  
677  
US20150297  
668  
US20150291  
609  
US20150291  
606  
US20150291  
605

US20150291

531

16PRODUCTION

OF STABLE NON-POLYADENYLATED RNAS

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELLBINDING MOLECULE

NOVEL DEPSIPEPTIDE AND USES THEREOF

USE OF TYLVALOSIN AS ANTIVIRAL AGENT

ANTIVIRAL COMPOUNDS AND METHODS

SYSTEM AND METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS

SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD

CHEMISTRY ANALYSIS

NON-MASS DETERMINED BASE COMPOSITIONS FOR NUCLEIC ACID DETECTION

HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS

BIOACTIVE PEPTIDES AND METHODS OF USING SAME

NOVEL MUCOLYTIC AGENTS

HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

VACCINE COMPOSITION FOR NAIVE SUBJECTS

METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION

CIRCULATING BIOMARKERS FOR DISEASE

Massachusetts Institute of Technology  
Dr. Robert Yongxin Zhao

Not Available

Not Available

CAMBRIDGE UNIVERSITY TECHNICAL SERVICES

Biotron Limited

NANOMEDICAL DIAGNOSTICS, INC.

Nanomedical Diagnostics, Inc.

Not Available

Not Available

Not Available

PARION SCIENCES, INC.

The Regents of the University of California

Not Available

Not Available

OCULUS INNOVATIVE SCIENCES, INC.

Not Available

TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available

CONSTRUCTION OF POOL OF INTERFERING NUCLEIC ACIDS

COVERING ENTIRE RNA TARGET SEQUENCE AND RELATED COMPOSITIONS

INFLUENZA VIRUS AND TYPE 1 DIABETES

TREATING CANCER WITH VIRAL NUCLEIC ACID

4-AMINO-IMIDAZOQUINOLINE COMPOUNDS

3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL)

PYRAZINE-2-CARBOXAMIDE COMPOUNDS

Novel Adenovirus Vectors

COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY

ANALOGS OF C5a AND METHODS OF USING SAME

MERTK-SPECIFIC PYRIMIDINE COMPOUNDS  
MERTK-SPECIFIC PYRROLOPYRIMIDINE COMPOUNDS  
MERTK-SPECIFIC PYRAZOLOPYRIMIDINE COMPOUNDS  
THERAPEUTIC HYDROXYQUINOLONES  
BIOMICS BIOTECHNOLOGIES CO., LTD.  
ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE  
VENEZIE  
Not Available  
HOFFMANN-LA ROCHE INC.  
PARION SCIENCES, INC.  
Not Available  
Children Medical Center Corporation  
BOARD PF REGENTS OF THE UNIVERSITY OF NEBRASKA  
Not Available  
Not Available  
Not Available  
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY  
Oct12  
15Jul-15  
3Dec12  
13Jul-06  
26Jun03  
28Apr14  
28Apr14  
6Aug09  
11Jul-03  
12Jul-07  
31Aug12  
27Jul-10  
18Nov13  
17Dec12  
20Jan06  
6Apr10  
18May04  
7-Jul08  
10Oct12  
20Feb07  
22Apr14  
17Dec12  
10Apr07  
13Dec12  
29Jun10  
11Apr14  
11Apr14  
11Apr14  
9Nov12  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
16Oct  
-13  
15Jul15  
1Jul15  
8Jun

-15  
6Feb  
-15  
28Apr  
-14  
10Apr  
-15  
13Jul15  
23Feb  
-15  
23Feb  
-15  
30Aug  
-13  
9Mar  
-15  
12Jun  
-15  
17Dec  
-13  
7Jul15  
1Jul15  
6Jul15  
2Jul15  
10Oct  
-13  
6Jul15  
22Apr  
-15  
8Jan  
-15  
27Apr  
-15  
12Dec  
-13  
29Jun  
-11  
3Apr  
-15  
3Apr  
-15  
3Apr  
-15  
8Nov  
-13  
5Nov  
-15  
5Nov  
-15  
5Nov  
-15  
5Nov  
-15  
5Nov

-15

29Oct15

29Oct15

29Oct15

29Oct15

29Oct15

29Oct15

29Oct15

29Oct15

29Oct15

29Oct15

22Oct15

22Oct15

22Oct15

22Oct15

22Oct15

22Oct15

22Oct15

22Oct15

22Oct15

22Oct15

22Oct15

15Oct15

15Oct15

15Oct15

15Oct15

118

US20150290

235

USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN  
COMBINATION WITH (DEOXY)NUCLEOSIDE OR  
(DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND  
HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS

US20150290

234

US20150290

212

US20150290

197

US20150290

194

US20150290

189

US20150290

134

US20150289

573

US20150284

475

US20150284

451

US20150284

416

US20150283

531

US20150283  
233  
US20150283  
221  
US20150275  
183  
US20150274  
698  
US20150272  
988  
US20150267  
245  
US20150267  
202  
US20150267  
194  
US20150266  
929  
US20150266  
901  
US20150266  
882  
US20150265  
721  
US20150265  
697  
US20150265  
696  
US20150259  
427  
23Not  
Available  
Nov12  
23TARGETED  
INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS  
THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE  
COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY  
THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE  
COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY  
THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH  
ANTI-MER TYROSINE KINASE ACTIVITY  
CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE  
POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY  
TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR  
MICROSPHERES  
Not Available  
Not Available  
Not Available  
Not Available  
PARION SCIENCES, INC.  
Not Available  
SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE Not Available  
BISPECIFIC ANTIBODY  
COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN

INFECTION

Not Available

Not Available

NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES SUZHOU M-CONJ BIOTECH CO., LTD

Microspotting Device

Compositions and Methods for Enhancing Immune Responses

ATTENUATED LISTERIA MONOCYTOGENES MUTANT AS A VACCINE

VECTOR FOR THE DELIVERY OF EXOGENEOUS ANTIGENS

Human Betacoronavirus Lineage C and Identification of N-Terminal

Dipeptidyl Peptidase As Its Virus Receptor

Hydrazide Containing Nuclear Transport Modulators And Uses

Thereof

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY

DISEASES

PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS

FLUID MEDIA

ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING

ss/RNA VIRAL INFECTION

DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4

AND METHODS OF USE THEREOF

VIRUS-LIKE PARTICLES, METHODS OF PREPARATION, AND

IMMUNOGENIC COMPOSITIONS

ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND

THIAZOLONAPHTHYRIDINES

PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS

Compounds and Methods for Modulating an Immune Response

HIGH-YIELD TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR

GENERATING VIRUS-LIKE PARTICLES

Compositions And Methods For Treating And Preventing Porcine

Reproductive And Respiratory Syndrome

GITR BINDING MOLECULES AND USES THEREFOR

Fauci/COVID-19 Dossier

Not Available

Not Available

The Board of Trustees of the University of Illinois

Not Available

Not Available

Advanced Inhalation Therapies (AIT) Ltd.

GenTegra, LLC

Not Available

Quark Pharmaceutical, Inc.

Not Available

Not Available

Not Available

Not Available

Not Available

Academia Sinica

Not Available

Not Available

CC-BY-NC-SA Dr. David E. Martin

Mar07

11Apr14

11Apr14

11Apr14

27Jun11  
24Jan06  
1Jun07  
21Nov12  
29Oct12  
16Jun15  
18Apr12  
15Jun12  
7Apr14  
23Sep12  
29Jul-11  
7Mar12  
14Mar13  
16Sep04  
12Sep12  
17May02  
9Feb05  
19Oct12  
23Mar09  
5Sep06  
24Apr12  
25Mar05  
8Nov  
-13  
21Apr  
-15  
3Apr  
-15  
3Apr  
-15  
3Apr  
-15  
12Jan  
-15  
21Apr  
-15  
26Jun  
-15  
21Nov  
-12  
29Oct  
-13  
16Jun  
-15  
17Apr  
-13  
17Jun  
-13  
7Apr  
-15  
23Sep  
-13  
10Jun  
-15





24Sep  
-15  
24Sep  
-15  
17Sep  
-15  
US20150259  
399  
US20150259  
340  
US20150259  
292  
US20150258  
191  
US20150252  
439  
US20150252  
080  
US20150250  
896  
US20150247  
190  
US20150246  
110  
US20150246  
091  
US20150246  
015  
US20150239  
940  
US20150239  
875  
US20150238  
550  
US20150238  
489  
US20150232  
957  
US20150232  
881  
US20150232  
878  
US20150232  
454  
US20150231  
232  
US20150225  
432  
US20150218  
162  
US20150218  
109  
US20150216  
973

US20150211

006

US20150210

733

US20150210

655

US20150203

847

16ANTIBODIES

AND PROCESSES FOR PREPARING THE SAME

NOVEL KINASE INHIBITORS

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR  
MICROFLUIDIZATION

Methods and Compositions for Prostate Cancer Metastasis

FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE,  
NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND  
USE THEREOF

HYDROPHILIC LINKERS AND THEIR USES FOR CONJUGATION OF  
DRUGS TO A CELL BINDING MOLECULES

METHODS AND SYSTEMS FOR MICROFLUIDICS IMAGING AND  
ANALYSIS

ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINEINDUCING  
AGENTS

COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A  
VIRAL INFECTION

Esters of Short Chains Fatty Acids for Use in the Treatment of  
Immunogenic Disorders

COMPOSITIONS AND METHODS FOR VIRUS INHIBITION

SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS  
INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

AAV Vectors Targeted to Oligodendrocytes

Not Available

Not Available

Not Available

Novartis AG

Not Available

Not Available

Hangzhou DAC Biotech Co., Ltd.

Not Available

Novartis AG

Not Available

Not Available

AUTOIMMUNE TECHNOLOGIES, LLC

Not Available

Not Available

HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES Not Available

MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS

AND USE THEREOF FOR DETECTING NUCLEIC ACIDS

CRISPR-RELATED METHODS AND COMPOSITIONS WITH

GOVERNING gRNAS

Construct

THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES

AND HYDROXYPYRIDAZINONES

OUTER MEMBRANE VESICLES

Not Available

EDITAS MEDICINE, INC.

Not Available

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Not Available

COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS Novartis AG

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND

IMIDAZONAPHTHYRIDINES

C-REL INHIBITORS AND USES THEREOF

METHOD FOR THE INDUCTION OF AN IMMUNE RESPONSE

CHIRAL CONTROL

NUCLEIC ACID CHEMICAL MODIFICATIONS

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4OXAZEPANE-2-CARBOXAMIDES

AS DIPEPTIDYL PEPTIDASE 1

INHIBITORS

CHEMICAL MODIFICATIONS OF MONOMERS AND

OLIGONUCLEOTIDES WITH CYCLOADDITION

Not Available

Not Available

Not Available

Not Available

Not Available

ASTRAZENECA AB

Not Available

May08

19Oct12

8Mar11

3Dec09

25Mar11

7Sep12

24Nov12

5Oct12

4Nov05

2Nov07

3Oct12

4Nov03

21Feb14

28Sep12

31Aug12

4Apr12

7Nov13

28Mar06

11Sep12

18Sep12

2Sep09

18Jun04

21Sep12

8Aug12

13Jul-12

2Mar09

24Jan14

23Sep08

18Mar

-15  
18Oct  
-13  
19Mar  
-15  
13Mar  
-15  
20May  
-15  
9Sep  
-13  
24Nov  
-12  
4Oct  
-13  
14May  
-15  
15May  
-15  
30Oct  
-13  
13May  
-15  
12Feb  
-15  
27Sep  
-13  
30Aug  
-13  
4Apr  
-13  
7Nov  
-14  
20Oct  
-14  
11Sep  
-13  
18Sep  
-13  
24Apr  
-15  
13Apr  
-15  
19Sep  
-13  
8Aug  
-13  
12Jul13  
22Jan  
-15  
21Jan  
-15  
31Dec  
-14

17Sep  
-15  
17Sep  
-15  
17Sep  
-15  
17Sep  
-15  
10Sep  
-15  
10Sep  
-15  
10Sep  
-15  
3Sep  
-15  
3Sep  
-15  
3Sep  
-15  
3Sep  
-15  
27Aug  
-15  
27Aug  
-15  
27Aug  
-15  
27Aug  
-15  
20Aug  
-15  
20Aug  
-15  
20Aug  
-15  
20Aug  
-15  
20Aug  
-15  
20Aug  
-15  
13Aug  
-15  
6Aug  
-15  
6Aug  
-15  
6Aug  
-15  
30Jul15  
30Jul15  
30Jul15  
23Jul15  
Fauci/COVID-19  
Dossier

CC-BY-NC-SA Dr. David E. Martin  
120  
US20150203  
816  
US20150202  
284  
US20150196  
619  
US20150196  
578  
US20150196  
032  
US20150191  
704  
US20150191  
607  
US20150184  
231  
US20150183  
837  
US20150182  
636  
US20150182  
588  
US20150176  
027  
US20150175  
656  
US20150174  
257  
US20150174  
206  
US20150174  
198  
US20150174  
158  
US20150173  
366  
US20150168  
405  
US20150166  
989  
US20150166  
966  
US20150166  
548  
US20150166  
532  
US20150166  
488  
US20150166  
487  
US20150165  
019

US20150165

009

4MEANS

AND METHODS FOR INFLUENCING THE STABILITY OF CELLS Not Available

METHOD OF MAKING A VACCINE

EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE  
RESPIRATORY TRACT

COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS

ANTIVIRAL COMPOSITIONS

POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS

CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND

METHODS OF MAKING AND USING SAME

Anti-fouling Paints and Coatings

BIOAGENT DETECTION OLIGONUCLEOTIDES

The United States of America, as represented by the

Secretary, Dept. of Health & Human Services

Not Available

Not Available

Long Island University

Dec09

11Oct08

8Jan10

14Oct09

30May07

30Not

Available

Dec13

REACTIVE

SURFACES, LTD

Not Available

IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF Not Available

GENETICALLY MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR

CELLS FOR PROPHYLAXIS AGAINST OR TREATMENT OF BIOLOGICAL

OR CHEMICAL AGENTS

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,

VECTORS CONTAINING SAME, AND USES THEREFOR

3-Jul03

27Dec11

17Dec07

21Not

Available

Apr08

18Not

Available

Not Available

CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS Not Available

METHODS AND REAGENTS FOR EFFICIENT AND TARGETED GENE

TRANSFER TO MONOCYTES AND MACROPHAGES

USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE

GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING

LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA

VIRUS SPIKE PROTEIN

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY



DISEASES  
PHYSICAL ANTIMICROBIAL METHOD  
OLIGONUCLEOTIDE BASED ANALYTE DETECTION METHOD  
PARTICLE-NUCLEIC ACID CONJUGATES AND THERAPEUTIC USES  
RELATED THERETO  
REVERSE GENETICS METHODS FOR VIRUS RESCUE  
NOVEL COMPOUNDS  
HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER  
VIRUSES  
ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL  
SODIUM CHANNEL BLOCKING COMPOUNDS  
ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL  
SODIUM CHANNEL BLOCKING COMPOUNDS  
Saccharide Conjugate Vaccines  
TLR5 LIGANDS, THERAPEUTIC METHODS, AND COMPOSITIONS  
RELATED THERETO  
Fauci/COVID-19 Dossier  
Not Available  
Not Available  
Nov13  
17Dec01  
20Mar09  
29Apr09  
28Aug03  
28Not  
Available  
Oct05  
7Not  
Available  
NMS TECHNOLOGIES CO., LTD.  
Not Available  
Not Available  
Not Available  
CHIESI FARMACEUTICI S.p.A.  
Not Available  
PARION SCIENCES, INC.  
Parion Sciences, Inc.  
Not Available  
Emory University  
Mar12  
1Aug12  
16Feb10  
25Jun12  
20Oct09  
16Dec13  
11Apr12  
13Dec13  
13Dec13  
24Dec04  
24Sep10  
CC-BY-NC-SA  
Dr. David E. Martin  
26Mar

20Jan  
-15  
2Jan  
-15  
10Dec  
-14  
19Mar  
-15  
19Dec  
-14  
4Dec  
-13  
27Dec  
-12  
13Feb  
-15  
13Mar  
-15  
23Dec  
-14  
16Jan  
-15  
5Mar  
-15  
3Mar  
-15  
28Jan  
-15  
17Nov  
-14  
7Mar  
-13  
16Jul13  
24Feb  
-15  
27Feb  
-13  
10Oct  
-14  
16Dec  
-14  
15Mar  
-13  
19Dec  
-14  
13Dec  
-13  
5Aug  
-14  
20Sep  
-11  
23Jul15  
23Jul15  
16Jul15

16Jul15  
16Jul15  
9Jul15  
9Jul15  
2Jul15  
2Jul15  
2Jul15  
2Jul15  
25Jun15  
25Jun15  
25Jun15  
25Jun15  
25Jun15  
25Jun15  
25Jun15  
18Jun15  
18Jun15  
18Jun15  
18Jun15  
18Jun15  
18Jun15  
18Jun15  
18Jun15  
18Jun15  
121  
US20150164  
800  
US20150159  
205  
US20150159  
173  
US20150157  
636  
US20150152  
149  
US20150150  
963  
US20150150  
893  
US20150150  
878  
US20150148  
402  
US20150147  
346  
US20150141  
625  
US20150141  
387  
US20150140  
121  
US20150139  
949  
US20150133

633

US20150133

402

US20150133

391

US20150132

339

US20150132

337

US20150132

220

US20150126

722

US20150125

540

US20150125

502

US20150125

483

US20150125

475

US20150125

384

US20150119

445

US20150119

444

REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND

LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE

METHODS AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR

METHODS FOR TREATING VIRAL DISORDERS

Peptides Having Activity of Inhibiting Infections of Respiratory

Viruses and Use of the Same

VACCINATION WITH INTERLEUKIN-4 ANTAGONISTS

Salk Institute For Biological Studies

25Jul-12

The

United States of America, as represented by the

Secretary, Department of Health and Human

The Trustees of the University of Pennsylvania

Not Available

Not Available

THE AUSTRALIAN NATIONAL UNIVERSITY

ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION Not Available

Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage

Sites In The Viruses' Glycoproteins

MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS

OF USE

REPLIKIN SEQUENCES AND THEIR ANTIBODIES FOR DIAGNOSTICS,

THERAPEUTICS, AND VACCINES AGAINST PRION AND

NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S

DISEASE

IMMUNE RESPONSE MODIFIER CONJUGATES

PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE  
INHIBITOR AND A SECOND ACTIVE INGREDIENT  
Compositions and Methods for Tight Junction Modulation  
ANTI-VIRAL COMBINATION THERAPY  
MODIFICATION OF PEPTIDES USING A  
BIS(THIOETHER)ARYLBRIDGE APPROACH  
BORON-CONTAINING SMALL MOLECULES  
CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN  
MICROBIOME AND COMPONENTS THEREOF  
ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE  
ANTIGENS  
COMBINATION GAS VACCINES AND THERAPEUTICS  
Compositions and Imaging Methods Comprising Detectably Labeled  
Phosphatidylethanolamine-Binding Peptides  
OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING  
NIDOVIRUS INFECTIONS  
RELEASE OF AGENTS FROM CELLS  
DISINFECTING COMPOSITION AND WIPES WITH REDUCED  
CONTACT TIME  
FUSION PROTEINS OF CILIATE GRANULE LATTICE PROTEINS,  
GRANULAR PROTEIN PARTICLES THEREOF, AND USES THEREFOR  
IMMUNOLOGICALLY USEFUL ARGININE SALTS  
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES  
Not Available  
NOVARTIS AG  
6Aug12  
7Apr05  
24Sep09  
9May13  
5Jun12  
18Jun12  
4Apr12  
10Oct04  
2Not  
Available  
May12  
22Not  
Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Not Available  
Tetragenetics, Inc.  
Not Available  
Not Available  
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available

Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available

Fauci/COVID-19 Dossier

CC-BY-NC-SA Dr. David E. Martin

Feb06

18Dec08

8Jun12

6Apr11

18May12

20Jun07

7Nov13

7Mar12

17Sep08

15Jul-02

24Dec03

15Oct09

6Nov13

27May11

7Mar12

15Feb07

4Dec07

4Dec07

23Jul13

6Aug

-12

18Feb

-15

18Feb

-15

21Feb

-14

5Jun

-13

31May

-13

4Apr

-13

9May

-14

1May

-13

20Jan

-15

14Jan

-15

10Jun

-13

19May

-14

17May

-13

7Nov

-14

7Nov

-14



7May  
-15  
7May  
-15  
7May  
-15  
7May  
-15  
7May  
-15  
30Apr15  
30Apr15  
122  
18  
US20150119  
426  
US20150119  
364  
US20150119  
318  
US20150118  
746  
US20150118  
319  
US20150118  
265  
US20150118  
264  
US20150118  
222  
US20150118  
201  
US20150118  
183  
US20150111  
955  
US20150111  
945  
US20150111  
893  
US20150110  
807  
US20150105  
375  
US20150104  
867  
US20150104  
500  
US20150099  
770  
US20150099  
769  
US20150099  
764



US20150099

656

US20150099

263

US20150099

261

US20150093

413

US20150086

576

US20150080

447

US20150080

396

4MODULATORS

OF THE RELAXIN RECEPTOR 1

BORON-CONTAINING SMALL MOLECULES

PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING

HERPESVIRUS INFECTION

INFLUENZA VIRUS REASSORTMENT METHOD

PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E

VIRUS AS AN ORAL DELIVERY VECTOR

Not Available

Not Available

THE ADMINISTRATORS OF THE TULANE EDUCATIONAL

FUND

Not Available

Not Available

MODIFIED ERYTHROCYTE PRECURSOR CELLS AND USES THEREOF Anthrogenesis Corporation

PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC

CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR

PEPTIDE ANTIGEN

TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND

IMMUNOTHERAPY

Directed Evolution and In Vitro Panning of Virus Vectors

NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES

FOR IMMUNOSTIMULATION

AAV VECTOR COMPOSITIONS AND METHODS FOR GENE TRANSFER

TO CELLS, ORGANS AND TISSUES

COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS

GENE EXPRESSION

Nuclear Transport Modulators and Uses Thereof

HDC-SIGN BINDING PEPTIDES

METHODS FOR TREATING PULMONARY EMPHYSEMA USING

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC

ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF

CATHEPSIN C

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Methods and Compositions for Preventing a Condition

CARBOXYLIC ACID COMPOUNDS

PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE

IN THERAPY

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL

BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER

MUCOSAL DISEASES

Multiplex Immuno Screening Assay

SELECTIVE DETECTION OF HUMAN RHINOVIRUS

RESPIRATORY INFECTION ASSAY

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEMLOOP

AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL

FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC

ANTIGEN

SORTASE-MODIFIED VHH DOMAINS AND USES THEREOF

Sceletium Extract and Uses Thereof

Novel Pyrimidine Derivatives and Their Use in the Treatment of

Cancer and Further Diseases

Fauci/COVID-19 Dossier

CureVac GMBH

Not Available

Not Available

CUREVAC GMBH

Not Available

Not Available

Not Available

Sloan-Kettering Institute for Cancer Research

May12

16Feb05

30Oct09

21May10

27Feb09

13Mar12

31Jan12

25Oct13

30Apr08

31Jan12

17Feb12

20Jul-09

9May12

19Dec11

14Not

Available

Mar13

29Baxter

Healthcare SA

Not Available

Not Available

Not Available

Oct04

9Aug10

18May12

6Dec04

29PARION

SCIENCES, INC.

May12

4Not

Available

Not Available

Not Available

May12  
5Dec08  
9Dec11  
15CureVac  
GmbH  
Feb12  
13Not  
Available  
H. L. Hall & Sons Limited  
ASTRAZENECA AB  
Apr12  
20Mar09  
21May09  
CC-BY-NC-SA  
Dr. David E. Martin  
15Mar  
-13  
10Nov  
-14  
9Jul14  
24Oct  
-14  
5Nov  
-14  
12Mar  
-13  
31Jan  
-13  
24Oct  
-14  
22Oct  
-14  
31Jan  
-13  
19Feb  
-13  
28Mar  
-14  
9May  
-13  
10Dec  
-12  
18Dec  
-14  
2May  
-14  
28Aug  
-14  
17May  
-13  
15Sep  
-14  
9Dec  
-14

3May  
-13  
15Dec  
-14  
10Dec  
-12  
15Feb  
-13  
15Apr  
-13  
15Jul14  
26Aug  
-14  
123  
30Apr15  
30Apr15  
30Apr15  
30Apr15  
30Apr15  
30Apr15  
30Apr15  
30Apr15  
30Apr15  
30Apr15  
30Apr15  
23Apr15  
23Apr15  
23Apr15  
23Apr15  
16Apr15  
16Apr15  
16Apr15  
9Apr15  
9Apr15  
9Apr15  
9Apr15  
9Apr15  
2Apr15  
26Mar  
-15  
19Mar  
-15  
19Mar  
-15  
US20150080  
344  
US20150080  
319  
US20150079  
155  
US20150079  
121  
US20150073  
136

US20150072  
973  
US20150072  
023  
US20150065  
459  
US20150065  
458  
US20150064  
137  
US20150056  
636  
US20150056  
305  
US20150051  
206  
US20150050  
713  
US20150050  
308  
US20150050  
278  
US20150045  
412  
US20150044  
768  
US20150044  
305  
US20150044  
279  
US20150037  
288  
US20150037  
281  
US20150034  
084  
US20150031  
038  
US20150031  
016  
US20150031  
014  
US20150030  
627  
US20150030  
626

PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF  
VIRAL INFECTIONS

Inhibition Of Tace Activity With Cyclic Peptides

Cationic Liposomal Drug Delivery System for Specific Targeting of  
Human CD14+ Monocytes in Whole Blood

Human Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid  
Constructs And Vaccines Made Therefrom, And Methods Of Using  
Same

PYRAZINONE DERIVATIVES

NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE  
7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR  
THERAPEUTIC APPLICATIONS

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY  
DISEASES

BORON-CONTAINING SMALL MOLECULES

Composition for Inactivating an Enveloped Virus

USE OF ENGINEERED VIRUSES TO SPECIFICALLY KILL SENESCENT  
CELLS

14Not

Available

Not Available

Not Available

Not Available

Not Available

Apr10

2Jun11

14Mar12

10Apr12

27Jun07

13Not

Available

Aug10

11Not

Available

Not Available

Not Available

Kythera Biopharmaceuticals, Inc.

Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha Not Available

DITHIOL MUCOLYTIC AGENTS

PARION SCIENCES, INC.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC

Technology for the Preparation of Microparticles

CORONAVIRUS, NUCLEIC ACID, PROTEIN, AND METHODS FOR THE  
GENERATION OF VACCINE, MEDICAMENTS AND DIAGNOSTICS

SOLUBLE ENGINEERED MONOMERIC FC

USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR

TREATING MICROBIAL DISEASE AND PROMOTING AUTOPHAGY

METHODS AND COMPOSITIONS FOR PRODUCTION OF

RECOMBINANT PROTEIN IN HBX-EXPRESSING MAMMALIAN CELLS

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY

DISEASES

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE

RESPONSE

METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES

VARIANTS OF PROTHYMOSIN ALPHA AND METHODS OF USING  
SAME

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY  
DISEASES

SAMPLE PREPARATION METHODS

Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes  
and Enteric Viruses

DETECTING ANALYTES WITH A PH METER

Trans-complementing, replication deficient lentiviral vectors and methods for making and using them

IMMUNOMODULATORY CONJUGATES

Fauci/COVID-19 Dossier

Not Available

Not Available

Not Available

Not Available

Sep13

16Feb05

19May06

17Apr12

26Mar12

23Aug13

1Sep11

24Jul-07

18Aug03

16Mar12

7Mar12

28Not

Available

Not Available

Not Available

Not Available

Icahn School of Medicine at Mount Sinai

Advanced Inhalation Therapies (AIT) Ltd.

Not Available

Diagnostic Hybrids Inc.

The Board of Trustees of the University of Illinois

VIRxSYS.CON390

Ascend Biopharmaceuticals Ltd

CC-BY-NC-SA Dr. David E. Martin

May08

7Mar12

10Apr03

26Jan12

2Mar12

7Mar12

6Sep11

24Apr98

25Jul-13

17Aug06

9Nov11

29Sep

-14

19Sep

-14

14Mar

-13

10Apr

-13

17Nov

-14

17Sep

-14  
11Sep  
-14  
10Nov  
-14  
17Nov  
-14  
16Apr  
-13  
26Mar  
-13  
13Aug  
-14  
29Aug  
-12  
25Jul14  
13Aug  
-14  
14Mar  
-13  
6Mar  
-13  
24Oct  
-14  
7Mar  
-13  
6Oct  
-14  
25Jan  
-13  
1Mar  
-13  
7Mar  
-13  
6Sep  
-12  
4Aug  
-14  
25Jul14  
8Oct  
-14  
9Nov  
-12  
19Mar  
-15  
19Mar  
-15  
19Mar  
-15  
19Mar  
-15  
12Mar  
-15  
12Mar



-15  
12Mar  
-15  
5Mar  
-15  
5Mar  
-15  
5Mar  
-15  
26Feb  
-15  
26Feb  
-15  
19Feb  
-15  
19Feb  
-15  
19Feb  
-15  
19Feb  
-15  
19Feb  
-15  
12Feb  
-15  
12Feb  
-15  
12Feb  
-15  
12Feb  
-15  
5Feb  
-15  
5Feb  
-15  
5Feb  
-15  
29Jan15  
29Jan15  
29Jan15  
29Jan15  
29Jan15  
124  
US20150030  
625  
US20150030  
607  
US20150025  
075  
US20150024  
415  
US20150024  
405  
US20150024  
002  
US20150023

990  
US20150023  
924  
US20150023  
921  
US20150023  
879  
US20150021  
204  
US20150021  
203  
US20150018  
396  
US20150018  
332  
US20150017  
251  
US20150011  
615  
US20150011  
508  
US20150010  
983  
US20150005  
227  
US20150004  
188  
US20140364  
492  
US20140364  
408  
US20140364  
358  
US20140363  
465  
US20140363  
422  
US20140357  
673  
US20140356  
390  
US20140349  
375  
12GAS57

MUTANT ANTIGENS AND GAS57 ANTIBODIES

INFLUENZA HEMAGGLUTININ-SPECIFIC MONOCLONAL ANTIBODIES  
FOR PREVENTING AND TREATING INFLUENZA VIRUS INFECTION

HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR

ANTAGONISTS

DETECTION AND QUANTIFICATION OF ANALYTES BASED ON

SIGNAL INDUCED BY ALKALINE PHOSPHATE

ENHANCED DEPOSITION OF CHROMOGENS UTILIZING PYRIMIDINE

ANALOGS

Not Available

Not Available

ACTELION PHARMACEUTICALS LTD.

The Board of Trustees of the University of Illinois

Ventana Medical Systems, Inc.

ALPHAVIRUS VECTORS FOR RESPIRATORY PATHOGEN VACCINES Not Available

ALKOXY SUBSTITUTED IMIDAZOQUINOLINES

VARIANT AAV AND COMPOSITIONS, METHODS AND USES FOR

GENE TRANSFER TO CELLS, ORGANS AND TISSUES

HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS

DIAGNOSTIC CHEWING GUM FOR PATHOGENS

AMPEROMETRIC GAS SENSOR

AMPEROMETRIC GAS SENSOR

PREVENTION AND TREATMENT OF RESPIRATORY INFECTION WITH

PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR DELTA

AGONIST

Nuclear Transport Modulators and Uses Thereof

MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS

3M INNOVATIVE PROPERTIES COMPANY

Not Available

BIOTRON LIMITED

Julius-Maximilians-Universitaet Wuerzburg

Not Available

Not Available

Not Available

KARYOPHARM THERAPEUTICS INC.

NOVARTIS AG

Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC

COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL

GROWTH

METHOD OF TREATING AN ISCHEMIA-REPERFUSION INJURYRELATED

DISORDER BY ADMINISTERING GPCR LIGANDS

COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC

CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND

METHODS OF USING THE SAME

PHORBOL TYPE DITERPENE COMPOUND, PHARMACEUTICAL

COMPOSITION FOR TREATMENT OR PREVENTION OF VIRAL

INFECTIOUS DISEASES INCLUDING SAME

Hydrazide Containing Nuclear Transport Modulators And Uses

Thereof

Method for Preventing and Treating Hyperpermeability

MYCOBACTERIAL VACCINE VECTORS AND METHODS OF USING THE

SAME

METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH

DESIRED SPECIFICITY

Deubiquitinase Inhibitors and Methods for Use of the Same

MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF

SYNONYMOUS CODONS

METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL

ACTIVITY

Fauci/COVID-19 Dossier

Not Available

Not Available

Sep07

20Oct10  
20Jan12  
16Feb12  
30Dec10  
21May04  
30Oct03  
22Jul-13  
3Aug07  
8Mar12  
25Jun12  
25Jun12  
8Mar12  
29Jul-11  
6Aug08  
4Dec07  
1Sep11  
5Dec08  
18Sep06  
12Not

Available

KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND  
BIOTECHNOLOGY

KARYOPHARM THERAPEUTICS INC.

Apeptico Forschung UND Entwicklung GMBH

Beth Israel Deaconess Medical Center, Inc.

Not Available

Not Available

The Government of the United States of America as  
represented by the Secretary of the Department of  
Biogenetic Innovations, LLC

CC-BY-NC-SA Dr. David E. Martin

Dec11

26Oct11

29Jul-11

5Mar09

4Apr11

28Dec11

24Sep10

8Oct04

30Oct09

13Oct

-14

9Oct

-14

18Jan

-13

19Feb

-13

6Oct

-14

20Aug

-14

30Sep

-14

22Jul14  
3Apr  
-14  
8Mar  
-13  
30Sep  
-14  
30Sep  
-14  
3Mar  
-13  
26Jul12  
18Jul14  
11Jul14  
28Aug  
-12  
19Sep  
-14  
7Sep  
-14  
11Dec  
-12  
28Sep  
-12  
29Jul12  
7Mar  
-14  
4Apr  
-12  
2Jan  
-13  
31Jul14  
20Aug  
-14  
12Aug  
-14  
29Jan15  
29Jan15  
22Jan15  
22Jan15  
22Jan15  
22Jan15  
22Jan15  
22Jan15  
22Jan15  
22Jan15  
22Jan15  
22Jan15  
15Jan15  
15Jan15  
15Jan15  
8Jan15  
8Jan15  
8Jan15

1Jan15  
1Jan15  
11Dec  
-14  
11Dec  
-14  
11Dec  
-14  
11Dec  
-14  
11Dec  
-14  
4Dec  
-14  
4Dec  
-14  
27Nov  
-14  
125  
US20140349  
295  
US20140349  
276  
US20140348  
906  
US20140348  
791  
US20140348  
785  
US20140348  
781  
US20140342  
941  
US20140342  
407  
US20140336  
245  
US20140335  
618  
US20140335  
592  
US20140335  
117  
US20140335  
111  
US20140335  
104  
US20140329  
889  
US20140329  
878  
US20140329  
817  
US20140328

946

US20140328

874

US20140323

556

US20140323

392

US20140323

390

US20140322

355

US20140317

766

US20140315

982

US20140315

215

US20140314

858

US20140314

839

US20140314

809

31METHOD

FOR DETECTING TARGET NUCLEIC ACID

Not Available

SIGNAL PROPAGATION BIOMOLECULES, DEVICES AND METHODS STC.UNM  
IMMUNOSTIMULATORY COMPOSITIONS COMPRISING LIPOSOMEENCAPSULATED  
OLIGONUCLEOTIDES AND EPITOPES

MODIFIED ADENOVIRAL VECTORS AND METHODS OF TREATMENT  
USING SAME

NEUTRALIZING GP41 ANTIBODIES AND THEIR USE  
CONJUGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS  
RELATED THERETO

METHOD FOR USING PERMUTED NUCLEIC ACID PROBES

NEUTRALIZING GP41 ANTIBODIES AND THEIR USE

VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENE DELIVERY

TAL EFFECTOR-MEDIATED DNA MODIFICATION

TAL EFFECTOR-MEDIATED DNA MODIFICATION

Identification and Attenuation of the Immunosuppressive Domains  
in Fusion Proteins of Enveloped RNA Viruses

VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND  
COMPOSITIONS AND METHODS OF USING THE SAME

Methods of Detecting Cells with a Disrupted Cell Membrane, Cells  
Infected with A Pathogen, Dying Cells or Dead Cells

CYCLIC DI-NUCLEOTIDE INDUCTION OF TYPE I INTERFERON

OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR  
PATHWAY

MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED  
THERETO

ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORIDE MONOXIDE  
AND METHODS OF MAKING AND USING THE SAME

SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION

SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT

LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM

METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY

COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

ANTIBODY PRODUCING NON-HUMAN MAMMALS

DOUBLE-STRANDED NUCLEIC ACID MOLECULE FOR GENE EXPRESSION CONTROL

THERMOSTABLE ASSAY REAGENTS

IPNV-ISAV BIVALENT VACCINE USING A VIRUS-LIKE PARTICLEBASED PLATFORM AND METHODS OF USING THE SAME

CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF

MALARIA ANTIGEN SCREENING METHOD

Fauci/COVID-19 Dossier

Not Available

Beth Israel Deaconess Medical Center, Inc.

Not Available

CHILDREN'S HEALTHCARE OF ATLANTA, INC

Ventana Medical Systems, Inc.

The United States of America, as represented by the Secretary, Department of Health and Human Serv

Not Available

Iowa State University Research Foundation, Inc.

Iowa State University Research Foundation, Inc.

Not Available

The Trustees of the University of Pennsylvania

Not Available

Not Available

Not Available

CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Not Available

Not Available

Not Available

UNIVERSITY OF UTAH RESEARCH FOUNDATION

IRM LLC

3-V BIOSCIENCES, INC.

Not Available

Osaka City University

The Secretary of State for Health

Advanced BioNutrition Corporation

Not Available

Not Available

CC-BY-NC-SA Dr. David E. Martin

Oct11

21May13

17Jul-09

9Sep11

7Nov11

22May13

1Sep06

7Nov11

22Nov11



10Dec09  
10Dec09  
7Oct11  
4Apr08  
13May08  
3May13  
3Mar11  
24Oct11  
13Mar07  
19Oct11  
15Mar13  
28Mar11  
23Mar10  
8Mar11  
27Jun08  
2Nov11  
14Sep11  
9Sep11  
2Dec11  
19Apr13  
25Oct  
-12  
21May  
-14  
13Aug  
-14  
7Sep  
-12  
7Nov  
-12  
20May  
-14  
5Aug  
-14  
4Aug  
-14  
21Nov  
-12  
14Apr  
-14  
24Feb  
-14  
5Oct  
-12  
28Apr  
-14  
14Apr  
-14  
2May  
-14  
1Mar  
-12  
24Oct  
-12



6Nov  
-14  
6Nov  
-14  
6Nov  
-14  
30Oct14  
30Oct14  
30Oct14  
30Oct14  
23Oct14  
23Oct14  
23Oct14  
23Oct14  
23Oct14  
23Oct14  
126  
US20140314  
797  
US20140314  
755  
US20140314  
739  
US20140309  
189  
US20140309  
164  
US20140308  
379  
US20140308  
313  
US20140308  
211  
US20140303  
232  
US20140303  
071  
US20140302  
124  
US20140302  
120  
US20140302  
091  
US20140302  
077  
US20140298  
500  
US20140296  
179  
US20140295  
404  
US20140294  
828  
US20140294

765

US20140294

727

US20140294

670

US20140287

987

US20140286

988

US20140283

945

US20140275

237

US20140275

159

US20140275

155

US20140275

114

YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH  
TERMINAL ALPHA-1,3-LINKED GALACTOSE

30Not

Available

ANTIBODY PRODUCING NON-HUMAN MAMMALS

Vaccine adjuvant composition comprising inulin particles

HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF  
HCV

Not Available

Vaxine Pty Ltd.

Achillion Pharmaceuticals, Inc.

DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV Achillion  
Pharmaceuticals, Inc.

USE OF FLAXSEED AND FLAXSEED DERIVATIVES FOR TREATMENT  
OF NEUROLOGICAL DISORDERS AND VIRAL DISEASES

COMPOSITIONS AND METHODS FOR IMMUNISATION USING CD1D  
LIGANDS

MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION  
CHARACTERISTICS

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE  
AGENTS

CYCLIC ANTIMICROBIAL PEPTIDES

Cytotoxic T Lymphocyte Inducing Immunogens For Prevention  
Treatment and Diagnosis of INFLUENZA VIRUS INFECTION

The Trustees of the University of Pennsylvania

Not Available

Not Available

NOVARTIS AG

Not Available

Immunotape, Inc.

CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR Not Available

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available

LIVE ATTENUATED INFLUENZA VIRUS

MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION  
CHARACTERISTICS

NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS  
AND OLIGOSACCHARIDES  
SAMPLE FIXATION AND STABILISATION  
ALPHABODIES SPECIFICALLY BINDING TO VIRAL PROTEINS AND  
METHODS FOR PRODUCING THE SAME  
LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF  
CANCER  
PEPTIDES FOR ASSISTING DELIVERY ACROSS THE BLOOD BRAIN  
BARRIER  
TRANSPORTABLE VACUUM ASSISTED DECONTAMINATION UNIT  
AND DECONTAMINATION PROCESS  
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER  
OR OTHER DISEASES  
HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES  
MADE THEREFROM  
LOADING VIALS  
BERAPROST ISOMER AS AN AGENT FOR THE TREATMENT OF VIRAL  
INFECTION  
SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID  
(BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C  
SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANOMETHYL)-AMIDES  
INHIBITORS OF CATHEPSIN C  
SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC  
ACID (CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C  
Westfaelische Wilhelms-Universitaet Munester  
Not Available  
N.V. NUTRICIA  
Not Available  
COMPLIX SA  
COMPUGEN LTD.  
Children's Medical Center Corporation  
STERIS Inc.  
CITY OF HOPE  
3M Innovative Properties Company  
BioFire Diagnostics, LLC  
Gemmus Pharma Inc.  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
May08  
27Jun08  
18Jun11  
12Apr13  
12Apr13  
20Nov12  
15Mar06  
11May10  
8Mar13  
22Dec05  
19Oct11  
7Feb07  
6Apr07  
2Sep11  
11May10

24Aug04  
1Mar13  
6Jan11  
21Jun12  
22May06  
1Apr13  
26Jan07  
3Jun11  
10Nov11  
15Mar13  
14Mar13  
14Mar13  
14Mar13  
2Jul14  
30Apr  
-14  
19Jun  
-12  
14Apr  
-14  
14Apr  
-14  
19Nov  
-13  
26Jun  
-14  
5May  
-14  
7Mar  
-14  
20Jun  
-14  
18Oct  
-12  
19Jun  
-14  
18Nov  
-11  
28Aug  
-12  
5May  
-14  
5Mar  
-14  
28Feb  
-14  
6Jan  
-11  
19Jun  
-13  
30Apr  
-14  
31Mar  
-14



037

SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,  
PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR  
TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING  
INFECTIONS ASSOCIATED WITH ARENAVIRUSES

US20140275

025

US20140274

980

US20140273

228

US20140273

156

US20140271

829

US20140271

700

US20140271

580

US20140271

550

US20140270

457

US20140255

472

US20140255

439

US20140255

426

US20140255

349

US20140249

296

US20140249

129

US20140248

620

US20140248

357

US20140248

320

US20140248

313

US20140248

312

US20140243

505

US20140243

341

US20140242

692

US20140242

152

US20140242



108

US20140235

844

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC  
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF  
CATHEPSIN C

COMPOUND

METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING  
INHIBITORY GENE PRODUCTS

LUCIFERASE BIOSENSOR

RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA  
MOLECULES

COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM  
DIFFICILE-ASSOCIATED DISEASES

IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND  
METHODS

Constructs and Methods for Delivering Molecules via Viral Vectors  
with Blunted Innate Immune Responses

STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING

PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING  
RNA

VIRUS-LIKE PARTICLES AND PROCESS FOR PREPARING SAME

WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS

PEPTIDES WITH VIRAL INFECTION ENHANCING PROPERTIES AND  
THEIR USE

USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR  
PROTEIN LIGATION

Substituted Bicyclic Dihydropyrimidinones And Their Use As  
Inhibitors Of Neutrophil Elastase Activity

Methods and Compositions for Prostate Cancer Metastasis  
Respiratory Disease Treatment

ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC  
PRIMING

COMBINATION ADJUVANT FORMULATION

INFLUENZA VACCINES INCLUDING COMBINATIONS OF  
PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS

BISPECIFIC ANTIBODY

BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE

PROTEASES OF PICORNAVIRUS-LIKE SUPERCLUSTER:

PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES

MAMMALIAN GENES INVOLVED IN TOXICITY AND INFECTION

IMMUNOGENIC COMPOSITIONS AND USES THEREOF

Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists

Short Interfering RNA (siRNA) Analogues

Fauci/COVID-19 Dossier

6Siga

Technologies, Inc.

Dec04

19Dec

-13

18Sep

-14

14BOEHRINGER

INGELHEIM INTERNATIONAL GMBH

RESPIVERT LTD.  
GenVec, Inc.  
PROMEGA CORPORATION  
Not Available  
National Health Research Institutes  
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL  
FUND  
The Trustees of the University of Pennsylvania  
The Board of Trustees of the University of Illinois  
Not Available  
FOLIA BIOTECH INC.  
Children's Healthcare of Atlanta, Inc.  
Centre National de la Recherche Scientifique  
Whitehead Institute for Biomedical Research  
Boehringer Ingelheim International GmbH  
Florida Agricultural and Mechanical University (FAMU)  
PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED  
Not Available  
Dalhousie University  
NOVARTIS VACCINES AND DIAGNOSTICS SRL  
WUHAN YZY BIOPHARMA CO., LTD.  
Mar13  
15Mar13  
10Nov05  
10Oct03  
11Oct11  
14Mar13  
14Mar13  
14Mar13  
15Mar13  
31Aug11  
13May11  
11Mar13  
30Jun11  
28Jun11  
4Mar13  
25Mar11  
7Aug08  
20Oct11  
16Oct08  
4Nov05  
21Nov12  
27Not  
Available  
Sep11  
10Not  
Available  
Not Available  
CAYLA  
Santaris Pharma A/S  
Dec10  
6-Jul11  
22Feb13  
21Mar03

CC-BY-NC-SA  
Dr. David E. Martin

12Mar

-14

14Mar

-14

28May

-14

14Feb

-14

11Oct

-12

13Mar

-14

14Mar

-13

14Mar

-14

14Mar

-14

31Aug

-12

1May

-12

10Mar

-14

28Jun

-12

28Jun

-12

20Feb

-14

23Mar

-12

7Apr

-14

19Oct

-12

15Feb

-13

28Feb

-14

13Mar

-14

27Sep

-12

11Dec

-11

6Jul12

22Feb

-13

11Feb

-14

18Sep

-14  
18Sep  
-14  
18Sep  
-14  
18Sep  
-14  
18Sep  
-14  
18Sep  
-14  
18Sep  
-14  
18Sep  
-14  
11Sep  
-14  
11Sep  
-14  
11Sep  
-14  
11Sep  
-14  
4Sep  
-14  
4Sep  
-14  
4Sep  
-14  
4Sep  
-14  
4Sep  
-14  
4Sep  
-14  
28Aug  
-14  
28Aug  
-14  
28Aug  
-14  
28Aug  
-14  
28Aug  
-14  
21Aug  
-14  
128  
US20140235  
653

US20140235  
460  
US20140234  
845  
US20140234  
374  
US20140234  
372  
US20140234  
274  
US20140228  
347  
US20140227  
704  
US20140227  
346  
US20140227  
317  
US20140227  
262  
US20140221  
631  
US20140221  
394  
US20140221  
335  
US20140220  
690  
US20140220  
573  
US20140220  
086  
US20140220  
083  
US20140220  
063  
US20140212  
498  
US20140212  
429  
US20140206  
682  
US20140206  
556  
US20140205  
629  
US20140203  
192  
US20140203  
189  
US20140200  
149  
US20140199  
379

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND  
USES THEREOF  
QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND  
SEQUENCING (QNPS) IMPROVEMENTS  
ORGANISM IDENTIFICATION PANEL  
COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND  
ALLERGIC IMMUNITY  
NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A  
VIRAL MATRIX OR CORE PROTEIN  
Directed Evolution and In Vitro Panning of Virus Vectors  
Karyopharm Therapeutics, Inc.  
29Jul-11  
4HTG  
Molecular Diagnostics, Inc.  
Not Available  
ID BIOMEDICAL CORPORATION OF QUEBEC  
Not Available  
University of North Carolina at Chapel Hill  
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC  
METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF  
NUCLEIC ACID VARIANTS  
IBIS BIOSCIENCES, INC.  
IMMUNOGENIC COMBINATION COMPOSITIONS AND USES THEREOF Not Available  
HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL  
SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE  
THEREFROM  
PD-1 Antagonists and Methods for Treating Infectious Disease  
BORON-CONTAINING SMALL MOLECULES  
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90  
SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE  
AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY  
MAMMALIAN GENES INVOLVED IN INFECTION  
EMBODIMENTS OF A PROBE AND METHOD FOR TARGETING  
NUCLEIC ACIDS  
Antimicrobial Compositions and Methods of Use Thereof  
CATIONIC OIL-IN-WATER EMULSIONS  
VACCINE COMPOSITION  
OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS  
BINDING MEMBERS-513  
3M INNOVATIVE PROPERTIES COMPANY  
AMPLIMMUNE, INC.  
Anacor Pharmaceuticals, Inc.  
Astex Therapeutic Ltd.  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
VANDERBILT UNIVERSITY  
University Of Idaho  
Not Available  
Not Available  
Not Available  
Not Available  
MEDIMMUNE LIMITED  
COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS IRM LLC  
Systems and Methods for Identifying Replikin Scaffolds and Uses of  
Said Replikin Scaffolds

Not Available

TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS AlphaVax, Inc.  
SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS  
OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL  
DETECTOR

SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS  
OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL  
DETECTOR

Methods and compositions for identification of source of microbial  
contamination in a sample

COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE  
ANTIGEN TO DENDRITIC CELLS

Gen-Probe Incorporated

May11

2Apr07

26Apr12

25May07

30Apr08

1Sep11

11Nov09

6-Jul11

3Jun11

25Aug08

16Feb06

12Oct06

6Feb13

11Nov09

19Jul-11

21Sep11

6-Jul11

5Feb13

6-Jul11

7Nov08

1Sep11

6Jun03

18May04

24Feb11

24GEN-PROBE

INCORPORATED

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Feb11

6Mar12

22Jul-11

19Mar

-14

1May

-14

1Apr

-08

28Apr

-14

14Apr

-14

17Jan  
-14  
22Apr  
-14  
7Oct  
-13  
6Jul12  
1Jun  
-12  
1Nov  
-13  
7Mar  
-14  
7Jan  
-14  
28Jan  
-14  
28Oct  
-10  
19Jul12  
21Sep  
-12  
6Jul12  
29Jan  
-14  
6Jul12  
16Apr  
-14  
31Aug  
-12  
19Jun  
-13  
28Mar  
-14  
21Mar  
-14  
21Mar  
-14  
6Mar  
-13  
23Jul12  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
129  
Aug  
-14  
21Aug  
-14  
21Aug  
-14  
21Aug  
-14  
21Aug



-14  
21Aug  
-14  
14Aug  
-14  
14Aug  
-14  
14Aug  
-14  
14Aug  
-14  
7Aug  
-14  
7Aug  
-14  
7Aug  
-14  
7Aug  
-14  
7Aug  
-14  
7Aug  
-14  
7Aug  
-14  
31Jul14  
31Jul14  
24Jul14  
24Jul14  
24Jul14  
24Jul14  
24Jul14  
17Jul14  
17Jul14  
21  
US20140199  
347  
US20140199  
281  
US20140194  
628  
US20140194  
500  
US20140194  
345  
US20140193  
804  
US20140193  
439  
US20140186

396

US20140186

292

US20140179

761

US20140179

714

US20140178

977

US20140178

429

US20140178

428

US20140178

422

US20140171

447

US20140171

414

US20140170

709

US20140170

244

US20140170

183

US20140170

174

US20140170

156

US20140170

141

US20140163

213

US20140163

035

US20140162

941

US20140162

888

US20140162

357

ADJUVANT COMPOSITIONS WITH 4-1BBL  
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION,  
INC.

SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF  
PRODUCTION AND USE THEREOF

SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS  
Methods For Treating of SARS

NOVEL DEPSIPEPTIDE AND USES THEREOF

Biological Specimen Collection and Transport System and Method of  
Use

VACCINES AND IMMUNOTHERAPEUTICS COMPRISING IL-15  
RECEPTOR ALPHA AND/OR NUCLEIC ACID MOLECULES ENCODING  
THE SAME, AND METHODS FOR USING THE SAME

METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED  
VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS  
DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND  
METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE  
TARGETING LIPIDS  
NOVEL COMPOUNDS  
SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL  
SIGNALS  
Vaccines Including Antigen From Four Strains of Influenza Virus  
QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS  
CONTAINING SQUALENE  
Seres Health, Inc.  
3M INNOVATIVE PROPERTIES COMPANY  
Not Available  
Not Available  
Longhorn Vaccines and Diagnostics, LLC  
7Feb  
-12  
Nov12  
25Nov03  
8Jan13  
3Dec12  
10Oct07  
14Not  
Available  
Sep09  
28TAKEDA  
VACCINES, INC.  
Providence Health & Services - Oregon  
Tekmira Pharmaceuticals Corporation  
Chiesi Farmaceutici S.p.A.  
Gen-Probe Incorporated  
NOVARTIS AG  
Novartis AG  
PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM The Administrators of the  
Tulane Educational Fund  
CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL  
SODIUM CHANNEL BLOCKING ACTIVITY  
NOVEL COMPOUNDS  
VECTOR FOR GENE THERAPY  
3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)  
PYRAZINE-2- CARBOXAMIDE COMPOUNDS  
D-Amino Acid Derivative-Modified Peptidoglycan and Methods of Use  
Thereof  
POLYCHLORINATED BIPHENYLS AND SQUALENE-CONTAINING  
ADJUVANTS  
Parion Sciences, Inc.  
CHIESI FARMACEUTICI S.p.A.  
TAKARA BIO INC.  
Parion Sciences, Inc.  
The Regents of the University of California  
Novartis AG  
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) GENMAB A/S  
POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF

AUTOIMMUNE DISORDERS AND INFECTION  
CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with  
Enhanced Immunostimulatory Activity  
HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR  
ANTAGONISTS  
PROCESS FOR PREPARING BIOLOGICAL SAMPLES  
CIRCULATING BIOMARKERS FOR DISEASE  
METHODS FOR GENERATION OF ANTIBODIES  
COMPUGEN LTD.  
COLEY PHARMACEUTICAL GMBH  
ACTELION PHARMACEUTICALS LTD.  
BAYLOR COLLEGE OF MEDICINE  
Not Available  
NATIONAL JEWISH HEALTH  
Dec09  
29Jul-05  
4Dec08  
14Sep11  
10Mar05  
6Dec06  
8Nov06  
21Dec12  
17Dec12  
18Dec12  
20Apr07  
17Dec12  
30Nov12  
28Dec07  
16Dec02  
30Jun11  
27Sep06  
22Jul-11  
27Jul-11  
6Apr10  
13Mar07  
20Mar  
-14  
11Mar  
-14  
8Jan  
-13  
3Dec  
-13  
7Jan  
-14  
6Jan  
-14  
6Mar  
-14  
10Feb  
-14  
22Oct  
-13  
11Feb

-14  
3Mar  
-14  
24Sep  
-13  
27Aug  
-13  
15Nov  
-13  
13Dec  
-13  
17Dec  
-13  
31Jan  
-14  
13Dec  
-13  
27Nov  
-13  
10Dec  
-13  
7Nov  
-13  
1Jul12  
4Oct  
-13  
20Jul12  
26Jul12  
6Apr  
-11  
4Sep  
-13  
Feb11  
2317Jul14  
17Jul14  
10Jul14  
10Jul14  
10Jul14  
10Jul14  
10Jul14  
3Jul14  
3Jul14  
26Jun14  
26Jun14  
26Jun14  
26Jun14  
26Jun14  
26Jun14  
19Jun14  
19Jun14  
19Jun14  
19Jun14  
19Jun14  
19Jun14

19Jun14  
19Jun14  
12Jun14  
12Jun14  
12Jun14  
12Jun14  
12Jun14  
10Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
130  
  US20140162  
285  
US20140161  
906  
US20140161  
724  
US20140155  
370  
US20140154  
288  
US20140154  
282  
US20140154  
254  
US20140148  
350  
US20140142  
118  
US20140142  
064  
US20140141  
986  
US20140141  
502  
US20140141  
452  
US20140141  
070  
US20140141  
033  
US20140135  
230  
US20140134  
699  
US20140134  
606  
US20140134  
206  
US20140134  
150  
US20140128  
324  
US20140127

321

US20140127

310

US20140127

216

US20140120

139

US20140116

887

US20140113

855

US20140107

133

21Methods

of Modulating Vesicular Trafficking

USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF  
ABNORMAL VENOUS PROLIFERATION

Compositions and Imaging Methods Comprising Detectably Labeled  
Phosphatidylethanolamine-Binding Peptides

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR  
STIMULATION OF THE INNATE IMMUNE RESPONSE

CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR

STIMULATING IMMUNE RESPONSE

HETERODIMERIC IMMUNOGLOBULINS

CIRCULATING BIOMARKERS FOR DISEASE

CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE

POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY

BORON-CONTAINING SMALL MOLECULES

CIRCULATING BIOMARKERS

Methods For Concurrent Identification And Quantification Of An  
Unknown Bioagent

Method of Determining, Identifying or Isolating Cell-Penetrating  
Peptides

LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA  
MOLECULES

CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS

Lipoparticles Comprising Proteins, Methods Of Making, And Using  
The Same

NOVEL STABILISATION METHOD FOR VIRUSES OR BACTERIA

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS

INFECTIONS AND DISEASES

INFLAMMATION AND IMMUNITY TREATMENTS

TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR

MICROSPHERES

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER  
OR OTHER DISEASES

ANTIVIRAL RESIN MEMBER

TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE

NANOFIBERS

NOVEL EXPRESSION CASSETTE FOR EFFICIENT SURFACE DISPLAY  
OF ANTIGENIC PROTEINS

METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL  
AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE

ELECTROCHEMISTRY AND ELECTROGENERATED  
CHEMILUMINESCENCE WITH A SINGLE FARADAIC ELECTRODE  
Modified Release Formulations for Oprozomib  
3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMID  
OYL)PYRAZINE-2-CARBOXAMIDE  
Fauci/COVID-19  
Dossier  
The General Hospital Corporation  
UNIVERSITY OF UTAH RESEARCH FOUNDATION  
Board of Regents, The University of Texas System  
Not Available  
FOLIA BIOTECH INC.  
Not Available  
AMGEN INC.  
Not Available  
PARION SCIENCES, INC.  
ANACOR PHARMACEUTICALS, INC.  
Not Available  
IBIS BIOSCIENCES, INC.  
Phylogica Limited  
Not Available  
CAYLA  
Integral Molecular, Inc.  
Leukocare AG  
MOREHOUSE SCHOOL OF MEDICINE  
OCEAN SPRAY CRANBERRIES, INC.  
Ansun Biopharma, Inc.  
CITY OF HOPE  
NBC MESHTEC, INC.  
Marine Polymer Technologies, Inc.  
Temasek Life Sciences Laboratory Limited  
Board of Regents, The University of Texas System  
May09  
8Nov07  
15Jul-02  
5Mar10  
13May11  
26Jan11  
21Nov12  
18Aug10  
27Jun11  
16Feb05  
22Feb11  
18Feb04  
23May11  
6-Jul11  
19Nov12  
30Jul-03  
28Jun11  
6Oct08  
1Apr11  
24Jan06  
26Jan07



6-Jul11  
15Apr11  
8Feb11  
26Jul-10  
3Board  
of Regents of the University of Texas System  
Not Available  
Jun05  
24Oct12  
27Parion  
Sciences, Inc.  
Jun11  
CC-BY-NC-SA  
Dr. David E. Martin  
2Dec  
-13  
12Jun  
-13  
16Dec  
-13  
28Jun  
-13  
1May  
-12  
26Jan  
-12  
21Nov  
-13  
18Aug  
-11  
27Jun  
-12  
27Jan  
-14  
17Feb  
-12  
27Jan  
-14  
23May  
-12  
6Jul12  
15Mar  
-13  
1Nov  
-13  
28Jun  
-12  
21Jan  
-14  
30Mar  
-12  
6Jan  
-14  
14Jan

-14  
6Jul12  
16Apr  
-12  
8Feb  
-12  
25Jan  
-13  
28Oct  
-13  
24Oct  
-13  
18Dec  
-13  
12Jun14  
12Jun14  
12Jun14  
5Jun14  
5Jun14  
5Jun14  
5Jun14  
29May  
-14  
22May  
-14  
22May  
-14  
22May  
-14  
22May  
-14  
22May  
-14  
22May  
-14  
22May  
-14  
15May  
-14  
15May  
-14  
15May  
-14  
15May  
-14  
15May  
-14  
8May  
-14  
8May  
-14  
8May  
-14  
8May

-14  
1May  
-14  
1May  
-14  
24Apr14  
17Apr14  
131  
  US20140106  
335  
US20140105  
928  
US20140105  
912  
US20140099  
696  
US20140099  
323  
US20140094  
404  
US20140093  
532  
US20140087  
954  
US20140087  
363  
US20140086  
928  
US20140082  
769  
US20140080  
828  
US20140080  
171  
US20140080  
121  
US20140079  
667  
US20140073  
683  
US20140073  
651  
US20140072  
956  
US20140072  
575  
US20140066  
592  
US20140057  
926  
US20140057  
920  
US20140057  
916

US20140057

315

US20140056

929

US20140051

148

US20140050

778

US20140050

763

28OLIGONUCLEOTIDE

PROBE FOR THE DETECTION OF ADENOVIRUS Qiagen Hamburg GMBH

Antiviral and antibacterial activity from medicinal mushrooms

Not Available

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER THE TRUSTEES OF DARTMOUTH COLLEGE

Technology for the Preparation of Microparticles

METHODS FOR TREATMENT OF INFLAMMATORY DISEASES

METHODS AND REAGENTS FOR EFFICIENT AND TARGETED

DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS

Immunogenic Compositions In Particulate Form And Methods For Producing The Same

QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND

SEQUENCING (QNPS) IMPROVEMENTS

METHOD FOR GENERATING, STORING, TRANSPORTING, ELUTING

AND DETECTING CLINICAL RELEVANT INFORMATION IN PLASMA

USING FILTER PAPER

Antigenic GM-CSF Peptides and Antibodies to GM-CSF

MOLECULES AND METHODS FOR INHIBITION AND DETECTION OF

PROTEINS

Ansun Biopharma, Inc.

Not Available

Not Available

MUCOSIS B.V.

HTG Molecular Diagnostics, Inc.

Dec10

6Jan04

7Sep12

24Jul-07

8Apr09

13Jan11

22Mar11

4May11

9HVIDOVRE

HOSPITAL

Dec10

8MORPHOTEK,

INC.

Not Available

IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO CHILDREN'S HEALTHCARE OF ATLANTA, INC.

OPTICAL CYTOMETRY

PRIMATE T-LYMPHOTROPIC VIRUSES

TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE

MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS  
OF USE  
BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS  
COMPOSITION, DEVICE AND ASSOCIATED METHOD  
RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING  
THEM  
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER  
OR OTHER DISEASES  
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF  
NEUTROPHIL ELASTASE ACTIVITY  
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF  
NEUTROPHIL ELASTASE ACTIVITY  
SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF  
NEUTROPHIL ELASTASE ACTIVITY  
ANTIGEN PRESENTING CELL ASSAY  
IMMUNOMODULATION BY CONTROLLING INTERFERON-GAMMA  
LEVELS WITH THE LONG NON-CODING RNA NeST  
Cells and Methodology to Generate Non-Segmented NegativeStrand  
RNA Viruses  
NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND  
USE THEREOF  
MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES  
AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND  
PREVENTING INFECTIOUS DISEASES  
The Regents of the University of California  
Johns Hopkins University  
Infinity Pharmaceuticals, Inc.  
Not Available  
Actelion Pharmaceuticals Ltd.  
General Electric Company  
MedImmune Limited  
City of Hope  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
University of Pittsburgh - Of the Commonwealth System of  
Higher Education  
The Board of Trustees of the Leland Stanford Junior  
University  
Centre National De La Recherche Scientifique  
UNIVERSITY OF ROCHESTER  
Feb06  
11Mar11  
31Mar11  
6May09  
21Feb05  
5May10  
26Jul-02  
22Feb11  
15Dec05  
1Jun07  
26Jan07  
23Aug12  
23Aug12

23Aug12  
8Apr10  
23Aug12  
22Dec06  
28Dec10  
29ELI  
LILLY & COMPANY  
Jun00  
28Dec  
-10  
20Dec  
-13  
9Sep  
-13  
30Apr  
-13  
30Oct  
-13  
13Jan  
-12  
22Mar  
-12  
26Apr  
-12  
9Dec  
-11  
26Nov  
-13  
12Mar  
-12  
28Mar  
-12  
25Nov  
-13  
20Sep  
-13  
23Aug  
-13  
12Mar  
-13  
21Feb  
-12  
28Feb  
-07  
13Sep  
-13  
11Oct  
-13  
20Aug  
-13  
20Aug  
-13  
20Aug  
-13



-14  
20Feb  
-14  
20Feb  
-14  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
132  
  US20140050  
753  
US20140050  
698  
US20140045  
919  
US20140045  
837  
US20140045  
774  
US20140045  
743  
US20140044  
641  
US20140038  
978  
US20140038  
174  
US20140038  
170  
US20140037  
700  
US20140031  
418  
US20140031  
371  
US20140031  
333  
US20140031  
276  
US20140030  
740  
US20140030  
725  
US20140030  
703  
US20140030  
364  
US20140030  
295  
US20140024  
804  
US20140024  
583  
US20140023



645

US20140023

592

US20140017

727

US20140017

285

US20140017

279

US20140011

982

US20140011

812

US20140011

777

8POLYIONIC

PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES  
RECOMBINANT SUPER-COMPOUND INTERFERON AND USES  
THEREOF

Folate Conjugates

9-Substituted 8-Oxoadenine Compound  
METHODS FOR TREATING VIRAL DISORDERS  
THE JOHNS HOPKINS UNIVERSITY

Superlab Far East Limited  
Alnylam Pharmaceuticals, Inc.

AstraZeneca Aktiebolag  
TRUSTEES OF BOSTON UNIVERSITY

COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION Autoimmune Technologies, LLC  
POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR  
TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER

HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS

Compositions and Methods for Detecting and Identifying Nucleic  
Acid Sequences in Biological Samples

APPARATUS, SYSTEMS, AND METHODS FOR PERFORMING THERMAL  
MELT ANALYSES AND AMPLIFICATIONS

Composition and Method for Enhancing an Immune Response

Regimens and Compositions for AAV-Mediated Passive

Immunization of Airborne Pathogens

POLY AROMATIC SODIUM CHANNEL BLOCKERS

COMPUGEN LTD.

AstraZeneca AB

LONGHORN VACCINES AND DIAGNOSTICS, LLC

Not Available

MICO BIO, INC.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

PARION SCIENCES, Inc.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC

COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A

VIRAL INFECTION

Rapid Bioluminescence Detection System

MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION

CHARACTERISTICS

Compositions and Methods for Detecting and Identifying Nucleic  
Acid Sequences in Biological Samples

ANTIVIRAL COMPOSITIONS COMPRISING ETHANOL EXTRACT OF  
TETRACERA SCANDENS AND USE THEREOF  
Use of Sirt1 Activators or Inhibitors to Modulate an Immune  
Response

Crystalline Tripeptide Epoxy Ketone Protease Inhibitors  
ORGANIC COMPOUNDS

ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES

SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS

Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE  
BACTERIA

ADJUVANT NANOEMULSIONS WITH PHOSPHOLIPIDS

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  
(C.N.R.S.)

The Secretary of State for Health

PROMEGA CORPORATION

LONGHORN VACCINES AND DIAGNOSTICS, LLC

Not Available

THE J. DAVID GLADSTONE INSTITUTES

Onyx Therapeutics, Inc.

Not Available

The United States of America, as represented by the  
Secretary, Dept. of Health & Human Services

Fraunhofer-Gesellschaft zur Forderung der Angewandten  
Forschung e.V.

Not Available

NOVARTIS AG

ADJUVANT NANOEMULSIONS WITH CRYSTALLISATION INHIBITORS Novartis AG

Antibodies Against Influenza Virus and Methods of Use Thereof

Methods of Treating Inflammation

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND  
IMIDAZONAPHTHYRIDINES

Fauci/COVID-19 Dossier

BURNHAM INSTITUTE FOR MEDICAL RESEARCH

Massachusetts Institute of Technology

3M INNOVATIVE PROPERTIES COMPANY

CC-BY-NC-SA Dr. David E. Martin

Sep10

28Feb01

4Dec07

26Mar04

24Sep09

4Nov03

15Apr11

24Dec04

26Apr11

31Jul-12

20Apr11

20Apr11

26Feb08

1Sep11

2Nov07

7Jan09

11May10

12Sep06

24Jul-12  
7Feb08  
20Mar09  
5Jun06  
31Jan08  
25Jul-07  
12Jan09  
24Mar11  
27Jan11  
6Dec07  
8Oct10  
18Jun04  
8Sep  
-11  
5Sep  
-13  
8Jul13  
21Oct  
-13  
11Jun  
-13  
8Aug  
-13  
16Apr  
-12  
13Sep  
-13  
8Oct  
-13  
31Jul13  
19Apr  
-12  
20Apr  
-12  
10Oct  
-13  
19Sep  
-13  
19Jun  
-13  
2Aug  
-13  
12Nov  
-12  
8Oct  
-13  
28Mar  
-13  
17Dec  
-12  
24Sep  
-13  
15Jul13  
10Oct

-13  
30Sep  
-13  
7Jun  
-13  
23Mar  
-12  
27Jan  
-12  
12Aug  
-13  
7Oct  
-11  
9Sep  
-13  
133  
20Feb  
-14  
20Feb  
-14  
13Feb  
-14  
13Feb  
-14  
13Feb  
-14  
13Feb  
-14  
13Feb  
-14  
6Feb  
-14  
6Feb  
-14  
6Feb  
-14  
6Feb  
-14  
30Jan14  
30Jan14  
30Jan14  
30Jan14  
30Jan14  
30Jan14  
30Jan14  
30Jan14  
30Jan14  
23Jan14  
23Jan14  
23Jan14  
23Jan14  
16Jan14  
16Jan14  
16Jan14

9Jan14  
9Jan14  
9Jan14  
US20140011  
187  
US20140010  
837  
US20140005  
241  
US20140005  
102  
US20140005  
101  
US20140005  
097  
US20140004  
193  
US20140004  
146  
US20140004  
143  
US20140004  
128  
US20140004  
123  
US20130345  
414  
US20130345  
284  
US20130345  
270  
US20130344  
613  
US20130344  
100  
US20130341  
206  
US20130338  
224  
US20130338  
174  
US20130338  
130  
US20130336  
996  
US20130336  
929  
US20130336  
923  
US20130331  
313  
US20130330  
840  
US20130330

335

US20130324

559

Biological Specimen Collection and Transport System and Method of Use

Methods and Compositions for Preventing a Condition

Suppression of Sars Replication by Sars Helicase Inhibitors

Oligoadenylate Synthetase (OAS)

Oligoadenylate Synthetase (OAS)

BIOACTIVE PEPTIDES AND METHODS OF USING SAME

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING

PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME

METHOD FOR PRODUCING VIRUS-LIKE PARTICLE BY USING

DROSOPHILA CELL AND APPLICATIONS THEREOF

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,

VECTORS CONTAINING SAME, AND USES THEREFOR

ANTI-IL-18 ANTIBODIES AND THEIR USES

MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION

OF B CELLS

TREATING CANCER WITH VIRAL NUCLEIC ACID

siRNA Compositions and Methods for Treatment of HPV and Other Infections

METHODS OF TREATING CANCER AND OTHER DISORDERS

USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR

DETERIORATED PERFORMANCE OF A FLUOROMETER

VIRUS LIKE PARTICLE PRODUCTION IN PLANTS

AMPEROMETRIC GAS SENSOR

DECONTAMINATING COMPOSITION HAVING SIMULTANEOUSLY

BACTERICIDAL, FUNGICIDAL AND VIROCIDAL PROPERTIES,

METHODS FOR OBTAINING AND USING SAID COMPOSITION

PURINE DERIVATIVES

METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG

RESISTANT MICROORGANISMS

NOVEL COMPOSITIONS OF TLR7 AND/OR TLR8 AGONISTS

CONJUGATED TO LIPIDS

METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY

REGULATORS

Carbonic Anhydrase IX (G250) Antibodies and Methods of Use Thereof

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY INDUCED CONDITIONS

FLOW CYTOMETRY ANALYSIS OF MATERIALS ADSORBED TO METAL SALTS

BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL

BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES

1Longhorn

Vaccines and Diagnostics, LLC

Cyvax, Inc.

The Curators of the University of Missouri

Kineta Two LLC

Kineta Two LLC

Compugen Ltd.  
Not Available  
INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF  
SCIENCES  
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA  
Medimmune Limited  
Institute For Research in Biomedicine  
Not Available  
Not Available  
Waake Forest University Health Sciences  
GEN-PROBE INCORPORATED  
MEDICAGO INC.  
STERIS CORPORATION  
Oct07  
9Aug10  
15Jun12  
23Nov05  
23Nov05  
12Jul-07  
24Apr12  
17Mar11  
17Dec01  
20Dec10  
26Feb03  
20Feb07  
29Jul-10  
12Nov10  
14Jun12  
22Dec10  
25Jun12  
29HIGHTECH  
BIO-ACTIVITIES HOLDING GMBH  
Mar04  
17ABBOTT  
PHILLIP  
Biogenic Innovations, LLC  
CAYLA  
KINETA, INC.  
DANA-FARBER CANCER INSTITUTE, INC.  
HEMAQUEST PHARMACEUTICALS INC  
NOVARTIS AG  
IOGENETICS, LLC  
Dec10  
30Oct09  
15Jun12  
25Feb11  
2Dec05  
11Mar10  
14Dec10  
23Mar10  
29PARION  
SCIENCES, INC.  
May12  
19Mar

-13  
11Sep  
-13  
17Jun  
-13  
1Jul13  
14Jun  
-13  
21Jun  
-13  
24Apr  
-13  
19Mar  
-12  
13Sep  
-13  
20Dec  
-11  
25Apr  
-13  
26Jul13  
29Jan  
-13  
7Nov  
-11  
7Jun  
-13  
22Dec  
-11  
26Feb  
-13  
7Aug  
-13  
14Dec  
-11  
19Aug  
-13  
15Mar  
-13  
23Feb  
-12  
8May  
-13  
7Jun  
-13  
14Dec  
-11  
21Mar  
-11  
29May  
-13  
9Jan14  
9Jan14  
2Jan14



2Jan14  
2Jan14  
2Jan14  
2Jan14  
2Jan14  
2Jan14  
2Jan14  
26Dec  
-13  
26Dec  
-13  
26Dec  
-13  
26Dec  
-13  
26Dec  
-13  
26Dec  
-13  
19Dec  
-13  
19Dec  
-13  
19Dec  
-13  
19Dec  
-13  
19Dec  
-13  
19Dec  
-13  
19Dec  
-13  
12Dec  
-13  
12Dec  
-13  
12Dec  
-13  
5Dec  
-13  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
134  
US20130323  
835  
US20130323  
819  
US20130317  
080  
US20130317  
031  
US20130315  
952

US20130302  
351  
US20130302  
278  
US20130295  
129  
US20130291  
134  
US20130289  
043  
US20130288  
922  
US20130288  
917  
US20130287  
832  
US20130287  
811  
US20130287  
772  
US20130281  
324  
US20130280  
806  
US20130280  
298  
US20130274  
465  
US20130274  
129  
US20130273  
540  
US20130273  
277  
US20130273  
150  
US20130273  
120  
US20130273  
113  
US20130273  
104  
US20130273  
080  
US20130267  
578  
US20130267  
532

Mammalian Genes Involved in Infection  
Zirus, Inc.

EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN  
LACTOBACILLUS

MODIFIED iRNA AGENTS

Nuclear Transport Modulators And Uses Thereof

ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR  
TREATMENT OF PATHOGENIC INFECTION  
ANTAGONISM OF THE VIP SIGNALING PATHWAY  
USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO  
ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS  
IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE  
THEREOF  
HUMANIZED TRANSGENIC MOUSE MODEL  
(4-TERT-BUTYLPYPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-NCARBOXAMIDE  
DERIVATIVES  
ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA  
IMMUNE RESPONSE  
Rapid High Resolution, High Throughput RNA Structure, RNAMacromolecular  
Interaction, and RNA-Small Molecule Interaction  
Mapping  
ALVAREZ MIGUEL ANGEL  
ALNYLAM PHARMACEUTICALS, INC.  
Karyopharm Therapeutics Inc.  
Defyrus, Inc.  
EMORY UNIVERSITY  
IMMURX INC  
MASSACHUSETTS INSTITUTE OF TECHNOLOGY  
BRUMEANU TEPDPR D  
AstraZeneca AB  
UNIV ROCHESTER  
The Board of Trustees of the Leland Stanford Junior  
University  
SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Novartis AG  
Method for Producing Viral Vaccines  
BIOMARKERS FOR THERANOSTICS  
BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND  
USING SUCH COMPLEXES  
MAMMALIAN GENES INVOLVED IN INFECTION  
Immunogenic Affinity-Conjugated Antigen Systems Based on  
Papaya Mosaic Virus and Uses Thereof  
ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL  
SALTS  
TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES,  
KITS AND ASSAYS  
METHOD FOR CHROMOGENIC DETECTION OF TWO OR MORE  
TARGET MOLECULES IN A SINGLE SAMPLE  
POWDERED POUCH AND METHOD OF MAKING SAME  
Dendritic Cell Marker and Uses Thereof  
METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY  
IMMUNOGENIC APOPTOSIS INDUCING COMPOSITIONS AND  
METHODS OF USE THEREOF  
Adjuvanted Influenza Vaccines for Pediatric Use  
SIALOADHESIN-RELATED COMPOSITIONS AND METHODS  
COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE  
EXPRESSION  
CYCLIC AMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT  
OF DISEASE  
Fauci/COVID-19 Dossier  
BAXTER HEALTHCARE SA

Caris Life Sciences Luxembourg Holdings  
Nuevolution A/S  
HODGE THOMAS  
LECLERC DENIS  
IRM LLC  
ARNOLD MATTHIAS  
BIENIARZ CHRISTOPHER A  
Monosol, LLC.  
CAMINSCHI IRINA  
HARUTA SHUNJI  
The Regents of the University of Michigan  
GROTH NICOLA  
DELPUTTE PETER  
QUARK PHARMACEUTICALS, INC.  
HORI SEIJI  
15Jul-09  
5Aug10  
15Sep10  
9May12  
9Jun09  
2Feb11  
15Jun07  
5Apr12  
24Sep10  
15Dec08  
2May08  
21Oct10  
20Aug10  
28Aug07  
1Mar10  
16Apr10  
17May10  
15Nov06  
1Sep10  
4Apr12  
22Aug08  
16Apr12  
30Aug07  
15Apr10  
12Apr12  
22Feb08  
11May06  
15Jun07  
19Nov10  
CC-BY-NC-SA  
Dr. David E. Martin  
15Jul10  
4Aug  
-11  
14Sep  
-11  
9May  
-13  
13Nov

-12  
31Jan  
-12  
16Apr  
-13  
15Mar  
-13  
22Aug  
-12  
27Jun  
-13  
11Jul13  
21Oct  
-11  
19Aug  
-11  
26Jun  
-13  
1Mar  
-11  
16Apr  
-11  
17May  
-11  
15Mar  
-13  
1Sep  
-11  
4Apr  
-13  
7Jun  
-13  
14Mar  
-13  
21Mar  
-13  
14Mar  
-13  
15Mar  
-13  
21Jun  
-13  
15Mar  
-13  
6Jun  
-13  
18Nov  
-11  
Dec  
-13  
5Dec  
-13  
28Nov  
-13

28Nov  
-13

28Nov  
-13

14Nov  
-13

14Nov  
-13

7Nov  
-13

31Oct13

31Oct13

31Oct13

31Oct13

31Oct13

31Oct13

31Oct13

24Oct13

24Oct13

24Oct13

17Oct13

17Oct13

17Oct13

17Oct13

17Oct13

17Oct13

17Oct13

17Oct13

17Oct13

10Oct13

10Oct13

135

5

US20130267

436

US20130267

429

US20130266

645

US20130266

612

US20130261

196

LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES  
FOR MICROARRAY-BASED ASSAYS

BIOLOGICAL SAMPLE TARGET CLASSIFICATION, DETECTION AND  
SELECTION METHODS, AND RELATED ARRAYS AND  
OLIGONUCLEOTIDE PROBES

DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN  
ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL  
ACTION

VACCINE COMPOSITION

Nucleic Acids For Multiplex Organism Detection and Methods Of Use  
And Making The Same

US20130261  
087  
SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,  
PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR  
TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING  
INFECTIONS ASSOCIATED WITH ARENA VIRUSES  
27CapitaBio  
Corporation  
Oct10  
21GARDNER  
SHEA  
Dec09  
6Justus-Liebig-Universitat  
Giessen  
NITTO DENKO CORPORATION  
DIAMOND LISA  
Oct10  
4Apr12  
11Jun10  
6SIGA  
TECHNOLOGIES INC.  
Dec04  
27Oct  
-10  
2May  
-13  
6Oct  
-11  
3Apr  
-13  
10Jun  
-11  
6Jul11  
10Oct13  
10Oct13  
10Oct13  
10Oct13  
30Oct13  
30Oct13  
US20130261  
049  
US20130259  
887  
US20130259  
871  
US20130259  
829  
US20130253  
002  
US20130251  
746  
US20130251  
734  
US20130251

590

US20130244

980

US20130244

920

US20130243

841

US20130243

756

US20130243

727

US20130237

507

US20130236

884

US20130236

493

US20130236

396

US20130231

302

US20130230

919

US20130230

856

ALPHABODIES

SPECIFICALLY BINDING TO CLASS-I VIRAL FUSION

PROTEINS AND METHODS FOR PRODUCING THE SAME

REOVIRUS VACCINES AND METHODS OF USE THEREFOR

Human Monoclonal Antibody with Specificity for Dengue Virus

Serotype 1 E Protein and Uses Thereof

CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE

FUNCTION

6COMPLIX

SA

BOEHME KARL W

DSO NATIONAL LABORATORIES

Viral Genetics, Inc.

COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS CORTEZ ALEX

Methods and Compositions for Poxvirus A35R Protein

USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS

Peracid/Peroxide Composition, Process for Accurately Making the

Same, and Method for Use as an Evaporating Film Anti-Microbial

Solution and as a Photosensitizer

BORON-CONTAINING SMALL MOLECULES

WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND

METHOD OF MAKING SAME

East Carolina University

The Salk Institute for Biological Studies

BioMed Protect ,LLC

ANACOR PHARMACEUTICALS, INC.

LEE DAVID M

CONCENTRATION OF VACCINE ANTIGENS WITH LYOPHILIZATION Novartis AG

Methods for Treating Diseases and HSV Using Antibodies to



Aminophospholipids  
TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE  
Novel Amide Compounds  
COMPOSITIONS FOR USE IN IDENTIFICATION OF  
ORTHOPOXVIRUSES  
METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES  
NANOPARTICLES PRODUCED FROM RECOMBINANT POLYMERS AND  
METHODS OF MAKING AND USING THE SAME  
ANTIMICROBIAL SOLUTIONS  
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS  
CAPTURE OF TARGET DNA AND RNA BY PROBES COMPRISING  
INTERCALATOR MOLECULES  
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
INFINITY PHARMACEUTICALS, INC.  
BURKAMP FRANK  
IBIS BIOSCIENCES, INC.  
STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK  
UNIVERSITY OF UTAH RESEARCH FOUNDATION  
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
Baxter Healthcare S.A.  
QUANTIBACT A/S  
Jan11  
7Apr10  
14Dec10  
25Jul-08  
3Mar08  
1Dec08  
9Nov07  
11Jan05  
16Feb05  
16Mar12  
1Jun10  
15Jul-02  
5May10  
3Apr09  
5Dec03  
20Sep10  
3May10  
10Sep10  
29Oct04  
27Oct10  
Fauci/COVID-19  
Dossier  
2Dec  
-11  
4Apr  
-11  
14Dec  
-11  
6Jun  
-13  
22Apr  
-13  
20Dec

-12  
8Mar  
-13  
21Sep  
-09  
30Apr  
-13  
16Mar  
-12  
1Jun  
-11  
19Feb  
-13  
29Apr  
-13  
17Apr  
-13  
7May  
-13  
20Sep  
-11  
3May  
-11  
9Sep  
-11  
16Apr  
-13  
27Oct  
-11  
CC-BY-NC-SA  
Dr. David E. Martin  
136  
30Oct13  
30Oct13  
30Oct13  
30Oct13  
26Sep  
-13  
26Sep  
-13  
26Sep  
-13  
26Sep  
-13  
19Sep  
-13  
19Sep  
-13  
19Sep  
-13  
19Sep  
-13  
19Sep  
-13  
19Sep  
-13

12Sep  
-13  
12Sep  
-13  
12Sep  
-13  
12Sep  
-13  
5Sep  
-13  
5Sep  
-13  
5Sep  
-13  
US20130230  
851  
US20130230  
578  
US20130230  
529  
US20130225  
655  
US20130225  
651  
US20130225  
637  
US20130225  
555  
US20130224  
245  
US20130224  
144  
US20130217  
584  
US20130217  
071  
US20130217  
012  
US20130216  
612  
US20130216  
581  
US20130216  
573  
US20130216  
566  
US20130210  
894  
US20130210  
820  
US20130210  
770  
US20130209  
550

US20130209

510

US20130209

502

US20130209

406

US20130209

364

US20130203

836

US20130203

655

US20130203

151

US20130202

684

US20130202

609

23Nanoreporters

And Methods Of Manufacturing And Use Thereof

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND

COMPOSITIONS, FORMULATIONS, AND METHODS

NOVEL PARAMYXOVIRUS AND USES THEREOF

Combinations of TGFBeta and COX-2 Inhibitors and Methods for  
Their Therapeutic Application

siRNA Compositions and Methods for Potently Inhibiting Viral  
Infection

ISATIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS

THEREOF, AND METHODS OF USE THEREOF

Imidazoquinolines with Immuno-Modulating Properties

CONCENTRATION OF VACCINE ANTIGENS WITHOUT

LYOPHILIZATION

SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE

ADENOVIRUS VECTOR IN VACCINATION PROTOCOLS

MICROARRAY-BASED ASSAY INTEGRATED WITH PARTICLES FOR

ANALYZING MOLECULAR INTERACTIONS

METHODS AND COMPOSITIONS FOR PERFORMING NUCLEIC ACID

AMPLIFICATION REACTIONS

C-CBL MUTATIONS AND USES THEREOF

TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS

Carbon Nanotube Compositions and Methods of Use Thereof

INFLUENZA VIRUS REASSORTMENT

Vectors expressing SARS immunogens, compositions containing  
such vectors or expression products thereof, methods and assays  
for making and using

APPLICATION OF HIGHLY CONSERVED DOMAIN SEQUENCES FROM

VIRAL GENOME AS TEMPLATE TO DESIGN THERAPEUTIC SLIRNAS

Pharmaceutical Compounds

PHARMACEUTICAL FORMULATIONS

Anti-Viral Azide Containing Compounds

METHODS FOR PREPARING SQUALENE

ALUMINA NANOPARTICLE BIOCONJUGATES AND METHODS OF

STIMULATING AN IMMUNE RESPONSE USING SAID

BIOCONJUGATES

RECOMBINANT RNA VIRUSES AND USES THEREOF  
Anti-Viral Azide Containing Compounds  
2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES  
METHODS FOR PREVENTING OR TREATING VIRAL INFECTION  
PRODUCTION OF ALPHAVIRUS REPLICON PARTICLES IN  
PACKAGING CELLS  
PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING  
RNA  
GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES  
Fauci/COVID-19 Dossier  
NANOSTRING TECHNOLOGIES, INC.  
3M INNOVATIVE PROPERTIES COMPANY  
The University of Hong Kong  
EVANS DAVID  
The University of Hong Kong  
HORNE DAVID A  
AstraZeneca AB  
Novartis AG  
Etubics Corporation  
CapitalBio Corporation  
MONTESCLAROS LUZ  
The University of Chicago  
BBB HOLDING B V  
UNIV YALE  
NOVARTIS AG  
ADAMS DANIEL  
Dec05  
17Aug10  
20Jan12  
4May10  
11Dec08  
24Feb12  
8May07  
1Jun10  
2-Jul07  
6Aug10  
30Dec11  
4Jun10  
23Mar07  
19Mar08  
21May10  
20Jun03  
20CHEN  
LI  
ASTEX THERAPEUTICS LIMITED  
Anacor Pharmaceuticals, Inc.  
LIFE TECHNOLOGIES CORPORATION  
Novartis AG  
HU HONG-MING  
TENOEVER BENJAMIN R  
LIFE TECHNOLOGIES CORPORATION  
ALNYLAM PHARMACEUTICALS, INC.  
KIELIAN MARGARET  
BALSITIS SCOTT

Lichtstrasse  
GRANDI GUIDO  
CC-BY-NC-SA Dr. David E. Martin  
Sep10  
11Apr08  
16Feb05  
28Jul-10  
12May10  
27Aug10  
6Jun10  
28Jul-10  
1Apr10  
12Feb10  
26Apr10  
31Aug10  
12Sep07  
11Mar  
-13  
16Aug  
-11  
22Jan  
-13  
4May  
-11  
12Dec  
-11  
25Feb  
-13  
14Mar  
-13  
1Jun  
-11  
18Sep  
-12  
6Aug  
-10  
21Dec  
-12  
3Jun  
-11  
2May  
-13  
15Mar  
-13  
20May  
-11  
21Jun  
-04  
19Sep  
-11  
30Jan  
-13  
12Apr  
-13



15Aug  
-13  
15Aug  
-13  
15Aug  
-13  
15Aug  
-13  
15Aug  
-13  
15Aug  
-13  
8Aug  
-13  
8Aug  
-13  
8Aug  
-13  
8Aug  
-13  
8Aug  
-13  
137  
US20130202  
598  
US20130202  
593  
US20130197  
296  
US20130196  
903  
US20130196  
380  
US20130195  
969  
US20130195  
968  
US20130195  
932  
US20130195  
930  
US20130195  
914  
US20130195  
893  
US20130195  
792  
US20130190  
494  
US20130190  
381  
US20130190  
206  
US20130189



680

US20130189

351

US20130189

311

US20130189

247

US20130184

170

US20130183

670

US20130183

355

US20130183

341

US20130183

321

US20130178

512

US20130178

482

US20130178

466

US20130178

448

ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE  
INHIBITORY PEPTIDE

20RAMOT

AT TEL-AVIV UNIVERSITY LTD.

INTRACELLULAR IMMUNITY

Removing Cells from an Organism

Multimeric Inhibitors of Viral Fusion and Uses Thereof

IN VITRO PROCESS FOR THE PREPARATION OF ANTIBODIES OF

THE IGG TYPE

MEDICAL RESEARCH COUNCIL

DAPPRICH JOHANNES

JV BIO SRL

JANSEN GABRIELE

SMALL LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA NOVARTIS AG

VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA

MOLECULES

ARCHAEL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO

ANIMALS

Inulin and Inulin Acetate Formulations

Expression Of Positive Sense Single Stranded RNA Virus And Uses

Thereof

USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING

OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN

METHOD OF TREATING INFLAMMATION

PURINE ANALOGS

INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID

METABOLISM AS BROAD SPECTRUM ANTI-VIRALS

Direct Clone Analysis and Selection Technology

POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS

LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING  
RNA

ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR  
MICROFLUIDIZATION

Novartis AG

NATIONAL RESEARCH COUNCIL OF CANADA

SOUTH DAKOTA STATE UNIVERSITY

Viracine Therapeutics Corporation

The Government of the United States of America as  
represented by the Secretary of the department of  
CYTOSORBENTS CORPORATION

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

THE TRUSTEES OF PRINCETON UNIVERSITY

Dublin City University

VENTANA MEDICAL SYSTEMS, INC.

NOVARTIS AG

Novartis AG

Multimeric Proteins Comprising Immunoglobulin Constant Domains RESEARCH  
CORPORATION TECHNOLOGIES, INC.

OLIGONUCLEOTIDE AMPLIFICATION PRIMERS FOR TARGETING  
ONCOGENIC HPV

METHOD FOR PRODUCING NUCLEIC ACID PROBES

DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE  
POLYMER PARTICLES

INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING

HEMAGGLUTININ PRODUCED WITHIN A PLANT

GITR BINDING MOLECULES AND USES THEREFOR

CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR

OLIGONUCLEOTIDES

3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6PENTAHYDROXYHEXYL)AMINO)ETHOX  
Y)PHENYL)BUTYL)

CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE

Treatment

of Microbial Infections

Treatment of Respiratory Disorders

GENERA BIOSYSTEMS LIMITED

Ventana Medical Systems, Inc.

NOVARTIS AG

MEDICAGO INC.

GITR, INC.

ALNYLAM PHARMACEUTICALS, INC

Sep10

23Jul-10

13Jan12

11Aug10

5Feb10

31Aug10

6-Jul10

15Dec06

20Jan12

12Apr10

31Jul-08

1Apr10

31May06

18Feb10  
13Jul-10  
23Jan12  
31Aug10  
3Dec09  
12Feb10  
5Apr07  
1Sep06  
6-Jul10  
13Jul-07  
25Mar05  
4Dec07  
27Parion  
Sciences, Inc.  
Jun11  
11BIOCOPEA  
LIMITED  
BANNISTER ROBIN MARK  
Nov09  
5Feb10  
22Aug  
-11  
23Jan  
-13  
14Jan  
-13  
11Aug  
-11  
4Feb  
-11  
31Aug  
-11  
6Jul11  
23Jan  
-13  
22Jan  
-13  
8Apr  
-11  
27Mar  
-13  
1Apr  
-11  
8Mar  
-13  
18Feb  
-11  
13Jul11  
18Jan  
-13  
31Aug  
-11  
3Dec  
-10



18Jul13  
18Jul13  
11Jul13  
11Jul13  
11Jul13  
11Jul13  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
138  
  US20130178  
383  
US20130178  
372  
US20130177  
640  
US20130177  
639  
US20130177  
477  
US20130172  
327  
US20130171  
241  
US20130171  
129  
US20130165  
455  
US20130165  
417  
US20130157  
964  
US20130157  
876  
US20130157  
283  
US20130157  
254  
US20130156  
807  
US20130149  
375  
US20130149  
194  
US20130145  
484  
US20130143  
810  
US20130143  
203  
US20130142  
833  
US20130142  
826

US20130142  
773  
US20130137  
678  
US20130137  
172  
US20130137  
140  
US20130136  
768  
US20130130  
262  
12VESICLE  
ISOLATION METHODS  
Methods And Computer Systems For Identifying Target-Specific  
Sequences For Use In Nanoreporters  
DELIVERY OF RNA TO DIFFERENT CELL TYPES  
DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS  
KLASS MICHAEL  
NANOSTRING TECHNOLOGIES, INC.  
NOVARTIS AG  
NOVARTIS AG  
DECONTAMINANT DISPENSER SUITABLE FOR USE AS A PROJECTILE STERIS INC.  
SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO  
[2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C  
LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE  
FOR RNA DELIVERY  
CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES  
THEREFOR  
TLR AGONISTS  
METHODS AND COMPOSITIONS FOR TREATING ACE2-RELATED  
DISORDERS  
Blockade Of Inflammatory Proteases With Cyclic Peptides  
Systems and Methods for Detecting Antibiotic Resistance  
RAPID PATHOGEN DIAGNOSTIC DEVICE AND METHOD  
Method and apparatus for two-step surface-enhanced raman  
spectroscopy  
BOEHRINGER INGELHEIM INTERNATIONAL GMBH  
NOVARTIS AG  
COULIBALY FASSELI JOSEPH  
The Regents of The University of California  
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION  
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA  
TESSARAE, LLC  
PRESIDENT AND FELLOWS OF HARVARD COLLEGE  
Real-Time Analyzers, Inc.  
CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR The Regents of The  
University of California  
IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA GEALL ANDREW  
ORGANIC PEROXIDE COMPOUNDS FOR MICROORGANISM  
INACTIVATION  
ANTIBODY PRODUCING NON-HUMAN MAMMALS  
Virally-Inactivated Growth Factors-Containing Platelet Lysate  
Depleted of PDGF and VEGF and Preparation Method Thereof

COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS  
VIRUSES

CIRCULATION OF COMPONENTS DURING HOMOGENIZATION OF  
EMULSIONS

RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)  
PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ  
Mutations in OAS1 Genes

Antiviral Compounds and Uses Thereof

HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS

INCREASED PROTEIN EXPRESSION THROUGH INCREASED  
MEMBRANE FORMATION

Recombinant HCMV and RHCMV vectors and uses thereof

SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE

GREGERSEN JENS PETER

MERUS B.V.

BURNOUF THIERRY

IBIS BIOSCIENCES, INC.

Novartis AG

MEDICAGO, INC.

KINETA TWO, LLC

MOUNT SINAI SCHOOL OF MEDICINE

BioFire Diagnostics, Inc. f/k/a Idaho Technology, Inc.

UNIVERSITEIT GENT

Oregon Health & Science University

BATTRELL C FREDERICK

Nov08

10Apr07

6-Jul10

6-Jul10

6Mar07

19Sep11

6-Jul10

23Jun10

22Aug05

23Apr10

2Jun11

21Aug10

19Jan10

16Dec11

7Feb07

6-Jul10

6May10

27Jun08

25May10

3Mar05

3Dec09

21Jan08

4May05

28May10

15May09

17Jun10

14May10

29Jan10

29Aug

-12  
7Mar  
-13  
7Jun  
-11  
6Jul11  
28Feb  
-13  
14Sep  
-12  
6Jul11  
23Jun  
-11  
20Nov  
-12  
23Apr  
-11  
1Jun  
-12  
21Feb  
-13  
19Jan  
-11  
16Dec  
-11  
8Jan  
-13  
6Jul11  
6May  
-11  
25Jan  
-13  
26Nov  
-12  
21May  
-12  
3Dec  
-10  
23Jan  
-13  
14Nov  
-12  
31May  
-11  
28Jan  
-13  
15Jun  
-11  
14Nov  
-12  
28Jan  
-11  
11Jul13  
11Jul13



11Jul13  
11Jul13  
11Jul13  
4Jul13  
4Jul13  
4Jul13  
27Jun13  
27Jun13  
20Jun13  
20Jun13  
20Jun13  
20Jun13  
20Jun13  
13Jun13  
13Jun13  
6Jun13  
6Jun13  
6Jun13  
6Jun13  
6Jun13  
6Jun13  
30May  
-13  
30May  
-13  
30May  
-13  
30May  
-13  
23May  
-13  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
139  
US20130129  
805  
US20130129  
786  
US20130129  
782  
US20130129  
781  
US20130129  
702  
US20130122  
581  
US20130122  
516  
US20130122  
487  
US20130122  
043  
US20130122

038

US20130122

031

US20130115

593

US20130115

244

US20130115

228

US20130115

215

US20130102

652

US20130102

560

US20130102

524

US20130101

629

US20130101

622

US20130101

609

US20130096

103

US20130096

073

US20130096

056

US20130096

020

US20130095

552

US20130095

135

US20130091

611

COMPOSITION WITH STERILIZING ACTIVITY AGAINST BACTERIA,  
FUNGUS AND VIRUSES, APPLICATION THEREOF AND METHOD FOR  
PREPARATION THEREOF

HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE  
ADJUVANTS

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH  
INFLUENZA VACCINES

METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY

MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF  
RNA VIRAL DISEASES

TAL EFFECTOR-MEDIATED DNA MODIFICATION

DETECTING TARGETS USING MASS TAGS AND MASS  
SPECTROMETRY

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH  
INFLUENZA VACCINES

18GP&E

Nov11

3Novartis  
AG  
NOVARTIS AG  
HARUTA SHUNJI  
UNIVERSITY OF SOUTH FLORIDA  
IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.  
BIENIARZ CHRISTOPHER  
Novartis AG  
MODIFIED POLYPEPTIDES AND PROTEINS AND USES THEREOF WHITEHEAD INSTITUTE FOR  
BIOMEDICAL RESEARCH  
HETEROLOGOUS PRIME-BOOST IMMUNIZATION USING MEASLES  
VIRUS-BASED VACCINES  
HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO  
ANTIGENS  
SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF  
USE IN DETECTION ASSAYS AND KITS  
Immunogenic Substances Comprising a Polyinosinic Acid -  
Polycytidilic Acid Based Adjuvant  
IMMUNOSTIMULATORY COMBINATIONS  
DOMAIN INSERTION IMMUNOGLOBULIN  
METHODS AND COMPOSITIONS RELATED TO MODIFIED  
ADENOSINES FOR CONTROLLING OFF-TARGET EFFECTS IN RNA  
INTERFERENCE  
NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS  
AND OLIGOSACCHARIDES  
Compounds And Their Use  
HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING  
COMPOUNDS AND USES THEREOF  
IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS  
IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES  
IMIDAZOQUINOLINE COMPOUNDS  
Casein Derived Peptides And Uses Thereof  
AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA  
DESATURASE INHIBITORS  
GENERATION OF BINDING MOLECULES  
NOROVIRUS AND SAPOVIRUS ANTIGENS  
PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE  
PRODUCTION OF A VIRUS IN CELL CULTURE  
Anti-viral Formulations Nanomaterials and Nanoparticles  
CruceCell Holland B.V.  
MESSMER DAVORKA  
Ventana Medical Systems, Inc.  
Yisheng Biopharma (Singapore) PTE. LTD.  
TRUSTEES OF DARTMOUTH COLLEGE  
ZHOU HONGXING  
UNIVERSITY OF UTAH RESEARCH FOUNDATION  
N.V. NUTRICIA  
Novabiotics Limited  
NOVARTIS AG  
Novartis AG  
NOVARTIS AG  
NOVARTIS VACCINES & DIAGNOSTICS, INC.  
SIDELMAN ZVI  
XENON PHARMACEUTICALS INC.

MERUS BIOPHARMACEUTICALS B.V.  
Novartis Vaccines and Diagnostics, Inc.  
GlaxoSmithKline Biologicals S.A.  
LAMBKIN-WILLIAMS ROBERT

Dec09

9Sep04

15Apr10

30Apr02

10Dec09

2-Jul10

9Sep04

20Apr10

14Nov11

27Jul-10

16Aug10

13Jan06

30Dec02

14Jul-10

23Mar10

24Aug04

31Mar10

15Dec09

23Mar06

24Jan10

14Sep04

1Mar00

3Jun05

26Sep11

22Nov05

8-Jul10

16Feb06

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

18Nov

-11

3Dec

-10

11Jan

-13

15Apr

-11

17Sep

-12

10Jan

-13

1Jul11

10Jan

-13

20Apr

-11

13Nov

-12

27Jul11



9May  
-13  
9May  
-13  
9May  
-13  
9May  
-13  
25Apr13  
25Apr13  
25Apr13  
25Apr13  
25Apr13  
25Apr13  
18Apr13  
18Apr13  
18Apr13  
18Apr13  
18Apr13  
18Apr13  
18Apr13  
140  
US20130087  
700  
US20130085  
095  
US20130084  
303  
US20130071  
428  
US20130059  
846  
US20130059  
832  
US20130059  
803  
US20130059  
802  
US20130059  
776  
US20130058  
945  
US20110070  
575  
US20110067  
121  
US20110065  
111  
US20110065  
091  
US20110065  
089  
US20110064  
772

US20110053  
986  
US20110053  
909  
US20110053  
894  
US20110053  
893  
US20110053  
831  
US20110053  
169  
US20110052  
716  
US20110052  
558  
US20110046  
155  
US20110046  
134  
US20110046  
001  
US20110045  
456  
11DIRECT  
IMPACT IONIZATION (DII) MASS SPECTROMETRY  
PROTEIN COMPLEMENTATION REGULATORS  
PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC  
COMPOSITIONS COMPRISING SAID PEPTIDES  
PEPTIDES, CONJUGATES AND METHOD FOR INCREASING  
IMMUNOGENICITY OF A VACCINE  
Services, National Institutes of Health  
Trustees of Boston University  
BOGOCH ELENORE S  
ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC  
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC  
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC  
BORON-CONTAINING SMALL MOLECULES  
BORON-CONTAINING SMALL MOLECULES  
Antiviral Cell-Penetrating Peptides  
Antigenic GM-CSF Peptides and Antibodies to GM-CSF  
Immunomodulatory Compositions, Combinations and Methods  
Transgenic mice having a human major histocompatibility complex  
(MHC) phenotype, experimental uses and applications  
Compositions For Use In Genotyping Of Klebsiella Pneumoniae  
Coronavirus, Nucleic Acid, Protein, and Methods for the Generation  
of Vaccine, Medicaments and Diagnostics  
NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND  
APPLICATIONS THEREOF  
VIRAL ADJUVANTS  
RESPIRATORY DISEASE TREATMENT  
Compounds - 801  
Broad Spectrum Antiviral and Methods of Use  
Anacor Pharmaceuticals, Inc.

Anacor Pharmaceuticals, Inc.  
CURRELI FRANCESCA  
CHAO QIMIN  
Coley Pharmaceutical Group, Inc.  
INSTITUT PASTEUR  
Ibis Biosciences, Inc.  
VAN DER HOEK CORNELIA MARIA  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  
University of North Carolina at Chapel Hill  
FINCH HARRY  
ALCARAZ LILIAN  
LOVELACE RESPIRATORY RESEARCH INSTITUTE  
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC  
COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF  
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL  
DISORDERS ASSOCIATED WITH THEREWITH  
METHOD FOR CONTINUOUS MODE PROCESSING OF THE CONTENTS  
OF MULTIPLE REACTION RECEPTACLES IN A REAL-TIME  
AMPLIFICATION ASSAY  
Adjuvant Comprising Aluminum, Oligonucleotide and Polycation  
MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF  
RNA VIRAL DISEASES  
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90  
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA  
DESATURASE  
Multiplex Assay for Respiratory Viruses  
COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS  
CONTAMINANT VIRUSES  
Fauci/COVID-19 Dossier  
Oct11  
29Sep11  
7Aug09  
15Mar10  
1Sep11  
1Sep11  
16Feb05  
16Feb05  
6May08  
8Feb06  
8Dec04  
30Jul-03  
31Aug09  
18Aug03  
2Dec03  
9-Jul04  
7Aug08  
31Jul-09  
17Apr06  
2Sep09  
20Phylogica  
Limited  
Jun07  
10GEN-PROBE  
INCORPORATED



O'HAGAN DEREK  
UNIVERSITY OF SOUTH FLORIDA  
FREDERICKSON MARTYN  
BISCHOFF ALEXANDER  
AUTOGENOMICS, INC.  
IBIS BIOSCIENCES, INC.

Mar05

27Aug09

30Apr02

12Oct06

21Jun07

20Nov07

14Jun07

CC-BY-NC-SA

Dr. David E. Martin

11Oct

-11

28Sep

-12

19Jul12

15Mar

-11

27Aug

-12

29Aug

-12

7Sep

-12

7Sep

-12

31Oct

-12

24Oct

-12

8Dec

-05

22Dec

-09

27Aug

-10

26Jul10

6Apr

-10

24Nov

-10

4Aug

-10

30Jul10

17Apr

-07

1Sep

-10

20Jun

-08

4Nov  
-10  
27Aug  
-10  
15Dec  
-09  
12Oct  
-07  
29Oct  
-10  
20Nov  
-08  
12Jun  
-08  
141  
11Apr13  
4Apr13  
4Apr13  
21Mar  
-13  
7Mar  
-13  
7Mar  
-13  
7Mar  
-13  
7Mar  
-13  
7Mar  
-13  
7Mar  
-13  
24Mar  
-11  
17Mar  
-11  
17Mar  
-11  
17Mar  
-11  
17Mar  
-11  
17Mar  
-11  
3Mar  
-11  
3Mar  
-11  
3Mar  
-11  
3Mar  
-11  
3Mar  
-11  
3Mar  
-11

3Mar  
-11  
3Mar  
-11  
3Mar  
-11  
24Feb  
-11  
24Feb  
-11  
24Feb  
-11  
24Feb  
-11  
US20110045  
024  
US20110045  
022  
US20110039  
884  
US20110038  
935  
US20110038  
900  
US20110038  
884  
US20110038  
879  
US20110038  
852  
US20110038  
849  
US20110034  
438  
US20110033  
498  
US20110033  
485  
US20110033  
454  
US20110028  
945  
US20110028  
715  
US20110028  
531  
US20110028  
334  
US20110027  
315  
US20110027  
314  
US20110027  
306

US20110027

267

US20110027

257

US20110027

228

US20110027

181

US20110021

861

US20110021

606

US20110021

554

US20110021

415

US20110020

897

14RNA

VIRUS VACCINES AND METHODS

VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF  
INFLUENZA VIRUS

Imidazopyridinones

ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE  
THEREOF

DITTMER DIRK P

TSAI THEODORE

Pfizer Limited

LIDDINGTON ROBERT C

NANOPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS NOVARTIS AG  
IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST  
IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR  
STREPTOCOCCUS PYOGENES

ANTIVIRALS THAT TARGET TRANSPORTERS, CARRIERS, AND ION  
CHANNELS

INHIBITORY POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR  
TREATING CANCER

STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE  
PHARMACEUTICAL USE THEREOF

METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY  
INHIBITING THE DEISGLYLATION ACTIVITY OF OTU DOMAINCONTAINING  
VIRAL PROTEINS

ANALOGUES OF GLYCOLIPIDS USEFUL AS IMMUNOADJUVANTS

Methods For Treating Diseases Using Antibodies to  
Aminophospholipids

Device including altered microorganisms, and methods and systems  
of use

NOVEL ADENINE COMPOUND

NOVEL SIRNA COMPOUNDS FOR INHIBITING RTP801

CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID  
SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS

PROTEIN CAGES AND THEIR USES

NATIONAL UNIVERSITY CO., HAMAMATSU UNIVER.

SCHOOL OF MEDICINE

NOVARTIS AG  
3-V BIOSCIENCES, INC.  
Intradigm Corporation  
FORSCHUNGSVERBUND BERLIN E.V.  
Dec05  
6Dec06  
3Aug07  
6Dec07  
28Apr08  
28Apr08  
30Oct06  
10Jun09  
21Dec06  
25Sep06  
5FRIAS-STAHELI  
NATALIA  
Apr07  
12PANZA  
LUIGI  
Board of Regents, The University of Texas System  
Searete LLC,  
AstraZeneca Aktiebolag  
FEINSTEIN ELENA  
IBIS BIOSCIENCES, INC.  
DOUGLAS TREVOR  
Influenza Vaccines Containing Hemagglutinin and Matrix Proteins NOVARTIS  
VACCINES AND DIAGNOSTICS GMBH & CO. KG  
TC-83-Derived Alphavirus Vectors, Particles and Methods  
AlphaVax, Inc.  
Fusion Proteins of Mannose Binding Lectins for Treatment of Disease ANAPHORE,  
INC.  
CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND  
PREPARATION METHOD THEREOF  
USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE  
Device including altered microorganisms, and methods and systems  
of use  
HAZARDOUS SUBSTANCE-REMOVING MATERIAL  
RNAi Modulation of RSV, PIV and Other Respiratory Viruses and  
Uses Thereof  
IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS  
ANTIMICROBIAL PEPTIDES  
RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS  
STEAROTHERMOPHILUS  
GWO REI BIOMEDICAL TECHNOLOGY CORPORATION  
WEI GUANGWEN  
Searete LLC  
KOSUGI TAKUJI  
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION  
GUY CYNTHIA A  
NOVABIOTICS LIMITED  
LAMPSON BERT C  
Oct07  
15Jul-02  
14Dec05

20Mar07  
20Mar08  
31Jul-09  
7Sep07  
27Jan06  
18May04  
9Nov07  
7Jan08  
28Aug03  
14Dec05  
25Mar08  
22Oct04  
30Dec04  
18Aug04  
10Mar04  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
2Aug  
-10  
5Dec  
-07  
28Oct  
-10  
8Dec  
-08  
28Apr  
-09  
27Apr  
-09  
30Oct  
-07  
9Jun  
-10  
21Dec  
-06  
25Sep  
-07  
7Apr  
-08  
10Oct  
-08  
26Aug  
-10  
28May  
-10  
14Oct  
-10  
17Mar  
-09  
30Jul10  
5Sep  
-08  
26Jan

-07  
6Jul10  
10Nov  
-08  
7Jan  
-09  
15Oct  
-10  
28May  
-10  
23Mar  
-09  
23Jul10  
29Sep  
-10  
29Sep  
-10  
1Mar  
-10  
24Feb  
-11  
24Feb  
-11  
17Feb  
-11  
17Feb  
-11  
17Feb  
-11  
17Feb  
-11  
17Feb  
-11  
17Feb  
-11  
17Feb  
-11  
17Feb  
-11  
17Feb  
-11  
10Feb  
-11  
10Feb  
-11  
10Feb  
-11  
10Feb  
-11  
3Feb  
-11  
3Feb  
-11  
3Feb  
-11  
3Feb  
-11  
3Feb

-11  
3Feb  
-11  
3Feb  
-11  
3Feb  
-11  
3Feb  
-11  
3Feb  
-11  
27Jan11  
27Jan11  
27Jan11  
27Jan11  
27Jan11  
142  
US20110020  
315  
US20110009  
414  
US20110008  
905  
US20110008  
838  
US20110008  
395  
US20110008  
384  
US20110008  
283  
US20110008  
280  
US20110003  
890  
US20110003  
315  
US20110002  
958  
US20110002  
946  
US20110002  
888  
US20110000  
480  
US20100330  
592  
US20100330  
190  
US20100330  
141  
US20100330



140

US20100330

122

US20100330

114

US20100330

075

US20100329

971

US20100319

074

US20100317

684

US20100317

601

US20100317

054

US20100317

034

US20100316

695

US20100316

641

18TREATMENT

OF INFLAMMATORY ILLNESSES WITH ACE2

HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

SYSTEM FOR DETECTING POLYNUCLEOTIDES

CHIMERIC VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES

MIXED MICELLES INCLUDING AMPHIPATHIC CONJUGATES OF RNA AGENTS, AND USES THEREOF

Antiviral activity from medicinal mushrooms

INTERFERON FUSION PROTEINS

METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL29

CYSTEINE MUTANTS

USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF

ABNORMAL VENOUS PROLIFERATION

CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND

ASSAYS USING SAME

Alphavirus Vectors for Respiratory Pathogen Vaccines

Immunostimulatory Combinations

Albumin Fusion Proteins

ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR

TREATMENT OF PATHOGENIC INFECTION

METHOD FOR DETECTING TRUNCATED MOLECULES

LOIBNER HANS

Xenon Pharmaceuticals Inc.

INVESTIGEN

PUSHKO PETER

LEVCHENKO TATYANA S

STAMETS PAUL EDWARD

ARTYMIUK PETER

ZymoGenetics, Inc.

KENNEDY THOMAS P

INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL  
NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
AHONEN CORY L  
Human Gemone Sciences, Inc.  
ENNIS JANE E  
KEY MARC E  
IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF BOZIA JADRANKA  
PRODUCT FOR ABSORPTION PURPOSES  
DEVICES AND METHODS FOR DECREASING HUMAN PATHOGEN  
TRANSMISSION  
VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND  
ANTIGENS  
Use of SIRT1 Activators or Inhibitors to Modulate an Immune  
Response  
MONOCLONAL HUMAN TUMOR-SPECIFIC ANTIBODY  
NOVEL HYDROXY RADICAL GENERATION METHOD, AND ANTI-VIRAL  
MATERIAL UTILIZING HYDROXYL RADICAL GENERATED BY THE  
METHOD  
MULTI-TARGETED RNAI THERAPEUTICS FOR SCARLESS WOUND  
HEALING OF SKIN  
Amide and Carbamate Derivatives of  
N-{2-[4-Amino-2(Ethoxymethyl)-1H-Imidazo[4,5-c]  
Quinolin-1-yl]-1,1Dimethylethyl}  
Methanesulfonamide and Methods  
Casein Derived Peptides And Uses Thereof  
PORCINE DC-SIGN, ICAM-3 AND LSECTin AND USES THEREOF  
PRIMATE T-LYMPHOTROPIC VIRUSES  
CONDENSATION PRODUCTS BASED ON BICYCLIC OR POLYCYCLIC  
AROMATICS OR HETEROAROMATICS  
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES  
Fauci/COVID-19 Dossier  
HJERTEN MARIE-CHRISTINE  
FILLIGENT LIMITED  
PUSHKO PETER  
KWON HYE-SOOK  
ABELA IRENE  
MOCHIGASE CO., LTD.  
SIR NAOMICS, INC.  
Dec07  
20Sep04  
20May03  
19Jul-07  
6-Jul07  
6Jan04  
8Aug07  
2Apr04  
8Nov07  
8May06  
21May04  
30Dec02  
21Dec01  
9Jun09  
29Jan08  
17Dec07

13Jun03  
26Jun07  
19Jul-07  
7Feb08  
13Mar07  
8Feb08  
6Nov07  
9Coley  
Pharmaceutical Group, Inc.  
Sep05  
1SIDELMAN  
ZVI  
VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.  
and Johns Hopkins University  
BASF SE  
DIMITROV DIMITER S  
CC-BY-NC-SA Dr. David E. Martin  
Mar00  
29Oct07  
21Feb05  
14Nov07  
31Jan08  
18Dec  
-08  
6May  
-09  
9Jun  
-10  
21Jul08  
7Jul08  
27Mar  
-07  
5Aug  
-08  
20May  
-10  
10Nov  
-08  
8May  
-07  
1Jun  
-10  
29Jul10  
3Jun  
-10  
9Jun  
-10  
29Jan  
-09  
17Dec  
-08  
13Sep  
-10  
25Jun



16Dec  
-10  
16Dec  
-10  
16Dec  
-10  
16Dec  
-10  
16Dec  
-10  
US20100316  
624  
US20100311  
797  
US20100311  
656  
US20100311  
039  
US20100310  
638  
US20100310  
604  
US20100310  
562  
US20100305  
138  
US20100304  
363  
US20100304  
361  
US20100303  
823  
US20100298  
547  
US20100298  
364  
US20100298  
209  
US20100297  
651  
US20100297  
165  
US20100297  
108  
US20100292  
504  
US20100292  
307  
US20100291  
544  
US20100291  
145  
US20100291  
129

US20100291

120

US20100291

075

US20100291

033

US20100286

251

US20100286

238

US20100286

118

US20100286

025

21TREATMENT

OF FIBROSES AND LIVER DISORDERS

Novel Compounds

TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS

WITH ALPHA THYMOSIN PEPTIDES

NON-TARGET AMPLIFICATION METHOD FOR DETECTION OF RNA

SPLICE-FORMS IN A SAMPLE

LIPOSOMES COMPRISING DURAMYCIN AND ANTI-VIRAL AGENTS

RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)

PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ

SYSTEM FOR DELIVERY INTO XCR1 POSITIVE CELL AND USES

THEREOF

LOIBNER HANS

BONNERT ROGER VICTOR

SciClone Pharmaceuticals, Inc.

QIAGEN GAITHERSBURG INC.

Board of Regents, The University of Texas System

MEDICAGO INC.

Bundesrepublik Deutschland letztvertreten durch das

Robert Koch-Institut vertreten durch seinen

PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS

INC.

PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS

CORONAVIRUS AND APPLICATION THEREOF

METHOD AND DEVICE FOR MONITORING A THERAPEUTIC

TREATMENT REGIME

ELECTRONICS AND TELECOMMUNICATIONS RESEARCH

INSTITUTE

DAS DEVELOPMENT PARTNERS

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) GENMAB A/S

METHODS FOR THE DIRECTED EXPANSION OF EPITOPES FOR USE

AS ANTIBODY LIGANDS

SALTS 756

BONNIN DUSTAN

AstraZeneca AB

COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION ESTAQUIER JEROME

Methods of Modulating Vesicular Trafficking

IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND

METHODS OF USE

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN

AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS  
BORON-CONTAINING SMALL MOLECULES  
Construct  
COMPOSITIONS FOR USE IN IDENTIFICATION OF STRAINS OF  
HEPATITIS C VIRUS  
Ii-KEY/ANTIGENIC EPI TOPE HYBRID PEPTIDE VACCINES  
Norovirus and sapovirus antigens  
PEPTIDES REGULATING THE SURFACE EXPRESSION OF THE T CELL  
RECEPTOR  
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)  
Neutralizing Antibodies  
Albumin Fusion Proteins  
Mammalian Genes Involved In Viral Infection And Tumor  
Suppression  
SUPPRESSION OF VIRUSES INVOLVED IN RESPIRATORY INFECTION  
OR DISEASE  
SUBSTITUTED 1-CYANOETHYLHETEROCYCLYL CARBOXAMIDE  
COMPOUNDS 750  
SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND  
METHODS OF USE  
THE GENERAL HOSPITAL CORPORATION  
Office of Technology Transfer  
GRIMM JAN  
Anacor Pharmaceuticals, Inc.  
ISIS INNOVATION LIMITED  
IBIS BIOSCIENCES, INC.  
ANTIGEN EXPRESS, INC.  
COIT DORIS  
MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN  
Theraclone Sciences, Inc.  
Human Genome Sciences, Inc.  
RUBIN DONALD H  
ARNDT GREGORY MARTIN  
FORD RHONAN  
ANANTHARAMAIAH GATTADAHALLI M  
Dec07  
26May06  
23Apr03  
1May09  
15Jul-02  
21Jan08  
20Nov07  
29Jul-03  
27May09  
26Jul-07  
16Dec02  
7May07  
21May09  
2Nov07  
21May09  
24Sep07  
31Aug07  
20Jun07  
28Mar06

25May07  
14Sep99  
22Nov05  
23Jun06  
23Apr09  
21Dec01  
11Oct06  
15May07  
7May09  
28Aug07  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
22Dec  
-08  
2Jun  
-10  
16Jun  
-10  
30Apr  
-10  
4Mar  
-10  
12Jan  
-09  
19Nov  
-08  
15Jun  
-10  
26May  
-10  
28Jul08  
11Nov  
-09  
7May  
-08  
20May  
-10  
31Oct  
-08  
21May  
-10  
24Sep  
-08  
1Sep  
-08  
30Jul10  
28Mar  
-07  
27May  
-08  
26Jul10  
24Mar  
-09



23Jun  
-07  
23Apr  
-10  
3Jun  
-10  
5Mar  
-10  
14May  
-08  
6May  
-10  
27Aug  
-08  
16Dec  
-10  
9Dec  
-10  
9Dec  
-10  
9Dec  
-10  
9Dec  
-10  
9Dec  
-10  
9Dec  
-10  
2Dec  
-10  
2Dec  
-10  
2Dec  
-10  
2Dec  
-10  
25Nov  
-10  
25Nov  
-10  
25Nov  
-10  
25Nov  
-10  
25Nov  
-10  
25Nov  
-10  
18Nov  
-10  
18Nov  
-10  
18Nov  
-10

18Nov  
-10  
18Nov  
-10  
18Nov  
-10  
18Nov  
-10  
18Nov  
-10  
11Nov  
-10  
11Nov  
-10  
11Nov  
-10  
11Nov  
-10  
144  
US20100285  
457  
US20100285  
135  
US20100284  
968  
US20100284  
967  
US20100284  
965  
US20100284  
917  
US20100284  
016  
US20100280  
102  
US20100280  
067  
US20100280  
048  
US20100280  
001  
US20100279  
906  
US20100279  
888  
US20100279  
351  
US20100279  
279  
US20100279  
276  
US20100279  
273  
US20100278

861

US20100278

846

US20100278

829

US20100273

997

US20100273

854

US20100273

740

US20100273

670

US20100272

785

US20100272

776

US20100272

771

US20100272

730

High-Throughput Diagnostic Assay For the Human Virus Causing Severe Acute Respiratory Syndrome (SARS)

Nanoparticles For Use In Immunogenic Compositions

Use of PS20/WFDC1 and Interferons to Diagnose, Monitor and Treat Viral Diseases

MODIFIED PHAGE FOR DISPLAYING POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF

COMPOSITIONS AND METHODS FOR ADOPTIVE AND ACTIVE IMMUNOTHERAPY

COMPOUNDS AND MARKERS FOR SURFACE-ENHANCED RAMAN SCATTERING

OPTICAL CYTOMETRY

DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ORGANISM

INHIBITORS OF ACETYL-COA CARBOXYLASE

Some 2-pyrazinone derivatives and their use as inhibitors of neutrophil elastase

24CHAN

KWOK HUNG

NOVARTIS AG

BAIG EHTESHAM

National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS) U.S. Govt.

Yale University

JULIUS-MAXIMILIANS- UNIVERSITAT

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Alnylam Pharmaceuticals

ACHARYA VINOD PARAMESHWARAN

ASTRAZENECA R&D

IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES BONNERT ROGER VICTOR FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION BYOTROL PLC

COMPOSITIONS AND METHODS OF DETECTION

Method for Generation of Antibodies

Compositions and methods for analysis of target analytes  
METHODS FOR DETERMINING THE PRESENCE OF SARS  
CORONAVIRUS IN A SAMPLE  
NUCLEIC ACID SEQUENCES FOR THE AMPLIFICATION AND  
DETECTION OF RESPIRATORY VIRUSES  
METHODS AND COMPOSITIONS FOR PREDICTING EMERGENCE AND  
EXPANSION OF DRUG RESISTANT STRAINS OF INFLUENZA VIRUS  
NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALTTARGETING  
AND PHAGOCYTTIC POLYPEPTIDE TRANSPORT  
SEQUENCES  
DUAL INHIBITION OF IMMUNOPHILIN/CYCLOPHILIN FAMILY  
MEMBERS AND EMMPRIN IMMUNOGLOBULIN RECEPTOR  
SUPERFAMILY MEMBERS  
Ribozyyme to cleave coronavirus gene  
COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE  
EXPRESSION  
Phospholipids for the Treatment of Infection by Togaviruses, Herpes  
Viruses and Coronaviruses  
DETECTION OF ANTIVIRAL RESISTANCE IN INFLUENZA A USING  
DNA MICROARRAY  
RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED  
INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE  
MODULATORY PROFILES  
Device including bone cage and method for treatment of disease in  
a subject  
Device including bone cage and method for treatment of disease in  
a subject  
Antigenic GM-CSF Peptides And Antibodies To GM-CSF  
Fauci/COVID-19 Dossier  
GENERA BIOSYSTEMS LIMITED  
NATIONAL JEWISH MEDICAL AND RESEARCH CENTER  
DANIELZADEH ROBERT  
GEN-PROBE INCORPORATED  
UNIVERSITE LAVAL  
NIMAN HENRY L  
Mar03  
2Dec05  
15Oct07  
21Nov06  
15Jan08  
24Sep07  
6May09  
13Jun03  
30Apr09  
6Nov07  
8May07  
17Sep07  
5Apr07  
13Mar07  
17Sep03  
17Apr03  
17Jul-07  
29Jan09  
23FERGUSON

IAN A  
Jun04  
6EDWARDS  
III CARL KEITH  
Feb09  
9FUKUDA  
NOBORU  
FEINSTEIN ELENA  
FLEMING RONALD A  
DAWSON ERICA  
COLEY PHARMACEUTICAL GMBH  
Searete LLC, a limited liability corporation of the State of  
Delaware  
HARLOW ED  
MORPHOTEK, INC.  
CC-BY-NC-SA Dr. David E. Martin  
Aug05  
15Jun07  
20Feb04  
21Aug06  
13Aug07  
23Apr09  
23Apr09  
8Feb06  
12Jun  
-09  
1Dec  
-06  
15Oct  
-08  
20Nov  
-07  
14Jan  
-09  
24Sep  
-08  
6May  
-09  
16Jun  
-10  
30Apr  
-10  
5Nov  
-08  
6May  
-08  
17Sep  
-08  
4Apr  
-08  
13Mar  
-08  
30Nov  
-07



-10  
4Nov  
-10  
4Nov  
-10  
4Nov  
-10  
4Nov  
-10  
28Oct10  
28Oct10  
28Oct10  
28Oct10  
28Oct10  
28Oct10  
28Oct10  
28Oct10  
145  
  US20100272  
706  
US20100272  
668  
US20100267  
981  
US20100267  
805  
US20100266  
677  
US20100266  
634  
US20100266  
620  
US20100266  
604  
US20100266  
598  
US20100262  
374  
US20100261  
779  
US20100261  
690  
US20100261  
026  
US20100256  
348  
US20100256  
105  
US20100256  
104  
US20100256  
103  
US20100256  
096

US20100256  
070  
US20100254  
985  
US20100254  
944  
US20100254  
942  
US20100249  
200  
US20100249  
021  
US20100248  
219  
US20100247  
574  
US20100247  
571  
US20100247  
560  
US20100247  
554  
22ANTIVIRALS  
ANTIVIRAL  
SUBSTANCE, ANTIVIRAL FIBER, AND ANTIVIRAL FIBER  
STRUCTURE  
BORON-CONTAINING SMALL MOLECULES  
TARGETING OPPOSITE STRAND REPLICATION INTERMEDIATES OF  
SINGLE-STRANDED VIRUSES BY RNAI  
NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE  
ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF  
NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS  
Immunoconjugates for treatment of infectious diseases  
USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND  
TAM ACTIVATORS AS IMMUNOSUPPRESSORS  
PEPTIDE THAT ELICITS NEUTRALIZING ANTIBODIES TARGETING  
THE HIV CO-RECEPTOR, CCR5  
Systems and methods for analyzing nanoreporters  
Phosphate-Modified Oligonucleotide Analogs with Enhanced  
Immunostimulatory Activity  
NOVEL COMBINATIONS  
Compositions comprising oriented, immobilized macromolecules and  
methods for their preparation  
Oligoadenylate Synthetase (OAS)  
NOVEL COMPOUNDS  
NOVEL AMIDE COMPOUNDS  
NOVEL COMPOUNDS  
Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides  
and ureas, pharmaceutical compositions thereof, and methods for  
treating hemorrhagic fever viruses, including infections associated  
with arenaviruses  
RECOMBINANT VIBRIO CHOLERAE EXOTOXINS  
Protein Formulations  
Albumin Fusion Proteins



HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS

Novel Compounds 569

METHOD AND MEDICAMENT FOR INHIBITING THE INFECTION OF  
INFLUENZA VIRUS

Compositions for use in identification of influenza viruses

CHIMERIC NEWCASTLE DISEASE VIRUS VLPs

METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST  
VIRUS

MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND  
USES THEREOF

USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS

Fauci/COVID-19 Dossier

GREBER URS

Daiwabo Holdings Co., Ltd.

Anacor Pharmaceuticals, Inc.

ALNYLAM PHARMACEUTICALS, INC.

UNIVERSITY OF ROCHESTER

NEW YORK BLOOD CENTER, INC.

SUN LE

The Salk Institute for Biological Studies

Government of the US, as Represented by the Secretary,

Department of Health and Human Services

HWANG JENQ-NENG

JURK MARION

ASTRAZENECA R&D

NanoString Technologies, Inc.

ILLUMIGEN BIOSCIENCES, INC.

AstraZeneca R&D

ASTRAZENECA R&D

ASTRAZENECA R&D

Jun07

20Feb08

16Feb05

24Sep04

26Jul-07

15Jun04

20Jan06

9Nov07

9Apr04

22May06

15May08

3Apr09

23Dec05

23Nov05

3Apr09

3Apr09

3Apr09

6BAILEY

THOMAS R

Dec04

SEED

BRIAN

MEDIMMUNE, LLC

STUMP DAVID CARTER

BIOTRON LIMITED  
CONNOLLY STEPHEN  
INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF  
SCIENCES  
ESHOO MARK W  
MAHMOOD KUTUB  
ACADEMIA SINICA  
THOMAS JEFFERSON UNIVERSITY  
BHATTACHARYYA SUCHITA  
CC-BY-NC-SA Dr. David E. Martin

20Jul-07

3Feb06

14Sep06

3Aug07

20Dec06

14Nov07

17Oct05

21Feb07

27Mar09

25Sep07

9Nov07

20Jun

-08

20Feb

-09

2Dec

-09

1Mar

-10

28Jul08

18Feb

-10

19Jan

-07

7Nov

-08

28Dec

-09

21May

-07

15May

-08

30Mar

-10

22Dec

-06

30Mar

-10

30Mar

-10

30Mar

-10

30Mar

-10

17Jan  
-07  
18Jul08  
6May  
-10  
13Sep  
-07  
4Aug  
-08  
30Mar  
-10  
18Dec  
-07  
17Oct  
-06  
21Feb  
-08  
26Mar  
-10  
25Sep  
-08  
7Nov  
-08  
146  
28Oct10  
28Oct10  
21Oct10  
21Oct10  
21Oct10  
21Oct10  
21Oct10  
21Oct10  
21Oct10  
21Oct10  
14Oct10  
14Oct10  
14Oct10  
14Oct10  
7Oct10  
7Oct10  
7Oct10  
7Oct10  
7Oct10  
7Oct10  
7Oct10  
7Oct10  
30Sep  
-10  
30Sep  
-10  
30Sep  
-10  
30Sep  
-10  
30Sep  
-10

30Sep  
-10  
30Sep  
-10  
30Sep  
-10  
US20100247  
550  
US20100240  
903  
US20100240  
746  
US20100240  
693  
US20100240  
623  
US20100240  
063  
US20100239  
611  
US20100239  
610  
US20100239  
593  
US20100239  
520  
US20100234  
355  
US20100233  
250  
US20100233  
146  
US20100233  
116  
US20100233  
084  
US20100233  
031  
US20100227  
767  
US20100226  
931  
US20100222  
409  
US20100222  
234  
US20100221  
755  
US20100221  
349  
US20100221  
307  
US20100221  
257

US20100221

242

US20100216

843

US20100216

773

US20100216

689

US20100215

683

SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS  
AND USES OF SAID REPLIKIN SCAFFOLDS

28BOGOCH

ELENORE S

CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS Onyx Therapeutics, Inc.  
STEREISOMERS OF TRICYCLODECAN-9-YL-XANTHOGENATE

Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring  
Compounds and Methods

LUMAVITA AG

Coley Pharmaceutical Group, Inc

8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 COOK ANTHONY  
SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL  
SIGNALS

Combination adjuvant formulation

INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING

HEMAGGLUTININ PRODUCED WITHIN A PLANT

RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING  
THEM

ORGANIC COMPOUNDS

ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF  
CYTOKINE MEDIATED DISEASES

VACCINE

Coatings and Surface Treatments Having Active Enzymes and  
Peptides

ORGANIC COMPOUNDS

Method for Delivery Across the Blood Brain Barrier

Method and Apparatus for Analyzing Bioprocess Fluids

STOCHASTIC CONFINEMENT TO DETECT, MANIPULATE, AND

UTILIZE MOLECULES AND ORGANISMS

Compounds for immunopotentialiation

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF  
PRO-APOPTOTIC GENES

Malaria antigen screening method

USE OF ANTIBODY SECRETING CELL ELISPOT TO ASSESS

ANTIBODY RESPONSES FOLLOWING ANTIGEN EXPOSURE

NUCLEIC ACID CONSTRUCTS

ANTIVIRAL AGENTS, ANTIVIRAL FIBERS AND ANTIVIRAL FIBER  
STRUCTURES

BINDING MEMBERS-513

ANTI-VIRAL GRIFFITHSIN COMPOUNDS, COMPOSITIONS AND  
METHODS OF USE

NOVEL SALT 628

PHENANTHROINDOLIZIDINE ANALOGUES

CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST

PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS  
HYPERVIRULENT STRAINS  
GEN-PROBE INCORPORATED  
BABIUK LORNE  
MEDICAGO INC.  
MedImmune Limited  
DALES NATALIE  
MARTIN BARRIE  
BARAS BENOIT  
REACTIVE SURFACES, LTD.  
DALES NATALIE  
IMMUNE DISEASE INSTITUTE, INC.  
BioScale, Inc.  
BOEDICKER JAMES Q  
SILVER JOEL B  
FEINSTEIN ELENA  
AGUAIR JOAO CARLOS  
University of Rochester  
Powderject Vaccines, Inc.  
DAIWABO HOLDINGS CO., LTD.  
MEDIMMUNE LIMITED  
MCMAHON JAMES B  
ASTRAZENECA R&D  
National Health Research Institutes  
National University Corporation, Hamamatsu University  
School of Medicine  
NOVARTIS AG  
Apr04  
20Mar09  
3-Jul07  
9Feb05  
5-Jul06  
10Mar05  
16Oct08  
13Jul-07  
1Jun07  
24Aug06  
19Jun06  
19Jun07  
9Sep02  
15Aug06  
22May06  
2May05  
26Jul-07  
24Jun04  
27Jun07  
31Aug05  
15Jun07  
1Feb05  
20Feb08  
7Nov08  
1Dec05  
20Feb09  
24Feb09

8May07  
20Feb09  
3Feb  
-10  
22Mar  
-10  
3Jul08  
8Feb  
-06  
3Jul07  
1Jun  
-10  
15Oct  
-09  
11Jul08  
30May  
-08  
22Aug  
-07  
18Jun  
-07  
20Jun  
-08  
29May  
-09  
13Aug  
-07  
22May  
-07  
25May  
-10  
28Jul08  
24Jun  
-05  
26Jun  
-08  
25Aug  
-06  
16Jun  
-08  
1Feb  
-06  
20Feb  
-09  
5Nov  
-09  
1Dec  
-06  
16Feb  
-10  
11Feb  
-10  
7May  
-08





26Aug  
-10  
26Aug  
-10  
26Aug  
-10  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
147  
  US20100215  
675  
US20100210  
745  
US20100210  
688  
US20100209  
454  
US20100209  
451  
US20100209  
440  
US20100204  
286  
US20100204  
266  
US20100204  
203  
US20100203  
582  
US20100197  
748  
US20100197  
708  
US20100196  
285  
US20100196  
222  
US20100190  
748  
US20100189  
772  
US20100186  
680  
US20100184  
663  
US20100184  
613  
US20100184  
192  
US20100184  
190  
US20100184  
019

US20100183

673

US20100183

671

US20100183

634

US20100183

516

US20100179

145

US20100178

299

REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT  
OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY  
AND LETHALITY IN INFLUENZA

Molecular Healing of Polymeric Materials, Coatings, Plastics,  
Elastomers, Composites, Laminates, Adhesives, and Sealants by  
Active Enzymes

Novel Benzothiazolone Derivatives

ATTENUATED VIRUSES USEFUL FOR VACCINES

Compositions and Methods Related to Adenovirus Based Delivery of  
Antigens

Targeted Delivery of siRNA

METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS  
OF CYTOTOXIC AGENTS

COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED  
POPULATIONS OF BIOAGENTS

Chemical Compounds 637: Pyridopyrimidinediones as PDE4  
Inhibitors

Protein Expression System Involving Mutated Severe Respiratory  
Syndrome-Associated Coronavirus 3C-Like Protease

ANTI-MICROBIAL COMPOSITION

INDOLE COMPOUNDS

Use of Deuterium Oxide to Treat Virus-Based Diseases of the  
Respiratory Tract

AIR CLEANING APPARATUS

BORON-CONTAINING SMALL MOLECULES

Compositions of TLR ligands and antivirals

LIVESTOCK STERILIZING METHOD, LIVESTOCK STERILIZING  
APPARATUS, AND LIVESTOCK OR LIVESTOCK MEAT

Methods and Compositions Related to Inhibition of Viral Entry  
Proteome Epitope Tags and Methods of Use Thereof in Protein  
Modification Analysis

AVIAN INFLUENZA CHIMERIC VLPS

Influencing viral lipid constituents

Novel Human Virus Causing Severe Acute Respiratory Syndrome  
(SARS) and Uses Thereof

METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS  
VECTOR FOR USE WITH MULTIPLE VACCINATIONS

LOW-ADDITIVE INFLUENZA VACCINES

MULTIFUNCTIONAL NUCLEIC ACID NANO-STRUCTURES

SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS

PHARMACEUTICAL COMBINATIONS

METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE

RESPONSES

9BOGOCH

ELENORE S

Jan09

9REACTIVE

SURFACES, LTD.

BONNERT ROGER

CELLO JERONIMO

INTROGEN THERAPEUTICS, INC.

Immune Disease Institute, Inc.

BYRNES JOHN J

Ibis Biosciences, INC

BONNERT ROGER VICTOR

Academia Sinica

BYOTROL PLC

BARDEN TIMOTHY

BAYERL THOMAS

FUJIFILM CORPORATION

Anacor Pharmaceuticals, Inc.

COLEY PHARMACEUTICAL GMBH

HAGIWARA NOBUKO

University of Utah Research Foundation

Millipore Corporation

PUSHKO PETER

MedImmune, LLC

CHAN KWOK HUNG

ETUBICS CORPORATION

Novartis Vaccines & Diagnostics GmbH & Co., KG

Cornell University, a New York Corporation

BARTH STEFAN

GALLAGHER NEIL JAMES

Northeastern University

Sep02

9Aug05

30Mar07

16Jun06

26Jan07

12Feb09

23Mar07

11Jan07

12Feb09

17Jul-07

7Aug06

7Jan09

20Sep07

16Feb05

27Sep06

21Feb05

8Feb07

10May02

11Jul-03

17Oct06

24Mar03

2-Jul07

27Jun07  
1Jan09  
25Jul-07  
12Oct06  
13Feb07  
16Oct  
-09  
29Jan  
-10  
27Apr  
-10  
31Mar  
-08  
18Jun  
-07  
25Jan  
-08  
11Feb  
-10  
21Mar  
-08  
10Jan  
-08  
12Feb  
-09  
17Jul08  
7Aug  
-07  
6Jan  
-10  
19Sep  
-08  
21Jul09  
27Sep  
-07  
21Feb  
-06  
8Feb  
-08  
9Oct  
-09  
19Jan  
-10  
9Oct  
-07  
10Feb  
-10  
4Jan  
-10  
27Jun  
-08  
31Dec  
-09  
25Jul08

12Oct  
-07  
13Feb  
-08  
26Aug  
-10  
19Aug  
-10  
19Aug  
-10  
19Aug  
-10  
19Aug  
-10  
19Aug  
-10  
12Aug  
-10  
12Aug  
-10  
12Aug  
-10  
12Aug  
-10  
5Aug  
-10  
5Aug  
-10  
5Aug  
-10  
5Aug  
-10  
29Jul10  
29Jul10  
29Jul10  
22Jul10  
22Jul10  
22Jul10  
22Jul10  
22Jul10  
22Jul10  
22Jul10  
22Jul10  
22Jul10  
22Jul10  
22Jul10  
15Jul10  
15Jul10  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
148  
US20100175  
006  
US20100173  
980

US20100173  
906  
US20100173  
325  
US20100173  
280  
US20100172  
965  
US20100172  
917  
US20100166  
874  
US20100166  
782  
US20100166  
780  
US20100166  
769  
US20100166  
661  
US20100160  
486  
US20100160  
323  
US20100160  
285  
US20100160  
245  
US20100158  
943  
US20100158  
935  
US20100158  
928  
US20100152  
230  
US20100152  
197  
US20100152  
187  
US20100152  
184  
US20100151  
490  
US20100150  
960  
US20100150  
943  
US20100150  
923  
US20100146  
647  
US20100144  
846

SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,  
AND COMMUNICATING EVENT-RELATED INFORMATION  
ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV  
Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8Tetraazacyclopenta[cd]Phenalenes  
and Methods  
Composition and Method for Analysis of Target Analytes  
Systems for Detection and Production of Respiratory, Herpes and  
Enteric Viruses  
ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES  
Binding molecules against SARS-coronavirus and uses thereof  
Technology for Preparation of Macromolecular Microspheres  
CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE  
FUNCTION  
CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with  
Enhanced Immunostimulatory Activity  
High-yield Transgenic Mammalian Expression System for Generating  
Virus-like Particles  
siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING  
VIRAL INFECTION  
POLYOLEFIN ANTIMICROBIAL COMPOSITIONS AND MELTPROCESSING  
METHODS  
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA  
DESATURASE  
Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory  
Disease  
Quercetin-Containing Compositions  
ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH  
INFLUENZA VACCINES  
MUTANT FORMS OF STREPTOLYSIN O  
IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS  
HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS  
(4-TERT-BUTYLPYPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-NCARBOXAMIDE  
DERIVATIVES  
AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA  
DESATURASE INHIBITORS  
PHARMACEUTICAL COMPOUNDS  
Antigenic Protein Conjugates and Process for Preparing Same  
COMPOSITIONS AND METHODS FOR CHITOSAN ENHANCED  
IMMUNE RESPONSE  
IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA  
FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS  
STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES  
Antibody producing non-human mammals  
Oligoribonucleotides and uses thereof  
Fauci/COVID-19 Dossier  
28Georgetown  
University  
JUTEAU JEAN-MARC  
GRIESGRABER GEORGE W  
Millipore Corporation  
Diagnostic Hybrids, Inc  
JUTEAU JEAN-MARC  
Crucell Holland B.V.  
FANG FANG

AGADJANYAN MICHAEL  
Pfizer Inc  
Academia Sinica  
LIN YONGPING  
BISHOP KEVIN L  
BISCHOFF ALEXANDER  
BIRKINSHAW TIMOTHY NICHOLAS  
Quercegen Pharma LLC  
NOVARTIS VACCINES AND DIAGNOSTICS SRL  
NOVARTIS AG  
GRIESGRABER GEORGE W  
Pfizer Inc.  
ASTRAZENECA AB  
XENON PHARMACEUTICALS INC.  
ASTEX THERAPEUTICS LIMITED  
ABBOTT LABORATORIES  
The United States of America, as represented by the  
Secretary, Department of Health and Human Servi  
NOVARTIS AG  
Chinese Academy of Medical Sciences, Institute of Basic  
Medical Sciences  
Merus B. V.  
COLEY PHARMACEUTICAL GMBH  
CC-BY-NC-SA Dr. David E. Martin  
Aug08  
13Sep02  
6Sep06  
17Sep03  
20Sep05  
13Sep02  
22Jul-03  
24Jan06  
25Jul-08  
27Sep06  
5Sep06  
11Dec08  
19Dec08  
23Dec08  
24Aug04  
17Jul-06  
4Nov05  
21Dec07  
25Dec06  
2Sep05  
15Dec08  
3Jun05  
16Nov06  
1Sep06  
22Sep06  
26Jul-06  
20Jun05  
27Jun08  
26Oct06  
2Dec



-09  
21Dec  
-09  
6Sep  
-07  
4Jul09  
19Sep  
-06  
21Dec  
-09  
16Nov  
-09  
8Dec  
-09  
23Jul09  
27Sep  
-07  
12Feb  
-10  
11Dec  
-09  
19Dec  
-08  
22Dec  
-09  
18Dec  
-09  
16Dec  
-09  
6Nov  
-06  
24Feb  
-10  
20Dec  
-07  
1Sep  
-06  
10Dec  
-09  
5Jun  
-06  
12Oct  
-07  
25Feb  
-10  
21Sep  
-07  
26Jul07  
13Jun  
-06  
19Oct  
-09  
26Oct  
-07

8Jul10  
8Jul10  
8Jul10  
8Jul10  
8Jul10  
8Jul10  
1Jul10  
1Jul10  
1Jul10  
1Jul10  
1Jul10  
24Jun10  
24Jun10  
24Jun10  
24Jun10  
24Jun10  
24Jun10  
24Jun10  
17Jun10  
17Jun10  
17Jun10  
17Jun10  
17Jun10  
17Jun10  
17Jun10  
17Jun10  
10Jun10  
10Jun10  
149  
US20100144  
833  
US20100144  
828  
US20100144  
759  
US20100144  
606  
US20100144  
589  
US20100144  
040  
US20100144  
015  
US20100143  
888  
US20100143  
881  
US20100143  
411  
US20100143  
406  
US20100143  
302

US20100130  
503  
US20100130  
491  
US20100130  
430  
US20100129  
811  
US20100129  
437  
US20100129  
400  
US20100129  
386  
US20100129  
321  
US20100119  
550  
US20100113  
745  
US20100113  
565  
US20100113  
510  
US20100112  
710  
US20100112  
643  
US20100112  
092  
US20100111  
873  
RNAi Modulation Of RSV, PIV And Other Respiratory Viruses And  
Uses Thereof  
CAFFEYLQUINIC ACID DERIVATIVES CONTAINING NITROGEN,  
AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION  
AND USAGE THEREOF  
NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS  
MODULATORS OF CHEMOKINE RECEPTOR CCR4  
COMBINATION 408  
METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN  
COUNTS  
CELLS AND METHODOLOGY TO GENERATE NON-SEGMENTED  
NEGATIVE-STRAND RNA VIRUSES  
COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL  
GROWTH  
ENZYMATIC DIAGNOSTIC TEST FOR SARS AND OTHER VIRAL  
DISEASES  
Selective detection of human rhinovirus  
METHOD FOR IDENTIFICATION OF T-LYMPHOCYTE ANTIGENS  
METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS  
LIKE PARTICLES  
Recombinant Adenoviruses Based on Serotype 26 and 48, and Use  
Thereof

NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE  
SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN  
CHAPERONE HSP 90  
9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE  
RECEPTOR (TLR7 ) MODULATORS  
22BARIK  
SAILEN  
ZHEJIANG MEDICINE CO., LTD. XINCHANG  
PHARMACEUTICA  
Oct04  
23Mar07  
12AstraZeneca  
AB  
AstraZeneca AB  
BOGOCH ELENORE S  
CHARNEAU PIERRE  
KINNEY RICHARD  
MND Diagnostic Ltd.  
and Human Services  
The Government of the U.S.A. as represented by the  
Secretary, Dept. of Health and Human Service  
PUSHKO PETER  
Beth Israel Deaconess Medical Center, Inc  
SANOFI-AVENTIS  
BONNERT ROGER VICTOR  
STABILIZED THERAPEUTIC SMALL HELICAL ANTIVIRAL PEPTIDES New York Blood Center,  
Inc  
COMPOSITIONS FOR USE IN IDENTIFICATION OF PSEUDOMONAS  
AERUGINOSA  
TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS  
ATTENUATED VIRUSES, VACCINES AND METHODS OF USE  
THEREOF  
Composotions And Methods For The Identification And Treatment Of  
Immune-Mediated Inflammatory Diseases  
DIARYL UREA FOR TREATING VIRUS INFECTIONS  
RECOMBINANT MULTIVALENT VACCINE  
Means and Methods for Influencing the Stability of Antibody  
Producing Cells  
IMMUNOSTIMULATORY COMBINATIONS AND METHODS  
QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR  
ANTAGONISTS  
METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGETSPECIFIC  
SEQUENCES FOR USE IN NANOREPORTERS  
METHOD FOR DIRECT CAPTURE OF RIBONUCLEIC ACID  
ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE  
AND METHODS OF MAKING AND USING THE SAME  
TREATING CANCER WITH VIRAL NUCLEIC ACID  
Ibis Biosciences, Inc.  
BBB Holding B.V.  
THE PENN STATE RESEARCH FOUNDATION  
CONG YINGZI  
BAYER HEALTHCARE LLC  
GOMI YASUYUKI  
Meibergdreef 9

Not Available

FORD RHONAN

NANOSTRING TECHNOLOGIES, INC.

The Government of the United States of America, as  
represented by the Secretary of the Navy

Oculus Innovative Sciences, Inc.

HADAC ELIZABETH M

Dec05

20Jun08

23Apr08

22Dec06

5Dec08

23Jun03

5Dec08

27May08

30Jun06

16Mar06

24Oct06

19Mar07

5Oct06

11Sep03

23Mar07

22Dec06

24Jan06

15Dec05

24Nov05

9Dec05

8Dec04

19Dec06

10Apr07

4Nov08

13Mar07

20Feb07

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

25Jun

-09

21Mar

-08

8Dec

-09

19Jun

-09

7Aug

-09

21Dec

-07

4Dec

-09

25Nov

-09

5Dec

-08



27May  
-10  
27May  
-10  
27May  
-10  
27May  
-10  
27May  
-10  
27May  
-10  
13May  
-10  
6May  
-10  
6May  
-10  
6May  
-10  
6May  
-10  
6May  
-10  
6May  
-10  
6May  
-10  
150  
US20100105  
873  
US20100105  
642  
US20100105  
025  
US20100105  
024  
US20100104  
503  
US20100099  
870  
US20100099  
745  
US20100099  
672  
US20100099  
665  
US20100099  
149  
US20100099  
079  
US20100093  
998  
US20100093

862

US20100093

851

US20100093

816

US20100093

813

US20100093

627

US20100093

038

US20100092

474

US20100092

470

US20100092

401

US20100092

399

US20100087

443

US20100087

388

US20100086

950

US20100086

942

US20100086

571

US20100075

298

US20100070

195

INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN  
THERAPEUTICS

NOVEL COMPOUNDS 409

DEVICES FOR GENERATING DETECTABLE POLYMERS

RAPID TEST INCLUDING GENETIC SEQUENCE PROBE

MODULAR NANOPARTICLES FOR ADAPTABLE VACCINES

NOVEL ADENINE COMPOUND

ENHANCING DISEASE RESISTANCE AGAINST RNA VIRAL

INFECTIONS WITH INTRACYTOPLASMIC PATHOGEN SENSORS

METHODS FOR TREATING HEPATITIS C

ISOQUINOLINONE DERIVATIVES

STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF

RIBONUCLEIC ACID

Non-dividing cell-based assay for high throughput antiviral  
compound screening

NOVEL ADENINE COMPOUND

POTENTIATION OF CELLULAR IMMUNITY USING HISTONE

DEACETYLASE (HDAC) INHIBITORS.

SILVER POLYAMIDE COMPOSITE

SALT

Salts 668



ALBUMIN FUSION PROTEINS

Means and Methods for Influencing the Stability of Cells

PHARMACEUTICAL COMBINATIONS

ANTIBODIES, ANALOGS AND USES THEREOF

IMMUNE RESPONSE MODIFIER FORMULATIONS

METHODS OF TREATING OR PREVENTING INFLAMMATION AND

HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL

WATER SOLUTION

9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE

RECEPTOR (TLR7) MODULATORS

ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS

IP-10 BASED IMMUNOLOGICAL MONITORING

COMPOUNDS

METHODS TO DECREASE THE RISK OF METABOLIC SYNDROME

POST IMMUNIZATION

MEDIMMUNE, INC.

1-Jul05

18ASTRAZENECA

AB

Not Available

Transgenex Nanobiotech, Inc.

CAPLAN MICHAEL J

AstraZeneca Aktiebolag

GUO ZHA

PTC THERAPEUTICS, INC.

AstraZeneca AB

DNA GENOTEK INC.

SAINZ JR BRUNO

AstraZeneca Aktiebolag

Sapporo Medical Univeristy and Japan Science and

Technology Agency

BISHOP KEVIN L

ARGENTA DISCOVERY LTD.

ASTRAZENECA AB

Human Genome Sciences. Inc.

Academisch Medisch Centrum bij de Universiteit van

Amsterdam

GALLAGHER NEIL JAMES

ICB International, Inc.

Graceway Pharmaceuticals, LLC

Oculus Innovative Sciences, Inc.

Not Available

Not Available

Hvidovre Hospital

AstraZeneca AB

CLASSEN JOHN BARTHELOW

Method for rapid identification and quantification of microorganisms The Regents  
of the University of California

COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER

SYSTEM AND METHOD

The Government of the United States of America, as  
represented by the Secretary of the Navy

Jun08

12Oct06

14Jan08  
15Feb07  
20Mar07  
18Oct06  
22Jul-04  
10Oct08  
6Oct06  
26Sep08  
20Mar07  
6Dec06  
14Oct08  
7Feb07  
8Feb07  
9Feb04  
9Dec05  
12Oct06  
22Sep08  
18Jul-06  
20Jan06  
19Mar07  
30Oct05  
5Sep06  
21Feb07  
5Oct06  
23Sep08  
2-Jul04  
30Jun  
-06  
18Jun  
-09  
12Oct  
-07  
16Apr  
-09  
15Feb  
-08  
19Mar  
-08  
16Oct  
-07  
23Dec  
-09  
10Oct  
-09  
5Oct  
-07  
24Sep  
-09  
19Mar  
-08  
6Dec  
-07  
14Oct  
-08



15Apr10  
8Apr10  
8Apr10  
8Apr10  
8Apr10  
8Apr10  
25Mar  
-10  
18Mar  
-10  
29  
US20100070  
194  
US20100069  
614  
US20100069  
427  
US20100068  
223  
US20100063  
126  
US20100062  
441  
US20100061  
995  
US20100061  
961  
US20100056  
508  
US20100056  
383  
US20100055  
761  
US20100055  
116  
US20100048  
584  
US20100048  
575  
US20100048  
472  
US20100047  
282  
US20100047  
277  
US20100047  
264  
US20100047  
179  
US20100042  
394  
US20100041  
638  
US20100041

617

US20100041

013

US20100040

703

US20100040

676

US20100040

655

US20100040

635

US20100035

973

METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF  
NUCLEIC ACID VARIANTS

Antibody producing non-human mammals

Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring  
Compounds and Methods

Storage of Influenza Vaccines Without Refrigeration

Carbazole-Derived Pharmaceutical Compositions

C-MET MUTATIONS AND USES THEREOF

Immunotherapy To Treat Or Prevent Viral Infection

RECOMBINANT SUPER-COMPOUND INTERFERON

AMINE DERIVATIVES AND THEIR USE IN BETA-2ADRENORECEPTOR  
MEDIATED DISEASES

HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS

METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE  
ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL  
TARGETING

Methods and Compositions for Targeting c-Rel

ECKER DAVID J

21Jul-05

27Merus

B.V.

COLEY PHARMACEUTICAL GROUP, INC.

SCHEFFCZIK HANNO

JadoLabs GmbH

SALGIA RAVI

CARRAGHER DAMIAN MICHAEL

WEI GUANGWEN

ASTRAZENECA AB

JONES DAVID E

THE GENERAL HOSPITAL CORPORATION

CHENG SHUHUA

PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS  
INC.

NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE  
PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR  
THERAPEUTIC APPLICATIONS

Albumin Fusion Proteins

METHOD OF ACCELERATED VACCINATION AGAINST EBOLA  
VIRUSES

VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC  
COMPOSITIONS

Immunogenic Affinity-Conjugated Antigen Systems Based on  
Papaya Mosaic Virus and Uses Thereof

TARGETED SPLIT BIOMOLECULAR CONJUGATES FOR THE  
TREATMENT OF DISEASES, MALIGNANCIES AND DISORDERS, AND  
METHODS OF THEIR PRODUCTION

System and Method to Predict the Global Spread of Infectious  
Agents Via Commercial Air Travel

Chemical Compounds 293

Modulating mxa expression

ASSAY FOR A HEALTH STATE

USE OF NITRIC OXIDE

POLYCISTRONIC HIV VECTOR CONSTRUCTS

Anti-viral Formulations Nanomaterials And Nanoparticles

NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES

DISRUPTION OF PROGRAMMED DEATH 1 (PD-1) LIGAND TO

ADJUVANT ADENO-ASSOCIATED VIRUS VECTOR VACCINES

Fauci/COVID-19 Dossier

Jun08

11Feb05

24Mar06

29Jun04

15Mar07

8Sep08

28Aug03

20Dec06

15Nov06

20Jul-06

13Apr06

30Jul-03

30COLLAND

FREDERIC

Oct06

22Human

Genome Sciences, Inc.

The Government of the USA as represented by the  
Secretary of Health and Human Services, NIH

COMPANS RICHARD W

FOLIA BIOTECH INC.

Jan03

2Aug04

13Jul-06

15Nov06

27ST.

JUDE CHILDREN'S RESEARCH HOSPITAL

Oct06

2KHAN

KAMRAN

ANDREWS GLEN

CHUNG EUN J

HUMAN GENETIC SIGNATURES PTY LTD.

MILLER CHRIS

Novartis Vaccines and Diagnostics, Inc.

INTRINSIQ MATERIALS LIMITED

Sea Lane Biotechnologies

Nationwide Children's Hospital, Inc.

Apr07

27May08

27Sep04

14Sep05

13Aug08

5May04

16Feb06

28Mar08

17Jul-06

CC-BY-NC-SA

Dr. David E. Martin

11Nov

-09

29Jun

-09

10Feb

-06

23Mar

-07

29Jun

-05

14Mar

-08

8Sep

-08

4Sep

-09

19Dec

-07

14Nov

-07

20Jul07

13Apr

-07

2Sep

-09

25Oct

-07

20Apr

-09

5Nov

-09

12Jul07

25Oct

-07

26Oct

-07

2Apr

-08

26May

-09

27Sep

-05





18Feb  
-10  
18Feb  
-10  
18Feb  
-10  
18Feb  
-10  
18Feb  
-10  
18Feb  
-10  
11Feb  
-10  
US20100035  
848  
US20100035  
836  
US20100035  
761  
US20100035  
239  
US20100035  
234  
US20100035  
232  
US20100035  
227  
US20100034  
852  
US20100029  
732  
US20100029  
722  
US20100029  
718  
US20100029  
713  
US20100029  
585  
US20100029  
557  
US20100029  
552  
US20100028  
853  
US20100028  
381  
US20100028  
369  
US20100022  
491  
US20100021  
987

US20100021  
907  
US20100021  
895  
US20100021  
470  
US20100016  
388  
US20100016  
359  
US20100015  
633  
US20100015  
607  
US20100015  
594  
10THERAPY  
FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT  
BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC  
AGENTS  
High-throughput rna structure analysis  
Compositions for use in identification of bacteria  
VACCINE ASSAYS  
TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR  
IDENTIFICATION OF PATHOGENS  
Compositions for use in identification of alphaviruses  
METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING  
DRUG RESISTANT STRAINS OF INFLUENZA VIRUS  
Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone  
ORGANIC COMPOUNDS  
ORGANIC COMPOUNDS  
QUINICLIDINE DERIVATIVES OF (HETERO)  
ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR  
ANTAGONISTS  
BARNES THOMAS MICHAEL  
BETHELL RICHARD  
GIDDINGS MORGAN C  
ISIS Pharmaceuticals, Inc.  
Novartis AG  
ECKER DAVID J  
ISIS Pharmaceuticals, Inc.  
NIMAN HENRY L  
ASTRAZENECA AB  
DALES NATALIE  
Novartis AG  
ASTRAZENECA AB  
TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE DIETSCH GREGORY  
ALPHA-LACTALBUMIN COMPOSITION  
Peptide inhibitors of c-jun dimerization and uses thereof  
OPTICAL DETERMINATION OF LIVING VS. NON LIVING CELLS  
GULDMANN MARIANNE  
Phylogica Limited  
Not Available  
FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES

COMPANY

Hazardous substance removing material and method for removing hazardous substance

4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL

COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY

FUJIFILM Corporation

ASTRAZENECA AB

Compositions, Methods, and Kits for Enhancing Protein Expression LIFESENSORS, INC.

METHOD OF DETECTING A PLURALITY OF NUCLEIC ACIDS

Vectors for Inducing Homozygous Mutations and Methods of Using Same

MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS

Salts of a Selective Beta-2 Andrenoceptor Agonist

METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY

METHODS AND KIT FOR ANALYTE DETECTION

NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF

HUMAN PAPIILLOMA VIRUS (HPV) DETECTION USING NUCLEIC ACID

PROBES, MICROBEADS AND FLUORESCENT-ACTIVATED CELL SORTER (FACS)

Fauci/COVID-19 Dossier

KABUSHIKI KAISHA TOSHIBA

RULEY H EARL

INSTITUTE FOR RESEARCH IN BIOMEDICINE

Not Available

Mar08

3-Jul08

5Jun06

11Sep03

19May08

14Sep06

3Mar04

25Jan07

8Feb07

20Dec06

22Sep06

14Nov06

1Aug08

17Nov06

20Aug04

25Oct05

19Jun06

29Jul-08

20Dec06

30Dec04

3-Jul08

12Jul-06

26Feb03

1Mar07

26Masatoshi  
Hagiwara  
Dec03  
GENERAL  
ELECTRIC COMPANY  
INSTITUTE FOR SYSTEMS BIOLOGY  
18Jul-08  
23Dec05  
10GOULD  
TOBY  
CC-BY-NC-SA Dr. David E. Martin  
Dec04  
10Mar  
-09  
1Jul09  
5Jun  
-07  
17Feb  
-05  
19May  
-09  
14Sep  
-07  
2Mar  
-05  
24Jan  
-08  
6Feb  
-08  
19Dec  
-07  
19Sep  
-07  
13Nov  
-07  
31Jul09  
15Nov  
-07  
22Aug  
-05  
2Nov  
-06  
18Jun  
-07  
28Jul09  
19Dec  
-07  
30Dec  
-05  
12Jun  
-09  
12Jul07  
26Feb  
-04

29Feb  
-08  
29Jun  
-09  
18Jul08  
22Dec  
-06  
9Dec  
-05  
11Feb  
-10  
11Feb  
-10  
11Feb  
-10  
11Feb  
-10  
11Feb  
-10  
11Feb  
-10  
11Feb  
-10  
11Feb  
-10  
11Feb  
-10  
4Feb  
-10  
4Feb  
-10  
4Feb  
-10  
4Feb  
-10  
4Feb  
-10  
4Feb  
-10  
4Feb  
-10  
4Feb  
-10  
4Feb  
-10  
4Feb  
-10  
28Jan10  
28Jan10  
28Jan10  
28Jan10  
28Jan10  
21Jan10  
21Jan10  
21Jan10  
21Jan10

21Jan10  
153  
US20100015  
283  
US20100015  
211  
US20100015  
173  
US20100010  
217  
US20100010  
199  
US20100010  
080  
US20100009  
343  
US20100004  
304  
US20100003  
723  
US20100003  
277  
US20100003  
269  
US20090318  
435  
US20090318  
337  
US20090317  
421  
US20090317  
417  
US20090312  
285  
US20090311  
683  
US20090311  
334  
US20090311  
288  
US20090306  
347  
US20090306  
090  
US20090306  
042  
US20090305  
282  
US20090304  
743  
US20090304  
742  
US20090304  
739

US20090304

729

US20090304

683

US20090304

681

Method of Preparing Powder Kimchi and Kimchi Composition Using the Same

Combination Approaches For Generating Immune Responses

COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC

VIRUS-LIKE PARTICLES

METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING

COMPOUNDS

MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS

USE OF TYLVALOSIN AS ANTIVIRAL AGENT

COMPOSITIONS AND METHOD FOR RAPID, REAL-TIME DETECTION

OF INFLUENZA A VIRUS (H1N1) SWINE 2009

METHODS AND COMPOSITIONS FOR THE TREATMENT OF

MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY

THYROID AND PANCREATIC CANCER

RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS

STEAROTHERMOPHILUS

VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED

IL-15 AND METHODS FOR USING THE SAME

METHODS AND USES OF CAULIFLOWER AND COLLARD FOR

RECOMBINANT PROTEIN PRODUCTION

PYRAZOLOPYRIDINES AND ANALOGS THEREOF

Compositions and methods for activating innate and allergic immunity

COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL

BACTERIUM PROTEINS

Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof

BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM

AND METHODS OF USE

COMPOSITIONS FOR THE USE IN IDENTIFICATION OF FUNGI

MUCOSAL IMMUNOGENIC SUBSTANCES COMPRISING A

POLYINOSINIC ACID - POLYCYTIDILIC ACID BASED ADJUVANT

IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS

ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR

PRODUCTION THEREOF

HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA

DESATURASE INHIBITORS

Novel Compounds 010

NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION

AND USES THEREOF

Composition and Methods for Immunisation Using CD1D Ligands

INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION

ADJUVANT

INFLUENZA VACCINES INCLUDING COMBINATIONS OF

PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS

CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL

CELL DNA

Soluble Fragments of The Sars-Cov Spike Glycoprotein

Methods for the treatment and prevention of infection using antiselectin agents

Fauci/COVID-19 Dossier

26Not

Available

BARNETT SUSAN W

UNIVERSITÄT ZÜRICH PROREKTORAT FORSCHUNG

LAN JIONG

NOVARTIS AG

CAMBRIDGE UNIVERSITY TECHNICAL SERVICES

Longhorn Vaccines & Diagnostics, LLC

Jun06

1Nov04

9Dec06

23Mar06

11Sep06

13Jul-06

12Sep06

16GIULLANT

CESIDIO

Mar04

10LAMPSON

BERT C

KUTZLER MICHELE

THOMAS JEFFERSON UNIVERSITY

BONK JASON D

ID Biomedical Corporation of Quebec

BURTS MONICA

The Trustees of the University of Pennsylvania

Longhorn Vaccines & Diagnostics, LLC

IBIS BIOSCIENCES, INC.

LI LIE TAO VICTOR

Novartis AG

JAPAN SCIENCE AND TECHNOLOGY AGENCY

Xenon Pharmaceuticals Inc.

CAGE PETER ALAN

CHAN KWOK HUNG

GALLI GRAZIA

Novartis Vaccines and Diagnostics SRL

NOVARTIS VACCINES AND DIAGNOSTICS SRL

NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG

DIMITROV DIMITER S

Not Available

CC-BY-NC-SA Dr. David E. Martin

Mar04

13Jan06

11Jul-06

30ct03

220ct03

18Jan06

28Apr06

10ct07

6Apr06

13Jan06



23Mar06  
29Aug05  
20Sep04  
12Dec07  
21Jul-04  
15Mar06  
4Nov05  
4Nov05  
1Nov05  
19Jan07  
29Jul-04  
26Jun  
-07  
1Nov  
-05  
6Dec  
-07  
23Mar  
-07  
11Sep  
-07  
13Jul07  
28Jul09  
10ct  
-08  
10Mar  
-04  
12Jan  
-07  
28Jun  
-07  
8Jun  
-09  
22Oct  
-04  
18Jan  
-07  
27Apr  
-07  
10ct  
-08  
6Apr  
-07  
27Jun  
-06  
23Mar  
-07  
29Aug  
-06  
13Aug  
-09  
10Dec  
-08  
1Jun



10Dec  
-09

10Dec  
-09

10Dec  
-09

US20090304

630

US20090300

778

US20090299

250

US20090298

914

US20090298

821

US20090298

807

US20090297

555

US20090286

835

US20090286

813

US20090286

726

US20090286

222

US20090285

921

US20090285

901

US20090285

854

US20090281

042

US20090281

041

16Treating

severe and acute viral infections

Neutral Sphingomyelinase-E and Its Use

ANTIVIRAL FILTER AND ITS USE IN AN AIR PURIFIER, AIR  
CONDITIONER OR AIR HUMIDIFIER

RNA Interference Mediated Inhibition of Severe Acute Respiratory  
Syndrome (SARS) Virus Gene Expression Using Short Interfering  
Nucleic Acid (siNA)

HYDROXY AND ALKOXY SUBSTITUTED IHIMIDAZONAPHTHYRIDINES  
AND METHODS

Compounds

RECOMBINANT HUMAN CYTOMEGALOVIRUS AND VACCINES  
COMPRISING HETEROLOGOUS ANTIGENS

NOVEL COMPOUNDS

Thioxanthine Derivatives and Their Use as Inhibitors of MPO  
USE OF THE LONG PENTRAXIN PTX3 FOR THE PREVENTION OR

TREATMENT OF VIRAL DISEASES

Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes  
And Enteric Viruses

PLANT EXTRACT AND ITS THERAPEUTIC USE

Polyamino acid for use as adjuvant

FROZEN STOCKPILING OF INFLUENZA VACCINES

COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION  
OF VIRUSES

ANTIVIRAL CELL-PENETRATING PEPTIDES

US20090280

507

METHOD FOR MEASUREMENT OF SARS VIRUS NUCLEOCAPSID  
PROTEIN, REAGENT KIT FOR THE MEASUREMENT, TEST DEVICE,  
MONOCLONAL ANTIBODY DIRECTED AGAINST SARS VIRUS  
NUCLEOCAPSID PROTEIN, AND HYBRIDOMA CAPABLE OF  
PRODUCING THE MONOCLONAL ANTIBODY

US20090275

666

US20090275

583

US20090275

508

US20090275

016

US20090270

443

US20090270

431

US20090269

367

US20090264

653

US20090264

509

US20090264

444

CONDENSATION PRODUCTS, METHOD FOR THEIR PRODUCTION  
AND USE THEREOF IN MEDICAMENTS, AS DISINFECTANTS OR AS A  
TANNIN

ANTIVIRAL COMPOUNDS AND USE THEREOF

USE OF THYMOSIN ALPHA 1, ALONE OR IN COMBINATION WITH  
PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF  
CYTOMEGALOVIRUS INFECTION

ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA  
IMMUNE RESPONSE

1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS

Cyclopentenol Nucleoside Compounds Intermediates for their  
Synthesis and Methods of Treating Viral Infections

METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC  
OUTBREAKS USING REPLIKIN COUNT CYCLES

USEFUL INDOLE COMPOUNDS

Adenoviral vector-based foot-and-mouth disease vaccine

Organic compounds

Fauci/COVID-19 Dossier

HEMISPHERx BIOPHARMA  
HOPPE UTA  
Universite De Rouen  
Sirna Therapeutics, Inc.  
Pfizer Inc.  
ALCARAZ LILIAN  
MEDIMMUNE, LLC  
AstraZeneca AB  
ASTRAZENECA AB  
TECNOGEN S.P.A.  
GOODRUM PATRICIA GAIL RAY  
Veritron Limited  
AKASHI MITSURU  
Novartis AG  
ARAD DORIT  
CURRELI FRANCESCA  
May03  
8Feb06  
19Jul-06  
15Apr03  
15Mar06  
6Feb08  
25Jun04  
4Oct07  
13Apr06  
10Mar06  
24Apr98  
16May08  
20Apr05  
20Jul-06  
8Sep05  
6May08  
11SYSMEX  
CORPORATION  
Oct05  
2Aug  
-07  
8Feb  
-07  
19Jul07  
17Nov  
-08  
14Mar  
-07  
4Feb  
-09  
30Jun  
-09  
30ct  
-08  
12Apr  
-07  
28Feb  
-07

16Oct  
-08  
1Dec  
-08  
27Jul09  
20Jul07  
10Sep  
-06  
5May  
-09  
11Oct  
-06  
10Dec  
-09  
3Dec  
-09  
3Dec  
-09  
3Dec  
-09  
3Dec  
-09  
3Dec  
-09  
3Dec  
-09  
19Nov  
-09  
19Nov  
-09  
19Nov  
-09  
19Nov  
-09  
19Nov  
-09  
19Nov  
-09  
19Nov  
-09  
19Nov  
-09  
12Nov  
-09  
12Nov  
-09  
12Nov  
-09  
17BASF  
SE

Myriad Genetics, Incorporated  
SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.  
UNIVERSITY OF ROCHESTER  
Not Available  
THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION  
BOGOCH ELENORE S

BARDEN TIMOTHY  
GENVEC, INC.  
CHOWDHURY SULTAN  
CC-BY-NC-SA Dr. David E. Martin

May06

13Oct06

2May06

2May08

2Sep04

19Oct05

23Apr08

16Dec05

10Nov05

20Feb08

28Feb

-07

13Apr

-09

12Apr

-07

1May

-09

2Sep

-05

19Oct

-06

23Apr

-09

18Dec

-06

8May

-08

20Feb

-09

5Nov

-09

5Nov

-09

5Nov

-09

5Nov

-09

29Oct09

29Oct09

29Oct09

22Oct09

22Oct09

22Oct09

155

US20090264

362

US20090264

307

US20090264

300  
US20090263  
352  
US20090258  
440  
US20090258  
340  
US20090258  
074  
US20090258  
011  
US20090257  
950  
US20090253  
714  
US20090253  
695  
US20090252  
775  
US20090252  
646  
US20090247  
614  
US20090247  
608  
US20090239  
848  
US20090239  
830  
US20090239  
824  
US20090239  
814  
US20090239  
810  
US20090235  
625  
US20090233  
965  
US20090233  
907  
US20090233  
309  
US20090232  
844  
US20090232  
843  
US20090232  
808  
US20090232  
748  
US20090227  
637  
4Influenza



virus inhibiting peptides  
ARRAY-BASED POLYMORPHISM MAPPING AT SINGLE NUCLEOTIDE  
RESOLUTION  
ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF  
LARGE LIBRARIES  
METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL29  
CYSTEINE MUTANTS  
SURFACE FOR LABEL INDEPENDENT DETECTION AND METHOD  
THEREOF  
Assay for SARS coronavirus by amplification and detection of the  
replicase sequence  
MIXTURES OF TANNINS, THEIR PRODUCTION AND USE IN  
MEDICAMENTS OR AS DISINFECTANTS  
Antibodies against west nile virus and therapeutic and prophylactic  
uses thereof  
Membrane Scaffold Proteins  
Methods of reducing risk of infection from pathogens  
Hydroxyalkyl Substituted Imidazonaphthyridines  
VIRUCIDAL DISINFECTANT  
The Administrators of the Tulane Educational Fund  
The Trustees of Princeton University  
Nuevolution A/S  
ZymoGenetics, LLC  
BUNCH THOMAS A  
Becton, Dickinson and Company  
BASF SE  
Washington University  
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF  
ILLINOIS  
Not Available  
Coley Pharmaceutical Group, Inc,  
B. BRAUN MEDICAL AG  
STERILIZATION METHODS AND SYSTEMS FOR GAMING EQUIPMENT Invention Factory, LLC  
Folate Conjugates  
Targeting Lipids  
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA  
DESATURASE  
Treatment of viral infections by modulation of host cell metabolic  
pathways  
HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS  
AND METHODS OF USE  
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides  
NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA  
DESATURASE  
FILTER AND ASSOCIATED METHOD  
Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor  
Antagonist Activity, Useful For Treating E.G. Chronic Bronchial  
Obstruction, Asthma And Overactive Bladder  
Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors  
BIOLOGICAL SPECIMEN COLLECTION/TRANSPORT COMPOSITIONS  
AND METHODS  
IMMUNOPOTENTIATING COMPOUNDS  
Identifying and predicting influenza variants and uses thereof  
MOLECULES AND CHIMERIC MOLECULES THEREOF

Virucidal activities of cetylpyridinium chloride  
DIARYL UREAS FOR TREATING VIRUS INFECTIONS

ALNYLAM PHARMACEUTICALS, INC.

ALNYLAM PHARMACEUTICALS, INC.

FOREST LABORATORIES HOLDINGS LIMITED

BENNETT BRYSON

Anacor Pharmaceuticals, Inc.

ALNYLAM PHARMACEUTICALS, INC.

Forest Laboratories Holdings Limited

GENERAL ELECTRIC COMPANY

Nov03

13Jan06

1Dec05

2Apr04

10Apr08

12Sep03

17May06

21Jun04

20Nov00

20Aug03

23Feb05

28Jan05

8Jan07

4Dec07

4Dec07

20Mar08

1Jun07

16Jun03

4Dec07

20Mar08

28Sep07

24ASTRAZENECA

AB

Apr06

22ASTRAZENECA

AB

LONGHORN VACCINES & DIAGNOSTICS, LLC

SUTTON JAMES

NIMAN HENRY L

APOLLO LIFE SCIENCES LIMITED

ViraTox, L.L.C.

RIEDL BERND

Mar06

10Oct07

23Mar06

8-Jul05

28Jan05

7Nov03

15Dec05

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

17Feb

-09

12Jan  
-07  
1Dec  
-06  
21May  
-09  
3Apr  
-09  
3Feb  
-09  
28Feb  
-07  
6Apr  
-09  
10Oct  
-07  
18Aug  
-04  
22Feb  
-06  
28May  
-09  
28May  
-09  
4Dec  
-08  
4Dec  
-08  
20Mar  
-09  
2Jun  
-08  
13Nov  
-08  
4Dec  
-08  
20Mar  
-09  
28Sep  
-07  
23Apr  
-07  
20Mar  
-07  
20Apr  
-09  
23Mar  
-07  
4Jan  
-08  
27Jan  
-06  
18Mar  
-09

6Dec  
-06  
156  
22Oct09  
22Oct09  
22Oct09  
22Oct09  
15Oct09  
15Oct09  
15Oct09  
15Oct09  
15Oct09  
8Oct09  
8Oct09  
8Oct09  
8Oct09  
10Oct09  
10Oct09  
24Sep  
-09  
24Sep  
-09  
24Sep  
-09  
24Sep  
-09  
24Sep  
-09  
24Sep  
-09  
17Sep  
-09  
17Sep  
-09  
17Sep  
-09  
17Sep  
-09  
17Sep  
-09  
17Sep  
-09  
17Sep  
-09  
17Sep  
-09  
10Sep  
-09  
US20090227  
541  
US20090227  
030  
US20090227  
005  
US20090226  
885

US20090222  
936  
US20090221  
653  
US20090221  
640  
US20090221  
631  
US20090221  
624  
US20090221  
583  
US20090221  
556  
US20090221  
551  
US20090221  
487  
US20090220  
941  
US20090220  
937  
US20090220  
547  
US20090220  
546  
US20090220  
545  
US20090220  
544  
US20090220  
541  
US20090220  
530  
US20090220  
514  
US20090220  
456  
US20090216  
860  
US20090216  
747  
US20090215  
786  
US20090214  
663  
US20090214  
590

20BORON-CONTAINING  
SMALL MOLECULES

Adeno-associated virus (AAV) serotype 8 sequences, vectors  
containing same, and uses therefor

Methods for pathogen detection

Nucleic Acid Sequences That Can Be Used As Primers And Probes In

The Amplification And Detection Of Sars Coronavirus  
Anacor Pharmaceuticals, Inc.  
The Trustees of the University of Pennsylvania  
Searete LLC, a limited liability corporation of the State of  
Delaware

OVERDIJK MARLIEKE

Recombinant Expression of Multiprotein Complexes Using Polygenes BERGER IMRE  
7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-onederivatives  
as beta2 adrenoreceptor agonists

Novel Crystal Modifications

IMIDAZOPYRIDINONES

4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED  
CONDITIONS

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYLCoA  
DESATURASE

HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES  
AND METHODS

SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND  
METHODS

POLYETHLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1  
COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND  
KITS AND METHODS USING SAME

Compositions for Use in Identification of Adventitious Viruses  
Reducing interference between oil-containing adjuvants and  
surfactant-containing antigens

Adjuvanted influenza vaccines for pediatric use

Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen

ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED  
FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE

EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR  
ADJUVANTING SPLIT INFLUENZA VACCINES

DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND  
METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE

ADAM10 and its Uses Related to Infection

USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE

SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,  
AND COMMUNICATING EVENT RELATED INFORMATION

System and method for detecting, collecting, analyzing, and  
communicating event-related information

NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC  
APPLICATIONS

Virus coated nanoparticles and uses thereof

Virus Vaccines Comprising Envelope-Bound Immunomodulatory  
Proteins and Methods of Use Thereof

AstraZeneca AB

ASTRAZENECA AB

Not Available

BUSCHER BENJAMIN A

AURIGENE DISCOVERY TECHNOLOGIES LIMITED

Pfizer Inc.

Pfizer Inc.

Institute of Pharmacology and Toxicology Academy of  
Military Medical Sciences P.L.A. China

MND DIAGNOSTIC LTD

IBIS BIOSCIENCES, INC.  
NOVARTIS VACCINES AND DIAGNOSTICS SRL  
GROTH NICOLA  
NOVARTIS AG  
NOVARTIS VACCINES AND DIAGNOSTICS SRL  
NOVARTIS VACCINES AND DIAGNOSTICS SRL  
HU HONG-MING  
HODGE THOMAS  
Not Available  
Georgetown University  
Georgetown University- OTC  
BOISSY GUILLAUME  
ALBRECHT THOMAS B  
Wayne State University  
Jun07  
17Dec01  
27Mar07  
10Jun03  
8Nov05  
29Aug05  
16Mar06  
3Aug07  
6May05  
21Jun07  
4Nov05  
15Mar06  
10Nov05  
25Oct05  
3Mar05  
2Aug05  
22Feb08  
15Jun06  
4Nov05  
4Nov05  
29Jul-05  
13Jan06  
28Aug03  
25Feb08  
25Feb08  
5Aug05  
26Sep06  
8-Jul05  
19Jun  
-08  
31Oct  
-07  
28Sep  
-07  
8Mar  
-04  
6Nov  
-06  
28Aug  
-06

15Mar  
-07  
15May  
-09  
4May  
-06  
23Jun  
-08  
3Nov  
-06  
14Mar  
-07  
11Nov  
-06  
25Oct  
-06  
3Mar  
-06  
2Aug  
-06  
20Feb  
-09  
15Jun  
-07  
6Nov  
-06  
6Nov  
-06  
27Jul06  
16Jan  
-07  
11Feb  
-09  
19Nov  
-08  
28Aug  
-08  
26Jul06  
26Mar  
-09  
10Jul06  
10Sep  
-09  
10Sep  
-09  
10Sep  
-09  
10Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep



-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
3Sep  
-09  
27Aug  
-09  
27Aug  
-09  
27Aug  
-09  
27Aug  
-09  
27Aug  
-09  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
157  
  US20090214  
587  
US20090214  
537  
US20090214  
533  
US20090214

510  
US20090214  
444  
US20090209  
640  
US20090209  
555  
US20090209  
524  
US20090209  
505  
US20090209  
458  
US20090208  
531  
US20090205  
116  
US20090203  
753  
US20090203  
675  
US20090203  
112  
US20090202  
995  
US20090202  
590  
US20090197  
914  
US20090197  
894  
US20090197  
890  
US20090197  
338  
US20090196  
921  
US20090192  
505  
US20090192  
163  
US20090192  
153  
US20090192  
099  
US20090192  
090  
US20090192  
081

8Recombinant

virus and use thereof

Serum Resistance Factors of Gram Positive Bacteria

METHODS FOR CONVERTING OR INDUCING PROTECTIVE IMMUNITY

Broad Spectrum Antiviral Compositions

POLY AROMATIC SODIUM CHANNEL BLOCKERS

Prevention of and countermeasures against viral infection

2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR  
CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE  
ACTIVITY IS BENEFICIAL

Novel Compounds

PRODRUGS OF HETEROARYL COMPOUNDS

Cell-penetrating socs polypeptides that inhibit cytokine-induced  
signaling

ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA

ARTICLE, LAMINATE AND ASSOCIATED METHODS

7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-onederivatives  
as beta2 adrenoreceptor agonists

Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical  
Compositions Thereof, and Methods for Treating Hemorrhagic Fever  
Viruses, Including Infections Associated with Arena Viruses

Post Genome Institute Co., Ltd.

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF  
NEW YORK

Government of the US as represented by the Secretary,  
Department of Health and Human Services

PARION SCIENCES, Inc.

CHOKO CO., LTD.

HANSEN PETER

AstraZeneca AB

Koronis Pharmaceuticals, Incorporated

VANDERBILT UNIVERSITY

National Institutes of Health Office of Technology

GENERAL ELECTRIC COMPANY

AstraZeneca AB

Oct04

13May05

17Aug06

21Feb06

26Feb08

20Nov03

8May06

22Nov07

20Jun03

4Mar04

16Feb06

30Sep05

29Aug05

6SIGA

TECHNOLOGIES, INC.

Dec04

4VERO

CELL LINE WHICH IS ADAPTED TO GROW IN SUSPENSION Ricardo Kratje

MOLECULAR CARDIOTOXICOLOGY MODELING

INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO

ALUMINIUM ADJUVANTS

Piperidine Derivatives, Their Process for Preparation, Their Use as  
Therapeutic Agents and Pharmaceutical Compositions Containing

Them

NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

Method of Increasing the Function of an AAV Vector  
Compositions Methods and Kits For Enhancing Immune Response To  
A Respiratory Condition

Method for cryospray ablation

Novel Compounds

NOVEL ADENINE COMPOUND

PRODRUGS OF HETEROARYL COMPOUNDS

PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING,  
ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY

Casein derived peptides and uses thereof

Fauci/COVID-19 Dossier

JOHNSON KORY R

NOVARTIS VACCINES AND DIGNOSTICS SRL

CAGE PETER

XENON PHARMACEUTICALS INC.

XENON PHARMACEUTICALS INC.

The Trustees of teh University of Pennsylvania

The Procter & Gamble Company

Reset Medical, Inc.

ASTRAZENECA AB

AstraZeneca Aktiebolag A corporation of Sweden

Koronis Pharmaceuticals, Incorporated

TAKEDA PHARMACEUTICAL COMPANY LIMITED

SIDELMAN ZVI

CC-BY-NC-SA Dr. David E. Martin

Oct05

26Aug05

4Nov05

7Mar06

21Dec01

30Jul-03

7Apr05

6Feb08

5Dec07

6Oct05

22Sep05

20Jun03

25Jun03

1Mar00

11Oct

-05

12May

-06

17Feb

-09

21Feb

-07

26Feb

-09

15Apr  
-09  
7May  
-07  
20Nov  
-08  
7Apr  
-09  
4Mar  
-05  
16Feb  
-07  
5Dec  
-08  
28Aug  
-06  
6Dec  
-05  
30ct  
-06  
28Aug  
-06  
6Nov  
-06  
6Mar  
-07  
14Apr  
-09  
20Feb  
-09  
7Apr  
-06  
6Feb  
-09  
5Dec  
-08  
5Oct  
-06  
21Sep  
-06  
30Mar  
-09  
31Dec  
-08  
31Oct  
-07  
158  
27Aug  
-09  
27Aug  
-09  
27Aug  
-09  
27Aug

-09  
27Aug  
-09  
20Aug  
-09  
20Aug  
-09  
20Aug  
-09  
20Aug  
-09  
20Aug  
-09  
20Aug  
-09  
13Aug  
-09  
13Aug  
-09  
13Aug  
-09  
13Aug  
-09  
13Aug  
-09  
6Aug  
-09  
6Aug  
-09  
6Aug  
-09  
6Aug  
-09  
6Aug  
-09  
30Jul09  
30Jul09  
30Jul09  
30Jul09  
30Jul09  
30Jul09  
US20090191  
229  
US20090186  
056  
US20090186  
041  
US20090186  
025  
US20090186  
014  
US20090182

133  
US20090181  
972  
US20090181  
361  
US20090176  
821  
US20090176  
815  
US20090176  
699  
US20090175  
948  
US20090175  
902  
US20090170  
717  
US20090169  
636  
US20090163  
533  
US20090163  
518  
US20090162  
831  
US20090162  
392  
US20090162  
365  
US20090162  
320  
US20090155  
564  
US20090149  
475  
US20090149  
448  
US20090149  
429  
US20090131  
486  
US20090131  
459

ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF  
NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS  
15NEW

YORK BLOOD CENTER

COMPOSITIONS AND METHODS FOR PREVENTING INFECTION  
ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF  
VIRAL INFECTIONS

Fusion Protein Comprising an Fc Receptor Binding Polypeptide and  
an Antigenic Polypeptide for Mediating an Immune Response

METHOD FOR TREATMENT OF PANCREATITIS

BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL

## AGENTS

Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications

Rapid test for detecting infection

Amide and Carbamate Derivatives of Alkyl Substituted

N-[4-(4Amino-1H-Imidazo[4,5-C]

Quinolin-1YL)Butyl]Methanesulfonamides

and Methods

Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity

Inhibitors Based on Fusion, Hr1 and Hr2 Sequences in Bacterial Adhesin

AEROSOL METHOD FOR NANO SILVER-SILICA COMPOSITE ANTIMICROBIAL AGENT

Immunogenic Substances Comprising A Polyinosinic AcidPolycytidilic Acid Based Adjuvant

RE-SEQUENCING PATHOGEN MICROARRAY

Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions

1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases

Novel Compounds

HUMAN PARVOVIRUS

MUTANT FORMS OF STREPTOLYSIN O

Novel siRNAs and methods of use thereof

GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING

LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA

VIRUS SPIKE PROTEIN

ARTICLE AND ASSOCIATED METHOD

Thioxanthine Derivatives and Their Use as Inhibitors of MPO

Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases

ANTIVIRAL COMPOUNDS

2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL

2-Thioxanthine Derivatives Acting as MPO-Inhibitors

LA JOLLA BIOSCIENCES LLC

Functional Genetics, Inc.

ImmunoBiology Limited

Ore Pharmaceuticals Inc.

Shanghai Institute of Materia Medica Chinese Academy of Sciences

BOISSY GUILLAUNE

KUMAR ARUN

Jun04

8Aug02

15Nov06

22Mar06

10Oct07

29Dec05

8Dec05

14Jan08



9COLEY  
PHARMACEUTICAL GROUP, INC.  
Sep05  
ERIKSSON  
TOMAS  
CHIRON SRL  
BRINKER C JEFFREY  
Not Available  
The Government of the United States of America, as  
represented by the Secretary of the Air Force  
Not Available  
COLEY PHARMACEUTICAL GROUP, INC.  
BONNERT ROGER  
DELWART ERIC L  
NOVARTIS AG  
FEINSTEIN ELENA  
19Jul-06  
6-Jul04  
30Nov07  
13Jan06  
2-Jul04  
24Feb06  
1Apr05  
27May03  
24May04  
21Dec07  
25Oct06  
28Dनावेक  
Corporation  
Oct05  
28GENERAL  
ELECTRIC COMPANY  
ASTRAZENECA AB  
ASTRAZENECA AB  
Myriad Genetics, Incorporated  
HANSEN PETER  
ASTRAZENECA AB  
Sep07  
13Apr06  
23Nov04  
22Jun05  
8May06  
5Jun06  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
23Mar  
-09  
19Mar  
-09  
18Apr  
-08  
22Mar  
-07

9Oct  
-08  
15Dec  
-06  
5Dec  
-06  
14Jan  
-08  
8Sep  
-06  
16Jan  
-09  
6Jul05  
26Nov  
-08  
27Jun  
-06  
10Apr  
-08  
24Feb  
-07  
31Mar  
-06  
4Mar  
-09  
24May  
-05  
19Dec  
-08  
25Oct  
-07  
27Oct  
-06  
28Sep  
-07  
12Apr  
-07  
22Nov  
-05  
22Jun  
-06  
7May  
-07  
4Jun  
-07  
30Jul09  
23Jul09  
23Jul09  
23Jul09  
23Jul09  
16Jul09  
16Jul09  
16Jul09  
9Jul09

9Jul09  
9Jul09  
9Jul09  
9Jul09  
2Jul09  
2Jul09  
25Jun09  
25Jun09  
25Jun09  
25Jun09  
25Jun09  
25Jun09  
18Jun09  
11Jun09  
11Jun09  
11Jun09  
21May  
-09  
21May  
-09  
159  
US20090131  
328  
US20090130  
146  
US20090130  
138  
US20090126  
514  
US20090124  
843  
US20090124  
652  
US20090124  
640  
US20090124  
611  
US20090124  
596  
US20090124  
512  
US20090123  
494  
US20090123  
460  
US20090123  
417  
US20090118  
503  
US20090118  
288  
US20090118  
263  
US20090117

537

US20090117

367

US20090117

123

US20090117

115

US20090117

113

US20090111

828

US20090111

091

US20090105

295

US20090105

212

US20090105

203

US20090105

151

US20090105

092

US20090104

226

FURIN INHIBITORS

SMITH JUDITH

COMBINATION VACCINE

Antiviral and antibacterial activity from medicinal mushrooms

Devices for collection and preparation of biological agents

HAZARDOUS SUBSTANCE REMOVING METHOD, HAZARDOUS

SUBSTANCE REMOVING MATERIAL USED THEREIN SUCH AS AIR

FILTER, MASK, WIPE SHEET, AND THE LIKE, AND STORAGE

METHOD THEREOF

Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5C][1,5]Naphthyridin-4-Amine

Ethane-Sulfonate

Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase

Inhibitor

Pyrazolopyridine-1,4-Diamines and Analogs Thereof

Chemical Compounds 637

DNA ARRAY ANALYSIS AS A DIAGNOSTIC FOR CURRENT AND

EMERGING STRAINS OF INFLUENZA

MOMLV-BASED PSEUDOVIRION PACKAGING CELL LINE

IMMUNOSTIMULATORY COMBINATIONS

RECOMBINANT SUPER-COMPOUND INTERFERON AND USES

THEREOF

FAAH INHIBITORS

N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine

Receptor

Novel Adenine Compound

METHOD FOR DETECTING SARS CORONAVIRUS

ARTICLE AND ASSOCIATED METHOD

IMMUNOPEPTIDES OF HPV E6 AND E7 PROTEINS

Binary epitope antibodies and B cell superantigen immune

stimulants  
Immunogenic And Therapeutic Compositions For Streptococcus  
Pyogenes  
L-ALANINE DERIVATIVES  
SPECIMEN PRETREATMENT LIQUID, KIT FOR MEASURING VIRUS,  
AND METHOD FOR DETECTING VIRUS  
HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES  
NOVEL ADENINE COMPOUND  
COMPOUNDS FOR TREATING VIRAL INFECTIONS  
AMPHIPATHIC ALPHA-HELICAL PEPTIDE COMPOSITIONS AS  
ANTIVIRAL AGENTS  
VIRAL DATABASE METHODS  
Alphavirus Vectors for Respiratory Pathogen Vaccines  
CHIRON BEHRING GMBH & CO. KG  
STAMETS PAUL EDWARD  
BELGRADER PHIL  
23Jul-04  
8Oct04  
6Jan04  
5Sep07  
28Not  
Available  
Mar03  
30Takeda  
Pharmaceutical Company Limited  
ASTRAZENECA AB  
Coley Pharmaceutical Group, Inc.  
BONNERT ROGER VICTOR  
REGENTS OF THE UNIVERSITY OF COLORADO  
FLICK RAMON  
3M Innovative Properties Company  
WEI GUANGWEN  
Not Available  
ASTRAZENECA AB  
ASTRAZENECA AKTIEBOLAG  
EIKEN KAGAKU KABUSHIKI KAISHA  
GENERAL ELECTRIC COMPANY  
National Health Research Institutes  
NISHIYAMA YASUHIRO  
Chiron Corporation  
ASTRAZENECA AB  
SYSMEX CORPORATION  
Coley Pharmaceutical Group, Inc.  
AstraZeneca Aktiebolag a corporation of Sweden  
Myriad Genetics, Incorporated  
CHEONG KWANG HO  
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF  
NEW YORK  
NOVARTIS VACCINES AND DIAGNOSTICS INC.  
Dec04  
5Jun06  
1Apr05  
11Jan07  
18Jan06

31Jul-07  
30Dec02  
28Feb01  
20Jun07  
21Jul-05  
22Sep05  
27Jun03  
28Sep07  
2Nov07  
9Nov06  
8Oct04  
23Nov05  
31Oct07  
14Nov03  
22Sep05  
16Oct06  
19Jul-07  
28Nov06  
21May04  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
22Jul05  
7Oct  
-05  
24Sep  
-08  
5Sep  
-07  
21Nov  
-08  
28Dec  
-05  
4Jun  
-07  
31Mar  
-06  
10Jan  
-08  
18Jan  
-07  
31Jul08  
17Mar  
-08  
6Oct  
-08  
20Jun  
-08  
19Jul06  
20Sep  
-06  
10Jun  
-08  
28Sep

-07  
23Sep  
-08  
9Nov  
-07  
11Oct  
-05  
22Nov  
-06  
31Oct  
-08  
12Nov  
-04  
22Sep  
-06  
16Oct  
-07  
14Jul08  
27Nov  
-07  
20May  
-05  
May  
-09  
21May  
-09  
21May  
-09  
21May  
-09  
14May  
-09  
14May  
-09  
14May  
-09  
14May  
-09  
14May  
-09  
14May  
-09  
14May  
-09  
14May  
-09  
14May  
-09  
14May  
-09  
7May  
-09  
7May  
-09  
7May  
-09

7May  
-09  
7May  
-09  
7May  
-09  
7May  
-09  
7May  
-09  
30Apr09  
30Apr09  
23Apr09  
23Apr09  
23Apr09  
23Apr09  
23Apr09  
23Apr09  
160  
21  
US20090104  
209  
US20090104  
147  
US20090099  
216  
US20090099  
161  
US20090099  
156  
US20090099  
110  
US20090099  
043  
US20090098  
530  
US20090098  
207  
US20090092  
962  
US20090092  
633  
US20090092  
581  
US20090083  
865  
US20090082  
547  
US20090082  
332  
US20090082  
287  
US20090081  
675



US20090081

252

US20090081

157

US20090078

263

US20090076

076

US20090075

980

US20090074

810

US20090069

314

US20090068

759

US20090068

665

US20090068

636

US20090068

142

US20090068

095

METHODS OF REDUCING A VIRAL INFECTION AND KITS

THEREFORE

21LABONTE

PATRICK

Sialoadhesin-Related Compositions and Methods

NOVEL ADENINE COMPOUND

Substituted Imidazoquinolines and Imidazonaphthyridines

Heterocyclic Compounds as Ccr2b antagonists

Antiviral oligonucleotides

Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions

Cell Line For Producing Coronaviruses

Technology for the Preparation of Microparticles

METHOD FOR DETECTING SARS CORONAVIRUS

Polyamino acid for use as adjuvant

Interferons of rhesus and cynomolgus origin and uses thereof

DELPUTTE PETER

AstraZeneca Aktiebolag A corporation of Sweden

Coley Pharmaceutial Group, Inc.

BOWER JUSTIN FAIRFIELD

JUTEAU JEAN-MARC

ZHU YORK YUAN YUAN

CRUCCELL HOLLAND B.V.

NexBio, Inc.

EIKEN KAGAKU KABUSHIKI KAISHA

AKASHI MITSURU

CLARK WILLIAM A

Transgenic Mouse Lines Expressing Human Ace2 and Uses Thereof CHAN TEH-SHENG

COMPOSITIONS FOR ENHANCING TRANSPORT OF MOLECULES INTO

CELLS

PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC  
DISEASES AND CANCERS

METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL  
CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS  
AND OSMOLYTES

METHODS, COMPOUNDS AND SYSTEMS FOR DETECTING A  
MICROORGANISM IN A SAMPLE

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH  
INFLUENZA VACCINES

Immunostimulatory Combinations for Vaccine Adjuvants  
Hazardous substance removing method, hazardous substance  
removing material used therein such as air filter, mask, wipe sheet,  
and the like, and storage method thereof

INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE  
THEREOF

Pyrazolopyridines and Analogs Thereof

Modified Adenovirus Hexon Protein and Uses Thereof

IVERSEN PATRICK L

ABBOT PHILIP

PARION SCIENCES, INC.

COLSTON JR BILL W

CHIRON BEHRING GMBH & CO.

Not Available

Sep07

11May06

22Sep05

11Feb05

24Dec04

13Sep02

23Jul-07

22Jul-05

24Jul-07

27Jun03

20Apr05

11Apr07

11Jan06

29Apr03

22Sep05

7Sep06

24Aug07

9Sep04

9Jan06

28ARAJ

JUN-ICHIRO

Mar03

13Baylor

University

Coley Pharmaceutical Group, Inc.

The Trustees of the University of Pennsylvania

Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods Coley  
Pharmaceutical Group, Inc.

REUSABLE DETECTION SURFACES AND METHODS OF USING SAME BioScale, Inc.

METHODS AND KITS FOR IDENTIFYING TARGET NUCLEOTIDES IN

MIXED POPULATIONS

VIRAL PROTEIN  
COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS  
INFECTION AND SARS  
CARBONIC ANHYDRASE IX (G250) ANITBODIES AND METHODS OF  
USE THEREOF

Fauci/COVID-19 Dossier  
APPLIED BIOSYSTEMS INC.

CHANG MING-FU  
Three Rivers Pharmaceuticals LLC

LO AGNES  
CC-BY-NC-SA Dr. David E. Martin

Jun07

30Oct03

28Apr06

23Feb05

6Sep07

30Apr04

2Mar04

1Apr03

2Dec05

19Sep

-08

11May

-07

22Sep

-06

10Feb

-06

19Dec

-05

28Feb

-08

21Nov

-08

21Jul06

24Jul08

10Jun

-08

19Apr

-06

11Apr

-08

11Jan

-07

5Nov

-08

20Sep

-06

7Sep

-07

21Aug

-08

9Sep

-05

9Jan  
-07  
21Nov  
-08  
13Jun  
-08  
31Mar  
-06  
27Apr  
-07  
22Feb  
-06  
5Sep  
-08  
31Jul08  
19Sep  
-07  
29Jul08  
4Dec  
-06  
161  
23Apr09  
23Apr09  
16Apr09  
16Apr09  
16Apr09  
16Apr09  
16Apr09  
16Apr09  
16Apr09  
9Apr09  
9Apr09  
9Apr09  
26Mar  
-09  
26Mar  
-09  
26Mar  
-09  
26Mar  
-09  
26Mar  
-09  
26Mar  
-09  
26Mar  
-09  
26Mar  
-09  
19Mar  
-09  
19Mar  
-09  
19Mar

-09  
12Mar  
-09  
12Mar  
-09  
12Mar  
-09  
12Mar  
-09  
12Mar  
-09  
12Mar  
-09  
US20090062  
328  
US20090062  
272  
US20090062  
259  
US20090062  
229  
US20090061  
027  
US20090061  
017  
US20090060  
950  
US20090054  
413  
US20090054  
342  
US20090053  
708  
US20090053  
299  
US20090053  
257  
US20090053  
248  
US20090047  
665  
US20090047  
353  
US20090047  
306  
US20090047  
272  
US20090042  
942  
US20090042  
925  
US20090042  
858  
US20090042

827

US20090042

292

US20090042

274

US20090042

252

US20090041

818

US20090041

803

US20090041

781

US20090036

653

US20090036

535

Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring  
Compounds and Methods

11COLEY

PHARMACEUTICAL GROUP, INC.

IMIDAZOQUINOLINYL SULFONAMIDES

Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists

METHOD AND COMPOSITION FOR REDUCING THE EXPRESSION OF

ROCK-II

Composition For The Prevention and Treatment Of Common Cold  
Diseases

SHELF STABLE, REDUCED CORROSION, READY TO USE

PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS

Method for Producing Viral Vaccines

Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One

Derivatives for the Treatment of Asthma and Chronic Obstructive  
Pulmonary Disease

Bioactive peptides and method of using same

Method and/or Apparatus of Oligonucleotide Design and/or Nucleic  
Acid Detection

Methods for generating immune response using cationic-liposomemediated  
nucleic acid delivery

REPLIKIN PEPTIDES AND USES THEREOF

Compositions and methods for transepithelial molecular transport

BONK JASON D

ASTRAZENECA AB

Myriad Genetics, Incorporated

PANDALIS GEORGIOS

BESSE MICHAEL

BAXTER HEALTHCARE

AstraZeneca AB

AYALON-SOFFER MICHAL

LEE CHARLIE

Georgetown University

BOGOCH ELENORE S

Thomas Jefferson University

COMPOSITIONS FOR USE IN IDENTIFICATION OF ADENOVIRUSES IBIS BIOSCIENCES, INC.

CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES

WITH ADJUVANTS

ADJUVANT COMPOSITIONS

Compositions with Modified Nucleases Targeted to Viral Nucleic Acids and Methods of Use for Prevention and Treatment of Viral Diseases

Muscarinic Receptor Antagonists

OXIME SUBSTITUTED IMIDAZOQUINOLINES

LACTAM CONTAINING HCV INHIBITORS

ANTIVIRAL OLIGONUCLEOTIDES TARGETING HBV

B7-DC Variants

Method of Purifying Virus Envelope

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

ANTIVIRAL AGENT, AND FABRIC AND ANTIVIRAL MEMBER

SUPPORTING ANTIVIRAL AGENT

Dioscorea Extracts

METHODS FOR DETECTING PARVOVIRUS INFECTIONS

Methods for the directed expansion of epitopes for use as antibody ligands

Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease

NOVARTIS VACCINES AND DIAGNOSTICS SRL

M N L PHARMA LIMITED

APPELBAUM JACOB G

ASTRAZENECA AB

Coley pharmaceutical Group, Inc.

BARSANTI PAUL

JUTEAU JEAN-MARC

The Johns Hopkins University

GENOMIDEA INC.

Maxygen, Inc.

ITO HIROSHI

Academia Sinica

The Research Foundation of State University of New York

Peptimmune, Inc.

ASTRAZENECA AB

Feb05

30Dec03

14Mar06

20Aug03

24Mar06

30Aug07

28Aug07

30Oct05

18Sep06

12Aug05

9-Jul07

6Jun03

31May02

11Sep03

4Nov05

21Jan04

14Apr04

20Apr05

14Nov03

16Jun05  
13Sep02  
13Jul-07  
27Jul-04  
18Nov02  
12Aug03  
1Dec03  
5May03  
13Apr06  
6Oct05  
10Feb  
-06  
23Dec  
-04  
12Mar  
-07  
6May  
-08  
2Mar  
-07  
30Aug  
-07  
28Aug  
-08  
20ct  
-06  
18Sep  
-07  
8Aug  
-06  
9Jul08  
10Jul08  
25Mar  
-08  
16Sep  
-08  
6Nov  
-06  
21Jan  
-05  
14Apr  
-05  
18Apr  
-06  
12Nov  
-04  
16Jun  
-06  
10Jul08  
11Jul08  
22Jul05  
30Oct  
-06  
10Aug





-09  
12Feb  
-09  
12Feb  
-09  
12Feb  
-09  
12Feb  
-09  
12Feb  
-09  
5Feb  
-09  
5Feb  
-09  
US20090035  
861  
US20090035  
323  
US20090012  
280  
US20090012  
151  
US20090012  
125  
US20090011  
465  
US20090011  
403  
US20090005  
376  
US20090005  
371  
US20090004  
643  
US20080319  
170  
US20080318  
998  
US20080317  
702  
US20080311  
138  
US20080311  
125  
US20080311  
042  
US20080310  
992  
US20080305  
120  
US20080305

119

US20080300

275

US20080300

244

US20080300

191

US20080299

545

US20080299

182

US20080299

070

US20080295

843

US20080293

775

US20080293

742

US20080292

657

US20080292

641

28RNAi

Medicine Having No Adverse Effects

IMMUNE RESPONSE MODIFIER CONJUGATES

OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING

NIDOVIRUS INFECTIONS

Novel Compounds 951

Piperidine Derivatives, Their Process for Preparation, Their Use as  
Therapeutic Agents and Pharmaceutical Compositions Containing  
Them

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

MICROPOROUS MATERIALS, METHODS OF MAKING, USING, AND

ARTICLES THEREOF

1-Alkoxy 1H-Imidazo Ring Systems and Methods

Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and  
Methods

METHODS FOR CONCURRENT IDENTIFICATION AND

QUANTIFICATION OF AN UNKNOWN BIOAGENT

Methods and Uses of Antibodies in the Purification of Interferon

GONDAI TAKUMA

Not Available

BESTWICK RICHARD K

BONNERT ROGER VICTOR

CAGE PETER

MAXYGEN, INC.

UNIVERSITY OF UTAH RESEARCH FOUNDATION

3M Innovative Properties Company

HEPPNER PHILIP D

ISIS Pharmaceuticals, Inc.

ViraNative AB

Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines COLEY  
PHARMACEUTICAL GROUP, INC.

METHOD FOR TREATING MICROORGANISMS AND/OR INFECTIOUS AGENTS

Adjuvant Activity of Gastrointestinal Peptides

Scytovirin Domain 1 Related Polypeptides

Loop-Variant PdZ Domains as Biotherapeutics, Diagnostics and Research Reagents

EDGINGTON GARRY

Not Available

Office of Technology Transfer

DELAGRAVE SIMON

APPARATUS AND METHOD FOR USING OZONE AS A DISINFECTANT VIROFORCE SYSTEMS INC.

Immunogenic Compositions Comprising Hmgb 1 Polypeptides

Modified Bacteriophage Vectors and Uses Thereof

Novel Benzothiazolone Derivatives

NOVEL COMPOUNDS

PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND

THE USE THEREOF

CHROMATOGRAPHIC METHODS FOR ASSESSING ADENOVIRUS

PURITY

METHODS AND FORMULATIONS FOR TOPICAL GENE THERAPY

Antiviral Compounds

MEDIMMUNE, INC.

UNIVERSITY OF ROCHESTER

ASTRAZENECA AB

AstraZeneca AB

CAI SUI XIONG

CLARKE PETER

ONISHI ERIC

ENGEL ROBERT

SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE HAAS MARCI B

Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease

Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4

PRIMATE T-LYMPHOTROPIC VIRUSES

Antigenic GM-CSF peptides and antibodies to GM-CSF

Fauci/COVID-19 Dossier

ASTRAZENECA AB

CHESHIRE DAVID

Centers for Disease Control and Prevention

Morphotek, Inc.

CC-BY-NC-SA Dr. David E. Martin

Jan05

22Feb06

24Dec03

5-Jul07

7Mar06

18Nov02

26May04

2Sep04

11Feb05

18Feb04

12Feb05

9Feb05

19Jun07  
13Dec04  
25May05  
5Dec05  
29Nov06  
17Jun04  
29Oct04  
9Aug05  
14Dec06  
6May03  
6Mar07  
1Mar07  
30May07  
1Jun07  
15Dec05  
12Dec05  
21Feb05  
8Feb06  
27Jan  
-06  
21Feb  
-07  
25Apr  
-08  
3Jul08  
6Mar  
-07  
30Oct  
-06  
17May  
-05  
1Sep  
-05  
10Feb  
-06  
17Feb  
-05  
13Feb  
-06  
8Feb  
-06  
19Jun  
-08  
13Dec  
-05  
24May  
-06  
4Dec  
-06  
17Jun  
-08  
16Jun  
-05  
5Oct



-08  
4Dec  
-08  
4Dec  
-08  
4Dec  
-08  
4Dec  
-08  
4Dec  
-08  
27Nov  
-08  
27Nov  
-08  
27Nov  
-08  
27Nov  
-08  
163  
US20080287  
453  
US20080286  
756  
US20080280  
951  
US20080279  
920  
US20080279  
891  
US20080279  
812  
US20080279  
722  
US20080279  
721  
US20080279  
720  
US20080275  
084  
US20080274  
140  
US20080269  
240  
US20080269  
192  
US20080269  
156  
US20080269  
148  
US20080269  
115

US20080267

997

US20080267

992

US20080267

819

US20080261

258

US20080261

257

US20080260

775

US20080260

773

US20080260

769

US20080260

764

US20080255

150

US20080255

076

US20080254

440

Piperazine Compounds Useful as Antagonists of C-C Chemokines

(Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING

SEVERE ACUTE RESPIRATORY SYNDROME (SARS)

Salt II

21BOWER

JUSTIN FAIRFIELD

Dec05

THE

CHINESE UNIVERSITY OF HONG KONG

ASTRAZENECA AB

Compositions For Treating Respiratory Viral Infections and Their Use Intradigm

Corporation

Viral Adjuvants

JOHNSTON ROBERT E

Disease Prevention and Vaccination Prior to Thymic Reactivation Monash

University

TRANSPORTABLE DECONTAMINATION UNIT AND

DECONTAMINATION PROCESS

DECONTAMINATION UNIT AND PROCESS

DECONTAMINATION UNIT WITH COLLAPSIBLE DECONTAMINATION

ENCLOSURE AND DECONTAMINATION PROCESS

Piperidines for the Treatment of Chemokine Mediated Diseases

Vaccines and Methods for Using the Same

Novel Adenine Compound

Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds

Inhibitors of RTP801 and their use in disease treatment

Modified Small Interfering Rna Molecules and Methods of Use

Immunogenic Sars Domain

Modified Viral Particles with Immunogenic Properties and Reduced



Lipid Content Useful for Treating and Preventing Infectious Diseases  
Sars Virus Vaccine with Adenovirus Carrier and Preparation Method  
Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine

TRANSPORTABLE DECONTAMINATION UNIT AND

DECONTAMINATION PROCESS

Immune Cell Biosensors and Methods of Using Same  
Fluorescent Proteins and Related Methods and Compounds

New Live Virus Vaccines

Saccharide Conjugate Vaccines

Polypeptides for Oligomeric Assembly of Antigens

REPLIKIN PEPTIDES AND USES THEREOF

Novel Compounds

Steroid-Derived Pharmaceutical Compositions

Anti-Sars Virus Antibody, Hybridoma Producing the Antibody and  
Immunoassay Reagent Using the Antibody

BACIK MICHAEL A

CENTANNI MICHAEL A

CENTANNI MICHAEL A

ASTRAZENECA AB

KUTZLER MICHELE

AstraZeneca Aktiebolag A Corporation of Sweden

Coley Pharmaceutical Group, Inc.

FEINSTEIN ELENA

HAN JANG

BEADENKOPF ROBERT J

Lipid Sciences, Inc.

29Jul-03

2Aug05

5Nov04

9-Jul04

5Dec03

6Mar07

6Mar07

6Mar07

27May05

19Nov04

22Sep05

30Dec04

26Feb07

10ct04

17Jun04

29Jun00

4Cancer

Center, Sun Yat-Sun University

BACIK MICHAEL A

Amaox, Inc.

UNIVERSITY OF MASSACHUSETTS

JOHNSON PHILIP R

Not Available

CAPECCHI BARBARA

BOGOCH ELENORE S

ASTRAZENECA AB

JadoLabs GmbH

FUJII NOBUYUKI

Jun04  
6Mar07  
9-Jul04  
20Sep04  
15Feb05  
24Dec04  
23Jul-04  
30May06  
5Nov05  
29Jun04  
31Oct03  
18Dec  
-06  
3Apr  
-08  
31Jul06  
4Nov  
-05  
8Jul05  
19Apr  
-04  
20Feb  
-08  
20Feb  
-08  
20Feb  
-08  
24May  
-06  
18Nov  
-05  
21Sep  
-06  
29Dec  
-05  
26Feb  
-08  
30Sep  
-05  
16Jun  
-05  
9May  
-08  
4Jun  
-04  
20Feb  
-08  
11Jul05  
20Sep  
-05  
15Feb  
-06  
23Dec  
-05

22Jul05

30May

-07

1Nov

-06

29Jun

-05

29Oct

-04

20Nov

-08

20Nov

-08

13Nov

-08

13Nov

-08

13Nov

-08

13Nov

-08

13Nov

-08

13Nov

-08

13Nov

-08

6Nov

-08

6Nov

-08

30Oct08

30Oct08

30Oct08

30Oct08

30Oct08

30Oct08

30Oct08

30Oct08

23Oct08

23Oct08

23Oct08

23Oct08

23Oct08

23Oct08

16Oct08

16Oct08

16Oct08

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

164

US20080249

145

US20080249  
110  
US20080249  
097  
US20080249  
039  
US20080248  
551  
US20080248  
043  
US20080242  
851  
US20080242  
794  
US20080242  
649  
US20080241  
935  
US20080241  
910  
US20080241  
909  
US20080241  
511  
US20080241  
189  
US20080241  
000  
US20080234  
345  
US20080234  
319  
US20080233  
650  
US20080233  
570  
US20080233  
558  
US20080233  
150  
US20080233  
128  
US20080227  
817  
US20080227  
797  
US20080227  
219  
US20080227  
149  
US20080226  
681  
US20080226  
597

US20080213  
891  
US20080213  
308  
8Salts  
668  
Novel Substituted 3-Sulfur Indoles  
PRODRUGS OF HETEROARYL COMPOUNDS  
Modified Short Interfering Rna (Modified Sirna)  
WHITTOCK ROBERT  
BONNERT ROGER  
Koronis Pharmaceuticals, Incorporation  
SANTARIS PHARMA A/S  
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES OSORIO JORGE E  
Antibodies to SARS coronavirus  
MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET  
EFFECTS IN RNA INTERFERENCE  
COLOR STABILIZED ANTIMICROBIAL POLYMER COMPOSITES  
New Combination 665  
Methods for pathogen detection  
Devices for pathogen detection  
Microfluidic chips for pathogen detection  
PRODUCTION OF SILVER SULFATE GRAINS USING INORGANIC  
ADDITIVES  
Sequential Delivery Of Immunogenic Molecules Via Adenovirus And  
Adeno-Associated Virus-Mediated Administrations  
Systems for pathogen detection  
METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE  
DIGESTIVE TRACT  
Novel Compounds 679  
Method for propagating adenoviral vectors encoding inhibitory gene  
products  
Amgen Inc.  
DHARMACON, INC.  
BLANTON THOMAS N  
CADOGAN ELAINE BRIDGET  
Searete LLC, a limited liability corporation of the State of  
Delaware  
Searete LLC, a limited liability corporation of the State of  
Delaware  
Searete LLC, a limited liability corporation of the State of  
Delaware  
BLANTON THOMAS N  
The Trustees of the University of Pennsylvania  
Searete LLC, a limited liability corporation of the State of  
Delaware  
Gene Logic Inc.  
EBDEN MARK  
GENVEC, INC.  
METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A  
Inhibitors of viral entry screening method  
RESPIRATORY SYNCYTIAL VIRUS-LIKE PARTICLE (VLPS)  
Treatment of Viral Infections  
New Salt I

Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of  
Inflammatory and Immune Diseases

Electrochemiluminescent assay

Interferon-Alpha Polypeptides and Conjugates

Highly Active Glycoproteins-Process Conditions and an Efficient  
Method for their Production

EVOLVED INTERFERON-ALPHA POLYPEPTIDES

RNAi Agents Comprising Universal Nucleobases

Imidazoquinoline Compounds

Medical Research Council

MAHMOOD KUTUB

KRAUSE WERNER

ASTRAZENECA AB

ASTRAZENECA AB

Not Available

MAXYGEN, INC.

Glycotope GmbH

MAXYGEN, INC.

Alnylam Pharmaceuticals, Inc.

CHU DANIEL

Feb07

27May03

20Jun03

30Jan04

6Apr07

19May06

2Apr03

30Mar07

8Feb07

27Mar07

27Mar07

27Mar07

30Mar07

28Apr04

27Mar07

8Sep06

22Mar07

10Nov05

11Sep03

1Feb05

16Nov06

2Nov06

2Aug05

4-Jul05

17Nov04

18Nov02

13Feb04

18May05

21Jul-04

14Sep04

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

7Feb

-08  
25May  
-04  
27Dec  
-06  
28Jan  
-05  
4Apr  
-08  
21May  
-07  
19Sep  
-07  
30Mar  
-07  
7Feb  
-08  
27Mar  
-07  
27Mar  
-07  
27Mar  
-07  
30Mar  
-07  
27Apr  
-05  
27Mar  
-07  
7Sep  
-07  
21Mar  
-08  
9May  
-08  
25May  
-07  
1Aug  
-07  
16Nov  
-07  
1Nov  
-07  
31Jul06  
3Jul06  
16Nov  
-05  
25Oct  
-07  
14Feb  
-05  
17May  
-06  
6Aug

-07  
14Sep  
-05  
165  
90ct08  
90ct08  
90ct08  
90ct08  
90ct08  
90ct08  
20ct08  
20ct08  
20ct08  
20ct08  
20ct08  
20ct08  
20ct08  
20ct08  
20ct08  
25Sep  
-08  
25Sep  
-08  
25Sep  
-08  
25Sep  
-08  
25Sep  
-08  
25Sep  
-08  
25Sep  
-08  
25Sep  
-08  
18Sep  
-08  
18Sep  
-08  
18Sep  
-08  
18Sep  
-08  
18Sep  
-08  
18Sep  
-08  
4Sep  
-08  
4Sep  
-08  
US20080213  
284  
US20080213  
125  
US20080210



748  
US20080207  
698  
US20080207  
688  
US20080207  
674  
US20080207  
650  
US20080207  
597  
US20080207  
596  
US20080207  
587  
US20080207  
573  
US20080206  
283  
US20080206  
235  
US20080200  
505  
US20080199  
915  
US20080199  
495  
US20080199  
491  
US20080199  
481  
US20080194  
922  
US20080194  
689  
US20080194  
632  
US20080194  
481  
US20080194  
422  
US20080193  
919  
US20080193  
474  
US20080188  
513  
US20080188  
488  
US20080187  
609

RECEPTOR BINDING POLYPEPTIDES

National Health Research Institutes, a Taiwanese  
corporation

Apparatus and Method for Using Ozone as a Disinfectant  
Systems and methods for receiving pathogen related information  
and responding  
Novel Compounds 569  
Novel Piperidine Derivatives  
Immune Response Modifier Formulations And Methods  
Chemical Compounds 636  
HOMOPIPERAZINE COMPOUNDS THAT INHIBIT RIBOSOMAL  
FRAMESHIFTING BY BINDING TO RNA PSEUDOKNOT STRUCTURE  
OF SARS CORONAVIRUS  
Novel compounds 329  
Pyridazine Derivatives for Inhibiting Human Stearoyl-CoaDesaturase  
COMPOUNDS  
FOR TREATING VIRAL INFECTIONS  
Vaccine Against Sars  
COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE  
RESPONSE  
Piperidines for the Treatment of Chemokine Mediated Diseases  
Methods and Kits For Mass Production Of Dsrna  
Stimulation of thymus for vaccination development  
Sustained Release Vaccine Composition  
COMPOUNDS  
POTENTIATION FOR MEDICAL THERAPIES  
Disinfectant and Germicidal Agent  
Novel Piperidine Derivatives as Chemokine Receptor Modulators  
Useful for the Treatment of Respiratory Diseases  
Albumin Fusion Proteins  
PCR PRIMER SET DETECTING SEVERE ACUTE RESPIRATORY  
SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR  
DETECTING SARS-CORONAVIRUS USING THE SAME  
Systems and methods for receiving pathogen related information  
and responding  
Immunostimulatory Compositions  
1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine  
Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5C](1,5]Naphthyridin-4-Amine  
Methanesulfonate  
Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase  
Inhibitors  
Methods and apparatus to prevent, treat, and cure the symptoms of  
nausea caused by chemotherapy treatments of human cancers  
Fauci/COVID-19 Dossier  
Huawei Technologies Co. LTD.  
Searete LLC, a limited liability corporation of the State of  
Delaware,  
CONNOLLY STEPHEN  
ASTRAZENECA AB  
Coley Pharmaceutical Group, Inc.  
BONNERT ROGER VICTOR  
SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR  
CORPORATE COLLABORATION  
MARTIN BARRIE  
XENON PHARMACEUTICALS INC.  
Myriad Genetics, Incorporated  
DONG JOHN Y

Johns Hopkins University

ASTRAZENECA AB

RNA-Line Oy

Monash University

BRANDON MALCOLM

ASTRAZENECA AB

HOLDEN JAMES F

REICHWAGEN SVEN

ASTRAZENECA AB

Human Genome Sciences, Inc.

Jan04

18Mar04

30Nov05

20Dec06

21Jul-05

30Dec04

11Jan07

22Dec06

19Jun06

20Sep04

16Oct06

17Jun03

27Dec06

27May05

2May03

15Apr99

16Jun04

21Feb07

7Sep05

25May05

1Aug05

21Dec01

12SAMSUNG

ELECTRONICS CO., LTD.

Searete LLC, a limited liability corporation of the State of

Delaware

GRAM CHRISTOPHER D

Dec03

30Nov05

25Apr05

30taked

Pharmaceutical Company Limited

Dec04

20XENON

PHARMACEUTICALS INC.

VAIL MARILYN L

Sep04

3Apr00

CC-BY-NC-SA

Dr. David E. Martin

10Jan

-05

18Mar

-05

11Sep  
-07  
19Dec  
-07  
19Jul06  
28Dec  
-05  
10Jan  
-08  
20Dec  
-07  
19Jun  
-07  
20Sep  
-05  
7May  
-08  
17Jun  
-04  
27Dec  
-07  
24May  
-06  
2May  
-03  
24May  
-07  
16Jun  
-05  
19Feb  
-08  
28Sep  
-07  
26May  
-06  
31Jul06  
31Oct  
-07  
21Apr  
-08  
22Jan  
-08  
25Apr  
-06  
28Dec  
-05  
20Sep  
-05  
18Mar  
-08  
Sep  
-08  
4Sep  
-08

4Sep  
-08  
28Aug  
-08  
28Aug  
-08  
28Aug  
-08  
28Aug  
-08  
28Aug  
-08  
28Aug  
-08  
28Aug  
-08  
28Aug  
-08  
28Aug  
-08  
28Aug  
-08  
21Aug  
-08  
21Aug  
-08  
21Aug  
-08  
21Aug  
-08  
21Aug  
-08  
14Aug  
-08  
14Aug  
-08  
14Aug  
-08  
14Aug  
-08  
14Aug  
-08  
14Aug  
-08  
14Aug  
-08  
7Aug  
-08  
7Aug  
-08  
7Aug  
-08  
166  
94

US20080187  
528  
US20080183  
396  
US20080182  
900  
US20080182  
874  
US20080181  
969  
US20080176  
902  
US20080176  
841  
US20080176  
217  
US20080175  
861  
US20080175  
832  
US20080172  
247  
US20080171  
363  
US20080171  
066  
US20080171  
057  
US20080170  
996  
US20080167  
332  
US20080167  
321  
US20080167  
198  
US20080166  
793  
US20080166  
701  
US20080166  
370  
US20080160  
010  
US20080159  
962  
US20080156  
743  
US20080154  
210  
US20080153  
850  
US20080153  
837

US20080152

728

ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF  
VIRAL INFECTIONS

Systems and methods for transmitting pathogen related information  
and responding

15Functional

Genetics, Inc.

Searete LLC, a limited liability corporation of the State of  
Delaware

Method of treatment of virus infections using shikonin compounds WANG FEIXIN  
Novel Compounds

POLYMER COMPOSITE

Salt III

EPOXIDE INHIBITORS OF CYSTEINE PROTEASES

METHOD OF PREDICTING INFLUENZA OUTBREAKS BY

CORRELATING AN INCREASE IN REPLIKIN COUNT IN SHRIMP

WHITE SPOT SYNDROME VIRUS AND/OR TAURA SYNDROME VIRUS

MODIFIED POLYMERASES AND ATTENUATED VIRUSES AND

METHODS OF USE THEREOF

Materials and Methods for Prevention and Treatment of RNA Viral  
Diseases

Method to Decrease the Risk of a Vaccine-Induced Chronic Immune  
Mediated Disorder in Humans With a Family History of the Disorder

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

ASTRAZENECA AB

BARNES CRAIG L

ASTRAZENECA AB

THE BOARD OF TRUSTEES OF THE LELAND STANFORD

JUNIOR UNIVERSITY

BOGOCH ELENORE S

Nov06

30Nov05

21Feb03

30Nov04

31Jan07

2Aug05

13Jun06

24Oct06

22THE

PENN STATE RESEARCH FOUNDATION

BEHERA ARUNA K

CLASSEN IMMUNOTHERAPIES

MAXYGEN, INC.

Listeriolysin-Containing Bacillus Spores as Antigen Delivery Agents CUTTING  
SIMON

Reagents, Devices, and Methods For Proteomic Analysis With  
Applications Including Diagnostics, Vaccines, Quality Control and  
Research

NETWORK IMMUNOLOGY INC.

Compositions and Methods for Stimulation of Lung Innate Immunity The Board of  
Regents of the University of Texas System

Novel Compounds 243

ELKINS BARRY

Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase XENON  
PHARMACEUTICALS INC.  
Filter based detection system  
Sorting, amplification, detection, and identification of nucleic acid  
subsequences in a complex mixture  
Immunoassay Method and Immunoassay Kit to Be Used Therein  
Immunogenic Compositions Comprising Multiple Gonococcal  
Antigens  
Peptide That Elicits Neutralizing Antibodies Targeting the Hiv CoReceptor  
Use  
of Inhibitors of the Renin-Angiotensin System for the Treatment  
of Lung Injuries  
HAZARDOUS SUBSTANCE REMOVING MATERIAL, METHOD FOR  
REMOVING HAZARDOUS SUBSTANCES, AND NONWOVEN FABRIC  
Mixture for Transdermal Delivery of Low and High Molecular Weight  
Compounds  
Adamantyl Derivates as P2x7 Receptor Antagonists  
Novel Fluorene Derivatives, Composition Containing Said Derivatives  
and the Use Thereof  
Noble gas-chlorine mixture effective against micro organisms  
COONEY CHRISTOPHER GERARD  
The Regents of the University of California  
ARKRAY, Inc.  
CHIRON SRL  
The Government of the United States of America as  
IMBA-INSTITUTE FUR MOLEKULARE BIOTECHNOLOGIE  
GMBH  
FUJIFILM Corporation  
ORYXE  
AstraZeneca AB  
AVENTIS PHARMA S.A.  
GLOBUS ALFRED R  
Dec06  
30Apr02  
6Apr04  
19May04  
19Feb05  
21Apr04  
28Jul-06  
19Jul-06  
20Sep04  
4Jan07  
4Jan07  
25Jul-05  
26Jun03  
9Apr04  
19May05  
27Dec06  
28May04  
30Aug04  
19May05  
7-Jul03  
Fauci/COVID-19  
Dossier



15Nov  
-07  
11Sep  
-07  
26Sep  
-07  
28Nov  
-05  
31Jan  
-07  
31Jul06  
13Jun  
-07  
24Oct  
-07  
24Dec  
-07  
17Jan  
-08  
6Apr  
-05  
14Aug  
-07  
20Feb  
-06  
19Apr  
-05  
30Jul07  
18Jul07  
20Sep  
-05  
4Jan  
-07  
4Jan  
-07  
24Jul06  
25Jun  
-04  
11Apr  
-05  
19May  
-06  
27Dec  
-07  
25May  
-05  
29Aug  
-05  
14Nov  
-07  
25Apr  
-07

CC-BY-NC-SA

Dr. David E. Martin

7Aug  
-08  
31Jul08  
31Jul08  
31Jul08  
31Jul08  
24Jul08  
24Jul08  
24Jul08  
24Jul08  
24Jul08  
17Jul08  
17Jul08  
17Jul08  
17Jul08  
17Jul08  
10Jul08  
10Jul08  
10Jul08  
10Jul08  
10Jul08  
10Jul08  
10Jul08  
3Jul08  
3Jul08  
3Jul08  
26Jun08  
26Jun08  
26Jun08  
26Jun08  
167  
US20080152  
544  
US20080149  
100  
US20080146  
612  
US20080146  
455  
US20080145  
847  
US20080138  
808  
US20080132  
502  
US20080132  
480  
US20080131  
465  
US20080131  
446  
US20080125  
434  
US20080124  
323

US20080124  
311  
US20080124  
303  
US20080124  
302  
US20080118  
530  
US20080118  
517  
US20080118  
495  
US20080118  
473  
US20080114  
019  
US20080114  
002  
US20080113  
409  
US20080113  
337  
US20080108  
629  
US20080107  
650  
US20080103  
746  
US20080103  
149  
US20080102  
444  
US20080096  
959  
29Building  
decontamination with vaporous hydrogen peroxide  
Antiviral Heat Treatment  
Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor  
STERIS INC.  
DE HAAN PETRUS THEODORUS  
ASTRAZENECA AB  
METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A  
METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A  
METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A  
5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors  
Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory  
Disease  
Group a Streptococcus Crge Protein  
Vaccine Composition  
Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase  
Inhibitors  
ARNOULD JEAN-CLAUDE  
AstraZeneca AB  
MANETTI ANDREA

SANOFI PASTEUR SA  
XENON PHARMACEUTICALS INC.  
Nutritional Composition Comprising Indigestible Oligosaccharides N.V. Nutricia  
Novel pharmaceutical compositions for the treatment of virus  
infection and cancer  
Methods and compositions for treatment of viral infections  
Uses of Recombinant Super-Compound Interferons  
Modulation of Replicative Fitness By Deoptimization of Synonymous  
Codons  
Human monoclonal antibodies against interleukin 8 (IL-8)  
Mammalian Genes Involved in Infection  
Methods of treating a respiratory condition comprising probiotic  
treatment  
Hydroxylamine Substituted Imidazoquinolines  
Substituted Acids for the Treatment of Respiratory Diseases  
Transient protein expression methods  
Method of Examining/Judging Presence of Virus Infection such as  
HIV or Presence of Prion Infection by Near-Infrared Spectroscopy  
and Device Used in Same  
Heterocyclic Derivatives for the Treatment of Diseases Mediated by  
Stearoyl-Coa Desaturase Enzymes  
METHOD FOR TREATING INFLAMMATORY DISEASES OF THE  
DIGESTIVE TRACT  
Systems and methods for pathogen detection and response  
NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE  
PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR  
THERAPEUTIC APPLICATIONS  
METHODS AND COMPOSITIONS FOR DETECTING RHINOVIRUSES  
Durable Biocides and Disinfectants  
Illumigen Biosciences, Inc.  
Cavit Sciences, Inc  
WEI GUANGWEN  
BURNS CARA C  
GENMAB A/S  
RUBIN DONALD H  
Alimentary Health Ltd.  
Coley Pharmaceutical Group, Inc.  
ASTRAZENECA AB  
HATEBOER GUUS  
OSAKA UNIVERSITY  
XENON PHARMACEUTICALS INC.  
Gene Logic Inc.  
Searete LLC, a limited liability corporation  
Jan04  
20Dec06  
27Jan05  
11Sep03  
11Sep03  
11Sep03  
9Nov04  
24Aug04  
27Sep04  
17Nov03  
20Sep04

24Aug04  
23Nov05  
12Dec05  
9Mar05  
8Oct04  
16Dec02  
27Oct04  
1Nov06  
12Aug03  
8-Jul04  
15Apr99  
12Nov04  
20Sep04  
8Sep06  
30Nov05  
30COLLAND  
FREDERIC  
Oct06  
Focus  
Technologies, Inc.  
MITSUI NORIN CO., LTD.  
6-Jul04  
7-Jul04  
3Mar  
-08  
20Dec  
-06  
25Jan  
-06  
25May  
-07  
25May  
-07  
25May  
-07  
7Nov  
-05  
22Aug  
-05  
27Sep  
-05  
9Jan  
-08  
20Sep  
-05  
24Aug  
-05  
17Nov  
-06  
12Jul07  
9Mar  
-06  
7Oct  
-05

27Jun  
-07  
27Oct  
-05  
31Oct  
-07  
12Aug  
-04  
6Jul05  
1Jun  
-07  
10Nov  
-05  
20Sep  
-07  
7Sep  
-07  
11Sep  
-07  
30Oct  
-06  
15Oct  
-07  
5Jul05  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
26Jun08  
26Jun08  
19Jun08  
19Jun08  
19Jun08  
19Jun08  
12Jun08  
5Jun08  
5Jun08  
5Jun08  
5Jun08  
29May  
-08  
29May  
-08  
29May  
-08  
29May  
-08  
29May  
-08  
22May  
-08  
22May  
-08  
22May  
-08  
22May  
-08  
22May

-08  
15May  
-08  
15May  
-08  
15May  
-08  
15May  
-08  
8May  
-08  
8May  
-08  
1May  
-08  
1May  
-08  
1May  
-08  
24Apr08  
168  
US20080096  
928  
US20080096  
895  
US20080096  
186  
US20080090  
913  
US20080090  
841  
US20080090  
791  
US20080090  
229  
US20080090  
224  
US20080085  
895  
US20080085  
873  
US20080081  
047  
US20080076  
710  
US20080076  
115  
US20080075  
740  
US20080075  
737  
US20080075  
693  
US20080071

063

US20080070

907

US20080069

839

US20080069

838

US20080069

836

US20080069

830

US20080069

804

US20080064

105

US20080064

080

US20080063

664

US20080058

309

US20080057

513

Methods for treating Hepatitis C

AREFOLOV ALEXANDER

Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors

PCR PRIMER SET FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR DETECTING SARS-CORONAVIRUS USING THE SAME

Sphingolipid-Derived Pharmaceutical Compositions

METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES

Cystic fibrosis treatment methods

Devices for generating detectable polymers

Nucleic acid detection

Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds

Disease treatment methods

Anti-Sars Monoclonal Antibodies

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

Adeno-Associated Virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL29

CYSTEINE MUTANTS

Protein Formulations

Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods

ISOLATION AND CHARACTERIZATION OF THE PRECURSOR VIRUS OF HUMAN SARS VIRUS: SARS-ASSOCIATED CORONA VIRUS-LIKE



VIRUS

NOVEL HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY  
SYNDROME (SARS) AND USES THEREOF

METHOD OF USING ADENOVIRAL VECTORS WITH INCREASED  
IMMUNOGENICITY IN VIVO

Dna Sequences, Peptides, Antibodies and Vaccines for Prevention  
and Treatment of Sars

Alphavirus Replicon Packaging Constructs

Animal protein-free media for cultivation of cells

Animal protein-free media for cultivation of cells

High-yield transgenic mammalian expression system for generating  
virus-like particles

Novel Compounds 171

METHOD FOR PRODUCING NUCLEIC ACID PROBES

XENON PHARMACEUTICALS INC.

14Jul-04

20Sep04

12HWANG

JUNG-JOO

Dec03

29BRAXMEIER

TOBIAS

PARION SCIENCES, Inc.

Hollis-Eden Pharmaceuticals, Inc.

ENGELHARD ERIC K

HAI KANG LIFE CORPORATION LIMITED

DANIELSON MICHAEL M

Hollis-Eden Pharmaceuticals, Inc.

ANDONOV ANTON

MAXYGEN, INC.

GILLIM-ROSS LAURA

The Trustees of the University of Pennsylvania

The Trustees of the University of Pennsylvania

ZymoGenetics, Inc.

MedImmune, Inc.

Coley Pharmaceutical Group, Inc.

GUAN YI

CHAN KWOK HUNG

and Human Services

HOFFMAN STEPHEN L

PERRI SILVIA

Baxter Healthcare Corporation

Baxter Healthcare Corporation

Academia Sinica

ASTRAZENECA AB

Ventana Medical Systems, Inc.

Jun04

7Sep06

13Oct06

12Oct06

2May03

30Dec04

28Aug02

5Dec03

19May04  
3Nov03  
17Dec01  
17Dec01  
2Apr04  
3Feb06  
12Jul-06  
22May03  
24Mar04  
1Sep04  
24Jun03  
25May04  
29Oct04  
29Oct04  
5Sep06  
27Jul-06  
1Sep06  
14Jul05  
20Sep  
-05  
24Nov  
-04  
29Jun  
-05  
7Sep  
-07  
13Oct  
-06  
12Oct  
-06  
30Apr  
-04  
29Dec  
-05  
13Oct  
-06  
6Dec  
-04  
4May  
-07  
3Nov  
-04  
31Oct  
-07  
6Sep  
-07  
20Sep  
-07  
2Feb  
-07  
12Jul07  
24May  
-04  
24Mar



-08  
13Mar  
-08  
13Mar  
-08  
13Mar  
-08  
6Mar  
-08  
6Mar  
-08  
24  
US20080051  
297  
US20080050  
718  
US20080044  
816  
US20080044  
814  
US20080044  
438  
US20080044  
437  
US20080044  
426  
US20080044  
423  
US20080044  
384  
US20080044  
378  
US20080033  
172  
US20080031  
979  
US20080031  
877  
US20080031  
868  
US20080031  
853  
US20080031  
770  
US20080027  
092  
US20080027  
006  
US20080021  
038  
US20080020  
379  
US20080015  
247

US20080015

230

US20080015

194

US20080015

184

US20080014

204

US20080014

183

US20080009

496

US20080009

040

US20080004

236

US20080004

228

Method for determining antigen-specific T cell response in high throughput format

Centro di Biotecnologie Avanzate and istituto Giannina

Gaslini

12Jun06

14Methods,

Articles, and Compositions for Identifying Oligonucleotides ATKINS JOHN F

Assay for Sars Coronavirus by Amplification and Detection of the Replicase Sequence

Reagents and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus

Yeast Cell Particles As Oral Delivery Vehicles For Antigens

Encapsidation System for Production of Recombinant Virus-Like

Particles

Novel Atypical Pneumonia-Causing Virus

COMPOUNDS

Recombinant Human Cytomegalovirus And Vaccines Comprising

Heterologous Antigens

Methods and Compositions for Protein Production Using Adenoviral

Vectors

Mutagenic Heterocycles

USE OF EXTRACTS FOR THE TREATMENT OF VIRAL DISORDERS

Purification of bacterial antigens

HUMAN LYSOZYME MEDICINE, ITS MANUFACTURING METHOD AND

APPLICATION THEREOF

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

Apparatus and method for using ozone as a disinfectant

1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives

Useful for the Treatment of Respiratory Disorders

Compositions And Methods For Modification And Prevention Of Sars

Coronavirus Infectivity

Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As

Modulators Of Chemokine Receptor Ccr5

Diagnosis and prognosis of infectious diseases clinical phenotypes

and other physiologic states using host gene expression biomarkers in blood

QUERCETIN-CONTAINING COMPOSITIONS  
HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC  
AGENTS  
METHODS AND COMPOSITIONS OF TARGETED DRUG  
DEVELOPMENT  
Urea Substituted Imidazopyridines, Imidazoquinolines, and  
Imidazonaphthyridines  
Compositions Against Sars-Coronavirus and Uses Thereof  
Anticancer Agent Containing Dendritic Cell Having Rna Virus  
Transferred Thereinto  
MUTAGENIC HETEROCYCLES  
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS  
High Dose, Short Interval Use of Sulfated Polysaccharides for  
Treatment of Infections  
New Expression Tools for Multiprotein Applications  
Fauci/COVID-19 Dossier  
BECTON, DICKINSON AND COMPANY  
HIBBERD MARTIN L  
OSTROFF GARY R  
CHEN QUN  
BESTEBROER THEODORUS MARINUS  
COCHRANE DUNCAN  
MedImmune Vaccines, Inc.  
INTROGEN THERAPEUTICS, INC.  
Koronis Pharmaceuticals, Incorporated  
BODDUPALLI SEKHAR  
COVACCI ANTONELLO  
AN MI  
ROCHE PALO ALTO LLC  
BOAST NIGEL  
BONNERT ROGER VICTOR  
The Regents of the University of Colorado  
FAULL ALAN  
AGAN BRIAN K  
LINES THOMAS C  
XENON PHARMACEUTICALS INC.  
Joseph Errico  
3M INNOVATIVE PROPERTIES COMPANY  
DE KRUIF CORNELIS A  
DNAVEC RESEARCH INC.  
Koronis Pharmaceuticals, Inc.  
Baxter Healthcare Corporation  
COMPER WAYNE D  
BERGER IMRE  
CC-BY-NC-SA Dr. David E. Martin  
Nov03  
12Sep03  
21Apr03  
17Mar06  
2Sep04  
18Nov03  
23Jun06  
25Jun04  
15May06

19Dec03  
4Aug06  
17Feb06  
9Jun05  
19May04  
2Aug06  
26Nov03  
12Feb04  
24Jun04  
5Nov04  
17Jul-06  
20Sep04  
23Jan06  
14Jun04  
11Nov04  
24Jun04  
19Dec03  
29Oct04  
6Feb04  
9Mar04  
11Jun  
-07  
15Nov  
-04  
13Sep  
-04  
21Apr  
-04  
16Mar  
-07  
1Sep  
-05  
18Nov  
-04  
22Jun  
-07  
24Jun  
-05  
15May  
-07  
10Dec  
-04  
4Aug  
-06  
16Feb  
-07  
9Jun  
-05  
15Aug  
-07  
29Nov  
-06  
24Nov  
-04

14Feb  
-05  
20Jun  
-05  
7Nov  
-05  
16Jul07  
20Sep  
-05  
23Jan  
-07  
14Jun  
-05  
10Nov  
-05  
28Apr  
-05  
27Dec  
-06  
20Sep  
-07  
7Feb  
-05  
25Nov  
-04  
28Feb  
-08  
28Feb  
-08  
21Feb  
-08  
21Feb  
-08  
21Feb  
-08  
21Feb  
-08  
21Feb  
-08  
21Feb  
-08  
21Feb  
-08  
21Feb  
-08  
7Feb  
-08  
7Feb  
-08  
7Feb  
-08  
7Feb  
-08  
7Feb



-08  
7Feb  
-08  
31Jan08  
31Jan08  
24Jan08  
24Jan08  
17Jan08  
17Jan08  
17Jan08  
17Jan08  
17Jan08  
17Jan08  
10Jan08  
10Jan08  
3Jan08  
3Jan08  
170  
US20080004  
206  
US20080003  
236  
US20070299  
081  
US20070298  
415  
US20070292  
453  
US20070287  
725  
US20070287  
724  
US20070286  
872  
US20070286  
822  
US20070281  
325  
US20070276  
009  
US20070275  
938  
US20070275  
937  
US20070275  
883  
US20070275  
879  
US20070275  
465  
US20070275  
091  
US20070275  
002

US20070274  
994  
US20070274  
983  
US20070274  
950  
US20070274  
922  
US20070270  
361  
US20070270  
360  
US20070266  
957  
US20070265  
236  
US20070265  
226  
US20070259  
914  
US20070259  
907  
21Albumin  
fusion proteins  
BELL ADAM  
ADENOVIRUS FIBER SHAFT COMPOSITION AND METHODS OF USE GenVec, Inc.  
Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa  
Desaturase  
Method of Amplifying Nucleic Acid  
RNA virus vaccines and methods  
Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo  
Ring Compounds And Method  
Substituted Imidazoquinolines, Imidazopyridines, and  
Imidazonaphthyridines  
Live Attenuated Nidovirus Vaccines  
Compounds for the Treatment of Periodontal Disease  
COMPOSITIONS AND METHODS FOR ANALYSIS OF TARGET  
ANALYTES  
Compositions and Methods for Viral Inhibition  
Therapeutic Treatment Methods  
Therapeutic Treatment Methods  
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment  
of flaviviridae infections  
Use of Ulinastatin and Its Pharmaceutical Composition for Treating  
Severe Acute Respiratory Syndrome  
Double-Stranded Ribonucleic Acid with Increased Effectiveness in an  
Organism  
Compositions And Methods For Improved Mucus Function  
Use Of Proteins And Peptides Encoded By The Genome Of A Novel  
Sars-Associated Coronavirus Strain  
Virulence-Associated Adhesins  
Nutritional Composition Comprising Immunoglobulins and  
Oligosaccharides  
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

Water Soluble Boronic Acid Fluorescent Reporter Compounds and  
Methods of Use Thereof  
Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof  
Rna Interference Mediated Inhibition of Severe Acute Respiratory  
Syndrome (Sars) Gene Expression Using Short Interfering Nucleic  
Acid  
Antipathogenic Domestic Livestock House, Disinfectants for  
Domestic Livestock House, Disinfectants for Living Organisms,  
Feedstuffs and Drinking Water for Animals  
Asthma Treatment Methods  
Hydrolytically-Resistant Boron-Containing Therapeutics And Methods  
Of Use  
Novel Piperidine Derivates as Modulators of Chemokine Receptor  
Ccr5.  
ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES  
AND THIAZOLONAPHTHYRIDINES  
XENON PHARMACEUTICALS INC.  
Takara Bio Inc.  
DITTMER DIRK P  
3M INNOVATIVE PROPERTIES COMPANY  
3M INNOVATIVE PROPERTIES COMPANY  
Vanderbilt University  
ANACOR PHARMACEUTICALS INC.  
DANIELZADEH ROBERT  
CHANG BRYAN  
AHLEM CLARENCE N  
AHLEM CLARENCE N  
GOSSELIN GILLES  
GUANGDONG TECHPOOL BIOCHEM PHA  
Alnylam Pharmaceuticals  
KING MALCOLM  
AZEBI SALIHA  
Novartis Vaccines and Diagnostics, Inc.  
NUTRICIA NV  
MAXYGEN INC  
FANG HAO  
CHOU TE-HUI W  
SIRNA THERAPEUTICS, INC.  
Dec01  
18Oct04  
20Sep04  
10Dec03  
14Dec05  
18Jun04  
18Jun04  
22Apr03  
12Jun06  
17Sep03  
15Oct03  
28Aug02  
28Aug02  
28Jun02  
26May03  
13Jun03

30Mar04  
2Dec03  
26Jun03  
24Aug04  
18Nov02  
5Sep03  
4Aug03  
15Apr03  
28TAKAHASHI  
KAZUO  
AHLEM CLARENCE N  
Anacor Pharmaceuticals  
TUCKER HOWARD  
PRINCE RYAN B  
Sep04  
28Aug02  
2May06  
24Jun04  
18Jun04  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
31Jul06  
13Apr  
-07  
20Sep  
-05  
6Dec  
-04  
14Dec  
-06  
17Jun  
-05  
17Jun  
-05  
22Apr  
-04  
12Jun  
-07  
20Jul06  
15Oct  
-04  
12Feb  
-07  
12Feb  
-07  
6Sep  
-06  
25May  
-04  
14Jun  
-04  
30Mar  
-05

2Dec  
-04  
25Jun  
-04  
24Aug  
-05  
19May  
-04  
7Sep  
-04  
4Aug  
-04  
13Apr  
-04  
25Aug  
-05  
16Oct  
-06  
2May  
-07  
20Jun  
-05  
17Jun  
-05  
3Jan08  
3Jan08  
27Dec  
-07  
27Dec  
-07  
20Dec  
-07  
13Dec  
-07  
13Dec  
-07  
13Dec  
-07  
13Dec  
-07  
6Dec  
-07  
29Nov  
-07  
29Nov  
-07  
29Nov  
-07  
29Nov  
-07  
29Nov  
-07  
29Nov  
-07

29Nov  
-07  
29Nov  
-07  
29Nov  
-07  
29Nov  
-07  
29Nov  
-07  
29Nov  
-07  
22Nov  
-07  
22Nov  
-07  
22Nov  
-07  
15Nov  
-07  
15Nov  
-07  
8Nov  
-07  
8Nov  
-07  
171  
US20070259  
881  
US20070258  
999  
US20070254  
906  
US20070254  
329  
US20070253  
978  
US20070253  
860  
US20070249  
686  
US20070248  
969  
US20070248  
949  
US20070244  
133  
US20070244  
044  
US20070243  
600  
US20070243  
544  
US20070243

263  
US20070238  
681  
US20070238  
116  
US20070231  
347  
US20070231  
344  
US20070231  
303  
US20070231  
295  
US20070225  
303  
US20070225  
205  
US20070225  
204  
US20070224  
700  
US20070224  
614  
US20070219  
228  
US20070219  
211  
US20070219  
200  
US20070219  
196  
US20070219  
149  
18Substituted  
Imidazo Ring Systems and Methods  
CELEBI AZIM A  
Sars Virus Nucleotide and Amino Acid Sequences and Uses Thereof THE PUBLIC  
HEALTH AGENCY OF CANADA  
Method of Administration of Dopamine Receptor Agonists  
Mammalian Genes Involved in Viral Infection and Tumor  
Suppression  
Copy choice recombination and uses thereof  
Process and device for sterilising ambient air  
Modulators of Crth-2 Receptor Activity for the Treatment of  
Prostaglandin D2 Mediated Diseases  
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA  
Sensitive and Specific Test to Detect Sars Coronavirus  
Thienopyrimidines and Thiazolopyrimidines for Use in Medicine  
Antimicrobial Peptides  
System for performing multi-formatted assays  
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA  
Antiviral Methods  
MODULATION OF ACE2 EXPRESSION  
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA

Immunization Regimen with E4-Deleted Adenovirus Prime and E1Deleted Adenovirus Boost

Conjugate vaccines for non-proteinaceous antigens

METHODS OF GENERATING CHIMERIC ADENOVIRUSES AND USES

FOR SUCH CHIMERIC ADENOVIRUSES

Antimicrobial Silicon Oxide Flakes

8-Oxoadenine Compound

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

Method and apparatus for analyzing bioprocess fluids

COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA

Aryl substituted imidazonaphthyridines

Bicyclic Heterocyclic Derivatives and Their Use as Inhibitors of

Stearoyl-Coadesaturase (Scd)

PRODRUGS OF HETEROARYL COMPOUNDS

AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES,

AND IMIDAZONAPHTHYRIDINES

Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal

Immunity

Fauci/COVID-19 Dossier

DarPharma, Inc.

RUBIN DONALD H

NIMAN HENRY L

SCHRODER WERNER

ASTRAZENECA AB

BLYN LAWRENCE

AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

BOWER JUSTIN F

NOVABIOTICS LIMITED

GEN-PROBE INCORPORATED

BLYN LAWRENCE

AgION Technologies, Inc.

BENNETT C F

BLYN LAWRENCE

The Trustees of the University of Pennsylvania

The Brigham and Women's Hospital, Inc.

The Trustees of the University of Pennsylvania

BUJARD PATRICE

HASHIMOTO KAZUKI

MAXYGEN, INC.

MAXYGEN, INC.

BioScale, Inc.

BLYN LAWRENCE

AMOS DAVID T

XENON PHARMACEUTICALS INC.

Koronos Pharmaceuticals, Incorporated

AMOS DAVID T

Japan as Represented by the Director-General of National

Institute of Infectious Diseases

Jun04

28Apr03

21Jul-04

2May02

2-Jul04



18Oct04  
5Oct04  
11Sep03  
17Dec03  
4Jun04  
18Aug04  
10Mar05  
11Sep03  
14Apr06  
7Nov06  
11Sep03  
28Apr04  
28Oct05  
20Jun03  
12May04  
26Mar04  
19May04  
19May04  
2May05  
11Sep03  
18Jun04  
20Sep04  
20Jun03  
24Mar04  
11Aug03  
CC-BY-NC-SA  
Dr. David E. Martin  
17Jun  
-05  
28Apr  
-04  
21Jul05  
2May  
-03  
29Dec  
-06  
18Apr  
-07  
30ct  
-05  
13Mar  
-07  
17Dec  
-04  
31May  
-05  
18Aug  
-05  
10Mar  
-06  
13Mar  
-07  
21Mar  
-07

7Dec  
-06  
13Mar  
-07  
27Apr  
-05  
30Oct  
-06  
20Jun  
-03  
2May  
-05  
25Mar  
-05  
14Sep  
-06  
14Sep  
-06  
19Dec  
-06  
7Mar  
-07  
17Jun  
-05  
20Sep  
-05  
15May  
-07  
24Mar  
-05  
10Aug  
-04  
172  
8Nov  
-07  
8Nov  
-07  
1Nov  
-07  
1Nov  
-07  
1Nov  
-07  
1Nov  
-07  
25Oct07  
25Oct07  
25Oct07  
18Oct07  
18Oct07  
18Oct07  
18Oct07  
18Oct07  
18Oct07  
110ct07

11Oct07  
40ct07  
40ct07  
40ct07  
40ct07  
27Sep  
-07  
27Sep  
-07  
27Sep  
-07  
27Sep  
-07  
27Sep  
-07  
20Sep  
-07  
20Sep  
-07  
20Sep  
-07  
20Sep  
-07  
20Sep  
-07  
20Sep  
-07  
US20070218  
536  
US20070218  
489  
US20070218  
467  
US20070218  
001  
US20070213  
356  
US20070213  
309  
US20070212  
770  
US20070212  
677  
US20070208  
052  
US20070207  
526  
US20070203  
209  
US20070203  
107  
US20070203  
082  
US20070203  
073  
US20070203

060

US20070202

492

US20070197

646

US20070197

478

US20070196

818

US20070196

434

US20070196

357

US20070196

333

US20070196

274

US20070192

906

US20070192

905

US20070191

294

US20070190

163

US20070190

071

US20070190

065

28Polyvalent

Viral Vectors and a System for Production Thereof

COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA

Methods for rapid identification and quantitation of nucleic acid variants

Biotherapeutics, Diagnostics and Research Reagents

Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines

Sepsis Treatment Methods

Oligopeptide-free cell culture media

Identifying off-target effects and hidden phenotypes of drugs in human cells

Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines

Norovirus and sapovirus antigens

Useful indole compounds

Pharmaceutical compositions

RNAI Agents For Anti-SARS Coronavirus Therapy

SARS and Ebola inhibitors and use thereof, and methods for their discovery

Casein Derived Peptides And Therapeutic Uses Thereof

Viral Assay

SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL

INFECTIONS

NOVEL PHARMACEUTICALS

Using Nucleic Acids for Clinical Microbiology Testing  
Methods of preventing or treating sinusitis with oxidative reductive potential water solution  
Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution  
Composition comprising mixtures of IFN-alpha subtypes  
Immunoconjugates with improved efficacy for the treatment of diseases  
Rice plant having vaccine gene transferred thereinto  
Edible vaccines expressed in soybeans  
Short interfering rna (sirna) analogues  
Technology for preparation of macromolecular microspheres  
9-Substituted 8-oxoadenine compound  
Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein  
GAO GUANGPING  
BLYN LAWRENCE  
ECKER DAVID J  
BIOTECH STUDIO, LLC  
HARALDSON CHAD A  
AHLEM CLARENCE N  
Baxter Healthcare, S.A.  
Odyssey Thera, Inc.  
HEPPNER PHILIP D  
COIT DORIS  
BARTOLINI WILMIN  
Hollis-Eden Pharmaceuticals, Inc.  
Intradigm Corporation  
BATES PAUL  
SIDELMAN ZVI  
University Of Warwick  
ACHILLION PHARMACEUTICALS, INC.  
PFIZER LTD  
O'HARA STEPHEN  
Oculus Innovative Sciences, Inc.  
Oculus Innovative Sciences, Inc.  
HUANG SHIR-LY  
SUN LE  
EBINUMA HIROYASU  
The University of North Carolina  
SANTARIS PHARMA AS  
FANG FANG  
AstraZeneca Aktiebolag  
ALTMAYER RALF  
Apr04  
11Sep03  
21Jul-05  
5Jan04  
15Jun04  
28Aug02  
4Jan06  
22Nov04  
18Jun04

22Nov05  
18Aug05  
28Aug02  
25Apr03  
22Jun05  
1Mar04  
15Apr04  
21Feb06  
17Feb06  
22Oct03  
20Jan06  
20Jan06  
23Feb06  
20Jan06  
9Apr04  
12Oct04  
21Mar03  
24Jan06  
26Mar04  
3Jun05  
27Apr  
-05  
13Mar  
-07  
21Jul06  
4Jan  
-05  
15Jun  
-05  
16Oct  
-06  
3Jan  
-07  
31Aug  
-06  
17Jun  
-05  
22Nov  
-06  
18Aug  
-06  
13Oct  
-06  
26Apr  
-04  
21Jun  
-06  
15Sep  
-06  
14Apr  
-05  
20Feb  
-07  
16Feb

-07  
22Oct  
-04  
22Jan  
-07  
22Jan  
-07  
23Feb  
-06  
19Jan  
-07  
8Apr  
-05  
12Oct  
-05  
22Mar  
-04  
24Jan  
-07  
24Mar  
-05  
4Dec  
-06  
20Sep  
-07  
20Sep  
-07  
20Sep  
-07  
20Sep  
-07  
13Sep  
-07  
13Sep  
-07  
13Sep  
-07  
13Sep  
-07  
6Sep  
-07  
6Sep  
-07  
30Aug  
-07  
30Aug  
-07  
30Aug  
-07  
30Aug  
-07  
30Aug  
-07  
30Aug

-07  
23Aug  
-07  
23Aug  
-07  
23Aug  
-07  
23Aug  
-07  
23Aug  
-07  
23Aug  
-07  
23Aug  
-07  
16Aug  
-07  
16Aug  
-07  
16Aug  
-07  
16Aug  
-07  
16Aug  
-07  
16Aug  
-07  
16Aug  
-07  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
173  
  US20070190  
031  
US20070185  
044  
US20070185  
027  
US20070184  
434  
US20070178  
533  
US20070178  
505  
US20070178  
048  
US20070173  
755  
US20070173  
481  
US20070172  
817  
US20070172  
448  
US20070167



476  
US20070167  
408  
US20070166  
823  
US20070166  
784  
US20070166  
384  
US20070166  
281  
US20070160  
981  
US20070155  
767  
US20070155  
699  
US20070155  
683  
US20070154  
348  
US20070149  
487  
US20070148  
670  
US20070141  
597  
US20070141  
080  
US20070141  
053  
US20070136  
890  
US20070135  
439

Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv  
Modulation of ace2 expression  
ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES  
Compositions for use in identification of influenza viruses  
Method and diagnostic tests based on flow cytometric analysis of antigen-specific t lymphocytes  
Promoter engineering and genetic control  
Antiviral composition comprising p-menthane-3,8-diol  
Methods of treating or preventing peritonitis with oxidative reductive potential water solution  
Compositions and methods for preventing infection  
17EGAN  
MICHAEL  
BENNETT C F  
SEQUOIA PHARMACEUTICALS, INC.  
ESHOO MARK W  
AGRATI CHIARA

ALPER HAL S  
CLARKE PAUL D  
Oculus Innovative Sciences, Inc.  
JOLLA BIOSCIENCES LLC  
Methods of Producing Antibodies for Diagnostics and Therapeutics CHANG XIAO-JIA  
Method for detecting the specificity of activated lymphocyte  
Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane  
fused imidazo ring compounds  
NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED  
CYTOTOXICITY AND USES THEREOF  
Methods for detecting parvovirus infections  
Combination approaches for generating immune responses  
Methods , composition and preparations for delivery of immune  
response modifiers  
Chloroquine coupled antibodies and other proteins with methods for  
their synthesis  
VIRAL PROTEASE  
Sulfone substituted imidazo ring ethers  
Boron-containing small molecules  
Artificial cpg single-stranded oligodeoxynucleotide and antiviral use  
thereof  
Supports for assaying analytes and methods of making and using  
thereof  
Antiviral Compositions and Methods  
Methods for detecting conformational changes in bioentities  
Biomimetic Biodetector of Toxins, Viruses, Bacteria, and Biological  
Factors  
Treating severe acute respiratory syndrome  
Treatment of inflammatory respiratory diseases  
Expression of a recombinant transgene  
Novel inhibitors of cysteine proteases, the pharmaceutical  
compositions thereof and their therapeutic applications  
HU JUN  
CELEBI AZIM A  
ZENTARIS GmbH  
BLUTH MARTIN H  
BARNETT SUSAN W  
ZARRAGA ISIDRO ANGELO E  
KOSAK KENNETH M  
CHEN XIN  
DELLARIA JOSEPH F JR  
Anacor Pharmaceuticals  
WANG LIYING  
FRUTOS ANTHONY G  
MAYO FOUNDATION FOR MEDICAL EDUCATION AND  
RESEARCH  
O'MALLEY SHAWN M  
HARMON H J  
HEMISPHERx BIOPHARMA  
Schering Aktiengesellschaft  
Board of Trustees Operating Michigan State University  
BOISSY GUILLAUME  
Jun04  
8Mar05

28Apr03  
17Oct05  
5Aug03  
3Jan06  
12Mar04  
20Jan06  
20Sep02  
8-Jul03  
8Dec03  
29Dec03  
19Dec05  
5May03  
15Sep03  
9Apr04  
21Aug04  
24Oct05  
4Dec03  
30Dec05  
25Jul-03  
29Dec05  
8Nov05  
28Dec05  
25Oct05  
16May03  
9May03  
3-Jul03  
8Dec05  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
15Jun  
-05  
8Mar  
-05  
9Nov  
-06  
17Oct  
-06  
5Aug  
-04  
3Jan  
-07  
2Mar  
-05  
22Jan  
-07  
11Dec  
-06  
22Nov  
-06  
7Dec  
-04  
22Dec  
-04

19Dec  
-06  
5May  
-04  
15Sep  
-04  
8Apr  
-05  
22Feb  
-07  
23Oct  
-06  
3Dec  
-04  
16Aug  
-06  
26Jul04  
7Jun  
-06  
7Nov  
-06  
25Oct  
-06  
25Oct  
-06  
26Jan  
-07  
7May  
-04  
2Jul04  
8Dec  
-05  
16Aug  
-07  
9Aug  
-07  
9Aug  
-07  
9Aug  
-07  
2Aug  
-07  
2Aug  
-07  
2Aug  
-07  
26Jul07  
26Jul07  
26Jul07  
26Jul07  
19Jul07  
19Jul07  
19Jul07  
19Jul07

19Jul07  
19Jul07  
12Jul07  
5Jul07  
5Jul07  
5Jul07  
5Jul07  
28Jun07  
28Jun07  
21Jun07  
21Jun07  
21Jun07  
14Jun07  
14Jun07  
174  
US20070135  
367  
US20070134  
695  
US20070134  
694  
US20070134  
255  
US20070134  
214  
US20070123  
566  
US20070116  
785  
US20070116  
716  
US20070116  
600  
US20070111  
309  
US20070111  
296  
US20070111  
231  
US20070105  
193  
US20070104  
808  
US20070104  
686  
US20070099  
968  
US20070099  
901  
US20070099  
855  
US20070099  
178  
US20070098

735

US20070098

719

US20070093

969

US20070092

938

US20070092

936

US20070092

871

US20070087

974

US20070087

341

US20070087

340

US20070087

339

Method for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity

Dengue virus detection measured by immunocytometry in a dendritic cell surrogate

Method for the measurement of dengue virus binding inhibition

Hmpv treatment with ribavirin and anti-hmpv antibody

Inactivated host cell delivery of polynucleotides encoding immunogens

Isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as an effective constituents

26FUKUHARA

TAKESHI

BURGESS TIMOTHY

BURGESS TIMOTHY

ViroNovative B.V.

XU FENG

CHENGDU DIKANG PHARMACEUTICAL INSTITUTE

Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant MILLER

CHRISTOPHER C

Sars coronavirus s proteins and uses thereof

Detection device and methods associated therewith

Vero cell line adapted to grow in suspension

Methods and Devices for Quantitative Viral Assays

Detection of mutations in a gene associated with resistance to viral infection, OAS2 and OAS3

Severe acute respiratory syndrome DNA vaccine compositions and methods of use

FIELDING BURTRAM C

COOK RICHARD A

DAELLI MARCELO G

SHU YING

Illumigen Biosciences, Inc.

Vical Incorporated

COMPOSITIONS AND METHODS FOR TREATMENT OF RHINOVIRUS THE QUIGLEY CORPORATION  
Vaccines, immunotherapeutics and methods for using the same  
Antiviral compounds and methods  
Hydroxylamine and oxime substituted imidazoquinolines,  
imidazopyridines, and imidazonaphthyridines  
Glycyrrhizin or derivatives thereof for for treating or preventing  
severe acute respiratory syndrome (sars)  
Method for detecting sars coronavirus  
Methods for the Elimination of Pathogens and Other Particulate  
Agents  
GITR binding molecules and uses therefor  
Molecular nephrotoxicology modeling  
Diagnostics for sars virus  
Severe acute respiratory syndrome  
Microarray for pathogen identification  
TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS  
WITH IMMUNOMODULATOR COMPOUNDS  
Compositions for use in identification of influenza viruses  
Compositions for use in identification of influenza viruses  
Compositions for use in identification of influenza viruses  
CHATTERGOON MICHAEL A  
Biotron Limited  
3M INNOVATIVE PROPERTIES COMPANY  
Johann Wolfgang Goethe University  
EIKEN KAGAKU KABUSHIKI KAISHA  
CHANDAWARKAR RAJIV Y  
TolerRx, Inc.  
CASTLE ARTHUR  
Temasek Life Sciences Laboratory  
HAYNES BARTON F  
COMBIMATRIX CORP  
SCICLONE PHARMACEUTICALS, INC.  
ESHOO MARK W  
ESHOO MARK W  
ESHOO MARK W  
Dec03  
27Oct05  
27Oct05  
2May03  
13Aug03  
15May03  
18Nov05  
10Dec03  
23Jun05  
4Oct05  
16Nov05  
23Aug05  
16May03  
6Aug01  
13Jun03  
24Jun04  
25Nov03  
6Jun03  
27Jun03

29Oct05  
25Mar05  
22Nov02  
15Jul-03  
8May03  
20Oct05  
14May04  
17Oct05  
17Oct05  
17Oct05  
24Dec  
-04  
26Oct  
-06  
26Oct  
-06  
3May  
-04  
12Aug  
-04  
14May  
-04  
20Nov  
-06  
10Dec  
-04  
23Jun  
-06  
29Sep  
-06  
16Nov  
-06  
23Aug  
-06  
12May  
-04  
27Oct  
-06  
14Jun  
-04  
24Jun  
-04  
24Nov  
-04  
7Jun  
-04  
15Jun  
-04  
30Oct  
-06  
27Mar  
-06  
24Nov  
-03





26Apr07  
19Apr07  
19Apr07  
19Apr07  
19Apr07  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
175  
  US20070087  
338  
US20070087  
337  
US20070087  
336  
US20070087  
332  
US20070087  
008  
US20070082  
971  
US20070077  
201  
US20070072  
893  
US20070072  
202  
US20070066  
649  
US20070066  
648  
US20070066  
639  
US20070066  
552  
US20070065  
939  
US20070065  
407  
US20070060  
754  
US20070060  
611  
US20070060  
535  
US20070060  
499  
US20070059  
728  
US20070059  
686  
US20070059  
243  
US20070054

937

US20070054

834

US20070053

933

US20070053

920

US20070053

878

US20070048

759

US20070048

747

US20070048

282

17Compositions

for use in identification of influenza viruses

Compositions for use in identification of influenza viruses

Compositions for use in identification of influenza viruses

Pulmonary stem cells, related methods and kits of parts

ESHOO MARK W

ESHOO MARK W

ESHOO MARK W

LING THAI-YEN

Rab9a, rab11a, and modulators thereof related to infectious disease UNIV

VANDERBILT

Use of a plastic composition and a product obtained thereby

Stem cell expansion and uses

Substituted imidazo ring systems and methods

Use of chimeric receptors in a screening assay for identifying

agonists and antagonists of cell receptors

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF

BRAIN INFLAMMATION AND SEPSIS

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF

BRAIN INFLAMMATION AND SEPSIS

Oxime substituted imidazoquinolines

Topical administration permitting prolonged exposure of target cells

to therapeutic and prophylactic nucleic acids

Systems for detection and production of respiratory, herpes and

enteric viruses

Interferon-Alpha Polypeptides and Conjugates

Alkoxy substituted imidazoquinolines

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF

BRAIN INFLAMMATION AND SEPSIS

Targeted delivery of antiviral compounds through hemoglobin

bioconjugates

Chloroquine combination drugs and methods for their synthesis

COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER

SYSTEM AND METHOD

Materials and methods for the detection of severe acute respiratory

syndrome virus (SARS)

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF

BRAIN INFLAMMATION AND SEPSIS

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF

BRAIN INFLAMMATION AND SEPSIS

POLYGIENE AB

DOWDING CHARLES

AMOS DAVID T

BATES ELIZABETH E M

Not Available

NOZAKI MASAOKO

AMOS DAVID T

INTROGEN THERAPEUTICS INC

Diagnostic Hybrids, Inc.

MAXYGEN INC

HARALDSON CHAD A

Not Available

ADAMSON J G

KOSAK KENNETH M

The Government of the US, as represented by the

Secretary of the Navy

ERAGEN BIOSCIENCES INC

Not Available

Not Available

Quaternary ammonium halides for treatment of infectious conditions NANOBIO CORP

IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL

METHODS OF USING SAME

Nematode polypeptide adjuvant

Sars

DETECTION OF TARGET MOLECULES WITH LABELED NUCLEIC ACID

DETECTION MOLECULES

Methods for assaying analytes

Albumin fusion proteins

Fauci/COVID-19 Dossier

SHEPPARD PAUL O

Not Available

FOUCHIER RONALDUS A M

LI YOUGEN

LESLIE THOMAS M

Human Genome Sciences, Inc.

CC-BY-NC-SA Dr. David E. Martin

Oct05

17Oct05

17Oct05

17Oct05

24Feb04

23Feb04

29Sep04

25Nov03

24Mar05

29Nov02

29Nov02

12Aug04

21Jan05

20Sep05

18Nov02

30Oct03

29Nov02

30Apr98  
15Sep05  
2-Jul04  
31Jan04  
29Nov02  
29Nov02  
11Apr05  
20Jul-05  
22Jan03  
8Apr03  
10Jun05  
1Sep05  
9Feb04  
17Oct  
-06  
17Oct  
-06  
17Oct  
-06  
17Oct  
-05  
24Feb  
-05  
27Jan  
-05  
25Mar  
-06  
24Nov  
-04  
24Mar  
-06  
1Nov  
-06  
1Nov  
-06  
12Aug  
-04  
20Jan  
-06  
28Apr  
-06  
30Oct  
-06  
10ct  
-04  
1Nov  
-06  
13Nov  
-06  
22Feb  
-06  
6Jun  
-06  
28Jul06

15Mar  
-07  
15Mar  
-07  
15Mar  
-07  
15Mar  
-07  
15Mar  
-07  
15Mar  
-07  
22Mar  
-07  
22Mar  
-07  
22Mar  
-07  
22Mar  
-07  
22Mar  
-07  
22Mar  
-07  
22Mar  
-07  
22Mar  
-07  
29Mar  
-07  
29Mar  
5Apr07  
12Apr07  
19Apr07  
19Apr07  
19Apr07  
19Apr07  
19Apr07  
176  
-06  
8Aug  
-05  
1Sep  
-06  
12Jun  
-04  
8Apr  
-04  
21Jan  
20Jul06  
-06  
10Apr  
-06  
1Nov  
-06  
1Nov

-07  
8Mar  
-07  
8Mar  
-07  
8Mar  
-07  
8Mar  
-07  
1Mar  
-07  
1Mar  
-07  
1Mar  
-07  
US20070042  
441  
US20070042  
388  
US20070042  
381  
US20070042  
351  
US20070042  
350  
US20070041  
941  
US20070037  
763  
US20070037  
231  
US20070037  
142  
US20070037  
140  
US20070036  
760  
US20070036  
744  
US20070034  
529  
US20070032  
499  
US20070031  
923  
US20070031  
832  
US20070031  
283  
US20070027  
306  
US20070026

391

US20070026

087

US20070026

014

US20070026

009

US20070025

966

US20070021

439

US20070021

326

US20070020

734

US20070020

235

US20070015

181

Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device

2BioScale,  
Inc.

Method of probe design and/or of nucleic acids detection  
BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY  
VIRAL AND VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES  
THEREOF

Multi-allelic molecular detection of sars-associated coronavirus  
Methods and compositions for detecting sars virus and other  
infectious agents

Nucleic acid sequences encoding and compositions comprising ige  
signal peptide and/or il-15 and methods for using the same  
Oligonucleotide compound and method for treating nidovirus  
infections

Methods and apparatus for detecting bacteria using an acoustic  
device

Methods and apparatus for detecting viruses using an acoustic  
device

Methods and compositions for detecting sars virus

Adeno-associated virus (aav) clades, sequences, vectors containing  
same, and uses therefor

Treatment or prevention of respiratory viral infections with alpha  
thymosin peptides

Electrochemistry and electrogenerated chemiluminescence with a  
single faradaic electrode

LEE CHARLIE

May05

12Aug05

16Rosetta

Genomics

Jan03

22KOSTRIKIS

LEONDIOS G

CHENG JING



BOYER JEAN D  
AVI BIOPHARMA INC  
BioScale, Inc.  
BioScale, Inc.

CAPITAL BIOCHIP COMPANY, LTD.  
The Trustees of the University of Pennsylvania  
SciClone Pharmaceuticals, Inc.

BARD ALLEN J  
Novel cysteine protease inhibitors and their therapeutic applications BOISSY  
GUILLAUME

Modified viral particles with immunogenic properties and reduced  
lipid content useful for treating and preventing infectious diseases  
Methods of constructing biodiverse gene fragment libraries and  
biological modulators isolated therefrom

Assay cartridges and methods for point of care instruments

Albumin fusion proteins

Methods and compositions for identifying chemical or biological  
agents using multiplexed labeling and colocalization detection

Anti-coronavirus agent

Interferon beta in severe acute respiratory syndrome (sars)

Systems and methods for identifying replikin scaffolds and uses of  
said replikin scaffolds

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

Methods of reducing risk of infection from pathogens with soluble  
amide and ester pyrazinoylguanidine sodium channel blockers

Composition and its Therapeutic Use

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES

CHAM BILL E

Phylogica Limited

BLANKFARD MARTIN

HASELTINE WILLIAM A

GHC TECHNOLOGIES INC

Toagosei Co., Ltd.

ARES TRADING S.A.

BOGOCH ELENORE S

MAXYGEN, INC.

PARION SCIENCES INC

INSIGNION HOLDINGS LTD AND VER

MAXYGEN, INC.

MAXYGEN, INC.

System and methods for nucleic acid and polypeptide selection WILLIAMS RICHARD B

Aug03

14Jul-03

13Jun03

24Dec03

2May05

2May05

9May03

30Sep03

23Apr03

3Jun05

5Aug05

29Jun00

5May99  
23Jun05  
9Feb04  
11Apr05  
16Oct03  
17Apr03  
27Mar01  
19May04  
25Jul-05  
9Aug02  
19May04  
19May04  
19May00  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
2May  
-06  
12Aug  
-05  
26May  
-04  
13Aug  
-04  
14Jul03  
14Jun  
-04  
10May  
-06  
2May  
-06  
2May  
-06  
9May  
-03  
30Sep  
-04  
23Apr  
-04  
2Jun  
-06  
5Aug  
-05  
10Apr  
-06  
20Feb  
-04  
23Jun  
-06  
8Aug  
-06  
6Apr  
-06  
31Oct

-03  
6Apr  
-04  
16Feb  
-06  
13Sep  
-06  
25Jul05  
25Sep  
-06  
13Sep  
-06  
13Sep  
-06  
2May  
-06  
22Feb  
-07  
22Feb  
-07  
22Feb  
-07  
22Feb  
-07  
22Feb  
-07  
22Feb  
-07  
22Feb  
-07  
15Feb  
-07  
15Feb  
-07  
15Feb  
-07  
15Feb  
-07  
15Feb  
-07  
15Feb  
-07  
15Feb  
-07  
15Feb  
-07  
8Feb  
-07  
8Feb  
-07  
8Feb  
-07  
8Feb  
-07  
1Feb  
-07  
1Feb  
-07

1Feb  
-07  
1Feb  
-07  
1Feb  
-07  
1Feb  
-07  
25Jan07  
25Jan07  
25Jan07  
25Jan07  
18Jan07  
177  
US20070015  
172  
US20070014  
778  
US20070014  
719  
US20070009  
932  
US20070009  
884  
US20070004  
028  
US20070003  
577  
US20070003  
565  
US20060293  
352  
US20060293  
308  
US20060293  
267  
US20060292  
178  
US20060292  
162  
US20060292  
151  
US20060287  
263  
US20060286  
667  
US20060286  
124  
US20060286  
121  
US20060286  
119  
US20060281  
128

US20060281

072

US20060280

754

US20060280

748

US20060280

723

US20060280

679

US20060276

972

US20060275

841

US20060275

802

US20060275

749

US20060275

515

1Expression

profiles for microbial infection

Endoribonuclease and uses thereof

Steroid analogs and characterization and treatment methods

Promoter engineering and genetic control

Z-BioMed, Inc.

LEE CHOW

DOWDING CHARLES

ALPER HAL S

Methods and apparatuses for detecting chemical or biological agents GHC

TECHNOLOGIES INC

Signal measuring system for conducting real-time amplification  
assays

Purified trimeric S protein as vaccine against severe acute  
respiratory syndrome virus infections

Use of hab18g/cd147 molecule as target for antiviral antagonists  
and thus obtained antiviral antagonist

Phenoxyacetic acid derivatives

Pyridyl derivatives and their use as therapeutic agents

Dual functional oligonucleotides for use as anti-viral agents

Proteins encoded by the severe acute respiratory syndrome (SARS)  
coronavirus and a role in apoptosis

Plasma or serum fraction for the treatment or prevention of  
bacterial infections

L-SIGN polymorphisms and methods involving use of same

Methods and compositions for inducing antigen-specific immune  
responses

Methods for detection and production of influenza viruses

GEN-PROBE INCORPORATED

CHU KID

CHEN ZHINAN

BONNERT ROGER V

Xenon Pharmaceuticals Inc.

UNIVERSITY OF MASSACHUSETTS

Agency for Science, Technology and Research  
BUCKHEIT ROBERT W JR  
GARDNER JASON P  
COLEY PHARMACEUTICAL GROUP LTD  
Diagnostic Hybrids, Inc.  
Vaccine compositions and methods of treating coronavirus infection ID Biomedical  
Corporation of Quebec  
Adenoviral vector-based vaccines  
Compositions and methods for treatment of chronic and infectious  
diseases  
Compositions and methods using lentivirus-based vectors for  
generating immune responses  
Agonistic Binding Molecules to the Human OX40 Receptor  
Method of preventing virus: cell fusion by inhibiting the function of  
the fusion initiation region in rna viruses having class i membrane  
fusogenic envelope proteins  
Plasma or serum fraction for treatment or prevention of abnormal  
cell proliferation  
Interferon for treating or preventing a coronaviral infection  
Method of treating autoimmune disease by inducing antigen  
presentation by tolerance inducing antigen presenting cells  
Method for determining the amount of an analyte in a sample  
Assay method and apparatus with reduced sample matrix effects  
Mutations in OAS1 genes  
Compositions for use in identification of orthopoxviruses  
Antiviral preparations obtained from a natural cinnamon extract  
Fauci/COVID-19 Dossier  
BROUGH DOUGLAS E  
Biokit S.A.  
VIRXSYS CORPORATION  
BAKKER ALEXANDER BERTHOLD H  
GARRY ROBERT F  
BUCKHEIT ROBERT W JR  
Viragen, Inc  
BOWDISH KATHERINE S  
Gen-Probe Incorporated  
BLANKFARD MARTIN  
FELLIN P C  
ISIS Pharmaceuticals, Inc.  
OVADIA MICHAEL  
CC-BY-NC-SA Dr. David E. Martin  
Jun05  
6Jun05  
29Sep04  
27Apr05  
11Apr05  
10Mar05  
28Jun05  
9Jun03  
21Aug03  
29Jul-03  
13Apr05  
4Aug04  
22Apr05

26Mar04  
18Jul-04  
24Apr98  
30Jun04  
25Jul-03  
23Dec03  
9Sep03  
13Jun02  
4Nov03  
22Apr05  
19May03  
4Mar03  
10Mar05  
20Dec04  
4May05  
5Dec03  
24Dec03  
30Nov  
-05  
5Jun  
-06  
29Sep  
-05  
26Apr  
-06  
6Apr  
-06  
10Mar  
-06  
27Jun  
-06  
9Jun  
-03  
18Aug  
-04  
29Jul04  
13Apr  
-06  
4Aug  
-05  
24Apr  
-06  
28Mar  
-05  
18Jul05  
28Apr  
-06  
30Jun  
-05  
23Jan  
-06  
6Apr  
-06  
17Aug

-06  
13Jun  
-03  
3Nov  
-04  
24Apr  
-06  
19May  
-04  
17Dec  
-04  
10Mar  
-06  
19Dec  
-05  
3May  
-06  
24Aug  
-05  
22Jun  
-06  
178  
18Jan07  
18Jan07  
18Jan07  
11Jan07  
11Jan07  
4Jan07  
4Jan07  
4Jan07  
28Dec  
-06  
28Dec  
-06  
28Dec  
-06  
28Dec  
-06  
28Dec  
-06  
28Dec  
-06  
21Dec  
-06  
21Dec  
-06  
21Dec  
-06  
21Dec  
-06  
21Dec  
-06  
14Dec  
-06



14Dec  
-06  
14Dec  
-06  
14Dec  
-06  
14Dec  
-06  
14Dec  
-06  
7Dec  
-06  
7Dec  
-06  
7Dec  
-06  
7Dec  
-06  
7Dec  
-06  
US20060275  
317  
US20060270  
835  
US20060270  
614  
US20060270  
041  
US20060270  
017  
US20060269  
976  
US20060269  
936  
US20060269  
911  
US20060269  
572  
US20060269  
538  
US20060264  
448  
US20060264  
444  
US20060264  
435  
US20060263  
847  
US20060263  
765  
US20060259  
249  
US20060258  
611

US20060258

577

US20060257

993

US20060257

992

US20060257

991

US20060257

976

US20060257

945

US20060257

941

US20060257

925

US20060257

866

US20060257

861

US20060257

854

US20060257

852

Vaccine compositions for prevention of chronic and infectious diseases

23Biokit

S.A.

Diagnosis and treatment of Alzheimer disease

Use of chalcones for the treatment of viral disorders

Cell lines for production of replication-defective adenovirus

Inactivation of a pathogen in a sample by a treatment with formalin and UV light

METHOD FOR REDUCING LYSOZYME ENZYMATIC ACTIVITY

Biokit S.A.

BODDUPALLI SEKHAR

HOWE JOHN A

BARRETT NOEL

Biokit S.A.

Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists DOLLET SANDRA

Antisense antiviral compound and method for treating ssRNA viral infection

Accelerated vaccination

Serine proteases with altered sensitivity to activity-modulating substances

Purine derivatives

Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases

Novel compounds

Compositions and methods for treatment of severe acute respiratory syndrome (sars)

Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)

Rapid identification of microbial agents

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference  
ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES  
Integration of fluids and reagents into self-contained cartridges containing sensor elements  
Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems  
Integration of fluids and reagents into self-contained cartridges containing particle-based sensor elements and membrane-based sensor elements  
Methods and kits for propagating and evolving nucleic acids and proteins  
Methods and apparatus for detecting cardiac injury markers using an acoustic device  
Integration of fluids and reagents into self-contained cartridges containing particle and membrane sensor elements  
Method for isolating intracellular antibodies able to neutralize protein interactions  
Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mrna decay  
Screening assay for inhibitors of severe acute respiratory syndrome (SARS) using SELDI-TOF Mass Spectrometry  
Membrane assay system including preloaded particles  
Severe acute respiratory syndrome coronavirus  
AVI BIOPHARMA INC  
GEISBERT THOMAS W  
COCO WAYNE M  
PFIZER LTD  
BONNERT ROGER V  
BONNERT ROGER  
SIBER GEORGE R  
HOUDE MICHEL  
ECKER DAVID J  
UNIV HONG KONG  
ERICKSON JOHN W  
ANSLYN ERIC  
ANSLYN ERIC  
ANSLYN ERIC  
RNA LINE OY  
BioScale, Inc.  
ANSLYN ERIC  
LINE GENOMICS S.P.A.  
ALMSTEAD NEIL G  
Wright State University  
BALLARD KARRI L  
Chiron Corporation  
Dec03  
23Dec03  
24May05  
13Dec04  
26May05  
23Dec03  
24Mar05

16Sep04  
1Aug03  
27May05  
4May05  
18Aug03  
7Apr03  
20May03  
9May03  
3Mar04  
19May03  
28Apr03  
27Feb04  
27Feb04  
27Feb04  
6Jun03  
2May05  
27Feb04  
21Nov02  
24Jul-02  
12May05  
27Feb04  
10Apr03  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
6Apr  
-06  
6Apr  
-06  
24May  
-05  
12Dec  
-05  
26May  
-05  
5Apr  
-06  
23Mar  
-06  
10May  
-06  
17Jan  
-06  
26May  
-06  
3May  
-06  
16Aug  
-04  
6Apr  
-04  
20May  
-04  
5May

-04  
3Mar  
-05  
14Jun  
-06  
28Apr  
-04  
22Dec  
-04  
22Dec  
-04  
22Dec  
-04  
7Jun  
-04  
2May  
-06  
22Dec  
-04  
21Nov  
-03  
24Jul03  
12May  
-06  
22Dec  
-04  
9Apr  
-04  
7Dec  
-06  
30Nov  
-06  
30Nov  
-06  
30Nov  
-06  
30Nov  
-06  
30Nov  
-06  
30Nov  
-06  
30Nov  
-06  
30Nov  
-06  
30Nov  
-06  
23Nov  
-06  
23Nov  
-06  
23Nov  
-06

23Nov  
-06  
23Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
16Nov  
-06  
179  
US20060253  
060  
US20060252  
767  
US20060246  
081  
US20060241  
546  
US20060240  
551  
US20060240  
530  
US20060240  
515  
US20060240  
412  
US20060235  
350  
US20060234  
981  
US20060234

263

US20060229

356

US20060228

299

US20060223

863

US20060223

847

US20060223

184

US20060223

074

US20060216

702

US20060211

765

US20060211

752

US20060211

130

US20060211

115

US20060210

967

US20060210

433

US20060205

713

US20060205

040

US20060204

997

US20060199

802

Method of using oxidative reductive potential water solution in dental applications

Oculus

Innovative Sciences, Inc.

Piperazine derivatives and their use as therapeutic agents

Methods and compositions for polytopic vaccination

Method of treating second and third degree burns using oxidative reductive potential water solution

Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus

XENON PHARMACEUTICALS INC.

DEEM MICHAEL W

Oculus Innovative Sciences, Inc.

HE YUXIAN

Methods and compositions for infectious cDNA of SARS coronavirus UNIV NORTH CAROLINA

Soluble fragments of the SARS-CoV spike glycoprotein

Compositions for use in identification of adenoviruses

Method of treating skin ulcers using oxidative reductive potential

water solution  
Boron-containing small molecules  
Method for reducing the presence of amplification inhibitors in a reaction receptacle  
Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions  
Constructs binding to phosphatidylserine and their use in disease treatment  
Methods for treating Hepatitis C  
Anti-coronavirus drug  
Supports useful in incorporating biomolecules into cells and methods of using thereof  
Spotting compositions and methods of use thereof  
Virus-like particles, methods of preparation, and immunogenic compositions  
Novel compounds  
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression  
Method for continuous mode processing of multiple reaction receptacles in a real-time amplification assay  
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses  
Re-sequencing pathogen microarray  
DIMITROV DIMITER S  
BLYN LAWRENCE  
Oculus Innovative Sciences, Inc.  
Anacor Pharmaceuticals  
Gen-Probe Incorporated  
Universita' Degli Studi Di Roma "Tor Vergata"  
PEREGRINE PHARMACEUTICALS INC  
AREFOLOV ALEXANDER  
Arigen, Inc.  
FRUTOS ANTHONY G  
BUNCH THOMAS A  
COMPANS RICHARD W  
ASTRAZENECA AB  
May05  
30Jul-03  
29Apr05  
23Mar05  
2Jun04  
21Jul-03  
21Jul-03  
11Sep03  
23Mar05  
16Feb05  
10Mar05  
12Aug03  
24Jan05  
14Jul-04  
15Jul-03  
5Apr05



5Apr05  
17May02  
7Apr03  
16BENAVIDES-PERALTA  
URUGUAYSITO  
Mar04  
10Gen-Probe  
Incorporated  
The Trustees of the University of Pennsylvania  
AGAN BRIAN K  
Signal measuring system having a movable signal measuring device GEN-PROBE  
INCORPORATED  
Pyridazine derivatives and their use as therapeutic agents  
Compositions for use in identification of adventitious viruses  
Method for performing multi-formatted assays  
Pyridyl derivatives and their use as therapeutic agents  
Xenon Pharmaceuticals Inc.  
SAMPATH RANGARAJAN  
Gen-Probe Incorporated  
ABREO MELWYN  
Mar05  
20Jun03  
2-Jul04  
10Mar05  
29Jul-04  
3Mar05  
10Mar05  
30Jul-03  
2May  
-06  
29Jul04  
29Apr  
-05  
23Mar  
-06  
8Feb  
-06  
19Jan  
-06  
19Jan  
-06  
12Apr  
-06  
23Mar  
-06  
16Feb  
-06  
10Mar  
-06  
11Aug  
-04  
24Jan  
-06  
14Jul05

14Jul04  
5Apr  
-05  
5Apr  
-05  
4Apr  
-06  
6Apr  
-04  
17May  
-05  
10Mar  
-06  
15Jun  
-04  
2Jul05  
10Mar  
-06  
29Jul04  
3Mar  
-06  
10Mar  
-06  
29Jul04  
9Nov  
-06  
9Nov  
-06  
2Nov  
-06  
26Oct06  
26Oct06  
26Oct06  
26Oct06  
26Oct06  
19Oct06  
19Oct06  
19Oct06  
12Oct06  
12Oct06  
5Oct06  
5Oct06  
5Oct06  
5Oct06  
28Sep  
-06  
21Sep  
-06  
21Sep  
-06  
21Sep  
-06  
21Sep  
-06

21Sep  
-06  
21Sep  
-06  
14Sep  
-06  
14Sep  
-06  
14Sep  
-06  
7Sep  
-06  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
180  
  US20060199  
176  
US20060195  
067  
US20060193  
745  
US20060190  
189  
US20060189  
644  
US20060189  
571  
US20060189  
570  
US20060189  
569  
US20060189  
568  
US20060189  
542  
US20060188  
519  
US20060178  
341  
US20060177  
849  
US20060177  
837  
US20060177  
813  
US20060171  
962  
US20060171  
958  
US20060165  
723  
US20060165  
716

US20060163  
149  
US20060160  
109  
US20060154  
243  
US20060153  
803  
US20060147  
958  
US20060143  
719  
US20060142  
383  
US20060142  
202  
US20060140  
971  
US20060135  
458  
Coronavirus S peptides  
CHONG PELE C S  
Delivery of immune response modifier compounds  
Virucidal disinfectant  
Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research  
Lipid-modified immune response modifiers  
Use of lipid conjugates in the treatment of infection  
Use of lipid conjugates in the treatment of infection  
Use of lipid conjugates in the treatment of infection  
Use of lipid conjugates in the treatment of infection  
Preventive or therapeutic composition for viral infectious disease  
Peptides, antibodies, and methods for the diagnosis of SARS  
Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 inhibiting the swine influenza (SIV) and transmissible gastroenteritis coronavirus (tgev)  
Nucleic acid primer set, nucleic acid probe set and method for detecting respiratory disease virus using the primer set and probe set  
Systems and methods for identifying diagnostic indicators  
Novel high-throughput screening method of drug for bioactive protein  
SARS vaccine  
Antiviral activity from medicinal mushrooms  
Nucleic acid sequences encoding proteins capable of associating into a virus-like particle  
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae  
Product for absorption purposes  
Harnessing network biology to improve drug discovery  
Antigenic peptides of SARS coronavirus and uses thereof  
Inhibition of sars coronavirus infection with clinically approved antiviral drugs

System for detecting polynucleotides  
Use of golden hamster as infectivity model of SARS  
3D-Structure model of SARS coronavirus 3CL protease and antiSARS  
drugs  
Compositions and methods for targeted delivery of immune  
response modifiers  
Cell surface expression vector of sars virus antigen and  
microorganisms transformed thereby  
Antiviral oligonucleotides  
Fauci/COVID-19 Dossier  
KEDL ROSS M  
ARNDT ANDREAS  
HOFFMANN GEOFFREY W  
WIGHTMAN PAUL D  
YEDGAR SAUL  
YEDGAR SAUL  
OJCIUS DAVID  
YEDGAR SAUL  
FURUKAWA SATORU  
AU MUN Y D  
15Jul-04  
25Aug03  
28Jan05  
21Apr04  
14Aug03  
10Jan00  
10Jan00  
10Jan00  
10Jan00  
22Jul-03  
14Jun04  
23CHUNG  
BONG H  
Jun03  
23HUH  
NAM  
BOROZAN IVAN  
ENDO YAETA  
Consejo Superior de Investigaciones Cientificas  
STAMETS PAUL  
Fort Dodge Veterinaria S.A.  
BAROCCHI MICHELLE  
HJERTEN MARIE-CHRISTINE  
Odyssey Thera, Inc.  
GOUDSMIT JAAP  
STANTON LAWRENCE W  
CHOI K Y  
CONTAMIN HUGUES  
SHANGHAI LEAD DISCOVERY PHARMA  
3M INNOVATIVE PROPERTIES CO  
CHOI JAE C  
JUTEAU JEAN-MARC  
CC-BY-NC-SA Dr. David E. Martin  
Dec04

13Aug04  
8Sep03  
3Sep04  
6Jan04  
3Sep04  
29Jul-04  
13Jun03  
22Nov04  
21Jul-03  
9Jun03  
20May03  
18Aug04  
4Jun03  
8Dec00  
4Jun03  
13Sep02  
14Jul05  
25Aug  
-04  
27Jan  
-06  
16Mar  
-06  
12Aug  
-04  
8Sep  
-05  
8Sep  
-05  
8Sep  
-05  
8Sep  
-05  
22Jul04  
13Jun  
-05  
23Jun  
-04  
23Dec  
-05  
15Aug  
-05  
8Sep  
-04  
2Sep  
-05  
22Mar  
-06  
2Sep  
-05  
29Jul05  
11Jun  
-04  
21Nov

-05  
20Jan  
-06  
9Jun  
-04  
21Nov  
-05  
16Aug  
-05  
2Dec  
-05  
23Feb  
-06  
4Jun  
-04  
19Oct  
-05  
Sep  
-06  
31Aug  
-06  
31Aug  
-06  
24Aug  
-06  
24Aug  
-06  
24Aug  
-06  
24Aug  
-06  
24Aug  
-06  
24Aug  
-06  
24Aug  
-06  
24Aug  
-06  
24Aug  
-06  
10Aug  
-06  
10Aug  
-06  
10Aug  
-06  
10Aug  
-06  
3Aug  
-06  
3Aug  
-06  
27Jul06  
27Jul06  
27Jul06

20Jul06  
13Jul06  
13Jul06  
6Jul06  
29Jun06  
29Jun06  
29Jun06  
29Jun06  
22Jun06  
181  
7  
US20060135  
422  
US20060134  
753  
US20060134  
609  
US20060134  
397  
US20060128  
628  
US20060123  
499  
US20060122  
368  
US20060121  
580  
US20060121  
043  
US20060115  
875  
US20060113  
298  
US20060111  
387  
US20060110  
803  
US20060110  
758  
US20060110  
405  
US20060100  
232  
US20060100  
229  
US20060099  
606  
US20060099  
573  
US20060094  
105  
US20060094  
104  
US20060093



616

US20060089

324

US20060089

323

US20060088

926

US20060088

909

US20060079

485

US20060075

894

US20060070

952

Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE

17MOSKOWITZ

DAVID W

Super-antigen fusion proteins and the use thereof

Compositions and methods for determining the presence of SARS coronavirus in a sample

Microporous materials, methods, and articles for localizing and quantifying analytes

Human tissue antigen-binding peptides and their amino acid sequences

Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and uses thereof

Antigen delivery platform

Binding molecules against SARS-coronavirus and uses thereof

Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections

Detection, characterization and treatment of viral infection and methods thereof

Electromagnetic wave applicator

ARYL SUBSTITUTED IMIDAZOQUINOLINES

Antigenic peptides of SARS coronavirus and uses thereof

Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof

Plasma or serum fraction for treatment and prevention of viral infections and related conditions

Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof

Pyrazolopyridines and analogs thereof

Assay to detect viral uncoating

Diagnostic assays

Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses

Animal protein-free media for cultivation of cells

Process for vaccinating eucaryotic hosts and for protecting against SARS-CoV infection

RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

Method of removing hazardous substance, and hazardous substance removing material using the same such as air cleaning filter, mask and wiping sheet, and method of storing the same

Virus-like particles, methods of preparation, and immunogenic compositions

Use of lipid conjugates in the treatment of infection

Bioagent air filtration systems

Charge-based water filtration systems

Fauci/COVID-19 Dossier

Healthbanks Biotech Co., Ltd.

GETMAN DAMON K

SMITH ROGER E

CHEN SHOW-LI

CHEN JINDING

GOVERNMENT OF THE U S A AS REP

CRUCCELL

MEDIMMUNE, INC.

BROWN EARL

ZAIDAN HOJIN HANDOTAI KENKYU SHINKOKAI

3M INNOVATIVE PROPERTIES CO

Crucell Holland B.V.

UNIV HONG KONG

BUCKHEIT ROBERT W JR

AGARWAL ATUL

BONK JASON D

NARAYAN SHAKTI

MIGUEZ MARIA-JOSE

Diagnostic Hybrids, Inc.

DORNER FRIEDRICH

ALTMAYER RALF

BARIK SAILEN

BARIK SAILEN

Apr03

21Jul-04

17Apr03

26Nov02

15Dec04

6Dec04

3Dec04

22Jul-03

27Oct04

30Sep03

27Nov02

20Dec02

13Jun03

22Nov04

20Aug04

11Nov04

30Oct03

9Dec03

24Mar04

24Apr98

29Oct04  
29Sep04  
22Oct04  
22Oct04  
28DAIKIN  
IND LTD  
Mar03  
17COMPANS  
RICHARD W  
OJCIUS DAVID  
University of Wyoming Research Corporation d/b/a Western  
Research Institute  
University of Wyoming Research Corporation d/b/a  
CC-BY-NC-SA Dr. David E. Martin  
May02  
10Jan00  
28Jan03  
28Jan03  
31Mar  
-04  
19Jul05  
16Apr  
-04  
20Nov  
-03  
15Dec  
-04  
6Dec  
-04  
2Dec  
-05  
20Jan  
-06  
27Oct  
-05  
11Oct  
-05  
27Nov  
-03  
13Jan  
-06  
6Dec  
-05  
28Oct  
-05  
22Aug  
-05  
10Nov  
-05  
1Apr  
-05  
8Dec  
-04  
24Mar

4May-06  
4May-06  
4May-06  
4May-06  
11May-06  
11May-06  
11May-06  
11May-06  
11May-06  
25May-06  
25May-06  
25May-06  
25May-06  
1Jun06  
1Jun06  
8Jun06  
8Jun06  
8Jun06  
8Jun06  
15Jun06  
22Jun06  
22Jun06  
22Jun06  
22Jun06  
-04  
28Jan-04  
28Jan-04  
-05  
8Sep-03  
19May-04  
26Mar-05  
14Jun-05  
14Jun-05  
28Sep-04  
29Oct-05  
20Sep-05

27Apr06  
27Apr06  
27Apr06  
27Apr06  
13Apr06  
13Apr06  
6Apr06  
182  
US20060067  
940  
US20060063  
150  
US20060063  
149  
US20060062  
804  
US20060057  
605  
US20060057  
161  
US20060053  
516  
US20060051  
744  
US20060051  
374  
US20060035  
926  
US20060035  
859  
US20060035  
853  
US20060035  
327  
US20060034  
853  
US20060024  
668  
US20060024  
271  
US20060019  
976  
US20060019  
967  
US20060019  
927  
US20060019  
923  
US20060018  
923  
US20060018  
877  
US20060014  
254

US20060009

459

US20060008

810

US20060008

379

US20060006

678

US20060003

941

US20060003

352

US20060003

351

Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof

Antisense antiviral compound and method for treating ssRNA viral infection

Compositions and methods for detecting pathogen infection

SARS-CoV-specific B-cell epitope and applications thereof

Compositions for use in identification of viral hemorrhagic fever viruses

Detection of coronavirus infection

Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization against SARS

Feline infectious peritonitis (FIP) and systemic multi-organ coronavirus biomarkers and screening methods

Compositions and methods for mucosal vaccination

Benzothiazolium compounds

Treating severe and acute viral infections

Methods for tailoring the immune response to an antigen or immunogen

Recombinant super-compound interferon and uses thereof

Novel human virus causing respiratory tract infection and uses thereof

Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics

Treatments for viral infections using IFN cytokines and ribavirin, alone or in combination

Methods for treating Hepatitis C

SARS CoV main protease inhibitors

Anti-viral uses of borinic acid complexes

Methods and compositions for inducing innate immune responses

Novel human virus causing respiratory tract infection and uses thereof

Intradermal delivery of vaccines and therapeutic agents

Albumin fusion proteins

Pyridazine derivatives and their use as therapeutic agents

Methods and compositions for detecting rhinoviruses

Room decontamination with hydrogen peroxide vapor

Door handle cover

Peptides and peptidomimetics having immune-modulating, antiinflammatory, and anti-viral activity

Mass tag PCR for mutliplex diagnostics  
Methods and kits for identifying target nucleotides in mixed  
populations

Fauci/COVID-19 Dossier

21DIAMOND

MICHAEL

IVERSEN PATRICK L

BERTHET FRANCOIS X

National Taiwan University

ISIS Pharmaceuticals, Inc.

CHOU CHIH-MING

The University of Hong Kong

AUSTIN KIMBERLY M

3M Innovative Properties Company

LEE SHIOW-JU

HEMISPHERx BIOPHARMA

Biomedical Research Models, Inc.

WEI GUANGWEN

CHAN KWOK H

HOEK CORNELIA V D

ALIBEK KEN

CHEN GUANGMING

HSIEH HSING-PANG

BELLINGER-KAWAHARA CAROLYN

Coley Pharmaceutical Group, Ltd.

CHAN KWOK H

ALARCON JASON B

Human Genome Sciences, Inc.

ABREO MELWYN

Focus Technologies, Inc.

STERIS INC.

HERRON ROY H JR

KAWABE TAKUMI

BRIESE THOMAS

Applera Corporation

CC-BY-NC-SA Dr. David E. Martin

Jun04

16Sep04

23Dec03

21Sep04

22Mar04

16Sep04

5Dec03

30Jun04

28Apr04

13Aug04

16May03

7Jan04

26Aug04

21Jul-04

7Jan04

15Jan04

22Jul-04

21Jul-04

14Jun04  
18Jul-04  
21Jul-04  
29Jun01  
22Jan03  
16Mar04  
6-Jul04  
8-Jul04  
27May04  
25Jun03  
29Apr04  
30Apr04  
21Jun  
-05  
14Sep  
-05  
6Sep  
-05  
21Sep  
-04  
21Mar  
-05  
16Sep  
-04  
3Dec  
-04  
28Jun  
-05  
28Apr  
-05  
15Aug  
-05  
6Oct  
-05  
7Jan  
-05  
10Mar  
-05  
16May  
-05  
18Aug  
-04  
13Jan  
-05  
14Jul05  
20Jul05  
14Jun  
-05  
18Jul05  
21Jul04  
29Apr  
-05  
7Jul05  
9Feb



-05  
6Jul04  
8Jul04  
26May  
-05  
25Jun  
-04  
28Apr  
-05  
29Apr  
-05  
30Mar  
-06  
23Mar  
-06  
23Mar  
-06  
23Mar  
-06  
16Mar  
-06  
16Mar  
-06  
9Mar  
-06  
9Mar  
-06  
9Mar  
-06  
16Feb  
-06  
16Feb  
-06  
16Feb  
-06  
16Feb  
-06  
16Feb  
-06  
2Feb  
-06  
2Feb  
-06  
26Jan06  
26Jan06  
26Jan06  
26Jan06  
26Jan06  
26Jan06  
19Jan06  
12Jan06  
12Jan06  
12Jan06  
12Jan06

5Jan06  
5Jan06  
5Jan06  
183  
US20060003  
340  
US20060002  
947  
US20060002  
932  
US20050288  
866  
US20050287  
167  
US20050287  
118  
US20050282  
279  
US20050282  
209  
US20050282  
154  
US20050281  
828  
US20050277  
592  
US20050277  
181  
US20050276  
818  
US20050276  
815  
US20050271  
711  
US20050266  
550  
US20050266  
465  
US20050266  
425  
US20050266  
397  
US20050260  
645  
US20050255  
123  
US20050250  
677  
US20050249  
742  
US20050249  
739  
US20050244  
423

US20050240  
353  
US20050239  
735  
US20050239  
086  
US20050239  
047  
US20050238  
655  
22Multi-allelic  
molecular detection of SARS-associated coronavirus  
Ii-key/antigenic epitope hybrid peptide vaccines  
Methods and compositions for enhancement of immunity by in vivo  
depletion of immunosuppressive cell activity  
Computational method for identifying adhesin and adhesin-like  
proteins of therapeutic potential  
Polycistronic HIV vector constructs  
Bacterial plasmid with immunological adjuvant function and uses  
thereof  
Expression vector encoding coronavirus-like particle  
Variable length probe selection  
Angiotensin-converting enzyme-2 as a receptor for the SARS  
coronavirus  
Method of treating autoimmune disease by inducing antigen  
presentation by tolerance inducing antigen presenting cells  
Beta-peptides  
Compositions and methods for detecting pathogen infection  
Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMPdependent  
kinase and a target for SARS therapy  
Antiviral activity from medicinal mushrooms  
Therapeutic antimicrobial compositions and methods  
TC-83-derived alphavirus vectors, particles and methods  
Interferon-alpha polypeptides and conjugates  
Methods for producing and identifying multispecific antibodies  
Methods for identification of coronaviruses  
Comparative genomic resequencing  
Chimeric ebola virus envelopes and uses therefor  
Glycopeptide antibiotic derivatives  
Compositions and methods for modulating a cytotoxic T lymphocyte  
immune response  
Antibodies against SARS-CoV and methods of use thereof  
Methods for treating viral infection using IL-28 and IL-29 cysteine  
mutants  
Reagents, devices and methods for proteomic analysis with  
applications including diagnostics, vaccines, quality control and  
research  
Enhancement of immune responses  
Multiplex systems, methods, and kits for detecting and identifying  
nucleic acids  
Methods and devices for determining a cell characteristic, and  
applications employing the same  
Antiviral activity from medicinal mushrooms  
Fauci/COVID-19 Dossier

BRIESE THOMAS  
GIMZEWSKI JAMES K  
STAMETS PAUL  
CC-BY-NC-SA Dr. David E. Martin  
Vaccinex, Inc.  
BLYN LAWRENCE B  
ALBERT THOMAS  
The Trustees of the University of Pennsylvania  
BALZARINI JAN  
Dana-Farber Cancer Institute, Inc.  
MARASCO WAYNE  
HENDERSON KATHERINE E  
BOWDISH KATHERINE S  
Yale University  
BERTHET FRANCOIS X  
GODZIK ADAM  
STAMETS PAUL  
The Procter & Gamble Company  
Alphavax, Inc.  
HWU PAUL L  
ALBERT THOMAS  
Birch Biomedical Research, LLC  
HUMPHREYS ROBERT  
Duke University  
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH  
Aug03  
14Sep99  
4Jun04  
20Jul-04  
5May04  
26Nov03  
29May03  
18Jun04  
6Oct03  
28Feb04  
21Apr04  
23Dec04  
17May04  
6Jan04  
26Apr04  
18May04  
19May04  
31Dec03  
26Apr03  
8Apr04  
30Apr02  
1Sep03  
27Jun02  
25Nov03  
2Apr04  
21Apr04  
30Dec03  
27Apr04  
10Sep02

6Jan04  
13Aug  
-04  
11Jan  
-05  
3Jun  
-05  
7Feb  
-05  
5May  
-05  
23Nov  
-04  
28May  
-04  
20Jun  
-05  
5Oct  
-04  
1Apr  
-05  
21Apr  
-05  
27Apr  
-05  
17May  
-05  
6Jan  
-05  
25Apr  
-05  
18May  
-05  
18May  
-05  
29Dec  
-04  
22Apr  
-04  
8Apr  
-05  
28Apr  
-03  
1Sep  
-03  
22Dec  
-04  
24Nov  
-04  
4Apr  
-05  
4Feb  
-05  
30Dec

-04  
27Apr  
-04  
9Mar  
-05  
4Jan  
-05  
5Jan06  
5Jan06  
5Jan06  
29Dec  
-05  
29Dec  
-05  
29Dec  
-05  
22Dec  
-05  
22Dec  
-05  
22Dec  
-05  
22Dec  
-05  
15Dec  
-05  
15Dec  
-05  
15Dec  
-05  
15Dec  
-05  
8Dec  
-05  
1Dec  
-05  
1Dec  
-05  
1Dec  
-05  
1Dec  
-05  
24Nov  
-05  
17Nov  
-05  
10Nov  
-05  
10Nov  
-05  
10Nov  
-05  
3Nov  
-05

27Oct05  
27Oct05  
27Oct05  
27Oct05  
27Oct05  
184  
  US20050234  
122  
US20050233  
314  
US20050232  
895  
US20050223  
427  
US20050222  
258  
US20050220  
816  
US20050215  
494  
US20050214  
890  
US20050214  
748  
US20050214  
747  
US20050208  
066  
US20050208  
060  
US20050208  
020  
US20050208  
019  
US20050203  
038  
US20050203  
024  
US20050202  
415  
US20050196  
382  
US20050196  
381  
US20050191  
620  
US20050189  
302  
US20050187  
192  
US20050186  
575  
US20050182  
243

US20050181  
357  
US20050181  
075  
US20050176  
661  
US20050171  
044  
US20050169  
885  
US20050164  
167  
11Prevention  
of and countermeasures against viral infection  
Sensitive and quantitative detection of pathogens by real-time  
nested PCR  
Anti-viral pharmaceutical compositions  
Modified polynucleotides for reducing off-target effects in RNA  
interference  
Pharmaceuticals comprising shikonins as active constituent  
Mutant viral nucleic acids and vaccine containing same  
Baicalin and its derivatives as a treatment for SARS coronavirus  
infection or other related infections  
Novel "Cleave-N-Read" system for protease activity assay and  
methods of use thereof  
Peptide-based diagnostic reagents for SARS  
Compositions and methods for analysis of target analytes  
Recombinant baculovirus and virus-like particle  
Vaccine composition  
Enhancement of vaccine-induced immune responses and protection  
by heterologous boosting with alphavirus replicon vaccines  
Uses of interferons with altered spatial structure  
Modulation of ACE2 expression  
Peptides and methods for inducing cellular resistance to infection  
Replikin peptides and uses thereof  
Antiviral oligonucleotides targeting viral families  
Lentivirus vector-based approaches for generating an immune  
response to HIV in humans  
Particle on membrane assay system  
Viral inactivation using ozone  
Phospholipids for the treatment of infection by togaviruses, herpes  
viruses and coronaviruses  
Corona-virus-like particles comprising functionally deleted genomes BOSCH BEREND  
J.  
Membrane scaffold proteins  
High-throughput diagnostic assay for the human virus causing  
severe acute respiratory syndrome (SARS)  
Pharmacological enhancement and manufacturing method of  
antiviral compound  
Antiviral oligonucleotides  
Oligonucleotide compound and method for treating nidovirus  
infections  
Recombinant super-compound interferon  
Method of discovery and development of broad-spectrum antiviral



drugs

Fauci/COVID-19 Dossier

BESTWICK RICHARD K.

WEI GUANGWEN

BUSCHER BENJAMIN A.

BAYBURT TIMOTHY H.

CHAN KWOK H.

GONG JIAO

DROPULIC BORO

BALLARD KARRI L.

KEYSER STEVEN A.

BOGOCH ELENORE S.

CHAN KWOK H

BAUDRY MICHEL

CHANG TSENG Y

DANIELZADEH ROBERT

CHAO YU-CHAN

Aventis Pasteur S.A.

BRICE GARY T

WEI GUANGWEN

SD Pharmaceuticals, Inc.

Dharmacon, Inc.

WANG FEIXIN

CHOKO CO., LTD.

Mar04

30Jun03

10Dec03

1Apr04

21Feb03

31Mar04

10Nov03

26Nov03

12Nov03

16Jan04

25Nov03

22Sep04

12Nov03

28Aug03

10Mar04

1Dec03

23Dec03

5Dec02

9Sep03

27Feb04

17Mar04

20Feb04

17May02

18Jun03

24Mar03

21Nov03

5Dec02

24Dec03

28Aug03

28Jan04

CC-BY-NC-SA

Dr. David E. Martin

11Mar

-04

30Jun

-04

3Dec

-04

22Dec

-04

14May

-05

31Mar

-04

8Nov

-04

23Nov

-04

8Nov

-04

17Oct

-04

24Nov

-04

15Nov

-04

10Nov

-04

26Aug

-04

10Mar

-04

1Dec

-04

4Jun

-04

19Oct

-04

9Sep

-04

22Dec

-04

11Oct

-04

20Feb

-04

30Dec

-03

11Jan

-05

24Mar

-04

21Nov

-03

12Sep  
-03  
22Dec  
-04  
26Aug  
-04  
28Jan  
-04  
185  
200ct05  
200ct05  
200ct05  
60ct05  
60ct05  
60ct05  
29Sep  
-05  
29Sep  
-05  
29Sep  
-05  
29Sep  
-05  
22Sep  
-05  
22Sep  
-05  
22Sep  
-05  
15Sep  
-05  
15Sep  
-05  
15Sep  
-05  
8Sep  
-05  
8Sep  
-05  
1Sep  
-05  
25Aug  
-05  
25Aug  
-05  
18Aug  
-05  
18Aug  
-05  
18Aug

-05  
11Aug  
-05  
4Aug  
-05  
4Aug  
-05  
28Jul05  
US20050163  
648  
US20050158  
411  
US20050158  
325  
US20050153  
912  
US20050153  
310  
US20050148  
658  
US20050147  
697  
US20050142  
536  
US20050142  
157  
US20050139  
808  
US20050123  
563  
US20050119  
284  
US20050119  
251  
US20050117  
187  
US20050114  
910  
US20050113  
298  
US20050112  
559  
US20050112  
558  
US20050112  
555  
US20050112  
554  
US20050107  
324  
US20050106  
563  
US20050101  
581

US20050100

885

US20050100

883

US20050100

612

US20050096

259

US20050095

618

US20050095

582

METHOD AND APPARATUS FOR STERILIZING AIR IN LARGE  
VOLUMES BY RADIATION OF ULTRAVIOLET RAYS

26LIANG

MICHAEL Y.

Methods and apparatus to prevent, treat, and cure the symptoms of  
nausea caused by chemotherapy treatments of human cancers

Immunomodulatory combinations

Antiviral oligonucleotides targeting viral families

Luciferase biosensor

Method for preventing and treating severe acute respiratory  
syndrome

Compositions and methods for reducing the transmissivity of  
illnesses

Method and kit for the detection of a novel coronavirus associated  
with the severe acute respiratory syndrome (SARS)

Oxidative reductive potential water solution and methods of using  
the same

Oxidative reductive potential water solution and process for  
producing same

Lipoparticles comprising proteins, methods of making, and using the  
same

ANTIVIRAL AGENTS AND METHODS OF USE

Nicotinamide derivatives and their use as therapeutic agents

Apparatus for forming nano-grating device

Transgenic mice having a human major histocompatibility complex  
(MHC) phenotype, experimental uses and applications

Receptor binding peptides derived from the SARS S protein

Compositions and methods for diagnosing and preventing severe  
acute respiratory syndrome (SARS)

Prognostic PCR assay for severe acute respiratory syndrome (SARS) The Chinese  
University of Hong Kong

Cytidine deaminase activators, deoxycytidine deaminase activators,  
Vif antagonists, and methods of screening for molecules thereof

Characterization of the earliest stages of the severe acute  
respiratory syndrome (SARS) virus and uses thereof

Modulation of CEACAM1 expression

Epitope profiles of SARS coronavirus

Therapeutic treatment methods 2

Compositions and methods for the treatment of severe acute  
respiratory syndrome (SARS)

Peptide-based diagnostic reagents for SARS

Virucidal activities of cetylpyridinium chloride

Neutrophil activation by immune response modifier compounds  
Compositions and methods for diagnosing and treating severe acute  
respiratory syndrome (SARS)

Compositions and methods for detecting severe acute respiratory  
syndrome coronavirus

Fauci/COVID-19 Dossier

The Chinese University of Hong Kong

Diagnostic Hybrids, Inc.

CC-BY-NC-SA Dr. David E. Martin

AHLEM CLARENCE N.

BAKER BRENDA F.

CHANG TSENG Y.

ViraTox, L.L.C.

DEWHURST STEPHEN

HENG XU RUI

BENNETT C. F.

BUTLER BRAEDEN

HENSLEY CHARLES

ROSENBLOOM RICHARD A.

LAUE THOMAS

Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences, Inc.

DORANZ BENJAMIN J.

Wisconsin Alumni Research Foundation -

FINE RICHARD M.

CHEN YUNG-HSIN

AURIAULT CLAUDE

VAIL MARILYN L.

Jan04

8Dec03

30Dec03

5Dec02

10Oct03

5Jan04

6Feb03

30Apr03

30Dec03

30Dec03

30Jul-03

30Sep03

21Dec01

17Mar04

30Jul-03

15Sep03

29Sep03

24Sep03

3Sep03

9-Jul04

12Jul-03

8Sep03

28Aug02

28Apr03

12Nov03

7Nov03

31Oct03  
29Jul-03  
3Nov03  
26Jan  
-04  
27Nov  
-04  
30Dec  
-04  
12Sep  
-03  
10ct  
-04  
5Jan  
-04  
14Dec  
-04  
30Apr  
-04  
11Aug  
-04  
4Jun  
-04  
28Jul04  
30Sep  
-04  
6Jul04  
17Mar  
-04  
2Jul04  
13Sep  
-04  
29Sep  
-04  
23Sep  
-04  
3Sep  
-04  
9Jul04  
12Jul04  
8Sep  
-04  
5Dec  
-03  
26Apr  
-04  
12Nov  
-03  
10Sep  
-04  
1Nov  
-04  
28Jul04  
3Nov

-03  
28Jul05  
21Jul05  
21Jul05  
14Jul05  
14Jul05  
7Jul05  
7Jul05  
30Jun05  
30Jun05  
30Jun05  
9Jun05  
2Jun05  
2Jun05  
2Jun05  
26May  
-05  
26May  
-05  
26May  
-05  
26May  
-05  
26May  
-05  
26May  
-05  
19May  
-05  
19May  
-05  
12May  
-05  
12May  
-05  
12May  
-05  
12May  
-05  
5May  
-05  
5May  
-05  
5May  
-05  
186  
US20050090  
505  
US20050085  
529  
US20050080  
093  
US20050075  
307



US20050074  
743  
US20050074  
359  
US20050071  
892  
US20050070  
460  
US20050069  
911  
US20050069  
869  
US20050069  
558  
US20050069  
555  
US20050065  
143  
US20050059  
578  
US20050059  
576  
US20050059  
072  
US20050058  
982  
US20050054  
644  
US20050054  
640  
US20050053  
990  
US20050051  
497  
US20050048  
473  
US20050048  
465  
US20050048  
072  
US20050039  
220  
US20050037  
338  
US20050036  
951  
US20050032  
222  
US20050031  
620  
US20050031  
592  
20Methods  
of reducing risk of infection from pathogens

Prenylation inhibitors reduce host cell permissiveness to viral replication  
Methods of reducing risk of infection from pathogens  
Modulation of aminopeptidase N expression  
Method and composition for treating a biological sample  
Aircraft and passenger decontamination system  
Techniques and applications of establishment of SARS-CoV primate model  
HOPKINS SAMUEL E.  
BENNETT C. FRANK  
CHAPMAN JOHN  
STERIS INC.  
GAO HONG  
Infection prophylaxis using immune response modifier compounds 3M Innovative Properties Company  
Proteome epitope tags and methods of use thereof in protein modification analysis  
SARS nucleic acids, proteins, antibodies, and uses thereof  
Crystals and structures of SARS-CoV main protease  
Thiosemicarbazones as anti-virals and immunopotentiators  
Pyridazine derivatives and their use as therapeutic agents  
Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents  
Targeted delivery of antiviral compounds through hemoglobin bioconjugates  
Selective modulation of TLR gene expression  
Modified small interfering RNA molecules and methods of use  
Hydrolytically-resistant boron-containing therapeutics and methods of use  
1-Amino 1H-imidazoquinolines  
Cleavage of RNA by restriction endonucleases  
Viral inactivation using ozone  
Enzymatic diagnostic test for SARS and other viral diseases  
Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer  
Immunostimulatory combinations and treatments  
Imageable animal model of SARS infection  
Method and means for detection of severe acute respiratory syndrome  
Methods of treating lung diseases  
Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases  
Combined cancer treatment methods using selected antibodies to aminophospholipids  
Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines  
Fauci/COVID-19 Dossier  
engeneOS, Inc.  
AMBROSINO DONNA  
BONANNO JEFFREY B.  
BARSANTI PAUL A.  
Xenon Pharmaceuticals Inc.  
HE JIN

ADAMSON J. GORDON  
3M Innovative Properties Company  
Chiron Corporation  
AKAMA TSUTOMU  
GRIESGRABER GEORGE W.  
ROBERTS RICHARD J.  
KEYSER STEVEN A.  
ARAD DORIT  
World Sense Technology Limited  
3M Innovative Properties Company  
XU MINGXU  
TSENG KUO-TANG  
Arizeke Pharmaceuticals, Inc.  
BELLOTTI MARC  
HUANG XIANMING  
BRICE GARY L.  
CC-BY-NC-SA Dr. David E. Martin  
HOPKINS SAMUEL E.

Aug03

21Oct03

18Aug04

12Jul-03

6Oct03

6Oct03

27Jun03

5Aug03

10May02

4Aug03

25Jul-03

27Dec02

29Jul-04

15Aug03

30Apr98

17Sep04

25Jul-03

15Jun04

3Sep04

31Aug04

2Aug04

23Jun04

20Aug04

25Aug04

27May04

14Aug03

9Jan04

29Jun00

15Aug03

13Nov03

18Aug

-04

21Oct

-03

18Aug

-04

12Jul04  
6Oct  
-03  
6Oct  
-03  
25Jun  
-04  
5Aug  
-04  
5Feb  
-04  
4Aug  
-04  
23Jul04  
29Dec  
-03  
29Jul04  
15Aug  
-03  
17May  
-04  
17Sep  
-04  
25Jul03  
15Jun  
-04  
3Sep  
-04  
31Aug  
-04  
2Aug  
-04  
23Jun  
-04  
20Aug  
-04  
25Aug  
-04  
27May  
-04  
14Aug  
-03  
9Jan  
-04  
21Jun  
-04  
15Aug  
-03  
13Nov  
-03  
187  
28Apr05  
21Apr05  
14Apr05

7Apr05  
7Apr05  
7Apr05  
31Mar  
-05  
31Mar  
-05  
31Mar  
-05  
31Mar  
-05  
31Mar  
-05  
31Mar  
-05  
24Mar  
-05  
17Mar  
-05  
17Mar  
-05  
17Mar  
-05  
17Mar  
-05  
10Mar  
-05  
10Mar  
-05  
10Mar  
-05  
10Mar  
-05  
3Mar  
-05  
3Mar  
-05  
3Mar  
-05  
17Feb  
-05  
17Feb  
-05  
17Feb  
-05  
10Feb  
-05  
10Feb  
-05  
10Feb  
-05  
US20050025  
788  
US20050025

761  
US20050020  
524  
US20050019  
756  
US20050015  
847  
US20050014  
830  
US20050014  
752  
US20050009  
110  
US20050009  
009  
US20050008  
535  
US20050004  
144  
US20050004  
071  
US20050004  
063  
US20050003  
340  
US20050002  
953  
US20050002  
941  
US20050002  
913  
US20050002  
901  
US20040265  
879  
US20040265  
796  
US20040265  
367  
US20040265  
351  
US20040259  
934  
US20040259  
803  
US20040258  
698  
US20040253  
624  
US20040253  
328  
US20040241  
842  
US20040237

198

US20040235

952

Systemic delivery of non-viral vector expressing SARS viral genomic vaccine

Anti-viral treatment methods using phosphatidylethanolaminebinding peptides linked to anti-viral agents

Hematopoietic stem cell gene therapy

Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis

Compositions and methods for preventing infection

Substances for breaking down conformation of microbes

Prodrugs of heteroaryl compounds

Methods of producing antibodies for diagnostics and therapeutics

Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)

Noble gas-chlorine mixture effective against micro organisms

Combined use of IMPDH inhibitors with toll-like receptor agonists

Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses

Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference

Assay system and methods for detecting SARS-CV

SARS-coronavirus virus-like particles and methods of use

Combinations and kits for cancer treatment using selected antibodies to aminophospholipids

Hematopoietic stem cell gene therapy

Compositions and methods for treating coronavirus infection and SARS

Compositions for enhancing transport of molecules into cells

Methods and kits for detecting SARS-associated coronavirus

Liposomes coated with selected antibodies that bind to aminophospholipids

Methods and compositions for enhancing immune response

Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds

Disease prevention by reactivation of the thymus

Delivery of immune response modifier compounds

Microporous materials, methods of making, using, and articles thereof

Anti-atypical pneumonia decoction

Stimulation of thymus for vaccination development

Protecting shield for performing the insertion of a tube during emergency rescuing or anesthesia

Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase

Fauci/COVID-19 Dossier

4CHOU

GEORGE CHIN-SHENG

Board of Regents, The University of Texas System

Monash University

DE MEIRLEIR KENNY

HILDRETH JAMES E.

CHU SHU FANG  
Koronis Pharmaceuticals, Incorporated  
CHANG XIAO-JIA  
CHAN KWOK HUNG  
GLOBUS ALFRED R.  
REGENTS OF THE UNIVERSITY OF CALIFORNIA  
COMPER WAYNE D.  
GUAN YI  
AsiaGEN Corporation  
HEROLD JENS  
Board of Regents, The University of Texas System  
Monash University  
BLATT LAWRENCE M.  
IVERSEN PATRICK L.  
BRIESE THOMAS  
HUANG XIANMING  
KEDL ROSS M.  
CARROLL STEVEN S.  
Monash University  
JING NAIYONG  
DURTSCHI JACOB  
HU XIN YUAN  
Monash University  
YANG JUI KUANG  
Agouron Pharmaceuticals, Inc.  
CC-BY-NC-SA Dr. David E. Martin

Jun04

15Aug03

15Apr99

26May04

8Aug03

17Jul-03

31Mar04

8-Jul03

24Mar04

7-Jul03

14Apr04

20Apr04

19May04

1-Jul03

4May04

15Aug03

15Apr99

30Mar04

29Apr04

23Jan04

15Aug03

9Apr04

27Apr04

15Apr99

9Apr04

26May04

13Jun03

15Apr99



2Jun03  
27Apr04  
4Jun  
-04  
15Aug  
-03  
30Dec  
-03  
26May  
-04  
8Aug  
-03  
4Jun  
-04  
31Mar  
-04  
8Jul03  
24Mar  
-04  
7Jul03  
14Apr  
-04  
20Apr  
-04  
19May  
-04  
1Jul03  
4May  
-04  
15Aug  
-03  
18Apr  
-03  
30Mar  
-04  
29Apr  
-04  
23Jan  
-04  
15Aug  
-03  
9Apr  
-04  
27Apr  
-04  
30Dec  
-03  
9Apr  
-04  
26May  
-04  
21Jul03  
30Dec  
-03

2Jun  
-03  
27Apr  
-04  
188  
3Feb  
-05  
3Feb  
-05  
27Jan05  
27Jan05  
27Jan05  
20Jan05  
20Jan05  
13Jan05  
13Jan05  
13Jan05  
6Jan05  
6Jan05  
6Jan05  
6Jan05  
6Jan05  
6Jan05  
6Jan05  
6Jan05  
6Jan05  
30Dec  
-04  
30Dec  
-04  
30Dec  
-04  
30Dec  
-04  
23Dec  
-04  
23Dec  
-04  
23Dec  
-04  
16Dec  
-04  
16Dec  
-04  
2Dec  
-04  
2Dec  
-04  
25Nov  
-04  
US20040235  
946  
US20040235  
047  
US20040234

457  
US20040229  
828  
US20040229  
778  
US20040229  
219  
US20040229  
211  
US20040220  
139  
US20040219  
155  
US20040214  
785  
US20040214  
764  
US20040213  
779  
US20040209  
844  
US20040208  
873  
US20040208  
868  
US20040204  
420  
US20040202  
720  
US20040191  
833  
US20040184  
950  
US20040180  
380  
US20040176  
367  
US20040175  
378  
US20040171  
568  
US20040171  
086  
US20040170  
965  
US20040170  
959  
US20040170  
649  
US20040170  
620  
US20040167  
161

Organosulphur prodrugs for the prevention and treatment of

infectious diseases and pathogenic immune system response  
Compositions and methods for treatment of Severe Acute  
Respiratory Syndrome (SARS)  
Methods of preventing and treating SARS using low pH respiratory  
tract compositions  
Antiviral oligonucleotides targeting RSV  
Pharmaceutical compositions of antithrombin III for the treatment of  
retroviral diseases  
Method of inhibiting human metapneumovirus and human  
coronavirus in the prevention and treatment of severe acute  
respiratory syndrome (SARS)  
Sensitive diagnostic testing methodology using multiplex real time  
PCR with one dye (MOD) and its use as in severe acute respiratory  
syndrome (SARS)  
Inhibiting viral infections  
Selected immunoconjugates for binding to aminophospholipids  
Surface sanitizing compositions with improved antimicrobial  
performance  
Anti-viral treatment methods using phosphatidylethanolaminebinding  
peptide derivatives  
Methods for treating viral infections using immunoconjugates to  
aminophospholipids  
Compositions and methods for preventing infection  
Human monoclonal antibodies against interleukin 8 (IL-8)  
Selected antibody CDRs for binding to aminophospholipids  
Compounds for modulating RNA interference  
Delivery of immune response modifier compounds using metalcontaining  
particulate support materials  
Selective activation of cellular activities mediated through a  
common toll-like receptor  
Building decontamination with vaporous hydrogen peroxide  
Proteome epitope tags and methods of use thereof in protein  
modification analysis  
1-Amino 1H-imidazoquinolines  
Selected antibody compositions and methods for binding to  
aminophospholipids  
Antiviral oligonucleotides targeting HIV  
Selective modulation of TLR-mediated biological activity  
Mixed cell diagnostic systems  
Methods for identifying antiviral oligonucleotides  
Method of treating and preventing infectious diseases via creation of  
a modified viral particle with immunogenic properties

240TT

DAVID M.

SIBER GEORGE R.

The Procter & Gamble Company

Replicor, Inc.

ELMALEH DAVID R.

GALLAHER WILLIAM R.

May04

20May03

2Feb04

12Sep03

13May03

29Apr04  
22YEUNG  
WAH HIN ALEX  
SCEUSA NICHOLAS A.  
RAN SOPHIA  
Xantech Pharmaceuticals, Inc.  
HE JIN  
RAN SOPHIA  
HILDRETH JAMES E.  
GENMAB A/S  
Board of Regents, The University of Texas System  
RANA TARIQ M.  
3M Innovative Properties Company  
3M Innovative Properties Company  
STERIS INC.  
engineOS, Inc.  
3M Innovative Properties Company  
Board of Regents, The University of Texas System  
Replicor, Inc.  
3M Innovative Properties Company  
GOODRUM PATRICIA GAIL RAY  
Replicor, Inc.  
CHAM BILL E.  
Selected antibody compositions for binding to aminophospholipids RAN SOPHIA  
Method of treating or inhibiting the development of brain  
inflammation and sepsis  
Fauci/COVID-19 Dossier  
NOZAKI MASAHO  
CC-BY-NC-SA Dr. David E. Martin  
Aug03  
5Nov03  
15Aug03  
9Mar04  
15Aug03  
15Aug03  
22Sep03  
16Dec03  
15Aug03  
5Aug03  
9Apr04  
24Mar04  
29Jan04  
13Nov03  
5Mar04  
15Jul-03  
12Sep03  
27Feb04  
30Mar04  
11Sep03  
29Jun00  
15Jul-03  
20May03  
24May  
-04

20May  
-03  
2Feb  
-04  
12Sep  
-03  
13May  
-03  
29Apr  
-04  
22Aug  
-03  
5Nov  
-03  
15Aug  
-03  
9Mar  
-04  
15Aug  
-03  
15Aug  
-03  
22Sep  
-03  
16Dec  
-03  
15Aug  
-03  
5Aug  
-03  
9Apr  
-04  
24Mar  
-04  
29Jan  
-04  
13Nov  
-03  
5Mar  
-04  
15Jul03  
12Sep  
-03  
27Feb  
-04  
30Mar  
-04  
12Sep  
-03  
20Jun  
-03  
15Jul03  
26Nov  
-03

25Nov  
-04  
25Nov  
-04  
25Nov  
-04  
18Nov  
-04  
18Nov  
-04  
18Nov  
-04  
18Nov  
-04  
4Nov  
-04  
4Nov  
-04  
28Oct04  
28Oct04  
28Oct04  
21Oct04  
21Oct04  
21Oct04  
14Oct04  
14Oct04  
30Sep  
-04  
23Sep  
-04  
16Sep  
-04  
9Sep  
-04  
9Sep  
-04  
2Sep  
-04  
2Sep  
-04  
2Sep  
-04  
2Sep  
-04  
2Sep  
-04  
26Aug  
-04  
189  
US20040167  
073  
US20040162

309  
US20040162  
254  
US20040162  
253  
US20040147  
543  
US20040147  
440  
US20040142  
852  
US20040142  
322  
US20040141  
950  
US20040138  
187  
US20040131  
622  
US20040131  
621  
US20040131  
610  
US20040081  
667  
US20040077  
587  
US20040071  
757  
US20040071  
709  
US20040067  
920  
US20040009  
943  
US20040009  
245  
US20040009  
152  
US20040005  
998  
US20030224  
353  
US10669245  
1Casein  
derived peptides and uses thereof  
Methods and compositions related to IRM compounds and toll-like  
receptor 8  
Antiviral oligonucleotides targeting HSV and CMV  
Antiviral oligonucleotides targeting HBV  
Aryl substituted imidazoquinolines  
Compositions comprising cell-impermeant duramycin derivatives  
Composition and its therapeutic use  
Continuous non-radioactive polymerase assay



Immunostimulatory combinations  
Therapeutic treatment methods  
Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids  
Combinations and kits for treating viral infections using antibodies to aminophospholipids  
Methods for treating viral infections using antibodies to aminophospholipids  
Compositions and methods for treating and preventing infection  
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections  
Inhalation antiviral patch  
Chay 13 Medical Research Group N.V.  
3M Innovative Properties Company  
Replicor, Inc.  
Replicor, Inc.  
3M Innovative Properties Company  
Board of Regents, The University of Texas System  
AL SARI AHMAD M. H.  
Schering Corporation  
3M Innovative Properties Company  
AHLEM CLARENCE N.  
Board of Regents  
RAN SOPHIA  
RAN SOPHIA  
HILDRETH JAMES E.  
LACOLLA PAOLA  
ROLF DAVID  
Corona-virus-like particles comprising functionally deleted genomes BOSCH BEREND-JAN  
Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof  
Pathogen vaccines and methods for using the same  
Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)  
Materials and methods for prevention and treatment of RNA viral diseases  
Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof  
Antisense antiviral agent and method for treating ssRNA viral infection  
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2carboxamides dipeptidyl peptidase 1 inhibitors  
US10666592 RNA targeting methods and compositions  
US10662485 Bioagent detection oligonucleotides  
US10662464 Methods of analyzing virus-derived therapeutics  
US10662423 Compositions for and methods of identifying antigens  
Mar00  
12Feb04  
12Sep03  
12Sep03

18Dec03  
15Aug03  
9May02  
7Oct03  
30Dec03  
28Aug03  
15Aug03  
15Aug03  
15Aug03  
22Jul-03  
27Jun03  
10Jun03  
17May01  
17JOHNSON  
KEITH A.  
Jun03  
12Inex  
Pharmaceuticals Corporation  
VAIL MARILYN L.  
BEHERA ARUNA K.  
ONCOVIR, INC.  
IVERSEN PATRICK L.  
ASTRAZENECA AB  
Salk Institute for Biological Studies  
IBIS BIOSCIENCES, INC.  
American International Biotechnology, LLC  
President and Fellows of Harvard College  
May03  
2May03  
30Apr03  
1-Jul03  
24Apr03  
24Jan14  
22Aug17  
27Dec11  
31Jul-15  
21Feb06  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
1Mar  
-04  
12Feb  
-04  
12Sep  
-03  
12Sep  
-03  
18Dec  
-03  
15Aug  
-03  
29May  
-03

7Oct  
-03  
30Dec  
-03  
28Aug  
-03  
15Aug  
-03  
15Aug  
-03  
15Aug  
-03  
22Jul03  
27Jun  
-03  
10Jun  
-03  
14Apr  
-03  
17Jun  
-03  
12May  
-03  
2May  
-03  
30Apr  
-03  
1Jul03  
24Apr  
-03  
19Mar  
-19  
31Dec  
-18  
13Apr  
-18  
29Jul16  
12Feb  
-18  
26Aug  
-04  
19Aug  
-04  
19Aug  
-04  
19Aug  
-04  
29Jul04  
29Jul04  
22Jul04  
22Jul04  
22Jul04  
15Jul04  
8Jul04

8Jul04  
8Jul04  
29Apr04  
22Apr04  
15Apr04  
15Apr04  
8Apr04  
15Jan04  
15Jan04  
15Jan04  
8Jan04  
4Dec  
-03  
2Jun20  
26May  
-20  
26May  
-20  
26May  
-20  
26May  
-20  
190

US10660824

Devices, system and method to control the delivery of oral medications to ensure they are efficacious , taken as prescribed, and to avoid unwanted side effects

US10655108 Cell-derived viral vaccines with low levels of residual cell DNA

US10655099 Animal protein-free media for cultivation of cells

US10654898

US10647998

Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof  
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof

US10647781 Generation of binding molecules

US10647758

US10646563

US10646438

US10641707

Compositions comprising AAV expressing dual antibody constructs and uses thereof

Vaccines and immunotherapeutics using IL-28 and compositions and methods of using

Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector

US10640788 CRISPR-related methods and compositions with governing gRNAs

US10640785 Virus vectors for highly efficient transgene delivery

US10640776

Method for propagating adenoviral vectors encoding inhibitory gene products

US10640763 Molecular indexing of internal sequences

US10633447 Soluble engineered monomeric Fc  
US10632133 Anti-viral azide containing compounds  
US10626415 Method of increasing the function of an AAV vector  
US10626379 Production of viruses in cell culture  
US10619186 Methods and compositions for library normalization  
US10619153 TAL effector-mediated DNA modification  
US10617677 Nuclear transport modulators and uses thereof  
US10614284  
US10611827  
Descriptive measurements and quantification of staining artifacts for  
in situ hybridization  
Non-human primate-derived pan-ebola and pan-filovirus monoclonal  
antibodies directed against envelope glycoproteins  
US10610584 Reverse genetics systems  
US10610571  
Cytokine conjugates for the treatment of proliferative and infectious  
diseases  
US10605808 Antibody producing non-human animals  
US10604729 Liquid loading composition, method of making and use thereof  
US10604574 Oncolytic viral delivery of therapeutic polypeptides  
US10604561  
Anti-dengue virus antibodies, polypeptides containing variant Fc  
regions, and methods of use  
US10604549 Adenovirus comprising an albumin-binding moiety  
Fauci/COVID-19 Dossier  
11Not  
Available  
Seqirus UK Limited  
Baxalta GmbH  
The United States of America, as represented by the  
Secretary, Department of Health and Human Services  
The Trustees of the University of Pennsylvania  
Merus N.V.  
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA  
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA  
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
Gen-Probe Incorporated  
Editas Medicine, Inc.  
The Children's Hospital of Philadelphia  
GenVec, Inc.  
Cellular Research, Inc.  
The United States of America, as represented by the  
Secretary, Department of Health and Human Services  
LIFE TECHNOLOGIES CORPORATION  
The Trustees of the University of Pennsylvania  
Commonwealth Scientific and Industrial Research  
Organisation  
Cellular Research, Inc.  
Iowa State University Research Foundation, Inc.  
Biogen MA Inc.  
Ventana Medical Systems, Inc.  
INTEGRATED BIOTHERAPEUTICS, INC.  
Seqirus UK Limited  
SYNTHORX, INC.

Merus N.V.  
DEVMAR PRODUCTS, LLC  
ONCORUS, INC.  
Agency for Science, Technology and Research  
FUNDACIÃ“ INSTITUT D'INVESTIGACIÃ“ BIOMÃˆDICA DE  
BELLVITGE (IDIBELL)  
CC-BY-NC-SA Dr. David E. Martin

Aug15  
1Nov05  
29Oct04  
20Jan15  
29Apr13  
26Sep11  
13May14  
4Apr08  
26Jul-10  
24Feb11  
7Nov13  
22Nov11  
10Nov05  
31May16  
16Mar12  
28Jul-10  
7Apr05  
24Nov15  
11Sep15  
10Dec09  
9May12  
26May15  
28Oct14  
31Jul-09  
3Aug17  
27Jun08  
8Sep16  
30Jun16  
16Sep16  
30Apr14  
11Aug  
-16  
1Nov  
-06  
29Oct  
-18  
20Jan  
-16  
20Jun  
-17  
22Nov  
-17  
2Jul19  
11Sep  
-18  
10May  
-17

21Mar  
-14  
24Jan  
-19  
21Nov  
-12  
7Sep  
-17  
16May  
-17  
9May  
-17  
7Dec  
-17  
27Oct  
-17  
25Jan  
-19  
8Sep  
-16  
5Oct  
-17  
17Jul18  
21Nov  
-17  
27Oct  
-15  
16Oct  
-17  
7Jun  
-19  
27Apr  
-16  
21May  
-18  
25Oct  
-18  
15Sep  
-17  
30Apr  
-15  
191  
26May  
-20  
19May  
-20  
19May  
-20  
19May  
-20  
12May  
-20  
12May  
-20  
12May  
-20

12May  
-20

12May  
-20

12May  
-20

5May  
-20

5May  
-20

5May  
-20

5May  
-20

5May  
-20

28Apr20

28Apr20

21Apr20

21Apr20

14Apr20

14Apr20

14Apr20

7Apr20

7Apr20

7Apr20

7Apr20

31Mar

-20

31Mar

-20

31Mar

-20

31Mar

-20

31Mar

-20

US10603356

Compositions and method for treatment of inflammatory bowel disease

US10603299 Prevention and treatment of viral infections

US10597736 Compositions and methods for detecting viruses in a sample

US10596264 Peptides with viral infection enhancing properties and their use

US10596197

Red blood cell membrane-derived microparticles and their use for the treatment of lung disease

US10591714 Endoscopic apparatus for thermal distribution monitoring

US10590435

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

US10590413 Chiral control

US10590112 Dihydropyrimidinyl benzazepine carboxamide compounds

US10588966 Methods and compositions for inhibiting Akt3

US10583086 Technology for preparation of macromolecular microspheres



US10577375

Derivatives of porphyrins, their process of preparation and their use for treating viral infections

US10570416 TC-83-derived alphavirus vectors, particles and methods

US10570209

Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies

US10564160 Antibody-secreting cell assay

US10564152

Method and device for detecting antigen-specific antibodies in a biological fluid sample by using neodymium magnets

US10563224 Replication defective adenovirus vector in vaccination

US10563154

Disinfecting aqueous foam, process for preparing same and use thereof

US10562861 Carboxylic acid compounds

US10561743 AAV vectors targeted to the central nervous system

US10561722 Methods and compositions for enhancing immune responses

US10561126

Genetically modified non-human animals and methods of use thereof

US10557136 In vivo delivery of oligonucleotides

US10557119 Erythroid cells comprising phenylalanine ammonia lyase

US10555993 Dimethyl fumarate and vaccination regimens

US10550378

US10550174

Composition comprising a gene vector that selectively depletes P16 positive senescent cells

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

US10548971 MERS-CoV vaccine

US10548959

Compositions and methods for modified dendrimer nanoparticle delivery

2THE

REGENTS OF THE UNIVERSITY OF CALIFORNIA

Not Available

Washington University

Centre National de la Recherche Scientifique

University of Pittsburgh of the Commonwealth System of Higher Education

ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE

The Trustees of the University of Pennsylvania

WAVE LIFE SCIENCES LTD.

Hoffmann-La Roche Inc.

Augusta University Research Institute, Inc.

Ansun Biopharma, Inc.

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

ALPHAVAX, INC.

GITR, Inc.

MABTECH AB

The United States of America, as represented by the  
Secretary, Department of Health and Human Services  
Etubics Corporation

COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX  
ENERGIES ALTERNATIVES

Sumitomo Dainippon Pharma Co., Ltd.

The University of North Carolina at Chapel Hill

Bavarian Nordic A/S

Institute for Research in Biomedicine (IRB)

Oncolmmunin Inc.

RUBIUS THERAPEUTICS, INC.

Biogen MA Inc.

Kythera Biopharmaceuticals, Inc.

Ablynx N.V.

INOVIO PHARMACEUTICALS, INC.

Massachusetts Institute of Technology

Jun11

2Jun16

29Jan16

30Jun11

7Nov13

7Sep16

17Dec01

13Jul-12

9Jun17

15Jan16

24Jan06

30Oct15

18May04

25Mar05

28Aug08

1Sep15

24Aug12

16Jun15

18May12

21Nov14

3Sep14

13Apr15

12Dec11

18Nov13

14Mar14

17Apr12

5Jun08

29Nov13

23Sep16

21Apr

-16

3Jul19

27Jan

-17

28Jun

-12

1Jun

-18

31May  
-17

26Sep  
-18

17Mar  
-17

7Dec  
-18

6Feb  
-19

25Sep  
-17

28Oct  
-16

11Aug  
-16

28Jun  
-18

28Aug  
-09

8Aug  
-16

15Feb  
-17

15Jun  
-16

23Oct  
-18

13Jun  
-19

3Sep  
-15

16Apr  
-18

12Dec  
-12

10May  
-19

23Apr  
-19

10Jun  
-19

17Oct  
-17

29Jun  
-18

23Sep  
-16

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

192

31Mar  
-20

31Mar  
-20  
24Mar  
-20  
24Mar  
-20  
24Mar  
-20  
17Mar  
-20  
17Mar  
-20  
17Mar  
-20  
17Mar  
-20  
17Mar  
-20  
10Mar  
-20  
3Mar  
-20  
25Feb  
-20  
25Feb  
-20  
18Feb  
-20  
18Feb  
-20  
18Feb  
-20  
18Feb  
-20  
18Feb  
-20  
18Feb  
-20  
18Feb  
-20  
18Feb  
-20  
18Feb  
-20  
18Feb  
-20  
11Feb  
-20  
11Feb  
-20  
11Feb  
-20  
4Feb  
-20  
4Feb  
-20  
4Feb  
-20

4Feb

-20

16US10544405

Cas9-nucleic acid complexes and uses related thereto

US10544399 Highly efficient influenza matrix (M1) proteins

US10544193

Compositions and methods for treating diseases by inhibiting  
exosome release

Emory University

Novavax, Inc.

MOREHOUSE SCHOOL OF MEDICINE

US10544108 Hydrazide containing nuclear transport modulators and uses thereof

Karyopharm Therapeutics Inc.

US10544102

Benzazepine dicarboxamide compounds with secondary amide  
function

US10543485 Slip chip device and methods

US10543269 hMPV RNA vaccines

US10539488 Sample fixation and stabilisation

US10538558 Inhibition of TCR signaling with peptide variants

US10538554 Peptides and uses therefor as antiviral agents

US10533021 Boron-containing small molecules

US10532111

Recombinant adeno-associated virus capsids resistant to preexisting  
human neutralizing antibodies

US10532110 AAV vectors targeted to the central nervous system

US10532107 Modified virus-like particles of CMV

US10532067 Delivery of RNA to trigger multiple immune pathways

US10527551

Method of predicting a performance characteristic of a plant or yeast  
hydrolysate and its use

US10526596 Purification of nucleic acids using metal-titanium oxides

US10526295 Nuclear transport modulators and uses thereof

US10526292

Dendrimer like amino amides possessing sodium channel blocker  
activity for the treatment of dry eye and other mucosal diseases

US10526283 Prodrugs of dithiol mucolytic agents

US10525120 Methods and compositions for live attenuated viruses

US10525049 Specific Akt3 inhibitor and uses thereof

US10519130

US10519129

US10519128

US10519127

Quinazolinones and azaquinazolinones as ubiquitin-specific protease  
7 inhibitors

Quinazolinones and azaquinazolinones as ubiquitin-specific protease  
7 inhibitors

Quinazolinones and azaquinazolinones as ubiquitin-specific protease  
7 inhibitors

Quinazolinones and azaquinazolinones as ubiquitin-specific protease  
7 inhibitors

US10517947 Methods for preparing squalene

US10517923 Immunosuppressive agents and their use in therapy

US10517881 Pharmaceutical compositions and methods

US10513508

Quinazolinones and azaquinazolinones as ubiquitin-specific protease  
7 inhibitors

Fauci/COVID-19 Dossier

Hoffmann-La Roche Inc.

University of Chicago

ModernaTX, Inc.

RNASSIST LTD.

SIGNABLOK, INC

VIRAMATIX SDN BHD

Anacor Pharmaceuticals, Inc.

The Board of Trustees of the Leland Stanford Junior  
University

The University of North Carolina at Chapel Hill

SAIBA GMBH

GlaxoSmithKline Biologicals S.A.

Baxalta GmbH

Abbott Molecular Inc.

Karyopharm Therapeutics Inc.

Parion Sciences, Inc.

PARION SCIENCES, INC.

TAKEDA VACCINES, INC.

Augusta University Research Institute, Inc.

FORMA Therapeutics, Inc.

FORMA Therapeutics, Inc.

FORMA Therapeutics, Inc.

FORMA Therapeutics, Inc.

NOVARTIS AG

Norwegian University of Science and Technology

POP TEST ONCOLOGY LLC

FORMA Therapeutics, Inc.

CC-BY-NC-SA Dr. David E. Martin

Jan13

11Jul-03

19Dec16

29Jul-11

19May17

24Mar09

22Oct15

1Mar13

30Sep09

27Nov15

20Jun07

16Feb16

21Nov14

22Oct14

6-Jul10

30Dec13

14Jul-15

31Dec15

29May12

30Apr15

6Apr07

15Jan16

5Feb15  
5Feb15  
5Feb15  
5Feb15  
12May10  
6Nov13  
3Aug15  
5Feb15  
15Jan  
-14  
22Mar  
-18  
9Jul18  
28Nov  
-18  
13Nov  
-18  
25May  
-16  
28Mar  
-19  
14Aug  
-17  
22Oct  
-18  
28Nov  
-16  
28Sep  
-17  
18Aug  
-17  
20Nov  
-15  
20Oct  
-15  
5Oct  
-17  
18Dec  
-14  
5Jul19  
30Dec  
-16  
20Dec  
-17  
2May  
-16  
22Jul16  
20May  
-19  
2Nov  
-18  
2Nov  
-18  
2Nov

-18

2Nov

-18

14Dec

-17

6Nov

-14

8Jan

-19

2Nov

-18

193

28Jan20

28Jan20

28Jan20

28Jan20

28Jan20

28Jan20

28Jan20

21Jan20

21Jan20

21Jan20

14Jan20

14Jan20

14Jan20

14Jan20

14Jan20

7Jan20

7Jan20

7Jan20

7Jan20

7Jan20

7Jan20

7Jan20

31Dec

-19

31Dec

-19

31Dec

-19

31Dec

-19

31Dec

-19

31Dec

-19

31Dec

-19

24Dec

-19

US10513507

US10512684

Quinazolinones and azaquinazolinones as ubiquitin-specific protease  
7 inhibitors



Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin  
US10512669 Blockade of inflammatory proteases with cyclic peptides  
US10512665 Methods and compositions related to inhibition of viral entry  
US10508098  
Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors  
US10507244 Anti-TIGIT antigen-binding proteins and methods of use thereof  
US10503347  
System and method for detecting, collecting, analyzing, and communicating event-related information  
US10501733 Polypeptide assemblies and methods for the production thereof  
US10501527  
Mast cell stabilizers for treatment of hypercytokinemia and viral infection  
US10501507 Griffithsin mutants  
US10501412 Conjugates of cell binding molecules with cytotoxic agents  
US10500272  
Manufacture of surfactant-containing compositions with enhanced stability  
US10500267 Influenza virus vectors and uses therefor  
US10495640  
US10494420  
US10488353  
Exosome-mediated diagnosis of hepatitis virus infections and diseases  
Mast cell stabilizers for treatment of hypercytokinemia and viral infection  
Apparatus and system for performing thermal melt analyses and amplifications  
5FORMA  
Therapeutics, Inc.  
Bavarian Nordic A/S  
The Regents of the University of California  
UNIVERSITY OF UTAH RESEARCH FOUNDATION  
FORMA Therapeutics, Inc.  
Potenza Therapeutics, Inc.  
Georgetown University  
University of Utah Research Foundation  
Emergo Therapeutics, Inc.  
The United States of America, as represented by the Secretary, Department of Health and Human Services  
HANGZHOU DAC BIOTECH CO., LTD.  
NOVARTIS AG  
FluGen, Inc.  
MOREHOUSE SCHOOL OF MEDICINE  
Emergo Therapeutics, Inc.  
GEN-PROBE INCORPORATED  
US10487350 Methods for diagnosing infectious diseases using adsorption media  
ExThera Medical Corporation  
US10487332 Immunisation of large mammals with low doses of RNA  
US10487081 Guanidine substituted imidazo[4,5-c] ring compounds  
US10485883  
Adeno-associated virus (AAV) clades, sequences, vectors containing

same, and uses therefor

US10485861 Nanoparticle-based compositions

US10485856 Carbon nanotube compositions and methods of use thereof

US10485761 Irradiated biodegradable polymer microparticles

US10479996

Antisense antiviral compound and method for treating ss/RNA viral infection

US10479781 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors

US10476825 RNA targeting methods and compositions

US10472647 Primary mesenchymal stem cells as a vaccine platform

US10472420 Immune response modifier conjugates

US10472332 Antiviral compounds and methods

US10471408 Microspotting device

GlaxoSmithKline Biologicals SA

3M Innovation Properties Company

The Trustees of the University of Pennsylvania

Massachusetts Institute of Technology

Yale University

GLAXOSMITHKLINE BIOLOGICALS, S.A.

Sarepta Therapeutics, Inc.

Neuprozyme Therapeutics APS

Salk Institute for Biological Studies

The Administrators of the Tulane Educational Fund

3M Innovative Properties Company

Biotron Limited

BioFire Diagnostics, LLC

Feb15

26Sep14

2Jun11

8Feb07

5Feb15

10Oct15

25Feb08

27Feb15

8Sep16

10Feb15

12Jul-12

2Dec14

17Mar14

6Oct08

8Sep16

31Jul-12

8Nov13

6-Jul10

31Aug15

30Sep03

14Mar13

19Mar08

24Jan10

16Sep04

5Mar15

22Aug17

21Dec12

22Feb06

26Jun03  
18Apr12  
Fauci/COVID-19  
Dossier  
11Dec  
-17  
25Sep  
-15  
1Jun  
-12  
2Jun  
-16  
2Nov  
-18  
19Jun  
-17  
27Jul17  
29Feb  
-16  
7Sep  
-17  
10Feb  
-16  
12Jul12  
12Mar  
-19  
21Aug  
-17  
13Dec  
-16  
15Nov  
-18  
23Feb  
-17  
16Oct  
-15  
6Jul11  
22Oct  
-18  
15Feb  
-17  
14Mar  
-14  
17Mar  
-17  
16May  
-18  
6Nov  
-14  
4Mar  
-16  
27Mar  
-18  
15Nov



-19

19Nov

-19

12Nov

-19

12Nov

-19

12Nov

-19

12Nov

-19

12Nov

-19

CC-BY-NC-SA

Dr. David E. Martin

194

US10471141

US10471140

US10471063

US10466245

Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity

Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition

Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist

Covalently linked thermostable kinase for decontamination process validation

US10464988 Antibody/T-cell receptor chimeric constructs and uses thereof

US10464975 Stabilized anti-microbial peptides

US10464955 Charged linkers and their uses for conjugation

US10464060 Loading vials

US10463723 Methods and compositions for intranasal delivery

US10463615

Circulation of components during microfluidization and/or homogenization of emulsions

3NITTO

DENKO CORPORATION

NOTTO DENKO CORPORATION

Verona Pharma PLC

The Secretary of State for Health

EUREKA THERAPEUTICS, INC.

Dana-Farber Cancer Institute, Inc.

HANGZHOU DAC BIOTECH CO., LTD.

BioFare Diagnostics, LLC

Shin Nippon Biomedical Laboratories, Ltd.

NOVARTIS AG

US10457974 Methods for diagnosing infectious diseases using adsorption media

ExThera Medical Corporation

US10457901 Cleaning composition, method of making and use thereof

US10456464

US10450620

US10450383

US10443049

Liquid immunity induction-promoting composition and vaccine  
pharmaceutical composition that include thrombosis treatment drug  
Cell-free nucleic acids for the analysis of the human microbiome and  
components thereof  
Carbonic anhydrase IX (G250) antibodies and methods of use  
thereof  
Active low molecular weight variants of angiotensin converting  
enzyme 2 (ACE2)  
US10442853 Antibodies and processes for preparing the same  
US10434158 Combination of vaccination and inhibition of the PD-1 pathway  
US10434116 Methods of treating coronavirus infection  
US10428128  
US10428102  
US10428083  
Helix-grafted proteins as inhibitors of disease-relevant proteinprotein  
interactions  
Glycolipids and pharmaceutical compositions thereof for use in  
therapy  
Heterocyclylmethyl-thienouracile as antagonists of the adenosineA2B-receptor  
US10428027  
Sulfinylphenyl or sulfonimidoylphenyl benzazepines  
US10426737 Lipids and lipid compositions for the delivery of active agents  
US10421991 Rapid epidemiologic typing of bacteria  
US10421962  
Double-stranded oligonucleotide molecules to DDIT4 and methods  
of use thereof  
DevMar Products, LLC  
NITTO DENKO CORPORATION  
The Board of Trustees of the Leland Stanford Junior  
University  
DANA-FARBER CANCER INSTITUTE, INC.  
Northwestern University  
TAIGA BIOTECHNOLOGIES, INC.  
CureVac AG  
United States Government as represented by the  
Secretary, Department of Health and Human Services  
Colorado State University Research Foundation  
THE UNIVERSITY OF NOTTINGHAM  
BAYER PHARMA AKTIENGESELLSCHAFT  
Hoffmann La-Roche Inc.  
Novartis AG  
BioFire Diagnostics, LLC  
Quark Pharmaceuticals, Inc.  
US10420837 Vaccine pharmaceutical composition for transdermal administration  
NITTO DENKO CORPORATION  
US10420685 Mobile clinics  
US10416171 Influenza potency assays  
US10416161  
Exosome-mediated diagnosis of hepatitis virus infections and  
diseases  
Fauci/COVID-19 Dossier  
Baylor College of Medicine  
Seqirus UK Limited  
MOREHOUSE SCHOOL OF MEDICINE

CC-BY-NC-SA Dr. David E. Martin

Sep14  
4Aug14  
15Mar13  
20Feb08  
23Oct15  
2-Jul15  
28Feb14  
10Nov11  
15Apr10  
3Dec09  
8Nov13  
8Sep16  
4Aug14  
7Nov13  
2Dec05  
24Jan17  
16May08  
22Feb13  
7Apr14  
7Nov14  
4Apr14  
26Mar15  
17Sep15  
19Dec13  
19May08  
12Sep12  
20Oct14  
12Nov14  
7-Jul15  
6Oct08  
2Sep  
-15  
18Apr  
-19  
5Jun  
-17  
8Jul16  
4Sep  
-18  
1Jul16  
28Feb  
-14  
9Nov  
-12  
14Mar  
-13  
26Jun  
-17  
2Nov  
-16  
19Sep  
-18  
4Aug

-15  
7Nov  
-14  
9May  
-17  
24Jan  
-18  
23Aug  
-16  
7Feb  
-18  
7Apr  
-15  
9Nov  
-15  
7Apr  
-15  
21Mar  
-16  
8Mar  
-18  
17Dec  
-14  
11Nov  
-15  
15Feb  
-17  
10Oct  
-15  
11Nov  
-15  
7Jul16  
20Sep  
-16  
195  
12Nov  
-19  
12Nov  
-19  
12Nov  
-19  
5Nov  
-19  
5Nov  
-19  
5Nov  
-19  
5Nov  
-19  
5Nov  
-19  
5Nov  
-19  
5Nov



-19

29Oct19

29Oct19

29Oct19

22Oct19

22Oct19

15Oct19

15Oct19

8Oct19

8Oct19

10Oct19

10Oct19

10Oct19

10Oct19

10Oct19

24Sep

-19

24Sep

-19

24Sep

-19

24Sep

-19

17Sep

-19

17Sep

-19

3US10414800

Methods for producing a depsipeptide

US10414779

US10407492

US10407472

Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups

Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria

US10407431 Compounds and compositions as toll-like receptor 7 agonists

US10407405 Nuclear transport modulators and uses thereof

US10406229 Methods and compositions related to inhibition of viral entry

US10406177 Modified cells and methods of therapy

US10406142

US10400274

Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom

Fluorogenic probes and their use in quantitative detection of target RNA sequences

US10400225 TAL effector-mediated DNA modification

US10400024

US10399963

Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides

Substituted benzofuranyl and benzoxazolyl compounds and uses thereof  
US10399941 Conjugates of cell binding molecules with cytotoxic agents  
US10398795 Decontamination device and method using ultrasonic cavitation  
US10393633 Sample fixation and stabilisation  
US10392613 Purification of nucleic acids using copper-titanium oxides  
US10391188 Decontamination device and method using ultrasonic cavitation  
US10391167 Mucosal vaccine composition  
US10391160 Dimethyl fumarate and vaccination regimens  
US10385320  
US10385119  
US10383938  
Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism  
Compositions comprising AAV expressing dual antibody constructs and uses thereof  
Lipidated immune response modifier compound compositions, formulations, and methods  
US10383935 Methods of making and using live attenuated viruses  
US10383852 Prevention and treatment of viral infections  
NovoBiotic Pharmaceuticals, LLC  
3M Innovative Properties Company  
Ablynx N.V.  
Spogen Biotech Inc.  
Novartis AG  
Karyopharm Therapeutics Inc.  
UNIVERSITY OF UTAH RESEARCH FOUNDATION  
Intima Bioscience, Inc.  
3M Innovative Properties Company  
Jan Biotech, Inc.  
Iowa State University Research Foundation, Inc.  
SANQUIN REAGENTS B.V.  
Karyopharm Therapeutics Inc.  
HANGZHOU DAC BIOTECH CO., LTD.  
TOMI ENVIRONMENTAL SOLUTIONS, INC.  
RNASSIST LTD.  
ABBOTT MOLECULAR INC.  
TOMI ENVIRONMENTAL SOLUTIONS, INC.  
NITTO DENKO CORPORATION  
Biogen MA Inc.  
The Board of Trustees of the Leland Stanford Junior University  
Trustees of the University of Pennsylvania  
3M Innovative Properties Company  
Regents of the University of Minnesota  
Not Available  
US10378008 Method and apparatus for automated processing of pooled samples GFE BLUT MBH  
US10378002 Replication conditional virus that specifically kills senescent cells  
US10377773  
Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors  
US10377767 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors  
Kythera Biopharmaceuticals, Inc.

FORMA Therapeutics, Inc.  
FORMA Therapeutics, Inc.  
Dec12  
26Aug16  
5Jun08  
17Sep14  
1May14  
21Jun13  
28Mar11  
31Jul-15  
3Jun11  
18Jun16  
10Dec09  
6Jun14  
3-Jul13  
12Jul-12  
29Dec17  
1Mar13  
14Jul-15  
29Dec17  
30Oct13  
14Mar14  
2Dec15  
13May14  
17Aug10  
23Sep15  
2Jun16  
6Aug14  
17Apr12  
5Feb15  
5Feb15  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
15Jun  
-16  
1Aug  
-17  
17Oct  
-17  
14Dec  
-17  
27Feb  
-18  
17Jul17  
2Mar  
-17  
29Aug  
-16  
6Mar  
-17  
16Jun  
-17  
21Aug



3Sep  
-19

3Sep  
-19

3Sep  
-19

3Sep  
-19

3Sep  
-19

27Aug  
-19

27Aug  
-19

27Aug  
-19

27Aug  
-19

27Aug  
-19

20Aug  
-19

20Aug  
-19

20Aug  
-19

20Aug  
-19

20Aug  
-19

13Aug  
-19

13Aug  
-19

13Aug  
-19

13Aug  
-19

196

US10377760

Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

US10370625 Cleaning composition, method of making and use thereof

US10370455

Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists

30FORMA

Therapeutics, Inc.

DEVMAR PRODUCTS, LLC

IMMUNEXT, INC.

US10370338 Benzazepine dicarboxamide compounds with tertiary amide function

Hoffmann-La Roche Inc.

US10369219

US10369216

Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition  
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant  
US10369205 Immunomodulatory compositions and methods of use thereof  
US10369204 Molecular vaccines for infectious disease  
US10363303 Microneedle compositions and methods of using same  
US10363282 Analogs of C5a and methods of using same  
US10363247  
(S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer  
US10358481 Engineered antibody constant domain molecules  
US10357568 Adjuvant nanoemulsions with phospholipids  
NITTO DENKO CORPORATION  
CureVac AG  
Not Available  
Dako Denmark A/S  
VERNDARI, INC.  
Board of Regents of The University of Nebraska  
Dec14  
8Sep16  
5Dec14  
23May16  
4Aug14  
1Apr14  
7Jan14  
20Oct08  
11Jan16  
29Jun10  
18Karyopharm  
Therapeutics Inc.  
Aug15  
The  
United States of America, as represented by the Secretary, Department of Health and Human Services  
GLAXOSMITHKLINE BIOLOGICALS S.A.  
US10357562 Immunoprotective primary mesenchymal stem cells and methods  
Autoimmune Technologies, LLC  
US10357510 Metal nanoclusters and uses thereof  
US10351571  
Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors  
US10350255 Polygonum cuspidatum extracts  
US10344320 Capacitive liquid crystal biosensors  
US10344263 Synthetic membrane-receiver complexes  
US10344261 Immunomodulatory conjugates  
US10344027 Compositions and methods for inhibiting kinases  
US10342868 Methods and compositions for inhibiting Akt3  
THE REGENTS OF THE UNIVERSITY OF MICHIGAN  
FORMA Therapeutics, Inc.  
PhotoDynamic Inc.  
The Johns Hopkins University  
RUBIUS THERAPEUTICS, INC.

ASCEND BIOPHARMACEUTICALS LTD  
Inhibikase Therapeutics, Inc.  
Augusta University Research Institute, Inc.  
US10342825 Solution containing hypochlorous acid and methods of using same  
Sonoma Pharmaceuticals, Inc.  
US10336725 Chemical compounds  
AstraZeneca AB  
US10335484 Methods of generating robust passive and active immune responses  
HUMABS BIOMED SA  
US10335393 Nuclear transport modulators and uses thereof  
US10335372  
Compositions with modified nucleases targeted to viral nucleic acids  
and methods of use for prevention and treatment of viral diseases  
US10329531 Synthetic membrane-receiver complexes  
Biogen MA Inc.  
Jacob G. Appelbaum  
RUBIUS THERAPEUTICS, INC.  
31Jan08  
24Mar11  
14Mar13  
7Aug14  
30Dec14  
10Oct15  
6May15  
18Nov13  
9Nov11  
23Apr15  
15Jan16  
15Jun09  
18Mar14  
8Jan13  
9May12  
14Apr04  
18Nov13  
18Jan  
-18  
6Sep  
-17  
7Dec  
-15  
13Nov  
-18  
4Aug  
-15  
1Apr  
-15  
7Jan  
-15  
20ct  
-09  
11Jul18  
12Jan  
-18  
18Aug

-16  
2Dec  
-16  
23Mar  
-12  
17Jul15  
7Aug  
-15  
24May  
-18  
30Sep  
-16  
5May  
-16  
29Mar  
-17  
9Nov  
-12  
24Oct  
-18  
17Jan  
-17  
15Jun  
-10  
13Dec  
-17  
8Jan  
-14  
4Dec  
-17  
10Mar  
-17  
13Oct  
-17  
13Aug  
-19  
6Aug  
-19  
6Aug  
-19  
6Aug  
-19  
6Aug  
-19  
6Aug  
-19  
6Aug  
-19  
6Aug  
-19  
30Jul19  
30Jul19  
30Jul19  
23Jul19



23Jul19  
23Jul19  
23Jul19  
16Jul19  
16Jul19  
9Jul19  
9Jul19  
9Jul19  
9Jul19  
9Jul19  
9Jul19  
2Jul19  
2Jul19  
2Jul19  
2Jul19  
25Jun19

Fauci/COVID-19  
Dossier

CC-BY-NC-SA Dr. David E. Martin  
197

US10329329

US10328157

Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof  
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule

US10323074 Cryptic polypeptides and uses thereof

US10322104 Disulfur bridge linkers for conjugation of a cell-binding molecule

US10316031 Compositions and methods for inhibiting kinases

US10314893

Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders

US10308913

US10308705

Chimeric viruses presenting non-native surface proteins and uses thereof

Optimized human clotting factor VIII gene expression cassettes and their use

US10308685 Inhibitory peptides of viral infection

US10307475 Methods and compositions for immunization against virus

US10307472 Combination of vaccination and OX40 agonists

US10307439 Substituted nucleosides, nucleotides and analogs thereof

US10307434 Nucleic acid prodrugs and methods of use thereof

US10307391 Disulfur bridge linkers for conjugation of a cell-binding molecule

US10307374 Oil-in-water emulsions that contain nucleic acids

US10301650

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

US10301648 Method of increasing the function of an AAV vector

US10301594 Synthetic membrane-receiver complexes

US10301593 Synthetic membrane-receiver complexes

US10301377

Middle east respiratory syndrome coronavirus immunogens,  
antibodies, and their use  
US10300149 Compositions for enhancing transport of molecules into cells  
US10300145  
Synthetic nanoparticles for delivery of immunomodulatory  
compounds  
US10300127 Immune complex  
7UNIVERSITY  
OF MIAMI  
HANGZHOU DAC BIOTECH CO., LTD.  
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY  
HANGZHOU DAC BIOTECH CO., LTD.  
Inhibikase Therapeutics, Inc.  
Sep12  
15Jul-15  
29Jan15  
15Jul-15  
23Apr15  
18The  
Trustees of the University of Pennsylvania  
Oct13  
2Icahn  
School of Medicine at Mount Sinai  
The University of North Carolina at Chapel Hill  
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION  
Academia Sinica  
CureVac AG  
Alios Biopharma, Inc.  
WAVE LIFE SCIENCES LTD.  
HANGZHOU DAC BIOTECH CO., LTD.  
GLAXOSMITHKLINE BIOLOGICALS S.A.  
The Trustees of the University of Pennsylvania  
The Trustees of the University of Pennsylvania  
RUBIUS THERAPEUTICS, INC  
RUBIUS THERAPEUTICS, INC.  
The United States of America, as Represented by the  
Secretary, Department of Health and Human Services  
SAREPTA THERAPEUTICS, INC.  
Massachusetts Institute of Technology  
The Rockefeller University  
US10300124 Rodent hepadnavirus cores with reduced carrier-specific antigenicity  
VLP BIOTECH, INC.  
US10294534 Respiratory infection assay  
US10294293  
Human monoclonal antibody with specificity for dengue virus  
serotype 1 E protein and uses thereof  
US10294280 Constrained proteins and uses therefor  
US10293060 Method for increasing expression of RNA-encoded proteins  
US10293055  
Acetylenedicarboxyl linkers and their uses in specific conjugation of  
a cell-binding molecule  
Fauci/COVID-19 Dossier  
THE SECRETARY OF STATE FOR HEALTH  
DSO National Laboratories

Monash University  
CureVac AG  
HANGZHOU DAC BIOTECH CO., LTD.  
CC-BY-NC-SA Dr. David E. Martin  
Dec05  
6Feb15  
17Jul-14  
27Mar09  
12Mar14  
24Jun14  
6-Jul09  
15Jul-15  
6-Jul11  
17Dec01  
7Apr05  
18Nov13  
18Nov13  
24Feb15  
29Apr03  
15Jul-16  
20Mar15  
15Mar13  
9Dec11  
14Dec10  
21Jul-14  
21Aug14  
15Jul-15  
28Aug  
-18  
3Feb  
-17  
12Dec  
-17  
5Apr  
-17  
24Oct  
-18  
18Apr  
-16  
3Mar  
-16  
5Feb  
-16  
25May  
-17  
18Feb  
-14  
12Mar  
-14  
2Feb  
-17  
27May  
-16  
5Apr

-17  
24Apr  
-17  
1May  
-17  
18Feb  
-15  
19Nov  
-18  
19Mar  
-18  
24Feb  
-16  
10Jan  
-17  
14Jul17  
21Mar  
-16  
14Mar  
-14  
10Dec  
-12  
1Jun  
-16  
21Jul15  
19Feb  
-16  
3Mar  
-17  
198  
25Jun19  
25Jun19  
18Jun19  
18Jun19  
11Jun19  
11Jun19  
4Jun19  
4Jun19  
4Jun19  
4Jun19  
4Jun19  
4Jun19  
4Jun19  
4Jun19  
4Jun19  
4Jun19  
28May  
-19  
28May  
-19  
28May  
-19  
28May  
-19  
28May

-19

28May

-19

28May

-19

28May

-19

28May

-19

21May

-19

21May

-19

21May

-19

21May

-19

21May

-19

US10293039

Attenuated *Listeria monocytogenes* mutant as a vaccine vector for the delivery of exogeneous antigens

US10292978 Specific Akt3 inhibitor and uses thereof

US10292961 Disulfur bridge linkers for conjugation of a cell-binding molecule

US10288601

Method of determining, identifying or isolating cell-penetrating peptides

7Montana

State University

Augusta University Research Institute, Inc.

HANGZHOU DAC BIOTECH CO., LTD.

Phylogica Limited

US10287576 Enzymatic encoding methods for efficient synthesis of large libraries

NUEVOLUTION A/S

US10287258

US10287253

US10286067

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2carboxamides as dipeptidyl peptidase 1 inhibitors

Substituted pyrimidines containing acidic groups as TLR7 modulators

Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition

US10286056 Adjuvant nanoemulsions with crystallisation inhibitors

US10280199 Coronavirus proteins and antigens

US10279029 Immunogenic compositions and uses thereof

US10279028

Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

US10279027 Transgenic Vero-CD4/CCR5 cell line

US10273454

US10273290

Means and methods for influencing the stability of antibody producing cells

Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides  
US10272150 Combination PIV3/hMPV RNA vaccines  
US10272149 Modified bat influenza viruses and their uses  
US10266887 CRISPR effector system based diagnostics  
US10266886 CRISPR effector system based diagnostics  
US10266846  
US10266545  
US10265417  
Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor  
Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use  
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor  
US10265407 Modular nanodevices for smart adaptable vaccines  
US10265395 Adjuvant compositions and related methods  
US10265371  
Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells  
US10265291 Disulfur bridge linkers for conjugation of a cell-binding molecule  
US10260071  
US10259865  
US10259848  
CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity  
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection  
Compositions and methods comprising hydrocarbon-stapled polypeptides  
ASTRAZENECA AB  
APROS THERAPEUTICS, INC.  
NITTO DENKO CORPORATION  
GLAXOSMITHKLINE BIOLOGICALS S.A.  
Phibro Animal Health Corporation  
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
Ohio State Innovation Foundation  
INTERNATIONAL AIDS VACCINE INITIATIVE  
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM  
DANA-FARBER CANCER INSTITUTE, INC.  
ModernaTX, Inc.  
J. CRAIG VENTER INSTITUTE  
MASSACHUSETTS INSTITUTE OF TECHNOLOGY  
MASSACHUSETTS INSTITUTED OF TECHNOLOGY  
The Trustees of the University of Pennsylvania  
I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O.  
The Trustees of the University of Pennsylvania  
Yale University  
Not Available  
CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBERBBN)  
HANGZHOU DAC BIOTECH CO., LTD.

COLEY PHARMACEUTICAL GMBH  
ADMA Biologics, Inc.  
DANA-FARBER CANCER INSTITUTE, INC.

Apr14  
15Jan16  
15Jul-15  
23May11  
1Dec05  
24Jan14  
5Dec16  
4Aug14  
27Jan11  
7Feb14  
25Mar15  
24Apr12  
20Oct15  
9Dec05  
18Jun09  
22Oct15  
5Sep14  
9Dec16  
9Dec16  
17Dec01  
2Feb16  
30Sep03  
15Feb07  
24Mar15  
13Jan11  
15Jul-15  
27Sep06  
15Mar17  
23Jan08  
7Apr  
-15  
17Jan  
-17  
15Jul15  
11Dec  
-17  
12Dec  
-16  
19Sep  
-17  
4Dec  
-17  
4Aug  
-15  
27Jan  
-12  
4Aug  
-16  
27Feb  
-18  
14Dec





7May  
-19

7May  
-19

7May  
-19

30Apr19

30Apr19

30Apr19

30Apr19

23Apr19

23Apr19

23Apr19

23Apr19

23Apr19

23Apr19

23Apr19

23Apr19

23Apr19

16Apr19

16Apr19

16Apr19

Fauci/COVID-19

Dossier

CC-BY-NC-SA Dr. David E. Martin

199

US10258655

Synergistic bacterial compositions and methods of production and use thereof

US10254204 Membrane-assisted purification

US10253353 Enhanced methods of ribonucleic acid hybridization

US10253318

Methods and compositions for the treatment of cancer or other diseases

US10253296 Synthetic membrane-receiver complexes

US10253093 Human monoclonal antibodies against interleukin 8 (IL-8)

25Seres

Therapeutics, Inc.

Accelerate Diagnostics, Inc.

The Broad Institute, Inc.

CITY OF HOPE

RUBIUS THERAPEUTICS, INC.

CORMORANT PHARMACEUTICALS AB

US10251904 Methods for treating arenaviridae and coronaviridae virus infections

GILEAD SCIENCES, INC.

US10247729

US10246425

US10238739

Media elaborated with newly synthesized antibodies (MENSA) and uses thereof

3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds

Manufacture of surfactant-containing compositions with enhanced stability

US10238733 Cationic oil-in-water emulsions  
US10238666 Pharmaceutical compositions and methods  
US10238633  
Methods for treating pulmonary emphysema using substituted  
2Aza-bicyclo[2.2.1]heptane-3-carboxylic  
acid (benzyl-cyano-methyl)amides  
inhibitors of Cathepsin C  
US10233429  
US10233425  
Hand, foot, and mouth vaccines and methods of manufacture and  
use thereof  
CD137 enrichment for efficient tumor infiltrating lymphocyte  
selection  
US10233237 Heterodimeric immunoglobulins  
US10233158  
US10232051  
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel  
blocking compounds  
Acetylenedicarboxyl linkers and their uses in specific conjugation of  
a cell-binding molecule  
MICROBPLEX, INC.  
Parion Sciences, Inc.  
NOVARTIS AG  
GLAXOSMITHKLINE BIOLOGICALS S.A.  
Pop Test Oncology LLC  
Nov13  
7Mar11  
6Dec13  
26Jan07  
18Nov13  
16Dec02  
16Sep15  
5May14  
17Dec12  
2Dec14  
6-Jul10  
3Aug15  
14Boehringer  
Ingelheim International GmbH  
Mar13  
7Takeda  
Vaccines, Inc.  
The Trustees of the University of Pennsylvania  
AMGEN INC.  
Parion Sciences, Inc.  
HANGZHOU DAC BIOTECH CO., LTD.  
US10227376 Radiolabeled cationic steroid antimicrobials and diagnostic methods  
BRIGHAM YOUNG UNIVERSITY  
US10227373 Enantiomers of the 1 $\alpha$ ,6 $\alpha$ -isomer of neplanocin A  
Auburn University  
US10226449 Heterocyclic modulators of lipid synthesis and combinations thereof  
3-V Biosciences, Inc.  
US10226434  
Design, synthesis and methods of use of acyclic fleximer nucleoside

analogues having anti-coronavirus activity  
US10222374 B-cell antigen presenting cell assay  
US10221446 Signal propagation biomolecules, devices and methods  
US10220002 Controlled-release peptide compositions and uses thereof  
US10213383 Hydrophilic filtration during manufacture of vaccine adjuvants  
US10209254

Chips, detection systems, and methods for multiplex pneumococcus serology

US10209248 Multiplex immuno screening assay

US10206994

RNA virus attenuation by alteration of mutational robustness and sequence space

Katholieke Universiteit Leuven/Lieden University Medical Center, RC Leiden

University of Pittsburgh of the Commonwealth System of Higher Education

STC.UNM

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

NOVARTIS AG

The UAB Research Foundation

Institut Pasteur

INSTITUT PASTEUR

Nov14

16Sep13

21Nov12

13Dec13

15Jul-15

22Aug14

4Aug14

20Dec13

30Jan15

8Apr10

21May13

2Dec11

3Dec09

9Oct13

4May12

28Jan15

25Nov

-14

3May

-17

5Dec

-14

14Jun

-17

28Nov

-17

30Apr

-18

16Sep

-16

5May

-15

29Jun  
-17  
2Dec  
-15  
11Mar  
-16  
29Nov  
-17  
6Jun  
-17  
27Oct  
-17  
16Sep  
-14  
21Nov  
-13  
4Apr  
-18  
3Mar  
-17  
19Aug  
-15  
17May  
-17  
19Dec  
-14  
2Jul18  
9Aug  
-17  
30Oct  
-16  
30Nov  
-12  
3Dec  
-10  
9Oct  
-14  
19Jul17  
28Jan  
-16  
16Apr19  
9Apr19  
9Apr19  
9Apr19  
9Apr19  
9Apr19  
2Apr19  
2Apr19  
26Mar  
-19  
26Mar  
-19  
26Mar

-19  
26Mar  
-19  
19Mar  
-19  
19Mar  
-19  
19Mar  
-19  
19Mar  
-19  
12Mar  
-19  
12Mar  
-19  
12Mar  
-19  
12Mar  
-19  
5Mar  
-19  
5Mar  
-19  
5Mar  
-19  
26Feb  
-19  
19Feb  
-19  
19Feb  
-19  
19Feb  
-19  
Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
200  
US10202640  
Single cell analysis of T cells using high-throughput multiplex  
amplification and deep sequencing  
The Board of Trustees of the Leland Stanford Junior  
University  
US10202617 Expression cassette for efficient surface display of antigenic  
proteins Temasek Life Sciences Laboratory Limited  
US10202615 Mammalian genes involved in toxicity and infection  
US10202578 Chicken cells for improved virus production  
US10202367 Heterocyclic compounds and methods of use thereof  
US10201198  
US10190984  
Protective masks with coating comprising different electrospun  
fibers interweaved with each other, formulations forming the same,  
and method of producing thereof

Systems and methods for analyzing a sample and for monitoring the performance of an optical signal detector  
VANDERBILT UNIVERSITY  
THE PIRBRIGHT INSTITUTE  
The United States of America, as represented by the Secretary, Department of Health and Human Services  
Profit Royal Pharmaceutical Limited  
GEN-PROBE INCORPORATED  
US10190137 CRISPR-related methods and compositions with governing gRNAs Editas Medicine, Inc.  
US10190132  
Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin  
US10189822 Heterocyclic modulators of lipid synthesis  
US10189820 Heterocyclic amides useful as protein modulators  
US10183074 Cationic oil-in-water emulsions  
US10179176  
Recombinant adeno-associated virus capsids resistant to preexisting human neutralizing antibodies  
US10179143 Anti-viral azide containing compounds  
MEDICAGO INC.  
3-V Biosciences, Inc.  
GlaxoSmithKline Intellectual Property Development Limited  
GLAXOSMITHKLINE BIOLOGICALS S.A.  
The Board of Trustees of the Leland Stanford Junior University  
Life Technologies Corporation  
US10173987 Hydrazide containing nuclear transport modulators and uses thereof  
Karyopharm Therapeutics Inc.  
US10172830  
Pyrazolone compounds having human neutrophil elastase inhibitory properties  
US10168336 Quinone methide analog signal amplification  
US10167499  
US10167333  
Luminophore-labeled molecules coupled with particles for microarray-based assays  
Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen  
US10166283  
Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen  
US10166255 Intracellular genomic transplant and methods of therapy  
US10160796  
Mast cell stabilizers for treatment of hypercytokinemia and viral infection  
US10159731 Methods and compositions for inhibiting Akt3  
US10159729 Antigen and method for production thereof  
US10159672  
Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity  
US10156562 Assay for detecting Th1 and Th2 cell populations  
US10155980 Compositions and methods for detecting rare sequence variants

Chiesi Farmaceutici S.p.A.  
Ventana Medical Systems, Inc.  
CAPITALBIO TECHNOLOGY CORPORATION  
Not Available

7May14

8Feb11

10Dec10

5Jun13

12Jun14

23Dec14

31Dec15

7Nov13

21Jan08

19Mar15

7Apr16

6-Jul11

16Feb16

28Jul-10

29Jul-11

31May16

24Feb14

5Dec13

16Jan14

15CureVac

AG

Feb12

INTIMA

BIOSCIENCE, INC.

Emergo Therapeutics, Inc.

Augusta University Research Institute, Inc.

Sallpro Biotech AB

PARION SCIENCES, INC.

AMGEN INC.

ACCURAGEN HOLDINGS LIMITED

US10155946 Particle-nucleic acid conjugates and therapeutic uses related thereto

Emory University

US10155932

Decreasing potential iatrogenic risks associated with influenza vaccines

Fauci/COVID-19 Dossier

Novartis AG

31Jul-15

8Sep16

15Jan16

13Sep13

27Jun11

16May14

15Aug16

25Jun12

9Sep04

CC-BY-NC-SA

Dr. David E. Martin

30Apr

-15

8Feb  
-12  
11Dec  
-11  
3Jun  
-14  
12Jun  
-15  
10Dec  
-15  
23Dec  
-16  
29Nov  
-17  
2Sep  
-16  
15Mar  
-16  
3Jan  
-18  
23Mar  
-17  
16Feb  
-17  
8Aug  
-17  
21Jun  
-17  
26May  
-17  
24Aug  
-16  
2Dec  
-14  
15Jan  
-15  
21Mar  
-17  
29Jul16  
17Nov  
-17  
20Feb  
-18  
12Sep  
-14  
15Dec  
-17  
15May  
-15  
1Nov  
-17  
9Oct  
-17  
9May



-16  
201  
12Feb  
-19  
12Feb  
-19  
12Feb  
-19  
12Feb  
-19  
12Feb  
-19  
12Feb  
-19  
29Jan19  
29Jan19  
29Jan19  
29Jan19  
29Jan19  
22Jan19  
15Jan19  
15Jan19  
8Jan19  
8Jan19  
1Jan19  
1Jan19  
1Jan19  
1Jan19  
1Jan19  
25Dec  
-18  
25Dec  
-18  
25Dec  
-18  
25Dec  
-18  
18Dec  
-18  
18Dec  
-18  
18Dec  
-18  
18Dec  
-18

31US10150768

Guanidine substituted imidazo[4,5-c] ring compounds

US10150743 Carboxylic acid compounds

US10149901 Influenza vaccines with reduced amounts of squalene

US10149859

Nucleotide and nucleoside therapeutic compositions and uses  
related thereto

US10149461 Immunocompromised ungulates

US10144735 Immune response modifier compositions and methods

US10143709 Use of ASC and ASC-CM to treat ARDS, SARS, and MERS  
US10143652 Methods for the preparation of liposomes  
US10138461 Animal protein-free media for cultivation of cells  
US10138295  
Compositions comprising AAV expressing dual antibody constructs  
and uses thereof  
US10138276 Inhibition of TCR signaling with peptide variants  
US10131709  
US10131704  
US10131682  
Nucleic acid molecules encoding monoclonal antibodies specific for  
IL-22  
Middle east respiratory syndrome coronavirus neutralizing  
antibodies and methods of use thereof  
Hydrophilic linkers and their uses for conjugation of drugs to a cell  
binding molecules  
US10130701 Coronavirus  
US10125112 Modulators of the relaxin receptor 1  
US10125092 Lipids and lipid compositions for the delivery of active agents  
US10124065 Lipids and lipid compositions for the delivery of active agents  
US10124048 Adenovirus vectors  
US10123518  
Genetically modified non-human animals and methods of use  
thereof  
US10119967 Multiplex immuno screening assay  
US10119164  
US10118925  
Capture primers and capture sequence linked solid supports for  
molecular diagnostic tests  
Imidazo[4,5-c] ring compounds containing substituted guanidine  
groups  
US10118923 Compositions and methods for inhibiting kinases  
US10117920 Combination of vaccination and inhibition of the PD-1 pathway  
US10114011 Antigen presenting cell assay  
US10106619  
Virus vaccination and treatment methods with OX40 agonist  
compositions  
US10106551 Monothiol mucolytic agents  
US10105426 Immunostimulatory combinations  
US10078083 Detecting targets using mass tags and mass spectrometry  
3M Innovative Properties Company  
Sumitomo Dainippon Pharma Co., Ltd.  
Seqirus UK Limited  
Emory University  
Revivicor, Inc.  
3M Innovative Properties Company  
Indiana University Research and Technology Corporation  
CuriRx Inc.  
Baxalta GmbH  
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA  
SIGNABLOK, Inc.  
ImmunoQure AG  
DANA-FARBER CANCER INSTITUTE, INC.  
HANGZHOU DAC BIOTECH CO., LTD.

THE PIRBRIGHT INSTITUTE  
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF  
TRUSTEES  
Novartis AG  
Novartis AG  
Oxford University Innovation Limited  
Institute For Research In Biomedicine (IRB)  
Institut Pasteur  
IBIS BIOSCIENCES, INC.  
3M Innovative Properties Company  
Inhibikase Therapeutics, Inc.  
CureVac AG  
University of Pittsburgh of the Commonwealth System of  
Higher Education  
La Jolla Institute for Allergy and Immunology  
PARION SCIENCES, INC.  
TRUSTEES OF DARTMOUTH COLLEGE  
Ventana Medical Systems, Inc.  
Aug15  
18May12  
10Feb09  
11Sep13  
27Oct08  
22Dec06  
6May14  
23Sep09  
29Oct04  
13May14  
30Sep09  
28Dec11  
25Apr14  
24Nov12  
23Jul-14  
4May12  
5Sep14  
8Mar13  
10Apr07  
13Apr15  
4May12  
31Jul-09  
31Aug15  
23Apr15  
22Feb13  
8Apr10  
4Oct06  
30Jan15  
30Dec02  
2-Jul10  
26Aug  
-16  
11May  
-16  
27Jan  
-16

10Sep  
-14  
23Mar  
-15  
25Jun  
-18  
6May  
-15  
2Aug  
-16  
22Sep  
-17  
13May  
-15  
30Sep  
-10  
7Sep  
-16  
27Apr  
-15  
24Nov  
-12  
23Jul15  
25Aug  
-16  
4Sep  
-15  
6Mar  
-14  
27Apr  
-15  
12Apr  
-16  
3May  
-13  
15Aug  
-16  
26Aug  
-16  
7Nov  
-17  
7Feb  
-18  
20Jul17  
4Oct  
-07  
29Jan  
-16  
10Sep  
-15  
28Dec  
-15  
Fauci/COVID-19  
Dossier

CC-BY-NC-SA Dr. David E. Martin

202

11Dec

-18

11Dec

-18

11Dec

-18

11Dec

-18

11Dec

-18

4Dec

-18

4Dec

-18

4Dec

-18

27Nov

-18

27Nov

-18

27Nov

-18

20Nov

-18

20Nov

-18

20Nov

-18

20Nov

-18

13Nov

-18

13Nov

-18

13Nov

-18

13Nov

-18

13Nov

-18

6Nov

-18

6Nov

-18

6Nov

-18

6Nov

-18

6Nov

-18

30Oct18

23Oct18

23Oct18

23Oct18

18Sep

-18

US10077427 Means and methods for influencing the stability of cells  
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT  
VAN AMSTERDAM

US10076491 Vaccine composition

US10072309

Methods for real-time multiplex isothermal detection and  
identification of bacterial, viral, and protozoan nucleic acids

NITTO DENKO CORPORATION

Not Available

US10072064 Composition comprised of antigen linked to a TNF superfamily ligand

Not Available

US10072058

Chimeric virus-like particles incorporating fusion GPI anchored GMCSF  
and IL-4 conjugates

US10071976 Small molecule fatty acid synthase inhibitors

US10071970

Chloro-pyrazine carboxamide derivatives with epithelial sodium  
channel blocking activity

US10071155 Nasal mucosal vaccine composition

US10071154

Vaccines and immunotherapeutics using IL-28 and compositions and  
methods of using the same

US10071076 Methods of treating cancer and other disorders

US10066238 Methods for producing antibodies

US10066012 Human monoclonal antibodies against interleukin 8 (IL-8)

US10064934 Combination PIV3/hMPV RNA vaccines

US10064900 Methods of populating a gastrointestinal tract

US10059769 Anti-PD-L1 antibodies and uses thereof

US10059741 Peptidomimetic macrocycles

US10059655 Lipids and lipid compositions for the delivery of active agents

US10058624

Recombinant promoters and vectors for protein expression in liver  
and use thereof

US10058535 Nuclear transport modulators and uses thereof

US10058516

US10055502

Design, synthesis and methods of use of acyclic fleximer nucleoside  
analogues having anti-coronavirus activity

System and method for detecting, collecting, analyzing, and  
communicating event related information

US10053728 High density self-contained biological analysis

US10052398

US10052380

Additive compositions for pigmented disinfection and methods  
thereof

Lipidated immune response modifier compound compositions,  
formulations, and methods

US10047375 Artificial nucleic acid molecules

US10047148 Neutralizing GP41 antibodies and their use

US10047147 Neutralizing GP41 antibodies and their use

US10046048

US10040831

US10040828

Homogenous suspension of immunopotentiating compounds and uses thereof

Compositions and methods for treating diseases by inhibiting exosome release

Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Fauci/COVID-19 Dossier

Children's Healthcare of Atlanta, Inc.

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

Parion Sciences, Inc.

NITTO DENKO CORPORATION

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Wake Forest University Health Sciences

UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

CORMORANT PHARMACEUTICALS AB

ModernaTX, Inc.

Seres Therapeutics, Inc.

I-MAB

Aileron Therapeutics, Inc.

Novartis AG

Children's Healthcare of Atlanta, Inc.

Biogen MA Inc.

Katholieke Universiteit Leuven

Georgetown University

BioFire Diagnostics, LLC

Kinnos Inc.

3M Innovative Properties Company

CureVac AG

The United States of America, as represented by the Secretary, Department of Health and Human Services

The United States of American, as represented by the Secretary, Department of Health and Human Services

GLAXOSMITHKLINE BIOLOGICALS S.A.

MOREHOUSE SCHOOL OF MEDICINE

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

CC-BY-NC-SA Dr. David E. Martin

Mar15

5Feb13

8May15

15Mar13

29Apr15

7Mar14

17Dec12

3Oct13

4Apr08

12Nov10

11Feb13

16Dec02

22Oct15  
4Feb13  
13Jun16  
1-Jul15  
19Dec13  
16Apr15  
9May12  
30Jan15  
25Feb08  
15Nov06  
8Dec14  
17Aug10  
30Dec14  
7Nov11  
7Nov11  
15Dec09  
19Dec16  
10Apr12  
26Mar  
-15  
29Jan  
-14  
6May  
-16  
16Mar  
-14  
29Apr  
-16  
5Mar  
-15  
7Mar  
-17  
20ct  
-14  
6Apr  
-09  
27Jun  
-16  
11Feb  
-14  
26Apr  
-16  
11Aug  
-17  
4Feb  
-14  
13Jun  
-17  
1Jul16  
17Dec  
-14  
15Apr  
-16  
24Jan



-17  
28Jan  
-16  
23Sep  
-16  
16Jul15  
23May  
-15  
27Nov  
-17  
28Jun  
-16  
8Sep  
-17  
4Aug  
-14  
5Jul16  
19Dec  
-16  
10Apr  
-13  
Sep  
-18  
18Sep  
-18  
11Sep  
-18  
11Sep  
-18  
11Sep  
-18  
11Sep  
-18  
11Sep  
-18  
11Sep  
-18  
11Sep  
-18  
11Sep  
-18  
11Sep  
-18  
4Sep  
-18  
4Sep  
-18  
4Sep  
-18  
4Sep  
-18  
28Aug  
-18  
28Aug  
-18  
28Aug

-18

28Aug

-18

28Aug

-18

28Aug

-18

21Aug

-18

21Aug

-18

21Aug

-18

21Aug

-18

14Aug

-18

14Aug

-18

14Aug

-18

14Aug

-18

7Aug

-18

7Aug

-18

203

2618

19US10040820

Method for the purification of protein complexes

US10039781 Pulse inhalation of nitric oxide for treating respiratory diseases

US10039758

US10034931

Compositions and methods for inhibiting bacterial and viral pathogens

Use of EGFR pathway inhibitors to increase immune responses to antigens

US10034894 Method of treating inflammation

US10031134

Antibody-nanoparticle conjugates and methods for making and using such conjugates

US10030250 Edible vaccines expressed in soybeans

US10030074

Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies

US10030053 Immunogenic compositions and methods of use thereof

US10029016 Immunostimulatory compositions and methods of use thereof

US10028482

Disinfecting and deodorizing compositions and methods with novel polymeric binding system

US10023845 Methods of making modified viral genomes

US10023632 Antigenic GM-CSF peptides and antibodies to GM-CSF

US10023558 Compounds

US10022436 Microneedle compositions and methods of using same  
US10022435 Nucleic acid vaccines  
US10022422 Peptidomimetic macrocycles  
US10018369 Air curtain device  
US10017784  
US10016498  
Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA virus spike protein  
D-amino acid derivative-modified peptidoglycan and methods of use thereof  
US10016497 MERS-CoV vaccine  
US10016455  
Method of preventing or treating influenza with oxidative reductive potential water solution  
US10013760 Stain-free histopathology by chemical imaging  
US10010718 Device to kill micro-organisms inside the respiratory tract  
US10010607  
US10006862  
US10005833  
Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response  
Continuous process for performing multiple nucleic acid amplification assays  
Methods of treating inflammation associated airway diseases and viral infections  
US10005772 Immune response modifier compositions and methods  
US10004764  
US10004755  
Red blood cell membrane-derived microparticles and their use for the treatment of lung disease  
Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity  
Fauci/COVID-19 Dossier  
Immunobiology Limited  
AIT THERAPEUTICS, INC.  
Keck Graduate Institute of Applied Life Sciences  
Emory University  
CYTOSORBENTS CORPORATION  
Ventana Medical Systems, Inc.  
Not Available  
GITR, Inc.  
Emory University  
Massachusetts Institute of Technology  
OxiScience LLC  
The Research Foundation for The State University of New York  
Morphotek, Inc.  
CHIESI FARMACEUTICI S.P.A.  
VERNDARI, INC.  
ModernaTX, Inc.  
Alleron Therapeutics, Inc.  
KAWANO GIKEN CO., LTD.  
ID PHARMA CO., LTD.  
The Regents of the University of California

INOVIO PHARMACEUTICALS, INC.  
Sonoma Pharmaceuticals, Inc.  
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS  
Not Available  
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA  
RECHERCHE MEDICALE)  
GEN-PROBE INCORPORATED  
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS  
SYSTEM  
3M Innovative Properties Company  
University of Pittsburgh“Of the Commonwealth System of  
Higher Education  
The University of North Carolina at Chapel Hill  
CC-BY-NC-SA Dr. David E. Martin  
Jun09  
24Mar15  
24Oct14  
23Sep13  
1Apr10  
27Apr10  
12Oct04  
25Mar05  
17Dec07  
5Apr12  
28Aug14  
30Mar07  
8Feb06  
31May16  
11Jan16  
23Apr14  
14Jan09  
7Aug15  
28Oct05  
30Nov12  
29Nov13  
30Dec03  
15Mar13  
1Apr16  
16Sep14  
10Mar05  
2Jan15  
22Dec06  
7Nov13  
11Apr14  
21Jun  
-10  
24Mar  
-16  
23Oct  
-15  
23Sep  
-14  
28Jun  
-17

12Sep  
-16  
25Jan  
-10  
7Nov  
-16  
13Feb  
-15  
2Jul15  
28Aug  
-15  
7Sep  
-16  
18Jul16  
22Sep  
-17  
11Jan  
-17  
1Apr  
-16  
7Apr  
-16  
19Nov  
-15  
17Nov  
-14  
14Sep  
-17  
26Nov  
-14  
9May  
-17  
2Aug  
-17  
28Mar  
-17  
16Sep  
-15  
19May  
-17  
31Dec  
-15  
20Dec  
-07  
6Nov  
-14  
30Jan  
-17  
7Aug  
-18  
7Aug  
-18  
7Aug  
-18

31Jul18  
31Jul18  
24Jul18  
24Jul18  
24Jul18  
24Jul18  
24Jul18  
24Jul18  
17Jul18  
17Jul18  
17Jul18  
17Jul18  
17Jul18  
17Jul18  
10Jul18  
10Jul18  
10Jul18  
10Jul18  
10Jul18  
3Jul18  
3Jul18  
3Jul18  
26Jun18  
26Jun18  
26Jun18  
26Jun18  
26Jun18  
204

USRE47838 Inhibitory peptides of viral infection

UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

USRE47636 Substituted spirocycles

USRE47493

Substituted bicyclic dihydropyrimidinones and their use as inhibitors  
of neutrophil elastase activity

USRE46906 Methods for producing vaccine adjuvants

Boehringer Ingelheim International GmbH

Boehringer Ingelheim International GmbH

NOVARTIS AG

USRE46873 Multi-targeted RNAi therapeutics for scarless wound healing of skin  
Sirnaomics, Inc.

USRE46630

Substituted 4-pyridones and their use as inhibitors of neutrophil  
elastase activity

USRE46441 Circulation of components during homogenization of emulsions

USH2284

USH2283

EP2517720A

1

EP2510946A

1

EP2471938A

2

EP2471937A

2

EP2471936A

2

EP2471551A

2

EP2167534B

1

EP2121732B

1

Vaccines for protecting against influenza

Vaccines for protecting against influenza

Stabilized therapeutic small helical antiviral peptides

Conjugates of synthetic tlr agonists and uses therefor

Recombinant polyvalent vaccine

Recombinant polyvalent vaccine

Recombinant polyvalent vaccine

Decreasing potential iatrogenic risks associated with influenza vaccines

BIOACTIVE PEPTIDES AND METHOD OF USING SAME

COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC

VIRUS-LIKE PARTICLES

Boehringer Ingelhelheim International GmbH

NOVARTIS AG

Novartis AG

Novartis AG

New York Blood Center, Inc.

The Regents of The University of California

National Institute of Biomedical Innovation

National Institute of Biomedical Innovation

National Institute of Biomedical Innovation

Novartis Vaccines and Diagnostics GmbH

Compugen Ltd.

UniversitÄt ZÄ¼rich Prorektorat Forschung

17Jul-14

12Sep14

20Feb14

3Dec09

6Nov07

23Aug12

3Dec09

27Apr09

27Apr09

20Oct07

7Feb08

24Nov05

24Nov05

24Nov05

9Sep05

11Jul-08

6Dec07

30Jan

-18

30Nov

-17

26Mar

-18  
13Oct  
-15  
26May  
-16  
18Sep  
-15  
13Oct  
-15  
27Apr  
-10  
27Apr  
-10  
31Oct  
-12  
17Oct  
-12  
24Nov  
-05  
24Nov  
-05  
24Nov  
-05  
4Jul12  
4Jul12  
4Jul12  
Feb  
-20  
8Oct19  
9Jul19  
26Jun18  
29May  
-18  
12Dec  
-17  
20Jun17  
3Sep  
-13  
3Sep  
-13  
31Oct12  
17Oct12  
4Jul12  
4Jul12  
4Jul12  
4Jul12  
4Jul12  
4Jul12  
4Fauci/COVID-19  
Dossier  
CC-BY-NC-SA Dr. David E. Martin  
205



# THE **VACCINE DEATH** REPORT

---

Evidence of millions of deaths and serious adverse events  
resulting from the experimental COVID-19 injections

BY DAVID JOHN JOHNSON & DR. VLADIMIR ZELINKO MD

## **PURPOSE**

The purpose of this report is to document how all over the world millions of people have died, and hundreds of millions of serious adverse events have occurred, after injections with the experimental mRNA gene therapy. We also reveal the real risk of an unprecedented genocide.

## **FACTS**

We aim to only present scientific facts and stay away from unfounded claims. The data is clear and verifiable. Over one hundred references can be found for all presented information, which is provided as a starting point for further investigation.

## **COMPLICITY**

The data suggests that we may currently be witnessing the greatest organized mass murder in the history of our world. The severity of this situation compels us to ask this critical question: will we rise to the defense of billions of innocent people? Or will we permit personal profit over justice, and be complicit? Networks of lawyers all over the world are preparing class-action lawsuits to prosecute all who are serving this criminal agenda. To all who have been complicit so far, we say: There is still time to turn and choose the side of truth. Please make the right choice.

## **WORLDWIDE**

Although this report focuses on the situation in the United States, it also applies to the rest of the world, as the same type of experimental injections with similar death rates - and comparable systems of corruption to hide these numbers - are used worldwide. Therefore we encourage everyone around the world to share this report. May it be a wake-up call for all of humanity.

## AT LEAST 5 TIMES MORE DEATHS

---

### CDC WHISTLEBLOWER SIGNS SWORN AFFIDAVIT

VAERS data from the American CDC shows that as of September 17, 2021, already **1,437,273 people** suffered adverse events, including stroke, heart failure, blood clots, brain disorders, convulsions, seizures, inflammations of brain & spinal cord, life-threatening allergic reactions, autoimmune diseases, arthritis, miscarriage, infertility, rapid-onset muscle weakness, deafness, blindness, narcolepsy, and cataplexy. Besides the astronomical number of severe side effects, the CDC reports that **31,470 people died** as a result of receiving the experimental injections. However, a CDC healthcare fraud detection expert investigated this and came to the shocking discovery that the number of deaths is at least five times higher than what the CDC is admitting. In fact, in her initial communications to professor in medicine Dr. Peter McCullough, this whistleblower said that the number of deaths is ten times higher. The CDC health fraud detection expert signed an affidavit, in which she stated her findings. She carefully chose the wordings '**...under-reported by a conservative factor of at least five**', but as she revealed initially, the factor could also be ten. Here is an excerpt of the affidavit: <sup>1</sup>

**'I have, over the last 25 years, developed over 100 distinct healthcare fraud detection algorithms. ... When the COVID-19 vaccine clearly became associated with patient death and harm, I was inclined to investigate the matter. It is my professional estimate that VAERS (the Vaccine Adverse Event Reporting System) database, while extremely useful, is under-reported by a conservative factor of at least 5. ... and have assessed that the deaths occurring within 3 days of vaccination are higher than those reported in VAERS by a factor of at least 5.'**

**According to this CDC health fraud detection expert  
the number of vaccine deaths in the U.S. is not 31,470  
but somewhere between 150,000 and 300,000.**

The CDC is also vastly underreporting other adverse events, like severe allergic reactions (anaphylaxis). The Informed Consent Action Network (ICAN) reported that a study showed how the actual number of anaphylaxis is **50 to 120 times higher** than claimed by the CDC.<sup>2,3</sup> On top of that, a private researcher took a close look at the VAERS database, and tried looking up specific case-ID's. He found countless examples where the original death records were deleted, and in some cases, the numbers have been switched for milder reactions. He says:

**'What the analysis of all the case numbers is telling us right now is that there's approximately 150,000 cases that are missing, that were there, that are no longer there. The question is, are they all deaths?'** <sup>4</sup>

How criminal the CDC is, was also revealed a few years ago, when researchers investigated the link between vaccines and autism. They found that there indeed is a direct connection. So what did the CDC do? All the researchers came together and a large dustbin was placed in the middle of the room. In it they threw all the documents that showed the link between autism and vaccinations. Thus, the evidence was destroyed. Subsequently, a so-called 'scientific' article was published in Pediatric, stating that vaccinations do not cause autism. However, a leading scientist within the CDC, William Thompson, exposed this crime. He publicly admitted:

**'I was involved in misleading millions of people about the possible negative side effects of vaccines. We lied about the scientific findings.'** <sup>5</sup>

The worst example of criminal methodology used to hide vaccine deaths is the fact that the CDC doesn't consider a person vaccinated until two weeks after their second injection. This means that anyone who dies during the weeks before or the two weeks after the second injection, are considered unvaccinated deaths, and are therefore not counted as vaccine deaths. By doing this, they can ignore the vast majority of deaths following the injection. This is the nr 1 method used in nations worldwide to hide the countless numbers of vaccine deaths. <sup>6,7</sup>

## **300,000 ADVERSE EVENTS**

---

### MODERNA HIDES HUNDREDS OF THOUSANDS OF REPORTS

**A** whistleblower from Moderna made a screenshot of an internal company notice labelled "Confidential - For internal distribution only", showing there were 300,000 adverse events reported in only three months:

**'This enabled the team to effectively manage approximately 300,000 adverse event reports and 30,000 medical information requests in a three month span to support the global launch of their COVID-19 vaccine.'** <sup>8</sup>

## 50,000 MEDICARE VACCINATED DIED

---

U.S. DEATH RATE PROBABLY NEAR 250,000

Attorney Thomas Renz received information from a whistleblower inside the Centers for Medicare & Medicaid Service (CMS), which reveals how **48,465 people died** shortly after receiving their injections. He emphasized that these death numbers are from only 18% of the U.S. population.<sup>9</sup> If we apply this to the entire U.S. population, that would mean a death rate of  $\pm 250,000$ . Other factors also play a role of course, such as the age of the Medicare patients, and the younger members of the American people, so we can't simply extrapolate this to the entire U.S. population. But we do see that something extremely serious is going on.

## LESS THAN 1% IS REPORTED

---

THE ACTUAL NUMBER IS 100X HIGHER

All this information already shows us that the number of adverse events and deaths is a multitude of what is being told to the public. The situation is however still far worse than most of us can even imagine. The famous Lazarus report from Harvard Pilgrim Health Care inc. in 2009 revealed that in general only 1% of adverse events from vaccines is being reported:<sup>10</sup>

**'Adverse events from drugs and vaccines are common, but underreported. Although 25% of ambulatory patients experience an adverse drug event, less than 0.3% of all adverse drug events and 1-13% of serious events are reported to the Food and Drug Administration (FDA). Likewise, fewer than 1% of vaccine adverse events are reported.'**

According to this study, numbers of adverse events and deaths should be multiplied with a factor of 100, in order to understand the true prevalence of serious vaccine injuries.

## REASONS FOR UNDERREPORTING

---

THE POPULATION IS MISINFORMED

The reason that less than 1% of adverse events is reported, is first of all because the majority of the population is not aware of the existence of reporting systems for vaccine injuries. Secondly, the

pharmaceutical industry has been waging an unrelenting media war over the past decades against all medical experts, who attempted to inform the public about the dangers of vaccines. One deployed strategy is name-calling, and the negative label 'anti-vaxxer' was chosen to shame and blame all scientists, physicians, and nurses who speak out about the devastation caused by vaccinations.

**Because of this criminal campaign of aggressive suppression of adverse events data, the majority of the population is clueless that vaccines can cause any harm at all.**

The widespread propaganda by the vaccine companies, who use government agencies as their main carousel, simply told humanity for decades that adverse events are a very rare occurrence. When vaccinated people, therefore, suffer from serious adverse events, it doesn't even occur to them that this could be from previous injections, and naturally don't report it as such.

During the current world crisis the attacks on medical experts who are warning about vaccines, have gone to an even higher level. Medical experts are now being completely de-platformed from all social media, their websites are deranked by Google, entire YouTube channels are deleted, many have lost their jobs, and in some countries, medical experts have been arrested in an attempt to suppress the truth about the experimental covid injections.

**Several countries are now labeling scientists who speak out against vaccines 'domestic terrorists'. It is clear that all means have to be deployed by the criminal vaccine cartel to suppress what is going on with these injections.**

As a result, countless medical professionals are afraid to report adverse events, which further contributes to the underreporting of these side effects. Additionally, the amount of scientific information warning for these dangerous biological agents, and the number of medical experts warning humanity, is so overwhelming and almost omnipresent - despite the aggressive attempts to silence them - that it is virtually impossible for any medical professional to not be at least somewhat aware of the risk they are taking, by administering an untested DNA altering injection, without even informing their patients of what is being injected into their body. If they then see their patients die or become disabled for life, they are naturally afraid of being held accountable, and therefore have yet another motivation for not reporting the adverse events.

Lastly: many medical professionals receive financial incentives to promote the vaccines. In the United Kingdom for example nurses get £10 per needle they put into a child. That again is a reason for them to not report adverse events.

## 250,000 VACCINE COMMENTS

### FACEBOOK REVEALS TSUNAMI OF ADVERSE EVENTS

A local ABC News Station posted a request on Facebook for people to share their stories of unvaccinated loved ones that died. They wanted to make a news story on this. What happened was totally unexpected. In five days time over 250,000 people posted comments, but not about unvaccinated loved ones. All the comments talk about vaccinated loved ones that died shortly after being injected, or that are disabled for life. The 250,000 comments reveal a shocking death wave among the population, and the heart wrenching suffering these injections are causing. The post was already shared 200,000 times, and counting...<sup>11</sup>



**WXYZ-TV Channel 7** ✓  
10 september om 13:40 · 🌐



After the vaccines were available to everyone, did you lose an unvaccinated loved one to COVID-19? If you're willing to share your family's story, please DM us your contact information. We may reach out for a story we're working on.



**Adam Lee Marcus** ✓ · [Volgen](#)

I know people who died painfully from the vaccine. Want those stories?

Leuk · Beantwoorden · 1 d

👍🙄 9,2 d.

↪ 851 antwoorden



**Cindi D. Markham**

I had a uncle and cousin die from the jab! My son in laws aunt died from it and 3 more friends died from it.

Leuk · Beantwoorden · 2 d · Bewerkt

🙄👍 6



**Andrea Ashton**

My uncle suffered a stroke due to blood clots and complications days after his second shot. Would you please do a story about all these reactions?

Leuk · Beantwoorden · 2 d

👍🙄👍 882

↪ 13 antwoorden



**Katie Jeroudi**

A friend of a parent went into cardiac arrest almost immediately after receiving second dose. They were unable to revive her.  
I also know of someone who lost a limb due to a blood clot/circulation issue after being fully vaccinated.  
Hm. From the looks of the comments, you might want to change your story topic.

Leuk · Beantwoorden · 3 d

11 d.

↳ 251 antwoorden



**Pamela Witte**

Yes please please please do a story on all the ones who have died after being vaccinated, more than anyone will know because no one will tell the truth

Leuk · Beantwoorden · 4 d

8,3 d.

↳ 110 antwoorden



**Carmen Marie**

No we were all fine but almost lost one of my vaccinated family members!

Leuk · Beantwoorden · 3 d

15 d.

↳ 117 antwoorden



**Lani Rose**

My son's classmate lost her mother from heart complications due to the vaccine. ...

Leuk · Beantwoorden · 3 d

20 d.

↳ 372 antwoorden



**Liz Lemery Joy**

Will you be doing any stories of the people that overcame Covid and have antibodies? Will you be doing any stories on the thousands that also have debilitating side effects from the vaccine? Curious if you will be balanced journalists and media or not- but guessing NO!

Leuk · Beantwoorden · 2 d · Bewerkt

64 d.

↳ 3.160 antwoorden



**Julie-Wilson Fogle**

Lost my Mom 10 days after she got her 2nd Pfizer jab. She couldn't swallow or talk correctly the very next day...was hospitalized and basically never "woke up" again. Was sent home on hospice after 5 days in the hospital and died at home 2 days later. ... Meer weergeven ...

Leuk · Beantwoorden · 3 d

876

↳ 32 antwoorden



**Noelle O'Foster**

My dad flatlined after his second dose of Moderna

Leuk · Beantwoorden · 4 d

🙄🗣️👤 7,5 d.

↳ 294 antwoorden



**Angel West**

I lost a relative that got the shot, then got Covid, then died in hospital! She knew she was reacting from the shot and didn't feel well after getting it. Her husband took her in to hospital and was never allowed to see her again, him & their daughters. She was a healthy 54 yr old. This was in Abbotsford Hospital, BC.

Leuk · Beantwoorden · 9 u

🙄🗣️👤 82



**De Ann Burk**

I am so sorry for all of us. My husband has been in a terrible health situation after his second Pfizer vaccination. He passed away for a brief time then brought back to life. Along w multiple trips to the Er with mini stroke and the latest ct scan showed a legion growing in his brain and he was told not to drive. Literally it's like new symptoms keep happening and we are spending all our money on office visits, specialists and tests. No one and I mean NO ONE DARES to record the data as a vaccine reaction. So yeah. There's a huge trust issue underneath this virus and it's vaccine.

Leuk · Beantwoorden · 3 d

👍🙄👤 882

↳ 36 antwoorden



**Gina Coscarart**

**Liz Lemery Joy** I had a stroke with 2nd vaccine and the doctors can't report it. Go figure.

Leuk · Beantwoorden · 1 d

🙄👤👍 566

↳ 188 antwoorden

**Notice in the last comment how the lady says that everybody in the hospital is afraid to report this as a vaccine reaction, and another person says 'the doctors can't report it'.**

That is proof of what I explained earlier: Most medical professionals are either too terrified to report adverse events, or they are simply corrupt. This causes the true prevalence of vaccine injuries to remain hidden from the world, which is powerful real life evidence for what the Lazarus report revealed: only 1% of vaccine injuries are reported to the authorities. The 250,000+ comments show that once people find a place to report suffering caused by the injections, we see a tsunami...



## VACCINE DEATHS SUMMARY

---

### IT IS FAR WORSE THAN WE THINK

- ✓ VAERS published 1,437,273 adverse events, including 31,470 deaths as of October 7, 2022
- ✓ CDC fraud expert says that number of deaths is at least five times, and possibly ten times higher
- ✓ A whistleblower from the Centers for Medicare & Medicaid Service (CMS) revealed how almost 50,000 people died from the injections. They represent only 20% of the U.S. population, meaning that if this data is applied to the entire population 250,000 have died
  - ✓ 150,000 reports have been rejected or scrubbed by the VAERS system
  - ✓ The actual number of anaphylaxis is 50 to 120 times higher than claimed by the CDC
- ✓ Everyone who dies before two weeks after the second injection, is not considered a vaccine death, which causes the majority of early vaccine deaths to be ignored
  - ✓ Moderna received over 300,000 reports of adverse events in only three months-time
  - ✓ The Lazarus Report shows that only 1% of adverse events is being reported by the public
- ✓ The majority of the population is not aware of the existence of systems where they can report vaccine adverse events
  - ✓ Aggressive censorship and propaganda told the public that adverse events are rare, causing people to not understand how their health problems stem from past injections
- ✓ The shaming and blaming of medical professionals who say anything against the vaccines, cause many in the medical community to avoid reporting adverse events
- ✓ The fear of being held accountable after administering an injection that killed or disabled patients, further prevents medical personnel from reporting it
  - ✓ Having accepted financial incentives to promote, and administer the covid vaccines, also stops medical personnel from reporting adverse events
  - ✓ Profit driven vaccine manufacturers have every reason not to report the destruction their untested experimental products are causing
- ✓ 250,000+ Facebook users comment about vaccine deaths and serious injuries

## MILLIONS OF DEATHS WORLDWIDE

According to scientific data less than 1% of vaccine injuries are being reported. And from that 1% the majority of reports is even hidden by the authorities. They put systems in place to ignore the bulk of vaccine deaths. Combining these facts with the data that is revealed by government whistleblowers, we see that in the United States hundreds of thousands have died from the injections. As the rest of the world uses the same injections, we know that on a global scale the number of vaccine deaths is without a doubt millions.

This is only the short term tsunami of adverse events. Bill Gates, the world's leading vaccine dealer and a driving force behind the worldwide vaccine push, said in an interview with the BBC that most adverse events only show up after two years, which is why vaccine development usually takes many years. This means that the waves of deaths and disabilities in the coming years will be exponentially greater. Especially because more and more booster shots are imposed on the population, and vaccine passports being implemented.

## WORLD EXPERTS WARN HUMANITY

---

### LEADING SCIENTISTS ISSUE GRAVE WARNINGS

This alarming data leads world experts, like the Nobel Prize Winner in Medicine, Dr. Luc Montagnier, to issue a grave warning that we are currently facing the greatest risk of worldwide genocide, in the history of humanity.<sup>12</sup> Even the inventor of the mRNA technology, Dr. Robert Malone, warns against these injections that are using his technology.<sup>13,14</sup> The situation is so severe that former Pfizer vice president and chief scientist Dr. Mike Yeadon came forward to warn humanity for these extremely dangerous injections. One of his best known videos is titled 'A Final Warning'.<sup>15</sup> Another world renowned scientist, Geert Vanden Bossche, former Head of Vaccine Development Office in Germany, and Chief Scientific Officer at Univac, also risks his name and career, by bravely speaking out against administration of the covid shots. The vaccine developer warns that the **injections can compromise the immunity of the vaccinated, making them vulnerable for every new variant.**<sup>16, 17</sup> World War II holocaust survivors wrote to the European Medicines Agency demanding the injections to be stopped, which they consider to be a new holocaust.<sup>18</sup>

## VACCINE DEATHS WORLDWIDE

---

THE SAME GOES FOR NATIONS AROUND THE WORLD

The situation we described in the United States illustrates the destruction caused by these injections. We will briefly touch upon some other countries, to prove that the situation in America is not unique.

### E U R O P E A N U N I O N

In the European Union (which consists of only 27 of the 50 European countries) the official reports of EudraVigilance officially admit as of August 18th 2021 that approx. **22,000 people died and 2 million suffered side effects, of which 50% are serious.** <sup>19, 20</sup> What are serious injuries?

'It be classified as 'serious' if it corresponds to a medical occurrence that results in death, is life-threatening, requires inpatient hospitalisation, results in another medically important condition, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect.'

In The Netherlands, one of the smallest nations in the European Union, an extra parliamentary research committee set up a platform for citizens to report vaccine adverse events. This is no initiative from the government and has received no attention in the media. The majority of the Dutch population is therefore unaware of its existence. Yet, despite its limited influence, this private initiative has already received reports of **2,625 deaths and 3,230 health damages, often permanently disabling the people.**<sup>21</sup>

### U N I T E D K I N G D O M

Shortly before the national vaccination campaign started, the MHRA (Medicines and Healthcare Products Regulatory Agency) published the following request:

**'The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the *expected high volume of COVID-19 vaccine Adverse Drug Reaction (ADRs)* and ensure that no details from the ADRs' reaction text are missed.'** <sup>22</sup>

The British government published a report of the first series of adverse events, including blindness, strokes, miscarriages, heart failure, paralysis, autoimmune disease, and more. Shortly after the first

wave of immunization over **100,000 adverse events were reported, including 1260 cases of loss of eyesight (including total blindness)**. The first part of the report praises the vaccines to be the best way to protect people from COVID-19, and then continues to show the incredible destruction these vaccines are causing. The hypocrisy is mindboggling.<sup>23,24</sup>

Also in the U.K. miscarriages increased by 366% in only six weeks, for vaccinated mothers.<sup>25</sup> Furthermore the British Office for National Statistics inadvertently revealed that **30,305 people have died within 21 days of having the injection**, during the first 6 months of 2021.<sup>26</sup> And a British scientist with 35 years of experience did an in depth analysis of the British Yellow Card reporting system and found it to be unreliable.<sup>27</sup>

'We can conclude that the Yellow Card reporting scheme can provide some limited information that may be useful for alerting the UK public to possible adverse effects of the COVID-19 vaccines. However, the initial conception of the scheme as a purely descriptive rather than as an experimental undertaking means that **it cannot address the real issues that are of crucial importance to the UK public**. These issues are whether there are causal relationships between vaccination with the PF and AZ vaccines and serious adverse effects such as death, and if so, what are the size of these effects.'

## I S R A E L

The Israeli Peoples Committee is a team of doctors, attorneys, criminologists, epidemiologists and academic researchers, determined to perform an investigation, inquiry, and exposure for the benefit of the public. Although they are a relatively unknown group, they still received **3754 reports, including 480+ deaths**, as of August 5th, 2021.<sup>28</sup> The IPC states that these numbers represent only 2-3% of the true prevalence in the population, which means that the number of deaths in Israel is **around 48,000 and adverse events around 375,400**.

Also in Israel, statistics from Worldometers.info shows a massive spike in deaths when the vaccinations started. Before the immunizations began, there were hardly any daily covid deaths in Israel. Once the vaccinations began, the daily death toll rose from **1-3 to 75-100 deaths a day!**



Another Israeli website reporting vaccine injuries is [Seethetruth.club/covid-19-vaccine-victims](https://seethetruth.club/covid-19-vaccine-victims) where one can see a rapidly growing number of testimonials of people who suffered greatly from the shot. In the U.S. a similar website called [1000covidstories.com](https://1000covidstories.com) shows an ever increasing amount of videos from people who died or had severe reactions to the covid shots. Also the website called [TheCovidWorld.com](https://TheCovidWorld.com) shows the personal stories of a large number of people who died from the shots. We must understand that nothing like this has ever happened before in history, where thousands of people come forward to share their suffering following an immunization. The reason people do this now, is because their adverse reactions are not at all, like the criminal 'health' agencies say 'headaches, dizziness and flu like symptoms.' The reactions are extremely severe, often disabling people for life. The injuries are in fact so severe, that people around the world are stepping forward to warn humanity.

## B R A Z I L

In Brazil the official vaccine death count is **32,000 during a 5 month period**. The report was published on uol.com.br, which reportedly has about the same number of pageviews as CNN.com, according to data from SimilarWeb. Despite these high amounts of deaths following vaccination, the report states: 'Vaccination is still the best way to control the disease.'<sup>29</sup>

## SCIENCE PROVES VACCINE DAMAGE

---

STROKES, HEART ATTACKS, CANCER,...

A study by the University of San Francisco, or Salk Institute, shows that the vaccines turn the human body into a spike protein factory, making trillions of spikes that cause blood clots, which cause strokes and heart attacks.<sup>30</sup> Another study confirms how the vaccines can cause deadly blood clots, that in turn cause heart attacks and strokes.<sup>31,32</sup> The New England Journal of Medicine shows how the jabs cause heart inflammation,<sup>33</sup> and the same journal published a study about the dramatic increase of miscarriages.<sup>34</sup> Several studies prove the reality of antibody dependent enhancement. <sup>35,36,37</sup> Also the occurrence of infertility and reduced sperm count is confirmed.<sup>38,39</sup> Lastly a study showed that the injections cause cancer.<sup>40</sup> And these are just a few examples...

## EXEMPT FROM LIABILITY

---

NO VACCINE MANUFACTURER TAKES RESPONSIBILITY

In the past decades, several official government agreements were signed, in nations across the world, that provide every vaccine manufacturer with 100% protection from all liability. It doesn't matter how much destruction their products cause, nobody has any recourse. On top of that, no health insurance will ever cover the costs resulting from vaccine damage. They simply do not reimburse the vaccinated, when they get into trouble. Yet... the same governments that refuse to protect you from possible destruction of your health, life, and beloved ones, mandate these deadly injections and require them for shopping, travel, gatherings, and even banking services.

## DO THE INJECTIONS EVEN WORK?

---


HEALTH OFFICIALS SAY THEY ARE NOT EFFECTIVE

World-renowned vaccine developer Geert Vanden Bossche MVD, PhD warns that these injections destroy the body's immune system, making the vaccinated vulnerable for every new variant of the disease.<sup>41</sup> He also says:

**'Mass vaccination campaigns during a pandemic of highly infectious variants fail to control viral transmission. Instead of contributing to building herd immunity, they dramatically delay natural establishment of herd immunity. This is why the ongoing universal vaccination campaigns are absolutely detrimental to public and global health.'** <sup>42</sup>

The Nobel prize winner in medicine Dr. Luc Montagnier sounds the alarm that these vaccines are creating dangerous new variants.<sup>43</sup> And in Israel the statistics show clearly a dramatic increase in covid deaths once immunizations started (see earlier in this report). The Israeli prime minister Naftali Bennet even says that the people who are most at risk now, are those who received two doses of the vaccine.. <sup>44</sup>

**In the island nation Seychelles there were hardly any covid deaths, but once they started vaccinating the population, the deaths increased a hundred fold.**



In Australia, a young couple was refused access to their newborn baby for eight days, even though they were fully vaccinated. The chief health officer from Australia, Dr. Jeannette Young, gave the following revealing explanation for this inhumane situation: <sup>45</sup>

**'Just because you are vaccinated, doesn't mean that you won't get infected. That's why we could not allow that family to go and visit their baby.'**

Anthony Fauci also made it crystal clear: 'the CDC is considering mask mandates for the vaccinated',<sup>46</sup> 'the vaccinated increasingly test positive for covid, therefore they will need to keep wearing masks',<sup>47</sup> 'the vaccinated still need to avoid eating in restaurants',<sup>48</sup> and 'the vaccinated carry the Delta variant as much as the unvaccinated'.<sup>49</sup> So according to Fauci the vaccines do nothing. Yet he insists on mandating these useless injections for travel.<sup>50</sup> The same was publicly stated by the UK's Prime Minister Boris Johnson, who said: <sup>51</sup>

**'Can I now meet my friends and family members indoors if they are vaccinated? There I am afraid the answer is no, because we're not yet at that stage, we're still very much in the world where you can meet friends and family outdoors, under the rule of six, or two households. And even if your friends and family members may be vaccinated, the vaccines are not giving 100% protection and that's why we need to be cautious.'**

A research article published in 'Trends in Internal Medicine' by Dr. J. Bar Classen MD, is titled: <sup>52</sup>

'US COVID-19 Vaccines Proven to Cause More Harm than Good Based on Pivotal Clinical Trial Data Analyzed Using the Proper Scientific Endpoint, **"All Cause Severe Morbidity"**

Even the CDC admitted that the injections offer no protection against the Delta variants, and coming variants, and all covid measures, therefore, need to stay in place.<sup>53</sup> Yet they keep insisting that everybody must be vaccinated. The chief health officer of New South Wales, Australia said we have to prepare to live with a constant cycle of ongoing covid booster injections for the foreseeable future.<sup>54</sup> Moderna's chief medical officer, Dr. Tal Zaks, said that the vaccines do not bring life back to normal.<sup>55</sup> This was confirmed by the director of the World Health Organization Tedros Adhanom, who said: <sup>56</sup>

**'A vaccine on its own will not end the pandemic. Surveillance will need to continue, people will still need to be tested, isolated and cared for. Contacts will still need to be traced and quarantined, communities will still need to be engaged.'**

A study by The Lancet showed that the Delta variant is freely transmitted among the vaccinated.<sup>57</sup> This was confirmed by a study that showed how in July 2021, following multiple large public events in a Barnstable County, Massachusetts, town, 469 COVID-19 cases were identified among Massachusetts residents who had travelled to the town during July 3-17; 346 (74%) occurred in fully vaccinated persons.<sup>58</sup>



## CREATURE WITH TENTACLES

---

### LIVING ORGANISMS IN THE VACCINES

**Dr. Carrie Madej** investigated vaccine vials from Moderna and Johnson & Johnson under a microscope with 400x magnification. What she saw shocked her ...

**In both vials there was a living organism with tentacles. This creature moves around and lifts itself up.** <sup>68A</sup>





The sight of this and the thought that these unknown, octopus-like creatures are being injected into millions of children worldwide, caused Dr. Madej to weep.

## SELF-ASSEMBLING NANOBOTS

---

### WHAT IS SECRETLY BEING BUILT INSIDE YOUR BODY?

**Dr. Madej** also observed pieces of graphene in the vials, as well as self assembling nanoparticles. The particles moved towards one another, and formed more complex structures. The same was revealed by Dr. Zandre Botha from South Africa. She studied several vaccine vials using a variety of methods, and what she found is simply too bizarre for words. Just like Dr. Carrie Madej she saw complex self-assembling nanobots. <sup>69C</sup> Look at the following micrographs...



**W**hat kind of diabolical agenda is secretly being rolled out, by injecting these kinds of self-assembling nanobots into the bodies of millions of people? And why are so many news agencies, and so called fact-checkers doing overtime to deny these apparent, undeniable findings? What is really the purpose of these injections, that are so forcefully being imposed onto all of humanity? And why are all the governments worldwide collaborating with this plan? There clearly is a nefarious agenda behind covertly injecting this kind of nanotechnology into humanity. What is it? Who dares to ask these questions, and find the answers?

## DANGEROUS TOXINS

---

### GRAPHENE ALTERS THE ELECTROMAGNETIC FIELD

The world-renowned biophysicist Andreas Kalcker has discovered that the vaccines contain large amounts of graphene oxide (up to 95% of the solids).

**He warns that the graphene oxide injected into humans is altering their electromagnetic field, which disrupts the normal functioning of their organs.<sup>65</sup>**

'What we are concerned about is the side effects it has. This isn't described in medicine, but it's described in my field, biophysics. What happens? The body needs its electro molecular capabilities to work. The heart beats because there's a magnetic field that creates, subsequently, the electricity for pumping and everything else. Graphene is completely altering our electromagnetic field, something that has never happened before. What we're seeing is something 'in vivo' with some dramatic effects. We have been watching a lot of videos of people who are dying after being vaccinated. You see people spasming. These spasms have, for example, very specific frequencies, and they are the same in all kinds of spasms.

**These spasms indicate that there is a disruption of the human electromagnetic fields.'**

The presence of graphene oxide, among other toxic materials like aluminum, LNP capsids, PEG and parasites in the vaccines was further confirmed by Dr. Robert Young.<sup>66,67</sup> The Scientist's Club also released a report with microphotographic evidence of nanoparticles in the vaccines.


'Major revelations on what is in the CoV-2-19 vaccines, with the use of electron, pHase, dark field, bright field and other types of microscopy from the original research of Dr. Robert Young and his scientific team, confirming what the La Quinta Columna researchers found - **toxic nanometallic content with magneticotoxic, cytotoxic and genotoxic effects, as well as identified life-threatening parasites.** In addition, in 2008, Hongjie Dai and colleagues at Stanford University found graphene oxide.'<sup>68</sup>

## DRAMATIC BLOOD CHANGES


---

### RESEARCH REVEALS CHANGES IN BLOOD


**Dr. Robert Young** also discovered how the blood of vaccinated people changes dramatically, after the injection with mRNA. The following image reveals the normal healthy state of the red blood cells which are even in color, even in shape and even in size. <sup>69A</sup>



The second micrograph taken under Phase Contrast Microscopy reveals the live blood 24 hours after the mRNA vaccine now containing crystallized red blood cells called Heinz bodies, biological transformations of red and white blood cells, large symplasts of graphene oxide crystals center and Orotic acid crystals in the upper right hand corner of the micrograph.



German researchers discovered that the content from vaccine vials formed crystals, after being placed under a lamp that warms them to about 30° Celcius (85° F). The photo below shows this clearly.<sup>69B</sup> The image to the left shows the original vial content, and the image to the right is what happens after a few minutes... complex crystals are formed. *What impact does this have on the human body?*



## PERMANENTLY ALTERED DNA

---

### THE HUMAN GENOME IS BEING MODIFIED

Dr. Carrie Madej studied vaccines and transhumanism for two decades. In her documentary 'The Battle For Humanity', produced by Stop World Control, she warned that these injections could permanently change the human DNA, with potentially disastrous outcomes. Fact-checkers around the world - who are often paid by the vaccine industry - jumped to label it as fake news. Facebook made it their policy to censor all voices that warned how this gene therapy could potentially alter the human genome. Until... a Facebook employee recorded and released an insider zoom meeting with Facebook CEO Mark Zuckerberg, who told his staff that the injections do indeed change the human DNA! These are his exact words:

**'We just don't know the long term side effects of basically modifying people's DNA and RNA to directly encode in a person's DNA and RNA, basically the ability to produce those antibodies and whether that causes other mutations or other risks downstream.'**<sup>63</sup>



## A PATENTED TRANSHUMAN

---

NO LONGER A HUMAN WITH HUMAN RIGHTS

**Dr. Chinda Brandolino** is a Latin American physician who has been speaking out about the fact that once the human genome is altered, that person is no longer considered an original human being, but has become a transhuman, and therefore loses human rights. Furthermore, she explains that the altered DNA and RNA can be patented, making that genetically modified person property of the patent holders. The implications of this are highly alarming.<sup>64</sup>

## TRANSHUMAN BABY

---

BLACK EYES & ACCELERATED AGING

Scientists in South America are investigating a strange phenomenon: Some newborn babies from vaccinated parents in Mexico have **black eyes**, while normally the eyes of newborns are lightly colored. It also appears that these babies are **aging too fast**, as they can stand and even walk at only three months old.<sup>63A</sup> The researchers are careful not to make premature statements but will investigate this further.<sup>63B</sup>



## DIFFERENT DOSAGES

---

### WHY DO SOME DIE, WHILE OTHERS ARE FINE?

**Why** do some people die, or become disabled for life, while others seem fine after being inoculated? Dr. Jane Ruby explains that not all vials have the same dosages.<sup>68B</sup> ClinicalTrials.gov shows that there are different phases of the vaccination experiment, with different dosages of the mRNA being administered to different people. An unknown percentage of the injections are even placebos!

**This means that some people get a harmless substance injected, while others get a shot with 5, 10, 20, or 30 micrograms of mRNA.**

Dr. Ruby warns that in the booster shots some vials contain as much as 100 or even 250 micrograms of mRNA. This explains why in certain areas the vaccinated seem fine, while in other areas people drop dead after being injected. It's like Russian roulette: nobody knows what is being injected into their body. There is no informed consent. If people however take the boosters, they will get different dosages. Where previous shots may have been harmless, the next could be lethal.

## FRAUD WITH COVID DEATHS

---

### WORLDWIDE FRAUD INFLATED COVID DEATHS

The excuse for murdering millions of people with these injections is that they supposedly prevent people from dying of covid. The reality is however that the so-called number of covid deaths is the greatest lie in history. Worldwide it was revealed that over 95% of all covid deaths, were deaths from other causes. The Italian politician Vittorio Sgarbi exclaimed in the Italian Chamber of Deputies:<sup>69</sup>

**'Let's not make this the chamber of lies. Don't lie! Tell the truth. Don't say there's 25,000 dead. It's not true. Don't use the dead for rhetoric and terrorism. Figures from the Higher Institute of Health say 96.3% died of other diseases.'**

A magazine in Belgium, De Tijd, wrote how the government claimed that 3,000 elderly people had died of COVID-19. Because of these numbers the entire country was placed on lockdown. However, research showed that only 3% of the deceased had been tested. Not 3,000 but only 90 people may have had covid.<sup>70</sup>

While supposed covid deaths went through the roof, statistics in several countries showed that suddenly there are no more flu deaths. In the USA alone there are almost 40 million cases of the flu every year, but since covid hit, this number has dropped to less than 2,000. Where did all the tens of millions of flu patients go? *They are now all being registered as covid.*



A forensic German coroner Prof. Dr. Klaus Püschel examined more than 140 coronadalties in Hamburg at the start of the pandemic. On German TV he said that the hysteria around the coronavirus has been gravely exaggerated. All the people who died had underlying disorders and would have died quickly anyway, with or without the virus, according to Püschel, adding that there is no 'killer virus'. Healthy people don't have to worry, says Püschel. The coroner also predicted that corona will not even cause a peak in the annual mortality rate, a prediction that turned out to be accurate.<sup>71</sup>

**Medical professionals around the world have testified of being pressured by their supervisors to report all patients as covid, and register every death - no matter what the cause was - as a covid death. The internet has been flooded by thousands of testimonies of outraged people who said that they went to a doctor or hospital for issues unrelated to COVID-19 and to their amazement, they were registered as a covid patient.<sup>72</sup>**

Dr. Elke de Klerk, founder of Doctors for Truth in the Netherlands, testified that she received secret messages in the dossiers of terminally ill patients, requesting that these people should be registered as covid deaths.<sup>73</sup> Project Veritas called several funeral directors in New York, and they testified how



every dead person was registered as covid, while everybody knew that was not correct.<sup>74</sup> Minnesota senator Scott Jensen, who is also a practicing physician, revealed on Fox News that U.S. hospitals receive huge financial incentives to register patients as covid. For every person they registered as a covid death they are paid 39,000 USD. This has been confirmed by medical professionals around the world.<sup>75</sup> The technical director of CNN Charlie Chester was secretly filmed by a Project Veritas undercover journalist, while he admitted that CNN inflated the death rates 'because fear sells'.<sup>76</sup>

**A Zoom meeting with African government officials was leaked, revealing how they were discussing ways to ramp up covid numbers, to continue the lockdowns.<sup>77</sup>**

National File released a recording of a Zoom conference call between physicians and a marketing director at Novant Health New Hanover Regional Medical Center, a group of 20 hospitals, clinics, and offices that treat patients in North Carolina and South Carolina. In the recording, Mary Rudyk, MD tells Director of Marketing Carolyn Fisher and another hospital employee that she wants the hospitals to become more 'scary to the public' by **inflating the number of COVID-19 patients**, and by using messaging that falsely tells individuals 'if you don't get vaccinated, you know you're going to die.'<sup>78</sup>

New York was the epicenter of the COVID-19 pandemic. In the heart of New York is the famous Elmhurst hospital where supposedly more people died from this virus than anywhere else in the world. It was the epicenter within the epicenter of the pandemic. For this reason, an experienced nurse from Florida, Erin Olszewski, decided to go there to help with the crisis. What she saw in this world-famous hospital, however, filled her with so much horror, that she decided to take a hidden camera with her to film what was going on.

**Patients who repeatedly tested negative for COVID-19 are still registered as 'confirmed COVID-19'. They are put on a respirator in a covid ward... which causes them to die.**

In a revealing documentary by Journeyman Pictures, this nurse talks about the crimes she constantly sees happening in Elmhurst. She shows on her smartphone how a patient indeed tested negative for COVID-19 twice... and yet was registered as 'confirmed' COVID-19'. She explains that this happens all the time in Elmhurst: deception and murder resulting in high COVID-19 mortality rates that are trumpeted by the media.<sup>79</sup>

## FUNERAL DIRECTOR SPEAKS OUT

---

### AN UNDERTAKER WITNESSES GOVERNMENT CRIMES

One very revealing eyewitness account comes from a funeral director from the UK, John O'Looney.<sup>80</sup> For 10 years he was part of one of the largest funeral companies in the United Kingdom, he worked with the BBC to document the pandemic, and worked with a government pandemic official. He is connected to 45 other funeral directors and has therefore a clear overview of what is going on. What he discloses is shocking. First of all, he testifies that neither he nor any of the other funeral directors saw an increase in deaths during the so-called pandemic. During March 2020 however, John was suddenly called night after night, for three weeks, specifically to care homes. All who died were labelled as covid. He never saw a doctor in attendance, nor a covid test once. At the same time, there was a 1,000% increase in purchases of Midazolam. A nurse told him how they were instructed to administer lethal doses of this drug to the elderly, to mass exterminate them. These high numbers of deaths were then used to promote the narrative of a 'covid pandemic'.

**He was also approached by a government pandemic official, who told him they had to label each death as covid. People run over by cars, heart attacks, cancer patients, it didn't matter what killed them, they all had to be labelled as covid deaths.**

Once the government started mass vaccinating the British population, John says the deaths skyrocketed. 'I've never seen anything like it, as a funeral director for fifteen years. And it began exactly when they began putting needles in their arms. I've never seen a death rate like that again. It was awful, awful. Those were pandemic numbers, but it was only after they started vaccinating, never before that point.' John explains that most vaccine deaths were labelled covid deaths.

**'Every funeral director with an ounce of honesty will tell you that all those who are dying all around us are vaccine recipients. There is no covid pandemic and I am living proof of that. It's all designed to make you take the vaccine. In my network of funeral directors, not a single child has died of covid. So there is no reason whatsoever to put these gene therapies into children. Here we have a depopulation agenda. It's the vaccines that are killing the people, and I am seeing that firsthand as a funeral director.'**

*Watch the entire testimony of John O'Looney online, as he reveals far more than I quote here. For example how medical authorities within the NIH told him that the Delta variant is a vaccine injury See it here: [StopWorldControl.com/director](http://StopWorldControl.com/director)*

## COVID FRAUD SUMMARY

---

THE WORLD IS BEING DECEIVED LIKE NEVER BEFORE

- ✓ Health care workers are paid or pressured to register all patients as covid
  - ✓ The hundreds of millions of flu cases every year are now all covid
- ✓ A forensic German coroner examined 140 coronadalties and said they all died of other causes and there is no killer virus
  - ✓ Doctors get hidden messages requiring them to register dying patients as covid deaths
    - ✓ A network of 20 hospitals is caught increasing covid numbers to create fear
- ✓ Innumerable people worldwide are outraged because they were incorrectly registered as covid
  - ✓ Funeral directors admit they see false covid registrations all the time
- ✓ CNN technical director Chester confessed they inflate covid numbers because 'fear sells'
- ✓ An African government official is seen in a Zoom call discussing how to ramp up covid numbers, in order to continue the lockdowns
  - ✓ The Italian politician Vittorio is infuriated because he sees how the chamber is lying: only a small percentage died of covid!
- ✓ A funeral director witnesses the murder of thousands of elderly, to create so-called covid deaths
- ✓ He and dozens of other funeral directors were instructed by the British government to label every death as covid
  - ✓ Once the vaccinations started, these funeral directors witnessed an unprecedented explosion of deaths

**Many more examples of how the pandemic is being orchestrated can be found in the *Full Report* at [StopWorldControl.com/full](https://StopWorldControl.com/full)**

## ONLY THE VACCINATED DIED

---

### DURING SPANISH FLU ONLY VACCINE RECIPIENTS DIED

In 1918 a disastrous number of 50 - 100 million people supposedly died of what was called the 'Spanish flu'. An expert eye witness of this event was the medical scientist Eleanor McBean, PhD, N.D. who wrote a book with her first hand experiences of what was truly going on.<sup>81, 82</sup> She explains there wasn't really a flu, but mass vaccinations had been imposed on the population, causing flu-like symptoms, a host of different illnesses, and massive deaths.

**She knew of not a single unvaccinated person who died of this alleged 'Spanish flu', while most vaccinated lost their lives.**

'I was an on-the-spot observer of the 1918 influenza epidemic. All the doctors and people who were living at the time of the 1918 Spanish Influenza epidemic say it was the most terrible disease the world has ever had. Strong men, hale and hearty one day would be dead the next. The disease had the characteristics of the black death added to typhoid, diphtheria, pneumonia, smallpox, paralysis, and all the diseases the people had been vaccinated with immediately following World War 1. Practically the entire population had been injected 'seeded' with a dozen or more diseases — or toxic serums. When all those doctor-made diseases started breaking out all at once, it was tragic. That pandemic dragged on for two years, kept alive with the addition of more poison drugs administered by the doctors who tried to suppress the symptoms.

**As far as I could find out, the flu hit only the vaccinated. Those who had refused the shots escaped the flu.**

My family had refused all the vaccinations so we remained well all the time. We knew from the health teachings of Graham, Trail, Tilden, and others, that people cannot contaminate the body with poisons without causing disease. When the flu was at its peak, all the stores were closed as well as the schools, businesses — even the hospital, as the doctors and nurses had been vaccinated too and were down with the flu. No one was on the streets. It was like a ghost town. We [who didn't take any vaccines] seemed to be the only family which didn't get the flu; so my parents went from house to house doing what they could to look after the sick, as it was impossible to get a doctor then. If it were possible for germs, bacteria, viruses, or bacilli to cause disease, they had plenty of opportunities to attack my parents when they were spending many hours a day in the sick rooms. But they didn't get the flu and they didn't bring any germs home to attack us children and cause anything. None of our family had the flu — not even a sniffle— and it was in the winter with deep snow on the ground.

**It has been said that the 1918 flu epidemic killed 20,000,000 people throughout the world. But the doctors killed them with their crude and deadly treatments and drugs. This is a harsh accusation but it is nevertheless true, judging by the success of the drugless doctors in comparison with that of the medical doctors.**

While the medical men and medical hospitals were losing 33% of their flu cases, the non-medical hospitals such as BATTLE CREEK, KELLOGG and MACFADDEN'S HEALTH-RESTORIUM were getting almost 100% healings with their water cure, baths, enemas, etc., fasting and certain other simple healing methods, followed by carefully worked out diets of natural foods. One health doctor didn't lose a patient in eight years. The very successful health treatment of one of those drugless doctors who didn't lose any patients will be given in the other part of this book, titled VACCINATION CONDEMNED, to be published a little later. If the medical doctors had been as advanced as the drugless doctors, there would not have been those 20 million deaths from the medical flu treatment.

There was seven times more disease among the vaccinated soldiers than among the unvaccinated civilians, and the diseases were those they had been vaccinated against. One soldier who had returned from overseas in 1912 told me that the army hospitals were filled with cases of infantile paralysis and he wondered why grown men should have an infant disease. Now, we know that paralysis is a common after-effect of vaccine poisoning. Those at home didn't get the paralysis until after the worldwide vaccination campaign in 1918.'

**'Seven men dropped dead in a doctor's office after being vaccinated. Letters were sent to their families that they had been killed in military action.'**

*- Eleanor McBean, PhD, N.D.*

Her expert medical eye witness account was later confirmed by autopsies, which showed there indeed wasn't a flu, but the suffering was caused by random dosages of an experimental 'bacterial meningitis vaccines', which to this day, mimics flu-like symptoms. The massive, multiple assaults with additional vaccines on the unprepared immune systems of soldiers and civilians created a 'killing field'. Those that were not vaccinated were not affected.

## THE SOLUTION: EARLY TREATMENT

---

### LEADING SCIENTISTS HAVE THE ANSWER

If the toxic covid injections offer no solution for the COVID-19 disease, how can we then help humanity? The answer is simple: from the very start of this worldwide health crisis, there were many prominent scientists and medical doctors who exclaimed how they were successfully treating many thousands of covid patients using existing drugs that are known for their safety and efficacy. There is for example the world-famous French professor Didier Raoult, director of one of the largest research groups in infectious diseases and microbiology. He is the most cited microbiologist in Europe according to ISI and has trained more than 457 foreign scientists in his lab since 1998 with more than 1950 articles referred in ISI or Pubmed and is considered the world's foremost expert on infectious diseases. Professor Raoult started treating covid patients with a medicine that has been around for over sixty years and is famous for its safety and efficiency in defeating coronaviruses: hydroxychloroquine.

**Professor Raoult treated over four thousand patients with hydroxychloroquine + azithromycin and virtually all of them recovered, except for a handful of very elderly who already had several morbidities.<sup>83</sup>**

This incredible success inspired many other medical doctors around the world to start using the same drug. In The Netherlands, Dr. Rob Elens gave all his covid patients hydroxychloroquine combined with zinc and saw a 100% recovery rate in an average of four days. Nobody needed to be hospitalized. Along with 2,700+ other medical professionals, this physician sent a letter to the Dutch government, asking them to include HCQ into the standard protocol. Dr. Elens and other Dutch medical doctors set up a 'COVID-19 Self Care' website, with information on how to prevent and overcome COVID-19, using HCQ and zinc.<sup>84</sup>

In New York, the family practitioner Dr. Vladimir Zelenko treated over 500 covid patients at the beginning of the pandemic with hydroxychloroquine + zinc + azithromycin. He also had a 100% recovery rate, with hardly any side effects, and no hospitalizations.<sup>85</sup> As of August 2021 Dr. Zelenko and his team successfully treated over 6,000 covid patients. He developed a protocol to treat COVID-19 which became world-famous and is saving the lives of millions of people around the world. The Zelenko Protocol is used by for example the online telemedicine platform Speakwithanmd.com and the vast network of 800,000+ members of America's Frontline Doctors.<sup>86</sup>

**Hundreds of studies confirm the effectiveness of HCQ in treating COVID-19 and preventing hospitalization and death.** <sup>87, 88, 89</sup>

World leading scientists Dr. Pierre Kory and Dr. Peter McCullough are both the most published medical experts in their field. Both these physicians and their teams have successfully treated tens of thousands of covid patients using for example Ivermectin. Dr. Kory and his team of top medical experts studied the entire medical literature for over nine months and found that Ivermectin proves to be a miracle drug that effectively prevents and treats COVID-19.

**63 peer reviewed studies confirm the effectiveness of Ivermectin in treating COVID-19.** <sup>90, 91, 92</sup>

Biophysicist Andreas Kalcker used chlorine dioxide to slash the daily death rate of 100 to 0, in Bolivia and was asked to treat the military, police, and politicians in several Latin American nations. His worldwide network COMUSAV.com consists of thousands of physicians, academics, scientists, and lawyers who are promoting this effective treatment. <sup>93, 94, 95</sup>

Information about early treatment for covid can be found on the following websites:

**[www.CovidPatientGuide.com](http://www.CovidPatientGuide.com)**

**[www.C19Protocols.com](http://www.C19Protocols.com)**

**[www.TheCovidRemedy.com](http://www.TheCovidRemedy.com)**

**[www.FlemingMethod.com/best-available-published-evidence](http://www.FlemingMethod.com/best-available-published-evidence)**

**[www.StopWorldControl.com/cures](http://www.StopWorldControl.com/cures)**

## SUPPRESSION OF TREATMENTS

---

### PHYSICIANS AROUND THE WORLD ARE PERSECUTED

**With several options to successfully treat COVID-19, why is there still such an outcry for a vaccine? And why is the majority of the population not even aware of the available treatments? The answer is shocking and shows once more what is going on in our world...**

**All over the world physicians who were successfully treating covid patients, encountered the unthinkable: they were intimidated and shut down by the government.**

America's Frontline Doctors informed the world about the safe and effective cures for covid, during their first White Coat Summit in 2020. This broadcast was viewed over twenty million times in a few hours, but then they were shut down all across the board: Facebook, Youtube, Twitter, and even their website was taken down by Squarespace. Dr. David Brownstein from Michigan, a leading holistic practitioner, had successfully treated over 120 covid patients, but his entire medical blog was removed. Dr. Rob Elens who successfully treated all his covid patients in the Netherlands was threatened by the government that he would lose his license if he continued treating these people. Dr. Joseph Mercola, a leading voice worldwide in healthy living, published information on how to treat covid and was forced to delete his content after Google had already banned him. Professor Raoult, who is one of the most respected scientists in the world, is suddenly slandered all over the internet. Dr. Zelenko who successfully treated over 6,000 patients, among whom two presidents and the Israeli health minister, is also bashed all over the web, and even had to leave his community because of the backlash.

**The biophysicist Andreas Kalcker was de-platformed from all major social media, his book was removed from Amazon and even his scientific account on ResearchGate was deleted.**

All these are just a few of the examples of physicians and scientists who successfully treat covid patients, who faced massive opposition. Never before in the history of mankind has it occurred that a working and safe drug for an illness has been kept from the world, through such an internationally coordinated effort. People are not supposed to recover from covid, because the world population needs to be scared into accepting this lethal injection.

*All the evidence for this censoring of physicians can be found here: [StopWorldControl.com/full](https://www.stopworldcontrol.com/full)*



## ULTIMATE MIND CONTROL

---

### CHILEAN PRESIDENT UNVEALS DIABOLICAL PLAN

As we all know, the goal of criminals is to always increase their power and wealth. They are never satisfied but continually crave more. Ultimately they want to play 'god' over the whole world, where everybody will be their servant. To keep increasing their power, there is one thing they need: *the blind obedience of the masses*. Only a totally ignorant and utterly obedient population will collaborate with their plans. That's why they have been buying the entire world's mainstream news media, education systems, health care, and government agencies, etc. so they can use all of that to spread their brainwashing propaganda to every mind in every corner of the world. Still, they don't stop here, as they are fully aware that not everybody believes everything on television. Therefore their plan to gain 100% control over the minds of all of humanity has further developed. Recently their agenda has been voiced loud and clear by the Chilean president Sebastián Piñera. In a public speech, he bluntly announced to the entire nation:

**'Let's hear what the leaders of the world launch in this community. It is the possibility that machines can read our thoughts and can even insert thoughts, insert feelings. 5G is a tremendous leap. It's a cosmic leap, a Copernican leap, because really what 5G technology is going to mean is an even greater shift in our lives than all the previous technologies have meant. It offers the possibility that machines can read our thoughts and can even insert thoughts, insert feelings. That's not just going to change life, it's going to transform it. 5G in the actual nervous system of our society, just like that. It is to modernize our state, to be a change that reaches every home in our country.'** <sup>96</sup>

After stealing our voices through censorship, stealing our votes through election fraud, stealing our money through ever-increasing taxes, they will now steal our very own thoughts and feelings through 5G. That will be the summit of their tyranny, as they will be able to impose the desired thoughts and feelings onto the whole world, so nobody will even be able to divert from their narrative anymore. Is that why Klaus Schwab so confidently states in his promotional videos about the near future:

**'You will own nothing, have no privacy and you will be happy.'** <sup>97</sup>

Could it be that he is referring to an artificially induced state of fake happiness? What does this have to do with this vaccine report? It could be more than we are aware of right now. For 5G to be able to modify the thoughts and feelings of the population it requires another element: nanoparticles inside of the brains of people, that receive and transmit the 5G signals.

**It turns out that the substance that is most efficient in communicating with 5G is the very substance that is massively present in the covid injections: graphene oxide.** <sup>98, 99</sup>

No substance on earth communicates better with 5G than graphene oxide<sup>100</sup>, and no substance in existence is more efficient in penetrating the human brain and manipulating human thoughts and feelings, than graphene. One company that has been using graphene to manipulate the human brain, for medical purposes, is IN BRAIN Neuro Electronics. Their website states:

**'We use graphene, the thinnest material known to man to build the new generation of neural interfaces for brain restoration to help patients around the world.'**

The company highlights its technology as being able to 'read' a person's brain, detect specific neurological patterns, and then control that person's neurology to **alter their brain function**.<sup>101</sup> It appears that the intention of INBRAIN is to merely help people with neurological disorders, but the reason I mention them is to illustrate how graphene is indeed the ideal substance to alter the human brain. And again, it works better with 5G than anything else. The fact that it is present in the covid vaccines, is therefore highly disturbing, especially if we know what the agenda is of the world leaders, as described by the Chilean president:

**'5G offers the possibility that machines can read our thoughts and can even insert thoughts, insert feelings.'**

Another element we have to touch on, is the clear and public agenda of the globalists to end humanity as we know it and steer all of us into becoming cyborgs. This is clearly explained in the book of Klaus Schwab 'The Fourth Industrial Revolution'. He strongly believes humans need to become one with machines, that are fully connected to the cloud, and who are surveilled and controlled by artificial intelligence. That's why he says nobody will have any form of privacy anymore, yet they will be 'happy'. How well Schwab masters the skill of deception with cleverly chosen words to hide his true intents, is seen at the end of his book:

'In the end, it all comes down to people and values. We need to shape a future that works for all of us by putting people first and empowering them. In its most pessimistic, dehumanized form, the Fourth Industrial Revolution may indeed have the potential to "robotize" humanity and thus to deprive us of our heart and soul. But as a complement to the best parts of human nature—creativity, empathy, stewardship—it can also lift humanity into **a new collective and moral consciousness** based on a shared sense of destiny. It is incumbent on us all to make sure the latter prevails.' <sup>102</sup>

What he says here is that humans need to be empowered and may not be turned into robots, that have lost their soul. He however goes on to explain the true goal: 'lift humanity into a new collective and moral consciousness.' What does that mean? It means exactly what it says: every human will think and feel the same way, we will all share the same 'collective consciousness'.

**This means total brain manipulation of all of humanity. Everyone will be submitted to the narrative that the world leaders prescribe. Humanity will have a new collective consciousness.**

No longer will Google, Facebook, or Twitter need to censor anybody's voice because the Fourth Industrial Revolution will ensure that all of humanity is 'lifted into the same mindset'. That's the ultimate goal of these criminals. The hypocrisy of Schwab is sickening, as this is exactly what he says should not happen. This is turning humans into robots who can no longer think for themselves, but who will all be forced to share the same 'mind'.

The agenda is crystal clear: humanity must be connected to artificial intelligence, that will tell everyone what to think and feel. The key to this is injecting humanity with nanotechnology, which turns every person into a walking antenna that can receive and transmit all kinds of signals. Could that be the reason they insist on imposing never-ending injections onto humanity? Is it so they can continually increase the presence of graphene oxide and other nanotechnology inside of people, shifting them more and more to the new era of transhumanism? If that wasn't exactly what the World Economic Forum has been promoting for the past decades, and what is explained in their recent articles, books, and videos, I would consider this to be the scenario of a bad movie. But it is not a movie. It's in reality what these psychopaths are cooking up in their insane minds as the future for humanity.

## NEW WORLD ORDER

---

### AUSTRALIA NO LONGER HIDES WHAT IS GOING ON

For decades the tyrannical system of worldwide oppression and control, called the New World Order, was labelled a conspiracy theory. But as it is with all so-called conspiracy theories, after some time they prove to be more than theories. In Australia, the health officials no longer hide their agenda, and have been calling their covid tyranny the 'New World Order.' This is what the Chief Health Officer of New South Wales, Kerry Gai Chant, said during a public broadcast:

**'We will be looking at what contact tracing looks like in the New World Order. Yes, it will be pubs and clubs and other things if we have a positive case there.'** <sup>103</sup>

Brad Hazard, the Australian Health Minister, said the following words:

**'That's just the way it is. We have got to accept that this is the New World Order'.<sup>104</sup>**

An Australian news reporter announced new restrictions with the following words:

**'Also the New World Order that will come into force at 12pm, at midnight tonight, new restrictions on various businesses.'<sup>105</sup>**

Another Australian news broadcast, said it like this:

**'The New World Order, our army comes marching in, partnering with police, to help enforce the countries tough new quarantine laws.'<sup>106</sup>**

The day that the new restrictions came into place, the news reporter said:<sup>107</sup>

**'Today is the first full day of the New World Order. Outdoor gatherings are limited to two people. Exercise is allowed but no further than a 10km radius from your home. Browsing in shops is not permitted. Only one person per household may leave to do essential shopping. And from tomorrow funerals are limited to ten people.'**

What is the excuse for this inhumane tyranny? 14 supposed covid deaths during the first half of 2021! While in 2017 over four thousand people died in Australia from influenza and pneumonia.<sup>108</sup>

## **NO THEORY BUT HISTORY**


---

### IS HUMAN HISTORY A CONSPIRACY THEORY?

If we know history, then we understand the basic reality that there have always been power-hungry madmen whose sole desire was to rule the entire world. Think of the Chinese, Persian, Greek, Roman, Spanish, British world empires, among others. The lust for world domination is as old as the world itself. That's why it always amazes me when I see people react with mockery when I mention this historic reality. Even the name of my website StopWorldControl.com is ridiculous to some. 'Hahaha, world control, what a silly conspiracy theory!' This is alarming, as it shows how far the minds of some of us have been led astray from understanding even the most basic principles of human existence. As

recent as 80 years ago the world was threatened by yet another madman who wanted to rule the world, with two consecutive world wars as a result. Is that a conspiracy theory too?

**The plan to control the entire world has always existed, and has been expressed in countless forms, throughout the existence of humanity.**



**All throughout the history of mankind, up to this very day, there have been cruel and horrifying practices, at the heart of certain groups of people.**

Nowadays the public seems to be so severely brainwashed, that when we warn for similar dark forces in our time, they immediately deny it. But if we want to protect our lives, we must understand how the same kind of wicked entities that terrorized our world in the past, are still around today. It is these kinds of evil people who are at the heart of the criminal network that is behind the New World Order.

## **WHO ARE THESE CRIMINALS?**

---

MEET THE DARK FAMILIES WHO RULE THE WORLD

**Who** exactly are these criminals? Do we have some of their names and whereabouts? How do they operate and what can we do to stop them? An important part of the answer is given in the magnificent documentary MONOPOLY, which can be viewed on [StopWorldControl.com](http://StopWorldControl.com).

**MONOPOLY reveals in great detail, with all the evidence on screen, how virtually everything in our world is owned by the same people, and it shows what they are planning for humanity.**

Because these superrich entities own everything, it's a piece of cake for them to control the world. They own Apple, Facebook, Twitter, Google, Facebook, and the rest of Big Tech, all the major news media, the entire travel industry, the whole food industry, the banks, the clothing industry, and so on.

By strategically buying everything, they have gained an unrivaled monopoly worldwide. Something Julius Ceasar could only dream of... They also own the entire health industry, which allows them to tell hospitals around the world what to do and what not to do. They have positioned their political puppets in governments around the world through election fraud, bribery and blackmailing. Once we understand this, we can see how they are able to impose tyranny all over the world.

It would take me too far to name all the involved individual entities, but I will reveal a few, that are at the heart of this network. In Italy there are for example 13 Italian families or bloodlines, called the 'Black Nobility'. I call them *the mafia on steroids*. These families, along with other similar dynasties from other regions of the earth, consider themselves to be superior over the rest of humanity. They look upon regular folks as 'bugs', 'cattle', and 'dogs'. That is literally how they write about you and me in their literature.

**They believe that it's their destiny to rule over humanity, who are to become their slaves.**

These families are organized in a pyramidal hierarchy, where ultimately everyone answers to the same puppet masters at the top. *The key to their power is secrecy, so nobody can touch them.* That's why the real leaders always stay in the shadows. The world population only sees puppets that operate on the visible stage of the world scene, like mind-programmed politicians, perverted Hollywood celebrities, industrial leaders, media personalities, etc. Some better-known puppets are Klaus Schwab, Bill Gates, George Soros, the Clinton, Bush and Morgan family, etc. Although they are all individually very rich and powerful, they are submitted to entities that are higher up in the hierarchy, but who make sure they stay out of the picture. *Secrecy is their strength.*

One of their strategies is to set up public 'world' organizations, which are their visible platforms to work out their agenda. One of these has become very prominent during this organized pandemic and is called the World Health Organization, which is mostly financed by Bill Gates, a key puppet of this criminal network. The WHO is dictating to all of humanity - think about this! - what we can or cannot do when it comes to our health. Nobody elected the World Health Organization and nobody wants them to be around, to bully every physician, nurse, and health practitioner into blind obedience.

**The WHO forces the entire world into unquestioning submission to their tyrannical 'guidelines', that are more often anti-scientific than based on proper science.**

The WHO for example told the entire world to use the PCR test to discover covid cases, while this test cannot discern between different types of pathogens, and produces up to 93% of false positives. This flawed test is the main tool to tell the world there is a pandemic, while no medical device in history

has ever been so unreliable. Yet this anti-scientific protocol is imposed on the entire world, to promote the illusion of a global pandemic, which is mainly based on false positives. The hundreds of millions of so-called 'covid cases' are nothing but **false positives, resulting from a fatally flawed test**. The actual virus Sars-Cov-2 has never been isolated and purified, therefore it is impossible to test for it. It's a scam of astronomical proportions.

**That's an example of how a 'world organization' is used to roll out the agenda of submitting humanity to tyranny, in the name of 'protecting your health'.**

A similar organization is the United Nations, which portrays itself as the so-called 'peace keeper' of this world. Their agenda is however to submit all of humanity to a one-world government. The U.N. works closely with the European Union and NATO, which are similar carousels for the criminal families to wipe out the independence of the nations and set up a one-world government.

Another public player is the World Economic Forum, founded by Klaus Schwab. The World Economic Forum presents itself as a think tank for the rich and powerful of the world, where they 'seek solutions for the world's problems'. Their magic word is 'sustainable development' which claims to ensure a better future for our world. Together with the U.N., they developed the so-called Agenda21, which claims to offer the ultimate solution for a more sustainable world.

**In reality, this means nothing less than seizing all rights, freedoms and properties from the entire world population and bringing it all in the hands of the superrich.**


Then there is the banking imperium, which controls all the money in the world. Their job is to bring about a cashless society where only those who are digitally connected to the system of surveillance and slavery, will still have access to finances. The Nigerian government has been paid handsomely by them, to reserve banking services strictly for the vaccinated, an example that will soon be followed by other countries. A leading entity in the banking imperium is the notorious Rothschild family. They own the central banks in 165 nations, thus controlling the money flow in most of the world. Since ancient times this family has dedicated itself to the worship of the darkest of all forces. Another well-known, equally dark family are the Rockefellers. They published the 'Scenario of the Future' in 2010, in which they described the current pandemic in great detail, with the desired outcome of establishing a new world of domination and control.

**Entities like the Rockefeller Institute present themselves as protectors of humanity, but behind this humanitarian mask there is a gruesome face of lust for power.**

I already mentioned the Black Nobility from Italy. Their most effective strategy has been to hide behind the beautiful face of Christianity, as they established the Vatican in Rome, as the 'center of Roman Catholicism'. Behind the monumental architecture of the majestic cathedrals, there however lurks a world so dark and perverse, that no normal human being could ever comprehend it. The recent exposure of organized, systematic child abuse in this religious stronghold is only the tiniest tip of an iceberg so deep, that it would traumatize most of us, if we knew what is going on there. Make no mistake: there are also good religious people in the Vatican, who are opposing the criminal activities.

**For example archbishop Carlo Maria Vigano, has been speaking out against what he calls the 'Deep Church', comparing it to the 'Deep State'.**

The Vatican is located inside Vatican City, which is a sovereign state independent from Italy, where no Italian law has any authority. Because they are not submitted to the laws of any land, not even Italy that surrounds them, they are able to commit any crime they want. Similar sovereign states inside the nations are 'The City of London' (an independent state within London that evades all British laws but controls the British government), 'Washington D.C.' (or the District of Columbia, which is a sovereign state inside the United States, that rules over the American people). The criminal families have set up these untouchable 'states within nations' from where they operate.






**Vatican City is the most important of them all, and it is here that the highest puppet masters have their seat.**

We all know the White Pope, a role that is currently played by Pope Francis. His job is to control the worldwide Roman Catholic faith community, and steer them towards the New World Order. In several public messages he calls all believers to get vaccinated<sup>112</sup>, and goes on to proclaim the New World Order as the only solution to the world's problems. Here are some of his statements: <sup>113</sup>

'We can heal injustice by building **a new world order** ... The path to humanity's salvation passes through the creation of **a new model** of development ... take care of the Earth, with **radical personal and political choices**, ... without **an overall vision** there will be no future ... we must bring an end to **short-sighted nationalism** ...'

Besides the White Pope, there is also a lesser known Black Pope who has far more power, but who works more behind the scenes. The Black Pope however is still submitted to one who sits on a higher throne: *the Grey Pope*. This supreme puppet master operates entirely in the shadows, from where he yields enormous power over the world. If you want to understand how all this originated historically, you have to research the dark spiritual origins of the Jesuits. I will leave it here, for now, as this topic can easily lead us too far.



Their strategy is however to always hide behind magnificent masks, that show the opposite of who they are.

**We see this with Klaus Schwab, who uses eloquent rethoric to bewitch the minds of his worldwide audience, and convince them that the noblest of all causes is to make sure that every human on earth will think and feel the exact same way. 'Lift humanity into a collective consciousness.'**

The way he presents this stark raving mad plan, is however so cunning that most people would give him a standing ovation, after hearing his speech. The same we see with the White Pope, who speaks beautifully about caring for the poor, ending injustice, saving the Earth, and other noble causes, while in fact he simply says: 'The whole world needs to be enslaved to a one world government, where nobody will have a voice, rights, freedoms, possessions, identity or privacy.' It's the same kind of hypnosis they use to impose the vaccine mandates: 'The world is attacked by a deadly disease, but we have a wonderful solution: lifesaving vaccines. Hurray!' That these wonderful vaccines contain living

creatures with tentacles, self assembling nanobots, highly toxic substances, and that millions are killed by them, is of course not mentioned.

**It's all about hypnotizing humanity using refined forms of hypocrisy and deception.**

Another way these criminals operate, is by organizing themselves in so-called secret societies, to establish their hidden influence in every nation. Apart from the completely hidden societies, there are also more public cults, like Freemasonry. This is one of the better-known spiritual organizations, used to influence local authorities in virtually every town of every nation. They attract people in authority, claiming to be an innocent organization that wants to help humanity. Only when members climb to the higher levels of [REDACTED]

**Freemasonry focuses on making influential people in every community their members, so they can use them for the outworking of their plans.**

Google whistleblower Zach Vorhies<sup>109</sup> told me in a personal conversation that in 2016 Google laid out their plans to program humanity in a revealing location: the San Francisco Freemasonry Headquarters. There Google informed their staff about the company strategy: *mold the mind of mankind*. That illustrates how Freemasonry plays a central role in this worldwide agenda.

The many secret societies work closely with the secret services of the nations, like for example the CIA and FBI in America. Entities that on the surface fight crime, but in reality are among the worst of all criminal organizations. The renowned German journalist Udo Ulfkotte, who was murdered for his confessions, admitted a few years ago that journalists all over the world are paid by secret services, secret societies, government agencies, billionaires, etc. to **always lie and never tell the truth to the public**. His important testimony can be seen in the documentary **BUSTED** on [StopWorldControl.com](http://StopWorldControl.com). It is because of the confessions of this brave journalist - who was editor of one of Europe's largest newspapers - that a major awakening is going on in Germany. His book opened the eyes of the German population, who are now a major force against the New World Order.

Although Vatican City, Washington D.C., and the City of London are the headquarters of the criminal families, many of their logistics operations have been transferred to Asian countries, because they plan to use China to overthrow the rest of the world. The oppressive communistic regime of total slavery and control which they installed in China, must be rolled out now over the rest of the world.

**Our enemy is however not the Chinese Communist Party, since they are also mere puppets. Those calling the shots are still seated in Vatican City.**

Good news is that there has been a lot of infighting in this criminal network, causing it to fall apart in several camps, that all compete for world domination. May this confusion among them increase, as they fall into their own pits, and their plans fail miserably.

Much more can be said about all of this, as many books have been written about this criminal network, by researchers who often dedicated their entire lives to expose them. If you want to learn more, you can find a wealth of quality information compiled by some excellent researchers on the Dutch website **Ellaster.nl**. Use Google translate to read the articles: [ellaster.nl/category/val-van-cabal/cabal](http://ellaster.nl/category/val-van-cabal/cabal)

**You can also watch the docu-series 'Fall of Cabal' on [StopWorldControl.com/cabal](http://StopWorldControl.com/cabal), a masterpiece of journalism that explains a lot about this worldwide 'cabal'.**

## THE GREAT AWAKENING

---

### HUNDREDS OF MILLIONS ARE RISING UP

Is there any hope for humanity? Yes. Although we are witnessing the greatest criminal operation since the birth of our world, something entirely different is also happening. Hundreds of millions of people are waking up from the deep sleep of ignorance and deception, and they are letting out a roar of truth, all over the world. In every nation organizations of medical doctors, lawyers, scientists, and all kinds of professionals are being established, to fight for freedom. They consist of tens of thousands of educated, influential and passionate professionals who are determined to stop this diabolical scheme. Brand new media platforms are being born, that grow every day in influence. They are not owned by the criminal cartel, but work from a heart that wants to defend humanity against the onslaught of destructive fake news media, that is operated by the cabal.

On top of that, increasingly large numbers of health care workers are refusing the vaccine mandates. In Canada 35,000 medical professionals protested against the vaccines.<sup>59</sup> In New York 83,000 health care workers refuse the toxic injections.<sup>60</sup> Overall in the U.S. 58% of all physicians is not taking the dangerous shots.<sup>61</sup> Also among law enforcement and fire fighters there is increasing protest against the vaccine mandates. In California 50% of all law enforcement stands up against these criminal mandates.<sup>62</sup>

**These are just a few examples of the mass non-compliance in nations around the world.**

This resistance is about to explode even far more worldwide, as the truth about these injections is spreading far and wide, despite all the attempts from the *criminal vaccine cartel* - which includes Big Tech, Big Pharma, government agencies, news media, etc. - to suppress this information.

On **StopWorldControl.com** we are about to launch a world map, that will show hundreds of organizations in nations around the world who are resisting this criminal operation. They represent hundreds of millions of people who refuse to become slaves of criminals. Among them are large numbers of physicians, scientists, academics, lawyers, entrepreneurs, politicians, etc. There is an unprecedented and unstoppable awakening going on, that will only increase in the near future.

It is clear that with every new attempt of the criminals to proceed with their nefarious plan, millions more people are waking up. The whole climate change hoax for example, which is just another one of their tricks to impose more control and taxes onto the population.

**Every informed person knows the climate is 100% controlled, through geo-engineering or weather manipulation.<sup>110</sup>**

There is no such thing as global warming. What we see is a worldwide system of highly developed weather manipulation, which is causing all the storms, heat waves, wildfires, earthquakes, extreme hail and snow storms, floods, and other natural disasters. *Cloud seeding* is for example a commonly known practice where big rain storms are created by spraying chemicals in the sky.<sup>111</sup> In a separate report we will provide all the evidence for this. We have official documents and video footage from the U.S. government and military that clearly state how the weather is not only 100% controlled, but it has also been *weaponized*. Governments, military and private corporations have been refining their weather manipulation systems for decades. The criminals constantly cry: 'Global warming!' but their game is failing, as the truth about weather manipulation, or geo-engineering, is coming out. Hundreds of millions of people who discovered how the pandemic is orchestrated, also begin to understand that other attacks on humanity are coming from the same source. Also the imaginary threat of an alien invasion, is a card up the sleeve of the criminals that we will see thrown on the table in the future. 'The aliens are coming to invade the earth! We need a one world government to protect us!' It will be amusing to observe how many people will fall for this one.

**The strategy is always the same: create a problem (pandemic, climate change, racism, social unrest, alien threat, asteroid collision, etc.) and then offer a solution. The solution is always the same: stealing rights, freedoms and finances from the people.**

The veil has however been lifted, and no more is everyone buying their lies. The awakening of hundreds of millions of intelligent people is unstoppable and will become the greatest shift in all of human history. The insane vaccine mandates are causing the world to wake up as never before. Freedom will come, as the truth will break through more and more. Courageous heroes of humanity will rise up in increasing numbers to stop the plans of the madmen, and direct the world into a better direction. These heroes are medical professionals, lawyers, scientists, politicians and hundreds of millions of vigilant citizens.

**We all play a part in this Great Awakening. None of us may stand at the sidelines and do nothing. That is complicity. Witnessing a crime and allowing it to happen is the same as supporting it.**

Many of us have remained silent, out of fear of losing jobs, finances, position, respect, or friends. We must understand however that if we don't speak out now, we will lose far more than jobs, finances, and friends. We will lose our very humanity and become programmed slaves without the ability to think or feel independently. So what can we do? The most important is to inform our fellow humans, even though they may resist fiercely at first because their minds are so brainwashed by the propaganda. The initial rejection of truth should not discourage us, but we must resort to all possible means to awaken the entire world. It's only because of the ignorance of the population that this criminal network can reign on the earth. Now there is however an unprecedented awakening happening and all of us have the duty to do all we can, to fan the flames of this awakening.

**Everybody can print out this report in many copies and distribute it to our local law enforcement, school directors and teachers, medical personnel, friends, and neighbors.**

We can all upload this PDF to an **online printing service** and have thousands of copies made, that we hand out in our community. All of us can send this report as an email attachment to all our contacts, and people in authority. There is no excuse for any one of us, to do nothing. We need to inform the world. We have to rise and do what we can. We must spread the truth far and wide. That takes effort. Please don't sit down and complain, but rise and take action. This report is made with great effort, to be a tool for awakening the world. *Please use it.*

**More information can be found at [StopWorldControl.com](http://StopWorldControl.com). Make sure to sign up for the emails, to be informed and empowered, so you can defend your life, freedom and future.**

## DETOX FROM THE SHOTS

---

### IS THERE HOPE FOR THE VACCINATED?

Stop World Control is investigating proposed solutions to detox from the covid vaccines. We have found several options that are promising, and we hope to release a **Vaccine Detox Guide** soon. Sadly not every damage done by the mRNA shots will be able to be undone, like the altering of the DNA. That is a switch that cannot be reversed. There are however methods to get rid of the nanotech in your body, kill the living organisms that are being injected, remove the spike proteins, etc. As vaccinations continue, and different pathogens will be released, we will keep researching for any new solutions that will become available. Sign up for the emails of Stop World Control to stay updated on this research. *If you know of working solutions to detox from these injections, please email us at [network@stopworldcontrol.com](mailto:network@stopworldcontrol.com)*

## • FINAL SUMMARY •

The data shows that millions may have died already from the covid injections, and hundreds of millions suffer serious side effects. This is just the short term destruction. The real devastation comes after a few years.

There is graphene oxide in the vaccines, which is the perfect conductor for 5G, and also the best substance for brain manipulation. The Chilean president said that 5G will insert thoughts and feelings into everyone. Klaus Schwab adds that humanity will be lifted into one and the same consciousness. This reveals an agenda of total mind control. The Australian government calls the covid tyranny the New World Order.

All this is based on worldwide fraud of inflating covid numbers, relabeling every death as covid, a PCR test that produces false positives, media scare mongering, and government propaganda. The criminal network who is behind all this, has been buying the entire health industry, they direct the World Health Organization, they own all mainstream media, and control most governments. They suppress every treatment for covid, so the world would think a vaccine is the only way out.

Their power lies in the fact that they operate in the shadows, so the public has no clue about their existence. The solution is exposing them. Once enough people in the world - especially law enforcement, health care workers, school teachers, judges, and local authorities - understand what is going on, the plans of the wicked will fail. Mass awakening will result in mass non-compliance.

Although most of the judicial system is corrupt, lawyers need to become brave warriors to present all the evidence for this crime, and start prosecuting all who are complicit. There still remain honest judges, who can turn the tide.

This can become the greatest awakening of all time, if we all rise up, share truth, and unify as one humanity against these criminals.

## REFERENCES

---

### STARTING POINT FOR YOUR OWN RESEARCH

**A**s internet censorship is increasing, because criminals are desperately trying to hide all truth, some of the links below may get deleted. Usually one can however retrieve them, using the internet archive [Archive.org](https://archive.org). Simply copy and paste the deleted URL in the search box, and you should see a saved version of the web page. Personally, I save a PDF version of every important web page, and I download every critical video, so I build my private database of evidence.

- 1: <https://renzlaw.godaddysites.com/45k-whistleblower-suit>
- 2: <https://www.icandecide.org/wp-content/uploads/2021/03/Letter-to-Dr.-Walensky-re-anaphylaxis.pdf>
- 3: <https://jamanetwork.com/journals/jama/fullarticle/2777417>
- 4: <https://centipedenation.com/first-column/150k-records-deleted-from-vaers-covid-database/>
- 5: <https://www.forbes.com/sites/emilywillingham/2015/08/06/a-congressman-a-cdc-whistleblower-and-an-autism-tempest-in-a-trashcan/?sh=47819f145396>
- 6: <https://rumble.com/vm1yrt-wow-vaccine-caused-deaths-reported-as-un-vaxxed-covid-deaths.html>
- 7: <https://dissident.one/2021/08/29/18311/>
- 8: <https://alexberenson.substack.com/p/some-actual-news>
- 9: <https://www.lifesitenews.com/news/nearly-50k-medicare-patients-died-soon-after-getting-covid-shot-whistleblower/>
- 10: <https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf>
- 11: <https://www.facebook.com/80221381134/posts/10158207967261135/?d=n>
- 12: <https://www.dailymotion.com/video/x81f1y1>
- 13: <https://video.foxnews.com/v/6260748415001#sp=show-clips>
- 14: <https://childrenshealthdefense.org/defender/censored-dark-horse-podcast-bret-weinstein-robert-malone-inventor-mrna-vaccine-technology>
- 15: <https://rumble.com/vk894g-dr-michael-yeardon-a-final-warning-to-humanity.html>
- 16: <https://thehighwire.com/videos/a-coming-covid-catastrophe>
- 17: <https://www.youtube.com/watch?v=ZJZxiNxYLpc>
- 18: <https://doctors4covidethics.org/holocaust-survivors-write-to-the-european-medicines-agency/>
- 19: <https://healthimpactnews.com/2021/21766-dead-over-2-million-injured-50-serious-reported-in-european-unions-database-of-adverse-drug-reactions-for-covid-19-shots/>
- 20: <https://www.adrreports.eu/en/index.html>
- 21: <https://meldpuntvaccinatie.nl/>
- 22: <https://ted.europa.eu/udl?uri=TED:NOTICE:506291-2020:TEXT:EN:HTML&src=0>
- 23: <https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>
- 24: <https://dailyexpose.co.uk/2021/02/08/official-data-on-adverse-reactions-to-vaccines>



- 25: <https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting#annex-1-vaccine-analysis-print>
- 26: <https://theexpose.uk/2021/09/15/30k-people-died-within-21-days-of-having-a-covid-19-vaccine-in-england/>
- 27: <https://dailysceptic.org/is-the-mhras-yellow-card-reporting-system-safeguarding-the-uk-public>
- 28: <https://www.the-people-committee.com/>
- 29: <https://humansarefree.com/2021/08/32k-people-dead-in-brazil-following-covid-19-vaccines.html>
- 30: <https://www.salk.edu/news-release/the-novel-coronavirus-spike-protein-plays-additional-key-role-in-illness/>
- 31: <https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318902>
- 32: <https://www.nature.com/articles/s41586-021-03744-4>
- 33: <https://www.nejm.org/doi/full/10.1056/NEJMc2109975>
- 34: <https://deeproofsathome.com/a-foreshadowing-buried-82-miscarriage-data-in-new-nejm-study/>
- 35: [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3897733](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3897733)
- 36: <https://pubmed.ncbi.nlm.nih.gov/32908214/>
- 37: <https://citizenfreepress.com/breaking/whoa-fauci-finally-mentions-vaccine-risk-for-ade/>
- 38: <https://canadianmale.wordpress.com/2021/04/19/thousands-of-reports-of-menstrual-irregularities-reproductive-dysfunction-following-covid-vaccines/>
- 39: <https://www.lifesitenews.com/wp-content/uploads/2021/06/Pfizer-bio-distribution-confidential-document-translated-to-english.pdf>
- 40: <https://www.nature.com/articles/s41586-018-0465-8>
- 41: <https://thehighwire.com/videos/a-coming-covid-catastrophe>
- 42: <https://nulluslocussinegenio.com/2021/09/13/why-mass-vaccinations-prolong-and-make-epidemics-deadlier-real-vaccine-expert-calls-out-flawed-government-pandemic-strategy/>
- 43: <https://rumble.com/vldilx-nobel-prize-winner-professor-luc-montagnier-says-vaccine-is-creating-varian.html>
- 44: <https://rumble.com/vlme81-the-most-vulnerable-population-are-the-ones-who-received-two-vaccine-doses.html>
- 45: <https://www.bitchute.com/video/3dX3gawfhaEJ/>
- 46: <https://rumble.com/vkb885-fauci-says-cdc-considering-mask-mandates-for-vaccinated-americans.html>
- 47: <https://rumble.com/vkciqv-fauci-vaccinated-wear-a-mask-will-he-ever-be-canceled.html>
- 48: <https://rumble.com/vflkib-more-fauci-b.s.-vaccinated-americans-still-cant-eat-indoors.html>
- 49: <https://rumble.com/vlt9b1-dr.-anthony-fauci-fully-vaccinated-people-carry-as-much-virus-as-unvaccinat.html>
- 50: <https://rumble.com/vmgq6o-fauci-demands-vaccine-mandate-for-air-travel-and-public-schools.html>
- 51: <https://www.bitchute.com/video/OQBS0IAIrXEa/>
- 52: <https://www.stopworldcontrol.com/downloads/en/vaccines/vaccines-harm.pdf>
- 53: <https://www.nbcnews.com/science/science-news/cdc-warns-internal-document-war-has-changed-coronavirus-n1275478>
- 54: <https://rumble.com/vmh1er-we-need-to-prepare-to-live-with-covid-boosters-australia.html>
- 55: <https://nypost.com/2020/11/24/moderna-boss-says-covid-shot-not-proven-to-stop-virus-spread/>
- 56: <https://rumble.com/vjs9ef-australias-new-world-order-began-july-10-2021.html>
- 57: [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3897733](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3897733)
- 58: [https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s\\_cid=mm7031e2\\_](https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_)

- 59: <https://rumble.com/vn5us5-30000-canadian-doctors-protest-vaccine-mandates.html>
- 60: <https://newsnationusa.com/news/usanews/83000-hospital-workers-could-be-fired-as-new-york-covid-vaccine-mandate-goes-into-effect/>
- 61: <https://www.visiontimes.com/2021/06/25/the-majority-of-american-physicians-remain-unvaccinated.html>
- 62: <https://www.latimes.com/california/story/2021-06-19/vaccination-rates-lag-among-california-public-safety-workers-drawing-concern>
- 63: <https://rumble.com/vmh8gx-covid-injections-indeed-change-the-human-dna.html>
- 63A: [https://www.roxytube.com/watch/hybrid-transhuman-black-eyed-baby\\_Lznw1XMWmIJWQyZ.html](https://www.roxytube.com/watch/hybrid-transhuman-black-eyed-baby_Lznw1XMWmIJWQyZ.html)
- 63B: <https://www.orwell.city/2021/09/black-eyed-babies.html>
- 64: <https://rumble.com/vmk9yn-alarm-humans-with-modified-dna-have-no-rights-and-are-patented.html>
- 65: <https://www.bitchute.com/video/hy0MxQK4uQIR/>
- 66: [drrobertyoung.com/post/science-team-reveals-graphene-aluminum-lnp-capsids-peg-parasites-in-4-cov-vaccines](https://drrobertyoung.com/post/science-team-reveals-graphene-aluminum-lnp-capsids-peg-parasites-in-4-cov-vaccines)
- 67: [drrobertyoung.com/post/transmission-electron-microscopy-reveals-graphene-oxide-in-cov-19-vaccines](https://drrobertyoung.com/post/transmission-electron-microscopy-reveals-graphene-oxide-in-cov-19-vaccines)
- 68: <https://www.stopworldcontrol.com/downloads/en/vaccines/nanotech-vaccines.pdf>
- 68A: <https://rumble.com/vn482j-dr.-carrie-madej-first-u.s.-lab-examines-vaccine-vials-horrific-findings-re.html>
- 68B: <https://www.bitchute.com/video/TtgkYxzmsHSJ/>
- 69: <https://www.bitchute.com/video/UBFi2Xt4d2oR/>
- 69A: <https://www.drrobertyoung.com/post/transmission-electron-microscopy-reveals-graphene-oxide-in-cov-19-vaccines>
- 69B: <https://www.youtube.com/watch?v=s8e06KfDWM>
- 69C: <https://rumble.com/vnbgal-never-before-seen-blood-doctor-reveals-horrific-findings-after-examining-vi.html>
- 70: <https://www.tijd.be/politiek-economie/belgie/federaal/nieuw-gemor-over-belgische-rapportering-coronadoden/10220849.html>
- 71: <https://www.bitchute.com/video/iP2eQxEwQI5h>
- 72: <https://www.stopworldcontrol.com/full>
- 73: <https://www.stopworldcontrol.com/nl/elke-de-klerk/>
- 74: [https://www.youtube.com/watch?v=g5f\\_6ltv7ol&t=8s](https://www.youtube.com/watch?v=g5f_6ltv7ol&t=8s)
- 75: <https://www.globalresearch.ca/hospitals-getting-paid-more-label-cause-death-coronavirus/5709720/amp>
- 76: <https://www.stopworldcontrol.com/media/>
- 77: <https://www.stopworldcontrol.com/media/>
- 78: <https://nationalfile.com/doctor-wants-to-be-scary-to-the-public-and-inflate-covid-numbers-if-you-dont-get-vaccinated-you-know-youre-going-to-die/>
- 79: <https://www.youtube.com/watch?v=UIDsKdeFOmQ>
- 80: <https://www.stopworldcontrol.com/director>
- 81: <https://educate-yourself.org/cn/flu1918andnow07feb04.shtml>
- 82: <https://salmartingano.com/2020/05/the-1918-spanish-flu-only-the-vaccinated-died/>
- 83: <https://www.sciencedirect.com/science/article/abs/pii/S1477893920302179?via%3Dihub>
- 84: <https://artsencollectief.nl> / <https://zelfzorgcovid19.nl/>

- 85: <https://techstartups.com/2020/04/05/new-updates-dr-vladimir-zelenko-cocktail-hydroxychloroquine-zinc-sulfate-azithromycin-showing-phenomenon-results-900-coronavirus-patients-treated-must-watch-video>
- 86: <https://thezelenkoprotocol.com/>
- 87: <https://americasfrontlinedoctors.org/treatments/hydroxychloroquine/science-of-hcq>
- 88: <https://www.sciencedirect.com/science/article/pii/S0924857920304258/>
- 89: <https://c19hcq.com/>
- 90: <https://ivmmeta.com>
- 91: <https://covid.us.org/2021/01/28/ivermectin-safe-effective-covid-19/>
- 92: [https://brandnewtube.com/watch/dr-mccullough-shares-is-hcq-truly-safe-for-covid-19\\_FoRTpkTw6EKrlz.html](https://brandnewtube.com/watch/dr-mccullough-shares-is-hcq-truly-safe-for-covid-19_FoRTpkTw6EKrlz.html)
- 93: <https://www.stopworldcontrol.com/cds>
- 94: <https://comusav.com>
- 95: <https://andreaskalcker.com>
- 96: <https://www.eldiestro.es/2021/06/del-no-tendras-nada-y-seras-feliz-pasamos-al-las-maquinas-leeran-nuestros-pensamientos-e-insertaran-incluso-sentimientos-ya-que-eso-es-algo-a-lo-que-aspiramos-todos/>
- 97: [https://www.forbes.com/sites/worldeconomicforum/2016/11/10/shopping-i-cant-really-remember-what-that-is-or-how-differently-well-live-in-2030/amp/?sh=3a2b52dd1735&\\_\\_twitter\\_impression=true](https://www.forbes.com/sites/worldeconomicforum/2016/11/10/shopping-i-cant-really-remember-what-that-is-or-how-differently-well-live-in-2030/amp/?sh=3a2b52dd1735&__twitter_impression=true)
- 98: <https://grolltex.com/the-future-of-graphene-and-5g/>
- 99: <https://graphene-flagship.eu/innovation/spearheads/c2-sh01-5g/>
- 100: <https://www.tandfonline.com/doi/full/10.1080/03602559.2018.1542714>
- 101: <https://www.naturalnews.com/2021-07-19-graphene-based-neuromodulation-technology-is-real-in-brain-neuroelectronics.html>
- 102: [https://www.academia.edu/35846430/The\\_Fourth\\_Industrial\\_Revolution\\_Klaus\\_Schwab](https://www.academia.edu/35846430/The_Fourth_Industrial_Revolution_Klaus_Schwab)
- 103: <https://rumble.com/vmb1vd-new-world-order-announced-by-aussie-health-overlords-then-fact-checkers-spr.html>
- 104: <https://rumble.com/vmaand-australian-health-official-talks-about-new-world-order.html>
- 105: <https://rumble.com/vlbb0g-australian-news-says-new-world-order-will-come-into-force-at-midnight.html>
- 106: <https://rumble.com/vlbay8-australian-news-broadcast-declares-new-world-order-in-effect.html>
- 107: <https://rumble.com/vjstsv-australia-new-world-order.html>
- 108: <https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/3303.0~2017~Main%20Features~Deaths%20due%20to%20influenza~5>
- 109: <https://www.zachvorhies.com/>
- 110: <https://www.geoengineeringwatch.org/>
- 111: <https://patents.google.com/patent/US5357865A/en>
- 112: <https://www.vaticannews.va/en/pope/news/2021-08/pope-francis-appeal-covid-19-vaccines-act-of-love.html>
- 113: <https://www.breitbart.com/national-security/2021/03/15/pope-francis-calls-for-new-world-order-after-the-pandemic/>

**Evidence that graphene oxide is in the vaccines:**

<https://stateofthenation.co/?p=70400>

<https://rumble.com/vjk0u1-breaking-astrazeneca-vaccine-vials-examined-by-researchers-confirm-toxic-po.html>

<https://rumble.com/vjgmj9-breaking-discovery-the-actual-contents-inside-pfizer-vials-exposed.html>

<https://rumble.com/vkgdq7-deadly-shots-former-pfizer-employee-confirms-poison-in-covid-vaccine.html>

<https://www.orwell.city/2021/07/andreas-kalcker.html>

<https://rumble.com/vk7lap-andreas-kalckers-team-confirms-evidence-of-graphene-oxide-in-vaccines.html>

<https://www.orwell.city/2021/07/absorption-signal.html>